PMID,OWN,STAT,DCOM,LR,IS,VI,IP,DP,TI,PG,AB,FAU,AU,LA,PT,PL,TA,JT,JID,SB,MH,PMC,EDAT,MHDA,CRDT,PHST,AID,PST,SO,RN,RF,TT,GR,OID,OAB,OABL,OTO,OT,GN,EIN,SI
4119829,NLM,MEDLINE,19730406,20210526,0003-6919 (Print) 0003-6919 (Linking),25,1,1973 Jan,An improved method for enumeration of X-C cell assay for murine leukemia virus.,149-50,"A modification for the enumeration of X-C syncytia is described wherein the projected image of the entire infected culture is observed. This method is rapid, reliable, and reproducible.","['Spahn, G J', 'Nims, R M', 'Peters, R L', 'Kenyon, K']","['Spahn GJ', 'Nims RM', 'Peters RL', 'Kenyon K']",['eng'],['Journal Article'],United States,Appl Microbiol,Applied microbiology,7605802,IM,"['Animals', 'Cell Line', 'Cytopathogenic Effect, Viral', 'Leukemia Virus, Murine/*isolation & purification', 'Methods', 'Mice', 'Retroviridae/growth & development/isolation & purification', 'Staining and Labeling', 'Ultraviolet Rays', 'Viral Plaque Assay/*instrumentation']",PMC380752,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",['10.1128/am.25.1.149-150.1973 [doi]'],ppublish,Appl Microbiol. 1973 Jan;25(1):149-50. doi: 10.1128/am.25.1.149-150.1973.,,,,,,,,,,,,
4119799,NLM,MEDLINE,19730405,20170214,0009-9228 (Print) 0009-9228 (Linking),12,2,1973 Feb,"Unusual palm creases and unusual children. The Sydney line and ""type C"" palmar lines and their clinical significance in a child development clinic.",101-12,,"['Johnson, C F', 'Opitz, E']","['Johnson CF', 'Opitz E']",['eng'],['Journal Article'],United States,Clin Pediatr (Phila),Clinical pediatrics,0372606,IM,"['Adult', 'Age Factors', 'Child', 'Child Behavior Disorders/diagnosis', 'Child Development', '*Child Health Services', 'Congenital Abnormalities/diagnosis', '*Dermatoglyphics', 'Developmental Disabilities/diagnosis', 'Evaluation Studies as Topic', 'Female', 'Genetics, Medical', '*Hand', 'Hearing Disorders/diagnosis', 'Humans', 'Intellectual Disability/diagnosis', 'Intelligence', 'Leukemia/diagnosis', 'Leukemia, Lymphoid/diagnosis', 'Male', 'Motor Skills', '*Physical Examination', 'Rubella/complications', 'Speech Disorders/diagnosis', 'Vision Disorders/diagnosis']",,1973/02/01 00:00,1973/02/01 00:01,['1973/02/01 00:00'],"['1973/02/01 00:00 [pubmed]', '1973/02/01 00:01 [medline]', '1973/02/01 00:00 [entrez]']",['10.1177/000992287301200214 [doi]'],ppublish,Clin Pediatr (Phila). 1973 Feb;12(2):101-12. doi: 10.1177/000992287301200214.,,,,,,,,,,,,
4119795,NLM,MEDLINE,19730405,20190613,0006-2960 (Print) 0006-2960 (Linking),12,5,1973 Feb 27,Isolation of poly(adenylic acid)-rich ribonucleic acid from mouse myeloma and synthesis of complementary deoxyribonucleic acid.,925-31,,"['Faust, C H Jr', 'Diggelmann, H', 'Mach, B']","['Faust CH Jr', 'Diggelmann H', 'Mach B']",['eng'],['Journal Article'],United States,Biochemistry,Biochemistry,0370623,IM,"['Adenine Nucleotides/*metabolism', 'Adenosine Monophosphate/metabolism', 'Animals', 'Cell Fractionation', 'Centrifugation, Density Gradient', 'Chromatography, Affinity', 'Electrophoresis, Polyacrylamide Gel', 'Leukemia, Myeloid, Acute/enzymology', 'Mice', 'Multiple Myeloma/*metabolism', 'Neoplasms, Experimental/metabolism', 'Nucleic Acid Denaturation', 'Nucleic Acid Hybridization', 'Nucleotides/isolation & purification', 'Oligonucleotides', 'Phosphorus/metabolism', 'Phosphorus Isotopes', 'Polynucleotides/*metabolism', 'Polyribosomes/metabolism', 'RNA, Neoplasm/*isolation & purification', 'RNA, Ribosomal/analysis', 'RNA-Directed DNA Polymerase', 'Templates, Genetic', 'Thymine Nucleotides', 'Ultracentrifugation']",,1973/02/27 00:00,2001/03/28 10:01,['1973/02/27 00:00'],"['1973/02/27 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1973/02/27 00:00 [entrez]']",['10.1021/bi00729a021 [doi]'],ppublish,Biochemistry. 1973 Feb 27;12(5):925-31. doi: 10.1021/bi00729a021.,"['0 (Adenine Nucleotides)', '0 (Nucleotides)', '0 (Oligonucleotides)', '0 (Phosphorus Isotopes)', '0 (Polynucleotides)', '0 (RNA, Neoplasm)', '0 (RNA, Ribosomal)', '0 (Thymine Nucleotides)', '27YLU75U4W (Phosphorus)', '415SHH325A (Adenosine Monophosphate)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,,,,,,,,,,
4119790,NLM,MEDLINE,19730405,20190501,0027-8424 (Print) 0027-8424 (Linking),70,2,1973 Feb,Crossreactive antigens on human cells infected with Rauscher leukemia virus and on human acute leukemia cells.,495-7,A water-soluble component of membranes of cells from a Burkitt's lymphoma cultured cell line was used to develop an antiserum that detects an antigen(s) on acute leukemia cells. This antiserum did not react with nonlymphoid cultured cell lines except for human embryonic kidney cells infected with the Rauscher murine leukemia virus. Absorption studies demonstrated this antigen to be crossreactive with the antigen detected on the human acute leukemia cells.,"['Mann, D L', 'Halterman, R', 'Leventhal, B G']","['Mann DL', 'Halterman R', 'Leventhal BG']",['eng'],['Journal Article'],United States,Proc Natl Acad Sci U S A,Proceedings of the National Academy of Sciences of the United States of America,7505876,IM,"['Animals', 'Antibodies, Neoplasm', 'Antigens, Neoplasm/*analysis', 'Antigens, Viral/*analysis', 'Burkitt Lymphoma/immunology', 'Carcinoma, Bronchogenic/immunology', 'Carcinoma, Hepatocellular/immunology', 'Cells, Cultured', 'Chromium Isotopes', '*Cross Reactions', 'Cytotoxicity Tests, Immunologic', 'Embryo, Mammalian', 'Epitopes', 'HeLa Cells/immunology', 'Hemadsorption', 'Humans', 'Kidney', 'Leukemia, Lymphoid/*immunology', 'Leukemia, Myeloid, Acute/*immunology', 'Liver Neoplasms', 'Mammary Neoplasms, Experimental/immunology', 'Mice', 'Osteosarcoma/immunology', 'Rabbits/immunology', 'Rauscher Virus/*immunology']",PMC433290,1973/02/01 00:00,1973/02/01 00:01,['1973/02/01 00:00'],"['1973/02/01 00:00 [pubmed]', '1973/02/01 00:01 [medline]', '1973/02/01 00:00 [entrez]']",['10.1073/pnas.70.2.495 [doi]'],ppublish,Proc Natl Acad Sci U S A. 1973 Feb;70(2):495-7. doi: 10.1073/pnas.70.2.495.,"['0 (Antibodies, Neoplasm)', '0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Chromium Isotopes)', '0 (Epitopes)']",,,,,,,,,,,
4119644,NLM,MEDLINE,19730403,20190903,0004-945X (Print) 0004-945X (Linking),50,5,1972 Oct,The colony stimulating factor (CSF).,547-57,,"['Metcalf, D']",['Metcalf D'],['eng'],"['Journal Article', 'Review']",Australia,Aust J Exp Biol Med Sci,The Australian journal of experimental biology and medical science,0416662,IM,"['Animals', 'Binding Sites, Antibody', 'Bone Marrow/*immunology', '*Bone Marrow Cells', 'Cell Differentiation/drug effects', 'Cell Division/drug effects', 'Cell Membrane/immunology', 'Centrifugation, Density Gradient', 'Clone Cells', 'Epitopes', '*Glycoproteins/antagonists & inhibitors/blood/metabolism/pharmacology/urine', 'Hematopoietic Stem Cells/drug effects/*immunology', 'Humans', 'Leukemia, Myeloid, Acute/blood/urine', 'Leukocytes', 'Macrophages/immunology/metabolism', 'Mice', 'Monocytes/immunology/metabolism', 'Stimulation, Chemical']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1038/icb.1972.48 [doi]'],ppublish,Aust J Exp Biol Med Sci. 1972 Oct;50(5):547-57. doi: 10.1038/icb.1972.48.,"['0 (Epitopes)', '0 (Glycoproteins)']",49,,,,,,,,,,
4119502,NLM,MEDLINE,19730329,20061115,0035-3019 (Print) 0035-3019 (Linking),17,7,1972 Aug-Sep,Immune complexes localized in the renal glomeruli of AKR mice: the presence of MuLV gs-I and C-type RNA tumor virus gs-3 determinants.,690-4,,"['Markham, R V', 'Sutherland, J C', 'Cimino, E F', 'Drake, W P', 'Mardiney, M R']","['Markham RV', 'Sutherland JC', 'Cimino EF', 'Drake WP', 'Mardiney MR']",['eng'],['Journal Article'],France,Rev Eur Etud Clin Biol,Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,0351323,IM,"['AKR murine leukemia virus/*immunology', 'Animals', 'Antibody Formation', '*Antigen-Antibody Complex', '*Antigens, Viral', 'Beta-Globulins/isolation & purification', '*Epitopes', 'Female', 'Fluorescent Antibody Technique', 'Immune Complex Diseases/etiology', '*Immune Tolerance', 'Immunoglobulin G/isolation & purification', 'Kidney Glomerulus/*immunology', 'Leukemia, Experimental/*immunology', 'Mice', 'Mice, Inbred AKR', 'Oncogenic Viruses/immunology', 'RNA Viruses/immunology', 'Retroviridae/immunology']",,1972/08/01 00:00,1972/08/01 00:01,['1972/08/01 00:00'],"['1972/08/01 00:00 [pubmed]', '1972/08/01 00:01 [medline]', '1972/08/01 00:00 [entrez]']",,ppublish,Rev Eur Etud Clin Biol. 1972 Aug-Sep;17(7):690-4.,"['0 (Antigen-Antibody Complex)', '0 (Antigens, Viral)', '0 (Beta-Globulins)', '0 (Epitopes)', '0 (Immunoglobulin G)']",,,,,,,,,,,
4119476,NLM,MEDLINE,19730328,20151008,0042-6423 (Print) 0042-6423 (Linking),358,3,1973,[Chronic NASDCl-negative eosinophilic leukemia with cardiac infarction].,265-71,,"['Ullmann, W', 'Heine, W D']","['Ullmann W', 'Heine WD']",['ger'],['Journal Article'],Germany,Virchows Arch A Pathol Pathol Anat,"Virchows Archiv. A, Pathology. Pathologische Anatomie",0141343,IM,"['Autopsy', 'Chronic Disease', 'Eosinophils', 'Female', 'Humans', 'Leukemia/*complications/pathology', 'Middle Aged', 'Myocardial Infarction/*complications', 'Staining and Labeling']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",,ppublish,Virchows Arch A Pathol Pathol Anat. 1973;358(3):265-71.,,,Chronische NASDCl-negative Eosinophilen-Leukamie mit Herzinfarkten.,,,,,,,,,
4119400,NLM,MEDLINE,19730323,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7797,1973 Feb 3,Down's syndrome and leukaemia.,260-1,,"['Harnden, D G', ""O'Riordan, M L""]","['Harnden DG', ""O'Riordan ML""]",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Child', 'Chromosome Aberrations', 'Down Syndrome/*complications', 'Female', 'Humans', 'Karyotyping', 'Leukemia/*complications/genetics', 'Male', 'Neoplasms/genetics']",,1973/02/03 00:00,1973/02/03 00:01,['1973/02/03 00:00'],"['1973/02/03 00:00 [pubmed]', '1973/02/03 00:01 [medline]', '1973/02/03 00:00 [entrez]']","['S0140-6736(73)90096-2 [pii]', '10.1016/s0140-6736(73)90096-2 [doi]']",ppublish,Lancet. 1973 Feb 3;1(7797):260-1. doi: 10.1016/s0140-6736(73)90096-2.,,,,,,,,,,,,
4119398,NLM,MEDLINE,19730323,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7797,1973 Feb 3,Lymphocyte populations in chronic lymphocytic leukaemia.,259-60,,"['Cohnen, G', 'Konig, E', 'Augener, W', 'Brittinger, G', 'Douglas, S D']","['Cohnen G', 'Konig E', 'Augener W', 'Brittinger G', 'Douglas SD']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Humans', 'Immune Adherence Reaction', 'Leukemia, Lymphoid/*blood', 'Leukocyte Count', 'Lymphocyte Activation', 'T-Lymphocytes/*immunology']",,1973/02/03 00:00,1973/02/03 00:01,['1973/02/03 00:00'],"['1973/02/03 00:00 [pubmed]', '1973/02/03 00:01 [medline]', '1973/02/03 00:00 [entrez]']","['S0140-6736(73)90094-9 [pii]', '10.1016/s0140-6736(73)90094-9 [doi]']",ppublish,Lancet. 1973 Feb 3;1(7797):259-60. doi: 10.1016/s0140-6736(73)90094-9.,,,,,,,,,,,,
4119363,NLM,MEDLINE,19730323,20180216,0009-3157 (Print) 0009-3157 (Linking),18,3,1973,"The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.",169-83,,"['Woodman, R J', 'Sirica, A E', 'Gang, M', 'Kline, I', 'Venditti, J M']","['Woodman RJ', 'Sirica AE', 'Gang M', 'Kline I', 'Venditti JM']",['eng'],['Journal Article'],Switzerland,Chemotherapy,Chemotherapy,0144731,IM,"['Amines/*therapeutic use', 'Animals', 'Antineoplastic Agents/*therapeutic use', 'Azacitidine/therapeutic use', 'Camptothecin/therapeutic use', 'Carmustine/therapeutic use', 'Chlorides/*therapeutic use', 'Cyclophosphamide/*therapeutic use', 'Cytarabine/therapeutic use', 'Drug Synergism', 'Emetine/therapeutic use', 'Fluorouracil/therapeutic use', 'Ketones/therapeutic use', 'Leukemia L1210/*drug therapy', 'Male', 'Methotrexate/therapeutic use', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Piperazines/*therapeutic use', 'Platinum/*therapeutic use', 'Propane/therapeutic use', 'Time Factors']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",['10.1159/000221259 [doi]'],ppublish,Chemotherapy. 1973;18(3):169-83. doi: 10.1159/000221259.,"['0 (Amines)', '0 (Antineoplastic Agents)', '0 (Chlorides)', '0 (Ketones)', '0 (Piperazines)', '04079A1RDZ (Cytarabine)', '49DFR088MY (Platinum)', '8N3DW7272P (Cyclophosphamide)', 'M801H13NRU (Azacitidine)', 'T75W9911L6 (Propane)', 'U3P01618RT (Fluorouracil)', 'U68WG3173Y (Carmustine)', 'X8D5EPO80M (Emetine)', 'XT3Z54Z28A (Camptothecin)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4119340,NLM,MEDLINE,19730321,20190720,0008-8749 (Print) 0008-8749 (Linking),6,1,1973 Jan,Hypothesis: a model for generalised autoimmunity.,1-11,,"['Bretscher, P']",['Bretscher P'],['eng'],['Journal Article'],Netherlands,Cell Immunol,Cellular immunology,1246405,IM,"['Animals', '*Antibody Formation', 'Antibody Specificity', 'Antibody-Producing Cells', 'Antigens, Neoplasm', 'Autoantibodies', '*Autoimmune Diseases', 'B-Lymphocytes/immunology', 'Binding Sites, Antibody', 'Cell Transformation, Neoplastic', 'Disease Models, Animal', 'Epitopes', 'Histocompatibility', '*Immune Tolerance', 'Immunity, Cellular', 'Leukemia Virus, Murine/immunology', 'Leukemia, Lymphoid/*immunology', 'Mice', 'Mice, Inbred NZB', 'T-Lymphocytes/immunology', 'Thymus Gland/cytology/immunology/transplantation']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']","['0008-8749(73)90001-4 [pii]', '10.1016/0008-8749(73)90001-4 [doi]']",ppublish,Cell Immunol. 1973 Jan;6(1):1-11. doi: 10.1016/0008-8749(73)90001-4.,"['0 (Antigens, Neoplasm)', '0 (Autoantibodies)', '0 (Epitopes)']",,,,,,,,,,,
4119276,NLM,MEDLINE,19730319,20190824,0004-8291 (Print) 0004-8291 (Linking),1,4,1971 Nov,The significance of monoclonal gammopathy in a normal population.,398-401,,"['Carrell, R W', 'Colls, B M', 'Murray, J T']","['Carrell RW', 'Colls BM', 'Murray JT']",['eng'],['Journal Article'],Australia,Aust N Z J Med,Australian and New Zealand journal of medicine,1264322,IM,"['Adult', 'Aged', 'Blood Protein Disorders/*epidemiology/etiology', 'Blood Protein Electrophoresis', 'Female', 'Humans', 'Immunodiffusion', 'Immunoglobulin G', 'Immunoglobulin M', 'Leukemia, Monocytic, Acute/blood', 'Lymphocytosis/blood', 'Lymphoma, Non-Hodgkin/blood', 'Male', 'Middle Aged', 'Multiple Myeloma/blood', 'New Zealand', 'Waldenstrom Macroglobulinemia/epidemiology', '*gamma-Globulins']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",['10.1111/j.1445-5994.1971.tb02551.x [doi]'],ppublish,Aust N Z J Med. 1971 Nov;1(4):398-401. doi: 10.1111/j.1445-5994.1971.tb02551.x.,"['0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (gamma-Globulins)']",,,,,,,,,,,
4119136,NLM,MEDLINE,19730313,20131121,0023-6748 (Print) 0023-6748 (Linking),12,,1972,[Complex immunomorphological study of thrombocytes in the diagnosis of thrombocytopathies and of the possibility of complex therapy].,750-3,,"['Germanov, V A', 'Kabanov, I N']","['Germanov VA', 'Kabanov IN']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Anemia/*immunology/therapy', '*Antibody Formation', 'Antigen-Antibody Complex', 'Antineoplastic Agents/therapeutic use', 'Autoantibodies', 'Blood Platelets/*immunology', 'Blood Transfusion', 'Diphenhydramine/therapeutic use', 'Glucocorticoids/therapeutic use', 'Humans', 'Isoantibodies', 'Leukemia/*immunology/therapy', 'Purpura, Thrombocytopenic/*immunology/therapy']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1972;12:750-3.,"['0 (Antigen-Antibody Complex)', '0 (Antineoplastic Agents)', '0 (Autoantibodies)', '0 (Glucocorticoids)', '0 (Isoantibodies)', '8GTS82S83M (Diphenhydramine)']",,Kompleksnoe immunomorfologicheskoe issledovanie trombotsitov v diagnostike trombotsitopatii i vozmozhnosti kompleksnoi terapii.,,,,,,,,,
4119130,NLM,MEDLINE,19730313,20071115,0023-6748 (Print) 0023-6748 (Linking),12,,1972,[Change in serum immunoglobulin fractions in chronic lympholeukosis].,733-5,,"['Masik, M G', 'Zhura, I I']","['Masik MG', 'Zhura II']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Chronic Disease', 'Female', 'Humans', 'Immunoglobulin A/*analysis', 'Immunoglobulin G/*analysis', 'Immunoglobulin M/*analysis', 'Leukemia, Lymphoid/*immunology', 'Male']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1972;12:733-5.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)']",,Izmenenie immunoglobulinovykh fraktsii krovi pri khronicheskom limfoleikoze.,,,,,,,,,
4119104,NLM,MEDLINE,19730313,20190913,0003-9012 (Print) 0003-9012 (Linking),39,4,1972,Isolation of a leukovirus from a continuous human cell line.,309-16,,"['Zhdanov, V M', 'Soloviev, V D', 'Bektemirov, T A', 'Filatov, F P', 'Bykovsky, A F']","['Zhdanov VM', 'Soloviev VD', 'Bektemirov TA', 'Filatov FP', 'Bykovsky AF']",['eng'],['Journal Article'],Austria,Arch Gesamte Virusforsch,Archiv fur die gesamte Virusforschung,7506868,IM,"['Antigens, Viral', 'Avian Sarcoma Viruses/immunology', 'Bromodeoxyuridine/pharmacology', 'Cell Line', 'Centrifugation, Density Gradient', 'Clone Cells', 'DNA, Viral/biosynthesis', 'Humans', 'Immune Sera', 'Immunodiffusion', 'Karyotyping', 'Leukemia', 'Microscopy, Electron', 'Mitomycins/pharmacology', 'Nucleic Acid Hybridization', 'RNA Viruses/*isolation & purification', 'RNA, Viral', 'RNA-Directed DNA Polymerase/metabolism', 'Rauscher Virus/immunology', 'Retroviridae/enzymology/immunology/*isolation & purification', 'Staining and Labeling', 'Tritium']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1007/BF01241009 [doi]'],ppublish,Arch Gesamte Virusforsch. 1972;39(4):309-16. doi: 10.1007/BF01241009.,"['0 (Antigens, Viral)', '0 (DNA, Viral)', '0 (Immune Sera)', '0 (Mitomycins)', '0 (RNA, Viral)', '10028-17-8 (Tritium)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'G34N38R2N1 (Bromodeoxyuridine)']",,,,,,,,,,,
4118985,NLM,MEDLINE,19730307,20041117,0485-1439 (Print) 0485-1439 (Linking),13,3,1972 Jun,[PAS positivity in erythroblasts and its clinical evaluation].,355-62,,"['Oguro, M']",['Oguro M'],['jpn'],['Journal Article'],Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['*Erythrocytes', 'Hematologic Diseases/pathology', 'Humans', 'Leukemia, Erythroblastic, Acute/pathology', 'Lymphocytes', '*Periodic Acid', '*Staining and Labeling']",,1972/06/01 00:00,1972/06/01 00:01,['1972/06/01 00:00'],"['1972/06/01 00:00 [pubmed]', '1972/06/01 00:01 [medline]', '1972/06/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1972 Jun;13(3):355-62.,['10450-60-9 (Periodic Acid)'],,,,,,,,,,,
4118956,NLM,MEDLINE,19730305,20080620,0032-3756 (Print) 0032-3756 (Linking),27,49,1972 Dec 4,[Content of proteins in the supernatant of leukocyte cell culture].,1922-5,,"['Kiersnowska, B', 'Bogdanikowa, B', 'Drozd, J', 'Bielawiec, M', 'Lukjan, H']","['Kiersnowska B', 'Bogdanikowa B', 'Drozd J', 'Bielawiec M', 'Lukjan H']",['pol'],['Journal Article'],Poland,Pol Tyg Lek,"Polski tygodnik lekarski (Warsaw, Poland : 1960)",9705468,IM,"['Alpha-Globulins/metabolism', 'Beta-Globulins/analysis', 'Cells, Cultured', 'Electrophoresis, Polyacrylamide Gel', 'Humans', 'Immunoelectrophoresis', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukocytes/*metabolism', 'Serum Globulins/*analysis', 'gamma-Globulins/metabolism']",,1972/12/04 00:00,1972/12/04 00:01,['1972/12/04 00:00'],"['1972/12/04 00:00 [pubmed]', '1972/12/04 00:01 [medline]', '1972/12/04 00:00 [entrez]']",,ppublish,Pol Tyg Lek. 1972 Dec 4;27(49):1922-5.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Serum Globulins)', '0 (gamma-Globulins)']",,Badania bialek w nadaczu hodowli krwinek bialych.,,,,,,,,,
4118952,NLM,MEDLINE,19730305,20031114,0002-3264 (Print) 0002-3264 (Linking),208,1,1973 Jan 1,[Biophysical and biochemical properties of a leukovirus passaged in monkeys].,230-2,,"['Zhdanov, V M', 'Lapin, B A', 'Bykovskii, A F', ""Al'tshtein, A D"", 'Iakovleva, L A']","['Zhdanov VM', 'Lapin BA', 'Bykovskii AF', ""Al'tshtein AD"", 'Iakovleva LA']",['rus'],['Journal Article'],Russia (Federation),Dokl Akad Nauk SSSR,Doklady Akademii nauk SSSR,7505465,IM,"['Animals', 'Antigens, Viral', 'Haplorhini', 'Leukemia, Experimental/microbiology/*veterinary', 'Macaca', 'Monkey Diseases/*microbiology', 'Papio', 'RNA-Directed DNA Polymerase', '*Retroviridae/immunology', 'Virus Diseases/*veterinary']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",,ppublish,Dokl Akad Nauk SSSR. 1973 Jan 1;208(1):230-2.,"['0 (Antigens, Viral)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,"Biofizicheskie i biokhimicheskie svoistva leikovirusa, passiruemogo na obez'ianakh.",,,,,,,,,
4118912,NLM,MEDLINE,19730305,20190619,0008-543X (Print) 0008-543X (Linking),31,1,1973 Jan,Studies on the acid mucopolysaccharide coat of viruses and transformed cells.,165-74,,"['Shigematsu, T', 'Dmochowski, L']","['Shigematsu T', 'Dmochowski L']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Ammonia', 'Animals', 'Antibody Specificity', '*Cell Line', '*Cell Transformation, Neoplastic', 'Chlorides', 'Coloring Agents', 'Cricetinae', 'Embryo, Mammalian', 'Glycosaminoglycans/*analysis', 'Goats/immunology', 'Hyaluronoglucosaminidase', 'Immune Sera', 'Leukemia Virus, Murine/analysis', 'Mammary Tumor Virus, Mouse/analysis', 'Mice', 'Oxides', 'RNA Viruses/*analysis', 'Rabbits/immunology', 'Rats', 'Retroviridae/analysis', 'Ruthenium', 'Sarcoma, Experimental/pathology', 'Sheep/enzymology', 'Species Specificity', '*Staining and Labeling']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",['10.1002/1097-0142(197301)31:1<165::aid-cncr2820310123>3.0.co;2-g [doi]'],ppublish,Cancer. 1973 Jan;31(1):165-74. doi: 10.1002/1097-0142(197301)31:1<165::aid-cncr2820310123>3.0.co;2-g.,"['0 (Chlorides)', '0 (Coloring Agents)', '0 (Glycosaminoglycans)', '0 (Immune Sera)', '0 (Oxides)', '7664-41-7 (Ammonia)', '7UI0TKC3U5 (Ruthenium)', 'EC 3.2.1.35 (Hyaluronoglucosaminidase)']",,,,,,,,,,,
4118900,NLM,MEDLINE,19730302,20071115,0036-7672 (Print) 0036-7672 (Linking),102,44,1972 Nov 4,[Nucleolar fragmentation in rapid proliferation].,1594-5,,"['Undritz, E']",['Undritz E'],['ger'],['Journal Article'],Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,IM,"['*Cell Nucleolus', '*Cell Transformation, Neoplastic', 'Chromatin/analysis', 'Chromosomes/analysis', 'Humans', 'Infectious Mononucleosis/blood', 'Leukemia, Lymphoid/blood', 'Staining and Labeling']",,1972/11/04 00:00,1972/11/04 00:01,['1972/11/04 00:00'],"['1972/11/04 00:00 [pubmed]', '1972/11/04 00:01 [medline]', '1972/11/04 00:00 [entrez]']",,ppublish,Schweiz Med Wochenschr. 1972 Nov 4;102(44):1594-5.,['0 (Chromatin)'],,Die Nukleolenzersplitterung der Zellkerne bei starker Proliferation.,,,,,,,,,
4118893,NLM,MEDLINE,19730302,20051117,0485-1439 (Print) 0485-1439 (Linking),13,4,1972 Aug,[Leukemia and malignant lymphoma].,518-26,,"['Sezaki, T']",['Sezaki T'],['jpn'],['Journal Article'],Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Autoimmune Diseases/complications', 'Humans', 'Leukemia/*immunology', 'Lymphoma/*immunology', 'Waldenstrom Macroglobulinemia/complications', 'gamma-Globulins/analysis']",,1972/08/01 00:00,1972/08/01 00:01,['1972/08/01 00:00'],"['1972/08/01 00:00 [pubmed]', '1972/08/01 00:01 [medline]', '1972/08/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1972 Aug;13(4):518-26.,['0 (gamma-Globulins)'],,,,,,,,,,,
4118886,NLM,MEDLINE,19730302,20171116,0066-4219 (Print) 0066-4219 (Linking),23,,1972,Treatment of acute lymphoblastic leukemia.,77-92,,"['Burchenal, J H', 'Dowling, M D Jr', 'Tan, C T']","['Burchenal JH', 'Dowling MD Jr', 'Tan CT']",['eng'],"['Journal Article', 'Review']",United States,Annu Rev Med,Annual review of medicine,2985151R,IM,"['Adrenal Cortex Hormones/therapeutic use', 'Adrenocorticotropic Hormone/therapeutic use', 'Animals', 'Antineoplastic Agents/administration & dosage/pharmacology', 'Asparaginase/therapeutic use', 'Central Nervous System Diseases/prevention & control', 'Child', 'Cyclophosphamide/therapeutic use', 'Cytarabine/therapeutic use', 'Cytopathogenic Effect, Viral', 'Daunorubicin/therapeutic use', 'Humans', 'Kinetics', 'Leukemia, Experimental/drug therapy', 'Leukemia, Lymphoid/*drug therapy/microbiology/mortality', 'Meninges', 'Mercaptopurine/therapeutic use', 'Methotrexate/therapeutic use', 'Mice', 'Oncogenic Viruses/pathogenicity', 'Patient Care Team', 'RNA Viruses/enzymology', 'RNA-Directed DNA Polymerase/metabolism', 'Remission, Spontaneous', 'Reverse Transcriptase Inhibitors', 'Time Factors', 'Vincristine/therapeutic use']",,1972/01/01 00:00,2001/03/28 10:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1146/annurev.me.23.020172.000453 [doi]'],ppublish,Annu Rev Med. 1972;23:77-92. doi: 10.1146/annurev.me.23.020172.000453.,"['0 (Adrenal Cortex Hormones)', '0 (Antineoplastic Agents)', '0 (Reverse Transcriptase Inhibitors)', '04079A1RDZ (Cytarabine)', '5J49Q6B70F (Vincristine)', '8N3DW7272P (Cyclophosphamide)', '9002-60-2 (Adrenocorticotropic Hormone)', 'E7WED276I5 (Mercaptopurine)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'EC 3.5.1.1 (Asparaginase)', 'YL5FZ2Y5U1 (Methotrexate)', 'ZS7284E0ZP (Daunorubicin)']",126,,,,,,,,,,
4118867,NLM,MEDLINE,19730302,20200724,0022-538X (Print) 0022-538X (Linking),10,6,1972 Dec,Ribonuclease H: a ubiquitous activity in virions of ribonucleic acid tumor viruses.,1136-42,"Ten ribonucleic acid (RNA) tumor viruses grown in five different host cell species and three non-oncogenic viruses from three different virus groups have been examined for ribonuclease H content. Three different substrates were used to assay ribonuclease H: calf thymus [(3)H]RNA-deoxyribonucleic acid (DNA) hybrid prepared with denatured calf thymus DNA and Escherichia coli DNA-directed RNA polymerase, (3)H-polydenylic acid [(3)H-poly(A)] complexed to polydeoxythymidylic acid [poly(dT)], and (3)H-polyuridylic acid [(3)H-poly(U)] complexed to polydeoxyadenylic acid [poly(dA)]. All ten RNA tumor viruses contained ribonuclease H activity which degraded the RNA of both the calf thymus hybrid and poly(A)-poly(dT), whereas only the ribonuclease H in the Moloney strain of murine sarcoma-leukemia virus and in RD-feline leukemia virus hydrolyzed the RNA strand of poly(U)-poly(dA). No appreciable ribonuclease H activity was detected in influenza, Sendai, or vesicular stomatitis virus. The ribonuclease H and RNA-directed DNA polymerase activities in Moloney murine sarcoma-leukemia virus were inseparable by phosphocellulose chromatography or glycerol gradient centrifugation, but appeared to be partially separated by diethylaminoethyl-cellulose chromatography.","['Grandgenett, D P', 'Gerard, G F', 'Green, M']","['Grandgenett DP', 'Gerard GF', 'Green M']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Cattle', 'Cell-Free System', 'Centrifugation, Density Gradient', 'Chromatography', 'Chromatography, DEAE-Cellulose', 'DNA', 'DNA-Directed RNA Polymerases/metabolism', 'Escherichia coli/enzymology', 'Gammaretrovirus/enzymology', 'Glycerol', 'Leukemia Virus, Feline/enzymology', 'Moloney murine leukemia virus/enzymology', 'Nucleic Acid Denaturation', 'Nucleic Acid Hybridization', 'Oncogenic Viruses/*enzymology', 'Polynucleotides/metabolism', 'RNA/metabolism', 'RNA Viruses/*enzymology', 'RNA-Directed DNA Polymerase/isolation & purification/metabolism', 'Ribonucleases/isolation & purification/*metabolism', 'Thymus Gland', 'Tritium']",PMC356594,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",['10.1128/JVI.10.6.1136-1142.1972 [doi]'],ppublish,J Virol. 1972 Dec;10(6):1136-42. doi: 10.1128/JVI.10.6.1136-1142.1972.,"['0 (Polynucleotides)', '10028-17-8 (Tritium)', '63231-63-0 (RNA)', '9007-49-2 (DNA)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'EC 2.7.7.6 (DNA-Directed RNA Polymerases)', 'EC 3.1.- (Ribonucleases)', 'PDC6A3C0OX (Glycerol)']",,,,,,,,,,,
4118783,NLM,MEDLINE,19730301,20131121,0323-4347 (Print) 0323-4347 (Linking),98,1,1972,[Cytochemistry of malignant erythroblastosis].,71-80,,"['Meister, H', 'Fuchs, R']","['Meister H', 'Fuchs R']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acid Phosphatase/analysis', 'Aminosalicylic Acids', 'Anemia, Pernicious/diagnosis', 'Bone Marrow/*enzymology', '*Bone Marrow Cells', 'Diagnosis, Differential', 'Esterases/analysis', 'Histocytochemistry', 'Humans', 'Iron/analysis', 'Leukemia, Erythroblastic, Acute/diagnosis/*enzymology', 'Leukemia, Myeloid, Acute/diagnosis', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;98(1):71-80.,"['0 (Aminosalicylic Acids)', 'E1UOL152H7 (Iron)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.2 (Acid Phosphatase)']",,Zytochemie der malignen Erythroblastose.,,,,,,,,,
4118764,NLM,MEDLINE,19730301,20061115,0008-5472 (Print) 0008-5472 (Linking),32,12,1972 Dec,Coating of Friend leukemia virus after treatment with specific antiserum.,2670-8,,"['Sato, T', 'Friend, C', 'Stackpole, C', 'De Harven, E']","['Sato T', 'Friend C', 'Stackpole C', 'De Harven E']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antibodies, Neoplasm/*analysis', 'Antibodies, Viral/*analysis', 'Cell Line', 'Clone Cells', 'Female', 'Ferritins', 'Friend murine leukemia virus/*immunology', 'Immune Sera', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Microscopy, Electron', 'Mosaic Viruses/immunology', 'gamma-Globulins/analysis']",,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Dec;32(12):2670-8.,"['0 (Antibodies, Neoplasm)', '0 (Antibodies, Viral)', '0 (Immune Sera)', '0 (gamma-Globulins)', '9007-73-2 (Ferritins)']",,,,,,,,,,,
4118763,NLM,MEDLINE,19730301,20211203,0008-5472 (Print) 0008-5472 (Linking),32,12,1972 Dec,Combination cancer therapy: Presidential address.,2593-607,,"['Frei, E 3rd']",['Frei E 3rd'],['eng'],"['Journal Article', 'Review']",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antibiotics, Antineoplastic/therapeutic use', 'Antineoplastic Agents/administration & dosage/*therapeutic use', 'Bleomycin/therapeutic use', 'Cell Division/drug effects', 'Cytarabine/therapeutic use', 'DNA Replication/drug effects', 'Hodgkin Disease/drug therapy/radiotherapy', 'Humans', 'Immunosuppression Therapy', 'Leukemia, Lymphoid/drug therapy', 'Mice', 'Neoplasm Metastasis', 'Neoplasms/*drug therapy', 'Neoplasms, Experimental/drug therapy', 'Prognosis', 'Remission, Spontaneous', 'Time Factors', 'Vincristine/therapeutic use']",,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Dec;32(12):2593-607.,"['0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '04079A1RDZ (Cytarabine)', '11056-06-7 (Bleomycin)', '5J49Q6B70F (Vincristine)']",28,,,,,,,,,,
4118652,NLM,MEDLINE,19730222,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7794,1973 Jan 13,Characterisation of malignant mediastinal lymphoid neoplasm (Sternberg sarcoma) as thymic in origin.,74-7,,"['Smith, J L', 'Clein, G P', 'Barker, C R', 'Collins, R D']","['Smith JL', 'Clein GP', 'Barker CR', 'Collins RD']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', 'Animals', 'Autoradiography', 'B-Lymphocytes', 'Biopsy', 'Cell Transformation, Neoplastic/diagnosis', 'Child, Preschool', 'Erythrocytes/immunology', 'Fluorescent Antibody Technique', 'Humans', 'Immune Adherence Reaction', 'Immune Sera', 'Leukemia, Lymphoid/pathology', 'Lymph Nodes/pathology', 'Lymphatic Metastasis', 'Male', 'Mediastinal Neoplasms/etiology/immunology/*pathology', 'Rabbits/immunology', 'Sarcoma/etiology/immunology/*pathology', 'Sex Factors', 'Sheep/immunology', '*T-Lymphocytes/immunology', 'Thymus Neoplasms/complications']",,1973/01/13 00:00,1973/01/13 00:01,['1973/01/13 00:00'],"['1973/01/13 00:00 [pubmed]', '1973/01/13 00:01 [medline]', '1973/01/13 00:00 [entrez]']","['S0140-6736(73)90469-8 [pii]', '10.1016/s0140-6736(73)90469-8 [doi]']",ppublish,Lancet. 1973 Jan 13;1(7794):74-7. doi: 10.1016/s0140-6736(73)90469-8.,['0 (Immune Sera)'],,,,,,,,,,,
4118643,NLM,MEDLINE,19730222,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7794,1973 Jan 13,Down's syndrome and acute leukaemia.,110,,"['Lee, S L', 'Rosner, F']","['Lee SL', 'Rosner F']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Down Syndrome/*complications', 'Humans', 'Leukemia, Lymphoid/*complications']",,1973/01/13 00:00,1973/01/13 00:01,['1973/01/13 00:00'],"['1973/01/13 00:00 [pubmed]', '1973/01/13 00:01 [medline]', '1973/01/13 00:00 [entrez]']","['S0140-6736(72)92606-2 [pii]', '10.1016/s0140-6736(73)90517-5 [doi]']",ppublish,Lancet. 1973 Jan 13;1(7794):110. doi: 10.1016/s0140-6736(73)90517-5.,,,,,,,,,,,,
4118592,NLM,MEDLINE,19730222,20051117,0028-2685 (Print) 0028-2685 (Linking),19,5,1972,Ultrastructure of avian leukosis sarcoma virus transformed avian and mammalian cells.,413-36,,"['Gazzolo, L']",['Gazzolo L'],['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['*Alpharetrovirus/immunology/pathogenicity', 'Animals', 'Antigen-Antibody Reactions', 'Antigens', 'Avian Leukosis/*pathology', 'Cell Transformation, Neoplastic/*pathology', 'Chick Embryo', 'Chickens', 'Cricetinae', 'Epitopes', 'Golgi Apparatus', 'Macrophages', 'Microscopy, Electron', 'Mitochondria', 'Pinocytosis', 'Primates', 'Rats', 'Virus Replication']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1972;19(5):413-36.,"['0 (Antigens)', '0 (Epitopes)']",,,,,,,,,,,
4118582,NLM,MEDLINE,19730222,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7793,1973 Jan 6,Down's syndrome and acute leukaemia.,53,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Down Syndrome/*complications', 'Female', 'Humans', 'Infant', 'Leukemia/*complications', 'Leukemia, Lymphoid/complications', 'Leukemia, Myeloid, Acute/complications', 'Male']",,1973/01/06 00:00,1973/01/06 00:01,['1973/01/06 00:00'],"['1973/01/06 00:00 [pubmed]', '1973/01/06 00:01 [medline]', '1973/01/06 00:00 [entrez]']",['S0140-6736(73)91999-5 [pii]'],ppublish,Lancet. 1973 Jan 6;1(7793):53.,,,,,,,,,,,,
4118535,NLM,MEDLINE,19730222,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7793,1973 Jan 6,"Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma.",10-4,,"['Arseneau, J C', 'Bagley, C M', 'Anderson, T', 'Canellos, G P']","['Arseneau JC', 'Bagley CM', 'Anderson T', 'Canellos GP']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Allopurinol/administration & dosage/therapeutic use', 'Animals', 'Ascitic Fluid/analysis', 'Blood Urea Nitrogen', 'Burkitt Lymphoma/complications/*drug therapy/mortality/pathology', 'Child', 'Cyclophosphamide/administration & dosage/adverse effects/therapeutic use', 'Death, Sudden', 'Female', 'Humans', 'Hyperkalemia/*chemically induced', 'Injections, Intravenous', 'Leukemia L1210/drug therapy', 'Male', 'Maryland', 'Mice', 'Nitrogen Mustard Compounds/therapeutic use', 'Potassium/analysis/blood', 'Retrospective Studies']",,1973/01/06 00:00,1973/01/06 00:01,['1973/01/06 00:00'],"['1973/01/06 00:00 [pubmed]', '1973/01/06 00:01 [medline]', '1973/01/06 00:00 [entrez]']","['S0140-6736(73)91223-3 [pii]', '10.1016/s0140-6736(73)91223-3 [doi]']",ppublish,Lancet. 1973 Jan 6;1(7793):10-4. doi: 10.1016/s0140-6736(73)91223-3.,"['0 (Nitrogen Mustard Compounds)', '63CZ7GJN5I (Allopurinol)', '8N3DW7272P (Cyclophosphamide)', 'RWP5GA015D (Potassium)']",,,,,,,,,,,
4118501,NLM,MEDLINE,19730221,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7795,1973 Jan 20,Ferritin in serum.,154-5,,"['Addison, G M', 'Jacobs, A', 'Walwalters, G O', 'Worwood, M']","['Addison GM', 'Jacobs A', 'Walwalters GO', 'Worwood M']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Anemia, Hypochromic/*blood', 'Ferritins/*blood', 'Hemochromatosis/*blood', 'Hodgkin Disease/blood', 'Humans', 'Iron/metabolism', 'Leukemia/blood', 'Siderosis/*blood']",,1973/01/20 00:00,1973/01/20 00:01,['1973/01/20 00:00'],"['1973/01/20 00:00 [pubmed]', '1973/01/20 00:01 [medline]', '1973/01/20 00:00 [entrez]']","['S0140-6736(73)90231-6 [pii]', '10.1016/s0140-6736(73)90231-6 [doi]']",ppublish,Lancet. 1973 Jan 20;1(7795):154-5. doi: 10.1016/s0140-6736(73)90231-6.,"['9007-73-2 (Ferritins)', 'E1UOL152H7 (Iron)']",,,,,,,,,,,
4118467,NLM,MEDLINE,19730221,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7795,1973 Jan 20,Isolation of normal T cells in chronic lymphatic leukaemia.,126-9,,"['Wybran, J', 'Chantler, S', 'Fudenberg, H H']","['Wybran J', 'Chantler S', 'Fudenberg HH']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['B-Lymphocytes/immunology', 'Fluorescent Antibody Technique', 'Humans', 'Immune Adherence Reaction', 'Immunoglobulin G', 'Lectins/pharmacology', 'Leukemia, Lymphoid/*immunology', 'Lymphocyte Activation', 'Mitogens/pharmacology', 'T-Lymphocytes/*immunology']",,1973/01/20 00:00,1973/01/20 00:01,['1973/01/20 00:00'],"['1973/01/20 00:00 [pubmed]', '1973/01/20 00:01 [medline]', '1973/01/20 00:00 [entrez]']",['10.1016/s0140-6736(73)90196-7 [doi]'],ppublish,Lancet. 1973 Jan 20;1(7795):126-9. doi: 10.1016/s0140-6736(73)90196-7.,"['0 (Immunoglobulin G)', '0 (Lectins)', '0 (Mitogens)']",,,,,,,,,,,
4118428,NLM,MEDLINE,19730221,20131121,0008-5472 (Print) 0008-5472 (Linking),33,1,1973 Jan,"Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.",159-65,,"['Heby, O', 'Russell, D H']","['Heby O', 'Russell DH']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antineoplastic Agents/*therapeutic use', 'Azacitidine/therapeutic use', 'Carboxy-Lyases/analysis', 'Cytidine/*therapeutic use', 'Depression, Chemical', 'Enzyme Repression', 'Injections, Intraperitoneal', 'Leukemia L1210/drug therapy/enzymology/*metabolism', 'Liver/analysis/metabolism', 'Male', 'Mice', 'Mice, Inbred Strains', 'Neoplasm Transplantation', 'Organ Size', 'Ornithine', 'Polyamines/analysis/*biosynthesis', 'Putrescine/analysis', 'S-Adenosylmethionine', 'Spermidine/analysis', 'Spleen/analysis/enzymology/metabolism', 'Triazines/*therapeutic use']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",,ppublish,Cancer Res. 1973 Jan;33(1):159-65.,"['0 (Antineoplastic Agents)', '0 (Polyamines)', '0 (Triazines)', '5CSZ8459RP (Cytidine)', '7LP2MPO46S (S-Adenosylmethionine)', 'E524N2IXA3 (Ornithine)', 'EC 4.1.1.- (Carboxy-Lyases)', 'M801H13NRU (Azacitidine)', 'U87FK77H25 (Spermidine)', 'V10TVZ52E4 (Putrescine)']",,,,,,,,,,,
4118405,NLM,MEDLINE,19730217,20190619,0008-543X (Print) 0008-543X (Linking),30,6,1972 Dec,New cancer chemotherapeutic agents.,1639-46,,"['Burchenal, J H', 'Carter, S K']","['Burchenal JH', 'Carter SK']",['eng'],"['Journal Article', 'Review']",United States,Cancer,Cancer,0374236,IM,"['Aldehydes/therapeutic use', 'Amides/therapeutic use', 'Amines/therapeutic use', 'Animals', 'Antineoplastic Agents/*therapeutic use', 'Asparaginase/therapeutic use', 'Azacitidine/therapeutic use', 'Azaguanine/therapeutic use', 'Bleomycin/therapeutic use', 'Carmustine/therapeutic use', 'Chlorides/therapeutic use', 'Cyclization', 'Cyclohexanes/therapeutic use', 'Cytarabine/therapeutic use', 'Cytidine/therapeutic use', 'Doxorubicin/therapeutic use', 'Glycosides/therapeutic use', 'Humans', 'Hydroxyurea/therapeutic use', 'Imidazoles/therapeutic use', 'Leukemia, Lymphoid/drug therapy', 'Leukemia, Myeloid/drug therapy', 'Mice', 'Nitrosourea Compounds/therapeutic use', 'Picolinic Acids/therapeutic use', 'Platinum/therapeutic use', 'Podophyllotoxin/therapeutic use', 'Streptozocin/therapeutic use', 'Thiosemicarbazones/therapeutic use', 'Triazenes/therapeutic use']",,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",['10.1002/1097-0142(197212)30:6<1639::aid-cncr2820300633>3.0.co;2-4 [doi]'],ppublish,Cancer. 1972 Dec;30(6):1639-46. doi: 10.1002/1097-0142(197212)30:6<1639::aid-cncr2820300633>3.0.co;2-4.,"['0 (Aldehydes)', '0 (Amides)', '0 (Amines)', '0 (Antineoplastic Agents)', '0 (Chlorides)', '0 (Cyclohexanes)', '0 (Glycosides)', '0 (Imidazoles)', '0 (Nitrosourea Compounds)', '0 (Picolinic Acids)', '0 (Thiosemicarbazones)', '0 (Triazenes)', '04079A1RDZ (Cytarabine)', '11056-06-7 (Bleomycin)', '49DFR088MY (Platinum)', '5CSZ8459RP (Cytidine)', '5W494URQ81 (Streptozocin)', '80168379AG (Doxorubicin)', 'EC 3.5.1.1 (Asparaginase)', 'L36H50F353 (Podophyllotoxin)', 'M801H13NRU (Azacitidine)', 'Q150359I72 (Azaguanine)', 'U68WG3173Y (Carmustine)', 'X6Q56QN5QC (Hydroxyurea)']",52,,,,,,,,,,
4118374,NLM,MEDLINE,19730217,20131121,0008-5472 (Print) 0008-5472 (Linking),32,9,1972 Sep,Serological detection of type C viruses found in bovine cultures.,1864-70,,"['Ferrer, J F', 'Avila, L', 'Stock, N D']","['Ferrer JF', 'Avila L', 'Stock ND']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Absorption', 'Acetone/pharmacology', 'Animals', 'Antigens, Viral/analysis', 'Cattle', 'Cattle Diseases/microbiology', 'Cell Line', 'Cells, Cultured', 'Culture Media', 'Fluoresceins', 'Fluorescent Antibody Technique', 'Goats/immunology', 'Leukemia/microbiology/veterinary', 'Lymphocytes', 'Lymphocytosis/microbiology', 'Methods', 'Microscopy, Electron', 'Oncogenic Viruses/*immunology', 'RNA Viruses/*immunology', 'Retroviridae/immunology/isolation & purification', 'Thiocyanates', 'gamma-Globulins']",,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Sep;32(9):1864-70.,"['0 (Antigens, Viral)', '0 (Culture Media)', '0 (Fluoresceins)', '0 (Thiocyanates)', '0 (gamma-Globulins)', '1364PS73AF (Acetone)']",,,,,,,,,,,
4118178,NLM,MEDLINE,19730208,20180216,0001-5792 (Print) 0001-5792 (Linking),48,5,1972,Ammoniacal silver staining of Reed-Sternberg cell in Hodgkin's disease.,288-91,,"['Kass, L', 'Schnitzer, B']","['Kass L', 'Schnitzer B']",['eng'],['Journal Article'],Switzerland,Acta Haematol,Acta haematologica,0141053,IM,"['Hodgkin Disease/*pathology', 'Humans', 'Leukemia, Lymphoid/pathology', 'Lymph Nodes/*cytology', 'Lymphoma, Large B-Cell, Diffuse/pathology', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1159/000208472 [doi]'],ppublish,Acta Haematol. 1972;48(5):288-91. doi: 10.1159/000208472.,,,,,,,,,,,,
4118165,NLM,MEDLINE,19730208,20041117,0022-2577 (Print) 0022-2577 (Linking),47,12,1972 Dec,Death and dying: a course for medical students.,945-51,,"['Barton, D', 'Flexner, J M', 'Van Eys, J', 'Scott, C E']","['Barton D', 'Flexner JM', 'Van Eys J', 'Scott CE']",['eng'],['Journal Article'],United States,J Med Educ,Journal of medical education,0375377,IM,"['Adaptation, Psychological', 'Adult', 'Attitude of Health Personnel', 'Attitude to Health', 'Child, Preschool', '*Curriculum', '*Death', '*Education, Medical, Undergraduate', 'Ethics, Medical', 'Female', 'Grief', 'Group Processes', 'Hodgkin Disease', 'Humans', 'Leukemia', 'Male', 'Middle Aged', 'Nursing Staff, Hospital', 'Palliative Care', 'Pastoral Care', 'Professional-Patient Relations', 'Psychodrama', 'Tennessee', '*Terminal Care']",,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",,ppublish,J Med Educ. 1972 Dec;47(12):945-51.,,,,,,,,,,,,
4118163,NLM,MEDLINE,19730208,20160823,0302-7430 (Print) 0302-7430 (Linking),55,4,1972 Jul-Aug,[Diffuse pneumopathy during chemotherapy with busulfan and bleomycin].,425-33,,"['Jeanmart, L', 'Klastersky, J', 'Verhest, A', 'Debusscher, L', 'Potvliege, P', 'Tagnon, H', 'Tombroff, M']","['Jeanmart L', 'Klastersky J', 'Verhest A', 'Debusscher L', 'Potvliege P', 'Tagnon H', 'Tombroff M']",['fre'],['Journal Article'],Belgium,J Belge Radiol,Journal belge de radiologie,0420407,IM,"['Aged', 'Antibiotics, Antineoplastic/*adverse effects', 'Bleomycin/adverse effects', 'Busulfan/*adverse effects', 'Carcinoma, Squamous Cell/drug therapy', 'Female', 'Humans', 'Leukemia, Myeloid/drug therapy', 'Male', 'Middle Aged', 'Pulmonary Fibrosis/*chemically induced', 'Tonsillar Neoplasms/drug therapy']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,J Belge Radiol. 1972 Jul-Aug;55(4):425-33.,"['0 (Antibiotics, Antineoplastic)', '11056-06-7 (Bleomycin)', 'G1LN9045DK (Busulfan)']",,Les pneumopathies diffuses au cours de la chimiotherapie par le busulfan et la bleomycine.,,,,,,,,,
4118134,NLM,MEDLINE,19730207,20191030,0065-230X (Print) 0065-230X (Linking),16,,1972,The expression of normal histocompatibility antigens in tumor cells.,235-71,,"['Lengerova, A']",['Lengerova A'],['eng'],"['Journal Article', 'Review']",United States,Adv Cancer Res,Advances in cancer research,0370416,IM,"['Animals', 'Antigens, Neoplasm/*analysis', 'Antigens, Viral', 'Cell Differentiation', 'Cell Membrane/*immunology', 'Cell Transformation, Neoplastic', 'Cells, Cultured', 'Crossing Over, Genetic', 'Epitopes', 'Friend murine leukemia virus/immunology', 'Genetic Linkage', 'Genetic Variation', 'Heterozygote', 'Histocompatibility Antigens/*analysis', 'Humans', 'Hybrid Cells/immunology', 'Lymphoma/immunology', 'Mice', 'Mitosis', 'Moloney murine leukemia virus/immunology', 'Mutation', 'Neoplasm Transplantation', 'Neoplasms/*immunology', 'Phenotype', 'Transplantation Immunology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']","['S0065-230X(08)60342-5 [pii]', '10.1016/s0065-230x(08)60342-5 [doi]']",ppublish,Adv Cancer Res. 1972;16:235-71. doi: 10.1016/s0065-230x(08)60342-5.,"['0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Histocompatibility Antigens)']",156,,,,,,,,,,
4118122,NLM,MEDLINE,19730205,20170214,0022-1554 (Print) 0022-1554 (Linking),20,10,1972 Oct,Demonstration of histones in proerythroblasts in pernicious anemia and the Di Guglielmo syndrome.,817-20,,"['Kass, L']",['Kass L'],['eng'],['Journal Article'],United States,J Histochem Cytochem,The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,9815334,IM,"['Anemia, Pernicious/*pathology', 'Arginine/analysis', 'Bone Marrow/analysis', 'Bone Marrow Cells', 'Histocytochemistry', 'Histones/*analysis', 'Humans', 'Leukemia, Erythroblastic, Acute/*pathology', 'Lysine/analysis', 'Staining and Labeling']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1177/20.10.817 [doi]'],ppublish,J Histochem Cytochem. 1972 Oct;20(10):817-20. doi: 10.1177/20.10.817.,"['0 (Histones)', '94ZLA3W45F (Arginine)', 'K3Z4F929H6 (Lysine)']",,,,,,,,,,,
4118108,NLM,MEDLINE,19730205,20210216,0006-4971 (Print) 0006-4971 (Linking),41,1,1973 Jan,Sideroblastic anemia in multiple myeloma: a preleukemic change.,17-25,,"['Khaleeli, M', 'Keane, W M', 'Lee, G R']","['Khaleeli M', 'Keane WM', 'Lee GR']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['Anemia, Sideroblastic/*chemically induced', 'Bone Marrow Examination', 'Cytarabine/therapeutic use', 'Female', 'Humans', 'Immunodiffusion', 'Immunoelectrophoresis', 'Immunoglobulins/analysis', 'Iron/blood', 'Leukemia, Monocytic, Acute/complications', 'Leukemia, Myeloid, Acute/complications/drug therapy', 'Male', 'Melphalan/therapeutic use', 'Mercaptopurine/therapeutic use', 'Middle Aged', 'Multiple Myeloma/*complications/drug therapy', 'Muramidase/blood', '*Precancerous Conditions', 'Prednisone/therapeutic use', 'Staining and Labeling', 'Vincristine/therapeutic use']",,1973/01/01 00:00,1973/01/01 00:01,['1973/01/01 00:00'],"['1973/01/01 00:00 [pubmed]', '1973/01/01 00:01 [medline]', '1973/01/01 00:00 [entrez]']",['S0006-4971(20)69284-9 [pii]'],ppublish,Blood. 1973 Jan;41(1):17-25.,"['0 (Immunoglobulins)', '04079A1RDZ (Cytarabine)', '5J49Q6B70F (Vincristine)', 'E1UOL152H7 (Iron)', 'E7WED276I5 (Mercaptopurine)', 'EC 3.2.1.17 (Muramidase)', 'Q41OR9510P (Melphalan)', 'VB0R961HZT (Prednisone)']",,,,,,,,,,,
4117983,NLM,MEDLINE,19730130,20210526,0019-9567 (Print) 0019-9567 (Linking),5,4,1972 Apr,Alkaline and acid phosphatase in murine leukemia.,461-6,"Alterations for acid and alkaline phosphatase levels and their pattern of splenic and lymph node activity in normal and virus-induced lymphoblastic leukemia were studied. Enzyme levels were examined by using both cytochemical and biochemical procedures. The GC leukemia virus, a ribonucleic acid murine virus antigenically related to the Rauscher-Moloney viruses, was used to stimulate acid and alkaline phosphatase by producing lymphomaceous disease in Ha/ICR mice. With the Burstone and Gomori cytochemical procedures, both enzymes were found in higher than normal levels in lymphomaceous spleen and lymph nodes. Confirmation of the cytochemical studies was obtained by enzyme assay of cell-free homogenates in each case with the exception of spleen acid phosphatase. The discrepancy between the cytochemical tests which showed significant elevation of spleen acid phosphatase and the enzyme assays which failed to reveal such elevation could be due to a labile acid phosphatase isozyme which is lost on cellular disruption during homogenate preparation. A significant spleen alkaline phosphatase specific activity elevation above normal was found with a 50% incidence only when leukemic spleen wet weight increased nearly threefold its normal value. This result suggests that alkaline phosphatase elevation is a secondary event occuring after the onset of disease and is not a fundamental metabolic alteration concerned with the onset of murine lymphoblastic leukemia.","['Wilson, D A', 'Sharma, N N', 'Brown, E R']","['Wilson DA', 'Sharma NN', 'Brown ER']",['eng'],['Journal Article'],United States,Infect Immun,Infection and immunity,0246127,IM,"['Acid Phosphatase/*analysis', 'Alkaline Phosphatase/*analysis', 'Animals', 'Cell-Free System', 'Female', 'Histocytochemistry', 'Leukemia Virus, Murine', 'Leukemia, Experimental/*enzymology/pathology', 'Leukemia, Lymphoid/*enzymology/pathology', 'Lymph Nodes/cytology/enzymology/pathology', 'Male', 'Mice', 'Mice, Inbred ICR', 'Organ Size', 'Spleen/cytology/enzymology/pathology', 'Staining and Labeling', 'Tissue Extracts/analysis']",PMC422393,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",['10.1128/iai.5.4.461-466.1972 [doi]'],ppublish,Infect Immun. 1972 Apr;5(4):461-6. doi: 10.1128/iai.5.4.461-466.1972.,"['0 (Tissue Extracts)', 'EC 3.1.3.1 (Alkaline Phosphatase)', 'EC 3.1.3.2 (Acid Phosphatase)']",,,,,,,,,,,
4117966,NLM,MEDLINE,19730130,20200724,0022-538X (Print) 0022-538X (Linking),10,5,1972 Nov,Serological analysis of the deoxyribonucleic acid polymerase of avian oncornaviruses. II. Comparison of avian deoxyribonucleic acid polymerases.,959-64,"Monospecific antiserum prepared against the isolated deoxyribonucleic acid (DNA) polymerase of avian myeloblastosis virus (AMV) neutralized the endogenous ribonucleic acid-instructed DNA polymerase activity of detergent-disrupted virus. The viral polymerase was serologically unrelated to the seven major structural polypeptides of AMV. Furthermore, the viral enzyme was distinguished from normal cellular DNA polymerases by serological criteria; thus, antiserum against the viral enzyme neutralized its homologous antigen but not normal cellular DNA polymerases. Neutralization by antibody of viral DNA polymerase activity was observed with all avian leukemia-sarcoma viruses tested, irrespective of viral antigenic subtype. The DNA polymerase activity of avian reticuloendotheliosis virus, and of a variety of mammalian oncornaviruses, was not neutralized by antisera against the AMV polymerase. Immunological analysis of the RSValpha(O) mutant, which is deficient in DNA polymerase activity, shows this mutant to lack demonstrable polymerase antigen. Viral polymerase was identified by immunofluorescence as a cytoplasmic constituent in virus-producing chicken cells; polymerase antigen was not detected in uninfected (gs(-)) chicken cells.","['Nowinski, R C', 'Watson, K F', 'Yaniv, A', 'Spiegelman, S']","['Nowinski RC', 'Watson KF', 'Yaniv A', 'Spiegelman S']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Alpharetrovirus/enzymology/*immunology', 'Animals', '*Antigens, Viral/isolation & purification', 'Cell-Free System', 'Cells, Cultured', 'Chick Embryo', 'Chickens', 'Fibroblasts', 'Fluorescent Antibody Technique', 'Immune Sera', 'Immunoglobulin G', 'Neutralization Tests', 'Oncogenic Viruses/enzymology/immunology', 'RNA Viruses/enzymology/immunology', '*RNA-Directed DNA Polymerase/isolation & purification/metabolism', 'Rats/immunology', 'Viral Proteins']",PMC356565,1972/11/01 00:00,1972/11/01 00:01,['1972/11/01 00:00'],"['1972/11/01 00:00 [pubmed]', '1972/11/01 00:01 [medline]', '1972/11/01 00:00 [entrez]']",['10.1128/JVI.10.5.959-964.1972 [doi]'],ppublish,J Virol. 1972 Nov;10(5):959-64. doi: 10.1128/JVI.10.5.959-964.1972.,"['0 (Antigens, Viral)', '0 (Immune Sera)', '0 (Immunoglobulin G)', '0 (Viral Proteins)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,,,,,,,,,,
4117964,NLM,MEDLINE,19730130,20200724,0022-538X (Print) 0022-538X (Linking),10,5,1972 Nov,Activation of guinea pig herpesvirus antigen in leukemic lymphoblasts of guinea pig.,933-6,"Herpesvirus (GPHV) antigen is either present in very small amounts, or absent in leukemic lymphoblasts taken directly from strain 2 guinea pigs. However, after maintenance in tissue culture for 72 hr, almost 100% of these lymphoblasts contained GPHV antigen. The expression of GPHV antigen could be demonstrated by indirect immunofluorescent technique as well as by the direct (125)I labeled antibody technique. However, infectious virus or virus capsids could not be detected in these cells either by infectivity tests or electron microscopy.","['Nayak, D P']",['Nayak DP'],['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', '*Antigens, Viral/isolation & purification', 'Cells, Cultured', 'Culture Media', 'Fluorescent Antibody Technique', 'Guinea Pigs', 'Herpesviridae/*immunology/isolation & purification/pathogenicity', 'Immune Sera', 'Iodine Isotopes', 'Leukemia, Experimental/*immunology', 'Lymphocytes/*immunology', 'Microscopy, Electron', 'Rabbits/immunology', 'gamma-Globulins']",PMC356561,1972/11/01 00:00,1972/11/01 00:01,['1972/11/01 00:00'],"['1972/11/01 00:00 [pubmed]', '1972/11/01 00:01 [medline]', '1972/11/01 00:00 [entrez]']",['10.1128/JVI.10.5.933-936.1972 [doi]'],ppublish,J Virol. 1972 Nov;10(5):933-6. doi: 10.1128/JVI.10.5.933-936.1972.,"['0 (Antigens, Viral)', '0 (Culture Media)', '0 (Immune Sera)', '0 (Iodine Isotopes)', '0 (gamma-Globulins)']",,,,,,,,,,,
4117903,NLM,MEDLINE,19730130,20180216,0001-5792 (Print) 0001-5792 (Linking),48,4,1972,Influence of cell density on the acridine orange binding to deoxyribonucleoprotein complex in leucocytes from patients with infectious mononucleosis and acute leukaemia.,227-33,,"['Bolund, L', 'De Bault, L E', 'Foley, G E', 'Gahrton, G', 'Killander, D', 'Moloney, W C', 'Rigler, R', 'Skarin, A', 'Wahren, B']","['Bolund L', 'De Bault LE', 'Foley GE', 'Gahrton G', 'Killander D', 'Moloney WC', 'Rigler R', 'Skarin A', 'Wahren B']",['eng'],['Journal Article'],Switzerland,Acta Haematol,Acta haematologica,0141053,IM,"['Acridines/*metabolism', 'Acute Disease', 'Cell Adhesion', 'Cells, Cultured', 'Fluorometry', 'Humans', 'Infectious Mononucleosis/*blood', 'Leukemia/*blood', 'Leukocytes/*metabolism', 'Lymphocytes/metabolism', 'Nucleoproteins/blood/*metabolism', '*Protein Binding', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1159/000208463 [doi]'],ppublish,Acta Haematol. 1972;48(4):227-33. doi: 10.1159/000208463.,"['0 (Acridines)', '0 (Nucleoproteins)']",,,,,,,,,,,
4117891,NLM,MEDLINE,19730130,20190908,0090-0028 (Print) 0090-0028 (Linking),240,98,1972 Nov 15,Human leukaemic cells contain reverse transcriptase associated with a high molecular weight virus-related RNA.,72-5,,"['Baxt, W', 'Hehlmann, R', 'Spiegelman, S']","['Baxt W', 'Hehlmann R', 'Spiegelman S']",['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['Centrifugation, Density Gradient', 'DNA, Neoplasm/biosynthesis', 'DNA, Viral/analysis/biosynthesis', 'Humans', 'Leukemia/*enzymology', 'Leukemia, Lymphoid/enzymology', 'Leukemia, Myeloid/enzymology', 'Leukemia, Myeloid, Acute/enzymology', 'Leukocytes/enzymology', 'Lymphoma, Non-Hodgkin/enzymology', 'Mammary Tumor Virus, Mouse', 'Nucleic Acid Hybridization', 'RNA, Viral/*isolation & purification/metabolism', 'RNA-Directed DNA Polymerase/*isolation & purification/metabolism', 'Rauscher Virus', 'Templates, Genetic', 'Tritium']",,1972/11/15 00:00,1972/11/15 00:01,['1972/11/15 00:00'],"['1972/11/15 00:00 [pubmed]', '1972/11/15 00:01 [medline]', '1972/11/15 00:00 [entrez]']",['10.1038/newbio240072a0 [doi]'],ppublish,Nat New Biol. 1972 Nov 15;240(98):72-5. doi: 10.1038/newbio240072a0.,"['0 (DNA, Neoplasm)', '0 (DNA, Viral)', '0 (RNA, Viral)', '10028-17-8 (Tritium)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,,,,,,,,,,
4117890,NLM,MEDLINE,19730130,20190908,0090-0028 (Print) 0090-0028 (Linking),240,98,1972 Nov 15,"Reverse transcriptase activity of human acute leukaemic cells: purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product.",67-72,,"['Sarngadharan, M G', 'Sarin, P S', 'Reitz, M S', 'Gallo, R C']","['Sarngadharan MG', 'Sarin PS', 'Reitz MS', 'Gallo RC']",['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['Adenosine Triphosphate/metabolism', '*Avian Leukosis Virus', 'Centrifugation, Density Gradient', 'Chromatography', 'Chromatography, DEAE-Cellulose', 'Chromatography, Gel', 'Cytosine Nucleotides/metabolism', 'DNA, Neoplasm/isolation & purification', 'DNA, Viral/analysis/*isolation & purification', 'Guanosine Triphosphate/metabolism', 'Humans', 'Leukemia, Lymphoid/*enzymology', 'Nucleic Acid Hybridization', 'Oligonucleotides/metabolism', 'Polynucleotides/metabolism', 'RNA, Viral/*metabolism', 'RNA-Directed DNA Polymerase/*isolation & purification/metabolism', 'Ribonucleases/metabolism', 'Templates, Genetic', 'Thymine Nucleotides/metabolism', 'Tritium']",,1972/11/15 00:00,1972/11/15 00:01,['1972/11/15 00:00'],"['1972/11/15 00:00 [pubmed]', '1972/11/15 00:01 [medline]', '1972/11/15 00:00 [entrez]']",['10.1038/newbio240067a0 [doi]'],ppublish,Nat New Biol. 1972 Nov 15;240(98):67-72. doi: 10.1038/newbio240067a0.,"['0 (Cytosine Nucleotides)', '0 (DNA, Neoplasm)', '0 (DNA, Viral)', '0 (Oligonucleotides)', '0 (Polynucleotides)', '0 (RNA, Viral)', '0 (Thymine Nucleotides)', '10028-17-8 (Tritium)', '86-01-1 (Guanosine Triphosphate)', '8L70Q75FXE (Adenosine Triphosphate)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'EC 3.1.- (Ribonucleases)']",,,,,,,,,,,
4117858,NLM,MEDLINE,19730130,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7790,1972 Dec 16,Down's syndrome and leukaemia.,1322,,"['Evans, D I', 'Steward, J K']","['Evans DI', 'Steward JK']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', 'Child', 'Child, Preschool', 'Down Syndrome/*complications', 'Humans', 'Leukemia/*etiology']",,1972/12/16 00:00,1972/12/16 00:01,['1972/12/16 00:00'],"['1972/12/16 00:00 [pubmed]', '1972/12/16 00:01 [medline]', '1972/12/16 00:00 [entrez]']",['10.1016/s0140-6736(72)92704-3 [doi]'],ppublish,Lancet. 1972 Dec 16;2(7790):1322. doi: 10.1016/s0140-6736(72)92704-3.,,,,,,,,,,,,
4117851,NLM,MEDLINE,19730130,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7790,1972 Dec 16,Lymphocyte cytochemistry.,1319,,"['Grozdea, J', 'Corberand, J']","['Grozdea J', 'Corberand J']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adenosine Triphosphatases/metabolism', 'Alkaline Phosphatase/metabolism', 'Chronic Disease', 'Hematologic Diseases/blood', 'Histocytochemistry', 'Humans', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/enzymology', 'Lymphocytes/*enzymology']",,1972/12/16 00:00,1972/12/16 00:01,['1972/12/16 00:00'],"['1972/12/16 00:00 [pubmed]', '1972/12/16 00:01 [medline]', '1972/12/16 00:00 [entrez]']","['S0140-6736(72)92697-9 [pii]', '10.1016/s0140-6736(72)92697-9 [doi]']",ppublish,Lancet. 1972 Dec 16;2(7790):1319. doi: 10.1016/s0140-6736(72)92697-9.,"['0 (Immunoglobulins)', 'EC 3.1.3.1 (Alkaline Phosphatase)', 'EC 3.6.1.- (Adenosine Triphosphatases)']",,,,,,,,,,,
4117850,NLM,MEDLINE,19730130,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7790,1972 Dec 16,Stimulation of D.N.A. synthesis in lymphocytes by chlorambucil.,1318-9,,"['Hill, B T']",['Hill BT'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Chlorambucil/*pharmacology/therapeutic use', 'DNA/*biosynthesis', 'Humans', 'Leukemia/blood', 'Leukemia, Lymphoid/blood/drug therapy', 'Lymphocytes/drug effects/*metabolism']",,1972/12/16 00:00,1972/12/16 00:01,['1972/12/16 00:00'],"['1972/12/16 00:00 [pubmed]', '1972/12/16 00:01 [medline]', '1972/12/16 00:00 [entrez]']","['S0140-6736(72)92696-7 [pii]', '10.1016/s0140-6736(72)92696-7 [doi]']",ppublish,Lancet. 1972 Dec 16;2(7790):1318-9. doi: 10.1016/s0140-6736(72)92696-7.,"['18D0SL7309 (Chlorambucil)', '9007-49-2 (DNA)']",,,,,,,,,,,
4117775,NLM,MEDLINE,19730129,20071115,0042-8809 (Print) 0042-8809 (Linking),18,5,1972 Sep-Oct,[Preparation and use of hybrid antibodies in electron microscopic immunocytochemistry].,461-7,,"['Dorfman, N A']",['Dorfman NA'],['rus'],['Journal Article'],Russia (Federation),Vopr Med Khim,Voprosy meditsinskoi khimii,0416601,IM,"['Animals', '*Antibodies, Heterophile', '*Antigen-Antibody Reactions', 'Antigens, Neoplasm/analysis', 'Chromatography, Gel', '*Ferritins', 'Immunoglobulin Fab Fragments', 'Leukemia, Experimental/immunology', 'Leukemia, Lymphoid/immunology', 'Mercaptoethanol', 'Methods', 'Mice', 'Microscopy, Electron', 'Rauscher Virus', 'gamma-Globulins']",,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,Vopr Med Khim. 1972 Sep-Oct;18(5):461-7.,"['0 (Antibodies, Heterophile)', '0 (Antigens, Neoplasm)', '0 (Immunoglobulin Fab Fragments)', '0 (gamma-Globulins)', '60-24-2 (Mercaptoethanol)', '9007-73-2 (Ferritins)']",,Poluchenie i primenenie gibridnykh antitel v elektronnomikroskopichekoi immunotsitokhimii.,,,,,,,,,
4117741,NLM,MEDLINE,19730129,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7789,1972 Dec 9,Apoptosis.,1252,,"['Warner, T F']",['Warner TF'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Binding Sites', 'DNA/*therapeutic use', 'Daunorubicin/*therapeutic use', 'Humans', 'Leukemia/*drug therapy', 'Lymphoma/*drug therapy']",,1972/12/09 00:00,1972/12/09 00:01,['1972/12/09 00:00'],"['1972/12/09 00:00 [pubmed]', '1972/12/09 00:01 [medline]', '1972/12/09 00:00 [entrez]']","['S0140-6736(72)92305-7 [pii]', '10.1016/s0140-6736(72)92305-7 [doi]']",ppublish,Lancet. 1972 Dec 9;2(7789):1252. doi: 10.1016/s0140-6736(72)92305-7.,"['9007-49-2 (DNA)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4117713,NLM,MEDLINE,19730129,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7789,1972 Dec 9,Philadelphia-chromosome-positive preleukaemic state.,1227-8,,"['Canellos, G P', 'Whang-Peng, J']","['Canellos GP', 'Whang-Peng J']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Blood Cell Count', 'Bone Marrow Cells', 'Bone Marrow Examination', '*Chromosome Aberrations', 'Cytarabine/therapeutic use', '*Cytogenetics', 'Daunorubicin/therapeutic use', 'Humans', 'Hydroxyurea/therapeutic use', 'Leukemia, Myeloid, Acute/diagnosis/drug therapy/*genetics', 'Male', 'Prednisone/therapeutic use', 'Thioguanine/therapeutic use', 'Vincristine/therapeutic use']",,1972/12/09 00:00,1972/12/09 00:01,['1972/12/09 00:00'],"['1972/12/09 00:00 [pubmed]', '1972/12/09 00:01 [medline]', '1972/12/09 00:00 [entrez]']","['S0140-6736(72)92274-X [pii]', '10.1016/s0140-6736(72)92274-x [doi]']",ppublish,Lancet. 1972 Dec 9;2(7789):1227-8. doi: 10.1016/s0140-6736(72)92274-x.,"['04079A1RDZ (Cytarabine)', '5J49Q6B70F (Vincristine)', 'FTK8U1GZNX (Thioguanine)', 'VB0R961HZT (Prednisone)', 'X6Q56QN5QC (Hydroxyurea)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4117678,NLM,MEDLINE,19730118,20191030,0079-6034 (Print) 0079-6034 (Linking),16,,1972,Antigens of the thymus.,214-99,,"['Schlesinger, M']",['Schlesinger M'],['eng'],"['Journal Article', 'Review']",Switzerland,Prog Allergy,Progress in allergy,0376440,IM,"['Animals', 'Antigen-Antibody Complex', '*Antigens', 'Antilymphocyte Serum', 'Autoimmune Diseases/immunology', 'B-Lymphocytes/immunology', 'Binding Sites, Antibody', 'Chickens', 'Complement System Proteins', 'Epitopes', 'Histocompatibility Antigens', 'Hormones', 'Humans', 'Leukemia/immunology', 'Lymphocytes/immunology', 'Mice', 'Myasthenia Gravis/immunology', 'Rats', 'Species Specificity', 'T-Lymphocytes/immunology', 'Thymus Gland/*immunology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1159/000313173 [doi]'],ppublish,Prog Allergy. 1972;16:214-99. doi: 10.1159/000313173.,"['0 (Antigen-Antibody Complex)', '0 (Antigens)', '0 (Antilymphocyte Serum)', '0 (Epitopes)', '0 (Histocompatibility Antigens)', '0 (Hormones)', '9007-36-7 (Complement System Proteins)']",0,,,,,,,,,,
4117662,NLM,MEDLINE,19730118,20181113,0002-9440 (Print) 0002-9440 (Linking),69,3,1972 Dec,"Ultrastructural cytochemical demonstration of tartrate-resistant acid phosphatase isoenzyme activity in ""hairy cells"" of leukemic reticuloendotheliosis.",471-82,"The pathognomonic ""hairy cell"" of leukemic reticuloendotheliosis was studied for ultrastructural localization of tartrate-resistant acid phosphatase activity. The enzyme activity could not be demonstrated by Gomori's method, but it was readily demonstrated in the cytoplasmic vesicles and Golgi saccules of the hairy cell by substitution of naphthol AS-BI phosphoric acid for Na-beta-glycerophosphate of Gomori's medium. This apparent substrate specificity may be used as a marker for electron microscopic identification of the hairy cell, and may facilitate the study of histogenesis of leukemic reticuloendotheliosis.","['Katayama, I', 'Li, C Y', 'Yam, L T']","['Katayama I', 'Li CY', 'Yam LT']",['eng'],['Journal Article'],United States,Am J Pathol,The American journal of pathology,0370502,IM,"['Acid Phosphatase/*metabolism', 'Cytoplasm/enzymology', 'Glycerophosphates', 'Histocytochemistry', 'Humans', 'Isoenzymes/*metabolism', 'Leukemia/*enzymology', 'Lymphatic Diseases/*enzymology', 'Methods', 'Naphthols', 'Phosphoric Acids', 'Staining and Labeling']",PMC2032805,1972/12/01 00:00,1972/12/01 00:01,['1972/12/01 00:00'],"['1972/12/01 00:00 [pubmed]', '1972/12/01 00:01 [medline]', '1972/12/01 00:00 [entrez]']",,ppublish,Am J Pathol. 1972 Dec;69(3):471-82.,"['0 (Glycerophosphates)', '0 (Isoenzymes)', '0 (Naphthols)', '0 (Phosphoric Acids)', 'EC 3.1.3.2 (Acid Phosphatase)']",,,,,,,,,,,
4117604,NLM,MEDLINE,19730118,20150616,0140-6736 (Print) 0140-6736 (Linking),2,7788,1972 Dec 2,Down's syndrome and acute leukaemia.,1187,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Age Factors', 'Child', 'Child, Preschool', 'Diagnosis, Differential', 'Down Syndrome/*complications', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*complications/diagnosis', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukemoid Reaction/blood/diagnosis', 'Syndrome']",,1972/12/02 00:00,1972/12/02 00:01,['1972/12/02 00:00'],"['1972/12/02 00:00 [pubmed]', '1972/12/02 00:01 [medline]', '1972/12/02 00:00 [entrez]']",['S0140-6736(72)92606-2 [pii]'],ppublish,Lancet. 1972 Dec 2;2(7788):1187.,,,,,,,,,,,,
4117567,NLM,MEDLINE,19730116,20161109,0507-4088 (Print) 0507-4088 (Linking),17,5,1972 Sep-Oct,[Leukemia-like virus isolated from a patient with hemocytoblastosis in a Syrian hamster experimental system. II. Use of the system to study the antigenic specificity of the virus and the transformed cells].,533-7,,"['Andzhaparidze, O G', 'Liozner, A L', 'Stepanova, L G', 'Shukhmina, N R']","['Andzhaparidze OG', 'Liozner AL', 'Stepanova LG', 'Shukhmina NR']",['rus'],['Journal Article'],Russia (Federation),Vopr Virusol,Voprosy virusologii,0417337,IM,"['Animals', '*Antigens, Viral', 'Cell Line', '*Cell Transformation, Neoplastic', 'Cricetinae', 'Cross Reactions', '*Epitopes', 'Humans', 'Neoplasm Transplantation', 'Retroviridae/*immunology', 'Transplantation Immunology']",,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,Vopr Virusol. 1972 Sep-Oct;17(5):533-7.,"['0 (Antigens, Viral)', '0 (Epitopes)']",,"Leikozopodobnyi virus, vydelennyi ot bol'nogo gemotsitoblastozom, v eksperimental'noi sisteme na siriiskikh khomiachkakh. II. Ispol'zovanie sistemy dlia izucheniia antigennoi spetsifichnosti virusa i transformirovannykh kletok.",,,,,,,,,
4117352,NLM,MEDLINE,19730109,20200724,0022-538X (Print) 0022-538X (Linking),10,4,1972 Oct,Reversible inactivation of the deoxyribonucleic acid polymerase of Rauscher leukemia virus.,885-8,"Rauscher leukemia virus deoxyribonucleic acid polymerase is reversibly inactivated by 6 m guanidine-hydrochloride. Gel filtration in 6 m guanidine-hydrochloride reveals that the viral deoxyribonucleic acid polymerase consists of a single polypeptide chain of approximately 70,000 molecular weight.","['Tronick, S R', 'Scolnick, E M', 'Parks, W P']","['Tronick SR', 'Scolnick EM', 'Parks WP']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Avian Sarcoma Viruses/enzymology', 'Chromatography, Gel', 'Dialysis', 'Dithiothreitol', 'Enzyme Repression', 'Guanidines/*pharmacology', 'Leukemia Virus, Feline/enzymology', 'Molecular Weight', 'Potassium Chloride', 'RNA-Directed DNA Polymerase/analysis/isolation & purification/*metabolism', 'Rauscher Virus/*enzymology', 'Serum Albumin, Bovine', 'Surface-Active Agents']",PMC356550,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1128/JVI.10.4.885-888.1972 [doi]'],ppublish,J Virol. 1972 Oct;10(4):885-8. doi: 10.1128/JVI.10.4.885-888.1972.,"['0 (Guanidines)', '0 (Surface-Active Agents)', '27432CM55Q (Serum Albumin, Bovine)', '660YQ98I10 (Potassium Chloride)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'T8ID5YZU6Y (Dithiothreitol)']",,,,,,,,,,,
4117346,NLM,MEDLINE,19730109,20200724,0022-538X (Print) 0022-538X (Linking),10,4,1972 Oct,Major group-specific protein of rat type C viruses.,746-50,"The major internal protein of a rat type C virus pseudotype of murine sarcoma virus, MSV(RaLV), was purified by isoelectric focusing (pI = 8.6) and used to prepare antibody in guinea pigs. The protein was identified by its reaction with antisera reactive with the mammalian type C virus group-specific (gs) antigenic determinant, gs-3. The guinea pig antisera mainly contained species-specific (gs-1) antibody for reactions in gel diffusion with other type C viruses were limited to those of rat origin, whereas in complement fixation tests heterologous reactions could be eliminated by use of appropriate antiserum concentrations without affecting homologous reactions. Guinea pig antisera against mouse, hamster, or cat gs-1 determinants did not react with MSV(RaLV) purified gs protein or with any of several other rat type C viruses.","['Oroszlan, S', 'Bova, D', 'Huebner, R J', 'Gilden, R V']","['Oroszlan S', 'Bova D', 'Huebner RJ', 'Gilden RV']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', '*Antigens, Viral/isolation & purification', 'Cell Line', 'Centrifugation, Density Gradient', 'Complement Fixation Tests', 'Electrophoresis, Polyacrylamide Gel', 'Epitopes', 'Female', 'Gammaretrovirus/*immunology', 'Guinea Pigs/immunology', 'Helper Viruses/immunology', 'Immune Sera', 'Immunodiffusion', 'Isoelectric Focusing', 'Leucine', 'Leukemia Virus, Feline/immunology', 'Leukemia Virus, Murine/immunology', 'Neoplasms, Experimental', 'Rats/immunology', 'Retroviridae/immunology/isolation & purification', 'Surface-Active Agents', 'Tritium', '*Viral Proteins']",PMC356529,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1128/JVI.10.4.746-750.1972 [doi]'],ppublish,J Virol. 1972 Oct;10(4):746-50. doi: 10.1128/JVI.10.4.746-750.1972.,"['0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Surface-Active Agents)', '0 (Viral Proteins)', '10028-17-8 (Tritium)', 'GMW67QNF9C (Leucine)']",,,,,,,,,,,
4117345,NLM,MEDLINE,19730109,20200724,0022-538X (Print) 0022-538X (Linking),10,4,1972 Oct,Isolation of temperature-sensitive mutants of murine sarcoma virus.,653-7,"Three separate murine sarcoma virus nonproducer cell lines have been isolated which are temperature sensitive for the maintenance of transformation. In each case, a viral rather than a cellular genetic mutation is the reason for the temperature-sensitive effect. Superinfection of one of the mutants with murine leukemia virus overcomes the temperature-sensitive change in the transformed state.","['Scolnick, E M', 'Stephenson, J R', 'Aaronson, S A']","['Scolnick EM', 'Stephenson JR', 'Aaronson SA']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Azacitidine', 'Bromodeoxyuridine', 'Cell Line', 'Cell Transformation, Neoplastic', 'Clone Cells', 'Contact Inhibition', 'Gammaretrovirus/growth & development/*isolation & purification/metabolism', 'Helper Viruses/growth & development', 'Kidney', 'Leukemia Virus, Murine/growth & development', 'Mice', 'Mutagens', '*Mutation', 'Nucleic Acid Hybridization', 'RNA, Viral/biosynthesis', 'Rats', 'Sarcoma, Experimental/microbiology', 'Temperature', 'Tritium', 'Viral Plaque Assay', 'Virus Replication']",PMC356516,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1128/JVI.10.4.653-657.1972 [doi]'],ppublish,J Virol. 1972 Oct;10(4):653-7. doi: 10.1128/JVI.10.4.653-657.1972.,"['0 (Mutagens)', '0 (RNA, Viral)', '10028-17-8 (Tritium)', 'G34N38R2N1 (Bromodeoxyuridine)', 'M801H13NRU (Azacitidine)']",,,,,,,,,,,
4117317,NLM,MEDLINE,19730105,20071115,0027-8874 (Print) 0027-8874 (Linking),49,4,1972 Oct,Tumorigenesis in strain DW-J mice and induction by prolactin of the group-specific antigen of endogenous C-type RNA tumor virus.,1145-54,,"['Chen, H W', 'Meier, H', 'Heiniger, H J', 'Huebner, R J']","['Chen HW', 'Meier H', 'Heiniger HJ', 'Huebner RJ']",['eng'],['Journal Article'],United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,IM,"['Adenocarcinoma/immunology', 'Adenoma', 'Animals', '*Antigens, Viral', 'Carcinoma, Hepatocellular/immunology', 'Complement Fixation Tests', 'Dwarfism, Pituitary/genetics', 'Epitopes', 'Female', 'Genotype', 'Growth/drug effects', 'Heterozygote', 'Homozygote', 'Leukemia/immunology', 'Liver Neoplasms', 'Lymphoma, Large B-Cell, Diffuse/immunology', 'Male', 'Mice', 'Mice, Inbred Strains', 'Mutation', 'Neoplasms, Experimental/immunology', 'Oncogenic Viruses/*immunology', 'Prolactin/*pharmacology', 'RNA Viruses/*immunology', 'Retroviridae/immunology/isolation & purification']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",,ppublish,J Natl Cancer Inst. 1972 Oct;49(4):1145-54.,"['0 (Antigens, Viral)', '0 (Epitopes)', '9002-62-4 (Prolactin)']",,,,,,,,,,,
4117316,NLM,MEDLINE,19730105,20211203,0027-8874 (Print) 0027-8874 (Linking),49,4,1972 Oct,Production of tumor-specific antibody in the xenogeneic host: use of blocking antibody.,1063-70,,"['Weiner, R S', 'Hubbard, J D', 'Mardiney, M R Jr']","['Weiner RS', 'Hubbard JD', 'Mardiney MR Jr']",['eng'],['Journal Article'],United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,IM,"['Absorption', 'Animals', '*Antibody Formation', 'Cells, Cultured', 'Cytotoxicity Tests, Immunologic', '*Epitopes', 'Immune Sera', 'Immunization', 'Immunization, Passive', 'Immunosuppression Therapy', 'Injections, Intravenous', 'Leukemia, Experimental/immunology', 'Lymphocytes/immunology', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Rabbits/immunology', 'Spleen/cytology/immunology', 'Thymus Gland/immunology']",,1972/10/01 00:00,2001/03/28 10:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1972/10/01 00:00 [entrez]']",,ppublish,J Natl Cancer Inst. 1972 Oct;49(4):1063-70.,"['0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4117298,NLM,MEDLINE,19730105,20151119,0026-895X (Print) 0026-895X (Linking),8,5,1972 Sep,Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells.,551-60,,"['Kann, H E Jr', 'Kohn, K W']","['Kann HE Jr', 'Kohn KW']",['eng'],['Journal Article'],United States,Mol Pharmacol,Molecular pharmacology,0035623,IM,"['Acridines/pharmacology', 'Acrylamides/pharmacology', 'Alkaloids/pharmacology', 'Animals', 'Antibiotics, Antineoplastic/pharmacology', 'Antineoplastic Agents/*pharmacology', 'Benzazepines/pharmacology', 'Camptothecin/pharmacology', 'Carbazoles/pharmacology', 'Carbon Isotopes', 'Cell Nucleolus/drug effects/metabolism', 'Cell Nucleus/drug effects/metabolism', 'Centrifugation, Density Gradient', 'DNA, Neoplasm/*metabolism', 'Dactinomycin/pharmacology', 'Daunorubicin/pharmacology', 'Deoxyadenosines/pharmacology', 'Ethidium/pharmacology', 'Leukemia L1210/*metabolism/pathology', 'Mechlorethamine/pharmacology', 'Methionine/metabolism', 'Phenanthridines/pharmacology', 'Pyridines/pharmacology', 'Pyrroles/pharmacology', 'RNA, Neoplasm/*biosynthesis', 'Tritium', 'Uridine/metabolism']",,1972/09/01 00:00,2001/03/28 10:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,Mol Pharmacol. 1972 Sep;8(5):551-60.,"['0 (Acridines)', '0 (Acrylamides)', '0 (Alkaloids)', '0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (Benzazepines)', '0 (Carbazoles)', '0 (Carbon Isotopes)', '0 (DNA, Neoplasm)', '0 (Deoxyadenosines)', '0 (Phenanthridines)', '0 (Pyridines)', '0 (Pyrroles)', '0 (RNA, Neoplasm)', '10028-17-8 (Tritium)', '1CC1JFE158 (Dactinomycin)', '50D9XSG0VR (Mechlorethamine)', 'AE28F7PNPL (Methionine)', 'EN464416SI (Ethidium)', 'WHI7HQ7H85 (Uridine)', 'XT3Z54Z28A (Camptothecin)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4117188,NLM,MEDLINE,19730103,20190508,0022-1007 (Print) 0022-1007 (Linking),136,5,1972 Nov 1,In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen.,1072-9,,"['Lamon, E W', 'Skurzak, H M', 'Klein, E', 'Wigzell, H']","['Lamon EW', 'Skurzak HM', 'Klein E', 'Wigzell H']",['eng'],['Journal Article'],United States,J Exp Med,The Journal of experimental medicine,2985109R,IM,"['Animals', 'Antigen-Antibody Reactions', 'Antigens, Neoplasm', '*Antigens, Viral', 'Antilymphocyte Serum', 'B-Lymphocytes/immunology', 'Binding Sites, Antibody', 'Bone Marrow/immunology', 'Bone Marrow Cells', 'Cell Membrane/immunology', 'Cells, Cultured', 'Cytotoxicity Tests, Immunologic', 'Epitopes', 'Female', 'Histocompatibility Antigens', 'Leukemia, Experimental/immunology', 'Lymphocytes/*immunology', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Moloney murine leukemia virus/*immunology', 'Neoplasm Transplantation', 'Sarcoma, Experimental/immunology', 'Transplantation, Homologous']",PMC2139303,1972/11/01 00:00,1972/11/01 00:01,['1972/11/01 00:00'],"['1972/11/01 00:00 [pubmed]', '1972/11/01 00:01 [medline]', '1972/11/01 00:00 [entrez]']",['10.1084/jem.136.5.1072 [doi]'],ppublish,J Exp Med. 1972 Nov 1;136(5):1072-9. doi: 10.1084/jem.136.5.1072.,"['0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Antilymphocyte Serum)', '0 (Epitopes)', '0 (Histocompatibility Antigens)']",,,,,,,,,,,
4117177,NLM,MEDLINE,19730103,20211203,0008-5472 (Print) 0008-5472 (Linking),32,11,1972 Nov,Appearance of abnormal catalase antigen and concurrent deletion of normal antigen in leukocytes of myelogenous leukemia.,2353-8,,"['Nishimura, E T', 'Hokama, Y', 'Jim, R']","['Nishimura ET', 'Hokama Y', 'Jim R']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Adult', 'Aged', 'Animals', 'Antigen-Antibody Complex', 'Antigens, Neoplasm/*analysis', 'Catalase/*blood', 'Child', 'Epitopes', 'Ethnicity', 'Female', 'Humans', 'Immune Sera', 'Immunoelectrophoresis', 'Leukemia, Myeloid/immunology', 'Leukemia, Myeloid, Acute/enzymology/*immunology', 'Leukocytes/enzymology/*immunology', 'Leukocytosis/immunology', 'Male', 'Middle Aged', 'Protein Conformation', 'Rabbits/immunology', 'Remission, Spontaneous']",,1972/11/01 00:00,1972/11/01 00:01,['1972/11/01 00:00'],"['1972/11/01 00:00 [pubmed]', '1972/11/01 00:01 [medline]', '1972/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Nov;32(11):2353-8.,"['0 (Antigen-Antibody Complex)', '0 (Antigens, Neoplasm)', '0 (Epitopes)', '0 (Immune Sera)', 'EC 1.11.1.6 (Catalase)']",,,,,,,,,,,
4117128,NLM,MEDLINE,19730103,20190714,0042-6822 (Print) 0042-6822 (Linking),50,1,1972 Oct,Revertants of mouse cells transformed by murine sarcoma virus. I. Characterization of flat and transformed sublines without a rescuable murine sarcoma virus.,51-64,,"['Nomura, S', 'Fischinger, P J', 'Mattern, C F', 'Peebles, P T', 'Bassin, R H', 'Friedman, G P']","['Nomura S', 'Fischinger PJ', 'Mattern CF', 'Peebles PT', 'Bassin RH', 'Friedman GP']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Antigens, Viral/analysis', 'Cats', 'Cell Line', '*Cell Transformation, Neoplastic', 'Cells, Cultured', 'Chromosomes/analysis', 'Clone Cells', 'Complement Fixation Tests', 'Gammaretrovirus/*growth & development/isolation & purification', 'Genetic Variation', 'Helper Viruses/growth & development', 'Idoxuridine/pharmacology', 'Leukemia Virus, Feline/growth & development', 'Mice', 'Microscopy, Electron', 'Moloney murine leukemia virus/growth & development/immunology', 'Neoplasms, Experimental/genetics/metabolism', 'RNA-Directed DNA Polymerase/metabolism', 'Rats', 'Tritium', 'Viral Plaque Assay', 'Virus Replication']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['10.1016/0042-6822(72)90345-5 [doi]'],ppublish,Virology. 1972 Oct;50(1):51-64. doi: 10.1016/0042-6822(72)90345-5.,"['0 (Antigens, Viral)', '10028-17-8 (Tritium)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'LGP81V5245 (Idoxuridine)']",,,,,,,,,,,
4117055,NLM,MEDLINE,19730103,20180216,0001-5792 (Print) 0001-5792 (Linking),48,2,1972,Actinomycin binding capacity in human leukaemic lymphoid cells.,89-97,,"['Pileri, A', 'Masera, P', 'Hulin, N', 'Brachet, J']","['Pileri A', 'Masera P', 'Hulin N', 'Brachet J']",['eng'],['Journal Article'],Switzerland,Acta Haematol,Acta haematologica,0141053,IM,"['Autoradiography', 'Bone Marrow/metabolism', 'Bone Marrow Cells', 'Cells, Cultured', 'Dactinomycin/*metabolism', 'Humans', 'In Vitro Techniques', 'Infectious Mononucleosis/metabolism', 'Lectins/pharmacology', 'Leukemia, Lymphoid/*genetics', 'Lymph Nodes/cytology', 'Lymphocyte Activation/drug effects', 'Lymphocytes/metabolism', '*Protein Binding', 'Tritium']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1159/000208443 [doi]'],ppublish,Acta Haematol. 1972;48(2):89-97. doi: 10.1159/000208443.,"['0 (Lectins)', '10028-17-8 (Tritium)', '1CC1JFE158 (Dactinomycin)']",,,,,,,,,,,
4117041,NLM,MEDLINE,19730103,20061115,0300-8630 (Print) 0300-8630 (Linking),184,4,1972 Jul,[Identification of numerical and structural anomalies of human G-group-chromosomes using the pankreatin-Giemsa-Banding-pattern].,265-71,,"['Muller, W', 'Rosenkranz, W']","['Muller W', 'Rosenkranz W']",['ger'],"['Comparative Study', 'Journal Article']",Germany,Klin Padiatr,Klinische Padiatrie,0326144,IM,"['Autoradiography', 'Chromosome Aberrations/*diagnosis', 'Chromosome Disorders', 'Chromosomes, Human, 1-3', 'Chromosomes, Human, 13-15', 'Chromosomes, Human, 16-18', 'Chromosomes, Human, 19-20', 'Chromosomes, Human, 21-22 and Y', 'Chromosomes, Human, 4-5', 'Chromosomes, Human, 6-12 and X', 'Down Syndrome/diagnosis', 'Humans', 'Karyotyping', 'Leukemia, Myeloid/diagnosis/genetics', 'Male', 'Methods', 'Pancreatin', 'Staining and Labeling', 'Trisomy']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,Klin Padiatr. 1972 Jul;184(4):265-71.,['8049-47-6 (Pancreatin)'],,Identifizierung numerischer und Struktureller Anomalien menschlicher G-chromosomen mit dem Pankreatin Giemsa-Banden-men mit dem Pankreatin-Giemsa-Banden muster.,,,,,,,,,
4117035,NLM,MEDLINE,19730103,20061115,0008-5472 (Print) 0008-5472 (Linking),32,10,1972 Oct,Autogenous immunity to endogenous RNA tumor virus antigens in mice with a low natural incidence of lymphoma.,2226-34,,"['Hanna, M G Jr', 'Tennant, R W', 'Yuhas, J M', 'Clapp, N K', 'Batzing, B L', 'Snodgrass, M J']","['Hanna MG Jr', 'Tennant RW', 'Yuhas JM', 'Clapp NK', 'Batzing BL', 'Snodgrass MJ']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['AKR murine leukemia virus/immunology', 'Animals', 'Antibodies, Neoplasm/*analysis', 'Antigen-Antibody Reactions', 'Antigens, Neoplasm/analysis', 'Autoradiography', 'Complement Fixation Tests', 'Epitopes', 'Female', 'Gammaretrovirus/*immunology', '*Immunity, Active', 'Iodine Isotopes', 'Kidney/immunology', 'Lymphoma/*immunology/veterinary', 'Male', 'Mice', 'Mice, Inbred Strains', 'Microscopy, Electron', 'Nephrosclerosis/immunology/veterinary', 'Rodent Diseases/*immunology', 'Spleen/immunology', 'Thymus Gland/immunology', 'gamma-Globulins/analysis']",,1972/10/01 00:00,2001/03/28 10:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1972/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Oct;32(10):2226-34.,"['0 (Antibodies, Neoplasm)', '0 (Antigens, Neoplasm)', '0 (Epitopes)', '0 (Iodine Isotopes)', '0 (gamma-Globulins)']",,,,,,,,,,,
4116977,NLM,MEDLINE,19730102,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7785,1972 Nov 11,Leukaemia and Poland's syndrome.,1038-9,,"['Hoefnagel, D', 'Rozycki, A', 'Wurster-Hill, D', 'Stern, P', 'Gregory, D']","['Hoefnagel D', 'Rozycki A', 'Wurster-Hill D', 'Stern P', 'Gregory D']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Humans', '*Leukemia, Myeloid, Acute', 'Male', 'Pectoralis Muscles/*abnormalities', '*Syndactyly', 'Syndrome']",,1972/11/11 00:00,1972/11/11 00:01,['1972/11/11 00:00'],"['1972/11/11 00:00 [pubmed]', '1972/11/11 00:01 [medline]', '1972/11/11 00:00 [entrez]']","['S0140-6736(72)92460-9 [pii]', '10.1016/s0140-6736(72)92460-9 [doi]']",ppublish,Lancet. 1972 Nov 11;2(7785):1038-9. doi: 10.1016/s0140-6736(72)92460-9.,,,,,,,,,,,,
4116976,NLM,MEDLINE,19730102,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7785,1972 Nov 11,"Regional ileitis, leukaemia, and humoral immune deficiency in a family.",1038,,"['Parker, J E', 'Thomas, J W']","['Parker JE', 'Thomas JW']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Child, Preschool', 'Crohn Disease/*genetics', 'Female', 'Humans', 'Immunoglobulins/analysis', 'Immunologic Deficiency Syndromes/*genetics', 'Infant', 'Infant, Newborn', 'Leukemia/*genetics', 'Lymphocyte Activation', 'Male']",,1972/11/11 00:00,1972/11/11 00:01,['1972/11/11 00:00'],"['1972/11/11 00:00 [pubmed]', '1972/11/11 00:01 [medline]', '1972/11/11 00:00 [entrez]']","['S0140-6736(72)92459-2 [pii]', '10.1016/s0140-6736(72)92459-2 [doi]']",ppublish,Lancet. 1972 Nov 11;2(7785):1038. doi: 10.1016/s0140-6736(72)92459-2.,['0 (Immunoglobulins)'],,,,,,,,,,,
4116924,NLM,MEDLINE,19730102,20190627,0002-9610 (Print) 0002-9610 (Linking),124,5,1972 Nov,Major surgery in patients with acute leukemia.,629-33,,"['Seligman, B R', 'Rosner, F', 'Ritz, N D']","['Seligman BR', 'Rosner F', 'Ritz ND']",['eng'],['Journal Article'],United States,Am J Surg,American journal of surgery,0370473,IM,"['Adult', 'Aged', 'Appendicitis/surgery', 'Biopsy/adverse effects', 'Child, Preschool', 'Diverticulum, Colon/surgery', 'Female', 'Gangrene/surgery', 'Hernia, Inguinal/surgery', 'Humans', 'Intestinal Fistula/surgery', 'Intestinal Obstruction/surgery', 'Leukemia, Lymphoid/*complications', 'Leukemia, Myeloid, Acute/*complications', 'Male', 'Prostatic Hyperplasia/surgery', 'Pulmonary Embolism/surgery', 'Splenic Rupture/surgery', '*Surgical Procedures, Operative']",,1972/11/01 00:00,1972/11/01 00:01,['1972/11/01 00:00'],"['1972/11/01 00:00 [pubmed]', '1972/11/01 00:01 [medline]', '1972/11/01 00:00 [entrez]']","['0002-9610(72)90101-8 [pii]', '10.1016/0002-9610(72)90101-8 [doi]']",ppublish,Am J Surg. 1972 Nov;124(5):629-33. doi: 10.1016/0002-9610(72)90101-8.,,,,,,,,,,,,
4116893,NLM,MEDLINE,19721229,20210526,0003-6919 (Print) 0003-6919 (Linking),24,3,1972 Sep,Purification of large amounts of murine ribonucleic acid tumor viruses produced in roller bottle cultures.,488-94,Murine ribonucleic acid tumor viruses and C-type virus particles are produced in relatively large quantities in roller bottle cultures. The viruses present in large volumes of culture fluids can be purified by a simple two-step procedure involving polyethylene glycol precipitation and equilibrium centrifugation in sucrose density gradients.,"['Syrewicz, J J', 'Naso, R B', 'Wang, C S', 'Arlinghaus, R B']","['Syrewicz JJ', 'Naso RB', 'Wang CS', 'Arlinghaus RB']",['eng'],['Journal Article'],United States,Appl Microbiol,Applied microbiology,7605802,IM,"['Animals', 'Cell Line', 'Centrifugation, Density Gradient', 'Chemical Precipitation', 'Cricetinae', 'Culture Techniques', 'Fibroblasts', 'Gammaretrovirus/growth & development/*isolation & purification', 'Inclusion Bodies, Viral', 'Kidney', 'Leukemia Virus, Murine/isolation & purification', 'Microscopy, Electron', 'Oncogenic Viruses/*isolation & purification', 'RNA Viruses/*isolation & purification', 'RNA, Viral/analysis/isolation & purification', 'RNA-Directed DNA Polymerase/metabolism', 'Rats/embryology', 'Rauscher Virus/analysis/enzymology/isolation & purification', 'Retroviridae/growth & development/isolation & purification', '*Virus Cultivation']",PMC376544,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",['10.1128/am.24.3.488-494.1972 [doi]'],ppublish,Appl Microbiol. 1972 Sep;24(3):488-94. doi: 10.1128/am.24.3.488-494.1972.,"['0 (RNA, Viral)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,,,,,,,,,,
4116806,NLM,MEDLINE,19721226,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7778,1972 Sep 23,Methotrexate meningitis.,656,,"['Mott, M G', 'Stevenson, P', 'Wood, C B']","['Mott MG', 'Stevenson P', 'Wood CB']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Child, Preschool', 'Humans', 'Injections, Spinal', 'Leukemia, Lymphoid/drug therapy', 'Male', 'Meningitis/*chemically induced', 'Methotrexate/administration & dosage/adverse effects']",,1972/09/23 00:00,1972/09/23 00:01,['1972/09/23 00:00'],"['1972/09/23 00:00 [pubmed]', '1972/09/23 00:01 [medline]', '1972/09/23 00:00 [entrez]']","['S0140-6736(72)93050-4 [pii]', '10.1016/s0140-6736(72)93050-4 [doi]']",ppublish,Lancet. 1972 Sep 23;2(7778):656. doi: 10.1016/s0140-6736(72)93050-4.,['YL5FZ2Y5U1 (Methotrexate)'],,,,,,,,,,,
4116716,NLM,MEDLINE,19721221,20181130,0003-4886 (Print) 0003-4886 (Linking),4,10,1972 Oct,Experimental study on the effects of insecticides on the rabbit eye.,874-5,,"['Slem, G', 'Ayan, Y', 'Baykal, E']","['Slem G', 'Ayan Y', 'Baykal E']",['eng'],['Journal Article'],United States,Ann Ophthalmol,Annals of ophthalmology,0210137,IM,"['Animals', 'Atrophy/chemically induced', 'Conjunctivitis/chemically induced', 'Copper/*toxicity', 'Corneal Ulcer/chemically induced', 'DDT/toxicity', 'Disease Models, Animal', 'Eye/*drug effects', 'Eye Diseases/*chemically induced', 'Eye Neoplasms/chemically induced', 'Hexachlorocyclohexane/toxicity', 'Insecticides/*toxicity', 'Iris/drug effects', 'Leukemia/chemically induced', 'Mercury/*toxicity', 'Organometallic Compounds/*toxicity', '*Organothiophosphorus Compounds', 'Pyrimidines/*toxicity', 'Rabbits']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",,ppublish,Ann Ophthalmol. 1972 Oct;4(10):874-5.,"['0 (Insecticides)', '0 (Organometallic Compounds)', '0 (Organothiophosphorus Compounds)', '0 (Pyrimidines)', '59NEE7PCAB (Hexachlorocyclohexane)', '789U1901C5 (Copper)', 'CIW5S16655 (DDT)', 'FXS1BY2PGL (Mercury)']",,,,,,,,,,,
4116712,NLM,MEDLINE,19721217,20190618,0036-8075 (Print) 0036-8075 (Linking),178,4058,1972 Oct 20,Cytotoxic antibody in normal human serums reactive with tumor cells from acute lymphocytic leukemia.,304-6,"Serums showing complement-dependent cytotoxic reactions to acute lymphocytic leukemia cells were detected in three normal unimmunized subjects. These serums were reactive with tumor cells from 514 (514 tested) acute lymphocytic leukemia patients, and three (12 tested) patients with acute myelocytic leukemia; they did not react with tumor cells from patients with acute monocytic leukemia (two tested), with chronic lymphocytic leukemia (two tested) or with leukolymphosarcoma (two tested); nor did they react with normal lymphocytes from 52 different donors. These reactive serums appear to recognize antigens primarily associated with acute lymphocytic leukemia.","['Bias, W B', 'Santos, G W', 'Burke, P J', 'Mullins, G M', 'Humphrey, R L']","['Bias WB', 'Santos GW', 'Burke PJ', 'Mullins GM', 'Humphrey RL']",['eng'],['Journal Article'],United States,Science,"Science (New York, N.Y.)",0404511,IM,"['Adult', 'Antibodies/*analysis', 'Antibody Specificity', 'Antigen-Antibody Reactions', 'Antigens, Neoplasm', 'Cytotoxicity Tests, Immunologic', 'Epitopes', 'Female', 'Histocompatibility', 'Humans', 'Leukemia/immunology', 'Leukemia, Lymphoid/*immunology', 'Leukemia, Monocytic, Acute/immunology', 'Leukemia, Myeloid, Acute/immunology', 'Lymphocytes/immunology', 'Male']",,1972/10/20 00:00,1972/10/20 00:01,['1972/10/20 00:00'],"['1972/10/20 00:00 [pubmed]', '1972/10/20 00:01 [medline]', '1972/10/20 00:00 [entrez]']",['10.1126/science.178.4058.304 [doi]'],ppublish,Science. 1972 Oct 20;178(4058):304-6. doi: 10.1126/science.178.4058.304.,"['0 (Antibodies)', '0 (Antigens, Neoplasm)', '0 (Epitopes)']",,,,,,,,,,,
4116692,NLM,MEDLINE,19721217,20190612,0006-291X (Print) 0006-291X (Linking),48,6,1972 Sep 26,Inhibition of RNA-directed DNA polymerase from Rauscher leukemia virus by the 5'-triphosphate of cytosine arabinoside.,1469-75,,"['Tuominen, F W', 'Kenney, F T']","['Tuominen FW', 'Kenney FT']",['eng'],['Journal Article'],United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,IM,"['Animals', 'Cell Transformation, Neoplastic/drug effects', 'Cytarabine/administration & dosage/*pharmacology', 'DNA, Viral/biosynthesis', 'Kinetics', 'Mice', 'Phosphates/administration & dosage/pharmacology', 'Rauscher Virus/*enzymology/isolation & purification', 'Reverse Transcriptase Inhibitors', 'Virus Replication']",,1972/09/26 00:00,1972/09/26 00:01,['1972/09/26 00:00'],"['1972/09/26 00:00 [pubmed]', '1972/09/26 00:01 [medline]', '1972/09/26 00:00 [entrez]']","['0006-291X(72)90879-0 [pii]', '10.1016/0006-291x(72)90879-0 [doi]']",ppublish,Biochem Biophys Res Commun. 1972 Sep 26;48(6):1469-75. doi: 10.1016/0006-291x(72)90879-0.,"['0 (DNA, Viral)', '0 (Phosphates)', '0 (Reverse Transcriptase Inhibitors)', '04079A1RDZ (Cytarabine)']",,,,,,,,,,,
4116662,NLM,MEDLINE,19721214,20131121,0069-0139 (Print) 0069-0139 (Linking),3,1,1972 May,Current status of new agents.,33-47,,"['Carter, S K']",['Carter SK'],['eng'],"['Journal Article', 'Review']",United States,Cancer Chemother Rep 3,Cancer chemotherapy reports. Part 3,7609154,IM,"['Alopecia/chemically induced', 'Animals', 'Antibiotics, Antineoplastic/therapeutic use', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Azacitidine/therapeutic use', 'Azaguanine/therapeutic use', 'Carmustine/therapeutic use', 'Cyclohexanes/therapeutic use', 'Drug Combinations/therapeutic use', 'Heart/drug effects', 'Humans', 'Leukemia L1210/drug therapy', 'Nitrosourea Compounds/administration & dosage/adverse effects/therapeutic use', 'Platinum/therapeutic use', 'Prednisone/therapeutic use', 'Remission, Spontaneous']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,Cancer Chemother Rep 3. 1972 May;3(1):33-47.,"['0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (Cyclohexanes)', '0 (Drug Combinations)', '0 (Nitrosourea Compounds)', '49DFR088MY (Platinum)', 'M801H13NRU (Azacitidine)', 'Q150359I72 (Azaguanine)', 'U68WG3173Y (Carmustine)', 'VB0R961HZT (Prednisone)']",45,,,,,,,,,,
4116608,NLM,MEDLINE,19721204,20150616,0140-6736 (Print) 0140-6736 (Linking),2,7783,1972 Oct 28,Radical treatment of acute leukaemia in childhood.,910-1,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Drug Synergism', 'Humans', 'Injections, Spinal', 'Leukemia/drug therapy/radiotherapy/*therapy', 'Leukemia, Lymphoid/therapy', 'Methotrexate/administration & dosage', 'Radiotherapy Dosage', 'Remission, Spontaneous', 'Time Factors']",,1972/10/28 00:00,1972/10/28 00:01,['1972/10/28 00:00'],"['1972/10/28 00:00 [pubmed]', '1972/10/28 00:01 [medline]', '1972/10/28 00:00 [entrez]']",['S0140-6736(72)92540-8 [pii]'],ppublish,Lancet. 1972 Oct 28;2(7783):910-1.,['YL5FZ2Y5U1 (Methotrexate)'],,,,,,,,,,,
4116579,NLM,MEDLINE,19721204,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7782,1972 Oct 21,Immunoprophylaxis and immunotherapy of leukaemia with B.C.G.,875-6,,"['Finklestein, J Z', 'Tittle, K L', 'Imagawa, D T']","['Finklestein JZ', 'Tittle KL', 'Imagawa DT']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Cyclophosphamide/therapeutic use', '*Immunotherapy', 'Injections, Intraperitoneal', 'Leukemia, Experimental/drug therapy/*prevention & control', 'Mice', '*Mycobacterium bovis', 'Remission, Spontaneous']",,1972/10/21 00:00,1972/10/21 00:01,['1972/10/21 00:00'],"['1972/10/21 00:00 [pubmed]', '1972/10/21 00:01 [medline]', '1972/10/21 00:00 [entrez]']","['S0140-6736(72)92238-6 [pii]', '10.1016/s0140-6736(72)92238-6 [doi]']",ppublish,Lancet. 1972 Oct 21;2(7782):875-6. doi: 10.1016/s0140-6736(72)92238-6.,['8N3DW7272P (Cyclophosphamide)'],,,,,,,,,,,
4116558,NLM,MEDLINE,19721204,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7782,1972 Oct 21,Malignant lymphomas of B-cell type.,855-7,,"['Stein, H', 'Lennert, K', 'Parwaresch, M R']","['Stein H', 'Lennert K', 'Parwaresch MR']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['B-Lymphocytes/*immunology', 'Humans', 'Immunoglobulin A', 'Immunoglobulin G', 'Immunoglobulin M', '*Immunoglobulins', 'Leukemia, Lymphoid/*immunology', 'Leukemia, Plasma Cell/*immunology', 'Lymphoma/*immunology', 'Lymphoma, Large B-Cell, Diffuse/immunology', 'Lymphoma, Non-Hodgkin/immunology', 'Multiple Myeloma/immunology', 'Plasmacytoma/immunology']",,1972/10/21 00:00,1972/10/21 00:01,['1972/10/21 00:00'],"['1972/10/21 00:00 [pubmed]', '1972/10/21 00:01 [medline]', '1972/10/21 00:00 [entrez]']","['S0140-6736(72)92215-5 [pii]', '10.1016/s0140-6736(72)92215-5 [doi]']",ppublish,Lancet. 1972 Oct 21;2(7782):855-7. doi: 10.1016/s0140-6736(72)92215-5.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)']",,,,,,,,,,,
4116553,NLM,MEDLINE,19721204,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7782,1972 Oct 21,Rectal abscesses in cancer patients.,844-7,,"['Schimpff, S C', 'Wiernik, P H', 'Block, J B']","['Schimpff SC', 'Wiernik PH', 'Block JB']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Abscess/diagnosis/*etiology/microbiology', 'Agranulocytosis/*complications', 'Anti-Bacterial Agents/therapeutic use', 'Brain Neoplasms/complications', 'Humans', 'Leukemia/complications', 'Leukemia, Lymphoid/complications', 'Leukemia, Monocytic, Acute/complications', 'Leukemia, Myeloid, Acute/complications', 'Lymphoma/complications', 'Multiple Myeloma/complications', 'Neoplasms/*complications', 'Pseudomonas Infections/etiology', 'Pseudomonas aeruginosa/isolation & purification', 'Rectal Diseases/diagnosis/*etiology/microbiology', 'Sepsis/etiology']",,1972/10/21 00:00,1972/10/21 00:01,['1972/10/21 00:00'],"['1972/10/21 00:00 [pubmed]', '1972/10/21 00:01 [medline]', '1972/10/21 00:00 [entrez]']","['S0140-6736(72)92210-6 [pii]', '10.1016/s0140-6736(72)92210-6 [doi]']",ppublish,Lancet. 1972 Oct 21;2(7782):844-7. doi: 10.1016/s0140-6736(72)92210-6.,['0 (Anti-Bacterial Agents)'],,,,,,,,,,,
4116529,NLM,MEDLINE,19721204,20191210,0028-0836 (Print) 0028-0836 (Linking),239,5368,1972 Sep 15,Differential staining patterns of human chromosomes treated with potassium permanganate.,168-70,,"['Utakoji, T']",['Utakoji T'],['eng'],['Journal Article'],England,Nature,Nature,0410462,IM,"['Animals', 'Carcinoma', 'Cells, Cultured', '*Chromosomes', 'Cricetinae', 'Fibroblasts/cytology', 'HeLa Cells/cytology', 'Humans', 'Karyotyping', 'L Cells/cytology', 'Leukemia', 'Leukocytes/cytology', 'Male', 'Mice', '*Potassium Permanganate', 'Rats', '*Staining and Labeling']",,1972/09/15 00:00,1972/09/15 00:01,['1972/09/15 00:00'],"['1972/09/15 00:00 [pubmed]', '1972/09/15 00:01 [medline]', '1972/09/15 00:00 [entrez]']",['10.1038/239168a0 [doi]'],ppublish,Nature. 1972 Sep 15;239(5368):168-70. doi: 10.1038/239168a0.,['00OT1QX5U4 (Potassium Permanganate)'],,,,,,,,,,,
4116501,NLM,MEDLINE,19721201,20190908,0090-0028 (Print) 0090-0028 (Linking),238,87,1972 Aug 30,Inactivation of DNA polymerases of murine leukaemia viruses by calcium elenolate.,277-9,,"['Hirschman, S Z']",['Hirschman SZ'],['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['Adenine Nucleotides/metabolism', 'Antiviral Agents/*pharmacology', 'Calcium/pharmacology', 'DNA/metabolism', 'DNA Nucleotidyltransferases/*antagonists & inhibitors', 'DNA, Viral/biosynthesis', 'Escherichia coli/enzymology', 'Kinetics', 'Leukemia Virus, Murine/*enzymology', 'Nucleotides/metabolism', 'Reverse Transcriptase Inhibitors', 'Templates, Genetic', 'Terpenes/*pharmacology', 'Thymine Nucleotides/metabolism', 'Thymus Gland', 'Tritium', 'Uracil Nucleotides/metabolism']",,1972/08/30 00:00,1972/08/30 00:01,['1972/08/30 00:00'],"['1972/08/30 00:00 [pubmed]', '1972/08/30 00:01 [medline]', '1972/08/30 00:00 [entrez]']",['10.1038/newbio238277a0 [doi]'],ppublish,Nat New Biol. 1972 Aug 30;238(87):277-9. doi: 10.1038/newbio238277a0.,"['0 (Adenine Nucleotides)', '0 (Antiviral Agents)', '0 (DNA, Viral)', '0 (Nucleotides)', '0 (Reverse Transcriptase Inhibitors)', '0 (Terpenes)', '0 (Thymine Nucleotides)', '0 (Uracil Nucleotides)', '10028-17-8 (Tritium)', '9007-49-2 (DNA)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'SY7Q814VUP (Calcium)']",,,,,,,,,,,
4116417,NLM,MEDLINE,19721129,20210216,0006-4971 (Print) 0006-4971 (Linking),40,4,1972 Oct,Vitamin B 12 -binding protein of leukocytes as a possible major source of the third vitamin B 12 -binding protein of serum.,542-9,,"['Carmel, R', 'Herbert, V']","['Carmel R', 'Herbert V']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['Alpha-Globulins/analysis', 'Autoradiography', 'Beta-Globulins/analysis', 'Blood Proteins/analysis/*metabolism', 'Chromatography, DEAE-Cellulose', 'Cobalt Isotopes', 'Humans', 'Leukemia, Myeloid/blood', 'Leukocytes/*metabolism', 'Polycythemia Vera/blood', 'Primary Myelofibrosis/blood', '*Protein Binding', 'Vitamin B 12/*metabolism']",,1972/10/01 00:00,1972/10/01 00:01,['1972/10/01 00:00'],"['1972/10/01 00:00 [pubmed]', '1972/10/01 00:01 [medline]', '1972/10/01 00:00 [entrez]']",['S0006-4971(20)78005-5 [pii]'],ppublish,Blood. 1972 Oct;40(4):542-9.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Blood Proteins)', '0 (Cobalt Isotopes)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4116404,NLM,MEDLINE,19721125,20131121,0041-8943 (Print),32,1,1972,[Demonstration by immunofluorescence of group-specific antigens of the C particles in spontaneous tumors of the lung and those induced by chemicl carcinogens in BALBc mice].,5-12,,"['Ribacchi, R']",['Ribacchi R'],['ita'],['Journal Article'],Italy,Lav Ist Anat Istol Patol Univ Studi Perugia,"Lavori dell'Istituto di anatomia e istologia patologica, Universita degli studi di Perugia",7505645,IM,"['Animals', 'Antigens/*analysis', 'Cytoplasmic Granules/analysis', 'Epitopes', 'Fluorescent Antibody Technique', 'Hydrazines', '*Inclusion Bodies, Viral', 'Leukemia, Experimental/*immunology', 'Lung Neoplasms/*immunology', 'Mice', 'Mice, Inbred BALB C', 'Neoplasms, Experimental/*chemically induced', 'Oncogenic Viruses', 'Retroviridae', 'Urethane']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lav Ist Anat Istol Patol Univ Studi Perugia. 1972;32(1):5-12.,"['0 (Antigens)', '0 (Epitopes)', '0 (Hydrazines)', '3IN71E75Z5 (Urethane)']",,"Dimostrazione, mediante immunofluorescenza, di antigeni gruppo-specifici delle particelle C nei tumori del polmone spontanei ed indotti da cancerogeni chimici nei topi BALB-c.",,,,,,,,,
4116379,NLM,MEDLINE,19721125,20190824,0001-2815 (Print) 0001-2815 (Linking),1,4,1971,HL-A haplotype frequencies in Denmark and Norway.,184-95,,"['Svejgaard, A', 'Hauge, M', 'Kissmeyer-Nielsen, F', 'Thorsby, E']","['Svejgaard A', 'Hauge M', 'Kissmeyer-Nielsen F', 'Thorsby E']",['eng'],['Journal Article'],England,Tissue Antigens,Tissue antigens,0331072,IM,"['Adolescent', 'Adult', 'Aged', 'Asthma/immunology', 'Child', 'Choriocarcinoma/immunology', 'Complement Fixation Tests', 'Cytotoxicity Tests, Immunologic', 'Denmark', 'Epitopes', 'Female', '*Gene Frequency', 'Genotype', '*Haploidy', 'Histocompatibility Antigens/*analysis', 'Humans', 'Leukemia/immunology', 'Male', 'Middle Aged', 'Norway', 'Phenotype', 'Pregnancy', 'Uremia/immunology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",['10.1111/j.1399-0039.1971.tb00096.x [doi]'],ppublish,Tissue Antigens. 1971;1(4):184-95. doi: 10.1111/j.1399-0039.1971.tb00096.x.,"['0 (Epitopes)', '0 (Histocompatibility Antigens)']",,,,,,,,,,,
4116374,NLM,MEDLINE,19721125,20041117,0036-553X (Print) 0036-553X (Linking),9,5,1972,Electronmicroscopy of leukaemic myeloblasts with numerous lipid-containing vacuoles.,437-41,,"['Pollack, A']",['Pollack A'],['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Bone Marrow/*analysis', '*Bone Marrow Cells', 'Cytoplasm/*analysis', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/*pathology', 'Lipids/*analysis', 'Microscopy, Electron', 'Middle Aged', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Scand J Haematol. 1972;9(5):437-41.,['0 (Lipids)'],,,,,,,,,,,
4116315,NLM,MEDLINE,19721118,20190908,0036-553X (Print) 0036-553X (Linking),9,4,1972,Serum myeloperoxidase in leukaemia and polycythaemia vera.,311-7,,"['Malmquist, J']",['Malmquist J'],['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Animals', 'Biological Assay', 'Blood Proteins', 'Cell Fractionation', 'Humans', 'Immune Sera', 'Immunodiffusion', 'Immunoelectrophoresis', 'Leukemia/*enzymology', 'Leukemia, Lymphoid/enzymology', 'Leukemia, Myeloid/enzymology', 'Leukocytes/enzymology', 'Monocytes/enzymology', 'Peroxidases/*blood/isolation & purification', 'Polycythemia Vera/*enzymology', 'Rabbits/immunology', 'Serum Albumin, Bovine', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1111/j.1600-0609.1972.tb00946.x [doi]'],ppublish,Scand J Haematol. 1972;9(4):311-7. doi: 10.1111/j.1600-0609.1972.tb00946.x.,"['0 (Blood Proteins)', '0 (Immune Sera)', '27432CM55Q (Serum Albumin, Bovine)', 'EC 1.11.1.- (Peroxidases)']",,,,,,,,,,,
4116213,NLM,MEDLINE,19721116,20171116,0016-450X (Print) 0016-450X (Linking),63,3,1972 Jun,"Sensitivity of transplantable rat leukemia, DBLA-6, to antitumor agents.",281-90,,"['Aoshima, M', 'Sakurai, Y']","['Aoshima M', 'Sakurai Y']",['eng'],['Journal Article'],Japan,Gan,Gan,0151745,IM,"['Alkanesulfonates/therapeutic use', 'Animals', 'Antineoplastic Agents/*therapeutic use', 'Asparaginase/therapeutic use', 'Biphenyl Compounds/therapeutic use', 'Bleomycin/therapeutic use', 'Cell Line', 'Cyclophosphamide/therapeutic use', 'Cytarabine/therapeutic use', 'Daunorubicin/therapeutic use', 'Female', 'Leukemia, Experimental/chemically induced/*drug therapy', 'Leukocyte Count', 'Mercaptopurine/therapeutic use', 'Methotrexate/therapeutic use', 'Mitomycins/therapeutic use', 'Neoplasm Transplantation', 'Nitrosourea Compounds', 'Rats', 'Streptococcus', 'Tosyl Compounds/therapeutic use', 'Vinblastine/therapeutic use', 'Vincristine/therapeutic use']",,1972/06/01 00:00,1972/06/01 00:01,['1972/06/01 00:00'],"['1972/06/01 00:00 [pubmed]', '1972/06/01 00:01 [medline]', '1972/06/01 00:00 [entrez]']",,ppublish,Gan. 1972 Jun;63(3):281-90.,"['0 (Alkanesulfonates)', '0 (Antineoplastic Agents)', '0 (Biphenyl Compounds)', '0 (Mitomycins)', '0 (Nitrosourea Compounds)', '0 (Tosyl Compounds)', '04079A1RDZ (Cytarabine)', '11056-06-7 (Bleomycin)', '5J49Q6B70F (Vincristine)', '5V9KLZ54CY (Vinblastine)', '8N3DW7272P (Cyclophosphamide)', 'E7WED276I5 (Mercaptopurine)', 'EC 3.5.1.1 (Asparaginase)', 'YL5FZ2Y5U1 (Methotrexate)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4116208,NLM,MEDLINE,19721116,20190829,0009-5915 (Print) 0009-5915 (Linking),38,3,1972,Human leukemic cells: cytochemical studies on nuclear proteins.,329-40,,"['Desai, L S', 'De Bault, L E', 'Morrissey, G', 'Foley, G E']","['Desai LS', 'De Bault LE', 'Morrissey G', 'Foley GE']",['eng'],['Journal Article'],Austria,Chromosoma,Chromosoma,2985138R,IM,"['Animals', 'Cell Line', 'Cell Nucleus/*analysis', 'Cells, Cultured', 'Cricetinae', 'DNA/analysis', 'Disease Models, Animal', 'Female', 'Genes', 'Histocytochemistry', 'Histones/analysis', 'Humans', 'Infectious Mononucleosis/*blood', 'Leukemia, Lymphoid/*blood', 'Lymphocytes/*analysis', 'Male', 'Methylation', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1007/BF00290930 [doi]'],ppublish,Chromosoma. 1972;38(3):329-40. doi: 10.1007/BF00290930.,"['0 (Histones)', '9007-49-2 (DNA)']",,,,,,,,,,,
4116151,NLM,MEDLINE,19721116,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7780,1972 Oct 7,Regulation of granulopoiesis: positive feed-back.,742-4,,"['Robinson, W A', 'Mangalik, A']","['Robinson WA', 'Mangalik A']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Agranulocytosis/urine', 'Anemia, Aplastic/urine', 'Animals', 'Bacterial Infections/blood', 'Bone Marrow/metabolism', 'Bone Marrow Cells', 'Cell Division', 'Feedback', '*Hematopoiesis', 'Humans', 'Leukemia/urine', '*Leukocytes/metabolism/physiology', 'Mice', 'Monocytes/metabolism', 'Time Factors']",,1972/10/07 00:00,1972/10/07 00:01,['1972/10/07 00:00'],"['1972/10/07 00:00 [pubmed]', '1972/10/07 00:01 [medline]', '1972/10/07 00:00 [entrez]']","['S0140-6736(72)92029-6 [pii]', '10.1016/s0140-6736(72)92029-6 [doi]']",ppublish,Lancet. 1972 Oct 7;2(7780):742-4. doi: 10.1016/s0140-6736(72)92029-6.,,,,,,,,,,,,
4116139,NLM,MEDLINE,19721116,20200724,0022-538X (Print) 0022-538X (Linking),10,3,1972 Sep,Theta particles: a structure found in hamster sarcoma virus.,477-83,"Hamster sarcoma virus (HaSV), a ribonucleic acid tumor virus, pelleted from tissue culture fluid manifests type C morphology by electron microscopy. However, if virus is first concentrated by polyethylene glycol or ammonium sulfate followed by density gradient banding, the virus shows a dramatically atypical barred core structure, termed ""theta particles."" This structure suggests a condensation of the ribonucleoprotein into a flat disc. Atypical particles are found with HaSV and not in similarly treated feline leukemia virus or Rauscher-murine leukemia virus. Differences in the composition of HaSV as compared with these other viruses may be responsible for the production of such particles.","['Albino, A P', 'DeHarven, E', 'Sanders, F K']","['Albino AP', 'DeHarven E', 'Sanders FK']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Ammonium Sulfate', 'Animals', 'Cell-Free System', 'Centrifugation, Density Gradient', 'Chemical Precipitation', 'Cricetinae', 'Glycols', 'Leukemia Virus, Feline/analysis/isolation & purification', 'Micropore Filters', 'Microscopy, Electron', '*Nucleoproteins', '*Oncogenic Viruses/analysis/isolation & purification', '*RNA Viruses/analysis/isolation & purification', 'Rauscher Virus/analysis/isolation & purification', 'Sarcoma, Experimental/*microbiology', 'Staining and Labeling', 'Sucrose', 'Virus Cultivation']",PMC356489,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",['10.1128/JVI.10.3.477-483.1972 [doi]'],ppublish,J Virol. 1972 Sep;10(3):477-83. doi: 10.1128/JVI.10.3.477-483.1972.,"['0 (Glycols)', '0 (Nucleoproteins)', '57-50-1 (Sucrose)', 'SU46BAM238 (Ammonium Sulfate)']",,,,,,,,,,,
4116119,NLM,MEDLINE,19721116,20071115,0323-4347 (Print) 0323-4347 (Linking),97,4,1972,[Serum lysozyme in the differential diagnosis of acute leukemias].,265-78,,"['Jaworkowsky, L', 'Bersin, W', 'Grant, H', 'Rudens, J']","['Jaworkowsky L', 'Bersin W', 'Grant H', 'Rudens J']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Adult', 'Aged', 'Diagnosis, Differential', 'Esterases/blood', 'Histocytochemistry', 'Humans', 'Leukemia, Lymphoid/diagnosis/*enzymology', 'Leukemia, Monocytic, Acute/diagnosis/*enzymology', 'Leukemia, Myeloid, Acute/diagnosis/*enzymology', 'Leukocytes/enzymology', 'Lymphocytes/enzymology', 'Middle Aged', 'Muramidase/*blood', 'Prognosis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(4):265-78.,"['EC 3.1.- (Esterases)', 'EC 3.2.1.17 (Muramidase)']",,Das Serulysozym in der Differentialdiagnose akuter Leukosen.,,,,,,,,,
4116117,NLM,MEDLINE,19721116,20071115,0323-4347 (Print) 0323-4347 (Linking),97,4,1972,[The HL-A-system].,245-58,,"['Mayr, W R']",['Mayr WR'],['ger'],"['Journal Article', 'Review']",Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Agranulocytosis/immunology', 'Anthropology', 'Austria', 'Blood Transfusion', 'Choriocarcinoma/immunology', 'Chromosome Mapping', 'Complement Fixation Tests', 'Female', 'Gene Frequency', '*Histocompatibility Antigens', 'Humans', 'Immunogenetics', 'Leukemia, Lymphoid/immunology', 'Lymphocytes', 'Paternity', 'Polymorphism, Genetic', 'Pregnancy', 'Serologic Tests', '*Transplantation Immunology', 'Transplantation, Homologous']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(4):245-58.,['0 (Histocompatibility Antigens)'],70,Das HL-A-System.,,,,,,,,,
4116091,NLM,MEDLINE,19721116,20071115,0012-0472 (Print) 0012-0472 (Linking),97,38,1972 Sep 22,[Studies on the significance of Auer's bodies in acute myelocytic leukemia].,1416-8 passim,,"['Hennekeuser, H H', 'Gerdes, H', 'Scholz, H']","['Hennekeuser HH', 'Gerdes H', 'Scholz H']",['ger'],['Journal Article'],Germany,Dtsch Med Wochenschr,Deutsche medizinische Wochenschrift (1946),0006723,IM,"['Adult', 'Age Factors', 'Blood Cell Count', 'Clinical Enzyme Tests', 'Germany, West', '*Hematopoietic Stem Cells', 'Humans', 'Leukemia, Myeloid/epidemiology', 'Leukemia, Myeloid, Acute/mortality/*pathology', '*Leukocytes/enzymology', 'Medical History Taking', 'Peroxidases', 'Physical Examination', 'Prognosis', 'Remission, Spontaneous/epidemiology', 'Sampling Studies', 'Staining and Labeling']",,1972/09/22 00:00,1972/09/22 00:01,['1972/09/22 00:00'],"['1972/09/22 00:00 [pubmed]', '1972/09/22 00:01 [medline]', '1972/09/22 00:00 [entrez]']",['10.1055/s-0028-1107575 [doi]'],ppublish,Dtsch Med Wochenschr. 1972 Sep 22;97(38):1416-8 passim. doi: 10.1055/s-0028-1107575.,['EC 1.11.1.- (Peroxidases)'],,Untersuchungen zur Bedeutung der Auer-Stabchen bei akuter myeloischer Leukamie.,,,,,,,,,
4115880,NLM,MEDLINE,19721108,20041117,0001-5555 (Print) 0001-5555 (Linking),52,4,1972,"Incontinentia pigmenti with associated lesions in two generations. Clinical, light microscopic, and electronmicroscopic examinations.",281-7,,"['Schmidt, H', 'Hvidberg-Hansen, J', 'Christensen, H E']","['Schmidt H', 'Hvidberg-Hansen J', 'Christensen HE']",['eng'],['Journal Article'],Sweden,Acta Derm Venereol,Acta dermato-venereologica,0370310,IM,"['*Abnormalities, Multiple', 'Acute Disease', 'Adult', 'Basement Membrane', 'Child', 'Child, Preschool', '*Cytoplasmic Granules', 'Eye Abnormalities', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/complications', 'Male', 'Microscopy, Electron', 'Nevus, Pigmented/complications', 'Pigmentation Disorders/complications/*genetics/pathology', 'Pregnancy', 'Retinoblastoma/complications', 'Skin/*pathology', 'Tooth Abnormalities/complications']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Acta Derm Venereol. 1972;52(4):281-7.,,,,,,,,,,,,
4115712,NLM,MEDLINE,19721025,20131121,0033-7587 (Print) 0033-7587 (Linking),51,3,1972 Sep,Further studies of radiation-induced interphase death of cultured mammalian cells.,685-95,,"['Goldstein, R', 'Okada, S']","['Goldstein R', 'Okada S']",['eng'],['Journal Article'],United States,Radiat Res,Radiation research,0401245,IM,"['Animals', 'Cell Division', 'Cell Line', 'Cell Survival', '*Cells, Cultured', 'Culture Media', 'Dinitrophenols/pharmacology', 'Leukemia, Experimental', 'Leukocytes/*radiation effects', 'Mice', 'Puromycin/pharmacology', '*Radiation Effects', 'Staining and Labeling', 'Temperature', 'Thymidine', 'Tritium', 'Uridine']",,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,Radiat Res. 1972 Sep;51(3):685-95.,"['0 (Culture Media)', '0 (Dinitrophenols)', '10028-17-8 (Tritium)', '4A6ZS6Q2CL (Puromycin)', 'VC2W18DGKR (Thymidine)', 'WHI7HQ7H85 (Uridine)']",,,,,,,,,,,
4115545,NLM,MEDLINE,19721019,20051117,0022-1767 (Print) 0022-1767 (Linking),109,3,1972 Sep,The alternate complement pathway in cell damage: antibody-mediated cytolysis of erythrocytes and nucleated cells.,595-601,,"['May, J E', 'Green, I', 'Frank, M M']","['May JE', 'Green I', 'Frank MM']",['eng'],['Journal Article'],United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,IM,"['Animals', 'Antibodies', 'Antilymphocyte Serum', 'Cattle/immunology', 'Chromatography, Gel', 'Chromium Isotopes', 'Complement Fixation Tests', 'Complement System Proteins/*metabolism', 'Cytotoxicity Tests, Immunologic', 'Dinitrophenols', 'Erythrocytes/*immunology', 'Guinea Pigs/immunology', 'Immunization', 'Leukemia/immunology', 'Lymph Nodes/immunology', 'Mice/immunology', 'Perissodactyla/immunology', 'Rabbits/immunology', 'Spleen/immunology', 'Thymus Gland/immunology', 'gamma-Globulins']",,1972/09/01 00:00,1972/09/01 00:01,['1972/09/01 00:00'],"['1972/09/01 00:00 [pubmed]', '1972/09/01 00:01 [medline]', '1972/09/01 00:00 [entrez]']",,ppublish,J Immunol. 1972 Sep;109(3):595-601.,"['0 (Antibodies)', '0 (Antilymphocyte Serum)', '0 (Chromium Isotopes)', '0 (Dinitrophenols)', '0 (gamma-Globulins)', '9007-36-7 (Complement System Proteins)']",,,,,,,,,,,
4115520,NLM,MEDLINE,19721018,20190618,0036-8075 (Print) 0036-8075 (Linking),177,4054,1972 Sep 22,DNA polymerases from RNA tumor viruses and human cells: inhibition by polyuridylic acid.,1111-4,"Polyuridylic acid inhibited DNA polymerases purified from three species of oncornaviruses as well as three out of seven DNA polymerases purified from cells. Viral and cellular DNA polymerases could not be distinguished by polyuridylic acid inhibition, but were easily distinguished by their template preferences in the presence of magnesium.","['Abrell, J W', 'Smith, R G', 'Robert, M S', 'Gallo, B C']","['Abrell JW', 'Smith RG', 'Robert MS', 'Gallo BC']",['eng'],['Journal Article'],United States,Science,"Science (New York, N.Y.)",0404511,IM,"['Animals', 'Avian Leukosis Virus/enzymology', 'DNA/metabolism', 'DNA Nucleotidyltransferases/*antagonists & inhibitors/isolation & purification/metabolism', 'Escherichia coli/enzymology', 'Haplorhini', 'Humans', 'Kinetics', 'Leukemia, Lymphoid/enzymology', 'Lymphocytes/enzymology', 'Mice', 'Oncogenic Viruses/*enzymology', 'Polynucleotides/metabolism/*pharmacology', 'RNA Viruses/*enzymology', 'RNA-Directed DNA Polymerase/isolation & purification/metabolism', 'Rauscher Virus/enzymology', 'Reverse Transcriptase Inhibitors', 'Templates, Genetic', 'Uracil Nucleotides/*pharmacology']",,1972/09/22 00:00,1972/09/22 00:01,['1972/09/22 00:00'],"['1972/09/22 00:00 [pubmed]', '1972/09/22 00:01 [medline]', '1972/09/22 00:00 [entrez]']",['10.1126/science.177.4054.1111 [doi]'],ppublish,Science. 1972 Sep 22;177(4054):1111-4. doi: 10.1126/science.177.4054.1111.,"['0 (Polynucleotides)', '0 (Reverse Transcriptase Inhibitors)', '0 (Uracil Nucleotides)', '9007-49-2 (DNA)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'EC 2.7.7.49 (RNA-Directed DNA Polymerase)']",,,,,,,,,,,
4115518,NLM,MEDLINE,19721018,20071115,0036-7672 (Print) 0036-7672 (Linking),102,33,1972 Aug 19,"HL-A antigens in chronic lymphocytic leukemia: preliminary evidence for the existence of ""leukemia specific"" antigens.",1170-2,,"['Jeannet, M', 'Alberto, P']","['Jeannet M', 'Alberto P']",['eng'],['Journal Article'],Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,IM,"['Animals', '*Antigens', 'Antigens, Neoplasm', 'Complement System Proteins', 'Epitopes', 'Histocompatibility', 'Humans', 'Immune Sera', 'Leukemia, Lymphoid/*immunology', 'Lymphocytes/*immunology', 'Rabbits/immunology']",,1972/08/19 00:00,1972/08/19 00:01,['1972/08/19 00:00'],"['1972/08/19 00:00 [pubmed]', '1972/08/19 00:01 [medline]', '1972/08/19 00:00 [entrez]']",,ppublish,Schweiz Med Wochenschr. 1972 Aug 19;102(33):1170-2.,"['0 (Antigens)', '0 (Antigens, Neoplasm)', '0 (Epitopes)', '0 (Immune Sera)', '9007-36-7 (Complement System Proteins)']",,,,,,,,,,,
4115510,NLM,MEDLINE,19721018,20041117,0021-8200 (Print) 0021-8200 (Linking),78,1,1972 Jan-Feb,[Prostatectomy in a chronic leukemic patient].,133-7,,"['Banchieri, F R', 'Provana, A', 'Viarengo, G']","['Banchieri FR', 'Provana A', 'Viarengo G']",['fre'],"['Case Reports', 'Journal Article']",France,J Urol Nephrol (Paris),Journal d'urologie et de nephrologie,7802652,IM,"['Asthenia/etiology', 'Humans', 'Leukemia, Myeloid/*complications/pathology', 'Male', 'Middle Aged', 'Postoperative Complications', 'Prognosis', 'Prostate/pathology', '*Prostatectomy', 'Prostatic Hyperplasia/*complications/pathology', 'Splenomegaly/etiology', 'Urinary Catheterization', 'Urination Disorders/etiology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,J Urol Nephrol (Paris). 1972 Jan-Feb;78(1):133-7.,,,Prostatectomie chez un leucemique chronique.,,,,,,,,,
4115491,NLM,MEDLINE,19721018,20061115,0028-2685 (Print) 0028-2685 (Linking),19,4,1972,Cytochemical methods in diagnosis of malignant neoplasms.,327-30,,"['Petrova, A S', 'Kazanova, L I', 'Solovieva, E A']","['Petrova AS', 'Kazanova LI', 'Solovieva EA']",['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Acid Phosphatase/analysis', 'Alkaline Phosphatase/analysis', 'Bone Neoplasms/diagnosis', 'Breast Neoplasms/diagnosis', 'Esterases/analysis', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia/diagnosis', 'Lipids/analysis', 'Lymphatic Metastasis', 'Male', 'Methods', 'Neoplasms/*diagnosis', 'Peroxidases/analysis', 'Polysaccharides/analysis', 'Salivary Gland Neoplasms/diagnosis', 'Sex Chromatin/analysis', 'Skin Neoplasms/diagnosis', 'Staining and Labeling', 'Uterine Neoplasms/diagnosis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1972;19(4):327-30.,"['0 (Lipids)', '0 (Polysaccharides)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.1 (Alkaline Phosphatase)', 'EC 3.1.3.2 (Acid Phosphatase)']",,,,,,,,,,,
4115478,NLM,MEDLINE,19721018,20151119,0009-9163 (Print) 0009-9163 (Linking),3,2,1972,Quantitative studies of Y chromosomal fluorescence in human interphase nuclei.,103-15,,"['Lamborot-Manzur, M', 'Tishler, P V', 'Atkins, L']","['Lamborot-Manzur M', 'Tishler PV', 'Atkins L']",['eng'],['Journal Article'],Denmark,Clin Genet,Clinical genetics,0253664,IM,"['Adult', 'Aneuploidy', 'Carcinoma, Bronchogenic/genetics', '*Chromosome Aberrations', 'Female', 'Fluorescence', 'Humans', 'Infant, Newborn', 'Karyotyping', 'Leukemia/genetics', 'Leukocytes', 'Lung Neoplasms/genetics', 'Male', 'Methods', 'Microscopy, Fluorescence', 'Mosaicism', 'Mouth Mucosa/cytology', 'Mustard Compounds', 'Quinacrine', '*Sex Chromatin', 'Sex Chromosome Aberrations/genetics', '*Sex Chromosomes', '*Sex Determination Analysis', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Clin Genet. 1972;3(2):103-15.,"['0 (Mustard Compounds)', 'H0C805XYDE (Quinacrine)']",,,,,,,,,,,
4115468,NLM,MEDLINE,19721012,20131121,0301-1518 (Print) 0301-1518 (Linking),1,26,1972 Jun 24,[The best chemotherapy in the world can only give what it can].,1753-6,,"['Mathe, G']",['Mathe G'],['fre'],['Journal Article'],France,Nouv Presse Med,La Nouvelle presse medicale,0312552,IM,"['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Asparaginase/therapeutic use', 'Drug Combinations', 'Drug Interactions', 'Humans', 'Leukemia, Lymphoid/drug therapy', 'Methotrexate/therapeutic use', 'Neoplasms/*drug therapy/radiotherapy/surgery', 'Palliative Care', 'Prognosis']",,1972/06/24 00:00,1972/06/24 00:01,['1972/06/24 00:00'],"['1972/06/24 00:00 [pubmed]', '1972/06/24 00:01 [medline]', '1972/06/24 00:00 [entrez]']",,ppublish,Nouv Presse Med. 1972 Jun 24;1(26):1753-6.,"['0 (Antineoplastic Agents)', '0 (Drug Combinations)', 'EC 3.5.1.1 (Asparaginase)', 'YL5FZ2Y5U1 (Methotrexate)']",,La meilleure chimiotherapie du monde ne peut donner que ce qu'elle peut.,,,,,,,,,
4115401,NLM,MEDLINE,19721006,20190714,0042-6822 (Print) 0042-6822 (Linking),49,2,1972 Aug,Properties of mouse leukemia viruses. 3. Electron microscopic appearance as revealed after conventional preparation techniques as well as freeze-drying and freeze-etching.,345-58,,"['Nermut, M V', 'Frank, H', 'Schafer, W']","['Nermut MV', 'Frank H', 'Schafer W']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['*AKR murine leukemia virus', 'Agar', 'Chromatography, Gel', 'Dimethyl Sulfoxide', '*Freeze Drying', 'Freeze Etching', '*Freezing', '*Friend murine leukemia virus', '*Histological Techniques', '*Leukemia Virus, Murine', '*Microscopy, Electron', 'Models, Structural', 'Phosphotungstic Acid', '*Rauscher Virus', 'Staining and Labeling', 'Surface-Active Agents', 'Trypsin', 'Viral Proteins']",,1972/08/01 00:00,1972/08/01 00:01,['1972/08/01 00:00'],"['1972/08/01 00:00 [pubmed]', '1972/08/01 00:01 [medline]', '1972/08/01 00:00 [entrez]']",['10.1016/0042-6822(72)90487-4 [doi]'],ppublish,Virology. 1972 Aug;49(2):345-58. doi: 10.1016/0042-6822(72)90487-4.,"['0 (Surface-Active Agents)', '0 (Viral Proteins)', '12067-99-1 (Phosphotungstic Acid)', '9002-18-0 (Agar)', 'EC 3.4.21.4 (Trypsin)', 'YOW8V9698H (Dimethyl Sulfoxide)']",,,,,,,,,,,
4115400,NLM,MEDLINE,19721006,20190903,0080-0015 (Print) 0080-0015 (Linking),33,,1970,Experimental investigations on problems of the clinical use of L-asparaginase.,114-24,,"['Bierling, R']",['Bierling R'],['eng'],['Journal Article'],Germany,Recent Results Cancer Res,Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,0044671,IM,"['Animals', 'Antibody Formation', 'Antineoplastic Agents/therapeutic use', 'Asparaginase/administration & dosage/*therapeutic use', 'Cytarabine/therapeutic use', 'Dactinomycin/therapeutic use', 'Drug Resistance', 'Drug Synergism', 'Escherichia coli/*enzymology', 'Immunization', 'Immunosuppressive Agents/therapeutic use', 'Leukemia, Experimental/*drug therapy/immunology', 'Melphalan/therapeutic use', 'Mice', 'Mice, Inbred Strains', 'Neoplasm Metastasis', 'Neoplasm Transplantation', 'Podophyllin/therapeutic use', 'Procarbazine/therapeutic use', 'Time Factors', 'Vincristine/therapeutic use']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",['10.1007/978-3-642-99984-0_13 [doi]'],ppublish,Recent Results Cancer Res. 1970;33:114-24. doi: 10.1007/978-3-642-99984-0_13.,"['0 (Antineoplastic Agents)', '0 (Immunosuppressive Agents)', '04079A1RDZ (Cytarabine)', '1CC1JFE158 (Dactinomycin)', '35S93Y190K (Procarbazine)', '5J49Q6B70F (Vincristine)', '9000-55-9 (Podophyllin)', 'EC 3.5.1.1 (Asparaginase)', 'Q41OR9510P (Melphalan)']",,,,,,,,,,,
4115356,NLM,MEDLINE,19721006,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7775,1972 Sep 2,Cure as the aim in therapy for the acute leukaemias.,473-5,,"['Spiers, A S']",['Spiers AS'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Age Factors', 'Antineoplastic Agents/pharmacology/therapeutic use', 'Central Nervous System/drug effects', 'Child', 'Humans', 'Injections, Spinal', 'Leukemia/drug therapy/radiotherapy/*therapy', 'Methotrexate/administration & dosage', 'Neoplastic Cells, Circulating/drug therapy', 'Palliative Care', 'Prognosis', 'Remission, Spontaneous', 'Time Factors']",,1972/09/02 00:00,1972/09/02 00:01,['1972/09/02 00:00'],"['1972/09/02 00:00 [pubmed]', '1972/09/02 00:01 [medline]', '1972/09/02 00:00 [entrez]']","['S0140-6736(72)91866-1 [pii]', '10.1016/s0140-6736(72)91866-1 [doi]']",ppublish,Lancet. 1972 Sep 2;2(7775):473-5. doi: 10.1016/s0140-6736(72)91866-1.,"['0 (Antineoplastic Agents)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4115311,NLM,MEDLINE,19721005,20190501,0027-8424 (Print) 0027-8424 (Linking),69,8,1972 Aug,Anti-human immunoglobulin G activity of membrane-bound monoclonal immunoglobulin M in lymphoproliferative disorders.,2132-5,"Lymphocytes from a patient with Waldenstrom's macroglobulinemia and known anti-immunoglobulin IgG activity of serum monoclonal IgM and lymphocytes from selected patients with chronic lymphocytic leukemia were studied by the membrane immunofluorescence procedure. Freshly drawn lymphocytes were shown to bear simultaneously mu, gamma, [unk], and lambda chain determinants. Experiments combining redistribution induced by antibody and double labeling proved that IgG was bound to surface IgM. After removal of surface immunoglobulins by treatment with trypsin followed by incubation in culture medium, or after redistribution induced by antibody, the exclusive presence of a newly synthetized monoclonal IgM was demonstrated. Several experiments showed that this surface IgM does specifically bind normal human IgG molecules devoid of aggregated material. The IgG molecules could be removed from the cell surface by lowering the pH. In addition to its high incidence among serum monoclonal macroglobulins, anti-IgG activity of membrane-bound monoclonal IgM is not uncommon in patients with chronic lymphocytic leukemia, a disease that provides homogeneous populations of lymphocytes derived from bone marrow, with receptor sites of defined antibody activity.","[""Preud'homme, J L"", 'Seligmann, M']","[""Preud'homme JL"", 'Seligmann M']",['eng'],['Journal Article'],United States,Proc Natl Acad Sci U S A,Proceedings of the National Academy of Sciences of the United States of America,7505876,IM,"['Cell Membrane/immunology', 'Chromatography, DEAE-Cellulose', 'Epitopes/*analysis', 'Fluorescent Antibody Technique', 'Humans', 'Hydrogen-Ion Concentration', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Leukemia, Lymphoid/*immunology', 'Lymphocytes/*immunology', 'Methods', 'Protein Binding', 'Receptors, Drug', 'Staining and Labeling', 'Trypsin', 'Waldenstrom Macroglobulinemia/*immunology']",PMC426885,1972/08/01 00:00,1972/08/01 00:01,['1972/08/01 00:00'],"['1972/08/01 00:00 [pubmed]', '1972/08/01 00:01 [medline]', '1972/08/01 00:00 [entrez]']",['10.1073/pnas.69.8.2132 [doi]'],ppublish,Proc Natl Acad Sci U S A. 1972 Aug;69(8):2132-5. doi: 10.1073/pnas.69.8.2132.,"['0 (Epitopes)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Receptors, Drug)', 'EC 3.4.21.4 (Trypsin)']",,,,,,,,,,,
4115181,NLM,MEDLINE,19721003,20131121,0029-4810 (Print) 0029-4810 (Linking),12,1,1972 Jan-Feb,[Double erythrocyte population in erythroleukemia with hemoglobin H. Study by electron microscope and microspectrophotometry].,43-63,,"['Najman, A', 'Breton-Gorius, J', 'Turpin, F', 'Duhamel, G', 'Andre, R']","['Najman A', 'Breton-Gorius J', 'Turpin F', 'Duhamel G', 'Andre R']",['fre'],['Journal Article'],France,Nouv Rev Fr Hematol,Nouvelle revue francaise d'hematologie,0401074,IM,"['Bone Marrow Cells', 'Bone Marrow Examination', '*Erythrocytes, Abnormal/analysis', 'Erythropoiesis', 'Glycogen/analysis', 'Hemoglobins, Abnormal/*analysis', 'Humans', 'Iron/analysis', 'Leukemia, Erythroblastic, Acute/*blood', 'Microscopy, Electron', 'Mitochondria/analysis', 'Reticulocytes/analysis', 'Spectrophotometry', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Nouv Rev Fr Hematol. 1972 Jan-Feb;12(1):43-63.,"['0 (Hemoglobins, Abnormal)', '9005-79-2 (Glycogen)', 'E1UOL152H7 (Iron)']",,Double population erythrocytaire au cours d'une erythro-leucemie avec hemoglobine H. Etude au microscope electronique et en micro-spectro-photometrie.,,,,,,,,,
4115152,NLM,MEDLINE,19721002,20091111,0036-5327 (Print) 0036-5327 (Linking),74,7,1972 Jul,[Finding of F body in blood cells of a woman with karyotype 46 XX with chronic lymphatic leukemia].,218-21,,"['Chrz, R', 'Michalova, K', 'Benesova, E', 'Possnerova, V']","['Chrz R', 'Michalova K', 'Benesova E', 'Possnerova V']",['cze'],['Journal Article'],Czech Republic,Sb Lek,Sbornik lekarsky,0025770,IM,"['Chromosome Aberrations', 'Female', '*Fluorescence', 'Humans', 'Karyotyping', 'Leukemia, Lymphoid/*blood', 'Microscopy, Fluorescence', 'Middle Aged', '*Sex Chromosomes', 'Staining and Labeling']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,Sb Lek. 1972 Jul;74(7):218-21.,,,Nalez F teliska v krevnich bunkach zeny karyotypu 46 XX s chronickou lymfatickou leukemii.,,,,,,,,,
4114997,NLM,MEDLINE,19720930,20131121,0069-0139 (Print) 0069-0139 (Linking),3,1,1972 May,Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: pharmacology.,69-71,,"['Oliverio, V T']",['Oliverio VT'],['eng'],['Journal Article'],United States,Cancer Chemother Rep 3,Cancer chemotherapy reports. Part 3,7609154,IM,"['Alkaloids/metabolism/therapeutic use', 'Animals', 'Antimetabolites/pharmacology', 'Antineoplastic Agents/*pharmacology', 'Autoradiography', 'Azacitidine/metabolism/therapeutic use', 'Carbazoles/therapeutic use', 'Carbon Isotopes', 'Cell Line/drug effects', 'Cells, Cultured/drug effects', 'Cricetinae', 'Cytarabine/pharmacology/therapeutic use', 'DNA/biosynthesis', 'DNA Nucleotidyltransferases/antagonists & inhibitors', 'Dogs', 'Half-Life', 'Humans', 'Leukemia L1210/drug therapy', 'Lung/drug effects', 'Pyridines/therapeutic use', 'RNA/biosynthesis']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,Cancer Chemother Rep 3. 1972 May;3(1):69-71.,"['0 (Alkaloids)', '0 (Antimetabolites)', '0 (Antineoplastic Agents)', '0 (Carbazoles)', '0 (Carbon Isotopes)', '0 (Pyridines)', '04079A1RDZ (Cytarabine)', '63231-63-0 (RNA)', '9007-49-2 (DNA)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'M801H13NRU (Azacitidine)']",,,,,,,,,,,
4114897,NLM,MEDLINE,19720922,20081121,0323-4347 (Print) 0323-4347 (Linking),97,3,1972,Occurrence of alkaline phosphatase reaction in the immature myeloid and reticular cells of the peripheral blood.,168-76,,"['Berzy, I', 'Solti, V']","['Berzy I', 'Solti V']",['eng'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Alkaline Phosphatase/*blood', 'Bone Marrow Cells', 'Clinical Enzyme Tests', 'Hematopoietic Stem Cells/enzymology', 'Humans', 'Leukemia, Myeloid/blood/*enzymology', 'Leukocytes/enzymology', 'Leukocytosis/blood/*enzymology', 'Lymphatic Diseases/blood/*enzymology', 'Reticulocytes/enzymology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(3):168-76.,['EC 3.1.3.1 (Alkaline Phosphatase)'],,,,,,,,,,,
4114896,NLM,MEDLINE,19720922,20071115,0323-4347 (Print) 0323-4347 (Linking),97,3,1972,"[Changes in the total serum levels of gamma globulin and immunoglobulins G, A and M in children with leukemia. 3. Discussion of the results].",157-67,,"['Blau, H J']",['Blau HJ'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Agammaglobulinemia/complications/etiology', 'Bacterial Infections/etiology', 'Child', 'Child, Preschool', 'Follow-Up Studies', 'Humans', 'Immunodiffusion', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/*analysis', 'Infant', 'Infant, Newborn', 'Leukemia, Myeloid/blood/complications/*immunology', 'Leukemia, Myeloid, Acute/blood/complications/*immunology', 'Remission, Spontaneous', 'gamma-Globulins/*analysis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(3):157-67.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,"Uber die Veranderungen des Gesamtgehalts an Gammaglobulin und der Immunglobuline G, A und M im Serum von Kindern mit Leukamie. 3. Diskussion der Ergebnisse.",,,,,,,,,
4114895,NLM,MEDLINE,19720922,20071115,0323-4347 (Print) 0323-4347 (Linking),97,3,1972,"[Changes in the total serum levels of gamma globulin and immunoglobulins G, A and M in children with leukemia. II. Quantitative changes of serum immunoglobulins G, A and M during leukemia in children].",146-56,,"['Blau, H J']",['Blau HJ'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Agammaglobulinemia/complications/etiology', 'Analysis of Variance', 'Bacterial Infections/etiology', 'Child', 'Child, Preschool', 'Humans', 'Immunodiffusion', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/*analysis', 'Infant', 'Infant, Newborn', 'Leukemia, Myeloid/blood/complications/*immunology', 'Leukemia, Myeloid, Acute/blood/complications/*immunology', 'Male', 'Remission, Spontaneous', 'gamma-Globulins/*analysis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(3):146-56.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,"Uber die Veranderungen des Gesamtgehalts an Gammaglobulin und der Immunglobuline G, A und M im Serum von Kindern mit Leukamie. II. Quantitative Veranderungen der Immunglobuline G, A und M im Serum wahrend der Leukamie bei Kindern.",,,,,,,,,
4114894,NLM,MEDLINE,19720922,20071115,0323-4347 (Print) 0323-4347 (Linking),97,3,1972,"[Changes in the total serum levels of gamma globulin and immunoglobulins G, A and M in children with leukemia. I. Changes of total gamma globulin levels and qualitative changes of serum immunoglobulins during leukemia in children].",139-45,,"['Blau, H J']",['Blau HJ'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Agammaglobulinemia/complications/etiology', 'Analysis of Variance', 'Bacterial Infections/etiology', 'Child', 'Child, Preschool', 'Electrophoresis, Paper', 'Humans', 'Immunoelectrophoresis', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/*analysis', 'Infant', 'Infant, Newborn', 'Leukemia, Myeloid/blood/complications/*immunology', 'Leukemia, Myeloid, Acute/blood/complications/*immunology', 'Male', 'Remission, Spontaneous', 'gamma-Globulins/*analysis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(3):139-45.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,Uber die Veranderungen des Gesamtgehalts an Gammaglobulin und der Immunglobuline G A und M im Serum von Kindern mit Leukamie. I. Die Veranderungen des Gesamtgehalts an Gammaglobulin und qualitative Immunglobulinveranderungen im Serum wahrend der Leukamie bei Kindern.,,,,,,,,,
4114893,NLM,MEDLINE,19720922,20171116,0323-4347 (Print) 0323-4347 (Linking),97,3,1972,[Cytostatics in hematology].,109-28,,"['Gross, R']",['Gross R'],['ger'],"['Historical Article', 'Journal Article']",Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Antineoplastic Agents/history/pharmacology/*therapeutic use/toxicity', 'Asparaginase/pharmacology', 'Cell Division', 'Chemistry', 'Culture Techniques', 'Cytarabine/pharmacology', 'DNA/biosynthesis', 'Daunorubicin/pharmacology', 'Depression, Chemical', 'Drug Combinations', 'Drug Resistance', 'Germ-Free Life', 'Half-Life', 'History, 20th Century', 'Hodgkin Disease/drug therapy', 'Humans', 'Leukemia/*drug therapy', 'Lymphatic Diseases/drug therapy', 'Mercaptopurine/pharmacology', 'Remission, Spontaneous', 'Stimulation, Chemical', 'Thioguanine/pharmacology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(3):109-28.,"['0 (Antineoplastic Agents)', '0 (Drug Combinations)', '04079A1RDZ (Cytarabine)', '9007-49-2 (DNA)', 'E7WED276I5 (Mercaptopurine)', 'EC 3.5.1.1 (Asparaginase)', 'FTK8U1GZNX (Thioguanine)', 'ZS7284E0ZP (Daunorubicin)']",,Zytostatika in der Hamatologie.,,,,,,,,,
4114866,NLM,MEDLINE,19720922,20081121,0001-5318 (Print) 0001-5318 (Linking),28,1,1972,"[Immunologic studies in virus-induced mouse and rat leukemia. II. Demonstration of a membrane-bound, group-specific leukemia antigen in Graffi and Gross leukemias of the mouse].",167-75,,"['Micheel, B', 'Pasternak, G', 'Bierwolf, D']","['Micheel B', 'Pasternak G', 'Bierwolf D']",['ger'],['Journal Article'],Germany,Acta Biol Med Ger,Acta biologica et medica Germanica,0370276,IM,"['AKR murine leukemia virus/immunology', 'Animals', 'Antigens/*analysis', 'Antigens, Neoplasm/analysis', 'Cell Membrane/immunology', 'Epitopes', 'Immune Sera', 'Leukemia, Experimental/*immunology', 'Mice', 'Mice, Inbred Strains', 'Neoplastic Cells, Circulating', 'Rats', 'Rats, Inbred Strains', 'Retroviridae/immunology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Acta Biol Med Ger. 1972;28(1):167-75.,"['0 (Antigens)', '0 (Antigens, Neoplasm)', '0 (Epitopes)', '0 (Immune Sera)']",,"Immunologische Untersuchungen an virusinduzierten Maus- und Rattenleukamien. II. Nachweis eines membrangebundenen, gruppenspezifischen Leukamienantigens in Graffi- und Gross-Leukamien der Maus.",,,,,,,,,
4114852,NLM,MEDLINE,19720922,20071115,0032-2938 (Print) 0032-2938 (Linking),11,3,1972,Serum proteolytic activity connected with 2 -macroglobulin in hemorrhagic diathesis.,488-94,,"['Szczeklik, A']",['Szczeklik A'],['eng'],['Journal Article'],Poland,Pol Med J,Polish medical journal,0376721,IM,"['Adolescent', 'Adult', 'Aged', '*Alpha-Globulins', 'Biliary Tract Diseases/blood', 'Blood Protein Electrophoresis', 'Blood Proteins/*metabolism', 'Cardiovascular Diseases/blood/drug therapy', 'Coumarins/adverse effects', 'Female', 'Gastrointestinal Diseases/blood', 'Hemorrhagic Disorders/chemically induced/*metabolism', 'Humans', 'Hydrolysis', 'Kidney Diseases/blood', 'Leukemia, Lymphoid/complications', 'Leukemia, Myeloid/complications', 'Lung Diseases/blood', 'Lymphoma, Non-Hodgkin/complications', '*Macroglobulins', 'Male', 'Middle Aged', 'Pancreatitis/blood', 'Prothrombin Time']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Pol Med J. 1972;11(3):488-94.,"['0 (Alpha-Globulins)', '0 (Blood Proteins)', '0 (Coumarins)', '0 (Macroglobulins)']",,,,,,,,,,,
4114839,NLM,MEDLINE,19720922,20190511,0002-9173 (Print) 0002-9173 (Linking),58,2,1972 Aug,Nuclear lobulation and cytoplasmic fibrils in leukemic plasma cells.,159-64,,"['Beltran, G', 'Stuckey, W J']","['Beltran G', 'Stuckey WJ']",['eng'],['Journal Article'],England,Am J Clin Pathol,American journal of clinical pathology,0370470,IM,"['Aged', 'Cell Nucleus', 'Cytoplasm', 'Humans', 'Leukemia, Plasma Cell/blood/complications/*pathology', 'Male', 'Methods', 'Microscopy, Electron', 'Multiple Myeloma/blood/complications/*pathology', '*Plasma Cells', 'Staining and Labeling']",,1972/08/01 00:00,1972/08/01 00:01,['1972/08/01 00:00'],"['1972/08/01 00:00 [pubmed]', '1972/08/01 00:01 [medline]', '1972/08/01 00:00 [entrez]']",['10.1093/ajcp/58.2.159 [doi]'],ppublish,Am J Clin Pathol. 1972 Aug;58(2):159-64. doi: 10.1093/ajcp/58.2.159.,,,,,,,,,,,,
4114813,NLM,MEDLINE,19720921,20190515,0007-0920 (Print) 0007-0920 (Linking),26,3,1972 Jun,Lymphocyte transformation in immunoproliferative disorders.,154-63,"Lymphocyte transformation with phytohaemagglutinin (PHA) was studied in 30 patients with immunoproliferative disorders (lymphoproliferative and plasma cell disorders).Lymphocyte transformation at 3 days was reduced in the lymphoproliferative disorders (chronic lymphocytic leukaemia (CLL), well-differentiated (lymphocytic) follicular lymphoma (FLL) and Waldenstrom's macroglobulinaemia (WM)), and normal in the plasma cell disorders (myelomatosis, primary systemic amyloidosis, alpha-chain disease and benign monoclonal gammopathy) and in idiopathic cold haemagglutinin disease. A case of plasma-cell leukaemia with increased numbers of abnormal cells in the circulation also showed reduced transformation. It is suggested that the presence in the circulation of abnormal lymphocytes (or plasma cells) accounts for the results in CLL and FLL, WM and plasma-cell leukaemia. In WM a correlation was found between the activity of the disease (expressed by the levels of IgM paraprotein) and the degree of blast transformation.The long-term (28 days) in vitro survival of lymphocytes using subconcentrations of PHA was also studied in 7 patients. The cell populations (PHA-non-responsive) of CLL and FLL, but not of WM, had a good in vitro survival, resembling in this respect the normal PHA-responsive population of lymphocytes, but they remained PHA-non-responsive after 4 weeks' culture. It is speculated that in CLL the long survival in vitro of the PHA-non-responsive (leukaemic) population corresponds to their long life-span in vivo.","['Catovsky, D', 'Holt, P J', 'Galton, D A']","['Catovsky D', 'Holt PJ', 'Galton DA']",['eng'],['Journal Article'],England,Br J Cancer,British journal of cancer,0370635,IM,"['Amyloidosis/immunology', 'Blood Protein Disorders/*immunology', 'Cell Survival', 'Cells, Cultured', 'Cryoglobulins', 'Humans', 'In Vitro Techniques', 'Lectins/pharmacology', 'Leukemia/*immunology', 'Leukemia, Lymphoid/immunology', 'Leukemia, Plasma Cell/immunology', '*Lymphocyte Activation', 'Lymphocytes/drug effects', 'Lymphoma/*immunology', 'Lymphoma, Non-Hodgkin/immunology', 'Multiple Myeloma/immunology', 'Waldenstrom Macroglobulinemia/immunology', 'gamma-Globulins']",PMC2008467,1972/06/01 00:00,1972/06/01 00:01,['1972/06/01 00:00'],"['1972/06/01 00:00 [pubmed]', '1972/06/01 00:01 [medline]', '1972/06/01 00:00 [entrez]']",['10.1038/bjc.1972.22 [doi]'],ppublish,Br J Cancer. 1972 Jun;26(3):154-63. doi: 10.1038/bjc.1972.22.,"['0 (Cryoglobulins)', '0 (Lectins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4114790,NLM,MEDLINE,19720921,20181113,0009-9104 (Print) 0009-9104 (Linking),10,2,1972 Feb,Unreleased intracellular monoclonal macroglobulin in chronic lymphocytic leukaemia.,223-34,,"['Hurez, D', 'Flandrin, G', ""Preud'homme, J L"", 'Seligmann, M']","['Hurez D', 'Flandrin G', ""Preud'homme JL"", 'Seligmann M']",['eng'],['Journal Article'],England,Clin Exp Immunol,Clinical and experimental immunology,0057202,IM,"['Aged', 'Cytoplasmic Granules', 'Electrophoresis, Disc', 'Electrophoresis, Paper', 'Endoplasmic Reticulum', 'Fluorescent Antibody Technique', 'Humans', 'Immune Sera', 'Immunodiffusion', 'Immunoelectrophoresis', 'Immunoglobulins', 'Leukemia, Lymphoid/*immunology', 'Lymphocytes', 'Macroglobulins/*analysis', 'Male', 'Microscopy, Electron', 'Middle Aged', 'gamma-Globulins']",PMC1713178,1972/02/01 00:00,1972/02/01 00:01,['1972/02/01 00:00'],"['1972/02/01 00:00 [pubmed]', '1972/02/01 00:01 [medline]', '1972/02/01 00:00 [entrez]']",,ppublish,Clin Exp Immunol. 1972 Feb;10(2):223-34.,"['0 (Immune Sera)', '0 (Immunoglobulins)', '0 (Macroglobulins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4114603,NLM,MEDLINE,19720919,20091111,0079-0184 (Print) 0079-0184 (Linking),7,,1972,Plasma cell myelomatosis and other monoclonal gammapathies.,1-17,,"['Azar, H A']",['Azar HA'],['eng'],"['Journal Article', 'Review']",United States,Pathol Annu,Pathology annual,0050610,IM,"['Amyloidosis/etiology', '*Blood Protein Disorders', 'Bone Neoplasms/pathology', 'Humans', 'Karyotyping', 'Kidney Diseases/etiology', 'Kinetics', 'Leukemia/enzymology', 'Leukemia, Lymphoid/pathology', 'Leukemia, Plasma Cell/pathology', 'Lung Neoplasms/pathology', 'Lymph Nodes/pathology', 'Lymphoma/pathology', 'Microscopy, Electron', '*Multiple Myeloma/complications/diagnosis/enzymology/pathology/physiopathology', 'Muramidase', 'Plasmacytoma', '*gamma-Globulins']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Pathol Annu. 1972;7:1-17.,"['0 (gamma-Globulins)', 'EC 3.2.1.17 (Muramidase)']",54,,,,,,,,,,
4114588,NLM,MEDLINE,19720919,20131121,0323-4347 (Print) 0323-4347 (Linking),97,1,1972,[Products of fibrinolytic cleavage and their clinical significance].,84-94,,"['Astedt, B', 'Nilsson, I M']","['Astedt B', 'Nilsson IM']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Abortion, Missed/blood', 'Abruptio Placentae/blood', '*Blood Coagulation Tests', 'Collagen Diseases/blood', 'Erythrocytes/immunology', 'Esters/pharmacology', 'Female', 'Fibrin/*analysis', 'Fibrinolysis/*drug effects', 'Fluorides/pharmacology', 'Hemagglutination Inhibition Tests', 'Humans', 'Kidney Diseases/blood', 'Latex Fixation Tests', 'Leukemia/blood', 'Ovarian Neoplasms/blood', 'Pre-Eclampsia/blood', 'Pregnancy', 'Pyruvates/pharmacology', 'Shock/blood', 'Staphylococcus', 'Uterine Neoplasms/blood']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(1):84-94.,"['0 (Esters)', '0 (Pyruvates)', '9001-31-4 (Fibrin)', 'Q80VPU408O (Fluorides)']",,Fibrinolytische Spaltprodukte und ihre klinische Bedeutung.,,,,,,,,,
4114587,NLM,MEDLINE,19720919,20041117,0323-4347 (Print) 0323-4347 (Linking),97,1,1972,[Therapy of consumption coagulopathies in malignant diseases (carcinoma and leukemia)].,71-83,,"['Niessner, H', 'Honetz, H', 'Stych, H', 'Thaler, E', 'Lechner, K']","['Niessner H', 'Honetz H', 'Stych H', 'Thaler E', 'Lechner K']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adenocarcinoma/*complications', 'Adult', 'Aged', 'Carcinoma/complications', 'Disseminated Intravascular Coagulation/drug therapy/*etiology/therapy', 'Female', 'Fibrinolysis', 'Heparin/therapeutic use', 'Humans', 'Leukemia/*complications', 'Male', 'Middle Aged', 'Ovarian Neoplasms/complications', 'Prostatic Neoplasms/*complications', 'Stomach Neoplasms/*complications']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;97(1):71-83.,['9005-49-6 (Heparin)'],,Therapie der Verbrauchskoagulopathien bei malignen Erkrankungen (Karzinomen und Leukamien.,,,,,,,,,
4114453,NLM,MEDLINE,19720913,20190711,0023-2173 (Print) 0023-2173 (Linking),50,10,1972 May 15,[Electron microscopy and cytochemistry of Gaucher cells in chronic granulocytic leukaemia].,510-6,,"['Keyserlingk, D G', 'Boll, I', 'Albrecht, M']","['Keyserlingk DG', 'Boll I', 'Albrecht M']",['ger'],['Journal Article'],Germany,Klin Wochenschr,Klinische Wochenschrift,2985205R,IM,"['Acid Phosphatase/analysis', 'Adult', 'Cells/pathology', 'Diagnosis, Differential', 'Gaucher Disease/diagnosis', 'Histocytochemistry', 'Humans', 'Inclusion Bodies', 'Leukemia, Myeloid/diagnosis/*pathology', 'Leukocytes/enzymology', 'Lipids/analysis', 'Male', 'Microscopy, Electron', 'Mononuclear Phagocyte System/pathology', 'Phagocytosis', 'Reticulocytes/analysis', 'Staining and Labeling']",,1972/05/15 00:00,1972/05/15 00:01,['1972/05/15 00:00'],"['1972/05/15 00:00 [pubmed]', '1972/05/15 00:01 [medline]', '1972/05/15 00:00 [entrez]']",['10.1007/BF01487295 [doi]'],ppublish,Klin Wochenschr. 1972 May 15;50(10):510-6. doi: 10.1007/BF01487295.,"['0 (Lipids)', 'EC 3.1.3.2 (Acid Phosphatase)']",,Elektronenmikroskopie und Cytochemie der Gaucher-Zellen bei chronischer myelose.,,,,,,,,,
4114452,NLM,MEDLINE,19720913,20190711,0023-2173 (Print) 0023-2173 (Linking),50,10,1972 May 15,[Comparison of cytological and cytochemical classification in 47 cases of acute leukaemia].,498-503,,"['Queisser, W', 'Dietrich, M', 'Finke, J', 'Kubanek, B', 'Neu, G', 'Olischlager, A', 'Heimpel, H']","['Queisser W', 'Dietrich M', 'Finke J', 'Kubanek B', 'Neu G', 'Olischlager A', 'Heimpel H']",['ger'],['Journal Article'],Germany,Klin Wochenschr,Klinische Wochenschrift,2985205R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Child', 'Child, Preschool', 'Cytodiagnosis', 'Esterases/analysis', 'Female', 'Histocytochemistry', 'Histological Techniques', 'Humans', 'Infant', 'Leukemia/*classification/diagnosis/enzymology/pathology/therapy', 'Leukemia, Erythroblastic, Acute/pathology/therapy', 'Leukemia, Monocytic, Acute/pathology/therapy', 'Leukemia, Myeloid, Acute/pathology/therapy', 'Male', 'Middle Aged', 'Peroxidases/analysis', 'Staining and Labeling']",,1972/05/15 00:00,1972/05/15 00:01,['1972/05/15 00:00'],"['1972/05/15 00:00 [pubmed]', '1972/05/15 00:01 [medline]', '1972/05/15 00:00 [entrez]']",['10.1007/BF01487293 [doi]'],ppublish,Klin Wochenschr. 1972 May 15;50(10):498-503. doi: 10.1007/BF01487293.,"['EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)']",,Vergleich zwischen cytologischer und cytochemischer Klassifizierung bei 47 Fallen von akuter Leukamie.,,,,,,,,,
4114370,NLM,MEDLINE,19720906,20061115,0037-1963 (Print) 0037-1963 (Linking),9,3,1972 Jul,"Acquired lipidosis: Gaucher-like cells and ""blue cells"" in chronic granulocytic leukemia.",309-16,,"['Dosik, H', 'Rosner, F', 'Sawitsky, A']","['Dosik H', 'Rosner F', 'Sawitsky A']",['eng'],['Journal Article'],United States,Semin Hematol,Seminars in hematology,0404514,IM,"['Bone Marrow Cells', 'Bone Marrow Examination', 'Gaucher Disease/metabolism', 'Histiocytes', 'Humans', 'Leukemia, Myeloid/complications/*metabolism', 'Lipidoses/*complications', 'Macrophages', 'Staining and Labeling']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,Semin Hematol. 1972 Jul;9(3):309-16.,,,,,,,,,,,,
4114180,NLM,MEDLINE,19720825,20190714,0042-6822 (Print) 0042-6822 (Linking),49,1,1972 Jul,Properties of the intracytoplasmic A particles purified from mouse tumors.,61-78,,"['Tanaka, H', 'Tamura, A', 'Tsujimura, D']","['Tanaka H', 'Tamura A', 'Tsujimura D']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Antigens, Viral/analysis', 'Centrifugation, Density Gradient', 'Cytoplasm/*microbiology', 'Female', '*Gammaretrovirus/analysis/immunology/isolation & purification', 'Immunodiffusion', 'Immunoelectrophoresis', '*Inclusion Bodies, Viral', 'Leukemia, Experimental/immunology/*microbiology/pathology', 'Mammary Neoplasms, Experimental/immunology/*microbiology/pathology', 'Mice', 'Mice, Inbred Strains', 'Microscopy, Electron', 'Phosphotungstic Acid', 'RNA, Viral/analysis', 'Staining and Labeling', 'Viral Proteins/analysis']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']","['S0042-6822(72)80007-2 [pii]', '10.1016/s0042-6822(72)80007-2 [doi]']",ppublish,Virology. 1972 Jul;49(1):61-78. doi: 10.1016/s0042-6822(72)80007-2.,"['0 (Antigens, Viral)', '0 (RNA, Viral)', '0 (Viral Proteins)', '12067-99-1 (Phosphotungstic Acid)']",,,,,,,,,,,
4114120,NLM,MEDLINE,19720825,20071115,0023-6748 (Print) 0023-6748 (Linking),10,,1971,[Analysis of the effect of rubomycin in cell cultures from patients with acute leukemia].,605-8,,"['Gerasimova, N A', 'Korenevskaia, M I', ""Dul'tsina, S M"", 'Kovaleva, L G', ""Terent'eva, E I""]","['Gerasimova NA', 'Korenevskaia MI', ""Dul'tsina SM"", 'Kovaleva LG', ""Terent'eva EI""]",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acute Disease', 'Antibiotics, Antineoplastic/*therapeutic use', 'Bone Marrow/*drug effects', '*Bone Marrow Cells', 'Cells, Cultured', 'Humans', '*Leukemia, Lymphoid', 'Leukemia, Myeloid, Acute/*drug therapy']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;10:605-8.,"['0 (Antibiotics, Antineoplastic)']",,Analiz deistviia rubomitsina v kul'turakh kletok bol'nykh ostrym leikozom.,,,,,,,,,
4114117,NLM,MEDLINE,19720825,20131121,0023-6748 (Print) 0023-6748 (Linking),10,,1971,[Cytochemical analysis of naphtol AS-D chloracetate esterases].,592-7,,"['Rudens, Iu F', 'Buikis, I M']","['Rudens IuF', 'Buikis IM']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acetates', 'Acute Disease', 'Anilides', 'Animals', 'Benzofurans', 'Bone Marrow/enzymology', 'Bone Marrow Cells', 'Chlorine', 'Esterases/*analysis', 'Guinea Pigs', 'Histocytochemistry', 'Humans', 'Leukemia, Monocytic, Acute/enzymology', 'Leukemia, Myeloid, Acute/enzymology', 'Leukocytes/enzymology', 'Methods', 'Mice', 'Rabbits', 'Rats']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;10:592-7.,"['0 (Acetates)', '0 (Anilides)', '0 (Benzofurans)', '4R7X1O2820 (Chlorine)', 'EC 3.1.- (Esterases)']",,Tsitokhimicheskoe vyiavlenie esterazy khloratsetata naftola AS-.,,,,,,,,,
4114101,NLM,MEDLINE,19720825,20190515,0007-0920 (Print) 0007-0920 (Linking),26,2,1972 Apr,Unimpeded growth of tumour in hosts pre-immunized with tyrosyl- or dinitrophenyl-coated tumour cells.,77-83,Techniques are described for hapten attachment to the cell membranes of mouse tumour cells. Dinitrophenylation and tyrosylation could be achieved without substantial loss of viability as measured by dye exclusion. In addition hapten coated tumour cells were capable of initiating new tumour formation in syngeneic hosts. Pre-immunization of recipient mice with hapten coated tumour cells did not increase their resistance to tumour formation upon subsequent challenge with graded doses of untreated tumour cells.,"['Bauminger, S', 'Yachnin, S']","['Bauminger S', 'Yachnin S']",['eng'],['Journal Article'],England,Br J Cancer,British journal of cancer,0370635,IM,"['Animals', 'Antigens', 'Cell Membrane/immunology', 'Cell Survival/drug effects', '*Dinitrophenols', 'Epitopes', 'Fluorine/pharmacology', '*Haptens', 'Hematopoietic Stem Cells', 'Immune Sera', 'Immunization', 'Leukemia, Experimental/*immunology', 'Male', 'Mice', 'Nitrobenzenes/pharmacology', 'Rabbits', 'Skin Tests', 'Spleen/immunology', '*Tyrosine', 'gamma-Globulins']",PMC2008434,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",['10.1038/bjc.1972.12 [doi]'],ppublish,Br J Cancer. 1972 Apr;26(2):77-83. doi: 10.1038/bjc.1972.12.,"['0 (Antigens)', '0 (Dinitrophenols)', '0 (Epitopes)', '0 (Haptens)', '0 (Immune Sera)', '0 (Nitrobenzenes)', '0 (gamma-Globulins)', '284SYP0193 (Fluorine)', '42HK56048U (Tyrosine)']",,,,,,,,,,,
4114074,NLM,MEDLINE,19720824,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7769,1972 Jul 22,Leukaemic transformation of grafted marrow.,179,,"['Mitchell, D N', 'Rees, R J', 'Salsbury, A J']","['Mitchell DN', 'Rees RJ', 'Salsbury AJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', '*Bone Marrow', '*Bone Marrow Cells', '*Bone Marrow Transplantation', '*Cell Transformation, Neoplastic', 'Female', 'Humans', 'Leukemia, Experimental', 'Leukemia, Lymphoid/*pathology', 'Mice', 'Neoplasm Transplantation', 'Time Factors', 'Transplantation, Homologous']",,1972/07/22 00:00,1972/07/22 00:01,['1972/07/22 00:00'],"['1972/07/22 00:00 [pubmed]', '1972/07/22 00:01 [medline]', '1972/07/22 00:00 [entrez]']","['S0140-6736(72)91344-X [pii]', '10.1016/s0140-6736(72)91343-8 [doi]']",ppublish,Lancet. 1972 Jul 22;2(7769):179. doi: 10.1016/s0140-6736(72)91343-8.,,,,,,,,,,,,
4114039,NLM,MEDLINE,19720824,20071115,0023-6748 (Print) 0023-6748 (Linking),8,,1971,[Cytochemical study of leukocytes in leukemia].,469-71,,"['Zuskovich, V V', 'Surzhikova, G S', 'Syrneva, L G', 'Mishchenko, G A']","['Zuskovich VV', 'Surzhikova GS', 'Syrneva LG', 'Mishchenko GA']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acute Disease', 'Chronic Disease', 'Histocytochemistry', 'Humans', 'Leukemia/*blood', 'Leukemia, Lymphoid/blood', 'Leukemia, Monocytic, Acute/blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukocytes/*analysis']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;8:469-71.,,,Tsitokhimicheskoe issledovanie leikotsitov pri leikozakh.,,,,,,,,,
4114038,NLM,MEDLINE,19720824,20071115,0023-6748 (Print) 0023-6748 (Linking),8,,1971,[Several aspects of leukocyte carbohydrate metabolism in patients with chronic leukemia].,466-9,,"['Vereshchagina, G V']",['Vereshchagina GV'],['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Adult', 'Aged', '*Carbohydrate Metabolism', 'Humans', 'Leukemia, Lymphoid/*blood', 'Leukemia, Myeloid/*blood', 'Leukocytes/*metabolism', 'Middle Aged']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;8:466-9.,,,Nekotorye storony uglevodnogo obmena v leikotsitakh bol'nykh khronicheskimi leikozami.,,,,,,,,,
4114037,NLM,MEDLINE,19720824,20041117,0023-6748 (Print) 0023-6748 (Linking),8,,1971,[Study of leukocytes in patients with chronic myeloleukemia].,462-6,,"['Morozova, V T', 'Shevchenko, N G', 'Vereshchagina, G V', 'Trusova, N F', 'Bektermirov, T A']","['Morozova VT', 'Shevchenko NG', 'Vereshchagina GV', 'Trusova NF', 'Bektermirov TA']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Humans', 'Interferons/biosynthesis', 'Leukemia, Myeloid/*blood/metabolism', '*Leukocytes/metabolism', 'Neutrophils/analysis', 'Phagocytosis']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;8:462-6.,['9008-11-1 (Interferons)'],,"Issledovanie leikotsitov bol""nykh khronicheskim mieloleikozom.",,,,,,,,,
4114015,NLM,MEDLINE,19720822,20190908,0036-553X (Print) 0036-553X (Linking),9,2,1972,"The 45, XO, Ph 1 subgroup of chronic granulocytic leukaemia.",186-92,,"['Garson, O M', 'Milligan, W J']","['Garson OM', 'Milligan WJ']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Bone Marrow Cells', '*Chromosome Aberrations', 'Chromosome Mapping', 'Fluorescence', 'Genotype', 'Humans', 'Karyotyping', 'Leukemia, Myeloid/classification/*genetics', 'Male', 'Middle Aged', 'Quinacrine', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1111/j.1600-0609.1972.tb00929.x [doi]'],ppublish,Scand J Haematol. 1972;9(2):186-92. doi: 10.1111/j.1600-0609.1972.tb00929.x.,['H0C805XYDE (Quinacrine)'],,,,,,,,,,,
4114002,NLM,MEDLINE,19720822,20131121,0027-8874 (Print) 0027-8874 (Linking),49,1,1972 Jul,Rifamycin antibiotics: inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts.,7-25,,"['Yang, S S', 'Herrera, F M', 'Smith, R G', 'Reitz, M S', 'Lancini, G', 'Ting, R C', 'Gallo, R C']","['Yang SS', 'Herrera FM', 'Smith RG', 'Reitz MS', 'Lancini G', 'Ting RC', 'Gallo RC']",['eng'],['Journal Article'],United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,IM,"['Antibiotics, Antineoplastic', 'DNA Nucleotidyltransferases/*antagonists & inhibitors', 'Humans', 'Imines', 'Leukemia/drug therapy', 'Leukemia, Lymphoid/blood', 'Lymphocytes/enzymology', 'Piperazines', 'Rauscher Virus/enzymology', 'Reverse Transcriptase Inhibitors', '*Rifampin', 'Structure-Activity Relationship']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,J Natl Cancer Inst. 1972 Jul;49(1):7-25.,"['0 (Antibiotics, Antineoplastic)', '0 (Imines)', '0 (Piperazines)', '0 (Reverse Transcriptase Inhibitors)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'VJT6J7R4TR (Rifampin)']",,,,,,,,,,,
4114001,NLM,MEDLINE,19720822,20131121,0027-8874 (Print) 0027-8874 (Linking),49,1,1972 Jul,Rifamycin derivatives strongly inhibiting RNA leads to DNA polymerase (reverse transcriptase) of murine sarcoma viruses.,61-79,,"['Gurgo, C', 'Ray, R', 'Green, M']","['Gurgo C', 'Ray R', 'Green M']",['eng'],['Journal Article'],United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,IM,"['DNA Nucleotidyltransferases/*antagonists & inhibitors', 'Hydrazones', 'Imines', 'Moloney murine leukemia virus/enzymology', 'Oximes', 'Reverse Transcriptase Inhibitors', '*Rifampin', 'Streptovaricin', 'Structure-Activity Relationship', 'Thymine Nucleotides/metabolism', 'Tritium']",,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",,ppublish,J Natl Cancer Inst. 1972 Jul;49(1):61-79.,"['0 (Hydrazones)', '0 (Imines)', '0 (Oximes)', '0 (Reverse Transcriptase Inhibitors)', '0 (Thymine Nucleotides)', '10028-17-8 (Tritium)', '1404-74-6 (Streptovaricin)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'VJT6J7R4TR (Rifampin)']",,,,,,,,,,,
4113928,NLM,MEDLINE,19720819,20191210,0301-1518 (Print) 0301-1518 (Linking),1,22,1972 May 27,[Seric gamma and alpha 2 globulins and prognosis of chronic lymphoid leukemia. 266 cases].,1493-8,,"['Coeur, P', 'Boissel, J P', 'Creyssel, R', 'Revol, L']","['Coeur P', 'Boissel JP', 'Creyssel R', 'Revol L']",['fre'],['Journal Article'],France,Nouv Presse Med,La Nouvelle presse medicale,0312552,IM,"['Agammaglobulinemia/complications/etiology', 'Alpha-Globulins/*analysis', 'Blood Protein Disorders/*complications', 'Humans', 'Hypergammaglobulinemia/complications', 'Infections/immunology', 'Leukemia, Lymphoid/*blood', '*Prognosis', 'Time Factors', 'gamma-Globulins/*analysis']",,1972/05/27 00:00,1972/05/27 00:01,['1972/05/27 00:00'],"['1972/05/27 00:00 [pubmed]', '1972/05/27 00:01 [medline]', '1972/05/27 00:00 [entrez]']",,ppublish,Nouv Presse Med. 1972 May 27;1(22):1493-8.,"['0 (Alpha-Globulins)', '0 (gamma-Globulins)']",,Gamma et alpha 2 globulines seriques et pronostic de la leucemie lymphoide chronique. 266 observations.,,,,,,,,,
4113873,NLM,MEDLINE,19720819,20131121,0001-527X (Print) 0001-527X (Linking),19,1,1972,Effect of different factors on liver thymidine monophosphate kinase in vivo and the synthesis of thymidine 5'-triphosphate in vitro.,3-10,,"['Greger, J', 'Filippovich, I V', 'Vesely, J', 'Cihak, A']","['Greger J', 'Filippovich IV', 'Vesely J', 'Cihak A']",['eng'],['Journal Article'],Poland,Acta Biochim Pol,Acta biochimica Polonica,14520300R,IM,"['Administration, Oral', 'Animals', 'Azacitidine/pharmacology', 'Cell-Free System', 'Cytidine/*pharmacology', 'Enzyme Induction', 'Female', 'Hepatectomy', 'Leukemia, Experimental/*enzymology', 'Liver/enzymology/*metabolism', '*Liver Regeneration', 'Mice', 'Mice, Inbred Strains', 'Rats', 'Thymidine Kinase/*metabolism', 'Thymine Nucleotides/*metabolism', 'Time Factors', 'Triazines/*pharmacology', 'Tryptophan/*pharmacology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Acta Biochim Pol. 1972;19(1):3-10.,"['0 (Thymine Nucleotides)', '0 (Triazines)', '5CSZ8459RP (Cytidine)', '8DUH1N11BX (Tryptophan)', 'EC 2.7.1.21 (Thymidine Kinase)', 'M801H13NRU (Azacitidine)']",,,,,,,,,,,
4113835,NLM,MEDLINE,19720818,20190908,0090-0028 (Print) 0090-0028 (Linking),237,76,1972 Jun 14,Loss and recovery of phenotypic expression of Gross leukaemia virus.,215-8,,"['Ioachim, H L', 'Dorsett, B', 'Sabbath, M', 'Keller, S']","['Ioachim HL', 'Dorsett B', 'Sabbath M', 'Keller S']",['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['AKR murine leukemia virus/*immunology', 'Animals', 'Antibody Specificity', 'Antigens, Viral', 'Cell Line', 'Cell Transformation, Neoplastic', 'Cells, Cultured/immunology/microbiology', 'Epitopes', 'Fluorescent Antibody Technique', 'Immunodiffusion', 'Leukemia/immunology', 'Microscopy, Electron', 'Neoplasm Transplantation', 'Neoplasms, Experimental/immunology/microbiology', '*Phenotype', 'Rats', 'Rats, Inbred Strains', 'Thymoma/immunology', 'Thymus Gland/immunology']",,1972/06/14 00:00,1972/06/14 00:01,['1972/06/14 00:00'],"['1972/06/14 00:00 [pubmed]', '1972/06/14 00:01 [medline]', '1972/06/14 00:00 [entrez]']",['10.1038/newbio237215b0 [doi]'],ppublish,Nat New Biol. 1972 Jun 14;237(76):215-8. doi: 10.1038/newbio237215b0.,"['0 (Antigens, Viral)', '0 (Epitopes)']",,,,,,,,,,,
4113815,NLM,MEDLINE,19720818,20190919,0073-5655 (Print) 0073-5655 (Linking),7,5,1972 Mar-Apr,The dye-exclusion test for cell viability: persistence of differential staining following fixation.,323-9,,"['Yip, D K', 'Auersperg, N']","['Yip DK', 'Auersperg N']",['eng'],['Journal Article'],United States,In Vitro,In vitro,0063733,IM,"['Aldehydes', 'Animals', 'Carcinoma', 'Cell Count', 'Cell Line', 'Cell Survival', '*Coloring Agents', 'Histological Techniques', 'Humans', 'Leukemia, Experimental', 'Molecular Weight', 'Mouth Neoplasms', 'Rats', '*Staining and Labeling', 'Time Factors']",,1972/03/01 00:00,1972/03/01 00:01,['1972/03/01 00:00'],"['1972/03/01 00:00 [pubmed]', '1972/03/01 00:01 [medline]', '1972/03/01 00:00 [entrez]']",['10.1007/BF02661722 [doi]'],ppublish,In Vitro. 1972 Mar-Apr;7(5):323-9. doi: 10.1007/BF02661722.,"['0 (Aldehydes)', '0 (Coloring Agents)']",,,,,,,,,,,
4113736,NLM,MEDLINE,19720815,20071115,0034-5164 (Print) 0034-5164 (Linking),3,3,1972 May,Alpha-2-M-globulin pathology.,655-61,,"['Sandor, G', 'Orley, C']","['Sandor G', 'Orley C']",['eng'],['Journal Article'],United States,Res Commun Chem Pathol Pharmacol,Research communications in chemical pathology and pharmacology,0244734,IM,"['Adolescent', 'Adult', 'Agammaglobulinemia/blood', 'Aging', 'Alpha-Globulins/*analysis', 'Anemia/blood', 'Ataxia Telangiectasia/blood', 'Bronchitis/blood', 'Colitis, Ulcerative/blood', 'Collagen Diseases/blood', 'Crohn Disease/blood', 'Diabetes Mellitus/blood', 'Heart Failure/blood', 'Hepatitis A/blood', 'Humans', 'Immune System Diseases/blood', 'Immunodiffusion', 'Leukemia, Lymphoid/blood', 'Liver Cirrhosis/blood', 'Liver Neoplasms/blood', 'Lymphoma, Non-Hodgkin/blood', 'Multiple Myeloma/blood', 'Waldenstrom Macroglobulinemia/blood']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,Res Commun Chem Pathol Pharmacol. 1972 May;3(3):655-61.,['0 (Alpha-Globulins)'],,,,,,,,,,,
4113726,NLM,MEDLINE,19720815,20191210,0022-1317 (Print) 0022-1317 (Linking),15,2,1972 May,On the relationship between the enzymatic composition and the susceptibility of the cell to viruses.,105-11,,"['Khesin, Y E', 'Amchenkova, A M']","['Khesin YE', 'Amchenkova AM']",['eng'],['Journal Article'],England,J Gen Virol,The Journal of general virology,0077340,IM,"['Adipose Tissue, Brown', 'Alkaline Phosphatase/analysis/*metabolism', 'Amnion', 'Animals', 'Carcinoma', 'Cell Line/enzymology', 'Cells, Cultured/*enzymology/microbiology', 'Chick Embryo', 'Clone Cells/enzymology/microbiology', 'Culture Techniques', 'Enterovirus/*growth & development', 'Fibroblasts/microbiology', 'Haplorhini', 'HeLa Cells/microbiology', 'Heart', 'Histocytochemistry', 'Humans', 'Kidney', 'L Cells/microbiology', 'Laryngeal Neoplasms', 'Leukemia', 'Macaca', 'Mice', 'Staining and Labeling', 'Swine']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",['10.1099/0022-1317-15-2-105 [doi]'],ppublish,J Gen Virol. 1972 May;15(2):105-11. doi: 10.1099/0022-1317-15-2-105.,['EC 3.1.3.1 (Alkaline Phosphatase)'],,,,,,,,,,,
4113564,NLM,MEDLINE,19720810,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7765,1972 Jun 24,Leucocyte function in Down's syndrome and acute leukaemia.,1359-61,,"['Gregory, L', 'Williams, R', 'Thompson, E']","['Gregory L', 'Williams R', 'Thompson E']",['eng'],"['Clinical Trial', 'Journal Article']",England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Blood Bactericidal Activity', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Down Syndrome/*immunology', 'Humans', 'Infant', 'Leukemia, Lymphoid/blood/*immunology', 'Leukemia, Myeloid, Acute/blood/*immunology', 'Leukocytes/*immunology', 'Phagocytosis', 'Staphylococcus']",,1972/06/24 00:00,1972/06/24 00:01,['1972/06/24 00:00'],"['1972/06/24 00:00 [pubmed]', '1972/06/24 00:01 [medline]', '1972/06/24 00:00 [entrez]']","['S0140-6736(72)92795-X [pii]', '10.1016/s0140-6736(72)91093-8 [doi]']",ppublish,Lancet. 1972 Jun 24;1(7765):1359-61. doi: 10.1016/s0140-6736(72)91093-8.,,,,,,,,,,,,
4113509,NLM,MEDLINE,19720810,20190508,0022-1007 (Print) 0022-1007 (Linking),136,1,1972 Jul 1,Genetic factors influencing C-type RNA virus induction.,175-84,Genetic factors were studied which affect the inducibility of C-type RNA viruses from embyro cultures of mouse strains with high and low incidence of spontaneous leukemia. Virus was inducible by chemical treatment from secondary embryo cultures of several inbred strains. Both virus inducibility and the capacity of the virus to persist in cells from which it was activated were found to be inherited as dominant genetic characteristics. The results show that the factors controlling virus activation and persistence in culture also play an important role in spontaneous virus expression in the animal.,"['Stephenson, J R', 'Aaronson, S A']","['Stephenson JR', 'Aaronson SA']",['eng'],['Journal Article'],United States,J Exp Med,The Journal of experimental medicine,2985109R,IM,"['Animals', 'Cells, Cultured', 'Embryo, Mammalian/microbiology', '*Genetics, Microbial', 'Idoxuridine/pharmacology', 'Kinetics', 'Leukemia Virus, Murine/enzymology/*growth & development', 'Mice', 'Mice, Inbred Strains', 'RNA-Directed DNA Polymerase/metabolism']",PMC2139189,1972/07/01 00:00,1972/07/01 00:01,['1972/07/01 00:00'],"['1972/07/01 00:00 [pubmed]', '1972/07/01 00:01 [medline]', '1972/07/01 00:00 [entrez]']",['10.1084/jem.136.1.175 [doi]'],ppublish,J Exp Med. 1972 Jul 1;136(1):175-84. doi: 10.1084/jem.136.1.175.,"['EC 2.7.7.49 (RNA-Directed DNA Polymerase)', 'LGP81V5245 (Idoxuridine)']",,,,,,,,,,,
4113402,NLM,MEDLINE,19720809,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7764,1972 Jun 17,Leukaemic transformation of engrafted human marrow cells in vivo.,1310-3,,"['Thomas, E D', 'Bryant, J I', 'Buckner, C D', 'Clift, R A', 'Fefer, A', 'Johnson, F L', 'Neiman, P', 'Ramberg, R E', 'Storb, R']","['Thomas ED', 'Bryant JI', 'Buckner CD', 'Clift RA', 'Fefer A', 'Johnson FL', 'Neiman P', 'Ramberg RE', 'Storb R']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Bone Marrow', '*Bone Marrow Cells', '*Bone Marrow Transplantation', '*Cell Transformation, Neoplastic', 'Child', 'Child, Preschool', 'Cytogenetics', 'Female', 'Humans', 'Leukemia, Lymphoid/drug therapy/radiotherapy/*therapy', '*Lymphocytes', 'Male', 'Microscopy, Fluorescence', 'Recurrence', 'Sex Chromosomes', 'Transplantation, Homologous']",,1972/06/17 00:00,1972/06/17 00:01,['1972/06/17 00:00'],"['1972/06/17 00:00 [pubmed]', '1972/06/17 00:01 [medline]', '1972/06/17 00:00 [entrez]']",['10.1016/s0140-6736(72)91037-9 [doi]'],ppublish,Lancet. 1972 Jun 17;1(7764):1310-3. doi: 10.1016/s0140-6736(72)91037-9.,,,,,,,,,,,,
4113369,NLM,MEDLINE,19720809,20181113,0012-1037 (Print) 0012-1037 (Linking),201,4,1972,[Therapy of leukemic and sarcomatous meningopathies in the adult age].,348-55,,"['Soyka, D', 'Taghavy, A', 'Hartwich, G']","['Soyka D', 'Taghavy A', 'Hartwich G']",['ger'],['Journal Article'],Germany,Z Neurol,Zeitschrift fur Neurologie,0424070,IM,"['Adult', 'Central Nervous System Diseases/*drug therapy', 'Chemical Phenomena', 'Chemistry', 'Humans', 'Injections, Spinal', 'Leukemia, Lymphoid/*drug therapy', 'Lymphoma, Non-Hodgkin/*drug therapy', 'Male', '*Meninges', 'Methotrexate/*therapeutic use', 'Neoplasms/drug therapy']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Z Neurol. 1972;201(4):348-55.,['YL5FZ2Y5U1 (Methotrexate)'],,Die Therapie leukamischer und sarkomatoser Meningopathien im Erwachsenenalter.,,,,,,,,,
4113351,NLM,MEDLINE,19720809,20071115,0007-1048 (Print) 0007-1048 (Linking),22,5,1972 May,Cytochemical demonstration of lysozyme and nitroblue tetrazolium reduction in leukaemia monocytes.,634-5,,"['Catovsky, D', 'Galton, D A']","['Catovsky D', 'Galton DA']",['eng'],['Journal Article'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Humans', 'Leukemia, Myeloid, Acute/*pathology', 'Monocytes/*analysis', '*Muramidase', 'Phagocytosis', 'Staining and Labeling', '*Tetrazolium Salts']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,Br J Haematol. 1972 May;22(5):634-5.,"['0 (Tetrazolium Salts)', 'EC 3.2.1.17 (Muramidase)']",,,,,,,,,,,
4113337,NLM,MEDLINE,19720808,20190908,0090-0028 (Print) 0090-0028 (Linking),236,67,1972 Apr 12,"Reverse transcriptase, RNA tumour virus transformation and derivatives of rifamycin SV.",163-6,,"['Ting, R C', 'Yang, S S', 'Gallo, R C']","['Ting RC', 'Yang SS', 'Gallo RC']",['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['Animals', 'Cell Division/drug effects', 'Cell Transformation, Neoplastic/*drug effects', 'Cells, Cultured', 'DNA Nucleotidyltransferases/*antagonists & inhibitors', 'Gammaretrovirus/*enzymology/growth & development', 'Kidney', 'Moloney murine leukemia virus/enzymology', 'Rats', 'Rauscher Virus/enzymology', 'Reverse Transcriptase Inhibitors', 'Rifampin/*pharmacology', 'Vesicular stomatitis Indiana virus/enzymology']",,1972/04/12 00:00,1972/04/12 00:01,['1972/04/12 00:00'],"['1972/04/12 00:00 [pubmed]', '1972/04/12 00:01 [medline]', '1972/04/12 00:00 [entrez]']",['10.1038/newbio236163a0 [doi]'],ppublish,Nat New Biol. 1972 Apr 12;236(67):163-6. doi: 10.1038/newbio236163a0.,"['0 (Reverse Transcriptase Inhibitors)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'VJT6J7R4TR (Rifampin)']",,,,,,,,,,,
4113328,NLM,MEDLINE,19720808,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7767,1972 Jul 8,Haemopoiesis.,90,,"['Baikie, A G', 'Morley, A A']","['Baikie AG', 'Morley AA']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Hematopoiesis', 'Humans', 'Leukemia, Erythroblastic, Acute/*physiopathology', 'Leukemia, Myeloid/*physiopathology']",,1972/07/08 00:00,1972/07/08 00:01,['1972/07/08 00:00'],"['1972/07/08 00:00 [pubmed]', '1972/07/08 00:01 [medline]', '1972/07/08 00:00 [entrez]']","['S0140-6736(72)91580-2 [pii]', '10.1016/s0140-6736(72)91580-2 [doi]']",ppublish,Lancet. 1972 Jul 8;2(7767):90. doi: 10.1016/s0140-6736(72)91580-2.,,,,,,,,,,,,
4113253,NLM,MEDLINE,19720808,20210526,0003-6919 (Print) 0003-6919 (Linking),23,5,1972 May,Large-volume purification of tumor viruses by use of zonal centrifuges.,1010-4,"Large volumes of fluids from selected cell cultures producing ribonucleic acid tumor viruses were processed by a double sucrose density gradient procedure using zonal centrifuges. The primary recovery utilized a Model K continuous-flow zonal centrifuge at 9 to 11 liters/hr. The virus zone from the Model K gradient was further purified on a second gradient in a B-29 rotor. The resulting viral concentrates at 2 x 10(11) particles per ml showed high purity by electron microscopy and gel analysis and were useful reagents in biochemical and immunological studies of the reverse transcriptase enzyme, virus structure, complement fixation, and other virus properties. Similar recovery methods were applied to other tumor virus systems.","['Toplin, I', 'Sottong, P']","['Toplin I', 'Sottong P']",['eng'],['Journal Article'],United States,Appl Microbiol,Applied microbiology,7605802,IM,"['Animals', 'Avian Sarcoma Viruses/isolation & purification', 'Bone Marrow/microbiology', 'Bone Marrow Cells', 'Cats/embryology', 'Cell Line/microbiology', 'Centrifugation, Zonal/*instrumentation', 'Chick Embryo', 'Methods', 'Mice/embryology', 'Mice, Inbred Strains', 'Microscopy, Electron', 'Moloney murine leukemia virus/isolation & purification', 'Oncogenic Viruses/growth & development/*isolation & purification', 'RNA Viruses/growth & development/*isolation & purification', 'Rauscher Virus/isolation & purification', 'Retroviridae/isolation & purification', 'Satellite Viruses/isolation & purification', 'Staining and Labeling', 'Sucrose', 'Thymus Gland/microbiology', 'Virus Cultivation']",PMC380491,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",['10.1128/am.23.5.1010-1014.1972 [doi]'],ppublish,Appl Microbiol. 1972 May;23(5):1010-4. doi: 10.1128/am.23.5.1010-1014.1972.,['57-50-1 (Sucrose)'],,,,,,,,,,,
4113218,NLM,MEDLINE,19720807,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7762,1972 Jun 3,Radiation-related leukaemia and lymphoma.,1236,,"['Black, P J']",['Black PJ'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Leukemia, Radiation-Induced', 'Lymphoma/*etiology', 'Radiation/adverse effects']",,1972/06/03 00:00,1972/06/03 00:01,['1972/06/03 00:00'],"['1972/06/03 00:00 [pubmed]', '1972/06/03 00:01 [medline]', '1972/06/03 00:00 [entrez]']",['10.1016/s0140-6736(72)90955-5 [doi]'],ppublish,Lancet. 1972 Jun 3;1(7762):1236. doi: 10.1016/s0140-6736(72)90955-5.,,,,,,,,,,,,
4113142,NLM,MEDLINE,19720807,20131121,0008-5472 (Print) 0008-5472 (Linking),32,6,1972 Jun,Electron microscope study of a B A L B-c leukemia virus in cell culture systems.,1108-16,,"['Lambertenghi, G', 'De Harven, E', 'Sato, T', 'Tennant, J R']","['Lambertenghi G', 'De Harven E', 'Sato T', 'Tennant JR']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Cell Line', 'Cells, Cultured', 'Ferritins/metabolism', 'Lanthanum/metabolism', '*Leukemia Virus, Murine/growth & development', 'Methods', 'Mice', 'Microscopy, Electron', 'Phagocytosis', 'Staining and Labeling', 'Time Factors', 'Virus Cultivation']",,1972/06/01 00:00,1972/06/01 00:01,['1972/06/01 00:00'],"['1972/06/01 00:00 [pubmed]', '1972/06/01 00:01 [medline]', '1972/06/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Jun;32(6):1108-16.,"['6I3K30563S (Lanthanum)', '9007-73-2 (Ferritins)']",,,,,,,,,,,
4113044,NLM,MEDLINE,19720801,20041117,0023-6748 (Print) 0023-6748 (Linking),3,,1972,[Differences in blood amino acid composition in men and women during acute leukemia].,169-71,,"['Abramovich, A B', 'Kovaleva, L G']","['Abramovich AB', 'Kovaleva LG']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acute Disease', 'Amino Acids/analysis/*blood', 'Female', 'Humans', 'Leukemia/*blood', 'Male', 'Sex Factors']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1972;3:169-71.,['0 (Amino Acids)'],,Razlichiia v izmeneniiakh aminokislotnogo sostava syvorotki krovi u muzhchin i zhenschin pri ostrom leikoze.,,,,,,,,,
4113043,NLM,MEDLINE,19720801,20041117,0023-6748 (Print) 0023-6748 (Linking),3,,1972,[Total blood protease activity in leukemias and purulent diseases].,167-9,,"['Petukhov, V I', 'Khazova, L A']","['Petukhov VI', 'Khazova LA']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Adolescent', 'Adult', 'Child', 'Focal Infection/blood/enzymology', 'Humans', 'Leukemia/blood/*enzymology', 'Middle Aged', 'Peptide Hydrolases/*blood', 'Suppuration/blood/*enzymology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1972;3:167-9.,['EC 3.4.- (Peptide Hydrolases)'],,Obshchaia proteaznaia aktivnost' krovi pri leikozakh i nagnoitel'nykh zabolevaniiakh.,,,,,,,,,
4112916,NLM,MEDLINE,19720729,20031114,0022-1767 (Print) 0022-1767 (Linking),108,5,1972 May,Immunoglobulin and theta-bearing murine leukemias and lymphomas.,1146-51,,"['Shevach, E M', 'Stobo, J D', 'Green, I']","['Shevach EM', 'Stobo JD', 'Green I']",['eng'],['Journal Article'],United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,IM,"['Animals', 'Bone Marrow/*immunology', '*Bone Marrow Cells', 'Cell Membrane/immunology', 'Chromium Isotopes', 'Cytotoxicity Tests, Immunologic', 'Epitopes/analysis', 'Fluorescent Antibody Technique', 'Immune Sera', 'Immunoglobulins/*analysis', 'Isoantigens/analysis', 'Leukemia, Experimental/*immunology', 'Lymphocytes/*immunology', 'Lymphoma/*immunology', 'Mice', 'Plasmacytoma/immunology', 'Rabbits/immunology', 'Thymus Gland/*immunology']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,J Immunol. 1972 May;108(5):1146-51.,"['0 (Chromium Isotopes)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Immunoglobulins)', '0 (Isoantigens)']",,,,,,,,,,,
4112884,NLM,MEDLINE,19720727,20041117,0028-2162 (Print) 0028-2162 (Linking),116,24,1972 Jun 10,[The importance of cytochemical staining in the diagnosis of leukemia].,1008-13,,"['de Vries, S I', 'Schreuder-van Gelder, R']","['de Vries SI', 'Schreuder-van Gelder R']",['dut'],['Journal Article'],Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,IM,"['Bone Marrow Cells', 'Hematopoietic Stem Cells/analysis', '*Histocytochemistry', 'Humans', 'Leukemia/*diagnosis', 'Staining and Labeling']",,1972/06/10 00:00,1972/06/10 00:01,['1972/06/10 00:00'],"['1972/06/10 00:00 [pubmed]', '1972/06/10 00:01 [medline]', '1972/06/10 00:00 [entrez]']",,ppublish,Ned Tijdschr Geneeskd. 1972 Jun 10;116(24):1008-13.,,,De betekenis van cytochemische kleuringen voor de diagnostiek van leukemie.,,,,,,,,,
4112865,NLM,MEDLINE,19720727,20190702,0038-4348 (Print) 0038-4348 (Linking),65,4,1972 Apr,Leukemic infiltration of the prostate.,417-9,,"['Weathers, E A', 'Lathem, J E']","['Weathers EA', 'Lathem JE']",['eng'],['Journal Article'],United States,South Med J,Southern medical journal,0404522,IM,"['Aged', 'Autopsy', 'Biopsy', 'Humans', 'Hyperplasia/complications', 'Leukemia/*complications', 'Leukocyte Count', 'Male', 'Middle Aged', 'Prostate/pathology', 'Prostatic Hyperplasia/*etiology']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",['10.1097/00007611-197204000-00008 [doi]'],ppublish,South Med J. 1972 Apr;65(4):417-9. doi: 10.1097/00007611-197204000-00008.,,,,,,,,,,,,
4112828,NLM,MEDLINE,19720727,20191030,0365-4184 (Print) 0365-4184 (Linking),80,2,1972,Thymic cysts in oestrogenized BALB-c mice.,211-21,,"['Ebbesen, P', 'Nielsen, M H']","['Ebbesen P', 'Nielsen MH']",['eng'],['Journal Article'],Denmark,Acta Pathol Microbiol Scand A,"Acta pathologica et microbiologica Scandinavica. Section A, Pathology",7508468,IM,"['Albumins/analysis', 'Amyloid/analysis', 'Animals', 'Autoantibodies/analysis', 'Castration', 'Cysts/chemically induced/*pathology', 'Cytotoxicity Tests, Immunologic', 'Estradiol', 'Female', 'Fluorescent Antibody Technique', 'Leukemia/chemically induced', 'Lymph Nodes/pathology', 'Lymphocytes', 'Male', 'Mice', 'Microscopy, Electron', 'Spleen/pathology', 'Staining and Labeling', 'Testicular Neoplasms/chemically induced', 'Thymectomy', 'Thymus Gland/*pathology/physiology', 'gamma-Globulins/analysis']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1111/j.1699-0463.1972.tb02167.x [doi]'],ppublish,Acta Pathol Microbiol Scand A. 1972;80(2):211-21. doi: 10.1111/j.1699-0463.1972.tb02167.x.,"['0 (Albumins)', '0 (Amyloid)', '0 (Autoantibodies)', '0 (gamma-Globulins)', '4TI98Z838E (Estradiol)']",,,,,,,,,,,
4112733,NLM,MEDLINE,19720725,20190919,0018-7348 (Print) 0018-7348 (Linking),14,2,1972,Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique.,167-9,,"['Zankl, H', 'Zang, K D']","['Zankl H', 'Zang KD']",['eng'],['Journal Article'],Germany,Humangenetik,Humangenetik,7607154,IM,"['Biopsy', 'Brain Neoplasms/*genetics/pathology', '*Chromosome Aberrations', '*Chromosomes, Human, 21-22 and Y', 'Cytogenetics', 'Histological Techniques', 'Humans', 'Karyotyping', 'Leukemia, Myeloid/genetics', 'Meningioma/*genetics/pathology', 'Microscopy, Fluorescence', 'Staining and Labeling']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1007/BF00273305 [doi]'],ppublish,Humangenetik. 1972;14(2):167-9. doi: 10.1007/BF00273305.,,,,,,,,,,,,
4112693,NLM,MEDLINE,19720725,20051117,0005-2086 (Print) 0005-2086 (Linking),16,1,1972 Apr,Bursal lesions in chickens inoculated with Marek's disease vaccines.,153-62,,"['Fletcher, O J', 'Eidson, C S', 'Kleven, S H']","['Fletcher OJ', 'Eidson CS', 'Kleven SH']",['eng'],['Journal Article'],United States,Avian Dis,Avian diseases,0370617,IM,"['Animals', 'Avian Leukosis/*pathology', 'Bursa of Fabricius/*pathology', '*Chickens', 'Herpesviridae/*immunology', 'Herpesviridae Infections/*veterinary', 'Injections, Intravenous', 'Injections, Subcutaneous', 'Marek Disease/immunology/pathology', 'Poultry Diseases/*pathology', 'Turkeys', 'Vaccination/*veterinary', '*Viral Vaccines/administration & dosage', 'gamma-Globulins/analysis']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",,ppublish,Avian Dis. 1972 Apr;16(1):153-62.,"['0 (Viral Vaccines)', '0 (gamma-Globulins)']",,,,,,,,,,,
4112680,NLM,MEDLINE,19720725,20041117,0001-5547 (Print) 0001-5547 (Linking),16,3,1972 May-Jun,Cytophotometric study of megakaryocyte ploidy in polycythemia vera and chronic granulocytic leukemia.,240-4,,"['Lagerlof, B']",['Lagerlof B'],['eng'],['Journal Article'],Switzerland,Acta Cytol,Acta cytologica,0370307,IM,"['Blood Platelets', 'Cytoplasm', 'DNA/analysis', 'Hematologic Diseases', 'Hematopoiesis', 'Humans', '*Leukemia, Myeloid', 'Megakaryocytes/analysis/*cytology', 'Photometry', '*Polycythemia Vera', '*Polyploidy', 'Staining and Labeling']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",,ppublish,Acta Cytol. 1972 May-Jun;16(3):240-4.,['9007-49-2 (DNA)'],,,,,,,,,,,
4112640,NLM,MEDLINE,19720720,20190501,0027-8424 (Print) 0027-8424 (Linking),69,4,1972 Apr,Group-specific antigens of RNA tumor viruses as markers for subinfectious expression of the RNA virus genome.,1021-5,"Antigenic markers associated with the major internal protein of RNA tumor viruses of the C-type have proven extremely useful in natural history studies of these viruses. This protein possesses species-specific antigenic determinants, and, in the case of mammalian C-type viruses, the protein possesses crossreactive determinants as well. These determinants are, thus, useful for species identification and classification of mammalian viruses. A unique distribution of antigens in embryonic tissues of several species (where tests are available) was detected, and in addition, antigen expression in tissues appears to be controlled by a dominant gene. These data have contributed greatly to the theory that RNA tumor-virus information is inherited as part of the cellular genome.","['Gilden, R V', 'Oroszlan, S']","['Gilden RV', 'Oroszlan S']",['eng'],"['Journal Article', 'Review']",United States,Proc Natl Acad Sci U S A,Proceedings of the National Academy of Sciences of the United States of America,7505876,IM,"['Animals', 'Antibody Specificity', '*Antigens', 'Antigens, Viral/analysis', 'Cats', 'Centrifugation, Density Gradient', '*Chromosomes', 'Cricetinae', 'Cross Reactions', 'Epitopes/analysis', 'Genetic Code', 'Immune Sera', 'Immunodiffusion', 'Immunoelectrophoresis', 'Isoelectric Focusing', 'Leukemia Virus, Murine/analysis/immunology', 'Mice', 'Peptides/analysis', 'RNA Viruses/*immunology', 'Rats', 'Retroviridae/analysis/immunology', 'Species Specificity', 'Viral Proteins/analysis']",PMC426619,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",['10.1073/pnas.69.4.1021 [doi]'],ppublish,Proc Natl Acad Sci U S A. 1972 Apr;69(4):1021-5. doi: 10.1073/pnas.69.4.1021.,"['0 (Antigens)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Peptides)', '0 (Viral Proteins)']",43,,,,,,,,,,
4112611,NLM,MEDLINE,19720718,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7760,1972 May 20,Lymphocyte transformation in chronic lymphocytic leukaemia.,1127-8,,"['Peckham, M J']",['Peckham MJ'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Aged', 'DNA/metabolism', 'Female', 'Humans', 'Leukemia, Lymphoid/*pathology', '*Lymphocyte Activation', 'Mitogens/pharmacology', 'Mitosis/drug effects']",,1972/05/20 00:00,1972/05/20 00:01,['1972/05/20 00:00'],"['1972/05/20 00:00 [pubmed]', '1972/05/20 00:01 [medline]', '1972/05/20 00:00 [entrez]']","['S0140-6736(72)92722-5 [pii]', '10.1016/s0140-6736(72)91476-6 [doi]']",ppublish,Lancet. 1972 May 20;1(7760):1127-8. doi: 10.1016/s0140-6736(72)91476-6.,"['0 (Mitogens)', '9007-49-2 (DNA)']",,,,,,,,,,,
4112515,NLM,MEDLINE,19720714,20071115,0067-7833 (Print) 0067-7833 (Linking),10,,1969,Retinal microaneurysmata.,281-7,,"['Francois, J', 'Neetens, A', 'Trau, S']","['Francois J', 'Neetens A', 'Trau S']",['eng'],['Journal Article'],Switzerland,Bibl Anat,Bibliotheca anatomica,0372510,IM,"['Aged', 'Aneurysm/*pathology', 'Animals', 'Blood Protein Disorders/pathology', 'Capillaries/pathology', 'Diabetic Retinopathy/pathology', 'Glaucoma/pathology', 'Histological Techniques', 'Humans', 'Leukemia, Lymphoid/pathology', 'Methods', 'Rabbits', 'Retinal Diseases/*pathology', 'Retinal Vessels/*pathology', 'Staining and Labeling']",,1969/01/01 00:00,1969/01/01 00:01,['1969/01/01 00:00'],"['1969/01/01 00:00 [pubmed]', '1969/01/01 00:01 [medline]', '1969/01/01 00:00 [entrez]']",,ppublish,Bibl Anat. 1969;10:281-7.,,,,,,,,,,,,
4112417,NLM,MEDLINE,19720710,20031114,0022-1767 (Print) 0022-1767 (Linking),108,4,1972 Apr,Genetic control by the H-2 gene complex of the alloantibody response to an H-2 antigen.,947-51,,"['Stimpfling, J H', 'Durham, T']","['Stimpfling JH', 'Durham T']",['eng'],['Journal Article'],United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,IM,"['Animals', '*Antibody Formation', 'Epitopes', 'Fibrosarcoma/immunology', '*Genes, Regulator', 'Hemagglutination Tests', '*Histocompatibility', '*Immunogenetics', '*Isoantigens', 'Leukemia, Experimental/immunology', 'Lymph Nodes/immunology', 'Mice', 'Mice, Inbred Strains', 'Recombination, Genetic', 'Spleen/immunology', 'Thymus Gland/immunology']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",,ppublish,J Immunol. 1972 Apr;108(4):947-51.,"['0 (Epitopes)', '0 (Isoantigens)']",,,,,,,,,,,
4112374,NLM,MEDLINE,19720708,20211203,0025-8458 (Print) 0025-8458 (Linking),67,12,1972 Mar 24,[Induction of tolerance of heterologous protein in therapy with antilymphocytic globulin in man].,410-3,,"['Tilz, G P']",['Tilz GP'],['ger'],"['Clinical Trial', 'Controlled Clinical Trial', 'Journal Article']",Germany,Med Klin,Medizinische Klinik,0376637,IM,"['Adolescent', 'Adult', 'Aged', 'Animals', 'Antilymphocyte Serum/*therapeutic use', 'Azathioprine/therapeutic use', 'Corneal Transplantation', 'Dermatomyositis/therapy', 'Female', 'Horses/immunology', 'Humans', '*Immune Tolerance', 'Immunization, Passive', 'Immunosuppression Therapy', 'Immunosuppressive Agents/therapeutic use', 'Kidney Transplantation', 'Leukemia, Lymphoid/therapy', 'Male', 'Multiple Sclerosis/therapy', ""Sjogren's Syndrome/therapy"", 'Steroids/therapeutic use', 'Time Factors', 'Transplantation Immunology', 'Transplantation, Homologous', 'gamma-Globulins/therapeutic use']",,1972/03/24 00:00,2000/03/22 09:00,['1972/03/24 00:00'],"['1972/03/24 00:00 [pubmed]', '2000/03/22 09:00 [medline]', '1972/03/24 00:00 [entrez]']",,ppublish,Med Klin. 1972 Mar 24;67(12):410-3.,"['0 (Antilymphocyte Serum)', '0 (Immunosuppressive Agents)', '0 (Steroids)', '0 (gamma-Globulins)', 'MRK240IY2L (Azathioprine)']",,Studien zur Toleranzerzeugung gegenuber heterologem Protein bei der therapie mit antilymphozytarem Globulin beim Menschen.,,,,,,,,,
4112228,NLM,MEDLINE,19720630,20071115,0036-7672 (Print) 0036-7672 (Linking),102,17,1972 Apr 29,[An unusual leukoerythroblastic blood dount in an immature leukosis with extramedullary hematopoiesis in the kidney].,617-9,,"['Meister, H', 'Lagemann, A']","['Meister H', 'Lagemann A']",['ger'],['Journal Article'],Switzerland,Schweiz Med Wochenschr,Schweizerische medizinische Wochenschrift,0404401,IM,"['Bone Marrow Examination', '*Erythrocyte Count', 'Female', '*Hematopoiesis', 'Hematopoietic Stem Cells', 'Humans', 'Kidney/*physiopathology', 'Leukemia, Erythroblastic, Acute/*blood/complications/diagnosis', 'Leukemia, Myeloid, Acute/*blood/diagnosis', '*Leukocyte Count', 'Middle Aged', 'Staining and Labeling']",,1972/04/29 00:00,1972/04/29 00:01,['1972/04/29 00:00'],"['1972/04/29 00:00 [pubmed]', '1972/04/29 00:01 [medline]', '1972/04/29 00:00 [entrez]']",,ppublish,Schweiz Med Wochenschr. 1972 Apr 29;102(17):617-9.,,,Ungewohnliches leukoerythroblastisches Blutbild einer unreifzelligen Leukose bei heterotoper renaler Blutbildung.,,,,,,,,,
4112192,NLM,MEDLINE,19720630,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7759,1972 May 13,Pathogenesis of radiation-related leukaemia and lymphoma. Speculations based primarily on experience of Hiroshima and Nagasaki.,1060-2,,"['Anderson, R E', 'Nishiyama, H', 'Ii, Y', 'Ishida, K', 'Okabe, N']","['Anderson RE', 'Nishiyama H', 'Ii Y', 'Ishida K', 'Okabe N']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Bone Marrow/radiation effects', 'Humans', 'Immunologic Deficiency Syndromes/complications', 'Japan', 'Leukemia, Radiation-Induced/*epidemiology', 'Lymphoma/complications/*epidemiology', 'Neoplasms, Radiation-Induced/*epidemiology', 'Radiation Dosage']",,1972/05/13 00:00,1972/05/13 00:01,['1972/05/13 00:00'],"['1972/05/13 00:00 [pubmed]', '1972/05/13 00:01 [medline]', '1972/05/13 00:00 [entrez]']","['S0140-6736(72)91232-9 [pii]', '10.1016/s0140-6736(72)91232-9 [doi]']",ppublish,Lancet. 1972 May 13;1(7759):1060-2. doi: 10.1016/s0140-6736(72)91232-9.,,,,,,,,,,,,
4112171,NLM,MEDLINE,19720630,20190619,0008-543X (Print) 0008-543X (Linking),29,5,1972 May,"Acridine orange metachromasia for characterization of leukocytes in leukemia, lymphoma, and other neoplasms.",1361-8,,"['Melamed, M R', 'Adams, L R', 'Traganos, F', 'Zimring, A', 'Kamentsky, L A']","['Melamed MR', 'Adams LR', 'Traganos F', 'Zimring A', 'Kamentsky LA']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['*Acridines', 'Breast Neoplasms/blood', 'Cell Nucleus', 'Cytoplasm', '*Fluorescent Dyes', 'Fluorometry', 'Hodgkin Disease/blood', 'Humans', 'Leukemia/*blood', 'Leukemia, Lymphoid/blood', 'Leukemia, Monocytic, Acute/blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukocytes/*cytology', 'Lymphoma/*blood', 'Lymphoma, Large B-Cell, Diffuse/blood', 'Lymphoma, Non-Hodgkin/blood', 'Mycosis Fungoides/blood', 'Neoplasms/*blood', 'Photometry', 'Polycythemia Vera/blood', '*Staining and Labeling']",,1972/05/01 00:00,1972/05/01 00:01,['1972/05/01 00:00'],"['1972/05/01 00:00 [pubmed]', '1972/05/01 00:01 [medline]', '1972/05/01 00:00 [entrez]']",['10.1002/1097-0142(197205)29:5<1361::aid-cncr2820290537>3.0.co;2-n [doi]'],ppublish,Cancer. 1972 May;29(5):1361-8. doi: 10.1002/1097-0142(197205)29:5<1361::aid-cncr2820290537>3.0.co;2-n.,"['0 (Acridines)', '0 (Fluorescent Dyes)']",,,,,,,,,,,
4112118,NLM,MEDLINE,19720629,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7757,1972 Apr 29,Dermatoglyphics in leukaemia.,956-7,,"['Menser, M A', 'Purvis-Smith, S G']","['Menser MA', 'Purvis-Smith SG']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Child', '*Dermatoglyphics', 'Humans', '*Leukemia', 'Sex Factors']",,1972/04/29 00:00,1972/04/29 00:01,['1972/04/29 00:00'],"['1972/04/29 00:00 [pubmed]', '1972/04/29 00:01 [medline]', '1972/04/29 00:00 [entrez]']","['S0140-6736(72)92477-4 [pii]', '10.1016/s0140-6736(72)91519-x [doi]']",ppublish,Lancet. 1972 Apr 29;1(7757):956-7. doi: 10.1016/s0140-6736(72)91519-x.,,,,,,,,,,,,
4112089,NLM,MEDLINE,19720629,20131121,0023-6748 (Print) 0023-6748 (Linking),2,,1972,[Methods of studying blood thrombocytopoietic activity (literature review)].,94-6,,"['Tsygankova, V A', 'Rudakov, I A']","['Tsygankova VA', 'Rudakov IA']",['rus'],"['Journal Article', 'Review']",Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Anemia/blood', 'Animals', '*Blood Platelets', 'Blood Transfusion', 'Busulfan/adverse effects', 'Hemorrhage/blood', 'Humans', 'Leukemia/blood', 'Methods', 'Mice', 'Phenylhydrazines/adverse effects', 'Polycythemia/blood', 'Purpura/blood', 'Rabbits', 'Radiation Effects', 'Rats', 'Splenectomy', 'Thrombocytosis/blood', 'Thrombopoietin']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1972;2:94-6.,"['0 (Phenylhydrazines)', '9014-42-0 (Thrombopoietin)', 'G1LN9045DK (Busulfan)']",35,Metody issledovaniia trombotsitpoeticheskoi aktivnosti krovi (obzor literatury.,,,,,,,,,
4111986,NLM,MEDLINE,19720628,20041117,0021-2547 (Print) 0021-2547 (Linking),50,3,1971 May-Jun,Viral aetiopathogenesis of tumors.,140-51,,"['Klein, E']",['Klein E'],['eng'],"['Journal Article', 'Review']",Italy,Boll Ist Sieroter Milan,Bollettino dell'Istituto sieroterapico milanese,17720040R,IM,"['Alpharetrovirus/immunology', 'Antibodies', 'Antigen-Antibody Reactions', 'Antigens, Neoplasm', 'Burkitt Lymphoma/drug therapy/immunology', 'Cell Line', 'Cell Membrane/immunology', 'Cell Transformation, Neoplastic', 'Cross Reactions', 'Cytopathogenic Effect, Viral', 'DNA Viruses/immunology', 'Epitopes', 'Fluorescent Antibody Technique', 'Herpesvirus 4, Human/immunology', 'Histocompatibility', 'Hodgkin Disease/immunology', 'Humans', 'Immune Sera', 'Immunity, Cellular', 'Isoantigens', 'Leukemia/immunology', 'Leukemia Virus, Murine/immunology', 'Neoplasms/immunology/*microbiology', 'Oncogenic Viruses/*immunology', 'RNA Viruses', 'Remission, Spontaneous', 'Species Specificity']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Boll Ist Sieroter Milan. 1971 May-Jun;50(3):140-51.,"['0 (Antibodies)', '0 (Antigens, Neoplasm)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Isoantigens)']",109,,,,,,,,,,
4111979,NLM,MEDLINE,19720627,20211203,0082-5948 (Print) 0082-5948 (Linking),7,,1971,Histocompatibility systems and disease states with particular reference to cancer.,78-111,,"['Walford, R L', 'Smith, G S', 'Waters, H']","['Walford RL', 'Smith GS', 'Waters H']",['eng'],"['Journal Article', 'Review']",Denmark,Transplant Rev,Transplantation reviews,0215244,IM,"['ABO Blood-Group System', 'Animals', 'Antigens', 'Asians', 'Choriocarcinoma/immunology', 'Epitopes', 'Female', 'Fetus/immunology', '*Histocompatibility', 'Hodgkin Disease/immunology', 'Humans', 'Immunity, Cellular', '*Isoantigens', 'Leukemia Virus, Murine/immunology', 'Leukemia, Experimental/immunology', 'Leukemia, Lymphoid/immunology', 'Leukemia, Myeloid/immunology', 'Leukemia, Myeloid, Acute/immunology', 'Lupus Erythematosus, Systemic/immunology', 'Mice', 'Pregnancy', 'Transplantation Immunology', 'Whites']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",['10.1111/j.1600-065x.1971.tb00464.x [doi]'],ppublish,Transplant Rev. 1971;7:78-111. doi: 10.1111/j.1600-065x.1971.tb00464.x.,"['0 (ABO Blood-Group System)', '0 (Antigens)', '0 (Epitopes)', '0 (Isoantigens)']",129,,,,,,,,,,
4111976,NLM,MEDLINE,19720627,20051117,0085-5189 (Print) 0085-5189 (Linking),3,,1971,Present status of radioiodine therapy of thyroid disease.,19-38,,"['Beierwaltes, W H']",['Beierwaltes WH'],['eng'],"['Journal Article', 'Review']",United States,Prog At Med,Progress in atomic medicine,7514072,IM,"['Age Factors', 'Animals', 'Female', 'Follow-Up Studies', 'Goiter, Nodular/radiotherapy', 'Graves Disease/radiotherapy', 'Humans', 'Hypothyroidism/diagnosis/etiology/radiotherapy', 'Iodine Isotopes/*therapeutic use', 'Leukemia/radiotherapy', 'Lung Neoplasms/radiotherapy', 'Mice', 'Mutation/radiation effects', 'Neoplasm Metastasis', 'Radiation Dosage', '*Radiation Effects', 'Radiotherapy Dosage', 'Thyroid Diseases/*radiotherapy', 'Thyroid Function Tests', 'Thyroid Neoplasms/mortality/radiotherapy', 'Thyroidectomy', 'Time Factors']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Prog At Med. 1971;3:19-38.,['0 (Iodine Isotopes)'],25,,,,,,,,,,
4111754,NLM,MEDLINE,19720620,20161122,0323-4347 (Print) 0323-4347 (Linking),96,3,1971,[Scintigraphic studies of bones in hemoblastoses].,308-12,,"['Hofer, R', 'Kolarz, G', 'Pietschmann, H', 'Willvonseder, R']","['Hofer R', 'Kolarz G', 'Pietschmann H', 'Willvonseder R']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Adult', 'Aged', 'Bone Marrow/pathology', '*Bone and Bones/diagnostic imaging', 'Calcium Isotopes', 'Fluorine', 'Humans', 'Leukemia/*diagnosis', 'Lymphoma/*diagnosis', 'Middle Aged', 'Radiography', 'Radioisotopes', '*Radionuclide Imaging', 'Strontium Isotopes']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(3):308-12.,"['0 (Calcium Isotopes)', '0 (Radioisotopes)', '0 (Strontium Isotopes)', '284SYP0193 (Fluorine)']",,Knochenszintigraphische Untersuchungen bei Hamoblastosen.,,,,,,,,,
4111753,NLM,MEDLINE,19720620,20131121,0323-4347 (Print) 0323-4347 (Linking),96,3,1971,[Quantitative behavior of basophilic and eosinophilic granulocytes in children suffering from leukemia].,300-7,,"['Blau, H J']",['Blau HJ'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Age Factors', 'Antineoplastic Agents/therapeutic use', '*Basophils', 'Child', 'Child, Preschool', '*Eosinophils', 'Germany, East', 'Humans', 'Infant', 'Leukemia, Myeloid/*blood/drug therapy/mortality', 'Leukemia, Myeloid, Acute/*blood/drug therapy/mortality', 'Leukocyte Count', 'Neoplasm Regression, Spontaneous', 'Prednisone/therapeutic use', 'Remission, Spontaneous', 'Statistics as Topic']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(3):300-7.,"['0 (Antineoplastic Agents)', 'VB0R961HZT (Prednisone)']",,Das quantitative Verhalten der basophilen und eosinophilen Granulozyten bei Kindern mit Leukamie.,,,,,,,,,
4111752,NLM,MEDLINE,19720620,20131121,0323-4347 (Print) 0323-4347 (Linking),96,3,1971,[Behavior of aminopeptidase activity in human leukemic leukocytes].,290-9,,"['Kotlarek-Haus, S']",['Kotlarek-Haus S'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acyltransferases/blood', 'Adolescent', 'Adult', 'Aged', 'Aminopeptidases/*blood', 'Aspartic Acid', 'Child', 'Clinical Enzyme Tests', 'Eosinophils/*enzymology', 'Female', 'Glutamine', 'Glycine', 'Histocytochemistry', 'Humans', 'Leucine', 'Leukemia/*enzymology', 'Leukemia, Lymphoid/enzymology', 'Leukemia, Myeloid/enzymology', 'Leukemia, Myeloid, Acute/enzymology', 'Leukocytes/enzymology', 'Male', 'Middle Aged', 'Naphthols', 'Peptide Hydrolases/blood']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(3):290-9.,"['0 (Naphthols)', '0RH81L854J (Glutamine)', '30KYC7MIAI (Aspartic Acid)', 'EC 2.3.- (Acyltransferases)', 'EC 3.4.- (Peptide Hydrolases)', 'EC 3.4.11.- (Aminopeptidases)', 'GMW67QNF9C (Leucine)', 'TE7660XO1C (Glycine)']",,Das Verhalten der Aminopeptidasenaktivitat in menschlichen leukamischen Leukozyten.,,,,,,,,,
4111751,NLM,MEDLINE,19720620,20071115,0323-4347 (Print) 0323-4347 (Linking),96,3,1971,[Cytochemical differentiation of lymphatic cells].,257-89,,"['Meister, H']",['Meister H'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acid Phosphatase/blood', 'Chronic Disease', 'Clinical Enzyme Tests', 'Esterases/blood', 'Hepatitis A/blood', 'Histocytochemistry', 'Humans', 'Infectious Mononucleosis/blood', 'Leukemia/blood', 'Leukemia, Lymphoid/blood', 'Lymphatic Diseases/blood', 'Lymphatic System/pathology', 'Lymphocytes/*analysis/enzymology/growth & development', 'Methods', 'Monocytes/analysis', 'Naphthols/blood', 'Peroxidases/blood', 'Reticulocytes/analysis', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(3):257-89.,"['0 (Naphthols)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.2 (Acid Phosphatase)']",,Zytochemische Differenzierung lymphatischer Zellen.,,,,,,,,,
4111651,NLM,MEDLINE,19720615,20071115,0323-4347 (Print) 0323-4347 (Linking),96,2,1971,[Lymphocytes in the skin window test].,191-6,,"['Richter, R', 'Apostoloff, E']","['Richter R', 'Apostoloff E']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Animals', 'Antigens', 'Arthritis, Rheumatoid/diagnosis', 'Cattle', 'Cell Count', 'DNA', 'Hodgkin Disease/diagnosis', 'Humans', '*Inflammation', 'Injections, Intradermal', 'Leukemia, Lymphoid/diagnosis', 'Lupus Erythematosus, Discoid/diagnosis', 'Lupus Erythematosus, Systemic/diagnosis', '*Lymphocytes/drug effects', '*Skin Window Technique', 'Thymus Gland', 'Time Factors']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(2):191-6.,"['0 (Antigens)', '9007-49-2 (DNA)']",,Lymphozyten im Hautfenster.,,,,,,,,,
4111650,NLM,MEDLINE,19720615,20071115,0323-4347 (Print) 0323-4347 (Linking),96,2,1971,[Reactive and neoplastic behavior of lymphocytes].,182-90,,"['Stobbe, H', 'Heine, K M', 'Neumann, P']","['Stobbe H', 'Heine KM', 'Neumann P']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Cell Division', 'Cells, Cultured', 'Hodgkin Disease/*physiopathology', 'Humans', 'Hypersensitivity, Delayed', 'Hypersensitivity, Immediate', 'Immunologic Deficiency Syndromes/physiopathology', 'Immunologic Memory', 'Leukemia, Lymphoid/*physiopathology', '*Lymphocyte Activation', 'Lymphopenia/physiopathology', 'Models, Biological']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(2):182-90.,,,Reaktives und neoplastisches Verhalten der Lymphozyten.,,,,,,,,,
4111649,NLM,MEDLINE,19720615,20071115,0323-4347 (Print) 0323-4347 (Linking),96,2,1971,[Clinical aspects of lymphatic reactions].,175-81,,"['Bohnel, J']",['Bohnel J'],['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Diagnosis, Differential', 'Hepatitis A/blood', 'Humans', 'Hypersensitivity, Delayed', 'Leukemia, Lymphoid/*blood', 'Lymphocyte Activation', 'Lymphocytosis/*etiology', 'Neoplasms/*blood', 'Tuberculosis, Pulmonary/blood']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(2):175-81.,,,Zur Klinik der lymphatischen Reaktionen.,,,,,,,,,
4111647,NLM,MEDLINE,19720615,20171116,0323-4347 (Print) 0323-4347 (Linking),96,2,1971,[Skin manifestations in monocytic leukemia].,156-66,,"['Meister, H', 'Schulze, B', 'Lehmann, K', 'Wessel, G']","['Meister H', 'Schulze B', 'Lehmann K', 'Wessel G']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Abscess/etiology', 'Antineoplastic Agents/therapeutic use', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/*complications/diagnosis/drug therapy', 'Male', 'Mercaptopurine/therapeutic use', 'Middle Aged', 'Necrosis/etiology', 'Prednisone/therapeutic use', 'Shwartzman Phenomenon/*etiology', '*Skin Manifestations']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(2):156-66.,"['0 (Antineoplastic Agents)', 'E7WED276I5 (Mercaptopurine)', 'VB0R961HZT (Prednisone)']",,Hautveranderungen bei Monozytenleukose.,,,,,,,,,
4111646,NLM,MEDLINE,19720615,20081121,0323-4347 (Print) 0323-4347 (Linking),96,2,1971,[Histological picture of the bone marrow in parablastic leukemia and malignant neoplastic reticulosis in childhood].,145-55,,"['Weissbach, G', 'Domula, M']","['Weissbach G', 'Domula M']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Antineoplastic Agents/therapeutic use', 'Autopsy', 'Biopsy', 'Bone Marrow/drug effects/*pathology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Leukemia/drug therapy/*pathology', 'Lymphatic Diseases/drug therapy/*pathology', 'Male', 'Primary Myelofibrosis/pathology', 'Reticulin', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(2):145-55.,"['0 (Antineoplastic Agents)', '0 (Reticulin)']",,Das histologische Markbild der Parablastenleukamie und malignen neoplastischen Retikulose im Kindesalter.,,,,,,,,,
4111610,NLM,MEDLINE,19720615,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7755,1972 Apr 15,Identification of isochromosome 17 in myeloid leukaemia.,849-50,,"['Lobb, D S', 'Reeves, B R', 'Lawler, S D']","['Lobb DS', 'Reeves BR', 'Lawler SD']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Child', '*Chromosome Aberrations', '*Chromosomes, Human, 16-18', 'Female', 'Humans', 'Leukemia, Myeloid/*genetics', 'Male', 'Middle Aged', 'Staining and Labeling']",,1972/04/15 00:00,1972/04/15 00:01,['1972/04/15 00:00'],"['1972/04/15 00:00 [pubmed]', '1972/04/15 00:01 [medline]', '1972/04/15 00:00 [entrez]']","['S0140-6736(72)90836-7 [pii]', '10.1016/s0140-6736(72)90836-7 [doi]']",ppublish,Lancet. 1972 Apr 15;1(7755):849-50. doi: 10.1016/s0140-6736(72)90836-7.,,,,,,,,,,,,
4111604,NLM,MEDLINE,19720615,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7755,1972 Apr 15,Tonsillectomy and leukaemia.,846-7,,"['Cuneo, J M']",['Cuneo JM'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Leukemia/*etiology', 'Leukemia, Lymphoid/etiology', 'Leukemia, Myeloid, Acute/etiology', 'New York', 'Time Factors', '*Tonsillectomy']",,1972/04/15 00:00,1972/04/15 00:01,['1972/04/15 00:00'],"['1972/04/15 00:00 [pubmed]', '1972/04/15 00:01 [medline]', '1972/04/15 00:00 [entrez]']","['S0140-6736(72)90829-X [pii]', '10.1016/s0140-6736(72)90829-x [doi]']",ppublish,Lancet. 1972 Apr 15;1(7755):846-7. doi: 10.1016/s0140-6736(72)90829-x.,,,,,,,,,,,,
4111597,NLM,MEDLINE,19720615,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7755,1972 Apr 15,Leucocyte-migration test.,842-3,,"['Foulis, A K']",['Foulis AK'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Cell Migration Inhibition', 'Fibrin/metabolism', 'Heparin/metabolism', 'Humans', 'In Vitro Techniques', 'Leukemia/blood', '*Leukocytes']",,1972/04/15 00:00,1972/04/15 00:01,['1972/04/15 00:00'],"['1972/04/15 00:00 [pubmed]', '1972/04/15 00:01 [medline]', '1972/04/15 00:00 [entrez]']","['S0140-6736(72)90821-5 [pii]', '10.1016/s0140-6736(72)90821-5 [doi]']",ppublish,Lancet. 1972 Apr 15;1(7755):842-3. doi: 10.1016/s0140-6736(72)90821-5.,"['9001-31-4 (Fibrin)', '9005-49-6 (Heparin)']",,,,,,,,,,,
4111528,NLM,MEDLINE,19720613,20191022,0008-8730 (Print) 0008-8730 (Linking),5,1,1972 Jan,Effects of actinomycin D and puromycin on the cell progress from M to G 1 and S stages in cultured mouse leukemia L5178Y cells.,15-26,,"['Doida, Y', 'Okada, S']","['Doida Y', 'Okada S']",['eng'],['Journal Article'],England,Cell Tissue Kinet,Cell and tissue kinetics,0174107,IM,"['Animals', 'Cell Count', 'Cell Division/*drug effects', 'Cell Line', 'Cells, Cultured/*drug effects', 'Culture Media', 'Dactinomycin/*pharmacology', 'Leucine/metabolism', 'Leukemia, Experimental', 'Methods', 'Mice', 'Mitosis/drug effects', 'Nucleoproteins/biosynthesis', 'Puromycin/*pharmacology', 'RNA, Messenger/metabolism', 'Staining and Labeling', 'Time Factors', 'Tritium', 'Uridine/metabolism']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1111/j.1365-2184.1972.tb00351.x [doi]'],ppublish,Cell Tissue Kinet. 1972 Jan;5(1):15-26. doi: 10.1111/j.1365-2184.1972.tb00351.x.,"['0 (Culture Media)', '0 (Nucleoproteins)', '0 (RNA, Messenger)', '10028-17-8 (Tritium)', '1CC1JFE158 (Dactinomycin)', '4A6ZS6Q2CL (Puromycin)', 'GMW67QNF9C (Leucine)', 'WHI7HQ7H85 (Uridine)']",,,,,,,,,,,
4111335,NLM,MEDLINE,19720602,20190711,0022-3549 (Print) 0022-3549 (Linking),61,4,1972 Apr,Some antineoplastic antibiotics.,485-501,,"['Cheng, C C', 'Zee-Cheng, K Y']","['Cheng CC', 'Zee-Cheng KY']",['eng'],"['Journal Article', 'Review']",United States,J Pharm Sci,Journal of pharmaceutical sciences,2985195R,IM,"['Adenocarcinoma/drug therapy', 'Amino Sugars/therapeutic use', 'Animals', 'Antibiotics, Antineoplastic/*therapeutic use', 'Azaserine/therapeutic use', 'Benzazepines/therapeutic use', 'Bleomycin/therapeutic use', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Carcinoma, Hepatocellular/drug therapy', 'Cricetinae', 'DNA/biosynthesis', 'Dactinomycin/therapeutic use', 'Daunorubicin/therapeutic use', 'Dogs', 'Glycosides/therapeutic use', 'Haplorhini', 'Humans', 'Leukemia L1210/drug therapy', 'Liver Neoplasms', 'Lymphoma/drug therapy', 'Mice', 'Mitomycins/therapeutic use', 'Naphthacenes/therapeutic use', 'Plicamycin/therapeutic use', 'Pyrroles/therapeutic use', 'RNA/biosynthesis', 'Rats', 'Sarcoma 180/drug therapy', 'Streptonigrin/therapeutic use', 'Streptozocin/therapeutic use']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']","['S0022-3549(15)38425-2 [pii]', '10.1002/jps.2600610402 [doi]']",ppublish,J Pharm Sci. 1972 Apr;61(4):485-501. doi: 10.1002/jps.2600610402.,"['0 (Amino Sugars)', '0 (Antibiotics, Antineoplastic)', '0 (Benzazepines)', '0 (Glycosides)', '0 (Mitomycins)', '0 (Naphthacenes)', '0 (Pyrroles)', '11056-06-7 (Bleomycin)', '1CC1JFE158 (Dactinomycin)', '261Q3JB310 (Streptonigrin)', '5W494URQ81 (Streptozocin)', '63231-63-0 (RNA)', '87299V3Q9W (Azaserine)', '9007-49-2 (DNA)', 'NIJ123W41V (Plicamycin)', 'ZS7284E0ZP (Daunorubicin)']",493,,,,,,,,,,
4111271,NLM,MEDLINE,19720601,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7754,1972 Apr 8,Response to phytohaemagglutinin and pokeweed mitogen in chronic lymphocytic leukemia.,794-6,,"['Catovsky, D', 'Tripp, E', 'Hoffbrand, A V', 'Konig, E', 'Cohnen, G', 'Brittinger, G', 'Douglas, S D', 'Froland, S S', 'Stavem, P']","['Catovsky D', 'Tripp E', 'Hoffbrand AV', 'Konig E', 'Cohnen G', 'Brittinger G', 'Douglas SD', 'Froland SS', 'Stavem P']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cells, Cultured', 'Chronic Disease', 'DNA/biosynthesis', 'Humans', 'Lectins/*pharmacology', 'Leukemia, Lymphoid/*immunology', '*Lymphocyte Activation', 'Mitogens/pharmacology', 'Waldenstrom Macroglobulinemia/immunology']",,1972/04/08 00:00,1972/04/08 00:01,['1972/04/08 00:00'],"['1972/04/08 00:00 [pubmed]', '1972/04/08 00:01 [medline]', '1972/04/08 00:00 [entrez]']",['S0140-6736(72)90549-1 [pii]'],ppublish,Lancet. 1972 Apr 8;1(7754):794-6.,"['0 (Lectins)', '0 (Mitogens)', '9007-49-2 (DNA)']",,,,,,,,,,,
4111270,NLM,MEDLINE,19720601,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7754,1972 Apr 8,Response to phytohaemagglutinin and pokeweed mitogen in chronic lymphocytic leukaemia.,794-5,,"['Catovsky, D', 'Tripp, E', 'Hoffbrand, A V']","['Catovsky D', 'Tripp E', 'Hoffbrand AV']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cells, Cultured', 'Chronic Disease', 'DNA/biosynthesis', 'Humans', 'Lectins/*pharmacology', 'Leukemia, Lymphoid/*immunology', '*Lymphocyte Activation', 'Mitogens/pharmacology', 'Waldenstrom Macroglobulinemia/immunology']",,1972/04/08 00:00,1972/04/08 00:01,['1972/04/08 00:00'],"['1972/04/08 00:00 [pubmed]', '1972/04/08 00:01 [medline]', '1972/04/08 00:00 [entrez]']",,ppublish,Lancet. 1972 Apr 8;1(7754):794-5.,"['0 (Lectins)', '0 (Mitogens)', '9007-49-2 (DNA)']",,,,,,,,,,,
4111255,NLM,MEDLINE,19720601,20161122,0140-6736 (Print) 0140-6736 (Linking),1,7754,1972 Apr 8,Of mouse and man too.,783,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Child', 'Financing, Organized', 'Humans', 'Leukemia', 'Lymphoma', '*Neoplasms', '*Research', 'United Kingdom']",,1972/04/08 00:00,1972/04/08 00:01,['1972/04/08 00:00'],"['1972/04/08 00:00 [pubmed]', '1972/04/08 00:01 [medline]', '1972/04/08 00:00 [entrez]']",['S0140-6736(72)90531-4 [pii]'],ppublish,Lancet. 1972 Apr 8;1(7754):783.,,,,,,,,,,,,
4111236,NLM,MEDLINE,19720601,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7753,1972 Apr 1,Treating the nervous system in acute leukaemia.,754,,"['Aur, R J']",['Aur RJ'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Humans', 'Leukemia, Lymphoid/*radiotherapy']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']","['S0140-6736(72)90298-X [pii]', '10.1016/s0140-6736(72)90277-2 [doi]']",ppublish,Lancet. 1972 Apr 1;1(7753):754. doi: 10.1016/s0140-6736(72)90277-2.,,,,,,,,,,,,
4111194,NLM,MEDLINE,19720601,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7753,1972 Apr 1,Cytogenetically abnormal cells in vitro in acute leukaemia.,715-8,,"['Duttera, M J', 'Whang-Peng, J', 'Bull, J M', 'Carbone, P P']","['Duttera MJ', 'Whang-Peng J', 'Bull JM', 'Carbone PP']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Bone Marrow/growth & development', 'Bone Marrow Cells', 'Cell Differentiation', 'Cell Line', 'Cells, Cultured', 'Humans', 'In Vitro Techniques', 'Leukemia/*genetics/pathology', 'Leukemia, Lymphoid/genetics', 'Leukemia, Myeloid/genetics', 'Leukemia, Myeloid, Acute/genetics', 'Remission, Spontaneous', '*Sex Chromosomes']",,1972/04/01 00:00,1972/04/01 00:01,['1972/04/01 00:00'],"['1972/04/01 00:00 [pubmed]', '1972/04/01 00:01 [medline]', '1972/04/01 00:00 [entrez]']",['10.1016/s0140-6736(72)90231-0 [doi]'],ppublish,Lancet. 1972 Apr 1;1(7753):715-8. doi: 10.1016/s0140-6736(72)90231-0.,,,,,,,,,,,,
4111117,NLM,MEDLINE,19720528,20061115,0004-069X (Print) 0004-069X (Linking),19,6,1971,Antigenic structure of spontaneous lymphatic leukemia cells in mice of the inbred AKR strain.,801-29,,"['Harlozinska, A', 'Richter, R']","['Harlozinska A', 'Richter R']",['eng'],['Journal Article'],Switzerland,Arch Immunol Ther Exp (Warsz),Archivum immunologiae et therapiae experimentalis,0114365,IM,"['AKR murine leukemia virus/*immunology', 'Absorption', 'Animals', 'Animals, Newborn', 'Antigens/*analysis', 'Antigens, Neoplasm/analysis', 'Antigens, Viral/analysis', 'Cell Membrane/immunology', 'Epitopes/analysis', 'Fluorescent Antibody Technique', 'Goats', 'Immune Sera', 'Lymphoid Tissue/immunology', 'Mice', 'Mice, Inbred Strains', 'Photomicrography', 'Rabbits', 'Spleen/immunology', 'Thymus Gland/immunology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Arch Immunol Ther Exp (Warsz). 1971;19(6):801-29.,"['0 (Antigens)', '0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4110980,NLM,MEDLINE,19720517,20171116,0022-1767 (Print) 0022-1767 (Linking),108,3,1972 Mar,The distribution of alloantigenic specificities of native H-2 products.,596-600,,"['Cullen, S E', 'Schwartz, B D', 'Nathenson, S G']","['Cullen SE', 'Schwartz BD', 'Nathenson SG']",['eng'],['Journal Article'],United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,IM,"['Animals', 'Ascitic Fluid/immunology', 'Cell Line', 'Electrophoresis, Disc', 'Epitopes/*analysis', 'Fucose/metabolism', 'Genes', 'Genotype', 'Goats', 'Histocompatibility', 'Immune Sera', 'Isoantigens/*analysis', 'Leukemia, Experimental/immunology', 'Mice', 'Precipitin Tests', 'Tritium']",,1972/03/01 00:00,1972/03/01 00:01,['1972/03/01 00:00'],"['1972/03/01 00:00 [pubmed]', '1972/03/01 00:01 [medline]', '1972/03/01 00:00 [entrez]']",,ppublish,J Immunol. 1972 Mar;108(3):596-600.,"['0 (Epitopes)', '0 (Immune Sera)', '0 (Isoantigens)', '10028-17-8 (Tritium)', '28RYY2IV3F (Fucose)']",,,,,,,,,,,
4110939,NLM,MEDLINE,19720516,20190626,0002-9343 (Print) 0002-9343 (Linking),52,3,1972 Mar,Vaccinia necrosum and its relationship to impaired immunologic responsiveness.,411-20,,"['Freed, E R', 'Duma, R J', 'Escobar, M R']","['Freed ER', 'Duma RJ', 'Escobar MR']",['eng'],"['Case Reports', 'Journal Article']",United States,Am J Med,The American journal of medicine,0267200,IM,"['Agammaglobulinemia/*complications', 'Antigen-Antibody Reactions', 'Humans', 'Hypersensitivity, Delayed/diagnosis', 'Immune Sera', 'Immunity, Cellular', 'Immunoglobulin A', 'Immunoglobulin G', 'Immunoglobulin M', 'Leukemia, Lymphoid/*complications', 'Lymphoma, Non-Hodgkin/*complications', 'Male', 'Middle Aged', 'Models, Biological', 'Necrosis', 'Skin Tests', 'Smallpox Vaccine/*adverse effects', 'Vaccination/*adverse effects', 'Vaccinia/*etiology/immunology/therapy', 'gamma-Globulins/therapeutic use']",,1972/03/01 00:00,1972/03/01 00:01,['1972/03/01 00:00'],"['1972/03/01 00:00 [pubmed]', '1972/03/01 00:01 [medline]', '1972/03/01 00:00 [entrez]']","['0002-9343(72)90031-9 [pii]', '10.1016/0002-9343(72)90031-9 [doi]']",ppublish,Am J Med. 1972 Mar;52(3):411-20. doi: 10.1016/0002-9343(72)90031-9.,"['0 (Immune Sera)', '0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Smallpox Vaccine)', '0 (gamma-Globulins)']",,,,,,,,,,,
4110901,NLM,MEDLINE,19720512,20151119,0083-1921 (Print) 0083-1921 (Linking),34,,1971 Dec,Studies on the effect of antifolics in mouse leukemia.,167-77,,"['Motycka, K']",['Motycka K'],['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Age Factors', 'Aminopterin/therapeutic use/toxicity', 'Animals', 'Antineoplastic Agents/*therapeutic use', 'Arylformamidase/metabolism', 'Carcinoma, Ehrlich Tumor/metabolism', 'Dactinomycin/therapeutic use', 'Drug Resistance', 'Folic Acid Antagonists/*therapeutic use', 'Leukemia, Experimental/*drug therapy', 'Liver/metabolism', 'Methotrexate/therapeutic use', 'Mice', 'Mitosis/drug effects', 'Oxidoreductases/metabolism', 'Spleen/metabolism', 'Tetrahydrofolate Dehydrogenase/metabolism', 'Vincristine/therapeutic use']",,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1971 Dec;34:167-77.,"['0 (Antineoplastic Agents)', '0 (Folic Acid Antagonists)', '1CC1JFE158 (Dactinomycin)', '5J49Q6B70F (Vincristine)', 'EC 1.- (Oxidoreductases)', 'EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)', 'EC 3.5.1.9 (Arylformamidase)', 'JYB41CTM2Q (Aminopterin)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4110884,NLM,MEDLINE,19720511,20071115,0043-5376 (Print) 0043-5376 (Linking),52,12,1971,[Case of basophilic promyelocytic-I-leukemia].,578-83,,"['Kahn, P', 'Plementas, H']","['Kahn P', 'Plementas H']",['ger'],['Journal Article'],Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,IM,"['Basophils', 'Bone Marrow Cells', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/classification/*diagnosis/pathology', 'Leukemia, Myeloid, Acute/diagnosis/pathology', 'Mast Cells', 'Middle Aged', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Wien Z Inn Med. 1971;52(12):578-83.,,,Ein Fall von basophiler Promyelozyten-I-Leukamie.,,,,,,,,,
4110790,NLM,MEDLINE,19720509,20190501,0021-9746 (Print) 0021-9746 (Linking),24,9,1971 Dec,Lysosomal enzyme cytochemistry in acute leukaemia.,831-6,A cytochemical study of the lysosomal enzyme beta-glucuronidase in 60 cases of acute leukaemia has shown a qualitative difference in the cytoplasmic distribution of the enzyme between blast cells of the lymphoid and myeloid cell series. This difference provides a useful additional method for cytochemical classification of cell type and is superior in this respect to the other lysosomal enzymes studied (aryl sulphatase and acid phosphatase). The beta-glucuronidase reaction is recommended in those cases of acute leukaemia in which the periodic acid-Schiff reaction is negative or equivocal.,"['Mann, J R', 'Simpson, J S', 'Munkley, R M', 'Stuart, J']","['Mann JR', 'Simpson JS', 'Munkley RM', 'Stuart J']",['eng'],['Journal Article'],England,J Clin Pathol,Journal of clinical pathology,0376601,IM,"['Acid Phosphatase/analysis', 'Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Blood Cells', 'Child', 'Child, Preschool', 'Cytoplasm/enzymology', 'Glucuronidase/*analysis', 'Histocytochemistry', 'Humans', 'Leukemia/*enzymology', 'Leukemia, Lymphoid/enzymology', 'Leukemia, Myeloid, Acute/enzymology', 'Lysosomes/*enzymology', 'Middle Aged', 'Staining and Labeling', 'Sulfatases/analysis']",PMC477194,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",['10.1136/jcp.24.9.831 [doi]'],ppublish,J Clin Pathol. 1971 Dec;24(9):831-6. doi: 10.1136/jcp.24.9.831.,"['EC 3.1.3.2 (Acid Phosphatase)', 'EC 3.1.6.- (Sulfatases)', 'EC 3.2.1.31 (Glucuronidase)']",,,,,,,,,,,
4110778,NLM,MEDLINE,19720509,20071115,0323-4347 (Print) 0323-4347 (Linking),96,1,1971,[Effect of antilymphocyte serum and antiparablast serum on lymphocyte transformation as immune reaction in leukemic children].,14-20,,"['Zintl, F', 'Aurich, G', 'Plenert, W']","['Zintl F', 'Aurich G', 'Plenert W']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Animals', 'Antilymphocyte Serum/*pharmacology', 'Cells, Cultured', 'Child', 'Cytotoxicity Tests, Immunologic', 'Globulins', 'Humans', 'Immunodiffusion', 'Leukemia, Lymphoid/*immunology', 'Lymphocyte Activation/*drug effects', 'Lymphocytes/immunology', 'Rabbits']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;96(1):14-20.,"['0 (Antilymphocyte Serum)', '0 (Globulins)']",,Die Lymphozytentransformation als Immunreaktion bei Kindern mit Leukosen und deren Beeinflussung durch Antilymphozyten- bzw. Antiparablastenseren.,,,,,,,,,
4110672,NLM,MEDLINE,19720503,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7747,1972 Feb 19,Use of antibiotics in patients with leukaemia and neutropenia.,440,,"['Smith, H']",['Smith H'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Agranulocytosis/*drug therapy', 'Anti-Bacterial Agents/*therapeutic use', 'Bacterial Infections/prevention & control', 'Drug Resistance, Microbial', 'Humans', 'Leukemia/*drug therapy']",,1972/02/19 00:00,1972/02/19 00:01,['1972/02/19 00:00'],"['1972/02/19 00:00 [pubmed]', '1972/02/19 00:01 [medline]', '1972/02/19 00:00 [entrez]']",['10.1016/s0140-6736(72)90894-x [doi]'],ppublish,Lancet. 1972 Feb 19;1(7747):440. doi: 10.1016/s0140-6736(72)90894-x.,['0 (Anti-Bacterial Agents)'],,,,,,,,,,,
4110659,NLM,MEDLINE,19720503,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7747,1972 Feb 19,Treating the nervous system in acute leukaemia.,433-4,,"['Spiers, A S', 'Firth, J L', 'Collins, C D']","['Spiers AS', 'Firth JL', 'Collins CD']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Brain Neoplasms/*therapy', 'Child', 'Cytarabine/*administration & dosage/therapeutic use', 'Humans', 'Injections, Spinal/instrumentation', 'Leukemia, Lymphoid/*therapy', '*Meninges', 'Methods', 'Methotrexate/*administration & dosage/therapeutic use', 'Neoplasm Metastasis']",,1972/02/19 00:00,1972/02/19 00:01,['1972/02/19 00:00'],"['1972/02/19 00:00 [pubmed]', '1972/02/19 00:01 [medline]', '1972/02/19 00:00 [entrez]']","['S0140-6736(72)90298-X [pii]', '10.1016/s0140-6736(72)90879-3 [doi]']",ppublish,Lancet. 1972 Feb 19;1(7747):433-4. doi: 10.1016/s0140-6736(72)90879-3.,"['04079A1RDZ (Cytarabine)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4110640,NLM,MEDLINE,19720503,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7747,1972 Feb 19,Antibodies to membrane antigen(s) common to thymocytes and a subpopulation of lymphocytes in infectious-mononucleosis sera.,399-403,,"['Thomas, D B']",['Thomas DB'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Animals', 'Antibody Formation', 'Antibody Specificity', 'Antibody-Producing Cells', '*Antigens', 'Bone Marrow Cells', 'Burkitt Lymphoma', 'Cell Line', 'Cell Membrane/immunology', 'Cells, Cultured', 'Epitopes', 'Fetus', 'Fluorescent Antibody Technique', 'Goats', 'Humans', 'Immune Sera', 'Immunity, Cellular', 'Immunoglobulin G', 'Immunoglobulin M/*isolation & purification', 'Infectious Mononucleosis/*immunology', 'Leukemia, Lymphoid/immunology', 'Liver', 'Lymphocytes/*immunology', 'Palatine Tonsil', 'Rabbits', 'Spleen', 'Thymus Gland/cytology/*immunology']",,1972/02/19 00:00,1972/02/19 00:01,['1972/02/19 00:00'],"['1972/02/19 00:00 [pubmed]', '1972/02/19 00:01 [medline]', '1972/02/19 00:00 [entrez]']","['S0140-6736(72)90854-9 [pii]', '10.1016/s0140-6736(72)90854-9 [doi]']",ppublish,Lancet. 1972 Feb 19;1(7747):399-403. doi: 10.1016/s0140-6736(72)90854-9.,"['0 (Antigens)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)']",,,,,,,,,,,
4110448,NLM,MEDLINE,19720425,20190501,0022-3050 (Print) 0022-3050 (Linking),34,6,1971 Dec,Listeria monocytogenes meningitis: an opportunistic infection.,657-63,"Meningitis caused by L. monocytogenes is discussed from the standpoints of clinical presentation and course, underlying illness, and altered host resistance. The `opportunistic' nature of the infection is emphasized, and case histories of patients with diseases which may specifically alter host resistance in such a fashion as to render the patient susceptible to this organism, or who are receiving drugs which may have the same result, are presented. The critical role of host macrophages, and the alteration of this role by Hodgkin's disease, leukaemia, and cytotoxic drug therapy are emphasized.","['Simpson, J F']",['Simpson JF'],['eng'],['Journal Article'],England,J Neurol Neurosurg Psychiatry,"Journal of neurology, neurosurgery, and psychiatry",2985191R,IM,"['Adolescent', 'Adult', 'Aged', 'Anemia, Pernicious/complications', 'Antineoplastic Agents/adverse effects', 'Cerebrospinal Fluid Proteins/analysis', 'Diabetes Complications', 'Female', 'Glucocorticoids/adverse effects', 'Glucose/cerebrospinal fluid', 'Hodgkin Disease/complications', 'Humans', 'Leukemia, Monocytic, Acute/complications', '*Listeria monocytogenes/isolation & purification', 'Male', 'Meningitis, Listeria/*etiology/*immunology', 'Middle Aged', 'Polycystic Kidney Diseases/complications', 'Skin Tests', 'gamma-Globulins/analysis']",PMC1083497,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",['10.1136/jnnp.34.6.657 [doi]'],ppublish,J Neurol Neurosurg Psychiatry. 1971 Dec;34(6):657-63. doi: 10.1136/jnnp.34.6.657.,"['0 (Antineoplastic Agents)', '0 (Cerebrospinal Fluid Proteins)', '0 (Glucocorticoids)', '0 (gamma-Globulins)', 'IY9XDZ35W2 (Glucose)']",,,,,,,,,,,
4110428,NLM,MEDLINE,19720425,20210526,0003-6919 (Print) 0003-6919 (Linking),23,1,1972 Jan,Semi-micro XC cell assay technique for murine leukemia virus.,200-1,The XC cell assay employed in in vitro titration of murine leukemia viruses was modified for use as a semi-micro procedure.,"['Bass, L R', 'Turner, W']","['Bass LR', 'Turner W']",['eng'],['Journal Article'],United States,Appl Microbiol,Applied microbiology,7605802,IM,"['AKR murine leukemia virus/isolation & purification', 'Animals', 'Cell Line/microbiology/radiation effects', 'Culture Media', 'Culture Techniques', 'Fibroblasts/microbiology', 'Friend murine leukemia virus/isolation & purification', 'Leukemia Virus, Murine/*isolation & purification', 'Methods', 'Mice', 'Mice, Inbred Strains', 'Moloney murine leukemia virus/isolation & purification', 'Radiation Effects', 'Rauscher Virus/isolation & purification', 'Staining and Labeling', 'Ultraviolet Rays', '*Virus Cultivation']",PMC380312,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1128/am.23.1.200-201.1972 [doi]'],ppublish,Appl Microbiol. 1972 Jan;23(1):200-1. doi: 10.1128/am.23.1.200-201.1972.,['0 (Culture Media)'],,,,,,,,,,,
4110412,NLM,MEDLINE,19720424,20131121,0031-4005 (Print) 0031-4005 (Linking),49,2,1972 Feb,Extensive skin manifestations of herpesvirus infection in an acute leukemic child.,294-7,,"['Nishimura, K', 'Nagamoto, A', 'Igarashi, M']","['Nishimura K', 'Nagamoto A', 'Igarashi M']",['eng'],['Journal Article'],United States,Pediatrics,Pediatrics,0376422,IM,"['Child, Preschool', 'Deoxyuridine/therapeutic use', 'Female', 'Herpes Labialis/*complications', 'Herpes Simplex/chemically induced/*complications/drug therapy', 'Humans', 'Immunosuppressive Agents/adverse effects', 'Leukemia/*complications', '*Skin Diseases, Infectious', 'gamma-Globulins/therapeutic use']",,1972/02/01 00:00,1972/02/01 00:01,['1972/02/01 00:00'],"['1972/02/01 00:00 [pubmed]', '1972/02/01 00:01 [medline]', '1972/02/01 00:00 [entrez]']",,ppublish,Pediatrics. 1972 Feb;49(2):294-7.,"['0 (Immunosuppressive Agents)', '0 (gamma-Globulins)', 'W78I7AY22C (Deoxyuridine)']",,,,,,,,,,,
4110370,NLM,MEDLINE,19720421,20190919,0074-7696 (Print) 0074-7696 (Linking),31,,1971,Morphological and histochemical aspects of glycoproteins at the surface of animal cells.,57-114,,"['Rambourg, A']",['Rambourg A'],['eng'],"['Journal Article', 'Review']",United States,Int Rev Cytol,International review of cytology,2985180R,IM,"['Animals', 'Autoradiography', 'Carbohydrates/*analysis', 'Carcinoma, Ehrlich Tumor', 'Cell Membrane/*analysis', 'Cells, Cultured/analysis', 'Coloring Agents', 'Erythrocytes/analysis', 'Glycoproteins/*analysis/biosynthesis', 'Golgi Apparatus/metabolism', 'Histocytochemistry', 'Humans', 'Hydrogen-Ion Concentration', 'Intestines/cytology', 'Leukemia L1210', 'Methenamine', 'Microscopy, Electron', 'Neuromuscular Junction/analysis', 'Neurons/analysis', 'Periodic Acid', 'Phosphotungstic Acid', 'Sea Urchins/embryology', 'Silver', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",['10.1016/s0074-7696(08)60057-1 [doi]'],ppublish,Int Rev Cytol. 1971;31:57-114. doi: 10.1016/s0074-7696(08)60057-1.,"['0 (Carbohydrates)', '0 (Coloring Agents)', '0 (Glycoproteins)', '10450-60-9 (Periodic Acid)', '12067-99-1 (Phosphotungstic Acid)', '3M4G523W1G (Silver)', 'J50OIX95QV (Methenamine)']",338,,,,,,,,,,
4110357,NLM,MEDLINE,19720421,20191210,0009-9104 (Print) 0009-9104 (Linking),9,6,1971 Dec,Metabolism of radio-iodinated IgG in patients with abnormal serum IgG levels. II. Hypogamma-globulinaemia.,775-83,,"['Wells, J V', 'Fudenberg, H H']","['Wells JV', 'Fudenberg HH']",['eng'],['Journal Article'],England,Clin Exp Immunol,Clinical and experimental immunology,0057202,IM,"['Adolescent', 'Adult', 'Agammaglobulinemia/*metabolism', 'Aged', 'Chronic Disease', 'Female', 'Half-Life', 'Humans', 'Hyperplasia/metabolism', 'Immunoglobulin G/analysis/biosynthesis/metabolism', 'Immunoglobulins/*metabolism', 'Infections/therapy', 'Iodine Isotopes/urine', 'Kidney Transplantation', 'Leukemia, Lymphoid/metabolism', 'Lymph Nodes', 'Male', 'Middle Aged', 'Multiple Myeloma/metabolism', 'Nephrotic Syndrome/metabolism', 'Protein Denaturation', 'Recurrence', 'Transplantation, Homologous', 'gamma-Globulins/therapeutic use']",PMC1713128,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",,ppublish,Clin Exp Immunol. 1971 Dec;9(6):775-83.,"['0 (Immunoglobulin G)', '0 (Immunoglobulins)', '0 (Iodine Isotopes)', '0 (gamma-Globulins)']",,,,,,,,,,,
4110293,NLM,MEDLINE,19720420,20190616,0077-8923 (Print) 0077-8923 (Linking),177,,1971 Jun 21,Surface immunoglobulin-moieties on lymphoid cells.,306-25,,"['Klein, E', 'Eskeland, T', 'Inoue, M', 'Strom, R', 'Johansson, B']","['Klein E', 'Eskeland T', 'Inoue M', 'Strom R', 'Johansson B']",['eng'],['Journal Article'],United States,Ann N Y Acad Sci,Annals of the New York Academy of Sciences,7506858,IM,"['Adult', 'Animals', 'Antibodies, Anti-Idiotypic', 'Bone Marrow/immunology', 'Bone Marrow Cells', 'Burkitt Lymphoma/*immunology', 'Cell Line/immunology', 'Cell Membrane/*immunology', 'Culture Techniques', 'Cytotoxicity Tests, Immunologic', 'Fetus/immunology', '*Fluorescent Antibody Technique', 'Hemagglutination', 'Humans', 'Immune Sera', 'Immunoglobulin A/analysis', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/*immunology', 'Liver/immunology', 'Lymphocytes', 'Methods', 'Mice', 'Rabbits', 'Spleen/immunology', 'Thymus Gland/immunology', 'gamma-Globulins/*analysis']",,1971/06/21 00:00,1971/06/21 00:01,['1971/06/21 00:00'],"['1971/06/21 00:00 [pubmed]', '1971/06/21 00:01 [medline]', '1971/06/21 00:00 [entrez]']",['10.1111/j.1749-6632.1971.tb35060.x [doi]'],ppublish,Ann N Y Acad Sci. 1971 Jun 21;177:306-25. doi: 10.1111/j.1749-6632.1971.tb35060.x.,"['0 (Antibodies, Anti-Idiotypic)', '0 (Immune Sera)', '0 (Immunoglobulin A)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4110255,NLM,MEDLINE,19720419,20041117,0012-1320 (Print) 0012-1320 (Linking),22,24,1971 Dec,[Methods of leukocyte study].,758-60,,"['Brucher, H']",['Brucher H'],['ger'],['Journal Article'],Germany,Dtsch Med J,Deutsches medizinisches Journal,0420573,IM,"['Chromosome Mapping', 'Humans', 'Leukemia/blood', 'Leukocytes/*cytology', 'Lymphocyte Activation', 'Methods', 'Phagocytosis', 'Staining and Labeling']",,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",,ppublish,Dtsch Med J. 1971 Dec;22(24):758-60.,,,Methoden der Leukozytenuntersuchung.,,,,,,,,,
4110127,NLM,MEDLINE,19720415,20191210,0042-6822 (Print) 0042-6822 (Linking),47,1,1972 Jan,Properties of mouse leukemia viruses. II. Isolation of viral components.,210-28,,"['Schafer, W', 'Lange, J', 'Fischinger, P J', 'Frank, H', 'Bolognesi, D P', 'Pister, L']","['Schafer W', 'Lange J', 'Fischinger PJ', 'Frank H', 'Bolognesi DP', 'Pister L']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['AKR murine leukemia virus/*immunology', 'Animals', 'Antigens/*isolation & purification', 'Antigens, Viral/analysis/isolation & purification', 'Centrifugation, Density Gradient', 'Chromatography, Ion Exchange', 'Complement Fixation Tests', 'Electrophoresis, Disc', 'Epitopes/*analysis', 'Ethyl Ethers', 'Friend murine leukemia virus/*immunology', 'Haplorhini', 'Hemagglutination Tests', 'Immune Sera', 'Immunodiffusion', 'L Cells', 'Leukemia Virus, Murine/*immunology', 'Macaca', 'Mice', 'Microscopy, Electron', 'Molecular Weight', 'Neutralization Tests', 'Rabbits', 'Rats', 'Rauscher Virus/*immunology', 'Staining and Labeling', 'Virus Cultivation']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']","['0042-6822(72)90253-X [pii]', '10.1016/0042-6822(72)90253-x [doi]']",ppublish,Virology. 1972 Jan;47(1):210-28. doi: 10.1016/0042-6822(72)90253-x.,"['0 (Antigens)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Ethyl Ethers)', '0 (Immune Sera)']",,,,,,,,,,,
4110108,NLM,MEDLINE,19720415,20041117,0047-1860 (Print) 0047-1860 (Linking),19,,1971 Aug,[Serum orosomucoid volume--quantitative methods and serum levels in various diseases].,Suppl:143-4,,"['Ishigami, S', 'Koda, T', 'Tanabe, S', 'Furuo, T', 'Ito, F']","['Ishigami S', 'Koda T', 'Tanabe S', 'Furuo T', 'Ito F']",['jpn'],['Journal Article'],Japan,Rinsho Byori,Rinsho byori. The Japanese journal of clinical pathology,2984781R,IM,"['Alpha-Globulins/blood', 'Chronic Disease', 'Esophageal Neoplasms/blood', 'Female', 'Fetal Proteins/analysis', 'Hepatitis/blood', 'Humans', 'Immunoelectrophoresis', 'Leukemia/blood', 'Liver Cirrhosis/blood', 'Liver Neoplasms/blood', 'Lung Neoplasms/blood', 'Lymphoma/blood', 'Male', 'Mucoproteins/*blood', 'Stomach Neoplasms/blood', 'Stomach Ulcer/blood', 'Uterine Neoplasms/blood']",,1971/08/01 00:00,1971/08/01 00:01,['1971/08/01 00:00'],"['1971/08/01 00:00 [pubmed]', '1971/08/01 00:01 [medline]', '1971/08/01 00:00 [entrez]']",,ppublish,Rinsho Byori. 1971 Aug;19:Suppl:143-4.,"['0 (Alpha-Globulins)', '0 (Fetal Proteins)', '0 (Mucoproteins)']",,,,,,,,,,,
4110040,NLM,MEDLINE,19720413,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7749,1972 Mar 4,Intrathecal methotrexate.,540,,"['Duttera, J M', 'Gallelli, J F', 'Kleinman, L M', 'Tangrea, J A', 'Wittgrove, A C']","['Duttera JM', 'Gallelli JF', 'Kleinman LM', 'Tangrea JA', 'Wittgrove AC']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Central Nervous System/drug effects', 'Cytarabine/administration & dosage', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Spinal', 'Leukemia/drug therapy', 'Methotrexate/*administration & dosage/adverse effects', 'Osmolar Concentration']",,1972/03/04 00:00,1972/03/04 00:01,['1972/03/04 00:00'],"['1972/03/04 00:00 [pubmed]', '1972/03/04 00:01 [medline]', '1972/03/04 00:00 [entrez]']",['10.1016/s0140-6736(72)90210-3 [doi]'],ppublish,Lancet. 1972 Mar 4;1(7749):540. doi: 10.1016/s0140-6736(72)90210-3.,"['04079A1RDZ (Cytarabine)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4110004,NLM,MEDLINE,19720413,20131121,0008-5472 (Print) 0008-5472 (Linking),32,2,1972 Feb,Analysis of serum protein changes in patients with advanced gastric cancer with special reference to -globulin fractions.,426-9,,"['Suga, S', 'Tamura, Z']","['Suga S', 'Tamura Z']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Adrenocorticotropic Hormone/pharmacology', 'Alpha-Globulins/*analysis', 'Animals', 'Blood Protein Electrophoresis', 'Cytarabine/therapeutic use', 'Drug Combinations', 'Fluorouracil/therapeutic use', 'Humans', 'Leukemia L1210/drug therapy', 'Male', 'Mitomycins/therapeutic use', 'Rats', 'Stomach Neoplasms/*blood/drug therapy']",,1972/02/01 00:00,1972/02/01 00:01,['1972/02/01 00:00'],"['1972/02/01 00:00 [pubmed]', '1972/02/01 00:01 [medline]', '1972/02/01 00:00 [entrez]']",,ppublish,Cancer Res. 1972 Feb;32(2):426-9.,"['0 (Alpha-Globulins)', '0 (Drug Combinations)', '0 (Mitomycins)', '04079A1RDZ (Cytarabine)', '9002-60-2 (Adrenocorticotropic Hormone)', 'U3P01618RT (Fluorouracil)']",,,,,,,,,,,
4109936,NLM,MEDLINE,19720412,20171116,0140-6736 (Print) 0140-6736 (Linking),1,7745,1972 Feb 5,Treating the nervous system in acute leukemia.,297-8,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Humans', 'Leukemia, Lymphoid/complications/*drug therapy/radiotherapy', 'Mercaptopurine/*therapeutic use', 'Methotrexate/adverse effects', 'Neoplasm Metastasis', 'Nervous System Diseases/complications/*drug therapy', 'Nitrosourea Compounds/therapeutic use', 'Pyrimethamine/*therapeutic use', 'Remission, Spontaneous', 'Time Factors']",,1972/02/05 00:00,1972/02/05 00:01,['1972/02/05 00:00'],"['1972/02/05 00:00 [pubmed]', '1972/02/05 00:01 [medline]', '1972/02/05 00:00 [entrez]']",['S0140-6736(72)90298-X [pii]'],ppublish,Lancet. 1972 Feb 5;1(7745):297-8.,"['0 (Nitrosourea Compounds)', 'E7WED276I5 (Mercaptopurine)', 'YL5FZ2Y5U1 (Methotrexate)', 'Z3614QOX8W (Pyrimethamine)']",,,,,,,,,,,
4109852,NLM,MEDLINE,19720407,20041117,0033-2526 (Print) 0033-2526 (Linking),58,6,1971 Nov-Dec,[Autoimmune phenomena in skin diseases with special reference to the role of viruses in the genesis of autoimmunity].,761-6,,"['Jablonska, S']",['Jablonska S'],['pol'],"['Journal Article', 'Review']",Poland,Przegl Dermatol,Przeglad dermatologiczny,19840710R,IM,"['Animals', 'Autoantibodies/*analysis', 'Autoimmune Diseases/*etiology', 'Cross Reactions', 'Humans', 'Leukemia Virus, Murine/immunology', 'Lupus Erythematosus, Systemic/immunology', 'Mice', 'Muscle, Smooth/immunology', 'Neoplasms/microbiology', 'Neutrophils', 'Oncogenic Viruses/immunology', 'RNA, Viral', 'Skin Diseases/*immunology/microbiology', 'Virus Diseases/*complications/immunology']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",,ppublish,Przegl Dermatol. 1971 Nov-Dec;58(6):761-6.,"['0 (Autoantibodies)', '0 (RNA, Viral)']",51,"Zjawiska autoimmunologiczne w chorobach skory, ze szczegolnym uwzglednieniem roli wirusow w powstawaniu autoimmunizacji.",,,,,,,,,
4109719,NLM,MEDLINE,19720406,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7744,1972 Jan 29,Initial therapy with combination of 5 antibiotics in febrile patients with leukaemia and neutropenia.,262,,"['Emmerson, A M']",['Emmerson AM'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Agranulocytosis/*complications', 'Anti-Bacterial Agents/*therapeutic use', 'Bacterial Infections/*prevention & control', 'Humans', 'Leukemia/*complications', 'Pseudomonas Infections/prevention & control']",,1972/01/29 00:00,1972/01/29 00:01,['1972/01/29 00:00'],"['1972/01/29 00:00 [pubmed]', '1972/01/29 00:01 [medline]', '1972/01/29 00:00 [entrez]']",['10.1016/s0140-6736(72)90650-2 [doi]'],ppublish,Lancet. 1972 Jan 29;1(7744):262. doi: 10.1016/s0140-6736(72)90650-2.,['0 (Anti-Bacterial Agents)'],,,,,,,,,,,
4109700,NLM,MEDLINE,19720406,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7744,1972 Jan 29,Response of lymphocytes in chronic lymphocytic leukaemia to plant mitogens.,229-33,,"['Smith, J L', 'Cowling, D C', 'Barker, C R']","['Smith JL', 'Cowling DC', 'Barker CR']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cells, Cultured', 'Chronic Disease', 'Concanavalin A/pharmacology', 'Humans', 'Lectins/*pharmacology', 'Leukemia, Lymphoid/*blood', '*Lymphocyte Activation', 'Lymphocytes/*metabolism', 'Thymidine', 'Tritium']",,1972/01/29 00:00,1972/01/29 00:01,['1972/01/29 00:00'],"['1972/01/29 00:00 [pubmed]', '1972/01/29 00:01 [medline]', '1972/01/29 00:00 [entrez]']",['10.1016/s0140-6736(72)90624-1 [doi]'],ppublish,Lancet. 1972 Jan 29;1(7744):229-33. doi: 10.1016/s0140-6736(72)90624-1.,"['0 (Lectins)', '10028-17-8 (Tritium)', '11028-71-0 (Concanavalin A)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4109545,NLM,MEDLINE,19720404,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7743,1972 Jan 22,Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia.,162-5,,"['Tattersall, M H', 'Spiers, A S', 'Darrell, J H']","['Tattersall MH', 'Spiers AS', 'Darrell JH']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Administration, Oral', 'Agranulocytosis/*complications', 'Anemia, Aplastic/*complications', 'Anti-Bacterial Agents/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Carbenicillin/administration & dosage', 'Cephalothin/administration & dosage', 'Clindamycin/administration & dosage', 'Drug Combinations', 'Drug Hypersensitivity/complications', 'Escherichia coli Infections/drug therapy', '*Fever', 'Gentamicins/administration & dosage', 'Humans', 'Injections, Intravenous', 'Kanamycin/administration & dosage', 'Klebsiella Infections/drug therapy', 'Leukemia/*complications', 'Leukocyte Count', 'Lymphoma/*complications', 'Methicillin/administration & dosage', 'Penicillin G/administration & dosage', 'Penicillin Resistance', 'Polymyxins/administration & dosage', 'Probenecid/administration & dosage', 'Pseudomonas Infections/drug therapy', 'Staphylococcal Infections/drug therapy']",,1972/01/22 00:00,1972/01/22 00:01,['1972/01/22 00:00'],"['1972/01/22 00:00 [pubmed]', '1972/01/22 00:01 [medline]', '1972/01/22 00:00 [entrez]']",['10.1016/s0140-6736(72)90567-3 [doi]'],ppublish,Lancet. 1972 Jan 22;1(7743):162-5. doi: 10.1016/s0140-6736(72)90567-3.,"['0 (Anti-Bacterial Agents)', '0 (Drug Combinations)', '0 (Gentamicins)', '0 (Polymyxins)', '3U02EL437C (Clindamycin)', '59-01-8 (Kanamycin)', 'G42ZU72N5G (Carbenicillin)', 'PO572Z7917 (Probenecid)', 'Q42T66VG0C (Penicillin G)', 'Q91FH1328A (Methicillin)', 'R72LW146E6 (Cephalothin)']",,,,,,,,,,,
4109484,NLM,MEDLINE,19720403,20161109,0507-4088 (Print) 0507-4088 (Linking),16,4,1971 Jul-Aug,[A study of various aspects of non-specific immunity in a model of mouse virus leukemia].,446-51,,"['Nadareishvili, A E', 'Tarba, M M', 'Mikaia, Z A', 'Pachaliia, N A']","['Nadareishvili AE', 'Tarba MM', 'Mikaia ZA', 'Pachaliia NA']",['rus'],['Journal Article'],Russia (Federation),Vopr Virusol,Voprosy virusologii,0417337,IM,"['Alpha-Globulins/analysis', 'Animals', 'Beta-Globulins/analysis', 'Guinea Pigs', 'Immunity/*radiation effects', 'Leukemia, Experimental/*immunology', 'Mice', '*Radiation Effects', '*Rauscher Virus', 'Serum Albumin/analysis', 'Spleen/analysis/*immunology/radiation effects']",,1971/07/01 00:00,1971/07/01 00:01,['1971/07/01 00:00'],"['1971/07/01 00:00 [pubmed]', '1971/07/01 00:01 [medline]', '1971/07/01 00:00 [entrez]']",,ppublish,Vopr Virusol. 1971 Jul-Aug;16(4):446-51.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Serum Albumin)']",,Izuchenie nekotorykh nespetsificheskogo immuniteta na modeli virusnogo leikoza myshei.,,,,,,,,,
4109482,NLM,MEDLINE,19720403,20041117,1013-2058 (Print) 1013-2058 (Linking),60,46,1971 Nov,[Cytochemical diagnosis of leukemia].,1543-4,,"['Folsch, E']",['Folsch E'],['ger'],['Journal Article'],Switzerland,Schweiz Rundsch Med Prax,Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,8403202,IM,"['Cytodiagnosis', 'Diagnosis, Differential', 'Humans', 'Leukemia/*diagnosis', 'Staining and Labeling']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",,ppublish,Schweiz Rundsch Med Prax. 1971 Nov;60(46):1543-4.,,,Zytochemische Diagnostik der Leukamien.,,,,,,,,,
4109467,NLM,MEDLINE,19720403,20190706,0009-8981 (Print) 0009-8981 (Linking),36,2,1972 Feb,Studies on the abnormal high binding capacity of blood for vitamin B 12 in chronic myeloid leukemia.,409-18,,"['Fischer, E']",['Fischer E'],['eng'],['Journal Article'],Netherlands,Clin Chim Acta,Clinica chimica acta; international journal of clinical chemistry,1302422,IM,"['Adult', 'Alpha-Globulins/metabolism', 'Animals', 'Antibodies', 'Antigens', 'Autoradiography', 'Beta-Globulins/metabolism', 'Blood Proteins', 'Cobalt Isotopes', 'Electrophoresis', 'Humans', 'Immunoelectrophoresis', 'Leukemia, Myeloid/*blood', 'Leukocyte Count', '*Leukocytes/metabolism', 'Protein Binding', 'Rabbits', 'Remission, Spontaneous', 'Vitamin B 12/*blood', 'gamma-Globulins/metabolism']",,1972/02/01 00:00,1972/02/01 00:01,['1972/02/01 00:00'],"['1972/02/01 00:00 [pubmed]', '1972/02/01 00:01 [medline]', '1972/02/01 00:00 [entrez]']","['0009-8981(72)90016-2 [pii]', '10.1016/0009-8981(72)90016-2 [doi]']",ppublish,Clin Chim Acta. 1972 Feb;36(2):409-18. doi: 10.1016/0009-8981(72)90016-2.,"['0 (Alpha-Globulins)', '0 (Antibodies)', '0 (Antigens)', '0 (Beta-Globulins)', '0 (Blood Proteins)', '0 (Cobalt Isotopes)', '0 (gamma-Globulins)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4109295,NLM,MEDLINE,19720324,20190919,0019-2791 (Print) 0019-2791 (Linking),8,9,1971 Sep,Structural basis for immune recognition of lysozymes. IV. Immunologically active peptide obtained by the action of cyanogen bromide on human lysozyme.,829-39,,"['Bonavida, B']",['Bonavida B'],['eng'],['Journal Article'],England,Immunochemistry,Immunochemistry,0010301,IM,"['Amino Acids/analysis', 'Animals', 'Antibodies', 'Antigen-Antibody Reactions', 'Chromatography, Gel', 'Coliphages', '*Cyanides', 'Cyanogen Bromide', 'Dextrans', 'Disulfides', '*Epitopes', 'Formates', 'Homoserine/analysis', 'Humans', 'Iodine Isotopes', 'Lactones/analysis', 'Leukemia, Myeloid/urine', 'Methionine/analysis', 'Muramidase/*analysis', 'Peptides/*analysis', 'Rabbits', '*Structure-Activity Relationship']",,1971/09/01 00:00,1971/09/01 00:01,['1971/09/01 00:00'],"['1971/09/01 00:00 [pubmed]', '1971/09/01 00:01 [medline]', '1971/09/01 00:00 [entrez]']","['0019-2791(71)90449-6 [pii]', '10.1016/0019-2791(71)90449-6 [doi]']",ppublish,Immunochemistry. 1971 Sep;8(9):829-39. doi: 10.1016/0019-2791(71)90449-6.,"['0 (Amino Acids)', '0 (Antibodies)', '0 (Cyanides)', '0 (Dextrans)', '0 (Disulfides)', '0 (Epitopes)', '0 (Formates)', '0 (Iodine Isotopes)', '0 (Lactones)', '0 (Peptides)', '6KA95X0IVO (Homoserine)', 'AE28F7PNPL (Methionine)', 'EC 3.2.1.17 (Muramidase)', 'OS382OHJ8P (Cyanogen Bromide)']",,,,,,,,,,,
4109111,NLM,MEDLINE,19720317,20190508,0022-1007 (Print) 0022-1007 (Linking),133,2,1971 Feb 1,Carrier function in anti-hapten antibody responses. 3. Stimulation of antibody synthesis and facilitation of hapten-specific secondary antibody responses by graft-versus-host reactions.,169-86,"The studies reported here demonstrate that immunocompetent lymphoid cells from allogeneic donor guinea pigs stimulate the synthesis of anti-DNP and anti-OVA antibodies by recipients previously primed with DNP-OVA. This allogeneic effect occurs spontaneously in the absence of any further anti-genic challenge. Furthermore, the transfer of allogeneic cells prepares DNP-OVA-primed recipients for a striking secondary anti-DNP response to DNP-BGG; this occurs in equal degree whether or not the cells are derived from BGG-primed donors. We suggest that the allogeneic cells function by virtue of a specific immunologic attack of grafted cells on host cells. This conclusion is made on the basis of the following evidence: (a) The failure of observing the phenomenon with L(2)C leukemia cells and irradiated strain 2 lymph node and spleen cells which, although capable of initiating a host-versus-graft response, are incapable of mediating graft-versus-host reactions; and (b) the inability of (strain 2 x strain 13) F(1) hybrids to mediate the allogeneic effect in strain 13 recipients. The analysis of this phenomenon may offer a key to the delineation of mechanisms involved in the activation of precursors of antibody-forming cells.","['Katz, D H', 'Paul, W E', 'Goidl, E A', 'Benacerraf, B']","['Katz DH', 'Paul WE', 'Goidl EA', 'Benacerraf B']",['eng'],['Journal Article'],United States,J Exp Med,The Journal of experimental medicine,2985109R,IM,"['Animals', '*Antibody Formation', '*Antibody Specificity', '*Antibody-Producing Cells', 'Carrier State', 'Dinitrophenols', '*Graft vs Host Reaction', 'Guinea Pigs', '*Haptens', 'Lymph Nodes/cytology', 'Lymphocytes', 'Ovalbumin', 'Spleen/cytology', 'gamma-Globulins']",PMC2138903,1971/02/01 00:00,1971/02/01 00:01,['1971/02/01 00:00'],"['1971/02/01 00:00 [pubmed]', '1971/02/01 00:01 [medline]', '1971/02/01 00:00 [entrez]']",['10.1084/jem.133.2.169 [doi]'],ppublish,J Exp Med. 1971 Feb 1;133(2):169-86. doi: 10.1084/jem.133.2.169.,"['0 (Dinitrophenols)', '0 (Haptens)', '0 (gamma-Globulins)', '9006-59-1 (Ovalbumin)']",,,,,,,,,,,
4109085,NLM,MEDLINE,19720316,20190619,0008-543X (Print) 0008-543X (Linking),29,1,1972 Jan,Treatment of malignant lymphomas with bleomycin.,58-60,,"['Kimura, I', 'Onoshi, T', 'Kunimasa, I', 'Takano, J']","['Kimura I', 'Onoshi T', 'Kunimasa I', 'Takano J']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Adult', 'Aged', 'Antibiotics, Antineoplastic/*therapeutic use', 'Bleomycin/therapeutic use', 'Female', 'Hodgkin Disease/drug therapy', 'Humans', 'Leukemia, Lymphoid/drug therapy', 'Lymphoma/*drug therapy', 'Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Lymphoma, Non-Hodgkin/drug therapy', 'Male', 'Middle Aged', 'Remission, Spontaneous']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1002/1097-0142(197201)29:1<58::aid-cncr2820290110>3.0.co;2-r [doi]'],ppublish,Cancer. 1972 Jan;29(1):58-60. doi: 10.1002/1097-0142(197201)29:1<58::aid-cncr2820290110>3.0.co;2-r.,"['0 (Antibiotics, Antineoplastic)', '11056-06-7 (Bleomycin)']",,,,,,,,,,,
4109041,NLM,MEDLINE,19720309,20071115,0023-6748 (Print) 0023-6748 (Linking),7,,1971 Jul,[Change in the osmotic stability of lymphocytes in patients with chronic lymphatic leukemia].,392-5,,"['Shustova, L N']",['Shustova LN'],['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Adult', 'Aged', 'Female', 'Humans', 'Leukemia, Lymphoid/*physiopathology', 'Lymphocytes/*physiopathology', 'Male', 'Middle Aged', '*Osmotic Fragility']",,1971/07/01 00:00,1971/07/01 00:01,['1971/07/01 00:00'],"['1971/07/01 00:00 [pubmed]', '1971/07/01 00:01 [medline]', '1971/07/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971 Jul;7:392-5.,,,Izmenenie osmoticheskoi stoikosti limfotsitov u bol'nykh khronicheskim limfoleikozom.,,,,,,,,,
4109040,NLM,MEDLINE,19720309,20071115,0023-6748 (Print) 0023-6748 (Linking),7,,1971 Jul,[Isolation of human lymphoid cells for obtaining antilymphocyte sera].,390-2,,"['Shabalin, V N', 'Klimova, K N']","['Shabalin VN', 'Klimova KN']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Animals', '*Antilymphocyte Serum', 'Leukemia, Lymphoid/immunology', 'Lymph Nodes/immunology', '*Lymphocytes', 'Methods', 'Rabbits', 'Spleen/immunology', 'Thymus Gland/immunology']",,1971/07/01 00:00,1971/07/01 00:01,['1971/07/01 00:00'],"['1971/07/01 00:00 [pubmed]', '1971/07/01 00:01 [medline]', '1971/07/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971 Jul;7:390-2.,['0 (Antilymphocyte Serum)'],,Vydelenie limfoidnykh kletok cheloveka dlia polucheniia antilimfotsitarnykh syvorotok.,,,,,,,,,
4109009,NLM,MEDLINE,19720309,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7742,1972 Jan 15,Concordance of leukaemia and twinning in Down's syndrome families.,150,,"['Kucera, J']",['Kucera J'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Czechoslovakia', 'Down Syndrome/*genetics', 'Female', 'Humans', 'Leukemia/*genetics', 'Male', 'Pregnancy', '*Twins']",,1972/01/15 00:00,1972/01/15 00:01,['1972/01/15 00:00'],"['1972/01/15 00:00 [pubmed]', '1972/01/15 00:01 [medline]', '1972/01/15 00:00 [entrez]']","['S0140-6736(72)90720-9 [pii]', '10.1016/s0140-6736(72)90719-2 [doi]']",ppublish,Lancet. 1972 Jan 15;1(7742):150. doi: 10.1016/s0140-6736(72)90719-2.,,,,,,,,,,,,
4108957,NLM,MEDLINE,19720309,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7741,1972 Jan 8,Epidemiology of leukaemia.,82-3,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', 'England', 'Environment', 'Humans', 'Leukemia/*epidemiology', 'Leukemia, Lymphoid/epidemiology', 'Leukemia, Myeloid/epidemiology', 'Leukemia, Myeloid, Acute/epidemiology', 'Sex Factors']",,1972/01/08 00:00,1972/01/08 00:01,['1972/01/08 00:00'],"['1972/01/08 00:00 [pubmed]', '1972/01/08 00:01 [medline]', '1972/01/08 00:00 [entrez]']",['S0140-6736(72)90075-X [pii]'],ppublish,Lancet. 1972 Jan 8;1(7741):82-3.,,,,,,,,,,,,
4108941,NLM,MEDLINE,19720309,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7741,1972 Jan 8,TRransformation of human lymphocytes by sodium periodate.,103-4,,"['Parker, J W', ""O'Brien, R L"", 'Lukes, R J', 'Steiner, J']","['Parker JW', ""O'Brien RL"", 'Lukes RJ', 'Steiner J']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Binding Sites', 'Cells, Cultured', 'Humans', 'Iodates', '*Iodine', 'Leukemia, Lymphoid', '*Lymphocyte Activation', 'Lymphocytes/drug effects', 'Thymidine/metabolism', 'Tritium']",,1972/01/08 00:00,1972/01/08 00:01,['1972/01/08 00:00'],"['1972/01/08 00:00 [pubmed]', '1972/01/08 00:01 [medline]', '1972/01/08 00:00 [entrez]']","['S0140-6736(72)90115-8 [pii]', '10.1016/s0140-6736(72)90115-8 [doi]']",ppublish,Lancet. 1972 Jan 8;1(7741):103-4. doi: 10.1016/s0140-6736(72)90115-8.,"['0 (Iodates)', '10028-17-8 (Tritium)', '9679TC07X4 (Iodine)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4108934,NLM,MEDLINE,19720309,20200724,0022-538X (Print) 0022-538X (Linking),8,5,1971 Nov,Electron microscopy of Friend murine leukemia virus in the mid-gut of experimentally infected mosquitoes.,801-4,"After 30 and 78 hr, Friend murine leukemia virus (FLV) particles were detected by electron microscopy in the mid-gut lumen of the mosquitoes Aedes aegypti (Linnaeus) and Anopheles stephensi Liston which had fed on leukemia BALB/c mice infected with FLV. Various developmental stages of the virions were observed within and on the surface of ingested blood cells, particularly young erythroblasts, as well as free in the lumen after budding. These preliminary findings indicate that FLV continues to multiply in the mid-gut of these species for at least 3 days despite the action of digestive enzymes. Detailed studies are in progress to determine the fate of FLV in these mosquito species.","['Hirumi, H', 'Burton, G J', 'Maramorosch, K']","['Hirumi H', 'Burton GJ', 'Maramorosch K']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Aedes', 'Animal Feed', 'Animals', 'Anopheles', 'Blood Cells/microbiology', '*Culicidae', 'Female', 'Friend murine leukemia virus/*growth & development/isolation & purification', 'Inclusion Bodies, Viral', 'Insect Vectors', 'Intestines/*microbiology', 'Leukemia, Experimental/blood', 'Methods', 'Mice', 'Mice, Inbred Strains', '*Microscopy, Electron', 'Staining and Labeling', 'Time Factors', 'Virus Replication']",PMC376263,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",['10.1128/JVI.8.5.801-804.1971 [doi]'],ppublish,J Virol. 1971 Nov;8(5):801-4. doi: 10.1128/JVI.8.5.801-804.1971.,,,,,,,,,,,,
4108879,NLM,MEDLINE,19720306,20171213,0300-8916 (Print) 0300-8916 (Linking),57,1,1971 Jan-Feb,"[Preliminary study of phase I of bleomycin, a new anti-tumor drug].",21-53,,"['Bonadonna, G', 'De Lena, M', 'Bartoli, C', 'Monfardini, S', 'Guzzon, A', 'Molinari, R', 'Bajetta, E', 'Beretta, G', 'Fossati-Bellani, F', 'Orefice, S']","['Bonadonna G', 'De Lena M', 'Bartoli C', 'Monfardini S', 'Guzzon A', 'Molinari R', 'Bajetta E', 'Beretta G', 'Fossati-Bellani F', 'Orefice S']",['ita'],"['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial']",United States,Tumori,Tumori,0111356,IM,"['Adolescent', 'Adult', 'Aged', 'Antibiotics, Antineoplastic/adverse effects/*therapeutic use', 'Bleomycin/therapeutic use', 'Carcinoma/drug therapy', 'Child', 'Female', 'Humans', 'Leukemia, Lymphoid/drug therapy', 'Male', 'Melanoma/drug therapy', 'Mesothelioma/drug therapy', 'Middle Aged', 'Neoplasms/*drug therapy', 'Sarcoma/drug therapy']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Tumori. 1971 Jan-Feb;57(1):21-53.,"['0 (Antibiotics, Antineoplastic)', '11056-06-7 (Bleomycin)']",,Studio preliminare della fase I della bleomicina. un nuovo farmaco antitumorale.,,,,,,,,,
4108837,NLM,MEDLINE,19720306,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7740,1972 Jan 1,Cytotoxicity of A.L.S. and anti-HL-A antibodies in human leukaemia.,39-40,,"['Ohayon, E', 'Ducos, J', 'Goret, P', 'Salmon, H', 'Toma, B']","['Ohayon E', 'Ducos J', 'Goret P', 'Salmon H', 'Toma B']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cytotoxicity Tests, Immunologic', 'Humans', 'Immune Sera', 'Leukemia/*immunology', 'Lymphocytes/*immunology']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']","['S0140-6736(72)90030-X [pii]', '10.1016/s0140-6736(72)90030-x [doi]']",ppublish,Lancet. 1972 Jan 1;1(7740):39-40. doi: 10.1016/s0140-6736(72)90030-x.,['0 (Immune Sera)'],,,,,,,,,,,
4108836,NLM,MEDLINE,19720306,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7740,1972 Jan 1,T or B lymphocytes in chronic lymphocytic leukaemia.,38-9,,"['Moore, G R', 'Minowada, J']","['Moore GR', 'Minowada J']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Cell Line', 'Cells, Cultured', 'Humans', 'Leukemia, Lymphoid/*classification', '*Lymphocytes']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['10.1016/s0140-6736(72)90029-3 [doi]'],ppublish,Lancet. 1972 Jan 1;1(7740):38-9. doi: 10.1016/s0140-6736(72)90029-3.,,,,,,,,,,,,
4108821,NLM,MEDLINE,19720306,20171116,0140-6736 (Print) 0140-6736 (Linking),1,7740,1972 Jan 1,Platelets for transfusion.,25-6,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Blood Platelet Disorders/therapy', '*Blood Platelets', '*Blood Transfusion', 'Hemorrhage/*therapy', 'Humans', 'Leukemia/therapy', 'Purpura, Thrombocytopenic/therapy', 'Transfusion Reaction']",,1972/01/01 00:00,1972/01/01 00:01,['1972/01/01 00:00'],"['1972/01/01 00:00 [pubmed]', '1972/01/01 00:01 [medline]', '1972/01/01 00:00 [entrez]']",['S0140-6736(72)90011-6 [pii]'],ppublish,Lancet. 1972 Jan 1;1(7740):25-6.,,,,,,,,,,,,
4108803,NLM,MEDLINE,19720306,20191210,0008-4166 (Print) 0008-4166 (Linking),17,10,1971 Oct,Therapeutic effects of a series of non-viral interferon inducers on a viral-induced leukemia.,1259-65,,"['Rheins, M S', 'Barker, A D', 'Wilson, H E']","['Rheins MS', 'Barker AD', 'Wilson HE']",['eng'],['Journal Article'],Canada,Can J Microbiol,Canadian journal of microbiology,0372707,IM,"['Administration, Oral', 'Animals', 'Antiviral Agents/*therapeutic use', 'Cytopathogenic Effect, Viral', 'Ethylamines/therapeutic use', 'Fluorenes/*therapeutic use', '*Friend murine leukemia virus/isolation & purification', 'Injections, Intraperitoneal', 'Injections, Subcutaneous', 'Interferons/analysis/*biosynthesis/blood', 'Ketones/therapeutic use', 'L Cells', 'Leukemia, Experimental/blood/*drug therapy/metabolism/pathology', 'Mice', 'Mice, Inbred Strains', 'Microscopy, Electron', 'Organ Size', 'Placebos', 'Poly I-C/therapeutic use', 'Polynucleotides/*therapeutic use', 'Polysaccharides/*therapeutic use', 'Spleen/analysis/microbiology/pathology', 'Staining and Labeling', 'Tissue Extracts', 'Vesicular stomatitis Indiana virus']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",['10.1139/m71-202 [doi]'],ppublish,Can J Microbiol. 1971 Oct;17(10):1259-65. doi: 10.1139/m71-202.,"['0 (Antiviral Agents)', '0 (Ethylamines)', '0 (Fluorenes)', '0 (Ketones)', '0 (Placebos)', '0 (Polynucleotides)', '0 (Polysaccharides)', '0 (Tissue Extracts)', '9008-11-1 (Interferons)', 'O84C90HH2L (Poly I-C)']",,,,,,,,,,,
4108784,NLM,MEDLINE,19720306,20071115,0017-0275 (Print) 0017-0275 (Linking),51,10,1970 Oct,[On chronic lymphatic leukemia and its therapy: study of 40 cases].,764-84,,"['Baccarani, M', 'Tura, S', 'Ricci Bitti, M L', 'Storti, E', 'Gugliotta, L', 'Ricci, P', 'Lauria, F', 'Bagnara, G P', 'Staffa, C', 'Pascucci, E']","['Baccarani M', 'Tura S', 'Ricci Bitti ML', 'Storti E', 'Gugliotta L', 'Ricci P', 'Lauria F', 'Bagnara GP', 'Staffa C', 'Pascucci E']",['ita'],['Journal Article'],Italy,G Clin Med,Giornale di clinica medica,0413411,IM,"['Adrenal Cortex Hormones/therapeutic use', 'Adult', 'Aged', 'Alkylating Agents/therapeutic use', 'Androgens/therapeutic use', 'Antilymphocyte Serum/therapeutic use', 'Blood Transfusion', 'Humans', 'Leukemia, Lymphoid/radiotherapy/*therapy', 'Middle Aged', 'Splenectomy', 'gamma-Globulins/therapeutic use']",,1970/10/01 00:00,1970/10/01 00:01,['1970/10/01 00:00'],"['1970/10/01 00:00 [pubmed]', '1970/10/01 00:01 [medline]', '1970/10/01 00:00 [entrez]']",,ppublish,G Clin Med. 1970 Oct;51(10):764-84.,"['0 (Adrenal Cortex Hormones)', '0 (Alkylating Agents)', '0 (Androgens)', '0 (Antilymphocyte Serum)', '0 (gamma-Globulins)']",,Osservazioni sulla leucemia linfatica cronica e la sua terapia: studio di 40 casi.,,,,,,,,,
4108767,NLM,MEDLINE,19720304,20150205,0582-8082 (Print),3,2,1970,The cytochemistry of monocytes and macrophages.,93-131,,"['Schmalzl, F', 'Braunsteiner, H']","['Schmalzl F', 'Braunsteiner H']",['eng'],"['Journal Article', 'Review']",Denmark,Ser Haematol,Series haematologica (1968),101650673,IM,"['Esterases/metabolism', 'Exudates and Transudates/cytology', 'Fluorides/analysis', 'Glucocorticoids/pharmacology', 'Glycogen/analysis', '*Histocytochemistry', 'Humans', 'Hydrolases/metabolism', 'Leukemia, Myeloid/blood', 'Macrophages/drug effects/enzymology/*metabolism', 'Monocytes/analysis/cytology/enzymology/*metabolism', 'Naphthaleneacetic Acids', 'Oxidoreductases/metabolism', 'Skin Window Technique', 'Sodium', 'Staining and Labeling']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Ser Haematol. 1970;3(2):93-131.,"['0 (Glucocorticoids)', '0 (Naphthaleneacetic Acids)', '9005-79-2 (Glycogen)', '9NEZ333N27 (Sodium)', 'EC 1.- (Oxidoreductases)', 'EC 3.- (Hydrolases)', 'EC 3.1.- (Esterases)', 'Q80VPU408O (Fluorides)']",164,,,,,,,,,,
4108731,NLM,MEDLINE,19720304,20081121,0023-6748 (Print) 0023-6748 (Linking),5,,1971,"[Functional characteristics of thrombocytes of healthy persons and patients with reticuloses, lymphogranulomatosis, chronic lymphatic leukemia].",294-8,,"['Pimenov, Iu S']",['Pimenov IuS'],['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Adult', 'Blood Coagulation', '*Blood Platelets', 'Female', 'Fibrinolysis', 'Hodgkin Disease/*blood', 'Humans', 'Leukemia, Lymphoid/*blood', 'Lymphatic Diseases/*blood', 'Middle Aged']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;5:294-8.,,,"Funktsional'nye osobennosti trombotsitov zdorovykh liudei i bol'nykh retikulezami, limfogranulematozom, khronicheskim limfoleikozom.",,,,,,,,,
4108707,NLM,MEDLINE,19720304,20131121,0023-6748 (Print) 0023-6748 (Linking),3,,1971,[Dynamic study of uric acid in acute leukemia].,151-4,,"['Poddubnaia, I V', 'Lorie, Iu I']","['Poddubnaia IV', 'Lorie IuI']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Child', 'Female', 'Humans', 'Leukemia/*blood/urine', 'Male', 'Middle Aged', 'Uric Acid/*blood/urine']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1971;3:151-4.,['268B43MJ25 (Uric Acid)'],,Dinamicheskoe issledovanie mochevoi kisloty pri ostrom leikoze.,,,,,,,,,
4108680,NLM,MEDLINE,19720303,20191210,,118,1,1970 Jan,[New viewpoints concerning leukemia in children. Treatment of complications].,12-3,,"['Vogt, D']",['Vogt D'],['ger'],['Journal Article'],Germany,Monatsschr Kinderheilkd,Monatsschrift fur Kinderheilkunde,0400751,IM,"['Acute Disease', 'Anemia, Aplastic/chemically induced', 'Antineoplastic Agents/adverse effects', 'Child', 'Humans', 'Infections/etiology', 'Leukemia/*complications/*drug therapy', 'Methotrexate/therapeutic use', 'Pain/etiology', 'gamma-Globulins/therapeutic use']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Monatsschr Kinderheilkd. 1970 Jan;118(1):12-3.,"['0 (Antineoplastic Agents)', '0 (gamma-Globulins)', 'YL5FZ2Y5U1 (Methotrexate)']",,Neuere Gesichtspunkte zur Leukamie des Kindes. Behandlung von Komplikationen.,,,,,,,,,
4108614,NLM,MEDLINE,19720229,20190714,0042-6822 (Print) 0042-6822 (Linking),46,2,1971 Nov,An electron microscope study of Rauscher leukemia virus.,277-97,,"['Luftig, R B', 'Kilham, S S']","['Luftig RB', 'Kilham SS']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Acetates', 'Aldehydes', 'Catalase', 'Centrifugation, Density Gradient', 'Centrifugation, Zonal', 'Cesium', 'Chlorides', 'Formaldehyde', '*Microscopy, Electron', 'Models, Structural', 'Molybdenum', 'Nucleoproteins', 'Phosphotungstic Acid', 'Quaternary Ammonium Compounds', 'RNA, Viral', '*Rauscher Virus/isolation & purification', 'Sodium', 'Spectrophotometry', 'Staining and Labeling', 'Sucrose', 'Sulfates', 'Surface-Active Agents', 'Uranium', 'Viral Proteins']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']","['0042-6822(71)90030-4 [pii]', '10.1016/0042-6822(71)90030-4 [doi]']",ppublish,Virology. 1971 Nov;46(2):277-97. doi: 10.1016/0042-6822(71)90030-4.,"['0 (Acetates)', '0 (Aldehydes)', '0 (Chlorides)', '0 (Nucleoproteins)', '0 (Quaternary Ammonium Compounds)', '0 (RNA, Viral)', '0 (Sulfates)', '0 (Surface-Active Agents)', '0 (Viral Proteins)', '12067-99-1 (Phosphotungstic Acid)', '1HG84L3525 (Formaldehyde)', '1KSV9V4Y4I (Cesium)', '4OC371KSTK (Uranium)', '57-50-1 (Sucrose)', '81AH48963U (Molybdenum)', '9NEZ333N27 (Sodium)', 'EC 1.11.1.6 (Catalase)']",,,,,,,,,,,
4108587,NLM,MEDLINE,19720226,20041117,0044-2542 (Print) 0044-2542 (Linking),25,8,1970 Apr 15,[Electrocardiogram and secondary heart tumors].,362-5,,"['Lafrenz, M', 'Korber, H G']","['Lafrenz M', 'Korber HG']",['ger'],['Journal Article'],Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,IM,"['Adolescent', 'Adrenal Gland Neoplasms', 'Adult', 'Aged', 'Atrial Fibrillation/diagnosis', 'Bile Duct Neoplasms', 'Breast Neoplasms', 'Bronchial Neoplasms', 'Carcinoid Tumor', 'Cardiac Complexes, Premature/diagnosis', '*Electrocardiography', 'Esophageal Neoplasms', 'Female', 'Gastrointestinal Neoplasms', 'Heart Neoplasms/*diagnosis/epidemiology', 'Hodgkin Disease', 'Humans', 'Leukemia', 'Male', 'Middle Aged', 'Neoplasm Metastasis/*diagnosis', 'Pancreatic Neoplasms', 'Tachycardia/etiology', 'Thyroid Neoplasms', 'Urogenital Neoplasms']",,1970/04/15 00:00,1970/04/15 00:01,['1970/04/15 00:00'],"['1970/04/15 00:00 [pubmed]', '1970/04/15 00:01 [medline]', '1970/04/15 00:00 [entrez]']",,ppublish,Z Gesamte Inn Med. 1970 Apr 15;25(8):362-5.,,,Elektrokardiogramm und sekundare Herztumoren.,,,,,,,,,
4108575,NLM,MEDLINE,19720226,20200724,0022-538X (Print) 0022-538X (Linking),8,4,1971 Oct,Isolation and characterization of a herpesvirus from leukemic guinea pigs.,579-88,"A guinea pig herpesvirus (GPHV) has consistently been isolated from leukemic lymphoblasts of strain-2 guinea pigs. GPHV is serologically related to the guinea pig herpes-like virus isolated by Hsiung and Kaplow. The virions of GPHV consist of an icosahedral capsid containing a dense nucleoprotein core enclosed in a double-layered membrane. The average diameters of GPHV virion and capsid were 166 and 101 nm, respectively. Studies on the morphogenesis of GPHV revealed that, as in other herpesvirus infections, only the naked capsids with or without the nucleoprotein core were found in the infected cell nuclei; it was also learned that the virion acquired its envelope by budding from the nuclear membrane of the infected cells. However, GPHV-infected cell nuclei also contained dense fibrous rods, resembling nucleo-protein core outside the capsids, and tubules resembling viral core protein. The capsids were often embedded in dense granular antigen. GPHV deoxyribonucleic acid (DNA) has a density of 1.716 g/ml in cesium chloride compared to herpes simplex virus DNA (rho = 1.728 g/ml) and cellular DNA (rho = 1.700 g/ml).","['Nayak, D P']",['Nayak DP'],['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Antigens, Viral/analysis', 'Carbon Isotopes', 'Centrifugation, Density Gradient', 'Cesium', 'Chlorides', 'Culture Techniques', 'Cytopathogenic Effect, Viral', 'DNA/analysis/isolation & purification', 'DNA, Viral/analysis/isolation & purification', 'Fibroblasts', 'Fluorescent Antibody Technique', 'Guinea Pigs', 'Herpesviridae/analysis/classification/growth & development/immunology/*isolation & purification/pathogenicity', 'Leukemia/*microbiology', 'Leukemia, Experimental/microbiology', 'Microscopy, Electron', 'Morphogenesis', 'Neutralization Tests', 'Nucleoproteins', 'Staining and Labeling', 'Sucrose', 'Thymidine', 'Tritium', 'Viral Proteins']",PMC376231,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",['10.1128/JVI.8.4.579-588.1971 [doi]'],ppublish,J Virol. 1971 Oct;8(4):579-88. doi: 10.1128/JVI.8.4.579-588.1971.,"['0 (Antigens, Viral)', '0 (Carbon Isotopes)', '0 (Chlorides)', '0 (DNA, Viral)', '0 (Nucleoproteins)', '0 (Viral Proteins)', '10028-17-8 (Tritium)', '1KSV9V4Y4I (Cesium)', '57-50-1 (Sucrose)', '9007-49-2 (DNA)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4108573,NLM,MEDLINE,19720226,20200724,0022-538X (Print) 0022-538X (Linking),8,4,1971 Oct,Helical nucleocapsid structure of the oncogenic ribonucleic acid viruses (oncornaviruses).,564-72,"Negative staining of virions and isolated nucleoids from avian myeloblastosis virus, murine leukemia virus, murine mammary tumor virus, and feline leukemia virus reveals common internal structures. The majority of virions that are penetrated by phosphotungstate show spherical nucleoids with no apparent symmetry. In a small percentage of virions, two distinctive structures are found: (i) single strands (3 to 5 nm in diameter) which are presumed to be the nucleoprotein and are found randomly oriented throughout the viral interior and (ii) helical structures (7 to 9 nm in diameter) which contain these nucleoprotein strands and are observed at the periphery of the nucleoid. The finding of helical nucleocapsid segments at the periphery of the nucleoid, as well as the hollow spherical structure observed in thin section of budding virions, has led to the hypothesis that the nucleocapsid of the freshly budded oncornavirus is supercoiled as a hollow sphere. This symmetry, however, is considered transient, as the internal structure of the extracellular virus undergoes a conformational rearrangement; thus, due to structural instability, the nucleocapsid uncoils and the nucleoprotein strands fill the interior of the virion. The extracellular virion is therefore considered degenerate in respect to symmetry, explaining the difficulty in detecting a helical nucleocapsid.","['Sarkar, N H', 'Nowinski, R C', 'Moore, D H']","['Sarkar NH', 'Nowinski RC', 'Moore DH']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Avian Leukosis Virus/*analysis/growth & development/isolation & purification', 'Centrifugation, Density Gradient', 'Citrates', 'Mammary Tumor Virus, Mouse/*analysis/growth & development/isolation & purification', 'Microscopy, Electron', 'Models, Structural', 'Morphogenesis', '*Nucleoproteins/isolation & purification', 'Phosphotungstic Acid', 'Polysaccharides', 'Potassium', 'Rauscher Virus/*analysis/growth & development/isolation & purification', 'Staining and Labeling', 'Sucrose', 'Surface-Active Agents']",PMC376229,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",['10.1128/JVI.8.4.564-572.1971 [doi]'],ppublish,J Virol. 1971 Oct;8(4):564-72. doi: 10.1128/JVI.8.4.564-572.1971.,"['0 (Citrates)', '0 (Nucleoproteins)', '0 (Polysaccharides)', '0 (Surface-Active Agents)', '12067-99-1 (Phosphotungstic Acid)', '57-50-1 (Sucrose)', 'RWP5GA015D (Potassium)']",,,,,,,,,,,
4108548,NLM,MEDLINE,19720225,20091027,0032-7867 (Print) 0032-7867 (Linking),79,51,1971 Nov 27,[Serum alpha 2 H in malignant hemopathies and cirrhosis. Prognostic value].,2313-6,,"['Martin, J P', 'Charlionet, R', 'Ropartz, C']","['Martin JP', 'Charlionet R', 'Ropartz C']",['fre'],['Journal Article'],France,Presse Med,La Presse medicale,0312556,IM,"['Acute Disease', 'Alpha-Globulins/*analysis', 'Antigens/analysis', 'Blood Protein Disorders/*blood', 'Chronic Disease', 'Hodgkin Disease/*blood', 'Humans', 'Immunodiffusion', 'Leukemia/*blood', 'Liver Cirrhosis/*blood', 'Multiple Myeloma/*blood', 'Prognosis']",,1971/11/27 00:00,1971/11/27 00:01,['1971/11/27 00:00'],"['1971/11/27 00:00 [pubmed]', '1971/11/27 00:01 [medline]', '1971/11/27 00:00 [entrez]']",,ppublish,Presse Med. 1971 Nov 27;79(51):2313-6.,"['0 (Alpha-Globulins)', '0 (Antigens)']",,L'alpha 2 H serique au cours des hemopathies malignes et des cirrhoses. Valeur evolutive.,,,,,,,,,
4108507,NLM,MEDLINE,19720223,20041117,0017-6559 (Print) 0017-6559 (Linking),5,3,1971,Immunology and malignant disease.,179-203,,"['Klein, E', 'Cochran, A J']","['Klein E', 'Cochran AJ']",['eng'],"['Journal Article', 'Review']",Netherlands,Haematologia (Budap),Haematologia,0130266,IM,"['Antibody Formation', 'Antibody Specificity', 'Antibody-Producing Cells', '*Antigen-Antibody Reactions', 'Antigens/*analysis', 'Antigens, Neoplasm', 'Autoantibodies', 'Burkitt Lymphoma/immunology', 'Cross Reactions', 'DNA Viruses/immunology', 'Epitopes', 'Graft Rejection', 'Herpesvirus 4, Human/immunology', 'Hodgkin Disease/immunology', 'Humans', 'Immunity, Cellular', 'Infectious Mononucleosis/immunology', 'Leukemia/immunology', 'Lymphocytes/immunology', 'Neoplasm Metastasis', 'Neoplasm Regression, Spontaneous', 'Neoplasm Transplantation', 'Neoplasms/chemically induced/*immunology', 'Oncogenic Viruses', 'Pharyngeal Neoplasms/immunology', 'RNA Viruses/immunology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Haematologia (Budap). 1971;5(3):179-203.,"['0 (Antigens)', '0 (Antigens, Neoplasm)', '0 (Autoantibodies)', '0 (Epitopes)']",189,,,,,,,,,,
4108309,NLM,MEDLINE,19720216,20071115,0029-4810 (Print) 0029-4810 (Linking),11,3,1971 May-Jun,[Immunological anomalies observed during hyperlymphocytic chronic lymphoid leukemia].,476-83,,"['Homberg, J C', 'Cartron, J', 'Ropars, C', 'Cavaroc, M', 'Salmon, C']","['Homberg JC', 'Cartron J', 'Ropars C', 'Cavaroc M', 'Salmon C']",['fre'],['Journal Article'],France,Nouv Rev Fr Hematol,Nouvelle revue francaise d'hematologie,0401074,IM,"['Antibodies/*analysis', 'Autoantibodies/analysis', 'Erythrocytes/immunology', 'Hodgkin Disease/immunology', 'Humans', 'Immunoelectrophoresis', 'Immunoglobulins/*analysis', 'Leukemia, Lymphoid/*immunology', 'Lymphoma/immunology', 'Waldenstrom Macroglobulinemia/immunology', 'gamma-Globulins/analysis']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Nouv Rev Fr Hematol. 1971 May-Jun;11(3):476-83.,"['0 (Antibodies)', '0 (Autoantibodies)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,Anomalies immunologiques observees au cours des leucemies lymphoides chroniques hyperlymphocytaires.,,,,,,,,,
4108308,NLM,MEDLINE,19720216,20071115,0029-4810 (Print) 0029-4810 (Linking),11,3,1971 May-Jun,"[Changes, caused by a liver diseases, in the level of serum immunoglobulins during chronic lymphoid leukemia].",365-71,,"['Najman, A', 'Gerbal, A', 'Ropars, C', 'Homberg, J C', 'Duhamel, G', 'Andre, R']","['Najman A', 'Gerbal A', 'Ropars C', 'Homberg JC', 'Duhamel G', 'Andre R']",['fre'],['Journal Article'],France,Nouv Rev Fr Hematol,Nouvelle revue francaise d'hematologie,0401074,IM,"['Electrophoresis', 'Female', 'Hepatitis/blood/*complications', 'Humans', 'Immunodiffusion', 'Immunoelectrophoresis', 'Immunoglobulins/*analysis', 'Leukemia, Lymphoid/blood/*complications', 'Liver Cirrhosis/blood/*complications', 'Liver Function Tests', 'Male', 'Middle Aged', 'gamma-Globulins/*analysis']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Nouv Rev Fr Hematol. 1971 May-Jun;11(3):365-71.,"['0 (Immunoglobulins)', '0 (gamma-Globulins)']",,"Variations, provoquees par une maladie hepatique, du taux des immunoglobulines seriques au cours des leucemies lymphoides chroniques.",,,,,,,,,
4108240,NLM,MEDLINE,19720216,20190511,0002-9173 (Print) 0002-9173 (Linking),56,6,1971 Dec,A slide centrifugation technic for concentrating blood leukocytes and nucleated cells from bone marrow blood.,719-22,,"['Martinazzi, M']",['Martinazzi M'],['eng'],['Journal Article'],England,Am J Clin Pathol,American journal of clinical pathology,0370470,IM,"['Blood Sedimentation', '*Bone Marrow', '*Bone Marrow Cells', '*Centrifugation', 'Hemolysis', 'Humans', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', '*Leukocytes/cytology', 'Leukocytosis/blood', 'Methods', 'Oxalates', 'Quaternary Ammonium Compounds', 'Staining and Labeling']",,1971/12/01 00:00,1971/12/01 00:01,['1971/12/01 00:00'],"['1971/12/01 00:00 [pubmed]', '1971/12/01 00:01 [medline]', '1971/12/01 00:00 [entrez]']",['10.1093/ajcp/56.6.719 [doi]'],ppublish,Am J Clin Pathol. 1971 Dec;56(6):719-22. doi: 10.1093/ajcp/56.6.719.,"['0 (Oxalates)', '0 (Quaternary Ammonium Compounds)']",,,,,,,,,,,
4108231,NLM,MEDLINE,19720214,20171116,0030-2260 (Print) 0030-2260 (Linking),48,3,1970 Jul-Sep,[Antineoplastic chemotherapy in dermatology. Clinical experimental and anatomico pathologic study on the activities of some antimitotics. Findings in the general and local therapy].,209-348,,"['Scotti, G']",['Scotti G'],['ita'],"['Journal Article', 'Review']",Italy,Omnia Med Ther,Omnia medica et therapeutica,0212414,IM,"['Adrenal Cortex Hormones/therapeutic use', 'Adult', 'Aged', 'Alkylating Agents/therapeutic use', 'Aminopterin/therapeutic use', 'Antimetabolites/therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Carcinoma, Basal Cell/drug therapy', 'Carcinoma, Squamous Cell/drug therapy', 'Colchicine/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Dactinomycin/therapeutic use', 'Estrogens/therapeutic use', 'Female', 'Fluorouracil/therapeutic use', 'Hodgkin Disease/drug therapy', 'Humans', 'Leukemia, Lymphoid/drug therapy', 'Male', 'Mercaptopurine/therapeutic use', 'Methotrexate/therapeutic use', 'Middle Aged', 'Mycosis Fungoides/drug therapy', 'Nitrogen Mustard Compounds/therapeutic use', 'Progesterone/therapeutic use', 'Sarcoma, Kaposi/drug therapy', 'Skin Neoplasms/*drug therapy', 'Testosterone/therapeutic use', 'Triaziquone/therapeutic use', 'Vinblastine/therapeutic use']",,1970/07/01 00:00,1970/07/01 00:01,['1970/07/01 00:00'],"['1970/07/01 00:00 [pubmed]', '1970/07/01 00:01 [medline]', '1970/07/01 00:00 [entrez]']",,ppublish,Omnia Med Ther. 1970 Jul-Sep;48(3):209-348.,"['0 (Adrenal Cortex Hormones)', '0 (Alkylating Agents)', '0 (Antimetabolites)', '0 (Antineoplastic Agents)', '0 (Estrogens)', '0 (Nitrogen Mustard Compounds)', '1CC1JFE158 (Dactinomycin)', '3XMK78S47O (Testosterone)', '4G7DS2Q64Y (Progesterone)', '5V9KLZ54CY (Vinblastine)', '8N3DW7272P (Cyclophosphamide)', 'E7WED276I5 (Mercaptopurine)', 'F3D5D9P25I (Triaziquone)', 'JYB41CTM2Q (Aminopterin)', 'SML2Y3J35T (Colchicine)', 'U3P01618RT (Fluorouracil)', 'YL5FZ2Y5U1 (Methotrexate)']",131,La chemioterapia antiblastica in campo dermatologico. Studio clinico-sperimentale ed anatomo-patologico sulle attivita di alcuni antimotoci. Rilievi di terapia generale e locale.,,,,,,,,,
4108199,NLM,MEDLINE,19720214,20190619,0008-543X (Print) 0008-543X (Linking),28,5,1971 Nov,Acute leukemia with megakaryocytic predominance.,1343-9,,"['Chan, B W', 'Flemans, R J', 'Zbinden, G']","['Chan BW', 'Flemans RJ', 'Zbinden G']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Acute Disease', 'Adult', 'Autopsy', 'Blood Platelets/analysis', 'Bone Marrow/analysis', 'Bone Marrow Cells', 'Female', 'Glycogen/analysis', 'Histocytochemistry', 'Humans', '*Leukemia/complications/metabolism/pathology/physiopathology', '*Megakaryocytes/analysis', 'Microscopy, Electron', 'Platelet Adhesiveness', 'Staining and Labeling']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",['10.1002/1097-0142(1971)28:5<1343::aid-cncr2820280538>3.0.co;2-1 [doi]'],ppublish,Cancer. 1971 Nov;28(5):1343-9. doi: 10.1002/1097-0142(1971)28:5<1343::aid-cncr2820280538>3.0.co;2-1.,['9005-79-2 (Glycogen)'],,,,,,,,,,,
4108143,NLM,MEDLINE,19720211,20051117,0035-3019 (Print) 0035-3019 (Linking),16,6,1971 Jun-Jul,Comparative effectiveness of restoration of the immune response with isogeneic bone marrow in irradiated AKR and C57BL mice.,582-5,,"['Umaly, R', 'Duplan, J F']","['Umaly R', 'Duplan JF']",['eng'],['Journal Article'],France,Rev Eur Etud Clin Biol,Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,0351323,IM,"['Animals', '*Bone Marrow Transplantation', 'Female', '*Leukemia, Radiation-Induced', 'Male', 'Mice', '*Radiation Chimera', 'Thymus Gland/*immunology', 'Transplantation, Homologous', 'gamma-Globulins']",,1971/06/01 00:00,1971/06/01 00:01,['1971/06/01 00:00'],"['1971/06/01 00:00 [pubmed]', '1971/06/01 00:01 [medline]', '1971/06/01 00:00 [entrez]']",,ppublish,Rev Eur Etud Clin Biol. 1971 Jun-Jul;16(6):582-5.,['0 (gamma-Globulins)'],,,,,,,,,,,
4108142,NLM,MEDLINE,19720211,20071115,0035-3019 (Print) 0035-3019 (Linking),16,6,1971 Jun-Jul,Subdivision of classical varieties of acute leukemia. Correlation with prognosis and cure expectancy.,554-60,,"['Mathe, G', 'Pouillart, P', 'Sterescu, M', 'Amiel, J L', 'Schwarzenberg, L', 'Schneider, M', 'Hayat, M', 'de Vassal, F', 'Jasmin, C', 'Lafleur, M']","['Mathe G', 'Pouillart P', 'Sterescu M', 'Amiel JL', 'Schwarzenberg L', 'Schneider M', 'Hayat M', 'de Vassal F', 'Jasmin C', 'Lafleur M']",['eng'],['Journal Article'],France,Rev Eur Etud Clin Biol,Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,0351323,IM,"['Acute Disease', 'Age Factors', '*Bone Marrow Examination', 'Female', 'Humans', 'Leukemia/*classification/pathology/therapy', 'Leukemia, Lymphoid/pathology', 'Leukemia, Monocytic, Acute/pathology', 'Leukemia, Myeloid, Acute/pathology', 'Male', 'Prognosis', 'Staining and Labeling']",,1971/06/01 00:00,1971/06/01 00:01,['1971/06/01 00:00'],"['1971/06/01 00:00 [pubmed]', '1971/06/01 00:01 [medline]', '1971/06/01 00:00 [entrez]']",,ppublish,Rev Eur Etud Clin Biol. 1971 Jun-Jul;16(6):554-60.,,,,,,,,,,,,
4108092,NLM,MEDLINE,19720210,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7732,1971 Nov,Serum copper and magnesium levels in leukaemia and malignant lymphoma.,1036-7,,"['Ilicin, G']",['Ilicin G'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Copper/*blood', 'Humans', 'Leukemia/*blood', 'Lymphoma/*blood', 'Magnesium/*blood']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']","['S0140-6736(71)90353-9 [pii]', '10.1016/s0140-6736(71)90353-9 [doi]']",ppublish,Lancet. 1971 Nov;2(7732):1036-7. doi: 10.1016/s0140-6736(71)90353-9.,"['789U1901C5 (Copper)', 'I38ZP9992A (Magnesium)']",,,,,,,,,,,
4108040,NLM,MEDLINE,19720210,20191210,0014-4827 (Print) 0014-4827 (Linking),68,2,1971 Oct,Surface antigens and release of virus in hybrid cells produced by the fusion of A9 fibroblasts with Moloney Lymphoma cells.,323-31,,"['Fenyo, E M', 'Grundner, G', 'Klein, G', 'Klein, E', 'Harris, H']","['Fenyo EM', 'Grundner G', 'Klein G', 'Klein E', 'Harris H']",['eng'],['Journal Article'],United States,Exp Cell Res,Experimental cell research,0373226,IM,"['Animals', 'Antigens/*analysis', 'Antigens, Viral/analysis', 'Cell Fusion', 'Cell Line', 'Cell Membrane/*immunology', 'Chromosomes/immunology', 'Culture Media', 'Culture Techniques', 'Cytotoxicity Tests, Immunologic', 'Diploidy', 'Epitopes', 'Fibroblasts', 'Fluorescent Antibody Technique', 'Hemadsorption Inhibition Tests', 'Hybrid Cells/*immunology', 'Immune Sera', 'L Cells', 'Lymphoma', 'Mice', 'Moloney murine leukemia virus/*immunology', 'Neoplasms, Experimental/immunology', 'Polyploidy', 'Time Factors']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']","['0014-4827(71)90157-1 [pii]', '10.1016/0014-4827(71)90157-1 [doi]']",ppublish,Exp Cell Res. 1971 Oct;68(2):323-31. doi: 10.1016/0014-4827(71)90157-1.,"['0 (Antigens)', '0 (Antigens, Viral)', '0 (Culture Media)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4108039,NLM,MEDLINE,19720210,20191210,0014-4827 (Print) 0014-4827 (Linking),68,2,1971 Oct,Surface antigen expression in malignant sublines derived from hybrid cells of low malignancy.,315-22,,"['Grundner, G', 'Fenyo, E M', 'Klein, E', 'Bregula, U', 'Harris, H']","['Grundner G', 'Fenyo EM', 'Klein E', 'Bregula U', 'Harris H']",['eng'],['Journal Article'],United States,Exp Cell Res,Experimental cell research,0373226,IM,"['Animals', 'Antigen-Antibody Reactions', 'Antigens/*analysis', 'Antigens, Viral/analysis', 'Carcinoma, Ehrlich Tumor/immunology', 'Cell Line', 'Cell Membrane/*immunology', 'Cell Transformation, Neoplastic', 'Chromosomes/immunology', 'Clone Cells', 'Culture Techniques', 'Cytogenetics', 'Cytotoxicity Tests, Immunologic', 'Epitopes', 'Fibroblasts', 'Fluorescent Antibody Technique', 'Hemadsorption Inhibition Tests', 'Hybrid Cells/*immunology', 'Immune Adherence Reaction', 'Immune Sera', 'Isoantigens/*analysis', 'L Cells', 'Mice', 'Moloney murine leukemia virus/immunology', 'Neoplasm Transplantation']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",['10.1016/0014-4827(71)90156-x [doi]'],ppublish,Exp Cell Res. 1971 Oct;68(2):315-22. doi: 10.1016/0014-4827(71)90156-x.,"['0 (Antigens)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Isoantigens)']",,,,,,,,,,,
4108013,NLM,MEDLINE,19720209,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7735,1971 Nov 27,Antileukaemic activity of hycanthone.,1206,,"['Adamson, R H']",['Adamson RH'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Injections, Intraperitoneal', 'Leukemia L1210/drug therapy', 'Leukemia, Experimental/*drug therapy', 'Mice', 'Xanthenes/administration & dosage/*therapeutic use']",,1971/11/27 00:00,1971/11/27 00:01,['1971/11/27 00:00'],"['1971/11/27 00:00 [pubmed]', '1971/11/27 00:01 [medline]', '1971/11/27 00:00 [entrez]']",['10.1016/s0140-6736(71)90526-5 [doi]'],ppublish,Lancet. 1971 Nov 27;2(7735):1206. doi: 10.1016/s0140-6736(71)90526-5.,['0 (Xanthenes)'],,,,,,,,,,,
4107925,NLM,MEDLINE,19720202,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7731,1971 Oct 30,T or B lymphocytes in chronic lymphocytic leukemaemia.,976-7,,"['Catovsky, D', 'Holt, P J']","['Catovsky D', 'Holt PJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Humans', 'Lectins/pharmacology', 'Leukemia, Lymphoid/*immunology', 'Leukocytes/drug effects', 'Lymphocyte Activation', 'Lymphocytes/cytology/*immunology', 'Microscopy, Electron']",,1971/10/30 00:00,1971/10/30 00:01,['1971/10/30 00:00'],"['1971/10/30 00:00 [pubmed]', '1971/10/30 00:01 [medline]', '1971/10/30 00:00 [entrez]']","['S0140-6736(71)90295-9 [pii]', '10.1016/s0140-6736(71)90295-9 [doi]']",ppublish,Lancet. 1971 Oct 30;2(7731):976-7. doi: 10.1016/s0140-6736(71)90295-9.,['0 (Lectins)'],,,,,,,,,,,
4107765,NLM,MEDLINE,19720131,20190706,0009-8981 (Print) 0009-8981 (Linking),32,2,1971 Apr,Gradient polyacylamide gel electrophoresis of human serum proteins: improved discontinuous gel electrophoretic technique and identification of individual serum components.,285-96,,"['Wright, G L Jr', 'Farrell, K B', 'Roberts, D B']","['Wright GL Jr', 'Farrell KB', 'Roberts DB']",['eng'],['Journal Article'],Netherlands,Clin Chim Acta,Clinica chimica acta; international journal of clinical chemistry,1302422,IM,"['Acrylamides', 'Adolescent', 'Adult', 'Aged', 'Blood Proteins/*isolation & purification', 'Ceruloplasmin/isolation & purification', 'Complement System Proteins/isolation & purification', '*Electrophoresis, Disc', 'Female', 'Glycoproteins/blood/isolation & purification', 'Haptoglobins/isolation & purification', 'Hodgkin Disease/blood', 'Humans', 'Immunodiffusion', 'Immunoelectrophoresis', 'Immunoglobulin A/isolation & purification', 'Immunoglobulin G/isolation & purification', 'Immunoglobulin M/isolation & purification', 'Leukemia/blood', 'Lipoproteins/blood/isolation & purification', 'Macroglobulins/isolation & purification', 'Male', 'Methods', 'Middle Aged', 'Multiple Myeloma/blood', 'Serum Albumin/isolation & purification', 'Staining and Labeling', 'Transferrin/isolation & purification', 'Trypsin Inhibitors/blood/isolation & purification', 'Waldenstrom Macroglobulinemia/blood']",,1971/04/01 00:00,2001/03/28 10:01,['1971/04/01 00:00'],"['1971/04/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1971/04/01 00:00 [entrez]']","['0009-8981(71)90345-7 [pii]', '10.1016/0009-8981(71)90345-7 [doi]']",ppublish,Clin Chim Acta. 1971 Apr;32(2):285-96. doi: 10.1016/0009-8981(71)90345-7.,"['0 (Acrylamides)', '0 (Blood Proteins)', '0 (Glycoproteins)', '0 (Haptoglobins)', '0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Lipoproteins)', '0 (Macroglobulins)', '0 (Serum Albumin)', '0 (Transferrin)', '0 (Trypsin Inhibitors)', '9007-36-7 (Complement System Proteins)', 'EC 1.16.3.1 (Ceruloplasmin)']",,,,,,,,,,,
4107762,NLM,MEDLINE,19720131,20031114,0002-9645 (Print) 0002-9645 (Linking),32,11,1971 Nov,Responses of cell cultures from various avian species to Marek's disease virus and herpesvirus of turkeys.,1811-23,,"['Purchase, H G', 'Burmester, B R', 'Cunningham, C H']","['Purchase HG', 'Burmester BR', 'Cunningham CH']",['eng'],['Journal Article'],United States,Am J Vet Res,American journal of veterinary research,0375011,IM,"['Alpharetrovirus/*growth & development/pathogenicity', 'Animals', 'Antibodies/analysis', 'Antigens/analysis', 'Avian Leukosis/prevention & control', 'Birds/embryology', '*Cells, Cultured', 'Clone Cells/growth & development', 'Fluorescent Antibody Technique/veterinary', 'Herpesviridae/*growth & development/pathogenicity', 'Histological Techniques', 'Immune Sera/analysis', 'Kidney', 'Peripheral Nervous System Diseases/prevention & control/veterinary', 'Poultry Diseases/prevention & control', 'Species Specificity', 'Staining and Labeling', '*Turkeys', 'Viral Vaccines']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']",,ppublish,Am J Vet Res. 1971 Nov;32(11):1811-23.,"['0 (Antibodies)', '0 (Antigens)', '0 (Immune Sera)', '0 (Viral Vaccines)']",,,,,,,,,,,
4107704,NLM,MEDLINE,19720126,20191030,0365-4184 (Print) 0365-4184 (Linking),79,5,1971,Histopathological findings of familial amyloidosis with cranial neuropathy as principal manifestation. Report on three cases.,432-40,,"['Meretoja, J', 'Teppo, L']","['Meretoja J', 'Teppo L']",['eng'],['Journal Article'],Denmark,Acta Pathol Microbiol Scand A,"Acta pathologica et microbiologica Scandinavica. Section A, Pathology",7508468,IM,"['Aged', 'Amyloidosis/*pathology', 'Bulbar Palsy, Progressive/pathology', 'Cerebral Hemorrhage/pathology', 'Corneal Dystrophies, Hereditary/*pathology', 'Cranial Nerves/*pathology', 'Facial Paralysis/*pathology', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/pathology', 'Male', 'Middle Aged', 'Nervous System Diseases/pathology', 'Pneumonia/pathology', 'Polycythemia Vera/pathology', 'Staining and Labeling', 'Vascular Diseases/pathology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",['10.1111/j.1699-0463.1971.tb01841.x [doi]'],ppublish,Acta Pathol Microbiol Scand A. 1971;79(5):432-40. doi: 10.1111/j.1699-0463.1971.tb01841.x.,,,,,,,,,,,,
4107574,NLM,MEDLINE,19720125,20041117,0323-4347 (Print) 0323-4347 (Linking),95,4,1971,[Cytochemical studies on beta-glucuronidase in white blood cells in various diseases of the hematopoietic system].,389-97,,"['Nilius, R', 'Krosch, H', 'Lotsch, V']","['Nilius R', 'Krosch H', 'Lotsch V']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acute Disease', 'Blood Platelets/enzymology', 'Eosinophils/enzymology', 'Erythrocytes/enzymology', 'Glucuronidase/*metabolism', 'Hematologic Diseases/*enzymology', 'Hematopoietic Stem Cells/enzymology', 'Histocytochemistry', 'Hodgkin Disease/enzymology', 'Humans', 'Leukemia/enzymology', 'Leukemia, Myeloid/enzymology', 'Leukocytes/*enzymology', 'Leukocytosis/blood', 'Lymphatic Diseases/enzymology', 'Monocytes/enzymology', 'Neutrophils/enzymology', 'Plasmacytoma/enzymology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(4):389-97.,['EC 3.2.1.31 (Glucuronidase)'],,Zytochemische Untersuchungen der beta-Glukuronidase in weissen Zellformen des Blutes bei verschiedenen Erkrankungen des hamopoetischen Systems.,,,,,,,,,
4107573,NLM,MEDLINE,19720125,20081121,0323-4347 (Print) 0323-4347 (Linking),95,4,1971,[Azurophilic granulation in lymphocytes. 3. Behavior of lymphocytes with azurophilic granulation in various hematologic diseases].,385-8,,"['Sahi, J', 'Stobbe, H', 'Klatt, R', 'Heine, K M', 'Hofer, E']","['Sahi J', 'Stobbe H', 'Klatt R', 'Heine KM', 'Hofer E']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adult', 'Aged', 'Blood Proteins/analysis', '*Cytoplasmic Granules', 'Electrophoresis, Paper', 'Female', 'Hematologic Diseases/*blood', 'Hodgkin Disease/blood/complications', 'Humans', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid/blood', 'Leukocyte Count', 'Leukopenia/etiology', 'Lymphocytes/*cytology', 'Male', 'Middle Aged', 'Osteosclerosis/blood', 'Primary Myelofibrosis/blood', 'Staining and Labeling', 'gamma-Globulins/analysis']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(4):385-8.,"['0 (Blood Proteins)', '0 (gamma-Globulins)']",,Die Azurgranulation der Lymphozyten. 3. Das Verhalten der azurgranulierten Lymphozyten bei einigen hamatologischen Erkrankungen.,,,,,,,,,
4107569,NLM,MEDLINE,19720125,20131121,0323-4347 (Print) 0323-4347 (Linking),95,4,1971,[Changes in the cerebrospinal fluid in leukemic meningosis].,357-65,,"['Wieczorek, V', 'Zintl, F', 'Stahl, J', 'Aurich, G']","['Wieczorek V', 'Zintl F', 'Stahl J', 'Aurich G']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Central Nervous System Diseases/*cerebrospinal fluid', 'Cerebrospinal Fluid/cytology', 'Cerebrospinal Fluid Proteins', 'Child', 'Glucose/cerebrospinal fluid', 'Hematopoietic Stem Cells', 'Humans', 'Leukemia/*cerebrospinal fluid', 'Meninges']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(4):357-65.,"['0 (Cerebrospinal Fluid Proteins)', 'IY9XDZ35W2 (Glucose)']",,Liquorveranderungen bei der Meningosis leucaemica.,,,,,,,,,
4107568,NLM,MEDLINE,19720125,20071115,0323-4347 (Print) 0323-4347 (Linking),95,4,1971,[Content of lactate dehydrogenase and its isoenzyme in normal and leukemic lymphocytes].,347-56,,"['Helbig, W', 'Sommer, H J', 'Parthum, K', 'Fleck, E', 'Janke, H']","['Helbig W', 'Sommer HJ', 'Parthum K', 'Fleck E', 'Janke H']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Erythrocytes/enzymology', 'Hodgkin Disease/enzymology', 'Humans', 'Isoenzymes', 'L-Lactate Dehydrogenase/*blood', 'Leukemia, Lymphoid/*enzymology', 'Lymphocytes/*enzymology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(4):347-56.,"['0 (Isoenzymes)', 'EC 1.1.1.27 (L-Lactate Dehydrogenase)']",,Laktatdehydrogenase-Gehalt und -Isoenzyme in normalen und leukamischen Lymphozyten.,,,,,,,,,
4107567,NLM,MEDLINE,19720125,20041117,0323-4347 (Print) 0323-4347 (Linking),95,4,1971,[Leukemia-specific antibodies in autologous infantile leukemia serums].,337-46,,"['Zintl, F', 'Aurich, G', 'Plenert, W']","['Zintl F', 'Aurich G', 'Plenert W']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acute Disease', 'Adolescent', '*Antibody Specificity', 'Antigens, Neoplasm/analysis', 'Autoantibodies/*analysis', 'Blood Cells/immunology', 'Bone Marrow/immunology', 'Bone Marrow Cells', 'Cerebrospinal Fluid/cytology/immunology', 'Child', 'Child, Preschool', 'Female', 'Fluorescent Antibody Technique', 'Humans', '*Immune Sera', 'Leukemia/*immunology', 'Male']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(4):337-46.,"['0 (Antigens, Neoplasm)', '0 (Autoantibodies)', '0 (Immune Sera)']",,Suche nach leukamiespezifischen Antikorpern in autologen kindlichen Leukamiesera.,,,,,,,,,
4107555,NLM,MEDLINE,19720125,20190714,0042-6822 (Print) 0042-6822 (Linking),43,3,1971 Mar,"Antigenic differentiation of M-MSV(O) from mouse, hamster, and cat C-type viruses.",722-4,,"['Gilden, R V', 'Oroszlan, S', 'Huebner, R J']","['Gilden RV', 'Oroszlan S', 'Huebner RJ']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Antigens/*analysis', 'Antigens, Viral/analysis', 'Cats', 'Cell Line', 'Centrifugation, Density Gradient', 'Complement Fixation Tests', 'Cricetinae', 'Cross Reactions', 'Dogs', 'Epitopes', 'Female', 'Guinea Pigs', 'Helper Viruses/immunology', 'Immune Sera', 'Immunodiffusion', 'Mice', 'Moloney murine leukemia virus/*immunology/isolation & purification', 'Oncogenic Viruses/*immunology', 'Rats', 'Species Specificity', 'Sucrose', 'Virus Cultivation']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",['10.1016/0042-6822(71)90298-4 [doi]'],ppublish,Virology. 1971 Mar;43(3):722-4. doi: 10.1016/0042-6822(71)90298-4.,"['0 (Antigens)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)', '57-50-1 (Sucrose)']",,,,,,,,,,,
4107497,NLM,MEDLINE,19720121,20081212,0032-7867 (Print) 0032-7867 (Linking),79,42,1971 Oct 9,[Polynuclear neutrophils with low peroxidase levels and unstained by Sudan black].,1859,,"['Grozdea, J']",['Grozdea J'],['fre'],['Journal Article'],France,Presse Med,La Presse medicale,0312556,IM,"['Coloring Agents/analysis', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/*blood', 'Neutrophils/*analysis', 'Peroxidases/analysis', 'Staining and Labeling']",,1971/10/09 00:00,1971/10/09 00:01,['1971/10/09 00:00'],"['1971/10/09 00:00 [pubmed]', '1971/10/09 00:01 [medline]', '1971/10/09 00:00 [entrez]']",,ppublish,Presse Med. 1971 Oct 9;79(42):1859.,"['0 (Coloring Agents)', 'EC 1.11.1.- (Peroxidases)']",,Polynucleaires neutrophiles depourvus de peroxydase et de noir Soudan.,,,,,,,,,
4107465,NLM,MEDLINE,19720114,20191022,0001-2998 (Print) 0001-2998 (Linking),1,4,1971 Oct,Radioiodine therapy of thyroid cancer.,503-15,,"['Pochin, E E']",['Pochin EE'],['eng'],"['Journal Article', 'Review']",United States,Semin Nucl Med,Seminars in nuclear medicine,1264464,IM,"['Adenocarcinoma/radiotherapy', 'Adenocarcinoma, Papillary/radiotherapy', 'Biopsy', 'Bone Marrow Diseases/complications', 'Carcinoma/radiotherapy', 'Half-Life', 'Humans', 'Iodine Isotopes/*therapeutic use', 'Leukemia/complications', 'Neoplasm Metastasis/radiotherapy', 'Prognosis', 'Thyroid Function Tests', 'Thyroid Neoplasms/*radiotherapy/surgery', 'Thyroxine/therapeutic use']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']","['S0001-2998(71)81043-7 [pii]', '10.1016/s0001-2998(71)81043-7 [doi]']",ppublish,Semin Nucl Med. 1971 Oct;1(4):503-15. doi: 10.1016/s0001-2998(71)81043-7.,"['0 (Iodine Isotopes)', 'Q51BO43MG4 (Thyroxine)']",29,,,,,,,,,,
4107462,NLM,MEDLINE,19720114,20191022,0001-2998 (Print) 0001-2998 (Linking),1,4,1971 Oct,Complications of radioiodine treatment of hyperthyroidism.,442-60,,"['Becker, D V', 'Hurley, J R']","['Becker DV', 'Hurley JR']",['eng'],"['Journal Article', 'Review']",United States,Semin Nucl Med,Seminars in nuclear medicine,1264464,IM,"['Adrenergic beta-Antagonists/therapeutic use', 'Antithyroid Agents/therapeutic use', 'Calcium/metabolism', 'Goiter, Nodular/etiology', 'Half-Life', 'Humans', 'Hyperthyroidism/complications/drug therapy/*radiotherapy', 'Hypothyroidism/etiology', 'Iodine Isotopes/administration & dosage/*adverse effects/therapeutic use', 'Leukemia, Radiation-Induced', 'Mutation', 'Radiotherapy/*adverse effects', 'Radiotherapy Dosage', 'Thyroid Crisis/etiology', 'Thyroid Function Tests', 'Thyroid Neoplasms/etiology', 'Thyroiditis/etiology']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']","['S0001-2998(71)81039-5 [pii]', '10.1016/s0001-2998(71)81039-5 [doi]']",ppublish,Semin Nucl Med. 1971 Oct;1(4):442-60. doi: 10.1016/s0001-2998(71)81039-5.,"['0 (Adrenergic beta-Antagonists)', '0 (Antithyroid Agents)', '0 (Iodine Isotopes)', 'SY7Q814VUP (Calcium)']",116,,,,,,,,,,
4107442,NLM,MEDLINE,19720114,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7734,1971 Nov 20,Australia antigen in patients with leukaemia in Finland.,1159,,"['Palva, I P', 'Raunio, V']","['Palva IP', 'Raunio V']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adult', 'Chronic Disease', 'Finland', '*Hepatitis B virus', 'Humans', 'Immunodiffusion', 'Leukemia/*microbiology']",,1971/11/20 00:00,1971/11/20 00:01,['1971/11/20 00:00'],"['1971/11/20 00:00 [pubmed]', '1971/11/20 00:01 [medline]', '1971/11/20 00:00 [entrez]']","['S0140-6736(71)91324-9 [pii]', '10.1016/s0140-6736(71)91324-9 [doi]']",ppublish,Lancet. 1971 Nov 20;2(7734):1159. doi: 10.1016/s0140-6736(71)91324-9.,,,,,,,,,,,,
4107430,NLM,MEDLINE,19720114,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7734,1971 Nov 20,The T or B cell nature of chronic lymphocytic leukaemic lymphocytes.,1153,,"['Wilson, J D', 'Nossal, G J']","['Wilson JD', 'Nossal GJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Chronic Disease', 'Humans', 'Immunoglobulin G', 'Leukemia, Lymphoid/*immunology', 'Lymphocyte Activation', 'Lymphocytes/*immunology']",,1971/11/20 00:00,1971/11/20 00:01,['1971/11/20 00:00'],"['1971/11/20 00:00 [pubmed]', '1971/11/20 00:01 [medline]', '1971/11/20 00:00 [entrez]']","['S0140-6736(71)91310-9 [pii]', '10.1016/s0140-6736(71)91310-9 [doi]']",ppublish,Lancet. 1971 Nov 20;2(7734):1153. doi: 10.1016/s0140-6736(71)91310-9.,['0 (Immunoglobulin G)'],,,,,,,,,,,
4107425,NLM,MEDLINE,19720114,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7734,1971 Nov 20,Differences in the two red-cell populations in erythroleukaemia.,1150,,"['Emerson, P M', 'Garrow, G H']","['Emerson PM', 'Garrow GH']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Diagnosis, Differential', 'Erythrocytes/*enzymology', 'Humans', 'Leukemia, Erythroblastic, Acute/diagnosis/*enzymology', 'Male']",,1971/11/20 00:00,1971/11/20 00:01,['1971/11/20 00:00'],"['1971/11/20 00:00 [pubmed]', '1971/11/20 00:01 [medline]', '1971/11/20 00:00 [entrez]']","['S0140-6736(71)91305-5 [pii]', '10.1016/s0140-6736(71)91305-5 [doi]']",ppublish,Lancet. 1971 Nov 20;2(7734):1150. doi: 10.1016/s0140-6736(71)91305-5.,,,,,,,,,,,,
4107307,NLM,MEDLINE,19720111,20210320,0021-9258 (Print) 0021-9258 (Linking),246,19,1971 Oct 10,The dependence of immunological cross-reactivity upon sequence resemblance among lysozymes. I. Micro-complement fixation studies.,5978-89,,"['Prager, E M', 'Wilson, A C']","['Prager EM', 'Wilson AC']",['eng'],['Journal Article'],United States,J Biol Chem,The Journal of biological chemistry,2985121R,IM,"['Amino Acid Sequence', 'Amino Acids/analysis', 'Animals', 'Biological Evolution', 'Birds', 'Cellulose', 'Chickens', 'Chromatography, Gel', 'Chromatography, Ion Exchange', 'Complement Fixation Tests', 'Cross Reactions', 'Ducks', 'Egg White', 'Electrophoresis', 'Epitopes', 'Humans', 'Hydrogen-Ion Concentration', 'Immune Sera', 'Immunization', 'Immunodiffusion', 'Immunoelectrophoresis', 'Ion Exchange Resins', 'Leukemia, Myeloid/enzymology', 'Male', 'Mathematics', '*Muramidase/analysis/isolation & purification', 'Protein Conformation', 'Rabbits', 'Species Specificity', 'Time Factors', 'Turkeys', 'Ultracentrifugation']",,1971/10/10 00:00,1971/10/10 00:01,['1971/10/10 00:00'],"['1971/10/10 00:00 [pubmed]', '1971/10/10 00:01 [medline]', '1971/10/10 00:00 [entrez]']",['S0021-9258(18)61823-X [pii]'],ppublish,J Biol Chem. 1971 Oct 10;246(19):5978-89.,"['0 (Amino Acids)', '0 (Epitopes)', '0 (Immune Sera)', '0 (Ion Exchange Resins)', '9004-34-6 (Cellulose)', 'EC 3.2.1.17 (Muramidase)']",,,,,,,,,,,
4107289,NLM,MEDLINE,19720111,20141120,0041-1345 (Print) 0041-1345 (Linking),2,1,1970 Mar,Immunogenetic approach to neoplasia.,104-16,,"['Tennant, J R']",['Tennant JR'],['eng'],['Journal Article'],United States,Transplant Proc,Transplantation proceedings,0243532,IM,"['Alleles', 'Animals', 'Antigens', 'Antigens, Neoplasm', 'Antigens, Viral', 'Cell Membrane/immunology', 'Cross Reactions', 'Epitopes', 'Genes', 'Histocompatibility', 'Immune Sera', 'Immune Tolerance', 'Immunity, Cellular', '*Immunogenetics', 'In Vitro Techniques', 'Leukemia Virus, Murine/immunology', 'Methods', 'Mice', 'Neoplasm Transplantation', 'Neoplasms/*immunology', 'Oncogenic Viruses', 'Radiation', 'Transplantation Immunology']",,1970/03/01 00:00,1970/03/01 00:01,['1970/03/01 00:00'],"['1970/03/01 00:00 [pubmed]', '1970/03/01 00:01 [medline]', '1970/03/01 00:00 [entrez]']",,ppublish,Transplant Proc. 1970 Mar;2(1):104-16.,"['0 (Antigens)', '0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4107243,NLM,MEDLINE,19720110,20071115,0027-8874 (Print) 0027-8874 (Linking),46,2,1971 Feb,Fluorescence complement fixation by lymphoblastoid cells.,383-90,,"['Floyd, R', 'Vonka, V', 'Benyesh-Melnick, M']","['Floyd R', 'Vonka V', 'Benyesh-Melnick M']",['eng'],['Journal Article'],United States,J Natl Cancer Inst,Journal of the National Cancer Institute,7503089,IM,"['Animals', 'Antigen-Antibody Complex/*analysis', 'Burkitt Lymphoma/*immunology', 'Cell Line/*immunology', '*Complement Fixation Tests', '*Fluorescent Antibody Technique', 'Guinea Pigs', 'Herpesviridae/*immunology', 'Herpesvirus 4, Human/immunology', 'Humans', 'Immune Sera', 'Immunoglobulins/analysis', 'Infectious Mononucleosis/*immunology/microbiology', 'Leukemia, Lymphoid/*immunology/microbiology', 'Leukemia, Myeloid/*immunology/microbiology', 'Methods', 'Microscopy, Fluorescence', 'Staining and Labeling']",,1971/02/01 00:00,1971/02/01 00:01,['1971/02/01 00:00'],"['1971/02/01 00:00 [pubmed]', '1971/02/01 00:01 [medline]', '1971/02/01 00:00 [entrez]']",,ppublish,J Natl Cancer Inst. 1971 Feb;46(2):383-90.,"['0 (Antigen-Antibody Complex)', '0 (Immune Sera)', '0 (Immunoglobulins)']",,,,,,,,,,,
4107228,NLM,MEDLINE,19720110,20190621,0022-5347 (Print) 0022-5347 (Linking),106,5,1971 Nov,Lymphoproliferative disease of the bladder.,687-91,,"['Tremann, J A', 'Norris, H T', 'McRoberts, J W']","['Tremann JA', 'Norris HT', 'McRoberts JW']",['eng'],['Journal Article'],United States,J Urol,The Journal of urology,0376374,IM,"['Aged', 'Diagnosis, Differential', 'Humans', 'Leukemia, Lymphoid/*diagnosis/pathology/therapy', 'Lymphoma, Non-Hodgkin/diagnosis', 'Male', 'Palliative Care', 'Urinary Bladder Neoplasms/*diagnosis/pathology/therapy']",,1971/11/01 00:00,1971/11/01 00:01,['1971/11/01 00:00'],"['1971/11/01 00:00 [pubmed]', '1971/11/01 00:01 [medline]', '1971/11/01 00:00 [entrez]']","['S0022-5347(17)61375-2 [pii]', '10.1016/s0022-5347(17)61375-2 [doi]']",ppublish,J Urol. 1971 Nov;106(5):687-91. doi: 10.1016/s0022-5347(17)61375-2.,,,,,,,,,,,,
4106939,NLM,MEDLINE,19711221,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7733,1971 Nov 13,Cellular origin of granulocyte colonies in chronic myeloid leukaemia.,1097-8,,"['Shadduck, R K', 'Nankin, H R']","['Shadduck RK', 'Nankin HR']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cells, Cultured', 'Chromosomes', 'Hematopoiesis', '*Hematopoietic Stem Cells', 'Humans', 'Leukemia, Myeloid/*pathology/physiopathology', '*Leukocytes']",,1971/11/13 00:00,1971/11/13 00:01,['1971/11/13 00:00'],"['1971/11/13 00:00 [pubmed]', '1971/11/13 00:01 [medline]', '1971/11/13 00:00 [entrez]']","['S0140-6736(71)90420-X [pii]', '10.1016/s0140-6736(71)90420-x [doi]']",ppublish,Lancet. 1971 Nov 13;2(7733):1097-8. doi: 10.1016/s0140-6736(71)90420-x.,,,,,,,,,,,,
4106914,NLM,MEDLINE,19711221,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7733,1971 Nov 13,Leukaemia and B.C.G. A controlled trial.,1062-3,,"['Comstock, G W']",['Comstock GW'],['eng'],"['Clinical Trial', 'Controlled Clinical Trial', 'Journal Article']",England,Lancet,"Lancet (London, England)",2985213R,IM,"['Alabama', '*BCG Vaccine', 'Georgia', 'Hodgkin Disease/epidemiology/*prevention & control', 'Humans', 'Leukemia/epidemiology/*prevention & control', 'Lymphoma, Non-Hodgkin/epidemiology/*prevention & control']",,1971/11/13 00:00,1971/11/13 00:01,['1971/11/13 00:00'],"['1971/11/13 00:00 [pubmed]', '1971/11/13 00:01 [medline]', '1971/11/13 00:00 [entrez]']","['S0140-6736(71)90381-3 [pii]', '10.1016/s0140-6736(71)90381-3 [doi]']",ppublish,Lancet. 1971 Nov 13;2(7733):1062-3. doi: 10.1016/s0140-6736(71)90381-3.,['0 (BCG Vaccine)'],,,,,,,,,,,
4106875,NLM,MEDLINE,19711221,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7729,1971 Oct 16,Immunoglobulins on the surface of human lymphocytes.,850-2,,"['Papamichail, M', 'Brown, J C', 'Holborow, E J']","['Papamichail M', 'Brown JC', 'Holborow EJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', 'Antibody-Producing Cells', 'Arthritis, Rheumatoid/blood/immunology', 'Fetus', 'Fluorescent Antibody Technique', 'Humans', '*Immunoglobulins', 'Infant, Newborn', 'Leukemia, Lymphoid/immunology', 'Lymphocytes/cytology/*immunology', 'Microscopy, Electron']",,1971/10/16 00:00,1971/10/16 00:01,['1971/10/16 00:00'],"['1971/10/16 00:00 [pubmed]', '1971/10/16 00:01 [medline]', '1971/10/16 00:00 [entrez]']","['S0140-6736(71)90224-8 [pii]', '10.1016/s0140-6736(71)90224-8 [doi]']",ppublish,Lancet. 1971 Oct 16;2(7729):850-2. doi: 10.1016/s0140-6736(71)90224-8.,['0 (Immunoglobulins)'],,,,,,,,,,,
4106788,NLM,MEDLINE,19711221,20061115,0043-5341 (Print) 0043-5341 (Linking),120,24,1970 Jun 13,[Classification of acute leukoses].,437-8,,"['Kahn, P']",['Kahn P'],['ger'],['Journal Article'],Austria,Wien Med Wochenschr,Wiener medizinische Wochenschrift (1946),8708475,IM,"['Acute Disease', 'Aminosalicylic Acids/analysis', 'Cytodiagnosis', 'Esterases/analysis', 'Histocytochemistry', 'Humans', 'Leukemia/*classification/pathology', 'Methods', 'Peroxidases/analysis', 'Staining and Labeling']",,1970/06/13 00:00,1970/06/13 00:01,['1970/06/13 00:00'],"['1970/06/13 00:00 [pubmed]', '1970/06/13 00:01 [medline]', '1970/06/13 00:00 [entrez]']",,ppublish,Wien Med Wochenschr. 1970 Jun 13;120(24):437-8.,"['0 (Aminosalicylic Acids)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)']",,Die Einteilung der akuten Leukosen.,,,,,,,,,
4106750,NLM,MEDLINE,19711216,20061115,0043-5376 (Print) 0043-5376 (Linking),52,8,1971,[Esterase defects in segmented granulocytes of leukemia].,371-7,,"['Pietschmann, H', 'Kolarz, G']","['Pietschmann H', 'Kolarz G']",['ger'],['Journal Article'],Austria,Wien Z Inn Med,Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete,7502231,IM,"['Adolescent', 'Adult', 'Aged', 'Erythrocyte Count', 'Esterases/*blood', 'Histocytochemistry', 'Humans', 'Leukemia, Myeloid/*enzymology', 'Leukocyte Count', 'Leukocytes/*enzymology', 'Middle Aged', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Wien Z Inn Med. 1971;52(8):371-7.,['EC 3.1.- (Esterases)'],,Esterasedefekte in segmentkernigen Granulozyten von Leukamien.,,,,,,,,,
4106701,NLM,MEDLINE,19711216,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7730,1971 Oct 23,Differences in the two red-cell populations in erythroleukaemia.,933,,"['Kahn, A', 'Vroclans, M', 'Hakim, J', 'Boivin, P']","['Kahn A', 'Vroclans M', 'Hakim J', 'Boivin P']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['ABO Blood-Group System', 'Blood Protein Electrophoresis', 'Erythrocytes/enzymology', 'Fetal Hemoglobin/analysis', 'Genes', 'Hemoglobins/analysis', 'Hemoglobins, Abnormal/analysis', 'Leukemia, Erythroblastic, Acute/*enzymology/immunology']",,1971/10/23 00:00,1971/10/23 00:01,['1971/10/23 00:00'],"['1971/10/23 00:00 [pubmed]', '1971/10/23 00:01 [medline]', '1971/10/23 00:00 [entrez]']",['10.1016/s0140-6736(71)92555-4 [doi]'],ppublish,Lancet. 1971 Oct 23;2(7730):933. doi: 10.1016/s0140-6736(71)92555-4.,"['0 (ABO Blood-Group System)', '0 (Hemoglobins)', '0 (Hemoglobins, Abnormal)', '9034-63-3 (Fetal Hemoglobin)']",,,,,,,,,,,
4106607,NLM,MEDLINE,19711216,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7728,1971 Oct 9,Identification of human T and B lymphocytes in normal peripheral blood and in chronic lymphocytic leukaemia.,788-91,,"['Wilson, J D', 'Nossal, G J']","['Wilson JD', 'Nossal GJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antibody-Producing Cells/*analysis', 'Bone Marrow/*immunology/pathology', 'Bone Marrow Cells', 'Humans', 'Immunoglobulins/analysis', 'Iodine Isotopes', 'Leukemia, Lymphoid/*immunology/pathology', 'Lymphocytes/*analysis', 'Monocytes/pathology', 'Neutrophils/pathology', 'Radioimmunoassay', 'Thymus Gland/cytology/immunology/pathology']",,1971/10/09 00:00,1971/10/09 00:01,['1971/10/09 00:00'],"['1971/10/09 00:00 [pubmed]', '1971/10/09 00:01 [medline]', '1971/10/09 00:00 [entrez]']","['S0140-6736(71)92741-3 [pii]', '10.1016/s0140-6736(71)92741-3 [doi]']",ppublish,Lancet. 1971 Oct 9;2(7728):788-91. doi: 10.1016/s0140-6736(71)92741-3.,"['0 (Immunoglobulins)', '0 (Iodine Isotopes)']",,,,,,,,,,,
4106485,NLM,MEDLINE,19711209,20190508,0022-1007 (Print) 0022-1007 (Linking),134,4,1971 Oct 1,Immunoglobulin and other surface antigens of cells of the immune system.,815-32,"Immunoglobulins (Ig) on cells of the immune system: The cytotoxicity test, with class-specific and type-specific anti-Ig sera, identifies kappa and micro determinants on mouse lymphocytes. The proportion of kappa(+) cells is characteristic for each source of cells: 30% of bone marrow cells, 40% of cells from peripheral lymph nodes, 45% of lymphocytes from peripheral blood or peritoneal cavity, and 50% of spleen cells. No Ig was demonstrable on thymocytes or on leukemia cells (most of which arise from thymus-derived [T] cells). Cytotoxicity tests were performed on various myelomas secreting different Ig; the only positive reactions were given by kappagamma1 myelomas (all four kappagamma1 myelomas tested were sensitive to both anti-kappa and anti-gamma1). Hemolytic plaque-forming cells (PFC) of IgG type had no demonstrable surface Ig, but a proportion of IgM PFC were kappa(+)micro(+). Virtually all rosette-forming cells (RFC) have surface Ig, more than 90% of them being inhibited by anti-kappa, 50% by anti-micro, and 10-30% by antisera to other heavy chains. Anti-lambda sera gave no positive reactions with any cell type, which is in keeping with the low level of this light chain in mouse serum. Ig and other differentiation antigens as markers for T and B cells: Thymocytes are hallmarked by the alloantigens TL, theta, and the Ly series, and it is generally held that extrathymic lymphoid cells that bear them are derived from thymocytes. There is one alloantigen marker for the thymus-independent (B) cell, and that is PC, which appears late in differentiation. (The mouse-specific lymphocyte (MSLA) and mouse-specific bone marrow-derived lymphocyte (MBLA) antigens recognized by heteroantisera, not used in the present study, are other candidates for T and B cell markers.) Making use of antisera to these surface antigens to inhibit the function of cells that carry them, we find the following: Approximately 30% of RFC, 60% of IgM PFC, and 90% of IgG are PC(+) and so are identified as B cells. No T markers were demonstrable on these cell populations. Thus if T cells do become RFC or PFC they presumably lose their T surface markers in the process (cf. the quantitative reduction of T markers accompanying the thymocyte --> lymphocyte transition). Cells that have the potential to initiate graft-versus-host (GVH) reactions have the T cell surface phenotype theta(+)Ig(-). Adoptive transfer of thymus-dependent antibody-forming capacity (response to sheep erythrocytes) required theta(+) cells but transfer of a thymus-independent immune response to Brucella antigen did not. Cells with surface Ig were involved in both types of adoptive transfers. Thus the presently available T markers do not provide evidence for T cells carrying surface Ig. Suppression of the Ig phenotype by antibody: antigenic modulation? A phenotypic change from Ig(+) to Ig(-) occurs when Ig(+) lymphocytes or myeloma cells are incubated with anti-Ig sera in vitro in the absence of complement (C). As with antigenic modulation in the TL system, which it resembles, this phenomenon is temperature dependent and in the case of lymph node cells (LNC) can be inhibited by high doses of actinomycin D.","['Takahashi, T', 'Old, L J', 'McIntire, K R', 'Boyse, E A']","['Takahashi T', 'Old LJ', 'McIntire KR', 'Boyse EA']",['eng'],['Journal Article'],United States,J Exp Med,The Journal of experimental medicine,2985109R,IM,"['Animals', 'Antigen-Antibody Reactions', 'Bone Marrow/immunology', 'Bone Marrow Cells', 'Cytotoxicity Tests, Immunologic', '*Epitopes', 'Hemolytic Plaque Technique', 'Immune Sera', '*Immunity, Cellular', 'Immunoglobulin M', '*Immunoglobulins', 'Leukemia, Experimental/immunology', 'Lymph Nodes/cytology', 'Lymphocytes/immunology', 'Mice', 'Multiple Myeloma/immunology', 'Neoplasms, Experimental/immunology', 'Phenotype', 'Spleen/cytology', 'Thymus Gland/cytology/immunology']",PMC2139003,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",['10.1084/jem.134.4.815 [doi]'],ppublish,J Exp Med. 1971 Oct 1;134(4):815-32. doi: 10.1084/jem.134.4.815.,"['0 (Epitopes)', '0 (Immune Sera)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)']",,,,,,,,,,,
4106326,NLM,MEDLINE,19711202,20071115,0041-1345 (Print) 0041-1345 (Linking),3,1,1971 Mar,HL-A and mixed leukocyte culture matched allogeneic bone marrow transplantation in patients with acute leukemia.,405-8,,"['Graw, R G Jr', 'Leventhal, B G', 'Yankee, R A', 'Rogentine, G N', 'Whang-Peng, J', 'Ginnif, M H', 'Herzig, G P', 'Halterman, R H', 'Henderson, E S']","['Graw RG Jr', 'Leventhal BG', 'Yankee RA', 'Rogentine GN', 'Whang-Peng J', 'Ginnif MH', 'Herzig GP', 'Halterman RH', 'Henderson ES']",['eng'],['Journal Article'],United States,Transplant Proc,Transplantation proceedings,0243532,IM,"['*Antigens', '*Bone Marrow Transplantation', 'Epitopes', 'Graft vs Host Disease', 'Graft vs Host Reaction', '*Histocompatibility Testing', 'Humans', 'Leukemia, Lymphoid/*therapy', 'Leukocytes/*immunology', '*Transplantation Immunology', 'Transplantation, Homologous']",,1971/03/01 00:00,2001/03/28 10:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Transplant Proc. 1971 Mar;3(1):405-8.,"['0 (Antigens)', '0 (Epitopes)']",,,,,,,,,,,
4106323,NLM,MEDLINE,19711202,20071115,0041-1345 (Print) 0041-1345 (Linking),3,1,1971 Mar,Bone marrow graft in man after conditioning by antilymphocytic serum.,325-32,,"['Mathe, G', 'Amiel, J L', 'Schwarzenberg, L', 'Choay, J', 'Trolard, P', 'Schneider, M', 'Hayat, M', 'Schlumberger, J R', 'Jasmin, C']","['Mathe G', 'Amiel JL', 'Schwarzenberg L', 'Choay J', 'Trolard P', 'Schneider M', 'Hayat M', 'Schlumberger JR', 'Jasmin C']",['eng'],['Journal Article'],United States,Transplant Proc,Transplantation proceedings,0243532,IM,"['Anemia, Aplastic/surgery', 'Antigens', '*Antilymphocyte Serum', '*Bone Marrow Transplantation', 'Epitopes', 'Graft vs Host Reaction', 'Histocompatibility', 'Humans', 'Leukemia, Lymphoid/surgery', 'Leukemia, Myeloid, Acute/surgery', 'Phenotype', '*Transplantation Immunology', 'Transplantation, Homologous']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Transplant Proc. 1971 Mar;3(1):325-32.,"['0 (Antigens)', '0 (Antilymphocyte Serum)', '0 (Epitopes)']",,,,,,,,,,,
4106314,NLM,MEDLINE,19711202,20141120,0041-1345 (Print) 0041-1345 (Linking),3,1,1971 Mar,Soluble mouse histocompatibility antigens.,231-3,,"['Koene, R', 'McKenzie, I F', 'Painter, E', 'Sachs, D H', 'Winn, H J', 'Russell, P S']","['Koene R', 'McKenzie IF', 'Painter E', 'Sachs DH', 'Winn HJ', 'Russell PS']",['eng'],['Journal Article'],United States,Transplant Proc,Transplantation proceedings,0243532,IM,"['Animals', 'Antibody Formation', 'Antibody Specificity', 'Antigens/*isolation & purification', 'Biological Assay', 'Chromatography', 'Cytotoxicity Tests, Immunologic', 'Epitopes', 'Guinea Pigs', 'Hemagglutination Tests', '*Histocompatibility', '*Histocompatibility Testing', 'Humans', 'Hypersensitivity, Delayed', 'Immune Sera', 'Immunoelectrophoresis', 'In Vitro Techniques', 'Leukemia/immunology', 'Lymphocytes/immunology', 'Methods', 'Mice', 'Neoplasm Transplantation', 'Neoplasms/immunology', 'Radioimmunoassay', 'Skin Transplantation', '*Solubility', 'Spleen/immunology', 'Transplantation Immunology', 'Transplantation, Homologous', 'Vibration']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Transplant Proc. 1971 Mar;3(1):231-3.,"['0 (Antigens)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4106296,NLM,MEDLINE,19711202,20071115,0041-1345 (Print) 0041-1345 (Linking),3,1,1971 Mar,Effects of cryogenic storage on human lymphocytes.,149-51,,"['Cohen, E', 'Gregory, S G', 'Rowe, A W']","['Cohen E', 'Gregory SG', 'Rowe AW']",['eng'],['Journal Article'],United States,Transplant Proc,Transplantation proceedings,0243532,IM,"['*Antigens', 'Blood Preservation', 'Epitopes', '*Freezing', 'Humans', 'Immune Sera', 'Leukemia, Lymphoid/immunology/pathology', 'Lymphocytes/*immunology', 'Methods', '*Tissue Preservation']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Transplant Proc. 1971 Mar;3(1):149-51.,"['0 (Antigens)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4106262,NLM,MEDLINE,19711202,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7727,1971 Oct 2,Intrathecal methotrexate.,771,,"['Mollica, F', 'Schiliro, G', 'Pavone, L', 'Collica, F']","['Mollica F', 'Schiliro G', 'Pavone L', 'Collica F']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Choriocarcinoma/drug therapy', 'Female', 'Humans', '*Injections, Spinal', 'Leukemia, Lymphoid/drug therapy', 'Methotrexate/administration & dosage/*adverse effects', 'Pregnancy']",,1971/10/02 00:00,1971/10/02 00:01,['1971/10/02 00:00'],"['1971/10/02 00:00 [pubmed]', '1971/10/02 00:01 [medline]', '1971/10/02 00:00 [entrez]']",['10.1016/s0140-6736(71)92139-8 [doi]'],ppublish,Lancet. 1971 Oct 2;2(7727):771. doi: 10.1016/s0140-6736(71)92139-8.,['YL5FZ2Y5U1 (Methotrexate)'],,,,,,,,,,,
4106212,NLM,MEDLINE,19711202,20131121,0008-5472 (Print) 0008-5472 (Linking),31,10,1971 Oct,Ultrastructural changes in Friend erythroleukemia cells treated with dimethyl sulfoxide.,1402-17,,"['Sato, T', 'Friend, C', 'De Harven, E']","['Sato T', 'Friend C', 'De Harven E']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Biphenyl Compounds', 'Cells, Cultured/microbiology', 'Dimethyl Sulfoxide/*pharmacology', 'Friend murine leukemia virus/*pathogenicity', 'Inclusion Bodies, Viral', 'Lanthanum', 'Leukemia, Erythroblastic, Acute/*pathology', 'Mice', 'Microscopy, Electron', 'Staining and Labeling']",,1971/10/01 00:00,1971/10/01 00:01,['1971/10/01 00:00'],"['1971/10/01 00:00 [pubmed]', '1971/10/01 00:01 [medline]', '1971/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1971 Oct;31(10):1402-17.,"['0 (Biphenyl Compounds)', '6I3K30563S (Lanthanum)', 'YOW8V9698H (Dimethyl Sulfoxide)']",,,,,,,,,,,
4106013,NLM,MEDLINE,19711130,20081121,0323-4347 (Print) 0323-4347 (Linking),95,3,1971,"[The total and isoenzyme-lactate dehydrogenase content of plasma, leukocytes and erythrocytes in myeloproliferative diseases].",229-37,,"['Helbig, W', 'Parthum, K', 'Sommer, H J']","['Helbig W', 'Parthum K', 'Sommer HJ']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Agar', 'Electrophoresis', 'Erythrocytes/*enzymology', 'Freezing', 'Gels', 'Hemolysis', 'Humans', 'Isoenzymes/*blood', 'L-Lactate Dehydrogenase/*blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukocytes/*enzymology', 'Lymphocytes/enzymology', 'Myeloproliferative Disorders/*blood', 'Primary Myelofibrosis/blood', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(3):229-37.,"['0 (Gels)', '0 (Isoenzymes)', '9002-18-0 (Agar)', 'EC 1.1.1.27 (L-Lactate Dehydrogenase)']",,"Der Gesamt- und Isoenzym-Laktatdehydrogenasegehalt von Plasma, Leukozyten und Erythrozyten bei myeloproliferativen Erkrankungen.",,,,,,,,,
4105996,NLM,MEDLINE,19711130,20180216,0001-5792 (Print) 0001-5792 (Linking),45,4,1971,The application of cytochemical methods to the study of acute leukemia. A review.,209-17,,"['Schmalzl, F', 'Braunsteiner, H']","['Schmalzl F', 'Braunsteiner H']",['eng'],"['Journal Article', 'Review']",Switzerland,Acta Haematol,Acta haematologica,0141053,IM,"['Acid Phosphatase/metabolism', 'Acute Disease', 'Alkaline Phosphatase/metabolism', 'Bone Marrow/enzymology', 'Bone Marrow Cells', 'Cytoplasmic Granules/enzymology', 'Diagnosis, Differential', 'Eosinophils/enzymology', 'Erythrocytes/enzymology', 'Esterases/metabolism', 'Hematopoietic Stem Cells/enzymology', 'Histocytochemistry', 'Humans', 'Iron/blood', 'Leukemia/*diagnosis', 'Leukemia, Erythroblastic, Acute/diagnosis', 'Leukemia, Lymphoid/diagnosis', 'Leukemia, Monocytic, Acute/diagnosis', 'Leukemia, Myeloid, Acute/diagnosis', 'Monocytes/enzymology', 'Multiple Myeloma/diagnosis', 'Naphthaleneacetic Acids', 'Neutrophils/enzymology', 'Peroxidases/metabolism', 'Plasma Cells/enzymology', 'Skin Window Technique', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",['10.1159/000208627 [doi]'],ppublish,Acta Haematol. 1971;45(4):209-17. doi: 10.1159/000208627.,"['0 (Naphthaleneacetic Acids)', 'E1UOL152H7 (Iron)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.1 (Alkaline Phosphatase)', 'EC 3.1.3.2 (Acid Phosphatase)']",59,,,,,,,,,,
4105993,NLM,MEDLINE,19711117,20190714,0042-6822 (Print) 0042-6822 (Linking),44,1,1971 Apr,A fluorescent antibody technique for the detection of the group-specific antigen of feline leukemia virus in infected tissue-culture cells.,219-22,,"['Ubertini, T', 'Noronha, F', 'Post, J E', 'Rickard, C G']","['Ubertini T', 'Noronha F', 'Post JE', 'Rickard CG']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Antigens/*analysis', 'Cat Diseases/microbiology', 'Cats', 'Cell Line', '*Culture Techniques', 'Cytoplasm/immunology', 'Fibroblasts', '*Fluorescent Antibody Technique', 'Goats', 'Immune Sera', 'Immunodiffusion', 'Leukemia/microbiology/veterinary', 'Microscopy, Electron', 'Retroviridae/*immunology/isolation & purification/pathogenicity', 'Species Specificity', 'Staining and Labeling']",,1971/04/01 00:00,1971/04/01 00:01,['1971/04/01 00:00'],"['1971/04/01 00:00 [pubmed]', '1971/04/01 00:01 [medline]', '1971/04/01 00:00 [entrez]']","['0042-6822(71)90168-1 [pii]', '10.1016/0042-6822(71)90168-1 [doi]']",ppublish,Virology. 1971 Apr;44(1):219-22. doi: 10.1016/0042-6822(71)90168-1.,"['0 (Antigens)', '0 (Immune Sera)']",,,,,,,,,,,
4105982,NLM,MEDLINE,19711117,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7725,1971 Sep 18,Cirrhosis and lymphoproliferative disorders.,665,,"['Scheuer-Karpin, R']",['Scheuer-Karpin R'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Cell Division', 'Humans', 'Leukemia/*complications', 'Liver Cirrhosis/*complications', 'Lymphoma/*complications', 'Mononuclear Phagocyte System/pathology']",,1971/09/18 00:00,1971/09/18 00:01,['1971/09/18 00:00'],"['1971/09/18 00:00 [pubmed]', '1971/09/18 00:01 [medline]', '1971/09/18 00:00 [entrez]']",['10.1016/s0140-6736(71)80111-3 [doi]'],ppublish,Lancet. 1971 Sep 18;2(7725):665. doi: 10.1016/s0140-6736(71)80111-3.,,,,,,,,,,,,
4105932,NLM,MEDLINE,19711117,20171116,0022-1767 (Print) 0022-1767 (Linking),107,3,1971 Sep,Quantitation of immunoglobulin- and virus-producing cells in rats infected with Moloney leukemia virus.,689-97,,"['Cremer, N E', 'Taylor, D O', 'Lennette, E H']","['Cremer NE', 'Taylor DO', 'Lennette EH']",['eng'],['Journal Article'],United States,J Immunol,"Journal of immunology (Baltimore, Md. : 1950)",2985117R,IM,"['Animals', 'Antibodies/analysis', '*Antibody Formation', 'Antibody-Producing Cells', 'Antigens/*analysis', 'Antigens, Viral', 'Cattle', 'Erythrocytes/immunology', 'Ferritins', 'Fluorescent Antibody Technique', 'Hemagglutination Tests', 'Immunoelectrophoresis', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/analysis', 'Iodine Isotopes', 'Lymph Nodes/cytology/*immunology', 'Lymphocytes/*immunology', 'Moloney murine leukemia virus/*immunology', 'Rats', 'Serum Albumin, Bovine', 'Spleen/immunology', 'Thymus Gland/immunology', 'gamma-Globulins/*analysis']",,1971/09/01 00:00,1971/09/01 00:01,['1971/09/01 00:00'],"['1971/09/01 00:00 [pubmed]', '1971/09/01 00:01 [medline]', '1971/09/01 00:00 [entrez]']",,ppublish,J Immunol. 1971 Sep;107(3):689-97.,"['0 (Antibodies)', '0 (Antigens)', '0 (Antigens, Viral)', '0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (Iodine Isotopes)', '0 (gamma-Globulins)', '27432CM55Q (Serum Albumin, Bovine)', '9007-73-2 (Ferritins)']",,,,,,,,,,,
4105730,NLM,MEDLINE,19711112,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7726,1971 Sep 25,Cirrhosis and lymphoproliferative disorders.,705,,"['Heimann, R']",['Heimann R'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antineoplastic Agents/adverse effects', 'Humans', 'Leukemia/*complications', 'Liver Cirrhosis/chemically induced/*etiology', 'Lymphoma/*complications']",,1971/09/25 00:00,1971/09/25 00:01,['1971/09/25 00:00'],"['1971/09/25 00:00 [pubmed]', '1971/09/25 00:01 [medline]', '1971/09/25 00:00 [entrez]']",['10.1016/s0140-6736(71)92270-7 [doi]'],ppublish,Lancet. 1971 Sep 25;2(7726):705. doi: 10.1016/s0140-6736(71)92270-7.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4105729,NLM,MEDLINE,19711112,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7726,1971 Sep 25,Enhanced immune response to leukaemia.,704-5,,"['Halterman, R H', 'Leventhal, B G']","['Halterman RH', 'Leventhal BG']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antigens/analysis', 'Antineoplastic Agents/therapeutic use', 'Humans', 'Immunity', 'Lectins', 'Leukemia/drug therapy/*immunology/*therapy', 'Lymphocytes/immunology', 'Methotrexate/therapeutic use', 'Prednisone/therapeutic use', 'Time Factors', 'Vincristine/therapeutic use']",,1971/09/25 00:00,1971/09/25 00:01,['1971/09/25 00:00'],"['1971/09/25 00:00 [pubmed]', '1971/09/25 00:01 [medline]', '1971/09/25 00:00 [entrez]']",['10.1016/s0140-6736(71)92269-0 [doi]'],ppublish,Lancet. 1971 Sep 25;2(7726):704-5. doi: 10.1016/s0140-6736(71)92269-0.,"['0 (Antigens)', '0 (Antineoplastic Agents)', '0 (Lectins)', '5J49Q6B70F (Vincristine)', 'VB0R961HZT (Prednisone)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4105552,NLM,MEDLINE,19711106,20151119,0028-2685 (Print) 0028-2685 (Linking),18,4,1971,Mitochondrial DNA of avian leukaemic myeloblast: isolation and electron-optical characterisation.,337-48,,"['Korb, J']",['Korb J'],['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Animals', 'Avian Leukosis/*metabolism', 'Avian Leukosis Virus/isolation & purification', 'Cell Membrane Permeability', 'Cell Transformation, Neoplastic', 'Chickens', 'DNA, Neoplasm/*isolation & purification', 'Methods', 'Microscopy, Electron', 'Mitochondria/*analysis/metabolism', 'Oncogenic Viruses', 'RNA Viruses/isolation & purification', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1971;18(4):337-48.,"['0 (DNA, Neoplasm)']",,,,,,,,,,,
4105452,NLM,MEDLINE,19711104,20190630,0022-3476 (Print) 0022-3476 (Linking),79,3,1971 Sep,Poliovirus antibody response in patients with acute leukemia.,444-9,,"['Ogra, P L', 'Sinks, L F', 'Karzon, D T']","['Ogra PL', 'Sinks LF', 'Karzon DT']",['eng'],['Journal Article'],United States,J Pediatr,The Journal of pediatrics,0375410,IM,"['*Antibody Formation', 'Bone Neoplasms/immunology', 'Child', 'Humans', 'Immunity, Active', 'Immunization', 'Immunization, Secondary', 'Immunodiffusion', 'Immunoglobulin A', 'Immunoglobulin G', 'Kidney Neoplasms/immunology', 'Leukemia, Lymphoid/*immunology', 'Osteosarcoma/immunology', '*Poliovirus Vaccine, Inactivated', 'Sarcoma, Ewing/immunology', 'Wilms Tumor/immunology', '*gamma-Globulins']",,1971/09/01 00:00,1971/09/01 00:01,['1971/09/01 00:00'],"['1971/09/01 00:00 [pubmed]', '1971/09/01 00:01 [medline]', '1971/09/01 00:00 [entrez]']","['S0022-3476(71)80154-3 [pii]', '10.1016/s0022-3476(71)80154-3 [doi]']",ppublish,J Pediatr. 1971 Sep;79(3):444-9. doi: 10.1016/s0022-3476(71)80154-3.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Poliovirus Vaccine, Inactivated)', '0 (gamma-Globulins)']",,,,,,,,,,,
4105424,NLM,MEDLINE,19711103,20131121,0022-2143 (Print) 0022-2143 (Linking),78,2,1971 Aug,Nonleukemic elevation of serum vitamin B 12 and B 12 -binding capacity levels resembling that in chronic myelogenous leukemia.,289-97,,"['Carmel, R', 'Coltman, C A Jr']","['Carmel R', 'Coltman CA Jr']",['eng'],['Journal Article'],United States,J Lab Clin Med,The Journal of laboratory and clinical medicine,0375375,IM,"['Adult', 'Alpha-Globulins', 'Beta-Globulins', 'Chromatography, DEAE-Cellulose', 'Cobalt Isotopes', 'Diagnosis, Differential', 'Electrophoresis, Disc', 'Female', 'Humans', 'Leukemia, Myeloid/*diagnosis', 'Leukemoid Reaction/*blood/diagnosis', 'Leukocyte Count', 'Leukocytosis/*blood', 'Male', 'Middle Aged', 'Neutrophils', 'Protein Binding', 'Vitamin B 12/*blood']",,1971/08/01 00:00,2001/03/28 10:01,['1971/08/01 00:00'],"['1971/08/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1971/08/01 00:00 [entrez]']",['0022-2143(71)90227-7 [pii]'],ppublish,J Lab Clin Med. 1971 Aug;78(2):289-97.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Cobalt Isotopes)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4105376,NLM,MEDLINE,19711030,20150813,0370-4106 (Print) 0370-4106 (Linking),41,2,1970 Feb,[New points of view on the differential diagnosis of hemoblastosis in childhood].,101-8,,"['Drescher, J']",['Drescher J'],['spa'],['Journal Article'],Chile,Rev Chil Pediatr,Revista chilena de pediatria,0404261,IM,"['Adolescent', 'Child', 'Child, Preschool', 'Cytodiagnosis', 'Diagnosis, Differential', 'Erythrocytes/enzymology', 'Humans', 'Infant', 'Leukemia/*diagnosis', 'Myeloproliferative Disorders/*diagnosis', 'Staining and Labeling']",,1970/02/01 00:00,1970/02/01 00:01,['1970/02/01 00:00'],"['1970/02/01 00:00 [pubmed]', '1970/02/01 00:01 [medline]', '1970/02/01 00:00 [entrez]']",,ppublish,Rev Chil Pediatr. 1970 Feb;41(2):101-8.,,,Nuevos puntos de vista sobre el diagnostico diferencial de las hemoblastosis en la infancia.,,,,,,,,,
4105319,NLM,MEDLINE,19711030,20051117,0015-5470 (Print) 0015-5470 (Linking),18,3,1971 May-Jun,[The formation of spontaneous rosettes by human lymphocytes of the peripheral blood].,215-23,,"['Loni, C', 'Ambrogi, F', 'Luvisi, P F', 'Chelli, E', 'Grassi, B']","['Loni C', 'Ambrogi F', 'Luvisi PF', 'Chelli E', 'Grassi B']",['ita'],['Journal Article'],Italy,Folia Allergol (Roma),Folia allergologica,7502074,IM,"['Adult', 'Animals', 'Antibodies/analysis', '*Antigen-Antibody Reactions', 'Erythrocytes/immunology', 'Hodgkin Disease/*immunology', 'Humans', 'Immune Adherence Reaction', 'Immunoglobulins/analysis', 'Leukemia/*immunology', 'Liver Diseases/*immunology', 'Lymphocytes/*immunology', 'Middle Aged', 'Sheep', 'gamma-Globulins/analysis']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Folia Allergol (Roma). 1971 May-Jun;18(3):215-23.,"['0 (Antibodies)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,La formazione delle rosette spontanee da parte dei linfociti umani del sangue periferico.,,,,,,,,,
4105262,NLM,MEDLINE,19711026,20061115,0043-5325 (Print) 0043-5325 (Linking),82,22,1970 May 29,[Case of acute leukemia with peroxidase and granular PAS-positive blasts].,411-3,,"['Kahn, P']",['Kahn P'],['ger'],['Journal Article'],Austria,Wien Klin Wochenschr,Wiener klinische Wochenschrift,21620870R,IM,"['Acute Disease', 'Aged', '*Aminosalicylic Acids', 'Antineoplastic Agents/therapeutic use', 'Cytodiagnosis', 'Glycogen/metabolism', 'Histocytochemistry', 'Humans', 'Leukemia/*diagnosis/drug therapy/metabolism/pathology', 'Leukocyte Count', 'Leukocytes/analysis', 'Male', '*Peroxidases', 'Staining and Labeling']",,1970/05/29 00:00,1970/05/29 00:01,['1970/05/29 00:00'],"['1970/05/29 00:00 [pubmed]', '1970/05/29 00:01 [medline]', '1970/05/29 00:00 [entrez]']",,ppublish,Wien Klin Wochenschr. 1970 May 29;82(22):411-3.,"['0 (Aminosalicylic Acids)', '0 (Antineoplastic Agents)', '9005-79-2 (Glycogen)', 'EC 1.11.1.- (Peroxidases)']",,Ein Fall von akuter Leukamie mit peroxydase- und granular PAS-positiven Blasten.,,,,,,,,,
4105231,NLM,MEDLINE,19711021,20071115,0039-4025 (Print) 0039-4025 (Linking),12,2,1971,[Value of some staining and morphological changes of the erythrocytes of the blood smear in the diagnosis of atypical paraproteinemias and dysproteinemias].,167-70,,"['Gingold, N']",['Gingold N'],['rum'],['Journal Article'],Romania,Stud Cercet Med Interna,Studii si cercetari de medicina interna,0417346,IM,"['Blood Protein Disorders/*diagnosis', 'Cryoglobulins', '*Erythrocytes', 'Humans', 'Hypergammaglobulinemia/diagnosis', 'Leukemia, Lymphoid/complications', 'Liver Diseases/complications', 'Multiple Myeloma/diagnosis', 'Plasmacytoma/diagnosis', 'Staining and Labeling', 'Waldenstrom Macroglobulinemia/diagnosis']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Stud Cercet Med Interna. 1971;12(2):167-70.,['0 (Cryoglobulins)'],,"Valoarea unor modificari tinotriale morfologice ale eritrocitelor din frotiul singe, in diagnosticul paraproteinemilor si disproteinemilor atipice.",,,,,,,,,
4105174,NLM,MEDLINE,19711021,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7721,1971 Aug 21,B.C.G. vaccination and leukaemia. Evidence of vital statistics.,398-402,,"['Kinlen, L J', 'Pike, M C']","['Kinlen LJ', 'Pike MC']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Age Factors', '*BCG Vaccine', 'Canada', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*epidemiology/*mortality/prevention & control', 'Scotland']",,1971/08/21 00:00,1971/08/21 00:01,['1971/08/21 00:00'],"['1971/08/21 00:00 [pubmed]', '1971/08/21 00:01 [medline]', '1971/08/21 00:00 [entrez]']","['S0140-6736(71)90114-0 [pii]', '10.1016/s0140-6736(71)90114-0 [doi]']",ppublish,Lancet. 1971 Aug 21;2(7721):398-402. doi: 10.1016/s0140-6736(71)90114-0.,['0 (BCG Vaccine)'],,,,,,,,,,,
4105072,NLM,MEDLINE,19711014,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7720,1971 Aug 14,Occurrence of Australia antigen in patients with leukaemia in Canada.,375-6,,"['Abu-Zahra, H T', 'Cowan, D H', 'Clarysse, A M', 'Hasselback, R', 'Leers, W D', 'Kouroupis, G M']","['Abu-Zahra HT', 'Cowan DH', 'Clarysse AM', 'Hasselback R', 'Leers WD', 'Kouroupis GM']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adult', 'Age Factors', 'Antibodies/analysis', 'Canada', 'Child', 'Complement Fixation Tests', 'Hepatitis B Antigens', 'Hepatitis B virus/*immunology', 'Humans', 'Leukemia/*immunology/microbiology', 'Liver/enzymology', 'Methods']",,1971/08/14 00:00,1971/08/14 00:01,['1971/08/14 00:00'],"['1971/08/14 00:00 [pubmed]', '1971/08/14 00:01 [medline]', '1971/08/14 00:00 [entrez]']","['S0140-6736(71)90090-0 [pii]', '10.1016/s0140-6736(71)90090-0 [doi]']",ppublish,Lancet. 1971 Aug 14;2(7720):375-6. doi: 10.1016/s0140-6736(71)90090-0.,"['0 (Antibodies)', '0 (Hepatitis B Antigens)']",,,,,,,,,,,
4104983,NLM,MEDLINE,19711013,20150616,0140-6736 (Print) 0140-6736 (Linking),2,7719,1971 Aug 7,The enigmatic bone-marrow stem cell.,304-5,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Bone Marrow/immunology/metabolism/physiology', '*Bone Marrow Cells', 'Cell Differentiation', '*Clone Cells', 'Culture Media', 'Culture Techniques', 'Hematopoiesis', 'Hematopoietic Stem Cells', 'Humans', 'Leukemia/metabolism', 'Time Factors']",,1971/08/07 00:00,1971/08/07 00:01,['1971/08/07 00:00'],"['1971/08/07 00:00 [pubmed]', '1971/08/07 00:01 [medline]', '1971/08/07 00:00 [entrez]']",['S0140-6736(71)91341-9 [pii]'],ppublish,Lancet. 1971 Aug 7;2(7719):304-5.,['0 (Culture Media)'],,,,,,,,,,,
4104788,NLM,MEDLINE,19711005,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7718,1971 Jul 31,Cirrhosis and lymphoproliferative disorders.,259,,"['Paton, A']",['Paton A'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Humans', 'Leukemia, Myeloid/complications', 'Liver Cirrhosis/*complications', 'Lymphatic Diseases/*complications', 'Male']",,1971/07/31 00:00,1971/07/31 00:01,['1971/07/31 00:00'],"['1971/07/31 00:00 [pubmed]', '1971/07/31 00:01 [medline]', '1971/07/31 00:00 [entrez]']",['10.1016/s0140-6736(71)92591-8 [doi]'],ppublish,Lancet. 1971 Jul 31;2(7718):259. doi: 10.1016/s0140-6736(71)92591-8.,,,,,,,,,,,,
4104719,NLM,MEDLINE,19711005,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7712,1971 Jun 19,Cytosine arabinoside in the treatment of acute myeloblastic leukaemia.,1268-71,,"['Bailey, C C', 'Geary, C G', 'Israels, M C', 'Whittaker, J A', 'Brown, M J', 'Weatherall, D J']","['Bailey CC', 'Geary CG', 'Israels MC', 'Whittaker JA', 'Brown MJ', 'Weatherall DJ']",['eng'],"['Comparative Study', 'Journal Article']",England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Administration, Oral', 'Adolescent', 'Adult', 'Age Factors', 'Aged', 'Amino Sugars/administration & dosage', 'Antibiotics, Antineoplastic/administration & dosage', 'Antineoplastic Agents/*therapeutic use', 'Cytarabine/administration & dosage/adverse effects/*therapeutic use', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Glycosides/administration & dosage', 'Humans', 'Injections, Intravenous', 'Leukemia, Myeloid/drug therapy', 'Leukemia, Myeloid, Acute/*drug therapy', 'Male', 'Mercaptopurine/therapeutic use', 'Middle Aged', 'Prednisolone/therapeutic use', 'Pregnancy', 'Remission, Spontaneous', 'Time Factors']",,1971/06/19 00:00,1971/06/19 00:01,['1971/06/19 00:00'],"['1971/06/19 00:00 [pubmed]', '1971/06/19 00:01 [medline]', '1971/06/19 00:00 [entrez]']","['S0140-6736(71)90594-0 [pii]', '10.1016/s0140-6736(71)91781-8 [doi]']",ppublish,Lancet. 1971 Jun 19;1(7712):1268-71. doi: 10.1016/s0140-6736(71)91781-8.,"['0 (Amino Sugars)', '0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (Glycosides)', '04079A1RDZ (Cytarabine)', '9PHQ9Y1OLM (Prednisolone)', 'E7WED276I5 (Mercaptopurine)']",,,,,,,,,,,
4104557,NLM,MEDLINE,19710927,20071115,0070-4113 (Print) 0070-4113 (Linking),54,,1970,[Autopsy findings in two cases of immunologically treated acute leukosis of childhood].,322-5,,"['Lange, H P', 'Kornhuber, B']","['Lange HP', 'Kornhuber B']",['ger'],['Journal Article'],Germany,Verh Dtsch Ges Pathol,Verhandlungen der Deutschen Gesellschaft fur Pathologie,7503704,IM,"['Adolescent', '*Antigen-Antibody Reactions', 'Autopsy', 'Child, Preschool', 'Humans', 'Kidney Diseases/pathology', 'Leukemia/*immunology/therapy', 'Leukemia, Myeloid, Acute/immunology', 'Liver Diseases/pathology', 'Male', 'Pancreatic Diseases/pathology']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Verh Dtsch Ges Pathol. 1970;54:322-5.,,,Obduktionsbefunde bei zwei Fallen immunologisch behandelter akuter Leukosen im Kindesalter.,,,,,,,,,
4104516,NLM,MEDLINE,19710927,20111117,0370-8241 (Print) 0370-8241 (Linking),26,5,1971 May,[Pain in malignant tumor and its relief].,866-73,,"['Sakita, T', 'Takasu, S', 'Takeuchi, T']","['Sakita T', 'Takasu S', 'Takeuchi T']",['jpn'],"['Journal Article', 'Review']",Japan,Saishin Igaku,Saishin igaku. Modern medicine,0413561,IM,"['Anesthesia', 'Esophageal Neoplasms/complications', 'Gastrointestinal Neoplasms/complications', 'Humans', 'Leukemia/complications', 'Liver Neoplasms/complications', 'Lung Neoplasms/complications', 'Neoplasms/*complications', 'Pain/drug therapy/etiology/radiotherapy/surgery', '*Pain Management', 'Palliative Care', 'Splenic Neoplasms/complications']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Saishin Igaku. 1971 May;26(5):866-73.,,46,,,,,,,,,,
4104494,NLM,MEDLINE,19710927,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7716,1971 Jul 17,Cytosine arabinoside and herpes zoster.,166,,"['Mann, J R']",['Mann JR'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Child, Preschool', 'Cytarabine/administration & dosage/pharmacology/*therapeutic use', 'Herpes Zoster/*drug therapy/prevention & control', 'Herpesvirus 3, Human/drug effects', 'Humans', 'Leukemia, Lymphoid/drug therapy', 'Leukemia, Myeloid/drug therapy', 'Leukemia, Myeloid, Acute/drug therapy', 'Male', 'Remission, Spontaneous', 'Time Factors']",,1971/07/17 00:00,1971/07/17 00:01,['1971/07/17 00:00'],"['1971/07/17 00:00 [pubmed]', '1971/07/17 00:01 [medline]', '1971/07/17 00:00 [entrez]']","['S0140-6736(71)92342-7 [pii]', '10.1016/s0140-6736(71)92341-5 [doi]']",ppublish,Lancet. 1971 Jul 17;2(7716):166. doi: 10.1016/s0140-6736(71)92341-5.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4104338,NLM,MEDLINE,19710916,20041117,0003-5637 (Print) 0003-5637 (Linking),16,3,1971 Mar,"[Distribution of Cl4-aurantin in the subcellular fractions of the liver, spleen and tumor tissues].",221-4,,"['Suskova, V S', 'Khasigov, P Z', 'Serebriakov, N G']","['Suskova VS', 'Khasigov PZ', 'Serebriakov NG']",['rus'],['Journal Article'],Russia (Federation),Antibiotiki,Antibiotiki,0375020,IM,"['Animals', 'Antibiotics, Antineoplastic/*analysis', 'Cell Nucleus/*analysis', 'Cytoplasm/*analysis', 'Depression, Chemical', 'Flavonoids/administration & dosage/analysis', 'Injections, Intraperitoneal', 'Injections, Subcutaneous', 'Leukemia, Experimental/*metabolism', 'Liver/cytology', 'Mice', 'Microsomes/*analysis', 'Microsomes, Liver/*analysis', 'Mitochondria/*analysis', 'Mitochondria, Liver/*analysis', 'Organ Size', 'Protein Binding/*drug effects', 'Spleen/anatomy & histology/cytology', 'Stimulation, Chemical', 'Time Factors']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Antibiotiki. 1971 Mar;16(3):221-4.,"['0 (Antibiotics, Antineoplastic)', '0 (Flavonoids)']",,"Raspredelenie Cl4-aurantina v subkletochnykh fraktsiiakh pecheni, selezenki i opukholi.",,,,,,,,,
4104081,NLM,MEDLINE,19710827,20071115,0323-4347 (Print) 0323-4347 (Linking),95,1,1971,Haptoglobin (Hp) level of blood serum in leukaemic patients.,37-41,,"['Gurda, M']",['Gurda M'],['eng'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Analysis of Variance', 'Child', 'Female', 'Haptoglobins/*analysis', 'Humans', 'Leukemia/*blood', 'Leukemia, Lymphoid/*blood', 'Leukemia, Myeloid/*blood', 'Male']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(1):37-41.,['0 (Haptoglobins)'],,,,,,,,,,,
4104079,NLM,MEDLINE,19710827,20051117,0323-4347 (Print) 0323-4347 (Linking),95,1,1971,[The use of immunotherapy in acute parablastic leukosis].,21-8,,"['Aurich, G', 'Plenert, W', 'Zintl, F', 'Polzin, G', 'Blau, H J', 'Kruse, H']","['Aurich G', 'Plenert W', 'Zintl F', 'Polzin G', 'Blau HJ', 'Kruse H']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Acute Disease', 'Antineoplastic Agents/therapeutic use', 'Blood Transfusion', 'Bone Marrow Transplantation', 'Child', 'Endotoxins/therapeutic use', 'Humans', 'Immunization', 'Immunization, Passive', 'Immunosuppressive Agents/therapeutic use', 'Leukemia/drug therapy/immunology/*therapy', 'Leukocytes/immunology', 'Transplantation, Homologous', 'gamma-Globulins/therapeutic use']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(1):21-8.,"['0 (Antineoplastic Agents)', '0 (Endotoxins)', '0 (Immunosuppressive Agents)', '0 (gamma-Globulins)']",,Die Anwendung der Immuntherapie bei akuten Parablastenleukosen.,,,,,,,,,
4104078,NLM,MEDLINE,19710827,20041117,0323-4347 (Print) 0323-4347 (Linking),95,1,1971,[The current state of the search for tumor-specific transplantation antigens in human leukemias].,1-20,,"['Zintl, F', 'Plenert, W']","['Zintl F', 'Plenert W']",['ger'],"['Journal Article', 'Review']",Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Animals', 'Antibody Formation', '*Antigens', 'Autoantibodies', 'Burkitt Lymphoma/etiology/immunology', 'Herpesvirus 4, Human/immunology', 'Humans', 'Immunity, Cellular', 'Immunization, Passive', 'Immunoglobulins', 'Infectious Mononucleosis/immunology', 'Isoantigens', 'Leukemia/etiology/*immunology/therapy', 'Leukemia Virus, Murine', 'Leukemia, Experimental/etiology/*immunology', 'Mice', 'Neoplasm Transplantation', 'Serologic Tests', 'Skin Tests', '*Transplantation Immunology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1971;95(1):1-20.,"['0 (Antigens)', '0 (Autoantibodies)', '0 (Immunoglobulins)', '0 (Isoantigens)']",124,Zum gegenwartigen Stand der Suche nach tumorspezifischen Transplantationsantigenen bei menschlichen Leukamien.,,,,,,,,,
4104072,NLM,MEDLINE,19710825,20041117,0035-3019 (Print) 0035-3019 (Linking),16,3,1971 Mar,The presence of alpha-2H in sera from patients with malignant haemopathies and cirrhosis.,266-8,,"['Martin, J P', 'Charlionet, R', 'Ropartz, C']","['Martin JP', 'Charlionet R', 'Ropartz C']",['eng'],['Journal Article'],France,Rev Eur Etud Clin Biol,Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,0351323,IM,"['Alpha-Globulins/*analysis', 'Antigens/analysis', 'Beta-Globulins/analysis', 'Blood Donors', 'Fetal Proteins/*analysis', 'Hodgkin Disease/*immunology', 'Humans', 'Immune Sera', 'Leukemia/*immunology', 'Liver Cirrhosis/*immunology', 'Multiple Myeloma/*immunology', 'Precipitin Tests', 'Prognosis']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Rev Eur Etud Clin Biol. 1971 Mar;16(3):266-8.,"['0 (Alpha-Globulins)', '0 (Antigens)', '0 (Beta-Globulins)', '0 (Fetal Proteins)', '0 (Immune Sera)']",,,,,,,,,,,
4103966,NLM,MEDLINE,19710823,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7715,1971 Jul 10,Leukaemic transformation of engrafted human cells in vivo.,101-2,,"['Goh, K', 'Fialkow, P J', 'Thomas, E D', 'Bryant, J I', 'Neiman, P E']","['Goh K', 'Fialkow PJ', 'Thomas ED', 'Bryant JI', 'Neiman PE']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Bone Marrow Cells', '*Cell Transformation, Neoplastic', 'Chromosome Aberrations', 'Female', 'Head', 'Head and Neck Neoplasms/complications', 'Humans', '*Leukemia/etiology/genetics', 'Leukemia, Lymphoid/*complications', 'Liver Cirrhosis/*complications', 'Lymphoma, Non-Hodgkin/*complications', 'Male', 'Neoplasms/complications', 'Radiation Effects', 'Sex Chromosomes/radiation effects']",,1971/07/10 00:00,1971/07/10 00:01,['1971/07/10 00:00'],"['1971/07/10 00:00 [pubmed]', '1971/07/10 00:01 [medline]', '1971/07/10 00:00 [entrez]']","['S0140-6736(71)92080-0 [pii]', '10.1016/s0140-6736(71)92080-0 [doi]']",ppublish,Lancet. 1971 Jul 10;2(7715):101-2. doi: 10.1016/s0140-6736(71)92080-0.,,,,,,,,,,,,
4103964,NLM,MEDLINE,19710823,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7715,1971 Jul 10,Cirrhosis and lymphoproliferative disorders.,101,,"['Heimann, R']",['Heimann R'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Head', 'Head and Neck Neoplasms/complications', 'Humans', 'Leukemia, Lymphoid/*complications', 'Liver Cirrhosis/*complications', 'Lymphoma, Non-Hodgkin/*complications', 'Neoplasms/complications']",,1971/07/10 00:00,1971/07/10 00:01,['1971/07/10 00:00'],"['1971/07/10 00:00 [pubmed]', '1971/07/10 00:01 [medline]', '1971/07/10 00:00 [entrez]']",['10.1016/s0140-6736(71)92079-4 [doi]'],ppublish,Lancet. 1971 Jul 10;2(7715):101. doi: 10.1016/s0140-6736(71)92079-4.,,,,,,,,,,,,
4103885,NLM,MEDLINE,19710820,20210216,0006-4971 (Print) 0006-4971 (Linking),38,2,1971 Aug,Appearance of bone marrow smears with necrotic tumor cells.,229-31,,"['Brittin, G M', 'Brecher, G']","['Brittin GM', 'Brecher G']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['*Bone Marrow Examination', 'Humans', 'Leukemia/*pathology', 'Methods', 'Necrosis/pathology', '*Staining and Labeling']",,1971/08/01 00:00,1971/08/01 00:01,['1971/08/01 00:00'],"['1971/08/01 00:00 [pubmed]', '1971/08/01 00:01 [medline]', '1971/08/01 00:00 [entrez]']",['S0006-4971(20)81625-5 [pii]'],ppublish,Blood. 1971 Aug;38(2):229-31.,,,,,,,,,,,,
4103879,NLM,MEDLINE,19710818,20211203,0032-745X (Print) 0032-745X (Linking),58,2,1971 Mar 12,[Immunotherapy of cancer].,75-91,,"['Lascano, F D', 'Mazzei, J A', 'Estevez, M E']","['Lascano FD', 'Mazzei JA', 'Estevez ME']",['spa'],"['Journal Article', 'Review']",Argentina,Prensa Med Argent,Prensa medica argentina,0204056,IM,"['Animals', 'Antigens', 'Bone Marrow Transplantation', 'Humans', 'Immune Sera', 'Immunity, Active', 'Immunity, Maternally-Acquired', '*Immunization, Passive', 'Immunosuppression Therapy', '*Immunotherapy', 'Leukemia/immunology/therapy', 'Neoplasms/*immunology/*therapy', 'Precancerous Conditions/immunology', 'Transplantation, Homologous', 'gamma-Globulins/*therapeutic use']",,1971/03/12 00:00,1971/03/12 00:01,['1971/03/12 00:00'],"['1971/03/12 00:00 [pubmed]', '1971/03/12 00:01 [medline]', '1971/03/12 00:00 [entrez]']",,ppublish,Prensa Med Argent. 1971 Mar 12;58(2):75-91.,"['0 (Antigens)', '0 (Immune Sera)', '0 (gamma-Globulins)']",156,Inmunoterapia del cancer.,,,,,,,,,
4103871,NLM,MEDLINE,19710818,20200304,0023-2173 (Print) 0023-2173 (Linking),48,21,1970 Nov 1,"[Clinico-pharmacologic, cytochemical and Feulgen photometric studies in adult undifferentiated cell leukemias under combination chemotherapy with vincristine, daunorubicine and prednisone].",1281-91,,"['Obrecht, P', 'Merker, H', 'Hennekeuser, H H', 'Meuret, G', 'Westerhausen, M', 'Simon, A']","['Obrecht P', 'Merker H', 'Hennekeuser HH', 'Meuret G', 'Westerhausen M', 'Simon A']",['ger'],['Journal Article'],Germany,Klin Wochenschr,Klinische Wochenschrift,2985205R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Age Factors', 'Aged', 'Antibiotics, Antineoplastic/*therapeutic use', 'Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Cell Count', 'Bone Marrow Examination', 'DNA, Neoplasm/analysis', 'Drug Synergism', 'Esterases/blood', 'Evaluation Studies as Topic', 'Female', 'Genetics, Medical', 'Histocytochemistry', 'Humans', 'Leukemia/blood/classification/*drug therapy/enzymology/metabolism', 'Male', 'Mercaptopurine/therapeutic use', 'Middle Aged', 'Peroxidases/blood', 'Photometry', 'Polyploidy', 'Prednisone/administration & dosage/adverse effects/*therapeutic use', 'Remission, Spontaneous', 'Staining and Labeling', 'Time Factors', 'Vincristine/administration & dosage/adverse effects/*therapeutic use']",,1970/11/01 00:00,1970/11/01 00:01,['1970/11/01 00:00'],"['1970/11/01 00:00 [pubmed]', '1970/11/01 00:01 [medline]', '1970/11/01 00:00 [entrez]']",['10.1007/BF01485520 [doi]'],ppublish,Klin Wochenschr. 1970 Nov 1;48(21):1281-91. doi: 10.1007/BF01485520.,"['0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '5J49Q6B70F (Vincristine)', 'E7WED276I5 (Mercaptopurine)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)', 'VB0R961HZT (Prednisone)']",,"Klinisch-pharmakologische, cytochemische und Feulgen-photometrische Untersuchungen bei unreifzelligen Erwachsenenleukosen unter kombinierter Chemotherapie mit Vincristin, Daunorubicin und Prednison.",,,,,,,,,
4103848,NLM,MEDLINE,19710818,20190711,0023-2173 (Print) 0023-2173 (Linking),48,15,1970 Aug 1,[Cell kinetics in lymph nodes. I. Determination of deoxyribonucleic acid synthesis time in patients with chronic lymphatic leukemia by means of double labeling with 3H-thymidine and 14C-thymidine in vivo].,923-9,,"['Tsirimbas, A D', 'Wittmann, K', 'Dormer, P']","['Tsirimbas AD', 'Wittmann K', 'Dormer P']",['ger'],['Journal Article'],Germany,Klin Wochenschr,Klinische Wochenschrift,2985205R,IM,"['Aged', 'Autoradiography', 'Blood Cell Count', '*Carbon Isotopes', 'DNA, Neoplasm/*biosynthesis', 'Female', 'Humans', 'Leukemia, Lymphoid/blood/drug therapy/*metabolism', 'Lymph Node Excision', 'Lymph Nodes/*metabolism', 'Male', 'Middle Aged', 'Prednisolone/therapeutic use', 'Staining and Labeling', 'Thymidine/*metabolism', 'Time Factors', '*Tritium', 'Vinblastine/therapeutic use']",,1970/08/01 00:00,1970/08/01 00:01,['1970/08/01 00:00'],"['1970/08/01 00:00 [pubmed]', '1970/08/01 00:01 [medline]', '1970/08/01 00:00 [entrez]']",['10.1007/BF01487632 [doi]'],ppublish,Klin Wochenschr. 1970 Aug 1;48(15):923-9. doi: 10.1007/BF01487632.,"['0 (Carbon Isotopes)', '0 (DNA, Neoplasm)', '10028-17-8 (Tritium)', '5V9KLZ54CY (Vinblastine)', '9PHQ9Y1OLM (Prednisolone)', 'VC2W18DGKR (Thymidine)']",,Zellkinetik in Lymphdrusen. I. Bestimmung der Desoxyribonucleinsaure-Synthesdauer bei Patienten mit chronischer lymphatischer Leukamie durch Doppelmarkierung mit 3H-Thymidin und 14C-Thymidin in vivo.,,,,,,,,,
4103817,NLM,MEDLINE,19710818,20071115,0001-5547 (Print) 0001-5547 (Linking),15,2,1971 Mar-Apr,Tumor diagnosis in pleural and ascitic effusions based on DNA cytophotometry.,154-62,,"['Freni, S C', 'James, J', 'Prop, F J']","['Freni SC', 'James J', 'Prop FJ']",['eng'],['Journal Article'],Switzerland,Acta Cytol,Acta cytologica,0370307,IM,"['Ascitic Fluid/*analysis', 'Carcinoma/diagnosis', 'Cell Nucleus/analysis', '*Cytodiagnosis', 'DNA/*analysis', 'Diploidy', 'False Negative Reactions', 'False Positive Reactions', 'Female', 'Humans', 'Leukemia, Lymphoid/diagnosis', 'Methods', 'Neoplasm Metastasis', 'Neoplasms/*diagnosis', 'Ovarian Neoplasms/diagnosis', '*Photometry', 'Pleural Effusion/*analysis', 'Polyploidy', 'Staining and Labeling']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Acta Cytol. 1971 Mar-Apr;15(2):154-62.,['9007-49-2 (DNA)'],,,,,,,,,,,
4103751,NLM,MEDLINE,19710812,20051117,0003-1488 (Print) 0003-1488 (Linking),158,6,1971 Mar 15,Structural and immunologic relationships among mammalian C-type viruses.,Suppl 2:1099+,,"['Gilden, R V', 'Oroszlan, S']","['Gilden RV', 'Oroszlan S']",['eng'],"['Journal Article', 'Review']",United States,J Am Vet Med Assoc,Journal of the American Veterinary Medical Association,7503067,IM,"['Animals', 'Antigen-Antibody Reactions', 'Antigens/analysis', '*Cats', 'Complement Fixation Tests/veterinary', 'Cricetinae', 'Cross Reactions', 'Epitopes/analysis', 'Gammaretrovirus/immunology', 'Glycopeptides/analysis', 'Immune Sera/analysis', 'Immunodiffusion/veterinary', 'Leukemia Virus, Murine/analysis/immunology', 'Mice', 'Oncogenic Viruses/analysis/classification/immunology', 'Peptides/analysis', 'Polysaccharides/analysis', '*RNA Viruses/analysis/classification/immunology', 'Retroviridae/analysis/immunology', '*Rodentia', 'Species Specificity']",,1971/03/15 00:00,1971/03/15 00:01,['1971/03/15 00:00'],"['1971/03/15 00:00 [pubmed]', '1971/03/15 00:01 [medline]', '1971/03/15 00:00 [entrez]']",,ppublish,J Am Vet Med Assoc. 1971 Mar 15;158(6):Suppl 2:1099+.,"['0 (Antigens)', '0 (Epitopes)', '0 (Glycopeptides)', '0 (Immune Sera)', '0 (Peptides)', '0 (Polysaccharides)']",29,,,,,,,,,,
4103699,NLM,MEDLINE,19710811,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7714,1971 Jul 3,Plasma-digoxin concentration.,50,,"['Bertler, A', 'Redfors, A']","['Bertler A', 'Redfors A']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'DNA/biosynthesis', 'Digitalis Glycosides/toxicity', 'Digoxin/*blood', 'Humans', 'Leukemia/metabolism', 'Leukocytes/metabolism', 'Ouabain/pharmacology', 'Radioimmunoassay', 'Time Factors']",,1971/07/03 00:00,1971/07/03 00:01,['1971/07/03 00:00'],"['1971/07/03 00:00 [pubmed]', '1971/07/03 00:01 [medline]', '1971/07/03 00:00 [entrez]']","['S0140-6736(71)90045-6 [pii]', '10.1016/s0140-6736(71)90044-4 [doi]']",ppublish,Lancet. 1971 Jul 3;2(7714):50. doi: 10.1016/s0140-6736(71)90044-4.,"['0 (Digitalis Glycosides)', '5ACL011P69 (Ouabain)', '73K4184T59 (Digoxin)', '9007-49-2 (DNA)']",,,,,,,,,,,
4103694,NLM,MEDLINE,19710811,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7714,1971 Jul 3,Antitumour activity of L-asparaginase and rifampicin.,48-9,,"['Sinkovics, J G']",['Sinkovics JG'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Asparaginase/*therapeutic use', 'Bicarbonates/therapeutic use', 'Carcinoma/drug therapy', 'Humans', 'Injections, Intraperitoneal', 'Leukemia Virus, Murine/pathogenicity', 'Leukemia, Experimental/*drug therapy', 'Mice', 'RNA Nucleotidyltransferases/antagonists & inhibitors', 'Rats', 'Rifampin/administration & dosage/pharmacology/*therapeutic use', 'Sodium/therapeutic use', 'Virulence']",,1971/07/03 00:00,1971/07/03 00:01,['1971/07/03 00:00'],"['1971/07/03 00:00 [pubmed]', '1971/07/03 00:01 [medline]', '1971/07/03 00:00 [entrez]']","['S0140-6736(71)90039-0 [pii]', '10.1016/s0140-6736(71)90039-0 [doi]']",ppublish,Lancet. 1971 Jul 3;2(7714):48-9. doi: 10.1016/s0140-6736(71)90039-0.,"['0 (Bicarbonates)', '9NEZ333N27 (Sodium)', 'EC 2.7.7.- (RNA Nucleotidyltransferases)', 'EC 3.5.1.1 (Asparaginase)', 'VJT6J7R4TR (Rifampin)']",,,,,,,,,,,
4103654,NLM,MEDLINE,19710811,20111117,0002-9645 (Print) 0002-9645 (Linking),32,7,1971 Jul,Immunoquantitation of transferrin in chickens with lymphoid tumors.,1121-3,,"['Fletcher, O J Jr']",['Fletcher OJ Jr'],['eng'],['Journal Article'],United States,Am J Vet Res,American journal of veterinary research,0375011,IM,"['Animals', 'Avian Leukosis/*immunology', 'Beta-Globulins/analysis', 'Blood Proteins/analysis', 'Chickens/*immunology', 'Immunodiffusion', 'Immunoelectrophoresis', 'Neoplasm Transplantation', 'Transferrin/*analysis']",,1971/07/01 00:00,2001/03/28 10:01,['1971/07/01 00:00'],"['1971/07/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1971/07/01 00:00 [entrez]']",,ppublish,Am J Vet Res. 1971 Jul;32(7):1121-3.,"['0 (Beta-Globulins)', '0 (Blood Proteins)', '0 (Transferrin)']",,,,,,,,,,,
4103403,NLM,MEDLINE,19710803,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7713,1971 Jun 26,The possible role of viruses in human cancer.,1344-7,,"['Epstein, M A']",['Epstein MA'],['eng'],"['Journal Article', 'Review']",England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Anura', 'Breast Neoplasms/etiology', 'Burkitt Lymphoma/etiology', 'Carcinoma/etiology', 'Cattle', 'Chickens', 'Child', 'DNA Viruses/pathogenicity', 'Female', 'Haplorhini', 'Herpesviridae/pathogenicity', 'Humans', 'Leukemia, Lymphoid/etiology', 'Mice', 'Neoplasms/*etiology', 'Neoplasms, Experimental/etiology', 'RNA Viruses/pathogenicity', 'Uterine Cervical Neoplasms/etiology', 'Viruses/*pathogenicity']",,1971/06/26 00:00,1971/06/26 00:01,['1971/06/26 00:00'],"['1971/06/26 00:00 [pubmed]', '1971/06/26 00:01 [medline]', '1971/06/26 00:00 [entrez]']","['S0140-6736(71)91898-8 [pii]', '10.1016/s0140-6736(71)91898-8 [doi]']",ppublish,Lancet. 1971 Jun 26;1(7713):1344-7. doi: 10.1016/s0140-6736(71)91898-8.,,77,,,,,,,,,,
4103391,NLM,MEDLINE,19710803,20190708,0020-7136 (Print) 0020-7136 (Linking),7,2,1971 Mar 15,Extractable herpesvirus antigens from chickens with Marek's disease.,339-45,,"['Ahmed, M', 'Leech, J B', 'Slattery, S M', 'Schidlovsky, G']","['Ahmed M', 'Leech JB', 'Slattery SM', 'Schidlovsky G']",['eng'],['Journal Article'],United States,Int J Cancer,International journal of cancer,0042124,IM,"['Animals', 'Antigens/*analysis', 'Avian Leukosis/*immunology', 'Cell Transformation, Neoplastic', 'Chickens', 'Epithelium/immunology', 'Epitopes', 'Feathers', 'Fluorescent Antibody Technique', 'Immunodiffusion', 'Microscopy, Electron', 'Peripheral Nervous System Diseases/immunology', 'Poultry Diseases/*immunology']",,1971/03/15 00:00,1971/03/15 00:01,['1971/03/15 00:00'],"['1971/03/15 00:00 [pubmed]', '1971/03/15 00:01 [medline]', '1971/03/15 00:00 [entrez]']",['10.1002/ijc.2910070219 [doi]'],ppublish,Int J Cancer. 1971 Mar 15;7(2):339-45. doi: 10.1002/ijc.2910070219.,"['0 (Antigens)', '0 (Epitopes)']",,,,,,,,,,,
4103361,NLM,MEDLINE,19710731,20151119,0003-911X (Print) 0003-911X (Linking),35,4,1970,Singularity of oncogenic activity of strain MC29 avian leukosis viruses.,315-25,,"['Beard, D', 'Chabot, J F', 'Langlois, A J', 'Hillman, E A', 'Beard, J W']","['Beard D', 'Chabot JF', 'Langlois AJ', 'Hillman EA', 'Beard JW']",['eng'],['Journal Article'],Germany,Arch Geschwulstforsch,Archiv fur Geschwulstforschung,0372411,IM,"['Animals', 'Avian Leukosis/blood/etiology/*pathology', 'Avian Leukosis Virus/classification/*pathogenicity', 'Blood Cells', 'Chick Embryo', 'Culture Techniques', 'Hematopoietic System/pathology', 'Kidney/pathology', 'Liver/pathology', 'Microscopy, Electron', 'Pericardium/pathology', 'Peritoneum/pathology', 'Staining and Labeling']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Arch Geschwulstforsch. 1970;35(4):315-25.,,,,,,,,,,,,
4103344,NLM,MEDLINE,19710729,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7704,1971 Apr 24,"HL-A typing of ""leukaemic"" cells.",852-3,,"['Pegrum, G D', 'Balfour, I C', 'Evans, C A', 'Middleton, V L']","['Pegrum GD', 'Balfour IC', 'Evans CA', 'Middleton VL']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Antigens', '*Histocompatibility Testing', 'Humans', 'Leukemia, Myeloid, Acute/*immunology']",,1971/04/24 00:00,1971/04/24 00:01,['1971/04/24 00:00'],"['1971/04/24 00:00 [pubmed]', '1971/04/24 00:01 [medline]', '1971/04/24 00:00 [entrez]']",['10.1016/s0140-6736(71)91511-x [doi]'],ppublish,Lancet. 1971 Apr 24;1(7704):852-3. doi: 10.1016/s0140-6736(71)91511-x.,['0 (Antigens)'],,,,,,,,,,,
4103327,NLM,MEDLINE,19710729,20190908,0090-0028 (Print) 0090-0028 (Linking),231,21,1971 May 26,Coexistence of intraspecies and interspecies specific antigenic determinants on the major structural polypeptide of mammalian C-type viruses.,107-8,,"['Gilden, R V', 'Oroszlan, S', 'Huebner, R J']","['Gilden RV', 'Oroszlan S', 'Huebner RJ']",['eng'],['Journal Article'],England,Nat New Biol,Nature: New biology,0410463,IM,"['Animals', '*Antigens', 'Complement Fixation Tests', 'Cross Reactions', 'Dogs', 'Epitopes', 'Guinea Pigs', 'Immunodiffusion', 'Isoelectric Focusing', 'Leukemia Virus, Murine/*immunology', '*Peptides', 'Rats', '*Species Specificity', 'Viruses, Unclassified/immunology']",,1971/05/26 00:00,1971/05/26 00:01,['1971/05/26 00:00'],"['1971/05/26 00:00 [pubmed]', '1971/05/26 00:01 [medline]', '1971/05/26 00:00 [entrez]']",['10.1038/newbio231107a0 [doi]'],ppublish,Nat New Biol. 1971 May 26;231(21):107-8. doi: 10.1038/newbio231107a0.,"['0 (Antigens)', '0 (Epitopes)', '0 (Peptides)']",,,,,,,,,,,
4103283,NLM,MEDLINE,19710727,20051117,0026-4806 (Print) 0026-4806 (Linking),62,38,1971 May 12,[Current problems in immunohematology].,1934-40,,"['Ricci, C', 'Blefari, D']","['Ricci C', 'Blefari D']",['ita'],['Journal Article'],Italy,Minerva Med,Minerva medica,0400732,IM,"['Anemia/immunology', 'Antibodies/*analysis', 'Antibodies, Anti-Idiotypic/analysis', 'Autoantibodies/analysis', '*Autoimmune Diseases', 'Blood Platelet Disorders/immunology', 'Collagen Diseases/immunology', 'Hematologic Diseases/*immunology', 'Hemoglobinopathies/immunology', 'Humans', 'Immunoglobulins/analysis', 'Leukemia/immunology', 'Thalassemia/immunology', 'gamma-Globulins/*analysis']",,1971/05/12 00:00,1971/05/12 00:01,['1971/05/12 00:00'],"['1971/05/12 00:00 [pubmed]', '1971/05/12 00:01 [medline]', '1971/05/12 00:00 [entrez]']",,ppublish,Minerva Med. 1971 May 12;62(38):1934-40.,"['0 (Antibodies)', '0 (Antibodies, Anti-Idiotypic)', '0 (Autoantibodies)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,Problemi attuali della immunoematologia.,,,,,,,,,
4103105,NLM,MEDLINE,19710723,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7711,1971 Jun 12,Potassium iodide--doses it potentiate the activity of cyclophosphamide?,1243,,"['Hart, M M', 'Adamson, R H']","['Hart MM', 'Adamson RH']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Culture Techniques', 'Cyclophosphamide/*therapeutic use/toxicity', '*Drug Synergism', 'Leukemia L1210/*drug therapy', 'Mice', 'Potassium Iodide/*therapeutic use']",,1971/06/12 00:00,1971/06/12 00:01,['1971/06/12 00:00'],"['1971/06/12 00:00 [pubmed]', '1971/06/12 00:01 [medline]', '1971/06/12 00:00 [entrez]']",['10.1016/s0140-6736(71)91759-4 [doi]'],ppublish,Lancet. 1971 Jun 12;1(7711):1243. doi: 10.1016/s0140-6736(71)91759-4.,"['1C4QK22F9J (Potassium Iodide)', '8N3DW7272P (Cyclophosphamide)']",,,,,,,,,,,
4103075,NLM,MEDLINE,19710723,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7711,1971 Jun 12,Frequency of Australia antigen in patients with leukaemia in different countries.,1200-2,,"['Sutnick, A I', 'London, W T', 'Levine, P H', 'Blumberg, B S']","['Sutnick AI', 'London WT', 'Levine PH', 'Blumberg BS']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Aged', 'Blood Transfusion', 'Canada', 'Child', 'Child, Preschool', 'Denmark', 'Female', 'Finland', 'Hepatitis A/complications/*epidemiology', 'Hepatitis B virus/*isolation & purification', 'Hodgkin Disease/epidemiology/*immunology', 'Humans', 'Infant', 'Leukemia, Lymphoid/epidemiology/*immunology', 'Male', 'Middle Aged', 'United States']",,1971/06/12 00:00,1971/06/12 00:01,['1971/06/12 00:00'],"['1971/06/12 00:00 [pubmed]', '1971/06/12 00:01 [medline]', '1971/06/12 00:00 [entrez]']",['10.1016/s0140-6736(71)91715-6 [doi]'],ppublish,Lancet. 1971 Jun 12;1(7711):1200-2. doi: 10.1016/s0140-6736(71)91715-6.,,,,,,,,,,,,
4103047,NLM,MEDLINE,19710722,20190704,0007-1048 (Print) 0007-1048 (Linking),20,5,1971 May,Coexistence of pernicious anaemia and chronic myeloid leukaemia: an experiment of nature involving vitamin B12 metabolism.,511-20,,"['Corcino, J J', 'Zalusky, R', 'Greenberg, M', 'Herbert, V']","['Corcino JJ', 'Zalusky R', 'Greenberg M', 'Herbert V']",['eng'],['Journal Article'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Alpha-Globulins/metabolism', 'Anemia, Pernicious/*complications/metabolism', 'Beta-Globulins/metabolism', 'Blood Cells/metabolism', 'Cobalt Isotopes', 'DNA/biosynthesis', 'Humans', 'Leukemia, Myeloid/*complications/metabolism', 'Male', 'Middle Aged', 'Protein Binding', 'Vitamin B 12/blood/*metabolism']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",['10.1111/j.1365-2141.1971.tb07066.x [doi]'],ppublish,Br J Haematol. 1971 May;20(5):511-20. doi: 10.1111/j.1365-2141.1971.tb07066.x.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Cobalt Isotopes)', '9007-49-2 (DNA)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4103035,NLM,MEDLINE,19710722,20131121,0001-5555 (Print) 0001-5555 (Linking),51,3,1971,Unusual granulomas of the skin seen in Lebanon.,225-31,,"['Kaidbey, K H', 'Kurban, A K']","['Kaidbey KH', 'Kurban AK']",['eng'],"['Case Reports', 'Journal Article']",Sweden,Acta Derm Venereol,Acta dermato-venereologica,0370310,IM,"['Adult', '*Blastomycosis/diagnosis', 'Busulfan/adverse effects', '*Candidiasis', 'Echinodermata', '*Granuloma', 'Humans', 'Lebanon', 'Leukemia, Myeloid/complications', 'Male', 'Middle Aged', 'Skin/pathology', '*Skin Diseases/pathology']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Acta Derm Venereol. 1971;51(3):225-31.,['G1LN9045DK (Busulfan)'],,,,,,,,,,,
4102998,NLM,MEDLINE,19710720,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7708,1971 May 22,Leukaemia in twins.,1072,,"['Edwards, J H']",['Edwards JH'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Diseases in Twins', 'Humans', 'Leukemia/*genetics', 'Statistics as Topic']",,1971/05/22 00:00,1971/05/22 00:01,['1971/05/22 00:00'],"['1971/05/22 00:00 [pubmed]', '1971/05/22 00:01 [medline]', '1971/05/22 00:00 [entrez]']",['10.1016/s0140-6736(71)91635-7 [doi]'],ppublish,Lancet. 1971 May 22;1(7708):1072. doi: 10.1016/s0140-6736(71)91635-7.,,,,,,,,,,,,
4102980,NLM,MEDLINE,19710720,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7708,1971 May 22,Acute childhood leukaemias.,1057-8,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Age Factors', 'Boston', 'Child', 'Child, Preschool', 'Humans', 'Leukemia/*diagnosis/epidemiology', 'Leukemia, Lymphoid/epidemiology', 'Leukemia, Myeloid/epidemiology']",,1971/05/22 00:00,1971/05/22 00:01,['1971/05/22 00:00'],"['1971/05/22 00:00 [pubmed]', '1971/05/22 00:01 [medline]', '1971/05/22 00:00 [entrez]']",['S0140-6736(71)91617-5 [pii]'],ppublish,Lancet. 1971 May 22;1(7708):1057-8.,,,,,,,,,,,,
4102967,NLM,MEDLINE,19710720,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7708,1971 May 22,Five-year analysis of protective isolation.,1034-40,,"['Lynch, J', 'Jameson, B', 'Gamble, D R', 'Kay, H E']","['Lynch J', 'Jameson B', 'Gamble DR', 'Kay HE']",['eng'],"['Comparative Study', 'Journal Article']",England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antibodies/analysis', 'Antibody Formation', 'Costs and Cost Analysis', 'Cross Infection/prevention & control', 'Cytomegalovirus/immunology', 'Feces/microbiology', 'Female', 'Humans', 'Leukemia/*therapy', 'Leukocyte Count', 'Leukopenia/immunology/microbiology/*therapy', '*Patient Isolators', 'Pseudomonas Infections/prevention & control', 'Remission, Spontaneous', 'Serologic Tests', 'Simplexvirus/isolation & purification', 'Staphylococcal Infections/prevention & control']",,1971/05/22 00:00,1971/05/22 00:01,['1971/05/22 00:00'],"['1971/05/22 00:00 [pubmed]', '1971/05/22 00:01 [medline]', '1971/05/22 00:00 [entrez]']","['S0140-6736(71)91603-5 [pii]', '10.1016/s0140-6736(71)91603-5 [doi]']",ppublish,Lancet. 1971 May 22;1(7708):1034-40. doi: 10.1016/s0140-6736(71)91603-5.,['0 (Antibodies)'],,,,,,,,,,,
4102661,NLM,MEDLINE,19710706,20190817,0025-7125 (Print) 0025-7125 (Linking),55,3,1971 May,The present status of cancer chemotherapy.,683-701,,"['Krakoff, I H']",['Krakoff IH'],['eng'],"['Journal Article', 'Review']",United States,Med Clin North Am,The Medical clinics of North America,2985236R,IM,"['Alkaloids/therapeutic use', 'Alkylating Agents/therapeutic use', 'Antibiotics, Antineoplastic/therapeutic use', 'Antimetabolites/therapeutic use', 'Antineoplastic Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Breast Neoplasms/drug therapy', 'Burkitt Lymphoma/drug therapy', 'DNA, Neoplasm/biosynthesis', 'Drug Synergism', 'Female', 'Hodgkin Disease/drug therapy', 'Humans', 'Immunosuppressive Agents/administration & dosage/pharmacology/*therapeutic use', 'Leukemia/drug therapy', 'Lymphoma, Non-Hodgkin/drug therapy', 'Male', 'Multiple Myeloma/drug therapy', 'Neoplasms/*drug therapy/metabolism', 'Neuroblastoma/drug therapy', 'Ovarian Neoplasms/drug therapy', 'Palliative Care', 'Pregnancy', 'Prostatic Neoplasms/drug therapy', 'RNA, Neoplasm/biosynthesis', 'Steroids/therapeutic use', 'Testicular Neoplasms/drug therapy', 'Trophoblastic Neoplasms/drug therapy', 'Wilms Tumor/drug therapy']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']","['S0025-7125(16)32511-1 [pii]', '10.1016/s0025-7125(16)32511-1 [doi]']",ppublish,Med Clin North Am. 1971 May;55(3):683-701. doi: 10.1016/s0025-7125(16)32511-1.,"['0 (Alkaloids)', '0 (Alkylating Agents)', '0 (Antibiotics, Antineoplastic)', '0 (Antimetabolites)', '0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (Immunosuppressive Agents)', '0 (RNA, Neoplasm)', '0 (Steroids)']",27,,,,,,,,,,
4102657,NLM,MEDLINE,19710706,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7709,1971 May 29,"HL-A, leukaemia, and leukaemia-associated antigens.",1134-5,,"['Harris, R', 'Viza, D']","['Harris R', 'Viza D']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antigens/*analysis', 'Child', 'Humans', 'Immune Sera', 'Leukemia/*immunology', 'Leukemia, Lymphoid/immunology', 'Lymphocytes/*immunology']",,1971/05/29 00:00,1971/05/29 00:01,['1971/05/29 00:00'],"['1971/05/29 00:00 [pubmed]', '1971/05/29 00:01 [medline]', '1971/05/29 00:00 [entrez]']",['10.1016/s0140-6736(71)91876-9 [doi]'],ppublish,Lancet. 1971 May 29;1(7709):1134-5. doi: 10.1016/s0140-6736(71)91876-9.,"['0 (Antigens)', '0 (Immune Sera)']",,,,,,,,,,,
4102645,NLM,MEDLINE,19710706,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7709,1971 May 29,Leukaemic transformation of engrafted human marrow cells in vivo.,1129,,"['Parker, J E']",['Parker JE'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Blood Transfusion', '*Bone Marrow', '*Bone Marrow Cells', 'Bone Marrow Transplantation', '*Cell Transformation, Neoplastic', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Immunity, Cellular', 'Immunoglobulins/analysis', 'Immunosuppressive Agents/therapeutic use', 'Leukemia/immunology/*pathology/therapy', 'Male', 'Transplantation, Homologous']",,1971/05/29 00:00,1971/05/29 00:01,['1971/05/29 00:00'],"['1971/05/29 00:00 [pubmed]', '1971/05/29 00:01 [medline]', '1971/05/29 00:00 [entrez]']",['10.1016/s0140-6736(71)91863-0 [doi]'],ppublish,Lancet. 1971 May 29;1(7709):1129. doi: 10.1016/s0140-6736(71)91863-0.,"['0 (Immunoglobulins)', '0 (Immunosuppressive Agents)']",,,,,,,,,,,
4102644,NLM,MEDLINE,19710706,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7709,1971 May 29,Previous tonsillectomy and the incidence of acute leukaemia of childhood.,1128,,"['Freeman, A I', 'Lieberman, N', 'Tidings, J', 'Bross, I', 'Glidewell, O']","['Freeman AI', 'Lieberman N', 'Tidings J', 'Bross I', 'Glidewell O']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Leukemia/*epidemiology/etiology', 'Maryland', 'Minnesota', 'New York', 'Postoperative Complications', '*Tonsillectomy']",,1971/05/29 00:00,1971/05/29 00:01,['1971/05/29 00:00'],"['1971/05/29 00:00 [pubmed]', '1971/05/29 00:01 [medline]', '1971/05/29 00:00 [entrez]']",['10.1016/s0140-6736(71)91862-9 [doi]'],ppublish,Lancet. 1971 May 29;1(7709):1128. doi: 10.1016/s0140-6736(71)91862-9.,,,,,,,,,,,,
4102584,NLM,MEDLINE,19710706,20061115,0003-1488 (Print) 0003-1488 (Linking),158,6,1971 Mar 15,A test system for identification of the antigen shared by leukemia viruses of the cat and other mammalian species.,Suppl 2:1092+,,"['Schafer, W', 'De Noronha, F']","['Schafer W', 'De Noronha F']",['eng'],"['Comparative Study', 'Journal Article']",United States,J Am Vet Med Assoc,Journal of the American Veterinary Medical Association,7503067,IM,"['Animals', 'Antibody Specificity', 'Antigen-Antibody Reactions', 'Antigens/*isolation & purification', 'Cats', 'Cattle', 'Complement Fixation Tests/veterinary', 'Cricetinae', 'Culture Media', 'Culture Techniques', 'Epitopes/isolation & purification', 'Immune Sera/analysis', 'Leukemia Virus, Murine/analysis', 'Mice', 'Rabbits', 'Rats', 'Retroviridae/analysis/growth & development/*immunology', 'Species Specificity']",,1971/03/15 00:00,1971/03/15 00:01,['1971/03/15 00:00'],"['1971/03/15 00:00 [pubmed]', '1971/03/15 00:01 [medline]', '1971/03/15 00:00 [entrez]']",,ppublish,J Am Vet Med Assoc. 1971 Mar 15;158(6):Suppl 2:1092+.,"['0 (Antigens)', '0 (Culture Media)', '0 (Epitopes)', '0 (Immune Sera)']",,,,,,,,,,,
4102562,NLM,MEDLINE,19710706,20190501,0027-8424 (Print) 0027-8424 (Linking),68,5,1971 May,Species-specific and interspecific antigenic determinants associated with the structural protein of feline C-type virus.,901-4,"The group-specific protein of feline leukemia viruses has been isolated by isoelectric focusing. This protein has a molecular weight, calculated from sodium dodecyl sulfate-acrylamide gel electrophoresis, of 25,000 and forms a resolved band in such gels when disrupted virions are analyzed. This protein contains both species-specific antigenic determinants, as well as interspecific cross-reactive determinants, as an integral part of its structure.","['Oroszlan, S', 'Huebner, R J', 'Gilden, R V']","['Oroszlan S', 'Huebner RJ', 'Gilden RV']",['eng'],['Journal Article'],United States,Proc Natl Acad Sci U S A,Proceedings of the National Academy of Sciences of the United States of America,7505876,IM,"['Animals', 'Antigens/*analysis', 'Cat Diseases/*microbiology', 'Cats', 'Complement Fixation Tests', 'Cross Reactions', 'Dogs', 'Electrophoresis, Disc', 'Epitopes/analysis', 'Guinea Pigs', 'Immunodiffusion', 'Isoelectric Focusing', 'Moloney murine leukemia virus/immunology', 'Rats', 'Retroviridae/*immunology', '*Species Specificity', 'Viral Proteins/*analysis']",PMC389076,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",['10.1073/pnas.68.5.901 [doi]'],ppublish,Proc Natl Acad Sci U S A. 1971 May;68(5):901-4. doi: 10.1073/pnas.68.5.901.,"['0 (Antigens)', '0 (Epitopes)', '0 (Viral Proteins)']",,,,,,,,,,,
4102536,NLM,MEDLINE,19710706,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7704,1971 Apr 24,Histocompatibility and acute lymphoblastic leukaemia.,853,,"['Burch, P R']",['Burch PR'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Antigens', '*Histocompatibility Testing', 'Humans', 'Leukemia, Lymphoid/*immunology']",,1971/04/24 00:00,1971/04/24 00:01,['1971/04/24 00:00'],"['1971/04/24 00:00 [pubmed]', '1971/04/24 00:01 [medline]', '1971/04/24 00:00 [entrez]']",['10.1016/s0140-6736(71)91512-1 [doi]'],ppublish,Lancet. 1971 Apr 24;1(7704):853. doi: 10.1016/s0140-6736(71)91512-1.,['0 (Antigens)'],,,,,,,,,,,
4102472,NLM,MEDLINE,19710701,20090604,0365-4184 (Print) 0365-4184 (Linking),79,3,1971,Variations in megakaryocyte ploidy in myeloproliferative disorders.,311,,"['Lagerlof, B']",['Lagerlof B'],['eng'],['Journal Article'],Denmark,Acta Pathol Microbiol Scand A,"Acta pathologica et microbiologica Scandinavica. Section A, Pathology",7508468,IM,"['Bone Marrow/*pathology', 'Diploidy', 'Humans', 'Leukemia, Myeloid/*pathology', 'Photography', 'Photometry', 'Polycythemia Vera/*pathology', '*Polyploidy', 'Staining and Labeling']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Acta Pathol Microbiol Scand A. 1971;79(3):311.,,,,,,,,,,,,
4102460,NLM,MEDLINE,19710630,20171116,,119,5,1971 May,[Varicella in antimetabolite and corticosteroid therapy].,178-80,,"['Bartsokas, S K']",['Bartsokas SK'],['ger'],['Journal Article'],Germany,Monatsschr Kinderheilkd,Monatsschrift fur Kinderheilkunde,0400751,IM,"['Acute Disease', 'Adrenal Cortex Hormones/*therapeutic use', 'Blood Transfusion', 'Chickenpox/*complications', 'Child', 'Female', 'Humans', 'Leukemia/*complications/drug therapy', 'Mercaptopurine/*adverse effects/therapeutic use', 'Prednisolone/therapeutic use', 'Purpura, Thrombocytopenic/drug therapy', 'gamma-Globulins/therapeutic use']",,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",,ppublish,Monatsschr Kinderheilkd. 1971 May;119(5):178-80.,"['0 (Adrenal Cortex Hormones)', '0 (gamma-Globulins)', '9PHQ9Y1OLM (Prednisolone)', 'E7WED276I5 (Mercaptopurine)']",,Windpochen unter Antimetaboliten- und Cortison-Therapie.,,,,,,,,,
4102446,NLM,MEDLINE,19710630,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7707,1971 May 15,Inhibition by ouabain of spontaneous D.N.A. synthesis in acute leukaemic leucocytes in vitro.,1026,,"['Grahame-Smith, D G', 'Hibble, A G']","['Grahame-Smith DG', 'Hibble AG']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'DNA/*antagonists & inhibitors/biosynthesis', 'Erythrocytes/metabolism', 'Humans', 'In Vitro Techniques', 'Leukemia/drug therapy/*metabolism', 'Leukocytes/*metabolism', 'Ouabain/administration & dosage/*pharmacology', 'Rubidium/metabolism', 'Thymidine/metabolism', 'Tritium']",,1971/05/15 00:00,1971/05/15 00:01,['1971/05/15 00:00'],"['1971/05/15 00:00 [pubmed]', '1971/05/15 00:01 [medline]', '1971/05/15 00:00 [entrez]']",['10.1016/s0140-6736(71)91429-2 [doi]'],ppublish,Lancet. 1971 May 15;1(7707):1026. doi: 10.1016/s0140-6736(71)91429-2.,"['10028-17-8 (Tritium)', '5ACL011P69 (Ouabain)', '9007-49-2 (DNA)', 'MLT4718TJW (Rubidium)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4102432,NLM,MEDLINE,19710630,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7707,1971 May 15,Lymphocyte-typing changes after short-term culture.,1019,,"['Mackintosh, P', 'Hardy, D A', 'Aviet, T']","['Mackintosh P', 'Hardy DA', 'Aviet T']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Blood Donors', 'Blood Group Antigens', 'Culture Techniques', 'Cytotoxicity Tests, Immunologic', 'Hemagglutination Tests', 'Histocompatibility Testing', 'Humans', 'Isoantigens', 'Leukemia/*blood', 'Lymphocytes/*immunology']",,1971/05/15 00:00,1971/05/15 00:01,['1971/05/15 00:00'],"['1971/05/15 00:00 [pubmed]', '1971/05/15 00:01 [medline]', '1971/05/15 00:00 [entrez]']",['10.1016/s0140-6736(71)91415-2 [doi]'],ppublish,Lancet. 1971 May 15;1(7707):1019. doi: 10.1016/s0140-6736(71)91415-2.,"['0 (Blood Group Antigens)', '0 (Isoantigens)']",,,,,,,,,,,
4102348,NLM,MEDLINE,19710626,20071115,0026-4946 (Print) 0026-4946 (Linking),22,20,1970 May 19,[Antiblastic chemotherapy and immunity in childhood].,1035-44,,"['Nigro, N', 'Madon, E', 'Baroncelli, P G', 'Martini Mauri, M']","['Nigro N', 'Madon E', 'Baroncelli PG', 'Martini Mauri M']",['ita'],['Journal Article'],Italy,Minerva Pediatr,Minerva pediatrica,0400740,IM,"['Animals', 'Antigen-Antibody Reactions/*drug effects', 'Antineoplastic Agents/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Hodgkin Disease/drug therapy', 'Humans', 'Immunoglobulins/biosynthesis', 'Infant', 'Leukemia/*drug therapy/immunology', 'Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Lymphoma, Non-Hodgkin/drug therapy', 'Male', 'Neoplasms/*drug therapy/immunology', 'Neuroblastoma/drug therapy', 'Wilms Tumor/drug therapy', 'gamma-Globulins/*biosynthesis']",,1970/05/19 00:00,1970/05/19 00:01,['1970/05/19 00:00'],"['1970/05/19 00:00 [pubmed]', '1970/05/19 00:01 [medline]', '1970/05/19 00:00 [entrez]']",,ppublish,Minerva Pediatr. 1970 May 19;22(20):1035-44.,"['0 (Antineoplastic Agents)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,Chemioterapia antiblastica ed immunita nell'infanzia.,,,,,,,,,
4102310,NLM,MEDLINE,19710624,20061122,0072-6575 (Print),310,,1971,Hypogammaglobulinaemia in the United Kingdom. XI. Reactions to immunoglobulin.,106-14,,"['Soothill, J F']",['Soothill JF'],['eng'],['Journal Article'],England,Spec Rep Ser Med Res Counc (G B),Special report series (Medical Research Council (Great Britain)),18530300R,IM,"['Adult', 'Agammaglobulinemia/complications/*drug therapy/genetics', 'Anxiety/chemically induced', 'Child', 'Drug Hypersensitivity/epidemiology', 'Female', 'Humans', 'Hypotension/chemically induced', 'Immunoglobulins/administration & dosage/adverse effects', 'Injections, Intramuscular/adverse effects', 'Leukemia/complications/genetics', 'Male', 'Skin Tests', 'Unconsciousness/chemically induced', 'gamma-Globulins/*adverse effects']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Spec Rep Ser Med Res Counc (G B). 1971;310:106-14.,"['0 (Immunoglobulins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4102266,NLM,MEDLINE,19710624,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7706,1971 May 8,Cancer in Japanese exposed as children to atomic bombs.,927-32,,"['Jablon, S', 'Tachikawa, K', 'Belsky, J L', 'Steer, A']","['Jablon S', 'Tachikawa K', 'Belsky JL', 'Steer A']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Japan', 'Leukemia, Radiation-Induced/*epidemiology/mortality', 'Male', 'Neoplasms, Radiation-Induced/*epidemiology/mortality', '*Nuclear Warfare', 'Radiometry', 'Thyroid Neoplasms/epidemiology']",,1971/05/08 00:00,1971/05/08 00:01,['1971/05/08 00:00'],"['1971/05/08 00:00 [pubmed]', '1971/05/08 00:01 [medline]', '1971/05/08 00:00 [entrez]']","['S0140-6736(71)91438-3 [pii]', '10.1016/s0140-6736(71)91438-3 [doi]']",ppublish,Lancet. 1971 May 8;1(7706):927-32. doi: 10.1016/s0140-6736(71)91438-3.,,,,,,,,,,,,
4102256,NLM,MEDLINE,19710624,20181113,0009-9104 (Print) 0009-9104 (Linking),8,2,1971 Feb,Precipitation of serum proteins by phytohaemagglutinin.,205-12,,"['Osunkoya, B O', 'Williams, A I']","['Osunkoya BO', 'Williams AI']",['eng'],['Journal Article'],England,Clin Exp Immunol,Clinical and experimental immunology,0057202,IM,"['Absorption', 'African Americans', 'Alpha-Globulins', 'Animals', 'Antibodies/analysis', 'Beta-Globulins', '*Blood Proteins', 'Cattle', 'Chickens', 'Female', 'Horses', 'Humans', 'Immunization', 'Immunodiffusion', 'Immunoelectrophoresis', '*Lectins', 'Leukemia/blood', 'Lymphoma/blood', 'Male', 'Mitosis/drug effects', '*Precipitins', 'Sheep', 'Species Specificity', 'gamma-Globulins']",PMC1712949,1971/02/01 00:00,1971/02/01 00:01,['1971/02/01 00:00'],"['1971/02/01 00:00 [pubmed]', '1971/02/01 00:01 [medline]', '1971/02/01 00:00 [entrez]']",,ppublish,Clin Exp Immunol. 1971 Feb;8(2):205-12.,"['0 (Alpha-Globulins)', '0 (Antibodies)', '0 (Beta-Globulins)', '0 (Blood Proteins)', '0 (Lectins)', '0 (Precipitins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4102200,NLM,MEDLINE,19710622,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7691,1971 Jan 23,B.C.G. and leukaemia.,183,,"['Hems, G', 'Stuart, A']","['Hems G', 'Stuart A']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Age Factors', '*BCG Vaccine', 'England', 'Female', 'Humans', 'Leukemia/*mortality/prevention & control', 'Male', 'Wales']",,1971/01/23 00:00,1971/01/23 00:01,['1971/01/23 00:00'],"['1971/01/23 00:00 [pubmed]', '1971/01/23 00:01 [medline]', '1971/01/23 00:00 [entrez]']",['10.1016/s0140-6736(71)91949-0 [doi]'],ppublish,Lancet. 1971 Jan 23;1(7691):183. doi: 10.1016/s0140-6736(71)91949-0.,['0 (BCG Vaccine)'],,,,,,,,,,,
4102134,NLM,MEDLINE,19710622,20071115,0009-9058 (Print) 0009-9058 (Linking),52,5,1970 May,[Serum levels of immunoglobulins in acute lymphoblastic leukemia in childhood].,185-98,,"['Masi, M', 'Vivarelli, F']","['Masi M', 'Vivarelli F']",['ita'],['Journal Article'],Italy,Clin Pediatr (Bologna),La Clinica pediatrica,0372603,IM,"['Adrenal Cortex Hormones/therapeutic use', 'Age Factors', 'Antineoplastic Agents/therapeutic use', 'Child', 'Child, Preschool', 'Humans', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/*immunology', 'gamma-Globulins/*analysis']",,1970/05/01 00:00,1970/05/01 00:01,['1970/05/01 00:00'],"['1970/05/01 00:00 [pubmed]', '1970/05/01 00:01 [medline]', '1970/05/01 00:00 [entrez]']",,ppublish,Clin Pediatr (Bologna). 1970 May;52(5):185-98.,"['0 (Adrenal Cortex Hormones)', '0 (Antineoplastic Agents)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,I livelli sierici delle immunoglobuline nella leucosi acuta linfoblastica della infanzia.,,,,,,,,,
4101894,NLM,MEDLINE,19710615,20071115,0031-3114 (Print) 0031-3114 (Linking),22,1,1971,[Studies on the presence of the anti-gamma 2-globulin factor in the serum of patients with leukemia].,97-103,,"['Szmigiel, Z', 'Pawlik, L']","['Szmigiel Z', 'Pawlik L']",['pol'],['Journal Article'],Poland,Patol Pol,Patologia polska,0404244,IM,"['Acute Disease', '*Autoantibodies', 'Chronic Disease', 'Humans', 'Leukemia/blood/*immunology', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid/blood', 'Rheumatoid Factor/analysis', '*gamma-Globulins']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Patol Pol. 1971;22(1):97-103.,"['0 (Autoantibodies)', '0 (gamma-Globulins)', '9009-79-4 (Rheumatoid Factor)']",,Badania nad obecnoscia czynnika anty-gamma 2-globulinowego w surowicach ludzi chorych na bialaczki.,,,,,,,,,
4101888,NLM,MEDLINE,19710615,20191021,,272,6,1971 Feb 8,[Ultrastructural study of acid carbohydrates of the cytoplasmic membrane of blood lymphocytes in human lymphoid leukemia patients].,884-5,,"['Calman, F', 'Binet, J L', 'Bernard, J']","['Calman F', 'Binet JL', 'Bernard J']",['fre'],['Journal Article'],France,C R Acad Hebd Seances Acad Sci D,Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,7501107,IM,"['Carbohydrates/*analysis', 'Cell Membrane/analysis', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia, Lymphoid/*blood', 'Lymphocytes/*analysis/*cytology', 'Male', 'Microscopy, Electron', 'Staining and Labeling']",,1971/02/08 00:00,1971/02/08 00:01,['1971/02/08 00:00'],"['1971/02/08 00:00 [pubmed]', '1971/02/08 00:01 [medline]', '1971/02/08 00:00 [entrez]']",,ppublish,C R Acad Hebd Seances Acad Sci D. 1971 Feb 8;272(6):884-5.,['0 (Carbohydrates)'],,Etude ultrastructurale des carbohydrates acides de la membrane cytoplasmique des lymphocytes sanguins chez l'homme atteint de leucemie lymphoide.,,,,,,,,,
4101834,NLM,MEDLINE,19710609,20071115,0020-9554 (Print) 0020-9554 (Linking),11,3,1970 Mar,[The cytochemical differentiation of acute leukoses].,129-30,,"['Schmidt, M']",['Schmidt M'],['ger'],['Journal Article'],Germany,Internist (Berl),Der Internist,0264620,IM,"['Acid Phosphatase/blood', 'Esterases/blood', '*Histocytochemistry', 'Humans', 'Leukemia/*classification', 'Leukemia, Lymphoid/*enzymology', 'Leukemia, Monocytic, Acute/*enzymology', 'Leukemia, Myeloid, Acute/*enzymology', 'Periodic Acid', 'Peroxidases/blood', 'Staining and Labeling']",,1970/03/01 00:00,1970/03/01 00:01,['1970/03/01 00:00'],"['1970/03/01 00:00 [pubmed]', '1970/03/01 00:01 [medline]', '1970/03/01 00:00 [entrez]']",,ppublish,Internist (Berl). 1970 Mar;11(3):129-30.,"['10450-60-9 (Periodic Acid)', 'EC 1.11.1.- (Peroxidases)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.2 (Acid Phosphatase)']",,Die cytochemische Differenzierung akuter Leukosen.,,,,,,,,,
4101637,NLM,MEDLINE,19710602,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7701,1971 Apr 3,Possible explanation of the high concoddance for acute leukaemia in monozygotic twins.,699-701,,"['Clarkson, B D', 'Boyse, E A']","['Clarkson BD', 'Boyse EA']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', '*Diseases in Twins', 'Humans', 'Leukemia/*genetics']",,1971/04/03 00:00,1971/04/03 00:01,['1971/04/03 00:00'],"['1971/04/03 00:00 [pubmed]', '1971/04/03 00:01 [medline]', '1971/04/03 00:00 [entrez]']",['10.1016/s0140-6736(71)92705-x [doi]'],ppublish,Lancet. 1971 Apr 3;1(7701):699-701. doi: 10.1016/s0140-6736(71)92705-x.,,,,,,,,,,,,
4101636,NLM,MEDLINE,19710602,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7701,1971 Apr 3,Histocompatibility and acute lymphoblastic leukaemia.,699,,"['Lawler, S D', 'Klouda, P T', 'Hardisty, R M', 'Till, M M']","['Lawler SD', 'Klouda PT', 'Hardisty RM', 'Till MM']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Adolescent', 'Child', 'Child, Preschool', '*Histocompatibility', 'Humans', 'Infant', 'Leukemia, Lymphoid/*immunology', 'Phenotype']",,1971/04/03 00:00,1971/04/03 00:01,['1971/04/03 00:00'],"['1971/04/03 00:00 [pubmed]', '1971/04/03 00:01 [medline]', '1971/04/03 00:00 [entrez]']",['10.1016/s0140-6736(71)92704-8 [doi]'],ppublish,Lancet. 1971 Apr 3;1(7701):699. doi: 10.1016/s0140-6736(71)92704-8.,,,,,,,,,,,,
4101621,NLM,MEDLINE,19710602,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7701,1971 Apr 3,Infectious mononucleosis and acute leukaemia.,688,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Hodgkin Disease/complications', 'Humans', 'Infectious Mononucleosis/*complications', 'Leukemia/*complications']",,1971/04/03 00:00,1971/04/03 00:01,['1971/04/03 00:00'],"['1971/04/03 00:00 [pubmed]', '1971/04/03 00:01 [medline]', '1971/04/03 00:00 [entrez]']",,ppublish,Lancet. 1971 Apr 3;1(7701):688.,,,,,,,,,,,,
4101618,NLM,MEDLINE,19710602,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7701,1971 Apr 3,Chlorama-like ocular manifestations in Turkish children with acute myelomonocytic leukaemia.,680-2,,"['Cavdar, A O', 'Gozdasoglu, S', 'Arcasoy, A', 'Demirag, B']","['Cavdar AO', 'Gozdasoglu S', 'Arcasoy A', 'Demirag B']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Acute Disease', 'Child', 'Child, Preschool', 'Exophthalmos/*etiology', '*Eye Manifestations', 'Female', 'Hemoglobins', 'Humans', 'Leukemia, Myeloid/*complications', 'Male', '*Orbital Neoplasms', 'Turkey']",,1971/04/03 00:00,1971/04/03 00:01,['1971/04/03 00:00'],"['1971/04/03 00:00 [pubmed]', '1971/04/03 00:01 [medline]', '1971/04/03 00:00 [entrez]']",['S0140-6736(71)92684-5 [pii]'],ppublish,Lancet. 1971 Apr 3;1(7701):680-2.,['0 (Hemoglobins)'],,,,,,,,,,,
4101593,NLM,MEDLINE,19710602,20210313,0025-729X (Print) 0025-729X (Linking),1,10,1971 Mar 6,Immunoglobulin levels in chronic lymphocytic leukaemia.,535-6,,"['Scamps, R A', 'Streeter, A M', ""O'Neill, B J""]","['Scamps RA', 'Streeter AM', ""O'Neill BJ""]",['eng'],['Journal Article'],Australia,Med J Aust,The Medical journal of Australia,0400714,IM,"['Adolescent', 'Adult', 'Child', 'Female', 'Humans', 'Immunoglobulin A/analysis', 'Immunoglobulin G/*analysis', 'Immunoglobulin M/*analysis', 'Leukemia, Lymphoid/*immunology', 'Male', 'Middle Aged', 'gamma-Globulins/analysis/therapeutic use']",,1971/03/06 00:00,1971/03/06 00:01,['1971/03/06 00:00'],"['1971/03/06 00:00 [pubmed]', '1971/03/06 00:01 [medline]', '1971/03/06 00:00 [entrez]']",['10.5694/j.1326-5377.1971.tb87693.x [doi]'],ppublish,Med J Aust. 1971 Mar 6;1(10):535-6. doi: 10.5694/j.1326-5377.1971.tb87693.x.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (gamma-Globulins)']",,,,,,,,,,,
4101590,NLM,MEDLINE,19710602,20181113,0021-9738 (Print) 0021-9738 (Linking),50,5,1971 May,Immunological responses to L-asparaginase.,1080-90,"In a series of 40 patients treated with L-asparaginase for various neoplastic diseases, 6 patients had generalized anaphylactic reactions to L-asparaginase. Each of these reactors had antibodies detectable by passive hemagglutination, but precipitins were detectable in only one of this group of six patients. That patient had received two courses of the enzyme. 1 wk after the anaphylactic reaction, complement-fixing antibodies were present in all the patients that were studied. Specific reagin antibodies (IgE) were demonstrated in one patient by the release of histamine from his leukocytes after incubation in vitro with L-asparaginase. Binding of L-asparaginase to serum antibodies after incubation in vitro was detected by selective precipitation of the complexes with 30% ammonium sulfate or by ultracentrifugation. Total inactivation of the enzyme did not occur even at optimal proportions or at antibody excess. Passive hemagglutinating antibodies to L-asparaginase were present in all patients who had an allergic reaction at least 1 day before the reaction occurred, when that sample was available, and were absent in all patients who did not manifest clinical allergy. Titration of antibodies by passive hemagglutination may thus provide a means of predicting impending anaphylaxis in this system, particularly when coupled with a sudden decrease in circulating levels of L-asparaginase activity.","['Peterson, R G', 'Handschumacher, R E', 'Mitchell, M S']","['Peterson RG', 'Handschumacher RE', 'Mitchell MS']",['eng'],"['Clinical Trial', 'Journal Article']",United States,J Clin Invest,The Journal of clinical investigation,7802877,IM,"['Adolescent', 'Adult', '*Anaphylaxis', '*Antibody Formation', 'Antigen-Antibody Complex', 'Asparaginase/*pharmacology/therapeutic use', 'Chemical Precipitation', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Complement Fixation Tests', 'Escherichia coli/enzymology', 'Female', 'Hemagglutination', 'Histamine Release', 'Humans', 'Immunodiffusion', 'Leukemia, Lymphoid/drug therapy', 'Leukemia, Myeloid/drug therapy', 'Male', 'Melanoma/drug therapy', 'Middle Aged', 'Stereoisomerism']",PMC292030,1971/05/01 00:00,1971/05/01 00:01,['1971/05/01 00:00'],"['1971/05/01 00:00 [pubmed]', '1971/05/01 00:01 [medline]', '1971/05/01 00:00 [entrez]']",['10.1172/JCI106579 [doi]'],ppublish,J Clin Invest. 1971 May;50(5):1080-90. doi: 10.1172/JCI106579.,"['0 (Antigen-Antibody Complex)', 'EC 3.5.1.1 (Asparaginase)']",,,,,,,,,,,
4101580,NLM,MEDLINE,19710602,20171116,0007-4551 (Print) 0007-4551 (Linking),56,4,1969 Oct-Dec,[Myelomonocytic leukemia of young children].,351-64,,"['Weisgerber, C', 'Schaison, G', 'Seligmann, M', 'Bernard, J']","['Weisgerber C', 'Schaison G', 'Seligmann M', 'Bernard J']",['fre'],['Journal Article'],France,Bull Cancer,Bulletin du cancer,0072416,IM,"['Anemia, Hypochromic/etiology', 'Biopsy', 'Blood Protein Disorders/*complications', 'Bone Marrow/pathology', 'Child, Preschool', 'Female', '*Hemoglobins, Abnormal', 'Hemorrhage/etiology', 'Humans', 'Hypergammaglobulinemia/complications', 'Immunoglobulins', 'Infant', 'Karyotyping', 'Leukemia, Myeloid/complications/drug therapy/*pathology', 'Leukocytosis/complications', 'Male', 'Mercaptopurine/*therapeutic use', 'Skin Manifestations', 'Skin Neoplasms/complications', 'Spleen/pathology', 'Splenomegaly/etiology', 'Xanthomatosis/complications', '*gamma-Globulins']",,1969/10/01 00:00,1969/10/01 00:01,['1969/10/01 00:00'],"['1969/10/01 00:00 [pubmed]', '1969/10/01 00:01 [medline]', '1969/10/01 00:00 [entrez]']",,ppublish,Bull Cancer. 1969 Oct-Dec;56(4):351-64.,"['0 (Hemoglobins, Abnormal)', '0 (Immunoglobulins)', '0 (gamma-Globulins)', 'E7WED276I5 (Mercaptopurine)']",,Les leucemies myelomonocytaires du petit enfant.,,,,,,,,,
4101555,NLM,MEDLINE,19710530,20051117,0040-8727 (Print) 0040-8727 (Linking),102,4,1970 Dec,Significance of M-components in plasma cell myeloma and related disorders.,341-67,,"['Kano, T']",['Kano T'],['eng'],['Journal Article'],Japan,Tohoku J Exp Med,The Tohoku journal of experimental medicine,0417355,IM,"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Animals', 'Bence Jones Protein/blood/urine', 'Blood Cell Count', 'Blood Protein Disorders/immunology', 'Blood Protein Electrophoresis', 'Bone Marrow Cells', 'Chromatography, DEAE-Cellulose', 'Electrophoresis', 'Humans', 'Immune System Diseases/immunology', 'Immunoelectrophoresis', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulins/analysis', 'Leukemia/immunology', 'Lymphoma/immunology', 'Middle Aged', 'Multiple Myeloma/diagnosis/*immunology', 'Plasma Cells', 'Plasmacytoma/diagnosis', 'Rabbits', 'Serum Albumin/analysis', 'Waldenstrom Macroglobulinemia/diagnosis/immunology', 'gamma-Globulins/*analysis']",,1970/12/01 00:00,1970/12/01 00:01,['1970/12/01 00:00'],"['1970/12/01 00:00 [pubmed]', '1970/12/01 00:01 [medline]', '1970/12/01 00:00 [entrez]']",,ppublish,Tohoku J Exp Med. 1970 Dec;102(4):341-67.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulins)', '0 (Serum Albumin)', '0 (gamma-Globulins)', '9006-99-9 (Bence Jones Protein)']",,,,,,,,,,,
4101547,NLM,MEDLINE,19710530,20041117,0011-9083 (Print) 0011-9083 (Linking),156,5,1970,[Immunologic reactivity against cancer and possibilities of its change].,372-7,,"['Pasternak, L', 'Pasternak, G']","['Pasternak L', 'Pasternak G']",['ger'],['Journal Article'],Germany,Dermatol Monatsschr,Dermatologische Monatschrift,0232053,IM,"['Animals', 'Antigen-Antibody Reactions', 'Colonic Neoplasms/immunology', 'Fluorescent Antibody Technique', 'Humans', 'Leukemia/immunology', 'Melanoma/immunology', 'Neoplasm Transplantation', 'Neoplasms/*immunology', 'Neoplasms, Experimental', 'Neuroblastoma/immunology', 'Oncogenic Viruses/immunology', 'Staining and Labeling']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Dermatol Monatsschr. 1970;156(5):372-7.,,,Die immunologische Reaktivitat gegen Krebs und Moglichkeiten ihrer Veranderung.,,,,,,,,,
4101482,NLM,MEDLINE,19710526,20190501,0007-1447 (Print) 0007-1447 (Linking),2,5753,1971 Apr 10,Immunocytoma o' mice an' men.,67-72,,"['Hobbs, J R']",['Hobbs JR'],['eng'],"['Journal Article', 'Review']",England,Br Med J,British medical journal,0372673,IM,"['Bence Jones Protein/urine', 'Blood Protein Electrophoresis', 'Bone Marrow Cells', 'Cell Count', 'Clone Cells', 'Cyclophosphamide/therapeutic use', 'DNA', 'Humans', 'Immunoglobulin G/analysis', 'Immunoglobulins/biosynthesis', 'Leukemia, Myeloid/drug therapy', 'Melphalan/therapeutic use', 'Middle Aged', 'Multiple Myeloma/drug therapy/immunology', 'Mutation', 'Plasmacytoma/*immunology', 'Ribosomes/metabolism', 'gamma-Globulins/analysis']",PMC1795561,1971/04/10 00:00,1971/04/10 00:01,['1971/04/10 00:00'],"['1971/04/10 00:00 [pubmed]', '1971/04/10 00:01 [medline]', '1971/04/10 00:00 [entrez]']",['10.1136/bmj.2.5753.67 [doi]'],ppublish,Br Med J. 1971 Apr 10;2(5753):67-72. doi: 10.1136/bmj.2.5753.67.,"['0 (Immunoglobulin G)', '0 (Immunoglobulins)', '0 (gamma-Globulins)', '8N3DW7272P (Cyclophosphamide)', '9006-99-9 (Bence Jones Protein)', '9007-49-2 (DNA)', 'Q41OR9510P (Melphalan)']",35,,,,,,,,,,
4101457,NLM,MEDLINE,19710526,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7702,1971 Apr 10,Leukaemia-antigen detection.,755,,"['Weiner, R S', 'Warnock, D G']","['Weiner RS', 'Warnock DG']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Antibody Specificity', 'Antigens/*analysis', 'Bone Marrow Transplantation', 'Cross Reactions', 'Humans', 'Immune Sera', 'Immunity, Maternally-Acquired', 'Leukemia, Lymphoid/*immunology', 'Mice', 'Rabbits', 'Transplantation Immunology', 'Transplantation, Homologous']",,1971/04/10 00:00,1971/04/10 00:01,['1971/04/10 00:00'],"['1971/04/10 00:00 [pubmed]', '1971/04/10 00:01 [medline]', '1971/04/10 00:00 [entrez]']",['10.1016/s0140-6736(71)92023-x [doi]'],ppublish,Lancet. 1971 Apr 10;1(7702):755. doi: 10.1016/s0140-6736(71)92023-x.,"['0 (Antigens)', '0 (Immune Sera)']",,,,,,,,,,,
4101451,NLM,MEDLINE,19710526,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7702,1971 Apr 10,B.C.G. vaccination and leukaemia mortality.,751,,"['Clark, J']",['Clark J'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', '*BCG Vaccine', 'Child', 'Humans', 'Infant', 'Leukemia/mortality', 'Scotland']",,1971/04/10 00:00,1971/04/10 00:01,['1971/04/10 00:00'],"['1971/04/10 00:00 [pubmed]', '1971/04/10 00:01 [medline]', '1971/04/10 00:00 [entrez]']",['10.1016/s0140-6736(71)92015-0 [doi]'],ppublish,Lancet. 1971 Apr 10;1(7702):751. doi: 10.1016/s0140-6736(71)92015-0.,['0 (BCG Vaccine)'],,,,,,,,,,,
4101450,NLM,MEDLINE,19710526,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7702,1971 Apr 10,Outpatient anaesthesia for a children's leukaemia clinic.,751,,"['Evans, D I', 'Jones, P M', 'Morris, P', 'Shaw, E A']","['Evans DI', 'Jones PM', 'Morris P', 'Shaw EA']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', '*Ambulatory Care', '*Anesthesia, General', 'Biopsy', '*Bone Marrow Examination', 'Child', 'Child, Preschool', 'Hospitals, Special', 'Humans', 'Leukemia/*diagnosis', 'Punctures']",,1971/04/10 00:00,1971/04/10 00:01,['1971/04/10 00:00'],"['1971/04/10 00:00 [pubmed]', '1971/04/10 00:01 [medline]', '1971/04/10 00:00 [entrez]']",['10.1016/s0140-6736(71)92014-9 [doi]'],ppublish,Lancet. 1971 Apr 10;1(7702):751. doi: 10.1016/s0140-6736(71)92014-9.,,,,,,,,,,,,
4101438,NLM,MEDLINE,19710526,20171116,0140-6736 (Print) 0140-6736 (Linking),1,7702,1971 Apr 10,Long remissions in leukaemia.,742-3,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Humans', 'Injections, Spinal', 'Leukemia/*therapy', 'Leukemia, Lymphoid/drug therapy', 'Leukemia, Myeloid, Acute/drug therapy', 'Male', 'Mercaptopurine/therapeutic use', 'Methotrexate/administration & dosage', 'Prednisone/therapeutic use', 'Time Factors', 'Vincristine/therapeutic use']",,1971/04/10 00:00,1971/04/10 00:01,['1971/04/10 00:00'],"['1971/04/10 00:00 [pubmed]', '1971/04/10 00:01 [medline]', '1971/04/10 00:00 [entrez]']",['S0140-6736(71)92001-0 [pii]'],ppublish,Lancet. 1971 Apr 10;1(7702):742-3.,"['5J49Q6B70F (Vincristine)', 'E7WED276I5 (Mercaptopurine)', 'VB0R961HZT (Prednisone)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4101299,NLM,MEDLINE,19710517,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7703,1971 Apr 17,Inhibition by ouabain of spontaneous D.N.A. synthesis in acute leukaemic leucocytes in vitro.,801-2,,"['Quastel, M R', 'Kaplan, J G', 'Abbatt, J D']","['Quastel MR', 'Kaplan JG', 'Abbatt JD']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Aged', 'Child', 'Child, Preschool', 'Cyclophosphamide/therapeutic use', 'DNA/antagonists & inhibitors', 'DNA, Neoplasm/*biosynthesis', 'Female', 'Humans', 'In Vitro Techniques', 'Lectins/pharmacology', '*Leukemia/drug therapy', 'Leukocytes/*drug effects/metabolism', 'Lymphocyte Activation', 'Male', 'Mercaptopurine/therapeutic use', 'Ouabain/*pharmacology/therapeutic use', 'Prednisone/therapeutic use', 'Thymidine/metabolism', 'Tritium']",,1971/04/17 00:00,1971/04/17 00:01,['1971/04/17 00:00'],"['1971/04/17 00:00 [pubmed]', '1971/04/17 00:01 [medline]', '1971/04/17 00:00 [entrez]']","['S0140-6736(71)91243-8 [pii]', '10.1016/s0140-6736(71)91243-8 [doi]']",ppublish,Lancet. 1971 Apr 17;1(7703):801-2. doi: 10.1016/s0140-6736(71)91243-8.,"['0 (DNA, Neoplasm)', '0 (Lectins)', '10028-17-8 (Tritium)', '5ACL011P69 (Ouabain)', '8N3DW7272P (Cyclophosphamide)', '9007-49-2 (DNA)', 'E7WED276I5 (Mercaptopurine)', 'VB0R961HZT (Prednisone)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4101294,NLM,MEDLINE,19710517,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7703,1971 Apr 17,B.C.G. vaccination and leukaemia mortality.,799,,"['Stewart, A', 'Draper, G']","['Stewart A', 'Draper G']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*BCG Vaccine', 'Child', 'Child, Preschool', 'Humans', 'Leukemia/immunology/*mortality', 'Medical Records', 'Quebec']",,1971/04/17 00:00,1971/04/17 00:01,['1971/04/17 00:00'],"['1971/04/17 00:00 [pubmed]', '1971/04/17 00:01 [medline]', '1971/04/17 00:00 [entrez]']",['10.1016/s0140-6736(71)91238-4 [doi]'],ppublish,Lancet. 1971 Apr 17;1(7703):799. doi: 10.1016/s0140-6736(71)91238-4.,['0 (BCG Vaccine)'],,,,,,,,,,,
4101287,NLM,MEDLINE,19710517,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7703,1971 Apr 17,Imperial Cancer Research Fund.,792,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antineoplastic Agents/therapeutic use', 'Colchicine/therapeutic use', 'England', 'Humans', 'Leukemia, Lymphoid/drug therapy/etiology', 'Lymphocytes/immunology', 'Neoplasm Transplantation', '*Neoplasms/immunology', 'Research Support as Topic', 'Transplantation Immunology']",,1971/04/17 00:00,1971/04/17 00:01,['1971/04/17 00:00'],"['1971/04/17 00:00 [pubmed]', '1971/04/17 00:01 [medline]', '1971/04/17 00:00 [entrez]']",['S0140-6736(71)91229-3 [pii]'],ppublish,Lancet. 1971 Apr 17;1(7703):792.,"['0 (Antineoplastic Agents)', 'SML2Y3J35T (Colchicine)']",,,,,,,,,,,
4101255,NLM,MEDLINE,19710517,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7700,1971 Mar 27,Intrathecal methotrexate.,649,,"['Baum, E S', 'Koch, H F', 'Corby, D G', 'Plunket, D C']","['Baum ES', 'Koch HF', 'Corby DG', 'Plunket DC']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Female', 'Humans', 'Injections, Spinal', 'Leukemia, Lymphoid/*drug therapy', 'Male', 'Methotrexate/*administration & dosage']",,1971/03/27 00:00,1971/03/27 00:01,['1971/03/27 00:00'],"['1971/03/27 00:00 [pubmed]', '1971/03/27 00:01 [medline]', '1971/03/27 00:00 [entrez]']",['10.1016/s0140-6736(71)91581-9 [doi]'],ppublish,Lancet. 1971 Mar 27;1(7700):649. doi: 10.1016/s0140-6736(71)91581-9.,['YL5FZ2Y5U1 (Methotrexate)'],,,,,,,,,,,
4101244,NLM,MEDLINE,19710517,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7700,1971 Mar 27,Development of leukemia in donor cells.,644,,"['Fisher, S', 'Moore, C E', 'von Heyden, H W']","['Fisher S', 'Moore CE', 'von Heyden HW']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Bone Marrow Cells', '*Bone Marrow Transplantation', 'Cell Line', '*Graft vs Host Reaction', 'Humans', 'Leukemia/*etiology', 'Transplantation, Homologous']",,1971/03/27 00:00,1971/03/27 00:01,['1971/03/27 00:00'],"['1971/03/27 00:00 [pubmed]', '1971/03/27 00:01 [medline]', '1971/03/27 00:00 [entrez]']",['10.1016/s0140-6736(71)91569-8 [doi]'],ppublish,Lancet. 1971 Mar 27;1(7700):644. doi: 10.1016/s0140-6736(71)91569-8.,,,,,,,,,,,,
4101224,NLM,MEDLINE,19710517,20200724,0022-538X (Print) 0022-538X (Linking),7,3,1971 Mar,Electron microscopic studies of tumor viruses. I. Entry of murine leukemia virus into mouse embryo fibroblasts.,395-406,"Entry of Rauscher leukemia virus into mouse embryo fibroblasts was studied by electron microscopy. The polycation diethylaminoethyl-dextran enhanced viral attachment and subsequent entry. At the site of viral attachment to the cell membrane, three distinct interactions occurred between the viral envelope and cell membrane, namely, (i) dissolution of viral envelopes on the cell membrane, which itself remained unaltered; (ii) simultaneous dissolution of both the envelope and cell membrane, resulting in passage of viral nucleoids directly into the cytoplasm; and (iii) dissolution of the cell membrane with direct penetration of intact enveloped particles into the cytoplasm, followed by intracytoplasmic disruption of the envelope, resulting in release of nucleoids into the cytoplasm. These interactions occurred with both mature and immature C-type particles. At no time was fusion of viral envelopes with the cell membrane observed. The mechanism of these interactions is discussed.","['Miyamoto, K', 'Gilden, R V']","['Miyamoto K', 'Gilden RV']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Adsorption', 'Animals', 'Binding Sites', 'Cell Membrane', 'Culture Media', '*Culture Techniques', 'Dextrans', 'Ethylamines', 'Fibroblasts/*microbiology', 'Mice', '*Microscopy, Electron', 'Models, Theoretical', 'Phagocytosis', '*Rauscher Virus/growth & development/pathogenicity', 'Staining and Labeling', 'Viral Proteins']",PMC356130,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",['10.1128/JVI.7.3.395-406.1971 [doi]'],ppublish,J Virol. 1971 Mar;7(3):395-406. doi: 10.1128/JVI.7.3.395-406.1971.,"['0 (Culture Media)', '0 (Dextrans)', '0 (Ethylamines)', '0 (Viral Proteins)']",,,,,,,,,,,
4101222,NLM,MEDLINE,19710517,20200724,0022-538X (Print) 0022-538X (Linking),7,3,1971 Mar,Size and composition of Marek's disease virus deoxyribonucleic acid.,289-94,"Deoxyribonucleic acid (DNA) extracted from purified nucleocapsids of Marek's disease herpesvirus (MDV) was cosedimented with T4 and with herpes simplex virus (HSV) DNA in neutral sucrose density gradients and with T4 DNA in alkaline sucrose density gradients. These experiments indicated that the intact MDV DNA had a sedimentation constant of 56S corresponding to a molecular weight of 1.2 x 10(8) daltons. In the alkaline gradients, the largest and most prominent band contains a DNA sedimenting at 70S corresponding to 6.0 x 10(7) daltons in molecular weight. The DNA is therefore double-stranded and not cross-linked. Isopycnic sedimentation of the MDV DNA molecules with SPO1, Micrococcus lysodeikticus, and HSV DNA gave a density of 1.705 g/cm(3) corresponding to 46 guanine plus cytosine moles per cent. Lastly, in hybridization tests the DNA hybridized with RNA of infected cells but not with that of uninfected cells supporting the conclusion that it is viral.","['Lee, L F', 'Kieff, E D', 'Bachenheimer, S L', 'Roizman, B', 'Spear, P G', 'Burmester, B R', 'Nazerian, K']","['Lee LF', 'Kieff ED', 'Bachenheimer SL', 'Roizman B', 'Spear PG', 'Burmester BR', 'Nazerian K']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Alpharetrovirus/*analysis/pathogenicity', 'Animals', 'Avian Leukosis/*microbiology', 'Carbon Isotopes', 'Carcinoma', 'Cell Line', 'Centrifugation, Density Gradient', 'Coliphages/analysis', 'DNA, Viral/*analysis/isolation & purification', 'Ducks', 'Fibroblasts', 'Genetics, Microbial', 'Humans', 'Hybridization, Genetic', 'Laryngeal Neoplasms', 'Microscopy, Electron', 'Molecular Weight', 'Nucleoproteins/isolation & purification', 'Poultry Diseases/*microbiology', 'RNA', 'Simplexvirus/analysis', 'Species Specificity', 'Staining and Labeling', 'Sucrose', 'Thymidine/metabolism', 'Tritium']",PMC356116,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",['10.1128/JVI.7.3.289-294.1971 [doi]'],ppublish,J Virol. 1971 Mar;7(3):289-94. doi: 10.1128/JVI.7.3.289-294.1971.,"['0 (Carbon Isotopes)', '0 (DNA, Viral)', '0 (Nucleoproteins)', '10028-17-8 (Tritium)', '57-50-1 (Sucrose)', '63231-63-0 (RNA)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4101216,NLM,MEDLINE,19710517,20081121,0440-0607 (Print) 0440-0607 (Linking),9,,1970,[Faulty immunoglobulin synthesis and lymphoma].,166-76,,"['Waldenstrom, J']",['Waldenstrom J'],['ger'],['Journal Article'],Germany,Hamatol Bluttransfus,Hamatologie und Bluttransfusion,7804332,IM,"['Aged', 'Aleutian Mink Disease/diagnosis', 'Animals', 'Antibodies/analysis', 'Autoimmune Diseases/metabolism', 'Bence Jones Protein/urine', 'Blood Protein Disorders/blood', 'Blood Protein Electrophoresis', 'Blood Proteins/analysis', 'Bone Marrow Diseases/metabolism', 'Cold Temperature', 'Female', 'Humans', 'Immunochemistry', 'Immunoglobulins/biosynthesis', 'Leukemia, Lymphoid/blood', 'Lymphoma/*immunology/metabolism', 'Lymphoma, Large B-Cell, Diffuse/pathology', 'Male', 'Middle Aged', 'Plasmacytoma/pathology', 'Spleen/pathology', 'Waldenstrom Macroglobulinemia/blood', 'gamma-Globulins/*biosynthesis']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Hamatol Bluttransfus. 1970;9:166-76.,"['0 (Antibodies)', '0 (Blood Proteins)', '0 (Immunoglobulins)', '0 (gamma-Globulins)', '9006-99-9 (Bence Jones Protein)']",,Gestorte Immunglobulinsynthese und Lymphom.,,,,,,,,,
4101193,NLM,MEDLINE,19710516,20210216,0006-4971 (Print) 0006-4971 (Linking),37,4,1971 Apr,Hemoglobin synthesis in murine virus-induced leukemic cells in vitro. I. Partial purification and identification of hemoglobins.,428-37,,"['Scher, W', 'Holland, J G', 'Friend, C']","['Scher W', 'Holland JG', 'Friend C']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['Animals', 'Blood Cells', 'Cell Differentiation', 'Clone Cells', 'Culture Media', 'Culture Techniques', 'Densitometry', 'Electrophoresis', 'Friend murine leukemia virus', 'Gels', 'Heme/biosynthesis', 'Hemoglobins/analysis/*biosynthesis/*isolation & purification', 'Histocytochemistry', 'Iron/metabolism', 'Iron Isotopes', 'Leukemia, Experimental/*blood', 'Mice', 'Peroxidases/analysis', 'Spectrum Analysis', 'Staining and Labeling']",,1971/04/01 00:00,1971/04/01 00:01,['1971/04/01 00:00'],"['1971/04/01 00:00 [pubmed]', '1971/04/01 00:01 [medline]', '1971/04/01 00:00 [entrez]']",['S0006-4971(20)69447-2 [pii]'],ppublish,Blood. 1971 Apr;37(4):428-37.,"['0 (Culture Media)', '0 (Gels)', '0 (Hemoglobins)', '0 (Iron Isotopes)', '42VZT0U6YR (Heme)', 'E1UOL152H7 (Iron)', 'EC 1.11.1.- (Peroxidases)']",,,,,,,,,,,
4101123,NLM,MEDLINE,19710506,20131121,0323-4347 (Print) 0323-4347 (Linking),94,4,1970,[Granulocyte kinetics with radioactive diisopropyl-fluorophosphate (DF32P)].,326-32,,"['Nowotny, P', 'Preussner, S', 'Konrad, H', 'Kiencke, H']","['Nowotny P', 'Preussner S', 'Konrad H', 'Kiencke H']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Bone Marrow Diseases/blood', '*Hematopoiesis', 'Humans', 'Isoflurophate/*metabolism', 'Kinetics', 'Leukemia, Myeloid/blood', '*Leukocytes/metabolism', 'Osteosclerosis/blood', 'Primary Myelofibrosis/blood', 'Radioisotopes']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(4):326-32.,"['0 (Radioisotopes)', '12UHW9R67N (Isoflurophate)']",,Granulozytenkinetik mit radioaktivem Diisopropylfluorophosphat (DF32P),,,,,,,,,
4101121,NLM,MEDLINE,19710506,20071115,0323-4347 (Print) 0323-4347 (Linking),94,4,1970,[Distribution of haptoglobin types in leukemic patients].,309-13,,"['Gurda, M', 'Turowska, B']","['Gurda M', 'Turowska B']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adult', 'Child', 'Electrophoresis', 'Female', 'Gels', 'Haptoglobins/*analysis', 'Humans', 'Leukemia/*immunology', 'Leukemia, Lymphoid/immunology', 'Leukemia, Myeloid/immunology', 'Leukemia, Myeloid, Acute/immunology', 'Male', 'Starch']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(4):309-13.,"['0 (Gels)', '0 (Haptoglobins)', '9005-25-8 (Starch)']",,Die Verteilung der Haptoglobintypen bei Leukamiekranken.,,,,,,,,,
4101120,NLM,MEDLINE,19710506,20071115,0323-4347 (Print) 0323-4347 (Linking),94,4,1970,[Distribution of the ABO and Rh-D systems in leukemic patients].,303-8,,"['Gurda, M', 'Turowska, B']","['Gurda M', 'Turowska B']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['*ABO Blood-Group System', 'Humans', 'Leukemia/*immunology', 'Leukemia, Lymphoid/immunology', 'Leukemia, Myeloid/immunology', 'Leukemia, Myeloid, Acute/immunology', '*Rh-Hr Blood-Group System']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(4):303-8.,"['0 (ABO Blood-Group System)', '0 (Rh-Hr Blood-Group System)']",,Verteilung des ABO- und Rh D-Systems bei Kranken mit Leukamien.,,,,,,,,,
4101119,NLM,MEDLINE,19710506,20041117,0323-4347 (Print) 0323-4347 (Linking),94,4,1970,"[Serological modifications of blood group antigens from human blood cells in malignant diseases. Causes, serological character and meaning].",281-302,,"['Majsky, A']",['Majsky A'],['ger'],"['Journal Article', 'Review']",Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['ABO Blood-Group System', 'Animals', 'Antineoplastic Agents/pharmacology', '*Blood Group Antigens/drug effects', 'Blood Platelets/immunology', 'Erythrocytes/immunology', 'Hemagglutination Tests', 'Histocompatibility', 'Humans', 'Immunogenetics', 'Isoantigens/*analysis', 'Leukemia/immunology', 'Leukocytes/immunology', 'Neoplasms/*immunology', 'Rabbits', 'Rh-Hr Blood-Group System', 'Transplantation Immunology']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(4):281-302.,"['0 (ABO Blood-Group System)', '0 (Antineoplastic Agents)', '0 (Blood Group Antigens)', '0 (Isoantigens)', '0 (Rh-Hr Blood-Group System)']",106,"Serologische Modifikationene der Blutgruppenantigene menschlicher Blutzellen bei malignen Erkrankungen. Grundlagen, serologischer Charakter und Bedeutung.",,,,,,,,,
4101092,NLM,MEDLINE,19710506,20210216,0006-4971 (Print) 0006-4971 (Linking),37,2,1971 Feb,Stimulation of DNA synthesis in vitro in mouse thymic cells by bone marrow preparation.,231-9,,"['Knyszynski, A', 'Burger, M']","['Knyszynski A', 'Burger M']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['Alpha-Globulins', 'Animals', '*Bone Marrow/drug effects/metabolism/radiation effects', 'Bone Marrow Cells', 'Carbon Isotopes', 'Carboxypeptidases/pharmacology', 'DNA/*biosynthesis', 'Deoxyribonucleases/pharmacology', 'Female', 'In Vitro Techniques', 'Kidney/cytology', 'Leucine/metabolism', 'Leukemia, Experimental/metabolism', 'Lymph Nodes/metabolism', 'Mice', 'Peptide Hydrolases/pharmacology', 'Radiation Effects', 'Ribonucleases/pharmacology', 'Spleen/cytology', 'Thymidine/metabolism', 'Thymus Gland/*cytology/metabolism', 'Tissue Extracts', 'Tritium']",,1971/02/01 00:00,1971/02/01 00:01,['1971/02/01 00:00'],"['1971/02/01 00:00 [pubmed]', '1971/02/01 00:01 [medline]', '1971/02/01 00:00 [entrez]']",['S0006-4971(20)69376-4 [pii]'],ppublish,Blood. 1971 Feb;37(2):231-9.,"['0 (Alpha-Globulins)', '0 (Carbon Isotopes)', '0 (Tissue Extracts)', '10028-17-8 (Tritium)', '9007-49-2 (DNA)', 'EC 3.1.- (Deoxyribonucleases)', 'EC 3.1.- (Ribonucleases)', 'EC 3.4.- (Carboxypeptidases)', 'EC 3.4.- (Peptide Hydrolases)', 'GMW67QNF9C (Leucine)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4101062,NLM,MEDLINE,19710505,20191021,,271,21,1970 Nov 23,[Increase in survival in acute lymphoblastic leukemia subjected to a protocol of polychemotherapy].,1919-21,,"['Bernard, J', 'Boiron, M', 'Jacquillat, C', 'Weil, M']","['Bernard J', 'Boiron M', 'Jacquillat C', 'Weil M']",['fre'],['Journal Article'],France,C R Acad Hebd Seances Acad Sci D,Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,7501107,IM,"['Adult', 'Antineoplastic Agents/*therapeutic use', 'Child', 'Humans', 'Leukemia, Lymphoid/drug therapy/*mortality', 'Mercaptopurine/administration & dosage', 'Methotrexate/administration & dosage', 'Palliative Care', 'Prednisone/administration & dosage', 'Prognosis', 'Vincristine/administration & dosage']",,1970/11/23 00:00,1970/11/23 00:01,['1970/11/23 00:00'],"['1970/11/23 00:00 [pubmed]', '1970/11/23 00:01 [medline]', '1970/11/23 00:00 [entrez]']",,ppublish,C R Acad Hebd Seances Acad Sci D. 1970 Nov 23;271(21):1919-21.,"['0 (Antineoplastic Agents)', '5J49Q6B70F (Vincristine)', 'E7WED276I5 (Mercaptopurine)', 'VB0R961HZT (Prednisone)', 'YL5FZ2Y5U1 (Methotrexate)']",,Augmentation de l'espoir de vie des leucemies aigues lymphoblastiques soumises a un protocole de polychimiotherapie.,,,,,,,,,
4100959,NLM,MEDLINE,19710503,20041117,0008-5472 (Print) 0008-5472 (Linking),30,4,1970 Apr,Ultrastructural and quantitative studies of mammary tumor virus production in cultured mouse mammary tumor cells.,1102-8,,"['Kramarsky, B', 'Lasfargues, E Y', 'Moore, D H']","['Kramarsky B', 'Lasfargues EY', 'Moore DH']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Binding Sites', 'Cell Line', '*Culture Techniques', 'Immune Sera', 'Leukemia Virus, Murine/immunology', 'Mammary Neoplasms, Experimental', '*Mammary Tumor Virus, Mouse/immunology', 'Methods', 'Mice', '*Microscopy, Electron', 'Rabbits', 'Staining and Labeling', 'Virus Cultivation', '*Virus Replication']",,1970/04/01 00:00,1970/04/01 00:01,['1970/04/01 00:00'],"['1970/04/01 00:00 [pubmed]', '1970/04/01 00:01 [medline]', '1970/04/01 00:00 [entrez]']",,ppublish,Cancer Res. 1970 Apr;30(4):1102-8.,['0 (Immune Sera)'],,,,,,,,,,,
4100824,NLM,MEDLINE,19710429,20191021,,271,22,1970 Nov 30,[The activity of chromatin of normal and leukemic leukocytes].,2070-3,,"['Brachet, J', 'Hulin, N', 'Masera, P', 'Pileri, A']","['Brachet J', 'Hulin N', 'Masera P', 'Pileri A']",['fre'],['Journal Article'],France,C R Acad Hebd Seances Acad Sci D,Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,7501107,IM,"['Autoradiography', '*Binding Sites', 'Cell Nucleus/metabolism', 'Chromosomes/*metabolism', 'DNA/*analysis', 'Dactinomycin/*metabolism', 'Humans', 'Kinetics', 'Leukemia/*metabolism', 'Leukemia, Lymphoid/metabolism', 'Leukemia, Myeloid, Acute/drug therapy/metabolism', 'Leukocytes/*metabolism', 'Methotrexate/therapeutic use', 'Staining and Labeling', 'Tritium']",,1970/11/30 00:00,1970/11/30 00:01,['1970/11/30 00:00'],"['1970/11/30 00:00 [pubmed]', '1970/11/30 00:01 [medline]', '1970/11/30 00:00 [entrez]']",,ppublish,C R Acad Hebd Seances Acad Sci D. 1970 Nov 30;271(22):2070-3.,"['10028-17-8 (Tritium)', '1CC1JFE158 (Dactinomycin)', '9007-49-2 (DNA)', 'YL5FZ2Y5U1 (Methotrexate)']",,L'activite de la chromatine des leucoytes normaux et leucemiques.,,,,,,,,,
4100730,NLM,MEDLINE,19710425,20071115,0023-6748 (Print) 0023-6748 (Linking),8,,1970,[Cytochemical studies of enzymes in leukocytes of patients with chronic lympholeukosis].,477-81,,"['Mikheeva, A I', 'Rutkovskii, V V', 'Kardos, V S', 'Klionskaia, A G', 'Magid, E M']","['Mikheeva AI', 'Rutkovskii VV', 'Kardos VS', 'Klionskaia AG', 'Magid EM']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Acid Phosphatase/blood', 'Alkaline Phosphatase/blood', 'Esterases/blood', 'Histocytochemistry', 'Humans', 'Leukemia, Lymphoid/*blood/drug therapy', 'Leukocytes/*enzymology', 'Male', 'Neutrophils/*enzymology', 'Steroids/*therapeutic use']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1970;8:477-81.,"['0 (Steroids)', 'EC 3.1.- (Esterases)', 'EC 3.1.3.1 (Alkaline Phosphatase)', 'EC 3.1.3.2 (Acid Phosphatase)']",,Tsitokhimicheskie issledovannia fermentov v leikotsitakh bol'nykh khronicheskim limfoleikozom.,,,,,,,,,
4100677,NLM,MEDLINE,19710422,20081121,0008-5472 (Print) 0008-5472 (Linking),31,3,1971 Mar,Polycation- treated tumor cells in vivo and in vitro.,373-80,,"['Moroson, H']",['Moroson H'],['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Amines/therapeutic use', 'Animals', 'Body Weight', 'Carcinoma, Ehrlich Tumor/*drug therapy', 'Cell Aggregation/drug effects', 'Cell Line', 'Chemical Phenomena', 'Chemistry', 'Culture Techniques', 'Electrolytes', 'Erythrocytes', 'Fibroblasts', 'HeLa Cells', 'Hydrogen-Ion Concentration', 'Imines/therapeutic use', 'Leukemia, Experimental/*drug therapy', 'Mice', 'Molecular Weight', 'Neoplasm Transplantation', 'Polyethylenes/therapeutic use', 'Polymers/*therapeutic use', 'Polyvinyls/therapeutic use', 'Radiation Effects', 'Staining and Labeling']",,1971/03/01 00:00,1971/03/01 00:01,['1971/03/01 00:00'],"['1971/03/01 00:00 [pubmed]', '1971/03/01 00:01 [medline]', '1971/03/01 00:00 [entrez]']",,ppublish,Cancer Res. 1971 Mar;31(3):373-80.,"['0 (Amines)', '0 (Electrolytes)', '0 (Imines)', '0 (Polyethylenes)', '0 (Polymers)', '0 (Polyvinyls)']",,,,,,,,,,,
4100669,NLM,MEDLINE,19710422,20051117,0005-2086 (Print) 0005-2086 (Linking),14,4,1970 Nov,The relation between infection of chickens with Marek's disease and the presence of precipitin antibodies.,723-37,,"['Bankowski, R A', 'Mikami, T', 'Reynolds, B']","['Bankowski RA', 'Mikami T', 'Reynolds B']",['eng'],['Journal Article'],United States,Avian Dis,Avian diseases,0370617,IM,"['Animals', 'Avian Leukosis/*immunology/microbiology', 'Blood/microbiology', '*Chickens', 'Culture Techniques', 'Female', 'Herpesviridae/isolation & purification', 'Immunity, Maternally-Acquired', 'Kidney/microbiology', 'Peripheral Nervous System Diseases/immunology/microbiology/veterinary', 'Poultry Diseases/*immunology/microbiology', 'Precipitins/*analysis', 'gamma-Globulins/analysis']",,1970/11/01 00:00,1970/11/01 00:01,['1970/11/01 00:00'],"['1970/11/01 00:00 [pubmed]', '1970/11/01 00:01 [medline]', '1970/11/01 00:00 [entrez]']",,ppublish,Avian Dis. 1970 Nov;14(4):723-37.,"['0 (Precipitins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4100623,NLM,MEDLINE,19710420,20081121,0025-8512 (Print) 0025-8512 (Linking),4,,1971 Jan 23,[Coagulation and immunoprotein changes under L-asparaginase therapy].,127-34,,"['Lechler, E', 'Schumacher, K', 'Hirschmann, W D']","['Lechler E', 'Schumacher K', 'Hirschmann WD']",['ger'],['Journal Article'],Germany,Med Welt,Die Medizinische Welt,0376641,IM,"['Adult', 'Asparaginase/*adverse effects', 'Blood Coagulation Disorders/*chemically induced', 'Blood Coagulation Factors/*analysis', 'Blood Proteins/*analysis', 'Chronic Disease', 'Female', 'Humans', 'Immunoglobulins/analysis', 'Leukemia/drug therapy', 'Male', 'Melanoma/drug therapy', 'Middle Aged', 'Primary Myelofibrosis/drug therapy', 'gamma-Globulins/*analysis']",,1971/01/23 00:00,1971/01/23 00:01,['1971/01/23 00:00'],"['1971/01/23 00:00 [pubmed]', '1971/01/23 00:01 [medline]', '1971/01/23 00:00 [entrez]']",,ppublish,Med Welt. 1971 Jan 23;4:127-34.,"['0 (Blood Coagulation Factors)', '0 (Blood Proteins)', '0 (Immunoglobulins)', '0 (gamma-Globulins)', 'EC 3.5.1.1 (Asparaginase)']",,Gerinnungs- und Immunproteinveranderungen unter L-Asparaginasetherapie.,,,,,,,,,
4100582,NLM,MEDLINE,19710415,20170214,0022-1554 (Print) 0022-1554 (Linking),18,12,1970 Dec,Studies of acid phosphatase isoenzymes in human leukocytes demonstration of isoenzyme cell specificity.,901-10,,"['Li, C Y', 'Yam, L T', 'Lam, K W']","['Li CY', 'Yam LT', 'Lam KW']",['eng'],['Journal Article'],United States,J Histochem Cytochem,The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,9815334,IM,"['Acid Phosphatase/*blood', 'Blood Platelets/enzymology', 'Bone Marrow/enzymology', 'Bone Marrow Cells', 'Chromatography, DEAE-Cellulose', 'Chromatography, Ion Exchange', 'Electrophoresis, Disc', 'Fluorides/pharmacology', 'Gaucher Disease/enzymology', 'Histocytochemistry', 'Humans', 'Isoenzymes/antagonists & inhibitors/*blood', 'Leukemia/blood/enzymology', 'Leukemia, Lymphoid/enzymology', 'Leukemia, Myeloid/enzymology', 'Leukemia, Myeloid, Acute/enzymology', 'Leukocytes/drug effects/*enzymology', 'Lymphatic Diseases/enzymology', 'Lymphocytes/enzymology', 'Lymphoma, Non-Hodgkin/enzymology', 'Molecular Weight', 'Monocytes/enzymology', 'Nitrophenols/pharmacology', 'Polycythemia Vera/enzymology', 'Staining and Labeling', 'Tartrates/pharmacology']",,1970/12/01 00:00,1970/12/01 00:01,['1970/12/01 00:00'],"['1970/12/01 00:00 [pubmed]', '1970/12/01 00:01 [medline]', '1970/12/01 00:00 [entrez]']",['10.1177/18.12.901 [doi]'],ppublish,J Histochem Cytochem. 1970 Dec;18(12):901-10. doi: 10.1177/18.12.901.,"['0 (Isoenzymes)', '0 (Nitrophenols)', '0 (Tartrates)', 'EC 3.1.3.2 (Acid Phosphatase)', 'Q80VPU408O (Fluorides)']",,,,,,,,,,,
4100552,NLM,MEDLINE,19710415,20190708,0020-7136 (Print) 0020-7136 (Linking),7,1,1971 Jan 15,"Malignant transformation inducedby 7,12-dimethylbenz(a)anthracene in rat embryo cells infected with Rauscher leukemia virus.",65-74,,"['Rhim, J S', 'Vass, W', 'Cho, H Y', 'Huebner, R J']","['Rhim JS', 'Vass W', 'Cho HY', 'Huebner RJ']",['eng'],['Journal Article'],United States,Int J Cancer,International journal of cancer,0042124,IM,"['Animals', 'Antigens', '*Benz(a)Anthracenes', 'Cell Transformation, Neoplastic/*chemically induced/immunology/pathology', 'Complement Fixation Tests', 'Culture Techniques', 'Embryo, Mammalian', 'Genetic Code', '*Leukemia, Experimental', 'Neoplasm Transplantation', 'RNA, Neoplasm', 'Rats', 'Rauscher Virus/immunology', 'Sarcoma, Experimental/etiology', 'Staining and Labeling']",,1971/01/15 00:00,1971/01/15 00:01,['1971/01/15 00:00'],"['1971/01/15 00:00 [pubmed]', '1971/01/15 00:01 [medline]', '1971/01/15 00:00 [entrez]']",['10.1002/ijc.2910070108 [doi]'],ppublish,Int J Cancer. 1971 Jan 15;7(1):65-74. doi: 10.1002/ijc.2910070108.,"['0 (Antigens)', '0 (Benz(a)Anthracenes)', '0 (RNA, Neoplasm)']",,,,,,,,,,,
4100531,NLM,MEDLINE,19710414,20190617,0028-0836 (Print) 0028-0836 (Linking),230,5290,1971 Mar 19,Distinguishing between the chromosomes involved in Down's syndrome (trisomy 21) and cronic myeloid leukaemia (Ph1) by fluorescence.,167-8,,"[""O'Riordan, M L"", 'Robinson, J A', 'Buckton, K E', 'Evans, H J']","[""O'Riordan ML"", 'Robinson JA', 'Buckton KE', 'Evans HJ']",['eng'],['Journal Article'],England,Nature,Nature,0410462,IM,"['Chromosomes/*analysis', '*Chromosomes, Human, 21-22 and Y', 'Down Syndrome/*genetics', 'Female', '*Fluorescent Dyes', 'Humans', 'Karyotyping', 'Lectins/pharmacology', 'Leukemia, Myeloid/*genetics', 'Leukocytes/cytology', 'Male', 'Methods', 'Microscopy, Fluorescence', '*Quinacrine', '*Staining and Labeling', '*Trisomy']",,1971/03/19 00:00,1971/03/19 00:01,['1971/03/19 00:00'],"['1971/03/19 00:00 [pubmed]', '1971/03/19 00:01 [medline]', '1971/03/19 00:00 [entrez]']",['10.1038/230167a0 [doi]'],ppublish,Nature. 1971 Mar 19;230(5290):167-8. doi: 10.1038/230167a0.,"['0 (Fluorescent Dyes)', '0 (Lectins)', 'H0C805XYDE (Quinacrine)']",,,,,,,,,,,
4100530,NLM,MEDLINE,19710414,20190617,0028-0836 (Print) 0028-0836 (Linking),230,5290,1971 Mar 19,Still more light on human chromosomes.,145,,,,['eng'],['Journal Article'],England,Nature,Nature,0410462,IM,"['Amniotic Fluid/cytology', 'Autoradiography', 'Cervix Mucus/cytology', 'Chromosomes, Human, 21-22 and Y', 'Cytogenetics', 'DNA/analysis', 'Down Syndrome/genetics', 'Female', '*Fluorescent Dyes', 'Humans', 'Leukemia, Myeloid/genetics', 'Methods', 'Pregnancy', '*Quinacrine', '*Sex Chromosomes', '*Staining and Labeling']",,1971/03/19 00:00,1971/03/19 00:01,['1971/03/19 00:00'],"['1971/03/19 00:00 [pubmed]', '1971/03/19 00:01 [medline]', '1971/03/19 00:00 [entrez]']",['10.1038/230145a0 [doi]'],ppublish,Nature. 1971 Mar 19;230(5290):145. doi: 10.1038/230145a0.,"['0 (Fluorescent Dyes)', '9007-49-2 (DNA)', 'H0C805XYDE (Quinacrine)']",,,,,,,,,,,
4100526,NLM,MEDLINE,19710414,20171116,0021-2180 (Print) 0021-2180 (Linking),7,1,1971 Jan,Basic proteins and synthetic polynucleotides as modifiers of immunogenicity of syngeneic tumor cells.,72-82,,"['Braun, W', 'Plescia, O J', 'Raskova, J', 'Webb, D']","['Braun W', 'Plescia OJ', 'Raskova J', 'Webb D']",['eng'],['Journal Article'],Israel,Isr J Med Sci,Israel journal of medical sciences,0013105,IM,"['Animals', 'Antibody Formation/*drug effects', 'Cattle', 'Cell Line', 'Complement Fixation Tests', 'DNA/pharmacology', 'Female', 'Immunity/*drug effects', 'Immunity, Cellular/drug effects', 'Immunization', 'Leukemia, Experimental/immunology', 'Male', 'Mice', 'Neoplasm Recurrence, Local', 'Neoplasm Transplantation', 'Neoplasms, Experimental/*immunology', 'Polynucleotides/*pharmacology', 'Sarcoma, Experimental/immunology', 'Serum Albumin, Bovine', 'Vaccination', 'gamma-Globulins']",,1971/01/01 00:00,1971/01/01 00:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '1971/01/01 00:01 [medline]', '1971/01/01 00:00 [entrez]']",,ppublish,Isr J Med Sci. 1971 Jan;7(1):72-82.,"['0 (Polynucleotides)', '0 (gamma-Globulins)', '27432CM55Q (Serum Albumin, Bovine)', '9007-49-2 (DNA)']",,,,,,,,,,,
4100502,NLM,MEDLINE,19710413,20190616,0077-8923 (Print) 0077-8923 (Linking),174,2,1970 Oct 30,"Morphological, biological, and immunological studies on isolates form tumors and leukemic bloods.",690-728,,"['Seibert, F B', 'Feldmann, F M', 'Davis, R L', 'Richmond, I S']","['Seibert FB', 'Feldmann FM', 'Davis RL', 'Richmond IS']",['eng'],['Journal Article'],United States,Ann N Y Acad Sci,Annals of the New York Academy of Sciences,7506858,IM,"['Agglutination Tests', 'Animals', 'Antibodies', 'Bacteria/growth & development/immunology/*isolation & purification', 'Fluorescent Antibody Technique', 'Humans', 'Immune Sera', 'Leukemia/blood/immunology/*microbiology', 'Mice', 'Microscopy, Electron', 'Neoplasms/immunology/*microbiology', 'Precipitin Tests', 'Rabbits', 'Staining and Labeling']",,1970/10/30 00:00,1970/10/30 00:01,['1970/10/30 00:00'],"['1970/10/30 00:00 [pubmed]', '1970/10/30 00:01 [medline]', '1970/10/30 00:00 [entrez]']",['10.1111/j.1749-6632.1970.tb45591.x [doi]'],ppublish,Ann N Y Acad Sci. 1970 Oct 30;174(2):690-728. doi: 10.1111/j.1749-6632.1970.tb45591.x.,"['0 (Antibodies)', '0 (Immune Sera)']",,,,,,,,,,,
4100352,NLM,MEDLINE,19710331,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7697,1971 Mar 6,Myelomonocytic leukaemia supervening on chronic lymphocytic leukaemia.,478-9,,"['Catovsky, D', 'Galton, D A']","['Catovsky D', 'Galton DA']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Chlorambucil/*adverse effects', 'Cyclophosphamide/adverse effects']",,1971/03/06 00:00,1971/03/06 00:01,['1971/03/06 00:00'],"['1971/03/06 00:00 [pubmed]', '1971/03/06 00:01 [medline]', '1971/03/06 00:00 [entrez]']",['10.1016/s0140-6736(71)91091-9 [doi]'],ppublish,Lancet. 1971 Mar 6;1(7697):478-9. doi: 10.1016/s0140-6736(71)91091-9.,"['18D0SL7309 (Chlorambucil)', '8N3DW7272P (Cyclophosphamide)']",,,,,,,,,,,
4100233,NLM,MEDLINE,19710324,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7695,1971 Feb 20,Measles and leukaemia.,397-8,,"['Gross, S']",['Gross S'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adjuvants, Immunologic', 'Child, Preschool', 'Humans']",,1971/02/20 00:00,1971/02/20 00:01,['1971/02/20 00:00'],"['1971/02/20 00:00 [pubmed]', '1971/02/20 00:01 [medline]', '1971/02/20 00:00 [entrez]']","['S0140-6736(71)92232-X [pii]', '10.1016/s0140-6736(71)92232-x [doi]']",ppublish,Lancet. 1971 Feb 20;1(7695):397-8. doi: 10.1016/s0140-6736(71)92232-x.,"['0 (Adjuvants, Immunologic)']",,,,,,,,,,,
4100196,NLM,MEDLINE,19710324,20131121,0323-4347 (Print) 0323-4347 (Linking),94,3,1970,[Effect of heterologous specific leukemia antibodies in vivo in human myeloses].,235-40,,"['Janele, J', 'Sekla, B', 'Holeckova, E']","['Janele J', 'Sekla B', 'Holeckova E']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adolescent', 'Adrenal Cortex Hormones/therapeutic use', '*Antibodies', 'Antigens', 'Busulfan/therapeutic use', 'Desensitization, Immunologic', 'Humans']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(3):235-40.,"['0 (Adrenal Cortex Hormones)', '0 (Antibodies)', '0 (Antigens)', 'G1LN9045DK (Busulfan)']",,Der Einfluss von heterologen spezifischen leukamischen Antikorpern in vivo bei Myelosen des Menschen.,,,,,,,,,
4100182,NLM,MEDLINE,19710320,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7694,1971 Feb 13,Poland's syndrome and leukaemia.,349-50,,"['Boaz, D', 'Mace, J W', 'Gotlin, R W']","['Boaz D', 'Mace JW', 'Gotlin RW']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Humans']",,1971/02/13 00:00,1971/02/13 00:01,['1971/02/13 00:00'],"['1971/02/13 00:00 [pubmed]', '1971/02/13 00:01 [medline]', '1971/02/13 00:00 [entrez]']","['S0140-6736(71)91077-4 [pii]', '10.1016/s0140-6736(71)91077-4 [doi]']",ppublish,Lancet. 1971 Feb 13;1(7694):349-50. doi: 10.1016/s0140-6736(71)91077-4.,,,,,,,,,,,,
4100012,NLM,MEDLINE,19710312,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7693,1971 Feb 6,Leukaemic transformation of engrafted human marrow cells in vivo.,251-5,,"['Fialkow, P J', 'Thomas, E D', 'Bryant, J I', 'Neiman, P E']","['Fialkow PJ', 'Thomas ED', 'Bryant JI', 'Neiman PE']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Antineoplastic Agents/therapeutic use', 'Biopsy', 'Blood Cell Count', 'Blood Cells/cytology', '*Bone Marrow', '*Bone Marrow Cells', '*Bone Marrow Transplantation', '*Cell Transformation, Neoplastic', 'Child', 'Chromosome Aberrations', 'Chromosomes/radiation effects', 'Female', 'Graft vs Host Reaction', 'Histocompatibility Testing', 'Humans', 'Karyotyping', 'Lectins/pharmacology', 'Leukemia, Lymphoid/genetics/*pathology/radiotherapy', 'Leukocyte Count', 'Male', 'Mitosis', 'Radiation Effects', 'Retroviridae', 'Sex Chromatin', 'Thymidine', 'Tissue Donors', 'Transplantation, Homologous', 'Tritium']",,1971/02/06 00:00,1971/02/06 00:01,['1971/02/06 00:00'],"['1971/02/06 00:00 [pubmed]', '1971/02/06 00:01 [medline]', '1971/02/06 00:00 [entrez]']","['S0140-6736(71)90998-6 [pii]', '10.1016/s0140-6736(71)90998-6 [doi]']",ppublish,Lancet. 1971 Feb 6;1(7693):251-5. doi: 10.1016/s0140-6736(71)90998-6.,"['0 (Antineoplastic Agents)', '0 (Lectins)', '10028-17-8 (Tritium)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4100001,NLM,MEDLINE,19710312,20071115,0023-6748 (Print) 0023-6748 (Linking),8,,1970,[Cytochemical and biochemical properties of leukocytes from patients with lympholeukosis].,473-7,,"['Morozova, V T', 'Shevchenko, N G', 'Trusova, N F', 'Bektemirov, T A', 'Fedorova, Iu B']","['Morozova VT', 'Shevchenko NG', 'Trusova NF', 'Bektemirov TA', 'Fedorova IuB']",['rus'],['Journal Article'],Russia (Federation),Lab Delo,Laboratornoe delo,18230140R,IM,"['Histocytochemistry', 'Humans', 'Interferons/biosynthesis', 'Leukemia, Lymphoid/*blood', 'Leukocytes/*analysis/enzymology/metabolism']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Lab Delo. 1970;8:473-7.,['9008-11-1 (Interferons)'],,Nekotorye tsitokhimicheskie i biokhimicheskie osobennosti leikotsitov bol'nykh limfoleikozom.,,,,,,,,,
4099980,NLM,MEDLINE,19710312,20031114,0065-1281 (Print) 0065-1281 (Linking),37,2,1970,Identification of the nucleic acid of mouse mammary tumor virus (MTV) using fluorescence microscopy.,323-9,,"['el-Fiky, S M', 'Sarkar, N H', 'Moore, D H']","['el-Fiky SM', 'Sarkar NH', 'Moore DH']",['eng'],['Journal Article'],Germany,Acta Histochem,Acta histochemica,0370320,IM,"['*Acridines', 'Animals', 'Deoxyribonucleases', 'Histocytochemistry', 'Leukemia Virus, Murine', 'Mammary Tumor Virus, Mouse/*analysis', 'Methods', 'Mice', 'Microscopy, Fluorescence', 'Milk/microbiology', 'Orthomyxoviridae', 'Pepsin A', 'RNA, Viral/*analysis', 'Rauscher Virus', 'Reoviridae', 'Ribonucleases', '*Staining and Labeling', 'Vaccinia virus']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Acta Histochem. 1970;37(2):323-9.,"['0 (Acridines)', '0 (RNA, Viral)', 'EC 3.1.- (Deoxyribonucleases)', 'EC 3.1.- (Ribonucleases)', 'EC 3.4.23.1 (Pepsin A)']",,,,,,,,,,,
4099974,NLM,MEDLINE,19710312,20071115,0029-4810 (Print) 0029-4810 (Linking),10,4,1970 Jul-Aug,[Prognostic value of the initial hemogram and myelogram in chronic lymphocytic leukemia (statistical study of 310 cases by an acturarial method)].,566-75,,"['Coeur, P', 'Gentilhomme, O', 'Morel, P', 'Germain, D']","['Coeur P', 'Gentilhomme O', 'Morel P', 'Germain D']",['fre'],['Journal Article'],France,Nouv Rev Fr Hematol,Nouvelle revue francaise d'hematologie,0401074,IM,"['Alpha-Globulins/analysis', 'Anemia/complications', '*Bone Marrow Examination', 'Hemolysis', 'Humans', 'Leukemia', 'Leukemia, Lymphoid/*blood/complications/*mortality', 'Leukocytosis/complications', 'Prognosis', 'Thrombocytopenia/complications']",,1970/07/01 00:00,1970/07/01 00:01,['1970/07/01 00:00'],"['1970/07/01 00:00 [pubmed]', '1970/07/01 00:01 [medline]', '1970/07/01 00:00 [entrez]']",,ppublish,Nouv Rev Fr Hematol. 1970 Jul-Aug;10(4):566-75.,['0 (Alpha-Globulins)'],,Valeur pronostique de l'hemogramme et de myelogramme initial dans la leucemie lymphoide chronique (etude statistique de 310 observations par la methode actuarielle),,,,,,,,,
4099973,NLM,MEDLINE,19710312,20161122,0029-4810 (Print) 0029-4810 (Linking),10,4,1970 Jul-Aug,[Cytochemical and chromosomal studies in hemopathies. I. Chronic myelocytic leukemia].,535-40,,"['Grozdea, J', 'Colombies, P', 'Bierme, R', 'Ducos, J', 'Kessous, A']","['Grozdea J', 'Colombies P', 'Bierme R', 'Ducos J', 'Kessous A']",['fre'],['Journal Article'],France,Nouv Rev Fr Hematol,Nouvelle revue francaise d'hematologie,0401074,IM,"['*Chromosome Aberrations', '*Chromosome Disorders', 'Cytodiagnosis', 'Histocytochemistry', 'Humans', 'Karyotyping', 'Leukemia, Myeloid/*diagnosis/enzymology/*genetics/pathology', 'Methods', 'Neutrophils/*cytology/enzymology', 'Peroxidases/blood', 'Phosphoric Monoester Hydrolases/blood', 'Staining and Labeling']",,1970/07/01 00:00,1970/07/01 00:01,['1970/07/01 00:00'],"['1970/07/01 00:00 [pubmed]', '1970/07/01 00:01 [medline]', '1970/07/01 00:00 [entrez]']",,ppublish,Nouv Rev Fr Hematol. 1970 Jul-Aug;10(4):535-40.,"['EC 1.11.1.- (Peroxidases)', 'EC 3.1.3.2 (Phosphoric Monoester Hydrolases)']",,Etudes cytochimiques et chromosomiques dans le cadre des hemopathies. I. La leucemie myeloide chronique.,,,,,,,,,
4099903,NLM,MEDLINE,19710309,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7692,1971 Jan 30,B.C.G. vaccination and leukemia mortality.,241,,"['Berkeley, J S']",['Berkeley JS'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', '*BCG Vaccine', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Leukemia/*mortality', 'Scotland']",,1971/01/30 00:00,1971/01/30 00:01,['1971/01/30 00:00'],"['1971/01/30 00:00 [pubmed]', '1971/01/30 00:01 [medline]', '1971/01/30 00:00 [entrez]']","['S0140-6736(71)90982-2 [pii]', '10.1016/s0140-6736(71)90982-2 [doi]']",ppublish,Lancet. 1971 Jan 30;1(7692):241. doi: 10.1016/s0140-6736(71)90982-2.,['0 (BCG Vaccine)'],,,,,,,,,,,
4099849,NLM,MEDLINE,19710308,20191030,0031-2959 (Print) 0031-2959 (Linking),36,3,1970,Growth of vesicular somatitis virus in human myeloblasts.,161-72,,"['Baumberger, U']",['Baumberger U'],['eng'],['Journal Article'],Switzerland,Pathol Microbiol (Basel),Pathologia et microbiologia,0401122,IM,"['Animals', 'Cell Line', 'Chick Embryo', '*Culture Techniques', 'Cytopathogenic Effect, Viral', 'Humans', 'Immune Sera', 'Leukemia, Lymphoid/blood', 'Leukemia, Myeloid/blood', 'Leukemia, Myeloid, Acute/blood', 'Leukocytes/*microbiology', 'Lung', 'Neutralization Tests', 'Rabbits', 'Staining and Labeling', 'Vesicular stomatitis Indiana virus/*growth & development/immunology/pathogenicity', 'Virus Cultivation']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",['10.1159/000162444 [doi]'],ppublish,Pathol Microbiol (Basel). 1970;36(3):161-72. doi: 10.1159/000162444.,['0 (Immune Sera)'],,,,,,,,,,,
4099624,NLM,MEDLINE,19710227,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7690,1971 Jan 16,Possible effect of measles on leukaemia.,136,,"['Pasquinucci, G']",['Pasquinucci G'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Child, Preschool', 'Female', 'Humans', '*Leukemia, Lymphoid', 'Male', '*Measles', 'Neoplasm Regression, Spontaneous', 'Rubella', 'Viral Interference']",,1971/01/16 00:00,1971/01/16 00:01,['1971/01/16 00:00'],"['1971/01/16 00:00 [pubmed]', '1971/01/16 00:01 [medline]', '1971/01/16 00:00 [entrez]']",['10.1016/s0140-6736(71)90869-5 [doi]'],ppublish,Lancet. 1971 Jan 16;1(7690):136. doi: 10.1016/s0140-6736(71)90869-5.,,,,,,,,,,,,
4099446,NLM,MEDLINE,19710224,20071115,0020-9554 (Print) 0020-9554 (Linking),11,11,1970 Nov,[Cytology of serous cavities].,401-12,,"['Zach, J']",['Zach J'],['ger'],['Journal Article'],Germany,Internist (Berl),Der Internist,0264620,IM,"['Acute Disease', 'Bronchial Neoplasms/diagnosis', '*Cytodiagnosis', 'Empyema/diagnosis', 'Empyema, Tuberculous/diagnosis', 'Eosinophils', 'Exudates and Transudates/*cytology', 'Female', 'Hemangioendothelioma/diagnosis', 'Hodgkin Disease/diagnosis', 'Humans', 'Leukemia/diagnosis', 'Leukemia, Lymphoid/diagnosis', 'Leukemia, Myeloid/diagnosis', 'Lupus Erythematosus, Systemic/diagnosis', 'Lymphoma, Follicular/diagnosis', 'Melanoma/diagnosis', 'Mesothelioma/diagnosis', 'Neoplasms/*diagnosis', 'Neutrophils', 'Ovarian Neoplasms/diagnosis', 'Pancreatitis/diagnosis', 'Pericardial Effusion/cytology/*diagnosis', 'Pleural Diseases/diagnosis', 'Pleural Effusion/cytology/*diagnosis', 'Pleural Neoplasms/diagnosis', 'Pleurisy/diagnosis']",,1970/11/01 00:00,1970/11/01 00:01,['1970/11/01 00:00'],"['1970/11/01 00:00 [pubmed]', '1970/11/01 00:01 [medline]', '1970/11/01 00:00 [entrez]']",,ppublish,Internist (Berl). 1970 Nov;11(11):401-12.,,,Die Cytologie der serosen Hohlen.,,,,,,,,,
4099408,NLM,MEDLINE,19710224,20210216,0006-4971 (Print) 0006-4971 (Linking),37,1,1971 Jan,Serum vitamin B12-binding capacity and muramidase changes with cyclic neutropenia induced by cytosine arabinoside.,31-9,,"['Carmel, R', 'Coltman, C A Jr']","['Carmel R', 'Coltman CA Jr']",['eng'],['Journal Article'],United States,Blood,Blood,7603509,IM,"['Adult', 'Agranulocytosis/*blood/chemically induced/enzymology', 'Alpha-Globulins/metabolism', 'Beta-Globulins/metabolism', 'Blood Cell Count', 'Blood Protein Electrophoresis', 'Bone Marrow Examination', 'Cobalt Isotopes', 'Cytarabine/*pharmacology/therapeutic use', 'Humans', 'Leukemia, Monocytic, Acute/blood/drug therapy', 'Leukemia, Myeloid, Acute/drug therapy', 'Male', 'Muramidase/*blood', 'Periodicity', 'Protein Binding', 'Vitamin B 12/*blood']",,1971/01/01 00:00,2001/03/28 10:01,['1971/01/01 00:00'],"['1971/01/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1971/01/01 00:00 [entrez]']",['S0006-4971(20)69507-6 [pii]'],ppublish,Blood. 1971 Jan;37(1):31-9.,"['0 (Alpha-Globulins)', '0 (Beta-Globulins)', '0 (Cobalt Isotopes)', '04079A1RDZ (Cytarabine)', 'EC 3.2.1.17 (Muramidase)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4099400,NLM,MEDLINE,19710223,20191030,0012-1037 (Print) 0012-1037 (Linking),198,1,1970,Demyelinative lesions in spinal cord of mouse following neonatal thymectomy. An electron microscopic study.,93-104,,"['Field, E J', 'Peat, A']","['Field EJ', 'Peat A']",['eng'],['Journal Article'],Germany,Z Neurol,Zeitschrift fur Neurologie,0424070,IM,"['Animals', 'Animals, Newborn', 'Demyelinating Diseases/*physiopathology', 'Leukemia Virus, Murine', 'Mice', 'Microscopy, Electron', 'Spinal Cord/*physiopathology', 'Thymectomy', 'Thymus Gland/*physiology']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",['10.1007/BF00316138 [doi]'],ppublish,Z Neurol. 1970;198(1):93-104. doi: 10.1007/BF00316138.,,,,,,,,,,,,
4099322,NLM,MEDLINE,19710223,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7688,1971 Jan 2,Bone-marrow transplantation: unexpected results.,26,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['ABO Blood-Group System', 'Antibody Specificity', 'Antigens/analysis', '*Bone Marrow Transplantation', 'Graft vs Host Reaction', 'Histocompatibility Testing', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leukemia, Lymphoid/therapy', 'Lymphocytes/immunology', 'Transplantation Immunology', 'Transplantation, Homologous']",,1971/01/02 00:00,1971/01/02 00:01,['1971/01/02 00:00'],"['1971/01/02 00:00 [pubmed]', '1971/01/02 00:01 [medline]', '1971/01/02 00:00 [entrez]']",['S0140-6736(71)80018-1 [pii]'],ppublish,Lancet. 1971 Jan 2;1(7688):26.,"['0 (ABO Blood-Group System)', '0 (Antigens)', '0 (Immunosuppressive Agents)']",,,,,,,,,,,
4099259,NLM,MEDLINE,19710211,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7689,1971 Jan 9,Lymphoma and malaria.,87,,"['Raafat, F']",['Raafat F'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Child', 'Humans', 'Leukemia, Lymphoid/complications', 'Lymphoma/*complications', 'Malaria/*complications']",,1971/01/09 00:00,1971/01/09 00:01,['1971/01/09 00:00'],"['1971/01/09 00:00 [pubmed]', '1971/01/09 00:01 [medline]', '1971/01/09 00:00 [entrez]']","['S0140-6736(71)90823-3 [pii]', '10.1016/s0140-6736(71)90823-3 [doi]']",ppublish,Lancet. 1971 Jan 9;1(7689):87. doi: 10.1016/s0140-6736(71)90823-3.,,,,,,,,,,,,
4099240,NLM,MEDLINE,19710211,20190611,0140-6736 (Print) 0140-6736 (Linking),1,7689,1971 Jan 9,B.C.G. vaccination and leukaemia mortality.,80-1,,"['Davignon, L', 'Lemonde, P', 'St-Pierre, J', 'Frappier, A']","['Davignon L', 'Lemonde P', 'St-Pierre J', 'Frappier A']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', '*BCG Vaccine', 'Canada', 'Child', 'Child, Preschool', 'Epidemiologic Methods', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*mortality', 'Medical Records']",,1971/01/09 00:00,1971/01/09 00:01,['1971/01/09 00:00'],"['1971/01/09 00:00 [pubmed]', '1971/01/09 00:01 [medline]', '1971/01/09 00:00 [entrez]']","['S0140-6736(71)92049-6 [pii]', '10.1016/s0140-6736(71)90804-x [doi]']",ppublish,Lancet. 1971 Jan 9;1(7689):80-1. doi: 10.1016/s0140-6736(71)90804-x.,['0 (BCG Vaccine)'],,,,,,,,,,,
4099223,NLM,MEDLINE,19710211,20150616,0140-6736 (Print) 0140-6736 (Linking),1,7689,1971 Jan 9,Leukaemia and cytotoxic drugs.,70-1,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Alkylating Agents/*adverse effects', 'Female', 'Humans', 'Leukemia/*chemically induced', 'Melphalan/adverse effects', 'Multiple Myeloma/drug therapy', 'Thiotepa/adverse effects']",,1971/01/09 00:00,1971/01/09 00:01,['1971/01/09 00:00'],"['1971/01/09 00:00 [pubmed]', '1971/01/09 00:01 [medline]', '1971/01/09 00:00 [entrez]']",,ppublish,Lancet. 1971 Jan 9;1(7689):70-1.,"['0 (Alkylating Agents)', '905Z5W3GKH (Thiotepa)', 'Q41OR9510P (Melphalan)']",,,,,,,,,,,
4099080,NLM,MEDLINE,19710209,20190714,0042-6822 (Print) 0042-6822 (Linking),42,4,1970 Dec,Plaque assay techniques for murine leukemia viruses.,1136-9,,"['Rowe, W P', 'Pugh, W E', 'Hartley, J W']","['Rowe WP', 'Pugh WE', 'Hartley JW']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Cell Line', '*Culture Techniques', 'Leukemia Virus, Murine/*growth & development', 'Methods', 'Mice', 'Neoplasms', 'Rats', 'Staining and Labeling', 'Ultraviolet Rays', '*Virus Cultivation']",,1970/12/01 00:00,1970/12/01 00:01,['1970/12/01 00:00'],"['1970/12/01 00:00 [pubmed]', '1970/12/01 00:01 [medline]', '1970/12/01 00:00 [entrez]']",['10.1016/0042-6822(70)90362-4 [doi]'],ppublish,Virology. 1970 Dec;42(4):1136-9. doi: 10.1016/0042-6822(70)90362-4.,,,,,,,,,,,,
4098946,NLM,MEDLINE,19710204,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7687,1970 Dec 26,Leukaemia or megaloblastic anaemia?,1367-8,,"['Hamblin, T J']",['Hamblin TJ'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Anemia, Macrocytic/*diagnosis', 'Diagnosis, Differential', 'Humans', 'Leukemia/*diagnosis']",,1970/12/26 00:00,1970/12/26 00:01,['1970/12/26 00:00'],"['1970/12/26 00:00 [pubmed]', '1970/12/26 00:01 [medline]', '1970/12/26 00:00 [entrez]']","['S0140-6736(70)92400-1 [pii]', '10.1016/s0140-6736(70)92400-1 [doi]']",ppublish,Lancet. 1970 Dec 26;2(7687):1367-8. doi: 10.1016/s0140-6736(70)92400-1.,,,,,,,,,,,,
4098859,NLM,MEDLINE,19710204,20041117,0020-9554 (Print) 0020-9554 (Linking),8,7,1967 Jul,[Radiotherapy of inflammatory and degenerative joint diseases].,253-8,,"['Stender, H S', 'Berndt, G']","['Stender HS', 'Berndt G']",['ger'],['Journal Article'],Germany,Internist (Berl),Der Internist,0264620,IM,"['Animals', 'Arthritis/*radiotherapy', 'Arthritis, Rheumatoid/radiotherapy', 'Humans', 'Joint Diseases/*radiotherapy', 'Leukemia, Radiation-Induced/etiology', 'Periarthritis/radiotherapy', 'Prognosis', 'Radiotherapy/adverse effects', 'Rats', 'Reflex Sympathetic Dystrophy/radiotherapy', 'Rheumatic Fever/radiotherapy', 'Spondylitis, Ankylosing/radiotherapy', 'Time Factors']",,1967/07/01 00:00,1967/07/01 00:01,['1967/07/01 00:00'],"['1967/07/01 00:00 [pubmed]', '1967/07/01 00:01 [medline]', '1967/07/01 00:00 [entrez]']",,ppublish,Internist (Berl). 1967 Jul;8(7):253-8.,,,Die Strahlentherapie entzundlicher und degenerativer Gelenkerkrankungen.,,,,,,,,,
4098812,NLM,MEDLINE,19710202,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7686,1970 Dec 19,Werner's syndrome.,1317,,"['Stecker, E', 'Gardner, H A']","['Stecker E', 'Gardner HA']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Aneuploidy', 'Autopsy', 'Chromosome Aberrations', 'Connective Tissue/metabolism', 'Diabetes Complications', 'Female', 'Humans', 'Karyotyping', 'Leukemia, Myeloid/complications/pathology', 'Skin/analysis', '*Werner Syndrome/complications']",,1970/12/19 00:00,1970/12/19 00:01,['1970/12/19 00:00'],"['1970/12/19 00:00 [pubmed]', '1970/12/19 00:01 [medline]', '1970/12/19 00:00 [entrez]']",['10.1016/s0140-6736(70)92284-1 [doi]'],ppublish,Lancet. 1970 Dec 19;2(7686):1317. doi: 10.1016/s0140-6736(70)92284-1.,,,,,,,,,,,,
4098805,NLM,MEDLINE,19710202,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7686,1970 Dec 19,B.C.G. and leukaemia mortality.,1314,,"['Waaler, H T']",['Waaler HT'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', '*BCG Vaccine', 'Child', 'Child, Preschool', 'Denmark', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*mortality/prevention & control', 'Norway', 'Sweden']",,1970/12/19 00:00,1970/12/19 00:01,['1970/12/19 00:00'],"['1970/12/19 00:00 [pubmed]', '1970/12/19 00:01 [medline]', '1970/12/19 00:00 [entrez]']",['10.1016/s0140-6736(70)92276-2 [doi]'],ppublish,Lancet. 1970 Dec 19;2(7686):1314. doi: 10.1016/s0140-6736(70)92276-2.,['0 (BCG Vaccine)'],,,,,,,,,,,
4098549,NLM,MEDLINE,19710121,20141120,0552-2080 (Print) 0552-2080 (Linking),15,7,1970 Jul,[Functional-morphologic characteristics of lymphocytes (review of the literature)].,41-6,,"['Kozinets, G I']",['Kozinets GI'],['rus'],"['Journal Article', 'Review']",Russia (Federation),Probl Gematol Pereliv Krovi,Problemy gematologii i perelivaniia krovi,0401232,IM,"['Animals', 'Antilymphocyte Serum/pharmacology', 'Cell Division', 'DNA/biosynthesis', 'Histocytochemistry', 'Hodgkin Disease/blood', 'In Vitro Techniques', 'Infectious Mononucleosis/blood', 'Karyometry', 'Lectins/pharmacology', 'Leukemia, Lymphoid/metabolism', 'Lymphocyte Activation', 'Lymphocytes/analysis/*cytology/drug effects/metabolism/*physiology', 'Microscopy, Electron', 'RNA/biosynthesis', 'Rats', 'Waldenstrom Macroglobulinemia/blood', 'gamma-Globulins/biosynthesis']",,1970/07/01 00:00,1970/07/01 00:01,['1970/07/01 00:00'],"['1970/07/01 00:00 [pubmed]', '1970/07/01 00:01 [medline]', '1970/07/01 00:00 [entrez]']",,ppublish,Probl Gematol Pereliv Krovi. 1970 Jul;15(7):41-6.,"['0 (Antilymphocyte Serum)', '0 (Lectins)', '0 (gamma-Globulins)', '63231-63-0 (RNA)', '9007-49-2 (DNA)']",100,Funktsional'no-morfologicheskaia kharakteristika limfotsitov (obzor literatury),,,,,,,,,
4098491,NLM,MEDLINE,19710115,20190619,0008-543X (Print) 0008-543X (Linking),26,6,1970 Dec,Leukemic infiltration of the prostate: a reversible form of urinary obstruction.,1361-5,,"['Mitch, W E Jr', 'Serpick, A A']","['Mitch WE Jr', 'Serpick AA']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Humans', 'Leukemia/*complications', 'Leukemia, Monocytic, Acute/*complications', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Prostatic Hyperplasia/complications/*etiology/pathology/radiotherapy/surgery', '*Prostatic Neoplasms', 'Urinary Incontinence/etiology']",,1970/12/01 00:00,2001/03/28 10:01,['1970/12/01 00:00'],"['1970/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1970/12/01 00:00 [entrez]']",['10.1002/1097-0142(197012)26:6<1361::aid-cncr2820260625>3.0.co;2-f [doi]'],ppublish,Cancer. 1970 Dec;26(6):1361-5. doi: 10.1002/1097-0142(197012)26:6<1361::aid-cncr2820260625>3.0.co;2-f.,,,,,,,,,,,,
4098463,NLM,MEDLINE,19710115,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7684,1970 Dec 5,Prenatal radiation exposure and childhood cancer.,1189-90,,"['Burch, P R', 'Stewart, A M', 'Kneale, G W']","['Burch PR', 'Stewart AM', 'Kneale GW']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Brain Neoplasms/etiology', 'Child', 'Child, Preschool', 'Female', 'Fetus/*radiation effects', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/etiology', 'Leukemia, Radiation-Induced', '*Neoplasms, Radiation-Induced', 'Neuroblastoma/etiology', 'Pregnancy', '*Radiation Effects', 'Wilms Tumor/etiology']",,1970/12/05 00:00,1970/12/05 00:01,['1970/12/05 00:00'],"['1970/12/05 00:00 [pubmed]', '1970/12/05 00:01 [medline]', '1970/12/05 00:00 [entrez]']","['S0140-6736(70)90376-4 [pii]', '10.1016/s0140-6736(70)90376-4 [doi]']",ppublish,Lancet. 1970 Dec 5;2(7684):1189-90. doi: 10.1016/s0140-6736(70)90376-4.,,,,,,,,,,,,
4098350,NLM,MEDLINE,19710115,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7682,1970 Nov 21,Graft-versus-host reaction complicating HL-A matched bone-marrow transplantation.,1053-5,,"['Graw, R G Jr', 'Rogentine, G N Jr', 'Leventhal, B G', 'Halterman, R H', 'Berard, C', 'Herzig, G P', 'Yankee, R A', 'Whang-Peng, J', 'Kruger, G', 'Henderson, E S']","['Graw RG Jr', 'Rogentine GN Jr', 'Leventhal BG', 'Halterman RH', 'Berard C', 'Herzig GP', 'Yankee RA', 'Whang-Peng J', 'Kruger G', 'Henderson ES']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Adult', 'Antigen-Antibody Reactions', 'Biopsy', 'Blood Group Incompatibility', 'Blood Transfusion', '*Bone Marrow Transplantation', 'Child', 'Female', '*Graft vs Host Reaction', 'Histocompatibility Testing', 'Humans', 'Leukemia, Lymphoid/immunology/*therapy', 'Male', 'Skin Manifestations', 'Tissue Donors', 'Transplantation Immunology', 'Transplantation, Homologous']",,1970/11/21 00:00,2001/03/28 10:01,['1970/11/21 00:00'],"['1970/11/21 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1970/11/21 00:00 [entrez]']","['S0140-6736(70)90285-0 [pii]', '10.1016/s0140-6736(70)90285-0 [doi]']",ppublish,Lancet. 1970 Nov 21;2(7682):1053-5. doi: 10.1016/s0140-6736(70)90285-0.,,,,,,,,,,,,
4098312,NLM,MEDLINE,19710113,20191030,0079-6263 (Print) 0079-6263 (Linking),13,,1970,Immunopathology and neoplasms in New Zealand black (NZB) and SJL-J mice.,84-134,,"['East, J']",['East J'],['eng'],"['Journal Article', 'Review']",Switzerland,Prog Exp Tumor Res,Progress in experimental tumor research,0376446,IM,"['Anemia, Hemolytic, Autoimmune/*immunology', 'Animals', 'Antibodies, Antinuclear/analysis', 'Antibody Formation', 'Antilymphocyte Serum/pharmacology', 'Autoantibodies/analysis', 'Complement System Proteins', 'Coombs Test', 'Erythrocytes/immunology', 'Immunity, Cellular', 'Immunity, Maternally-Acquired', 'Immunization, Passive', 'Immunoglobulins/analysis', 'Kidney/pathology', 'Leukemia, Lymphoid/immunology', 'Macroglobulins/analysis', 'Mice/*immunology', 'Neoplasm Transplantation', 'Neoplasms/*immunology', 'Oncogenic Viruses/immunology', 'Radiation Chimera', 'Spleen/immunology', 'Thymectomy', 'Thymus Gland/immunology', 'gamma-Globulins/analysis']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",['10.1159/000386038 [doi]'],ppublish,Prog Exp Tumor Res. 1970;13:84-134. doi: 10.1159/000386038.,"['0 (Antibodies, Antinuclear)', '0 (Antilymphocyte Serum)', '0 (Autoantibodies)', '0 (Immunoglobulins)', '0 (Macroglobulins)', '0 (gamma-Globulins)', '9007-36-7 (Complement System Proteins)']",0,,,,,,,,,,
4098102,NLM,MEDLINE,19710109,20210526,0003-6919 (Print) 0003-6919 (Linking),20,2,1970 Aug,Rapid semiquantitative method for screening large numbers of virus samples by negative staining electron microscopy.,259-62,"A rapid, semiquantitative method for screening large numbers of virus samples by negative staining electron microscopy is presented. Results obtained by this method are compared with results obtained by the pseudoreplica method and a measureddrop method. A figure is presented which represents the limit of detectability for virus by negative staining.","['Monroe, J H', 'Brandt, P M']","['Monroe JH', 'Brandt PM']",['eng'],"['Comparative Study', 'Journal Article']",United States,Appl Microbiol,Applied microbiology,7605802,IM,"['Herpesviridae/*isolation & purification', 'Herpesvirus 4, Human/isolation & purification', 'Latex', 'Leukemia Virus, Murine/*isolation & purification', 'Methods', '*Microscopy, Electron', 'Microspheres', 'Phosphotungstic Acid', 'Rauscher Virus/isolation & purification', 'Serum Albumin, Bovine', 'Simplexvirus/isolation & purification', '*Staining and Labeling']",PMC376912,1970/08/01 00:00,1970/08/01 00:01,['1970/08/01 00:00'],"['1970/08/01 00:00 [pubmed]', '1970/08/01 00:01 [medline]', '1970/08/01 00:00 [entrez]']",['10.1128/am.20.2.259-262.1970 [doi]'],ppublish,Appl Microbiol. 1970 Aug;20(2):259-62. doi: 10.1128/am.20.2.259-262.1970.,"['0 (Latex)', '12067-99-1 (Phosphotungstic Acid)', '27432CM55Q (Serum Albumin, Bovine)']",,,,,,,,,,,
4098077,NLM,MEDLINE,19710108,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7681,1970 Nov 14,Acute erythromegakaryocytic leukaemia after treatment with cytostatic agents.,1037,,"['Garfield, D H']",['Garfield DH'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adenocarcinoma/drug therapy', 'Aged', 'Bone Marrow Diseases/chemically induced', '*Erythrocytes', 'Humans', 'Leukemia/*chemically induced/drug therapy', 'Lung Neoplasms/drug therapy', 'Male', '*Megakaryocytes', 'Mercaptopurine/therapeutic use', 'Middle Aged', 'Thiotepa/*adverse effects', 'Thrombocythemia, Essential/*chemically induced']",,1970/11/14 00:00,1970/11/14 00:01,['1970/11/14 00:00'],"['1970/11/14 00:00 [pubmed]', '1970/11/14 00:01 [medline]', '1970/11/14 00:00 [entrez]']",['10.1016/s0140-6736(70)92855-2 [doi]'],ppublish,Lancet. 1970 Nov 14;2(7681):1037. doi: 10.1016/s0140-6736(70)92855-2.,"['905Z5W3GKH (Thiotepa)', 'E7WED276I5 (Mercaptopurine)']",,,,,,,,,,,
4097913,NLM,MEDLINE,19710106,20170920,0140-6736 (Print) 0140-6736 (Linking),2,7683,1970 Nov 28,Malaria and lymphoma.,1121-2,,,,['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Animals', 'Antibody Formation', 'Antigen-Antibody Reactions', 'Burkitt Lymphoma/immunology', 'Chronic Disease', 'Immune Tolerance', 'Immunity, Cellular', 'Lymphoid Tissue/analysis', 'Lymphoma/*etiology', 'Malaria/*complications/immunology', 'Mice', 'Moloney murine leukemia virus/pathogenicity', 'Plasmodium/pathogenicity', 'Plasmodium malariae/analysis', 'Time Factors']",,1970/11/28 00:00,1970/11/28 00:01,['1970/11/28 00:00'],"['1970/11/28 00:00 [pubmed]', '1970/11/28 00:01 [medline]', '1970/11/28 00:00 [entrez]']",['S0140-6736(70)92304-4 [pii]'],ppublish,Lancet. 1970 Nov 28;2(7683):1121-2.,,,,,,,,,,,,
4097911,NLM,MEDLINE,19710106,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7683,1970 Nov 28,Prolonged intermittent cytotoxic therapy in children using a microinfusion pump.,1116-7,,"['Mann, J R', 'Abrams, L D', 'Deeble, T J', 'Stuart, J']","['Mann JR', 'Abrams LD', 'Deeble TJ', 'Stuart J']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Antineoplastic Agents/*administration & dosage', 'Catheterization/instrumentation', 'Child, Preschool', 'Humans', 'Injections, Intravenous/*instrumentation', 'Leukemia, Lymphoid/drug therapy/immunology', 'Methods', 'Time Factors']",,1970/11/28 00:00,1970/11/28 00:01,['1970/11/28 00:00'],"['1970/11/28 00:00 [pubmed]', '1970/11/28 00:01 [medline]', '1970/11/28 00:00 [entrez]']","['S0140-6736(70)92301-9 [pii]', '10.1016/s0140-6736(70)92301-9 [doi]']",ppublish,Lancet. 1970 Nov 28;2(7683):1116-7. doi: 10.1016/s0140-6736(70)92301-9.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4097910,NLM,MEDLINE,19710106,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7683,1970 Nov 28,Effect of concurrent malarial infection on development of virus-induced lymphoma in Balb-c mice.,1114-6,,"['Wedderburn, N']",['Wedderburn N'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Age Factors', 'Animals', 'Autoimmune Diseases', 'Burkitt Lymphoma/etiology/immunology', 'Herpesvirus 4, Human/pathogenicity', 'Humans', 'Lymphoma/*etiology/immunology', 'Malaria/*complications/immunology', 'Mice', 'Moloney murine leukemia virus/pathogenicity', 'Neoplasms, Experimental', 'Oncogenic Viruses/pathogenicity', 'Plasmodium/pathogenicity', 'Thymoma/complications/immunology', 'Thymus Neoplasms/complications/immunology', 'Time Factors']",,1970/11/28 00:00,1970/11/28 00:01,['1970/11/28 00:00'],"['1970/11/28 00:00 [pubmed]', '1970/11/28 00:01 [medline]', '1970/11/28 00:00 [entrez]']","['S0140-6736(70)92300-7 [pii]', '10.1016/s0140-6736(70)92300-7 [doi]']",ppublish,Lancet. 1970 Nov 28;2(7683):1114-6. doi: 10.1016/s0140-6736(70)92300-7.,,,,,,,,,,,,
4097895,NLM,MEDLINE,19710106,20051117,0026-8526 (Print) 0026-8526 (Linking),7,3,1970 May,Factors predisposing to illness.,531-8,,"['Utz, J P']",['Utz JP'],['eng'],"['Journal Article', 'Review']",United States,Mod Treat,Modern treatment,7511504,IM,"['Adrenal Cortex Hormones/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anuria/complications', 'Diabetes Complications', 'Humans', 'Immunosuppressive Agents/adverse effects', 'Kidney Failure, Chronic/complications', 'Leukemia/complications', 'Leukopenia/complications', 'Lung Diseases/complications', 'Lymphoma/complications', 'Mycoses/*etiology', 'Radiotherapy/adverse effects', 'gamma-Globulins/analysis']",,1970/05/01 00:00,1970/05/01 00:01,['1970/05/01 00:00'],"['1970/05/01 00:00 [pubmed]', '1970/05/01 00:01 [medline]', '1970/05/01 00:00 [entrez]']",,ppublish,Mod Treat. 1970 May;7(3):531-8.,"['0 (Adrenal Cortex Hormones)', '0 (Anti-Bacterial Agents)', '0 (Immunosuppressive Agents)', '0 (gamma-Globulins)']",18,,,,,,,,,,
4097840,NLM,MEDLINE,19701231,20210313,0025-729X (Print) 0025-729X (Linking),2,15,1970 Oct 10,Trends in immunological therapy.,683-8,,"['Simons, M J']",['Simons MJ'],['eng'],"['Journal Article', 'Review']",Australia,Med J Aust,The Medical journal of Australia,0400714,IM,"['Autoimmune Diseases/drug therapy', 'Humans', 'Immunity, Cellular', 'Immunoglobulins/therapeutic use', 'Immunologic Deficiency Syndromes/*drug therapy', 'Immunosuppressive Agents/*therapeutic use', 'Leukemia/drug therapy', 'Lymphoma/drug therapy', 'gamma-Globulins/*therapeutic use']",,1970/10/10 00:00,1970/10/10 00:01,['1970/10/10 00:00'],"['1970/10/10 00:00 [pubmed]', '1970/10/10 00:01 [medline]', '1970/10/10 00:00 [entrez]']",['10.5694/j.1326-5377.1970.tb63112.x [doi]'],ppublish,Med J Aust. 1970 Oct 10;2(15):683-8. doi: 10.5694/j.1326-5377.1970.tb63112.x.,"['0 (Immunoglobulins)', '0 (Immunosuppressive Agents)', '0 (gamma-Globulins)']",54,,,,,,,,,,
4097804,NLM,MEDLINE,19701228,20190501,1468-2044 (Electronic) 0003-9888 (Linking),45,243,1970 Oct,Immunological studies in acute leukaemia.,709-10,,"['Sutton, R H']",['Sutton RH'],['eng'],['Journal Article'],England,Arch Dis Child,Archives of disease in childhood,0372434,IM,"['Acute Disease', 'Child', 'Herpesviridae Infections/complications', 'Humans', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/etiology/genetics/*immunology', 'gamma-Globulins/*analysis']",PMC1647518,1970/10/01 00:00,1970/10/01 00:01,['1970/10/01 00:00'],"['1970/10/01 00:00 [pubmed]', '1970/10/01 00:01 [medline]', '1970/10/01 00:00 [entrez]']",['10.1136/adc.45.243.709-f [doi]'],ppublish,Arch Dis Child. 1970 Oct;45(243):709-10. doi: 10.1136/adc.45.243.709-f.,"['0 (Immunoglobulin G)', '0 (Immunoglobulin M)', '0 (Immunoglobulins)', '0 (gamma-Globulins)']",,,,,,,,,,,
4097793,NLM,MEDLINE,19701223,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7678,1970 Oct 24,Dermatoglyphics in leukaemia.,882-3,,"['Rosner, F']",['Rosner F'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Dermatoglyphics', 'Female', 'Humans', 'Leukemia/*diagnosis', 'Leukemia, Lymphoid/diagnosis', 'Leukemia, Monocytic, Acute/diagnosis', 'Leukemia, Myeloid/diagnosis', 'Male', 'Sex Factors']",,1970/10/24 00:00,1970/10/24 00:01,['1970/10/24 00:00'],"['1970/10/24 00:00 [pubmed]', '1970/10/24 00:01 [medline]', '1970/10/24 00:00 [entrez]']","['S0140-6736(70)92059-3 [pii]', '10.1016/s0140-6736(70)92059-3 [doi]']",ppublish,Lancet. 1970 Oct 24;2(7678):882-3. doi: 10.1016/s0140-6736(70)92059-3.,,,,,,,,,,,,
4097711,NLM,MEDLINE,19701222,20041117,0098-6151 (Print) 0098-6151 (Linking),70,2,1970 Oct,Aberrant nuclear division configurations occurring in the bone marrow of cancer patients.,114-22,,"['Perencevich, E N']",['Perencevich EN'],['eng'],['Journal Article'],United States,J Am Osteopath Assoc,The Journal of the American Osteopathic Association,7503065,IM,"['*Bone Marrow', '*Bone Marrow Cells', 'Bone Marrow Diseases/diagnosis', '*Cell Nucleus', 'Chromosome Aberrations', 'Humans', 'Leukemia/diagnosis', 'Lymphoma/diagnosis', 'Neoplasms/*diagnosis/pathology', '*Staining and Labeling']",,1970/10/01 00:00,1970/10/01 00:01,['1970/10/01 00:00'],"['1970/10/01 00:00 [pubmed]', '1970/10/01 00:01 [medline]', '1970/10/01 00:00 [entrez]']",,ppublish,J Am Osteopath Assoc. 1970 Oct;70(2):114-22.,,,,,,,,,,,,
4097627,NLM,MEDLINE,19701213,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7680,1970 Nov 7,B.C.G. vaccination and leukaemia mortality.,983-4,,"['Stewart, A M', 'Draper, G J']","['Stewart AM', 'Draper GJ']",['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adolescent', 'Age Factors', '*BCG Vaccine', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Leukemia/epidemiology/*mortality', 'Quebec']",,1970/11/07 00:00,1970/11/07 00:01,['1970/11/07 00:00'],"['1970/11/07 00:00 [pubmed]', '1970/11/07 00:01 [medline]', '1970/11/07 00:00 [entrez]']","['S0140-6736(70)92162-8 [pii]', '10.1016/s0140-6736(70)92162-8 [doi]']",ppublish,Lancet. 1970 Nov 7;2(7680):983-4. doi: 10.1016/s0140-6736(70)92162-8.,['0 (BCG Vaccine)'],,,,,,,,,,,
4097614,NLM,MEDLINE,19701213,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7680,1970 Nov 7,Working with human cell lines.,978-9,,"['Moore, G']",['Moore G'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['Adult', 'Antibodies/analysis', 'Cell Line', '*Culture Techniques', 'Female', 'Herpesviridae/immunology', 'Humans', 'Laboratory Infection/prevention & control', 'Leukemia, Myeloid/epidemiology', 'Lymphocytes', 'Male', 'Occupational Diseases/epidemiology/*etiology/prevention & control', 'Pregnancy']",,1970/11/07 00:00,1970/11/07 00:01,['1970/11/07 00:00'],"['1970/11/07 00:00 [pubmed]', '1970/11/07 00:01 [medline]', '1970/11/07 00:00 [entrez]']","['S0140-6736(70)92149-5 [pii]', '10.1016/s0140-6736(70)92149-5 [doi]']",ppublish,Lancet. 1970 Nov 7;2(7680):978-9. doi: 10.1016/s0140-6736(70)92149-5.,['0 (Antibodies)'],,,,,,,,,,,
4097582,NLM,MEDLINE,19701213,20141120,0003-911X (Print) 0003-911X (Linking),34,2,1969,The cellular pattern of organs from mice with leukemia induced by the Graffi virus in in vitro cultures.,156-64,,"['Niezabitowski, A']",['Niezabitowski A'],['eng'],['Journal Article'],Germany,Arch Geschwulstforsch,Archiv fur Geschwulstforschung,0372411,IM,"['Animals', 'Bacteriological Techniques', 'Bone Marrow Cells', 'Cell Transformation, Neoplastic', 'Culture Techniques', 'Leukemia, Experimental/etiology/*pathology', 'Lymph Nodes/pathology', 'Mice', 'Neoplasms, Experimental/immunology', 'Organ Culture Techniques', 'Organ Specificity', '*Retroviridae', 'Splenic Neoplasms/pathology', 'Staining and Labeling', 'Thymus Neoplasms/pathology']",,1969/01/01 00:00,1969/01/01 00:01,['1969/01/01 00:00'],"['1969/01/01 00:00 [pubmed]', '1969/01/01 00:01 [medline]', '1969/01/01 00:00 [entrez]']",,ppublish,Arch Geschwulstforsch. 1969;34(2):156-64.,,,,,,,,,,,,
4097402,NLM,MEDLINE,19701210,20071115,0003-956X (Print) 0003-956X (Linking),24,3,1968,[In vitro formation of immunoglobulins by lymphocytes and plasma cells].,277-87,,"['van Furth, R']",['van Furth R'],['dut'],['Journal Article'],Belgium,Arch Belg Dermatol Syphiligr,Archives belges de dermatologie et de syphiligraphie,0412670,IM,"['Agammaglobulinemia/immunology', 'Culture Techniques', 'Digestive System/immunology', 'Humans', 'Immunoglobulins/biosynthesis', 'Leukemia, Lymphoid/immunology', 'Lymphatic Diseases/immunology', 'Lymphocytes/*immunology', 'Lymphoid Tissue/immunology', 'Plasma Cells/*immunology', 'Respiratory System/immunology', 'Rubella/immunology', 'Skin/immunology', 'gamma-Globulins/*biosynthesis']",,1968/01/01 00:00,1968/01/01 00:01,['1968/01/01 00:00'],"['1968/01/01 00:00 [pubmed]', '1968/01/01 00:01 [medline]', '1968/01/01 00:00 [entrez]']",,ppublish,Arch Belg Dermatol Syphiligr. 1968;24(3):277-87.,"['0 (Immunoglobulins)', '0 (gamma-Globulins)']",,In vitro vorming van immuunglobulinen door lymfocyten en plasmacellen.,,,,,,,,,
4097372,NLM,MEDLINE,19701209,20071115,0323-4347 (Print) 0323-4347 (Linking),94,1,1970,[Determination of antibodies against various blastic type cells in acute infantile leukemias in contact persons using indirect immunofluorescence methods].,31-40,,"['Zintl, F', 'Aurich, G', 'Plenert, W']","['Zintl F', 'Aurich G', 'Plenert W']",['ger'],['Journal Article'],Germany,Folia Haematol Int Mag Klin Morphol Blutforsch,"Folia haematologica (Leipzig, Germany : 1928)",0374615,IM,"['Adult', '*Antibody Formation', 'Antigens/analysis', 'Child, Preschool', 'Female', 'Fluorescent Antibody Technique', 'Humans', 'Immunodiffusion', 'Infant', 'Leukemia, Lymphoid/*immunology', 'Leukemia, Monocytic, Acute/*immunology', 'Leukemia, Myeloid, Acute/*immunology', 'Male', 'Nursing Staff, Hospital']",,1970/01/01 00:00,1970/01/01 00:01,['1970/01/01 00:00'],"['1970/01/01 00:00 [pubmed]', '1970/01/01 00:01 [medline]', '1970/01/01 00:00 [entrez]']",,ppublish,Folia Haematol Int Mag Klin Morphol Blutforsch. 1970;94(1):31-40.,['0 (Antigens)'],,Vorlaufige Mitteilung uber den Nachweis von Antikorpern bei Kontaktpersonen gegen verschiedene Blastentypen der akuten kindlichen Leukosen mit Hilfe der indirekten Immunofluoreszenzmethode.,,,,,,,,,
4097317,NLM,MEDLINE,19701206,20190611,0140-6736 (Print) 0140-6736 (Linking),2,7679,1970 Oct 31,Dermatoglyphics in leukaemia.,934,,"['Verbov, J']",['Verbov J'],['eng'],['Journal Article'],England,Lancet,"Lancet (London, England)",2985213R,IM,"['*Dermatoglyphics', 'Humans', '*Leukemia']",,1970/10/31 00:00,1970/10/31 00:01,['1970/10/31 00:00'],"['1970/10/31 00:00 [pubmed]', '1970/10/31 00:01 [medline]', '1970/10/31 00:00 [entrez]']",['10.1016/s0140-6736(70)92111-2 [doi]'],ppublish,Lancet. 1970 Oct 31;2(7679):934. doi: 10.1016/s0140-6736(70)92111-2.,,,,,,,,,,,,
4097256,NLM,MEDLINE,19701206,20071115,0017-6575 (Print) 0017-6575 (Linking),12,3,1969 Jul-Dec,[Therapy of chronic lymphocytic leukemia].,711-42,,"['Marmont, A']",['Marmont A'],['ita'],['Journal Article'],Italy,Haematol Lat,Haematologica Latina,0373001,IM,"['Adrenal Cortex Hormones/therapeutic use', 'Alkylating Agents/therapeutic use', 'Antibody Formation', 'Antilymphocyte Serum/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Cerebrospinal Fluid/microbiology', 'Cesium Isotopes/therapeutic use', 'Cobalt Isotopes/therapeutic use', 'Histoplasma/isolation & purification', 'Humans', 'Leukemia, Lymphoid/classification/*drug therapy/immunology/physiopathology/radiotherapy', 'Radioisotope Teletherapy', 'Spleen/pathology', 'Thoracic Duct/*immunology', 'gamma-Globulins/analysis/therapeutic use']",,1969/07/01 00:00,1969/07/01 00:01,['1969/07/01 00:00'],"['1969/07/01 00:00 [pubmed]', '1969/07/01 00:01 [medline]', '1969/07/01 00:00 [entrez]']",,ppublish,Haematol Lat. 1969 Jul-Dec;12(3):711-42.,"['0 (Adrenal Cortex Hormones)', '0 (Alkylating Agents)', '0 (Antilymphocyte Serum)', '0 (Antineoplastic Agents)', '0 (Cesium Isotopes)', '0 (Cobalt Isotopes)', '0 (gamma-Globulins)']",,La terapia della leucemia linfatica cronica.,,,,,,,,,
4097050,NLM,MEDLINE,19701127,20131121,0026-4806 (Print) 0026-4806 (Linking),61,37,1970 May 19,[Observations on the terminal course of chronic myeloid leukemia treated by alkylating agents (busulfan)].,2038-41,,"['Giovanelli, E']",['Giovanelli E'],['ita'],['Journal Article'],Italy,Minerva Med,Minerva medica,0400732,IM,"['Adult', 'Aged', 'Busulfan/*therapeutic use', 'Female', 'Humans', 'Leukemia, Myeloid/blood/*drug therapy', 'Male', 'Middle Aged', 'Palliative Care']",,1970/05/19 00:00,1970/05/19 00:01,['1970/05/19 00:00'],"['1970/05/19 00:00 [pubmed]', '1970/05/19 00:01 [medline]', '1970/05/19 00:00 [entrez]']",,ppublish,Minerva Med. 1970 May 19;61(37):2038-41.,['G1LN9045DK (Busulfan)'],,Osservazioni sulla fase terminale della leucemia mieloide cronica trattata con agenti alchilanti (busulfan),,,,,,,,,
4096900,NLM,MEDLINE,19860514,20190613,0006-2960 (Print) 0006-2960 (Linking),24,5,1985 Feb 26,Effects of DNA binding proteins on DNA methylation in vitro.,1193-6,"The inheritance of DNA methylation patterns may play an important role in the stability of the differentiated state. We have therefore studied the inhibitory effects of DNA binding proteins on DNA methylation in vitro. Mouse L1210 cells grown in the presence of 5-azacytidine acquire hemimethylated sites in their DNA. Purified hemimethylated DNA accepted methyl groups from S-adenosyl-L-methionine in the presence of a crude maintenance methylase more readily than purified DNA isolated from cells not exposed to 5-azacytidine. On the other hand, chromatin fractions isolated from cells grown in the presence or absence of 5-azacytidine were poor substrates for the maintenance methylase irrespective of the number of hemimethylated sites present in the DNA. Inhibition of DNA methylation was shown to be associated primarily with chromatin proteins bound to DNA, and trypsinization of nuclei increased their methyl accepting abilities. Methyl acceptance was increased by salt extraction of chromosomal proteins. These data suggest that association of histones with DNA may play a role in the modulation of methylation patterns.","['Kautiainen, T L', 'Jones, P A']","['Kautiainen TL', 'Jones PA']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Biochemistry,Biochemistry,0370623,IM,"['Animals', 'Cell Nucleus/metabolism', 'Chromatin/metabolism', 'DNA, Neoplasm/*metabolism', 'DNA-Binding Proteins/*metabolism', 'Histones/isolation & purification', 'Leukemia L1210/metabolism', 'Methylation', 'Mice', 'S-Adenosylmethionine/metabolism', 'Tritium']",,1985/02/26 00:00,1985/02/26 00:01,['1985/02/26 00:00'],"['1985/02/26 00:00 [pubmed]', '1985/02/26 00:01 [medline]', '1985/02/26 00:00 [entrez]']",['10.1021/bi00326a021 [doi]'],ppublish,Biochemistry. 1985 Feb 26;24(5):1193-6. doi: 10.1021/bi00326a021.,"['0 (Chromatin)', '0 (DNA, Neoplasm)', '0 (DNA-Binding Proteins)', '0 (Histones)', '10028-17-8 (Tritium)', '7LP2MPO46S (S-Adenosylmethionine)']",,,['GM30892/GM/NIGMS NIH HHS/United States'],,,,,,,,
4096684,NLM,MEDLINE,19860409,20151119,0391-7258 (Print) 0391-7258 (Linking),29,4,1985,"Inhibition of mitosis by avarol, a natural product isolated from the sponge Dysidea avara.",321-30,"Avarol, a sesquiterpenoid hydroquinone, is a cytostatic agent, isolated from the sponge Dysidea avara. Autoradiographic studies show that in vivo (L5178y mouse lymphoma cells) avarol changes the labelling index in favour of the fraction of unlabelled cells (from 1.24 to 1.04). At concentrations below the 50% inhibition dose, the mitotic index increases from 6.5 +/- 0.5 to 10.4 +/- 0.8; at higher concentrations the formation of mitotic figures is almost completely suppressed. In vitro studies applying the methods of viscosimetry and electron microscopy demonstrate that avarol inhibits assembly of brain microtubule protein at an at least stoichiometric concentration ratio. Moreover, evidence is presented that the new antimitotic agent avarol inhibits protofilament elongation rather than lateral association of tubulin during protofilament formation. The results suggest that avarol interferes with polymerization of tubulin both in interphase and during mitosis.","['Muller, W E', 'Dogovic, N', 'Zahn, R K', 'Maidhof, A', 'Diehl-Seifert, B', 'Becker, C', 'Sachsse, W', 'Gasic, M J', 'Schroder, H C']","['Muller WE', 'Dogovic N', 'Zahn RK', 'Maidhof A', 'Diehl-Seifert B', 'Becker C', 'Sachsse W', 'Gasic MJ', 'Schroder HC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Italy,Basic Appl Histochem,Basic and applied histochemistry,7910664,IM,"['Animals', 'Cell Division/drug effects', 'Chromosomes/drug effects', 'Growth Inhibitors/*pharmacology', 'Leukemia L5178/pathology', 'Mice', 'Microtubule Proteins/metabolism', 'Mitosis/*drug effects', 'Mitotic Index/drug effects', 'Porifera', 'Sesquiterpenes/*pharmacology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Basic Appl Histochem. 1985;29(4):321-30.,"['0 (Growth Inhibitors)', '0 (Microtubule Proteins)', '0 (Sesquiterpenes)', 'KZX416VN2B (avarol)']",,,,,,,,,,,
4095742,NLM,MEDLINE,19860407,20131121,0371-3822 (Print) 0371-3822 (Linking),80,,1985,The leukaemogenic dose from 224Ra in male CBA mice.,83-7,,"['Humphreys, E R', 'Papworth, D G', 'Stones, V A']","['Humphreys ER', 'Papworth DG', 'Stones VA']",['eng'],['Journal Article'],Germany,Strahlentherapie Sonderb,Strahlentherapie. Sonderbande,0404544,IM,"['Animals', 'Dose-Response Relationship, Radiation', 'Femur/radiation effects', 'Hematopoietic Stem Cells/radiation effects', 'Leukemia, Radiation-Induced/*etiology', 'Male', 'Mice', 'Mice, Inbred CBA', '*Radium', 'Thorium']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Strahlentherapie Sonderb. 1985;80:83-7.,"['13233-32-4 (thorium X)', '60YU5MIG9W (Thorium)', 'W90AYD6R3Q (Radium)']",,,,,,,,,,,
4095735,NLM,MEDLINE,19860407,20131121,0371-3822 (Print) 0371-3822 (Linking),80,,1985,224Ra: risk to bone and haematopoietic tissue in ankylosing spondylitis patients.,38-44,,"['Wick, R R', 'Chmelevsky, D', 'Gossner, W']","['Wick RR', 'Chmelevsky D', 'Gossner W']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Strahlentherapie Sonderb,Strahlentherapie. Sonderbande,0404544,IM,"['Bone Neoplasms/*epidemiology/etiology', 'Female', 'Follow-Up Studies', 'Germany, West', 'Humans', 'Leukemia, Radiation-Induced/*epidemiology', 'Male', 'Neoplasms, Radiation-Induced/*epidemiology', 'Radiation Dosage', 'Radium/*adverse effects/therapeutic use', 'Risk', 'Spondylitis, Ankylosing/*radiotherapy', 'Thorium', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Strahlentherapie Sonderb. 1985;80:38-44.,"['13233-32-4 (thorium X)', '60YU5MIG9W (Thorium)', 'W90AYD6R3Q (Radium)']",,,,,,,,,,,
4095718,NLM,MEDLINE,19860407,20131121,0371-3822 (Print) 0371-3822 (Linking),80,,1985,Report on the German Thorotrast Study.,114-8,,"['van Kaick, G', 'Muth, H', 'Kaul, A', 'Wesch, H', 'Immich, H', 'Liebermann, D', 'Lorenz, D', 'Lorenz, W J', 'Luhrs, H', 'Scheer, K E']","['van Kaick G', 'Muth H', 'Kaul A', 'Wesch H', 'Immich H', 'Liebermann D', 'Lorenz D', 'Lorenz WJ', 'Luhrs H', 'Scheer KE', 'et al.']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Strahlentherapie Sonderb,Strahlentherapie. Sonderbande,0404544,IM,"['Female', 'Follow-Up Studies', 'Germany, West', 'Humans', 'Leukemia, Radiation-Induced/epidemiology/etiology', 'Liver Neoplasms/epidemiology/etiology', 'Male', 'Neoplasms, Radiation-Induced/*epidemiology', 'Radiation Dosage', 'Risk', 'Thorium Dioxide/*adverse effects']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Strahlentherapie Sonderb. 1985;80:114-8.,['9XA7X17UQC (Thorium Dioxide)'],,,,,,,,,,,
4095697,NLM,MEDLINE,19860331,20080324,0376-7442 (Print) 0376-7442 (Linking),53,6,1985 Dec,[The decline in mortality in leukemia and malignant tumors in children].,221-4,"This study is an analysis of the mortality, due to malignant tumours and leukemia in Dutch children (0-14 years), based on data obtained from the 'Centraal Bureau voor de Statistiek' (Netherlands Central Bureau of Statistics). In the period 1971-1983, this mortality showed a gradual decrease. The mortality of leukemia and lymphomas, which contribute about 50% of all childhood cancer, contributed a major part to this decrease. The solid tumours have also shown a decrease in mortality. The registered mortality of brain tumours increased. The decrease in mortality had already begun before the centralization of treatment had been started in 1974/'75. Detailed research into the influence of centralization on mortality is required. The authors also recommend research into the apparent increase in mortality of brain tumours.","['Hermans, M D', 'Koot, R A']","['Hermans MD', 'Koot RA']",['dut'],"['English Abstract', 'Journal Article']",Netherlands,Tijdschr Kindergeneeskd,Tijdschrift voor kindergeneeskunde,7704039,IM,"['Adolescent', 'Brain Neoplasms/mortality', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Leukemia/*mortality', 'Lymphoma/mortality', 'Neoplasms/*mortality', 'Netherlands']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Tijdschr Kindergeneeskd. 1985 Dec;53(6):221-4.,,,De afname van de mortaliteit aan leukemie en maligne tumoren bij kinderen.,,,,,,,,,
4095607,NLM,MEDLINE,19860418,20131121,0125-1562 (Print) 0125-1562 (Linking),16,3,1985 Sep,Therapy related acute non-lymphocytic leukemia: report of 4 cases.,421-30,"Four cases of acute myelodysplastic-non-lymphocytic leukemia secondary to cytotoxic agents were reported. Primary diseases were breast cancer (1 patient), ovarian cancer (2 patients) and multiple myeloma (1 patient). All except one (with multiple myeloma) were in clinical remission of their primary diseases. Common cytotoxic agent used was melphalan. Median total drug dose and median latent period from diagnosis of primary diseases were 1299 mg and 63 months respectively. None with the exception of one received specific treatment. All died except one who is in a very poor condition. Survival from the diagnosis of hematologic diseases ranged from 3-9 months. Clinical features, cytogenetic findings, pathogenetic mechanism and risk of the disease were briefly discussed.","['Atichartakarn, V', 'Punyammalee, B', 'Nitiyanant, P']","['Atichartakarn V', 'Punyammalee B', 'Nitiyanant P']",['eng'],"['Case Reports', 'Journal Article']",Thailand,Southeast Asian J Trop Med Public Health,The Southeast Asian journal of tropical medicine and public health,0266303,IM,"['Acute Disease', 'Adult', 'Breast Neoplasms/therapy', 'Chromosome Aberrations', 'Female', 'Humans', 'Leukemia/*etiology/mortality', 'Leukemia, Radiation-Induced/etiology', 'Melphalan/*adverse effects', 'Middle Aged', 'Multiple Myeloma/therapy', 'Ovarian Neoplasms/therapy', 'Radiotherapy/*adverse effects']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Southeast Asian J Trop Med Public Health. 1985 Sep;16(3):421-30.,['Q41OR9510P (Melphalan)'],,,,,,,,,,,
4095454,NLM,MEDLINE,19860328,20061115,0390-5748 (Print) 0390-5748 (Linking),15 Suppl 2,,1985,"[Immunological deficiency syndromes, immunosuppression by drugs and occurrence of neoplasms: a casual association?].",11-23,"Although supported by a number of experimental models, the assumption assigning a crucial role to the immune system in the antineoplastic defense mechanisms has not been convincingly demonstrated so far for human tumors. Should the theory be correct, severe functional impairment of the immune system would obviously result in the occurrence of tumors with abnormally high frequency. Registry holdings systematically collecting pertinent information on the malignancies developed in patients with primary immunodeficiency diseases or in organ transplant recipients maintained on therapeutically-induced immune depression, as well as the observation of tumors occurring in patients treated with immunosuppressive agents and of second malignancies arising after radio- and/or chemotherapy of the primary tumor consistently indicate that depressed immunity is usually associated with an increased incidence of cancer as compared with that expected in the general control populations. However, not all types of tumors are increased to the same extent, in that lymphoreticular neoplasias (especially non-Hodgkin's lymphomas), acute leukemias as second tumors and, among solid neoplasms, squamous cell carcinomas are those most frequently reported. These observations suggest that even deeply impaired tumoricidal immune mechanisms may facilitate the growth of certain tumors only, especially of those arising from the cells of the immune system itself, in remarkable contrast with their frequency in the general population. Oncogenesis may be favoured in various states of depressed immunity by a number of ways. Their elucidation might have bearing on the comprehension of the more general phenomenon of the neoplastic transformation.","['Dammacco, F', 'Iodice, G', 'Romagno, D', 'Campobasso, N']","['Dammacco F', 'Iodice G', 'Romagno D', 'Campobasso N']",['ita'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Italy,Ric Clin Lab,La Ricerca in clinica e in laboratorio,7613947,IM,"['Carcinoma, Squamous Cell/chemically induced/immunology', 'Cell Transformation, Neoplastic/immunology', 'Humans', 'Immunologic Deficiency Syndromes/*chemically induced', 'Immunosuppressive Agents/adverse effects', 'Leukemia/chemically induced/immunology', 'Lymphoma/chemically induced/immunology', 'Neoplasms/chemically induced/*immunology', 'Transplantation Immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ric Clin Lab. 1985;15 Suppl 2:11-23.,['0 (Immunosuppressive Agents)'],,"Sindromi da deficienza immunologica, immunodepressione da farmaci ed insorgenza di neoplasie: un'associazione casuale?",,,,,,,,,
4095428,NLM,MEDLINE,19860328,20161123,0761-8417 (Print) 0761-8417 (Linking),41,5,1985,[Pleuropulmonary localizations of non-typhoid Salmonella infections].,320-4,"Non-typhoid salmonella infections are extremely common, usually taking the form of a benign toxi-infection. In the context of the rare extra-digestive manifestations, the authors report 3 cases of pleuro-pulmonary involvement, in infections due to Salmonella Dublin. In 2 cases, the organism was identified from blood cultures, whilst in the 3rd case it was isolated from pleural fluid. As with other extra-digestive sites, pleuro-pulmonary involvement is favored by underlying pathology, accounting for the grave nature of the problem (amongst the 3 cases, gastrectomy and acute myeloblastic leukemia in one case and obliterative arterial disease in another case). Non-typhoid salmonella infections are sensitive to Sulfamethoxazole-trimethoprim which diffuses well in the respiratory system. They are also sensitive to Amoxicillin and to Chloramphenicol.","['Le Chevalier, B', 'Jehan, A', 'Brun, J', 'Vergnaud, M']","['Le Chevalier B', 'Jehan A', 'Brun J', 'Vergnaud M']",['fre'],"['Case Reports', 'Journal Article']",France,Rev Pneumol Clin,Revue de pneumologie clinique,8406312,IM,"['Aged', 'Bronchitis/microbiology', 'Female', 'Humans', 'Male', 'Pleurisy/diagnostic imaging/*microbiology', 'Pneumonia/*microbiology', 'Radiography', 'Salmonella Infections/*diagnosis/drug therapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Rev Pneumol Clin. 1985;41(5):320-4.,,,Localisations pleuro-pulmonaires des salmonelloses non typhoidiques.,,,,,,,,,
4095306,NLM,MEDLINE,19860402,20150813,0370-4106 (Print) 0370-4106 (Linking),56,3,1985 May-Jun,[Acute infantile leukemia in the 10th administrative region of Chile. FAB classification and epidemiological factors].,150-6,,"['Zolezzi, P', 'Zapata, C', 'Bustos, M E', 'Mansilla, C', 'Leon, A']","['Zolezzi P', 'Zapata C', 'Bustos ME', 'Mansilla C', 'Leon A']",['spa'],"['English Abstract', 'Journal Article']",Chile,Rev Chil Pediatr,Revista chilena de pediatria,0404261,IM,"['Acute Disease', 'Adolescent', 'Bone Marrow Examination', 'Child', 'Child, Preschool', 'Chile', 'Female', 'Humans', 'Indians, South American', 'Infant', 'Leukemia/classification/*epidemiology/pathology', 'Male']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Rev Chil Pediatr. 1985 May-Jun;56(3):150-6.,,,Leucemia aguda infantil en la Xa Region. Clasificacion FAB y factores epidemiologicos.,,,,,,,,,
4094939,NLM,MEDLINE,19860411,20080620,0032-3756 (Print) 0032-3756 (Linking),40,46-47,1985 Nov 18-25,[Family's attitude to the patient with hematologic disorders and the patient's knowledge of his illness].,1308-11,,"['Szmajke, K', 'Luczys, E']","['Szmajke K', 'Luczys E']",['pol'],"['English Abstract', 'Journal Article']",Poland,Pol Tyg Lek,"Polski tygodnik lekarski (Warsaw, Poland : 1960)",9705468,IM,"['Adolescent', 'Adult', '*Attitude to Health', '*Family', 'Female', 'Humans', 'Leukemia/*psychology', 'Male', '*Self Concept', 'Truth Disclosure']",,1985/11/18 00:00,1985/11/18 00:01,['1985/11/18 00:00'],"['1985/11/18 00:00 [pubmed]', '1985/11/18 00:01 [medline]', '1985/11/18 00:00 [entrez]']",,ppublish,Pol Tyg Lek. 1985 Nov 18-25;40(46-47):1308-11.,,,Zachowanie rodziny wobec chorego z zaburzeniami hematologicznymi a jego wiedza o wlasnej chorobie.,,,,,,,,,
4094938,NLM,MEDLINE,19860411,20080620,0032-3756 (Print) 0032-3756 (Linking),40,46-47,1985 Nov 18-25,[Anxiety level and duration of the disease in patients with leukemia].,1304-7,,"['Wrona-Polanska, H']",['Wrona-Polanska H'],['pol'],"['Comparative Study', 'English Abstract', 'Journal Article']",Poland,Pol Tyg Lek,"Polski tygodnik lekarski (Warsaw, Poland : 1960)",9705468,IM,"['Adult', 'Anxiety/diagnosis/*etiology', 'Cattell Personality Factor Questionnaire', '*Fear', 'Female', 'Humans', 'Leukemia/*psychology', 'Male', 'Middle Aged', 'Time Factors']",,1985/11/18 00:00,1985/11/18 00:01,['1985/11/18 00:00'],"['1985/11/18 00:00 [pubmed]', '1985/11/18 00:01 [medline]', '1985/11/18 00:00 [entrez]']",,ppublish,Pol Tyg Lek. 1985 Nov 18-25;40(46-47):1304-7.,,,Poziom leku a czas trwania choroby u chorych na bialaczki.,,,,,,,,,
4094078,NLM,MEDLINE,19860401,20061115,0485-1439 (Print) 0485-1439 (Linking),26,10,1985 Oct,[DNA aneuploidy in childhood acute leukemia. Children's Cancer and Leukemia Study Group].,1614-20,,"['Tsurusawa, M', 'Katano, N', 'Kawai, S', 'Fujimotn, T']","['Tsurusawa M', 'Katano N', 'Kawai S', 'Fujimotn T']",['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Acute Disease', 'Adolescent', '*Aneuploidy', 'Child', 'Child, Preschool', 'DNA, Neoplasm/*genetics', 'Female', 'Flow Cytometry', 'Humans', 'Infant', 'Leukemia/*genetics', 'Male']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Oct;26(10):1614-20.,"['0 (DNA, Neoplasm)']",,,,,,,,,,,
4094050,NLM,MEDLINE,19860421,20161116,0368-2781 (Print) 0368-2781 (Linking),38,11,1985 Nov,[A clinical study of cefotaxime in patients with infections complicating a disorder of the hemopoietic tissue. Its therapeutic effect and influence on the coagulation system].,3145-55,"Twenty infectious episodes were caused mainly by Gram-negative rods in 16 patients with a disorder of the hemopoietic tissue. The ages of the patients ranged between 20 and 76 years. Cefotaxime (CTX) was used alone in 9 infectious episodes (group I) and in combination with other antibiotics in the remaining 11 infectious episodes (group II). The following results were obtained. A good response to CTX was noted. The clinical and bacteriological success rates were 100% and 83% in group I, and 82% and 100% in group II, respectively. Bleeding was not clinically found during and after treatment of any infectious episodes with CTX. No change in PT and aPTT was noted during CTX treatment, either. CTX was thus evaluated to be an effective and safe cephem antibiotic in the treatment of infectious episodes secondary to a disorder of the hemopoietic tissue, which is usually accompanied by a marked hemorrhagic tendency.","['Kaneko, H', 'Shirai, T', 'Katoh, M', 'Shimura, H', 'Nojima, Z', 'Senzui, N']","['Kaneko H', 'Shirai T', 'Katoh M', 'Shimura H', 'Nojima Z', 'Senzui N']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Jpn J Antibiot,The Japanese journal of antibiotics,0154402,IM,"['Adult', 'Aged', 'Bacterial Infections/*drug therapy', 'Blood Coagulation/*drug effects', 'Cefotaxime/pharmacology/*therapeutic use', 'Drug Evaluation', 'Female', 'Humans', 'Infusions, Parenteral', 'Leukemia/blood/*complications', 'Lymphoma/complications', 'Male', 'Middle Aged', 'Multiple Myeloma/complications', 'Partial Thromboplastin Time', 'Prothrombin Time']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Jpn J Antibiot. 1985 Nov;38(11):3145-55.,['N2GI8B1GK7 (Cefotaxime)'],,,,,,,,,,,
4093989,NLM,MEDLINE,19860403,20131121,0098-4108 (Print) 0098-4108 (Linking),16,5,1985,Quinones as toxic metabolites of benzene.,673-8,"Occupational exposure to benzene has long been associated with toxicity to the blood and bone marrow, including lymphocytopenia, pancytopenia, aplastic anemia, acute myelogenous leukemia, and possibly lymphoma. A variety of studies have established that benzene itself is not the toxic species but requires metabolism to reactive intermediates. The bioactivation of benzene is complex. Both primary and secondary oxidation of benzene and its metabolites are mediated via cytochrome P-450 in the liver, although the role of secondary metabolism in the bone marrow is not clear. Toxicity is associated with the dihydroxy metabolites, hydroquinone and catechol, which concentrate in bone marrow. Hydroquinone and its terminal oxidation product, p-benzoquinone, have been demonstrated to be potent suppressors of cell growth in culture. Suppression of lymphocyte blastogenesis by these compounds is a sulfhydryl-dependent process and occurs at concentrations that do not result in cell death, or in detectable alterations in energy metabolism, intracellular glutathione concentration, or protein synthesis. Recent studies suggest that these compounds and other membrane-penetrating sulfhydryl alkylating agents, such as N-ethylmaleimide and cytochalasin A, and endogenous regulatory molecules, such as soluble immune response suppressor (SIRS), interfere with microtubule assembly in vitro and selectively interfere with microtubule-dependent cell functions at identical concentrations. These agents appear to react with nucleophilic sulfhydryl groups essential for guanosine triphosphate binding to tubulin that are particularly sensitive to sulfhydryl-alkylating agents.","['Irons, R D']",['Irons RD'],['eng'],['Journal Article'],United States,J Toxicol Environ Health,Journal of toxicology and environmental health,7513622,IM,"['Animals', 'Benzene/*metabolism/toxicity', 'Biotransformation', 'Cell Cycle/drug effects', 'Humans', 'Quinones/*metabolism/toxicity', 'Sulfhydryl Compounds/physiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1080/15287398509530777 [doi]'],ppublish,J Toxicol Environ Health. 1985;16(5):673-8. doi: 10.1080/15287398509530777.,"['0 (Quinones)', '0 (Sulfhydryl Compounds)', 'J64922108F (Benzene)']",,,,,,,,,,,
4093908,NLM,MEDLINE,19860402,20191022,0165-0378 (Print) 0165-0378 (Linking),8,2-3,1985 Nov,Immune reactivity of allogeneically pregnant mice to paternal MHC antigens on fetal and placental cells assessed by second set rejection of ascites tumor cells.,139-51,"In vivo immunogenicity of fetus- and placenta-derived cells as well as the immune reactivity of pregnant mice to fetal cells were examined for graft rejecting response (GRR). Systemic administration of small numbers of fetal cells but not placental cells from allogeneically pregnant mice (10(6) cells per mouse) or adult allogeneic spleen cells (10(4) cells) sensitized mice for second-set rejection of an ascitic tumor bearing paternal major histocompatibility complex (MHC) antigens. Despite this fact and the known positive humoral response, pregnant and parous mice are not even minimally sensitized with fetal MHC antigens for GRR transplacentally. Nevertheless, any pregnancy-related systemically active control, which would selectively prevent the mother from being sensitized for GRR by limiting numbers of semi-allogeneic fetal cells, was not demonstrable in either allogeneically or syngeneically pregnant mice. Irrespective of pregnancy, mice did not, however, respond to repeated administration of very small numbers of allogeneic spleen cells (5 X 10(2) cells per mouse) for graft rejection. These findings support the notion that deviation of maternal immunity to fetal antigens away from harmful GRR is mediated principally by local mechanisms which inhibit fetal cells from gaining access to the mother for GRR, and additionally by the innate inability of mice to respond to very small numbers of allogeneic cells that might escape past the local maternal-fetal barrier.","['Saito, M', 'Nakashima, I', 'Mizoguchi, K', 'Isobe, K', 'Nagase, F', 'Goto, S', 'Tomoda, Y']","['Saito M', 'Nakashima I', 'Mizoguchi K', 'Isobe K', 'Nagase F', 'Goto S', 'Tomoda Y']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Ireland,J Reprod Immunol,Journal of reproductive immunology,8001906,IM,"['Animals', 'Female', 'Fetus/*immunology', '*Graft Rejection', 'Leukemia L1210/*immunology', 'Liver/immunology', 'Lymphocytes/immunology', '*Major Histocompatibility Complex', 'Male', 'Mice', 'Mice, Inbred Strains', 'Neoplasm Transplantation', 'Placenta/*immunology', 'Pregnancy', '*Pregnancy, Animal', 'Species Specificity', 'Spleen/immunology', 'Thymus Gland/immunology', 'Transplantation, Homologous']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0165-0378(85)90037-3 [pii]', '10.1016/0165-0378(85)90037-3 [doi]']",ppublish,J Reprod Immunol. 1985 Nov;8(2-3):139-51. doi: 10.1016/0165-0378(85)90037-3.,,,,,,,,,,,,
4093894,NLM,MEDLINE,19860331,20061115,0221-0363 (Print) 0221-0363 (Linking),66,8-9,1985 Aug-Sep,[Lymphography and fine needle puncture biopsy in the evaluation of lymph node involvement. Apropos of 207 cases].,519-26,"Percutaneous fine needle puncture biopsy was performed on lymph nodes taking up contrast during lymphography in 207 patients with various disorders: urogenital (174 cases), gynecologic (13 cases), hematologic (17), others (3). At the present time, in fact, and simultaneously with the development of physical methods of diagnostic exploration (ultrasonography, computed tomography) needle puncture biopsy has become of increasing importance to confirm a suspected diagnosis. Needle puncture biopsy under television control is a simple, painless and practically nontraumatic procedure. When performed under precise conditions and a strict methodology (routine sampling as a function of the primary glandular chains), it establishes the correct diagnosis in a large number of lymphographies, enabling a rapid and more precise evaluation of the degree of extension and thus a better therapeutic choice.","['Roger, B', 'Cochand-Priollet, B', 'Katz, M', 'Leduc, A', 'Boccon-Gibod, L', 'Blery, M']","['Roger B', 'Cochand-Priollet B', 'Katz M', 'Leduc A', 'Boccon-Gibod L', 'Blery M']",['fre'],"['English Abstract', 'Journal Article']",France,J Radiol,Journal de radiologie,7906266,IM,"['Adult', 'Aged', '*Biopsy, Needle', 'Female', 'Hodgkin Disease/pathology', 'Humans', 'Leukemia/pathology', 'Lymph Nodes/*pathology', '*Lymphography', 'Lymphoma/pathology', 'Male', 'Middle Aged', 'Neoplasm Staging/methods', 'Neoplasms/*pathology', 'Prostatic Neoplasms/pathology', 'Testicular Neoplasms/pathology', 'Urinary Bladder Neoplasms/pathology', 'Uterine Neoplasms/pathology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,J Radiol. 1985 Aug-Sep;66(8-9):519-26.,,,Lymphographie et cytoponction a l'aiguille fine dans l'etude des bilans d'extension ganglionnaire. A propos de 207 cas.,,,,,,,,,
4093400,NLM,MEDLINE,19860328,20041117,0004-5772 (Print) 0004-5772 (Linking),33,9,1985 Sep,Renal involvement in hematological malignancies.,565-8,,"['Khanna, U B', 'Almeida, A F', 'Bhivandkar, M G', 'Shah, B V', 'Mittal, B V', 'Kinare, S G', 'Acharya, V N']","['Khanna UB', 'Almeida AF', 'Bhivandkar MG', 'Shah BV', 'Mittal BV', 'Kinare SG', 'Acharya VN']",['eng'],['Journal Article'],India,J Assoc Physicians India,The Journal of the Association of Physicians of India,7505585,IM,"['Adolescent', 'Adult', 'Aged', 'Child', 'Female', 'Humans', 'Kidney/pathology', 'Kidney Diseases/*etiology/pathology', 'Leukemia/*complications', 'Lymphoma/*complications', 'Male', 'Middle Aged', 'Multiple Myeloma/*complications', 'Prospective Studies']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,J Assoc Physicians India. 1985 Sep;33(9):565-8.,,,,,,,,,,,,
4093331,NLM,MEDLINE,19860410,20190723,0021-8820 (Print) 0021-8820 (Linking),38,12,1985 Dec,"A novel macromolecular antibiotic, SN-07. Taxonomy of producing organism, isolation, characterization and biological activities.",1670-6,"A novel macromolecular antibiotic SN-07 was obtained from the cultural supernatant of Actinomadura roseoviolacea var. miuraensis nov. var. The antibiotic was soluble in water, had a molecular weight of 18,000-22,000 daltons in 50 mM Tris-HCl buffer, pH 7.0, containing 2.0 M KCl as compared with authentic proteins. Its major constituents were nucleic acids. The substance had antibacterial activity against Gram-positive bacteria. It was also effective against lymphocytic leukemia P388 in vivo.","['Kikuchi, Y', 'Niwano, M', 'Yajima, N', 'Nakamura, G', 'Miyata, N']","['Kikuchi Y', 'Niwano M', 'Yajima N', 'Nakamura G', 'Miyata N']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Actinomycetales/classification/*metabolism', 'Animals', '*Anthracyclines', 'Antibiotics, Antineoplastic/*isolation & purification/pharmacology', 'Bacteria/drug effects', 'Chemical Phenomena', 'Chemistry', 'Fermentation', 'Leukemia P388/drug therapy', 'Mice', 'Nucleic Acids/isolation & purification/pharmacology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.7164/antibiotics.38.1670 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Dec;38(12):1670-6. doi: 10.7164/antibiotics.38.1670.,"['0 (Anthracyclines)', '0 (Antibiotics, Antineoplastic)', '0 (Nucleic Acids)', '0 (SN-07)']",,,,,,,,,,,
4093298,NLM,MEDLINE,19860403,20041117,0021-2180 (Print) 0021-2180 (Linking),21,12,1985 Dec,"Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.",977-81,"A new type of human interferon (IFN), IFN-alpha-C, produced in Escherichia coli and purified on monoclonal antibodies, was given at a dose of 3 X 10(6) u (3 micrograms)/day to a terminally ill unsplenectomized patient with hairy cell leukemia, who had had severe recurrent infections and pancytopenia. There was marked reduction in the size of the spleen after 2 weeks, and platelet counts returned to normal after 1 month of treatment. The IFN treatment also raised the granulocyte counts and hemoglobin levels, improved the normal repopulation of the bone marrow, and restored resistance to infections. IFN-alpha-C was well tolerated, without serious side effects, and treatment has been continued for 10 months.","['Aderka, D', 'Levo, Y', 'Rahmani, R', 'Mory, Y', 'Vaks, B', 'Horowitz, O', 'Doerner, T', 'Shoham, J', 'Wallach, D', 'Revel, M']","['Aderka D', 'Levo Y', 'Rahmani R', 'Mory Y', 'Vaks B', 'Horowitz O', 'Doerner T', 'Shoham J', 'Wallach D', 'Revel M']",['eng'],"['Case Reports', 'Journal Article']",Israel,Isr J Med Sci,Israel journal of medical sciences,0013105,IM,"['Cytotoxicity Tests, Immunologic', 'Humans', 'Interferon Type I/adverse effects/*therapeutic use', 'Leukemia, Hairy Cell/blood/immunology/*therapy', 'Leukocyte Count', 'Male', 'Middle Aged', 'Platelet Count', 'Recombinant Proteins/adverse effects/*therapeutic use', 'Spleen/pathology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Isr J Med Sci. 1985 Dec;21(12):977-81.,"['0 (Interferon Type I)', '0 (Recombinant Proteins)']",,,,,,,,,,,
4093184,NLM,MEDLINE,19860417,20061115,0300-5038 (Print) 0300-5038 (Linking),,66,1985,Second cancers as a result of cancer treatment.,133-41,,"['Day, N E', 'Engholm, G']","['Day NE', 'Engholm G']",['eng'],"['Comparative Study', 'Journal Article']",France,IARC Sci Publ,IARC scientific publications,8009542,IM,"['Female', 'Follow-Up Studies', 'Genital Neoplasms, Female/radiotherapy', 'Humans', 'Leukemia, Radiation-Induced/etiology', 'Neoplasms/radiotherapy', 'Neoplasms, Radiation-Induced/epidemiology/*etiology', 'Radiotherapy/*adverse effects', '*Registries', 'Uterine Cervical Neoplasms/radiotherapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,IARC Sci Publ. 1985;(66):133-41.,,,,,,,,,,,,
4092421,NLM,MEDLINE,19860404,20061115,0142-2456 (Print) 0142-2456 (Linking),7,4,1985 Nov,Trends and clusters in leukaemia in Mersey region.,272-7,,"['Pinder, D C']",['Pinder DC'],['eng'],"['Comparative Study', 'Journal Article']",England,Community Med,Community medicine,7907617,IM,"['Adolescent', 'Child', 'Child, Preschool', 'Disease Outbreaks/*epidemiology', 'England', 'Humans', 'Leukemia/*epidemiology', 'Registries', 'Space-Time Clustering']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Community Med. 1985 Nov;7(4):272-7.,,,,,,,,,,,,
4092307,NLM,MEDLINE,19860328,20190705,0009-2363 (Print) 0009-2363 (Linking),33,9,1985 Sep,Synthesis of new antineoplastic alkylidenecyclopentenones.,4120-3,,"['Sugiura, S', 'Hazato, A', 'Tanaka, T', 'Okamura, N', 'Bannai, K', 'Manabe, K', 'Kurozumi, S', 'Suzuki, M', 'Noyori, R']","['Sugiura S', 'Hazato A', 'Tanaka T', 'Okamura N', 'Bannai K', 'Manabe K', 'Kurozumi S', 'Suzuki M', 'Noyori R']",['eng'],['Journal Article'],Japan,Chem Pharm Bull (Tokyo),Chemical & pharmaceutical bulletin,0377775,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Cyclopentanes/*chemical synthesis/pharmacology', 'Leukemia L1210/drug therapy', 'Mice']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1248/cpb.33.4120 [doi]'],ppublish,Chem Pharm Bull (Tokyo). 1985 Sep;33(9):4120-3. doi: 10.1248/cpb.33.4120.,"['0 (Antineoplastic Agents)', '0 (Cyclopentanes)']",,,,,,,,,,,
4092209,NLM,MEDLINE,19860404,20190813,0008-6215 (Print) 0008-6215 (Linking),144,2,1985 Dec 1,Synthesis and antitumor activity of 2'-bromo- and 2'-chloro-3'-acetoxy-3'-deaminodaunorubicin analogs.,305-15,"Bromination of 3,4-di-O-acetyl-L-rhamnal (7) and subsequent glycosidic coupling under Koenigs-Knorr conditions with daunomycinone gave a mixture of three compounds having the beta-L-gluco (10), alpha-L-gluco (11), and alpha-L-manno (12) configurations. Analogous bromination of 3,4-di-O-acetyl-L-fucal (13) followed by coupling with daunomycinone gave a mixture of three glycosides having the beta-L-galacto (16), alpha-L-galacto (17), and alpha-L-talo (18) configurations. Chlorination of 7 and coupling with daunomycinone in the presence of silver triflate gave products having the alpha-L-gluco (21) and alpha-L-manno (22) configurations, whereas 13, under similar conditions, gave only one stereoisomeric product, that having the alpha-L-galacto (24) configuration. Compounds 12 and 22 showed high in vivo activity in the P-388 lymphocytic leukemia assay.","['Horton, D', 'Priebe, W', 'Varela, O']","['Horton D', 'Priebe W', 'Varela O']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,Carbohydr Res,Carbohydrate research,0043535,IM,"['Animals', 'Antibiotics, Antineoplastic/*chemical synthesis', 'Daunorubicin/*analogs & derivatives/chemical synthesis/therapeutic use', 'Indicators and Reagents', 'Leukemia P388/drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice', 'Structure-Activity Relationship']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['S0008-6215(00)90678-5 [pii]', '10.1016/s0008-6215(00)90678-5 [doi]']",ppublish,Carbohydr Res. 1985 Dec 1;144(2):305-15. doi: 10.1016/s0008-6215(00)90678-5.,"['0 (Antibiotics, Antineoplastic)', '0 (Indicators and Reagents)', 'ZS7284E0ZP (Daunorubicin)']",,,['GM-11976/GM/NIGMS NIH HHS/United States'],,,,,,,,
4092198,NLM,MEDLINE,19860418,20131121,0361-5960 (Print) 0361-5960 (Linking),69,11,1985 Nov,Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.,1331-3,,"['Finklestein, J Z', 'Shore, N', 'Krivit, W', 'Hammond, D', 'Higgins, G']","['Finklestein JZ', 'Shore N', 'Krivit W', 'Hammond D', 'Higgins G']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Treat Rep,Cancer treatment reports,7607107,IM,"['Child', 'Dianhydrogalactitol/adverse effects/*therapeutic use', 'Drug Evaluation', 'Hemorrhage/chemically induced', 'Humans', 'Leukemia/drug therapy', 'Leukopenia/chemically induced', 'Neoplasms/drug therapy', 'Sugar Alcohols/*therapeutic use', 'Thrombocytopenia/chemically induced']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Treat Rep. 1985 Nov;69(11):1331-3.,"['0 (Sugar Alcohols)', '4S465RYF7M (Dianhydrogalactitol)']",,,"['CA-02971/CA/NCI NIH HHS/United States', 'CA-13539/CA/NCI NIH HHS/United States', 'CA-17829/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4091574,NLM,MEDLINE,19860320,20151119,0003-9594 (Print) 0003-9594 (Linking),74,2,1985,[The periosteum in experimental avian hyperostosis induced by MAV 2-0 myeloblastosis virus. Differential diagnosis from osteopetrosis].,151-66,"Diaphyseal tibial bones of 11-14-17 th day-old hatched chicks infected with retrovirus myeloblastic MAV 2-0 were examined by conventional optical microscopy. The characteristic lesion is osteoblastic hyperplasia with the development of spongious bone. The new formed bone contains abnormal chondroid tissue. The relation between osseous and cartilaginous tissues in this experimental model is discussed. As connective tissue took part in the constitution of this hyperostosis, this osteopathy may be considered as an hyperplastic, monodermic mesenchymatous, pluritissular tumour. The numerous works concerning the ""avian hyperostosis osteopetrosis"" are commented.","['Graf, B', 'Coudert, F', 'Mazzella, O', 'Cauchy, L']","['Graf B', 'Coudert F', 'Mazzella O', 'Cauchy L']",['fre'],"['English Abstract', 'Journal Article']",France,Arch Anat Microsc Morphol Exp,Archives d'anatomie microscopique et de morphologie experimentale,0406007,IM,"['Animals', 'Avian Leukosis/*pathology', 'Avian Myeloblastosis Virus', 'Bone Diseases/diagnosis/*microbiology/pathology', 'Chickens', 'Diagnosis, Differential', 'Osteopetrosis/diagnosis', 'Periosteum/*pathology', 'Tibia/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arch Anat Microsc Morphol Exp. 1985;74(2):151-66.,,,Le perioste dans l'hyperostose aviaire experimentale induite par le virus myeloblastique mav 2-0. Diagnostic differentiel de l'osteopetrose.,,,,,,,,,
4091300,NLM,MEDLINE,19860306,20061115,0003-3898 (Print) 0003-3898 (Linking),43,4,1985,[Myelodysplastic syndromes].,369-79,,,,['fre'],"['Comparative Study', 'Journal Article']",France,Ann Biol Clin (Paris),Annales de biologie clinique,2984690R,IM,"['Acute Disease', 'Adult', 'Anemia, Refractory/diagnosis/therapy', 'Anemia, Sideroblastic/diagnosis/therapy', 'Diagnosis, Differential', 'Female', 'Humans', 'Leukemia/diagnosis', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/*diagnosis/mortality/therapy', 'Neutropenia/diagnosis', 'Prognosis', 'Thrombocytopenia/diagnosis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ann Biol Clin (Paris). 1985;43(4):369-79.,,,Syndromes myelodysplasiques.,,,,,,,,,
4090932,NLM,MEDLINE,19860228,20110728,0001-5806 (Print) 0001-5806 (Linking),48,7,1985 Nov,[Platelet function in chronic lymphocytic leukemia].,1579-86,,"['Mohri, H', 'Maruta, I', 'Itoh, A', 'Ohkubo, T']","['Mohri H', 'Maruta I', 'Itoh A', 'Ohkubo T']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Adult', 'Aged', 'Blood Platelets/*physiology', 'Female', 'Humans', 'Leukemia, Lymphoid/*blood', 'Male', 'Middle Aged']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 Nov;48(7):1579-86.,,,,,,,,,,,,
4090930,NLM,MEDLINE,19860228,20110728,0001-5806 (Print) 0001-5806 (Linking),48,7,1985 Nov,[Causes of fever in adult patients with acute leukemia].,1514-21,,"['Kanakura, Y', 'Teshima, H', 'Hirayama, F', 'Tani, Y', 'Kubota, Y', 'Oguma, S', 'Ueda, T', 'Nakamura, H', 'Shibata, H', 'Masaoka, T']","['Kanakura Y', 'Teshima H', 'Hirayama F', 'Tani Y', 'Kubota Y', 'Oguma S', 'Ueda T', 'Nakamura H', 'Shibata H', 'Masaoka T', 'et al.']",['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Acute Disease', 'Adult', 'Fever/*etiology', 'Fever of Unknown Origin', 'Humans', 'Leukemia/*complications/drug therapy']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 Nov;48(7):1514-21.,,,,,,,,,,,,
4090929,NLM,MEDLINE,19860228,20110728,0001-5806 (Print) 0001-5806 (Linking),48,7,1985 Nov,[Macrophage-like transformation of leukemia cells in vitro liquid culture and its biological significance].,1493-507,,"['Sakai, C']",['Sakai C'],['jpn'],"['English Abstract', 'Journal Article']",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Cell Adhesion', 'Cell Differentiation', 'Cells, Cultured', 'Humans', 'Leukemia/*pathology', 'Macrophages/*pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 Nov;48(7):1493-507.,,,,,,,,,,,,
4090558,NLM,MEDLINE,19860324,20061115,0044-2542 (Print) 0044-2542 (Linking),40,22,1985 Nov 15,[Rational hematologic diagnosis with reference to modern laboratory procedures].,658-60,"The spectre of methods for the diagnostics and differentiation of haemolytic anaemias, particularly for the establishment of congenital, autoimmune haemolytic, drug-conditioned and other anaemias is treated. The clear delimitation of an iron deficiency from a disturbance of the iron distribution is advantageously to be achieved by iron staining of the bone marrow and by a determination of serum ferritin. The value of the diagnostic methods in megaloblastic anaemia is classified according to newer knowledge, in which case the vitamin-B12-absorption test and the serum level determination of vitamin B12 by no means range in the first place. Long-term culture results of haematopoietic stem cells are particularly evident in the aplastic syndrome of the bone marrow and further haematological diseases concerning the establishment of the intensiveness of proliferation. The classification of the acute leukemias demands conventional as well as cytochemical staining methods; recently, it is essentially improved using monoclonal antibodies. In leukemias cytogenetic investigations are more and more attracted to the estimation of the prognoses. In lymphogranulomatosis among others functional disturbances of the cellular immunity, in the group of the non-Hodgkin-lymphomas haematological, protein-analytic and immunological laboratory investigations are methods supporting the diagnosis. Altogether is to be established that the haematological diagnostics has become more and more perfect, in which case apart from new techniques old approved methods are still further used.","['Stobbe, H']",['Stobbe H'],['ger'],"['English Abstract', 'Journal Article']",Germany,Z Gesamte Inn Med,Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,21730470R,IM,"['Anemia, Aplastic/diagnosis', 'Anemia, Hemolytic/*diagnosis', 'Anemia, Hemolytic, Autoimmune/diagnosis', 'Anemia, Hemolytic, Congenital/diagnosis', 'Anemia, Hypochromic/diagnosis', 'Blood Cell Count', 'Diagnosis, Differential', 'Erythrocytes/ultrastructure', 'Ferritins/blood', 'Haptoglobins/metabolism', 'Heart Valve Prosthesis', 'Heinz Bodies/ultrastructure', 'Humans', 'Leukemia/diagnosis', 'Postoperative Complications/diagnosis', 'Reticulocytes']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",,ppublish,Z Gesamte Inn Med. 1985 Nov 15;40(22):658-60.,"['0 (Haptoglobins)', '9007-73-2 (Ferritins)']",,Rationale hamatologische Diagnostik unter Berucksichtigung moderner Laboratoriumsverfahren.,,,,,,,,,
4090180,NLM,MEDLINE,19860224,20071115,0042-4625 (Print) 0042-4625 (Linking),135,10,1985 Oct,[A new one-catheter system of hemosorption].,124-6,,"['Nakhimov, E I', 'Lakhonia, A P']","['Nakhimov EI', 'Lakhonia AP']",['rus'],['Journal Article'],Russia (Federation),Vestn Khir Im I I Grek,Vestnik khirurgii imeni I. I. Grekova,0411377,IM,"['Catheterization/instrumentation', 'Charcoal/*therapeutic use', 'Female', 'Femoral Vein', 'Hemoperfusion/*instrumentation', 'Hodgkin Disease/blood', 'Humans', 'Leukemia, Lymphoid/blood', 'Ovarian Neoplasms/blood', 'Toxemia/*therapy']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Vestn Khir Im I I Grek. 1985 Oct;135(10):124-6.,['16291-96-6 (Charcoal)'],,Novaia odnokateternaia skhema gemosorbtsii.,,,,,,,,,
4089802,NLM,MEDLINE,19860226,20041117,0340-6245 (Print) 0340-6245 (Linking),54,3,1985 Oct 30,High fibrinopeptide A levels modified by heparin in acute nonlymphocytic leukemia.,727,,"['Pogliani, E M', 'Cofrancesco, E', 'Salvatore, M', 'Boschetti, C', 'Cortellaro, M']","['Pogliani EM', 'Cofrancesco E', 'Salvatore M', 'Boschetti C', 'Cortellaro M']",['eng'],['Letter'],Germany,Thromb Haemost,Thrombosis and haemostasis,7608063,IM,"['Fibrinogen/*blood', 'Fibrinopeptide A/*blood', 'Heparin/*pharmacology', 'Humans', 'Leukemia/*blood']",,1985/10/30 00:00,1985/10/30 00:01,['1985/10/30 00:00'],"['1985/10/30 00:00 [pubmed]', '1985/10/30 00:01 [medline]', '1985/10/30 00:00 [entrez]']",,ppublish,Thromb Haemost. 1985 Oct 30;54(3):727.,"['25422-31-5 (Fibrinopeptide A)', '9001-32-5 (Fibrinogen)', '9005-49-6 (Heparin)']",,,,,,,,,,,
4089753,NLM,MEDLINE,19860310,20061115,0036-4355 (Print) 0036-4355 (Linking),30,5,1985,[Acute leukemia of hypoplastic presentation with myeloid and lymphoid markers and monosomy 7].,913-6,,"['Gomis, F', 'Sanz, M A', 'Amigo, V', 'Perez-Sirvent, M L', 'Sanz, G', 'Martin-Aragones, G']","['Gomis F', 'Sanz MA', 'Amigo V', 'Perez-Sirvent ML', 'Sanz G', 'Martin-Aragones G']",['spa'],"['Case Reports', 'English Abstract', 'Journal Article']",Spain,Sangre (Barc),Sangre,0404373,IM,"['Acute Disease', 'Adolescent', 'Bone Marrow/pathology', 'Chromosomes, Human, 6-12 and X', 'Female', 'Hematopoietic System/pathology', 'Humans', 'Leukemia/genetics/*pathology', 'Monosomy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Sangre (Barc). 1985;30(5):913-6.,,,Leucemia aguda de presentacion hipoplasica con marcadores mieloides y linfoides y monosomia 7.,,,,,,,,,
4089740,NLM,MEDLINE,19860228,20061115,0036-4355 (Print) 0036-4355 (Linking),30,4-C,1985,"[Clinical semiology, development and therapy of myelodysplastic syndromes].",705-12,,"['Giralt, M', 'Rubio-Felix, D', 'Sala, F', 'Perdiguer, L', 'Raichs, A']","['Giralt M', 'Rubio-Felix D', 'Sala F', 'Perdiguer L', 'Raichs A']",['spa'],"['English Abstract', 'Journal Article']",Spain,Sangre (Barc),Sangre,0404373,IM,"['Adult', 'Aged', 'Antineoplastic Agents/therapeutic use', 'Cell Transformation, Neoplastic/pathology', 'Female', 'Humans', 'Leukemia/drug therapy', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/*diagnosis/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Sangre (Barc). 1985;30(4-C):705-12.,['0 (Antineoplastic Agents)'],,"Semiologia clinica, evolucion y terapeutica de los sindromes mielodisplasicos.",,,,,,,,,
4089535,NLM,MEDLINE,19860326,20190908,0036-553X (Print) 0036-553X (Linking),35,5,1985 Nov,Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases.,570-8,"The clinical and laboratory studies of 6 patients with primary plasma cell leukaemia are described. The leukaemic cells had a variable morphology, ranging from lymphoplasmacytic and mature plasma cells to poorly differentiated blasts. The neoplastic plasma cells had a characteristic phenotype: they were positive for CyIg and the McAb OKT10 and Ri-3, and did not express the B-cell antigens Ia, B1 and B4. Ultrastructural studies confirmed the plasma cell nature of the leukaemic cells and showed the presence of a meshwork of cytoplasmic fibrils in 50 to 90% of the neoplastic cells from all cases. The distinct ultrastructural and immunological features of PCL described in this study will help the diagnosis and further characterisation of this disease entity.","['Parreira, A', 'Robinson, D S', 'Melo, J V', 'Ayliffe, M', 'Ball, S', 'Hegde, U', 'Baughan, A', 'Fairhead, S', 'Talavera, J G', 'Katzmann, J A']","['Parreira A', 'Robinson DS', 'Melo JV', 'Ayliffe M', 'Ball S', 'Hegde U', 'Baughan A', 'Fairhead S', 'Talavera JG', 'Katzmann JA', 'et al.']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Adult', 'Aged', 'Antibodies, Neoplasm/analysis', 'Antigens, Neoplasm/*analysis', 'Antigens, Surface/*analysis', 'Cell Differentiation', 'Female', 'Humans', 'Leukemia, Plasma Cell/*diagnosis/immunology/pathology', 'Male', 'Middle Aged', 'Plasma Cells/immunology/ultrastructure', 'Receptors, Antigen, B-Cell/analysis']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb02830.x [doi]'],ppublish,Scand J Haematol. 1985 Nov;35(5):570-8. doi: 10.1111/j.1600-0609.1985.tb02830.x.,"['0 (Antibodies, Neoplasm)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)', '0 (Receptors, Antigen, B-Cell)']",,,,,,,,,,,
4089533,NLM,MEDLINE,19860326,20190908,0036-553X (Print) 0036-553X (Linking),35,5,1985 Nov,Serum procollagen III peptide in chronic myeloproliferative disorders.,550-7,"Using a radioimmunoassay the serum concentration of the N-terminal propeptide of type III procollagen (P-III-P) was measured in 35 patients with chronic myeloproliferative disorders, including idiopathic myelofibrosis (n = 10), osteomyelosclerosis (n = 4), transitional myeloproliferative disorder (n = 5), polycythaemia vera (n = 10) and chronic myelogenous leukaemia (n = 6). The normal range in 35 healthy controls was 4.9-11.7 ng/ml. The serum concentration of P-III-P increased with increasing degrees of bone marrow reticulin fibrosis. By contrast, almost normal levels were detected in osteomyelosclerosis with an indolent clinical course, in which an excessive deposition of mature collagen fibres was found, representing mainly type I collagen. These observations indicate that the serum P-III-P level is positively correlated to the degree of bone marrow reticulin fibrosis, whereas levels are near normal in patients with osteomyelosclerosis and stable disease. Measurement of serum P-III-P may be a useful indicator of disease activity in myelofibrosing conditions.","['Hasselbalch, H', 'Junker, P', 'Lisse, I', 'Bentsen, K D']","['Hasselbalch H', 'Junker P', 'Lisse I', 'Bentsen KD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Adult', 'Aged', 'Alkaline Phosphatase/blood', 'Bone Marrow/pathology', 'Creatinine/blood', 'Humans', 'Leukocyte Count', 'Middle Aged', 'Myeloproliferative Disorders/*blood/pathology', 'Organ Size', 'Peptide Fragments/*blood', 'Primary Myelofibrosis/blood/pathology', 'Procollagen/*blood', 'Spleen/pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb02827.x [doi]'],ppublish,Scand J Haematol. 1985 Nov;35(5):550-7. doi: 10.1111/j.1600-0609.1985.tb02827.x.,"['0 (Peptide Fragments)', '0 (Procollagen)', '0 (procollagen Type III-N-terminal peptide)', 'AYI8EX34EU (Creatinine)', 'EC 3.1.3.1 (Alkaline Phosphatase)']",,,,,,,,,,,
4089529,NLM,MEDLINE,19860326,20190908,0036-553X (Print) 0036-553X (Linking),35,5,1985 Nov,Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients.,497-500,"11 courses of EACA were given to 9 acutely ill, severely thrombocytopenic patients (platelet count less than 20 X 10(9)/l). 6 patients were being treated for acute leukaemia while 1 each had cyclical amegakaryocytic thrombocytopenia, dysmyelopoietic syndrome and advanced chronic lymphocytic leukaemia. 8 were refractory to HLA-matched platelets and 1 refused blood product transfusion. All had simultaneous major medical complications such as infection and granulocytopenia. The highest dose of EACA used was 24 mg/d. Improvement in haemostasis was noted in all patients with successful control of epistaxis in 1, control of gastrointestinal bleeding in 3 and lack of significant bleeding for 4-29 d in the remaining 5 patients. The only toxicity was dose-related nausea. Since this patient group was at extremely high risk for haemorrhage, we conclude that EACA is safe and useful in the management of thrombocytopenia including that occurring during leukaemic induction.","['Garewal, H S', 'Durie, B G']","['Garewal HS', 'Durie BG']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Adult', 'Aminocaproates/*therapeutic use', 'Aminocaproic Acid/*therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Female', 'Fibrinolysis/drug effects', 'Hemorrhage/etiology/prevention & control', 'Humans', 'Leukemia/complications/drug therapy', 'Male', 'Middle Aged', 'Platelet Count', 'Risk', 'Thrombocytopenia/chemically induced/complications/*drug therapy/physiopathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb02818.x [doi]'],ppublish,Scand J Haematol. 1985 Nov;35(5):497-500. doi: 10.1111/j.1600-0609.1985.tb02818.x.,"['0 (Aminocaproates)', '0 (Antineoplastic Agents)', 'U6F3787206 (Aminocaproic Acid)']",,,,,,,,,,,
4089371,NLM,MEDLINE,19860304,20061115,1013-2058 (Print) 1013-2058 (Linking),74,12,1985 Mar 19,[Identification of chromosome abnormalities in malignant hematologic diseases: an essential stage in the comprehension of mechanisms of oncogenesis].,292-6,,"['Werner-Favre, C', 'Engel, E']","['Werner-Favre C', 'Engel E']",['fre'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Switzerland,Schweiz Rundsch Med Prax,Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,8403202,IM,"['Acute Disease', 'Adult', 'Child', '*Chromosome Aberrations', 'Chromosome Deletion', 'Chromosome Fragility', 'Humans', 'Karyotyping', 'Leukemia/*genetics', 'Lymphoma/genetics', 'Oncogenes', 'Preleukemia/genetics', 'Translocation, Genetic']",,1985/03/19 00:00,1985/03/19 00:01,['1985/03/19 00:00'],"['1985/03/19 00:00 [pubmed]', '1985/03/19 00:01 [medline]', '1985/03/19 00:00 [entrez]']",,ppublish,Schweiz Rundsch Med Prax. 1985 Mar 19;74(12):292-6.,,,L'identification d'anomalies chromosomiques dans les hemopathies malignes: une etape essentielle a la comprehension des mecanismes de l'oncogenese.,,,,,,,,,
4089352,NLM,MEDLINE,19860318,20190829,0277-6715 (Print) 0277-6715 (Linking),4,4,1985 Oct-Dec,An application of Bayesian analysis to medical follow-up data.,509-20,"Posterior distributions can provide effective summaries of the main conclusions of medical follow-up studies. In this article, we use Bayesian methods for the analysis of survival data. We describe posterior distributions for various parameters of clinical interest in the presence of arbitrary right censorship. Non-informative reference priors result from transformation of a two-parameter Weibull model into a location-scale family. We suggest an approach for checking adequacy. For illustration, we apply the methods to a well-known acute leukemia data set.","['Achcar, J A', 'Brookmeyer, R', 'Hunter, W G']","['Achcar JA', 'Brookmeyer R', 'Hunter WG']",['eng'],['Journal Article'],England,Stat Med,Statistics in medicine,8215016,IM,"['*Bayes Theorem', '*Follow-Up Studies', 'Humans', 'Leukemia/mortality', '*Probability']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/sim.4780040411 [doi]'],ppublish,Stat Med. 1985 Oct-Dec;4(4):509-20. doi: 10.1002/sim.4780040411.,,,,,,,,,,,,
4088888,NLM,MEDLINE,19860321,20061115,0261-3166 (Print) 0261-3166 (Linking),,16,1985,"Synthesis of 1-beta-D-ribofuranosyl-1,2-dihydropyrimidin-2-one derivatives and their biological activities.",77-80,"Several alkyl substituted 1-beta-D-ribofuranosyl-1,2-dihydropyrimidin-2-one derivatives were synthesized by the method of stannic chloride-catalyzed glycosidation method to elucidate their inhibitory activity of cytidine deaminase and also their antitumor activities in vitro and in vivo. Alkyl substitution at position 4 or 6 of the derivatives decreased their inhibitory activity for cytidine deaminase and also decreased antitumor activity against L1210 cells in vitro.","['Maeda, M', 'Kaneko, C', 'Uchida, N A', 'Sasaki, T']","['Maeda M', 'Kaneko C', 'Uchida NA', 'Sasaki T']",['eng'],['Journal Article'],England,Nucleic Acids Symp Ser,Nucleic acids symposium series,8007206,IM,"['Animals', 'Cytidine Deaminase/*antagonists & inhibitors', 'Drug Evaluation, Preclinical', 'Indicators and Reagents', 'Kinetics', 'Leukemia L1210/drug therapy', 'Mice', 'Nucleoside Deaminases/*antagonists & inhibitors', 'Pyrimidine Nucleosides/*chemical synthesis/pharmacology/therapeutic use', 'Structure-Activity Relationship']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Nucleic Acids Symp Ser. 1985;(16):77-80.,"['0 (Indicators and Reagents)', '0 (Pyrimidine Nucleosides)', 'EC 3.5.4.- (Nucleoside Deaminases)', 'EC 3.5.4.5 (Cytidine Deaminase)']",,,,,,,,,,,
4088440,NLM,MEDLINE,19860317,20061115,0301-2603 (Print) 0301-2603 (Linking),13,11,1985 Nov,[A case of Burkitt's lymphoma with total ophthalmoplegia].,1183-9,"Burkitt's lymphoma was first reported by Burkitt in 1958 as a sarcoma involving the jaw in African children with characteristic symptoms. Forty three Japanese cases have been reported since the first description by Oboshi et al. in 1969. We report a case of Burkitt's lymphoma with left total ophthalmoplegia. A 73-year-old Japanese female was admitted in Sadamoto Hospital on July 11, 1983 with a two-week history of headache, ptosis and double vision. The patient was exposed to the atomic bomb in Hiroshima and had ten-year history of hypertension. On admission, physical examination showed hypertension and neurological examination revealed only left total ophthalmoplegia (such as left ptosis, external ophthalmoplegia, mydriasis and deficit of light reflex). Plain X-ray film and enhanced CT scan showed no remarkable abnormalities. Laboratory examinations revealed high serum levels of GOT(51 K.U.) and LDH (1300 U.). Left carotid and right retrograde branchial angiograms showed no remarkable abnormal findings. While the patient was treated only conservatively, left abducent and trochleal nerve palsy appeared on August 5, 1983. On plain and enhanced CT scans at the time, abnormal density mass with bone destruction of the left sphenoidal sinus was demonstrated. Biopsy specimen from the left sphenoidal sinus showed lymphosarcomatous cells. Peripheral blood and bone marrow smears showed lymphoma cells which are compatible with L3-Burkitt's type according to FAB leukemia classification. The patient was diagnosed as leukemic transformation of Burkitt's lymphoma and treated with CHOP; Cyclophosphamide (C), Hydroxydaunorubicin(H), Vincristine (O), and Prednisolone (P).(ABSTRACT TRUNCATED AT 250 WORDS)","['Fukui, K', 'Takeda, S', 'Sadamoto, K', 'Koike, S', 'Okabe, K', 'Toki, H', 'Moriwaki, S']","['Fukui K', 'Takeda S', 'Sadamoto K', 'Koike S', 'Okabe K', 'Toki H', 'Moriwaki S']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,No Shinkei Geka,No shinkei geka. Neurological surgery,0377015,IM,"['Aged', 'Burkitt Lymphoma/complications/*diagnosis/pathology', 'Female', 'Humans', 'Ophthalmoplegia/*complications', 'Skull Neoplasms/complications/*diagnosis/pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,No Shinkei Geka. 1985 Nov;13(11):1183-9.,,,,,,,,,,,,
4088393,NLM,MEDLINE,19860320,20071115,0028-2685 (Print) 0028-2685 (Linking),32,6,1985,Problems with prognostic criteria in patients with chronic lymphocytic leukemia with special reference to DPP II assessment.,737-40,"106 consecutive patients with chronic lymphocytic leukemia (CLL) were entered into prospective study with the aims of finding out whether a detailed clinical, biochemical, immunological and cytochemical examination might help to subclassify CLL with respect to prognosis. None of the biochemical and immunological parameters studied correlated either with the clinical stage of the disease according to Rai, or with further evolution of the disease. On the other hand, the results of cytochemical tests indicated that the reaction for DPP II (dipeptidylaminopeptidase) might be of prognostic value, because in patients with stable disease, significantly lower number of DPP II positive lymphocytes were found when compared with patients suffering from progressive disease. The authors also point out some short-comings of Rai's staging system in respect to its prognostic significance.","['Klener, P', 'Lojda, Z', 'Haber, J', 'Kvasnicka, J', 'Cmunt, E']","['Klener P', 'Lojda Z', 'Haber J', 'Kvasnicka J', 'Cmunt E']",['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Female', 'Humans', 'Leukemia, Lymphoid/*classification/complications', 'Male', 'Prognosis', 'Prospective Studies', 'Thrombocytopenia/complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1985;32(6):737-40.,,,,,,,,,,,,
4088390,NLM,MEDLINE,19860320,20031114,0028-2685 (Print) 0028-2685 (Linking),32,6,1985,Acceleration of neoplasms of reticular tissue with syngeneic thymic graft under renal capsule and gamma radiation.,715-21,"Weanling ICRC female mice were given syngeneic neonatal thymus graft under renal capsule and two weeks later whole-body gamma-radiation (group ITR). The findings on ITR were compared with three controls--untreated (C), thymus grafted (IT) and irradiated (IR). In ITR group 15/15 developed generalized neoplasms of reticular tissue at 5 to 8 months and single mammary tumor at 7 months. In IR group 12/13, 21/25 in IT and 5/23 in C had neoplastic changes at 7-month onwards. Microscopically these neoplasms had diffuse or focal proliferation of modified reticulum cells, histiocytes, lymphocytes and giant cells. Localized thymic tumors showed either the same picture or prominence of small lymphocytes. Mammary tumors developed in 12/25 IT, and 8/25 in C and nil in IR.","['Pai, S R', 'Sequeira, B']","['Pai SR', 'Sequeira B']",['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Animals', 'Female', 'Gamma Rays', 'Leukemia, Hairy Cell/etiology', 'Lymphoma/etiology', 'Mammary Neoplasms, Experimental/etiology', 'Mice', 'Neoplasms, Experimental/*etiology', 'Neoplasms, Radiation-Induced/*etiology', 'Thymus Gland/*transplantation', 'Thymus Neoplasms/etiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1985;32(6):715-21.,,,,,,,,,,,,
4088385,NLM,MEDLINE,19860320,20041117,0028-2685 (Print) 0028-2685 (Linking),32,6,1985,Studies on the distribution of the antigens detected by some newly prepared monoclonal antibodies in normal hemopoietic and leukemic cells.,657-62,"A great number of hybridoma clones has been developed in two independent fusions after immunization with cells of a human non-T, non-B REH leukemic cell line, recognizing different differentiation antigens on leukocytes. Only four of these new murine monoclonal hybridoma-derived antibodies (Bra20, Bra30, BraFB6 and BraEA10) have been used in our study for determination of their reactivity spectrum in normal blood cells and fresh lymphoid and non-lymphoid leukemic cells. The resulting reactivity spectra of these four monoclonal antibodies in normal hemopoietic and leukemic cells in indirect immunofluorescence assay are in agreement with supposed Ia-like reactivity for Bra20, Bra30 and Bra FB6 monoclonal antibodies and ""common"" leukocyte specificity for BraEA10 monoclonal antibody.","['Babusikova, O', 'Ujhazy, P', 'Hrivnakova, A', 'Chorvath, B', 'Polakova, K']","['Babusikova O', 'Ujhazy P', 'Hrivnakova A', 'Chorvath B', 'Polakova K']",['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Antibodies, Monoclonal/*immunology', 'Antibody Specificity', 'Antigens, Neoplasm/*analysis', 'Antigens, Surface/*analysis', 'Blood Platelets/immunology', 'Erythrocytes/immunology', 'Granulocytes/immunology', 'Hematopoietic Stem Cells/immunology', 'Humans', 'Leukemia/*immunology', 'Leukocytes/*immunology', 'Lymphocyte Activation', 'Lymphocytes/immunology', 'Lymphoma/*immunology', 'Monocytes/immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1985;32(6):657-62.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)']",,,,,,,,,,,
4088315,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the breast in Connecticut, 1935-82.",99-112,"Among 41,109 women diagnosed with breast cancer between 1935 and 1982 in Connecticut, 3,984 developed a second cancer, whereas 2,426 were expected [relative risk (RR) = 1.64; 95% CI = 1.6-1.7]. This increased risk persisted for 30 years and was highest in women under 55 years of age at the time of breast cancer diagnosis. Second primary breast cancers (RR = 3.0) accounted for almost one-half of all new neoplasms. However, if subsequent breast cancers were excluded, the risk for all other second cancers was only 1.15 (95% CI = 1.10-1.20), and no excess risk was seen among women over age 55 at initial breast cancer. Significant risks were found for cancers of the ovary (RR = 1.7) and uterine corpus (RR = 1.4), possibly linked with shared reproductive factors such as nulliparity or late age at menopause. Malignant melanoma (RR = 1.5), thyroid cancer (RR = 1.6), and colon cancer (RR = 1.2) were also significantly elevated; possible shared risk factors remain to be elucidated. Significant deficits of multiple myeloma and chronic lymphocytic leukemia were noted. Women who received initial radiotherapy compared with those who did not were at slightly higher risk of developing a second cancer, most notably acute nonlymphocytic leukemia, non-Hodgkin's lymphoma, and cancers of the esophagus, kidney, and connective tissue, although the nature of the associations was not always clear. Some of the soft tissue sarcomas were lymphangiosarcomas of the arm, a consequence of the lymphedema that may complicate radical mastectomy (Stewart-Treves syndrome). Women treated with radiation were at higher risk of developing a second breast neoplasm (RR = 3.9) than nonirradiated women (RR = 2.8). Further investigation should focus on the mechanisms underlying the relationships between breast, genital tract, and colon cancers, and on the effects of treatment modalities on the risk of subsequent neoplasms.","['Harvey, E B', 'Brinton, L A']","['Harvey EB', 'Brinton LA']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Breast Neoplasms/*epidemiology/radiotherapy', 'Connecticut', 'Female', 'Humans', 'Neoplasms, Multiple Primary/*epidemiology', 'Neoplasms, Radiation-Induced/epidemiology', 'Registries', 'Risk', 'Time Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:99-112.,,,,,,,,,,,,
4088314,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the respiratory system in Connecticut, 1935-1982.",83-98,"The risk of a person developing a second primary cancer was evaluated in approximately 30,000 persons who developed cancer of the respiratory system in Connecticut between 1935 and 1982. A significant 44% excess of all second cancers was observed following cancer of the lung (614 observed vs. 426 expected). The excess of second tumors was 72% following cancer of the larynx (541 vs. 314) and 34% following cancer of the nasal cavities and sinuses (43 vs. 32). For cancers of the lung and larynx, second cancers arose mainly along the respiratory tract or other sites associated with cigarette smoking (oral cavity, bladder, kidney). A threefold excess of esophageal cancer followed cancer of the larynx, which was indicative of risk factors in common (alcohol and tobacco) and possibly an effect of radiotherapy. Radiotherapy may have contributed also to the increased risk of second lung and breast cancers. A slight excess risk of leukemia after lung cancer points to a possible effect of chemotherapy given for certain histologic types. An unexpected finding was a significant 50% increased risk of colon cancer following cancer of the larynx. Significant excesses of prostate cancer are probably artifacts associated with increased medical surveillance and higher autopsy rates among cancer patients than in the general population. No deficits of any second cancers were observed. The risk of a second cancer developing did not appear to vary by sex or time since initial diagnosis, except that the risks following cancer of the nasal cavities and sinuses returned to normal levels among long-term survivors. Among persons observed for 10 or more years after their initial diagnosis of cancers of the lung or larynx, the risk of developing a second cancer remained high, i.e., on the order of 50% above expectation. Further analytic studies should clarify the role of smoking, alcohol, other life-style and host factors, and various forms of therapy on the risk of second cancers following cancer of the respiratory system.","['Boice, J D Jr', 'Fraumeni, J F Jr']","['Boice JD Jr', 'Fraumeni JF Jr']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Connecticut', 'Female', 'Humans', 'Laryngeal Neoplasms/epidemiology', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Nose Neoplasms/epidemiology', 'Paranasal Sinus Neoplasms/epidemiology', 'Registries', 'Respiratory Tract Neoplasms/*epidemiology', 'Risk', 'Sex Factors']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:83-98.,,,,,,,,,,,,
4088311,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80.",389-409,"In Denmark, approximately 5% of all malignant neoplasms occur within the lymphatic and hematopoietic tissues. Between 1943 and 1980, 23,367 persons with these diseases fulfilled the criteria for entering the study. The risk of developing a second primary cancer was significantly increased only after Hodgkin's disease [relative risk (RR) = 1.6], whereas no increase was found after non-Hodgkin's lymphoma [(NHL); RR = 1.0] or leukemia (RR = 1.1), and a significant deficit occurred after multiple myeloma (RR = 0.8). All initial cancer sites showed a higher incidence of second primary cancers among males than females. Significant elevated risks for acute non-lymphocytic leukemia occurred after Hodgkin's disease (RR = 17), NHL (3.8), and multiple myeloma (9.1). Among persons initially diagnosed with leukemia, NHL was significantly elevated (RR = 2.6). However, these RR should be regarded as minimum figures due to the likelihood of serious underreporting of second primary hematologic cancers in Denmark. The secondary leukemias were likely induced by the treatment of the first primary cancer (chemotherapy, radiotherapy), but common etiologies, misclassification, or progression of the initial cancer cannot be ruled out entirely. Other second primary cancers found to be above expectation following Hodgkin's disease were cancers of the pancreas, lung, and urinary bladder. The risk for bladder cancer increased with time, which suggested a causal relation to radiation or chemotherapy, or both. Cancers of the colon and rectum following NHL and female breast cancer following leukemia occurred below expectation and remain unexplained.","['Storm, H H', 'Prener, A']","['Storm HH', 'Prener A']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Denmark', 'Female', 'Hodgkin Disease/epidemiology', 'Humans', 'Leukemia/*epidemiology', 'Lymphoma/*epidemiology', 'Male', 'Multiple Myeloma/epidemiology', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Sex Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:389-409.,,,,,,,,,,,,
4088310,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80.",361-88,"Second primary cancers were studied in persons with rare tumors between 1943 and 1980. The risk of developing a new cancer was evaluated in 7,211 persons with cutaneous melanoma, 1,784 persons with eye cancer, 10,273 persons with tumors of the brain and nervous system, 1,935 persons with thyroid cancer, 1,542 persons with bone tumors, and 2,318 persons with malignant neoplasms of the connective tissue. All cancer patients were diagnosed in Denmark between 1943 and 1980 and survived for 2 or more months. Nonmelanoma skin cancers were excluded from the analysis, whereas tumors of the brain and nervous system included both benign and malignant neoplasms. Overall, patients with these cancers showed no greater incidence of new tumors than expected from comparisons with the general population. An excess of chronic lymphocytic leukemia was observed subsequent to all cancers derived from the neural tube, i.e., melanoma and tumors of the eye, brain, and nervous system. Bone cancer occurred excessively, although the possibility of misclassified metastases could not be eliminated. Patients with tumors of the brain and nervous system who survived for 10 or more years developed significantly more cancers of the kidney and connective tissue and melanoma than anticipated. A deficit of second cancers of the digestive system was noted after primary bone and connective tissue cancers, in contrast to an excess of second cancers of the lung and kidney. Although based on few cases, patients with bone cancer showed a large excess of eye cancer as a second primary. The association between cancers of the breast and connective tissue was found to be bidirectional. Persons with connective tissue cancer were at increased risk of developing non-Hodgkin's lymphoma. Thyroid cancer patients were at high risk of subsequent tumors of the brain and nervous tissue and non-Hodgkin's lymphoma. However, contrary to previous reports, the risk of breast cancer was not elevated following thyroid cancer.","['Osterlind, A', 'Olsen, J H', 'Lynge, E', 'Ewertz, M']","['Osterlind A', 'Olsen JH', 'Lynge E', 'Ewertz M']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Bone Neoplasms/*epidemiology', 'Brain Neoplasms/*epidemiology', 'Connective Tissue Diseases/*epidemiology', 'Denmark', 'Eye Neoplasms/*epidemiology', 'Female', 'Humans', 'Male', 'Melanoma/*epidemiology', 'Neoplasms/*epidemiology', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Sex Factors', 'Skin Neoplasms/*epidemiology', 'Thyroid Neoplasms/*epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:361-88.,,,,,,,,,,,,
4088308,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the male genital system in Denmark, 1943-80.",341-7,"The incidence of second primary cancers was investigated among 19,886 patients with prostate cancer. The analysis disclosed 594 new cancers, which was significantly less than the expected 1,176 cases (relative risk = 0.51). Deficits were observed for most sites but were only significant for cancers of the lip, lung, and gastrointestinal organs. The average age at diagnosis of prostate cancer was 72 years. It is likely that the apparent deficit in the incidence of second neoplasms resulted from less diagnostic aggressiveness in elderly patients with cancer compared with younger patients. The risk of developing a second primary cancer was also investigated in 4,290 men with testis cancer reported to the Danish Cancer Registry between 1943 and 1980. A significant 29% excess of second cancers was found (174 observed vs. 135 expected). A bimodal distribution of risk over time was found with a 67% excess seen among patients followed for 1-4 years that was mainly due to increased incidence of acute nonlymphocytic leukemia and malignant lymphomas. Among patients surviving 10 or more years, the overall excess of 32% observed was mainly due to cancers of the gastrointestinal tract and the urinary bladder. As part of the initial treatment for testis cancer, 82% of the patients received radiotherapy. Chemotherapy was rarely given before 1975 and then mostly to patients with a poor prognosis. Late effects of radiotherapy conceivably could account for some of the excess of second hematologic as well as solid neoplasms.","['Osterlind, A', 'Rorth, M', 'Prener, A']","['Osterlind A', 'Rorth M', 'Prener A']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Denmark', 'Female', 'Genital Neoplasms, Male/*epidemiology', 'Humans', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Testicular Neoplasms/epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:341-7.,,,,,,,,,,,,
4088307,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the female genital system in Denmark, 1943-80.",331-40,"Between 1943 and 1980, approximately 53,000 women in Denmark survived 2 or more months after initial diagnosis of cancers of the cervix uteri, corpus uteri, ovaries, fallopian tubes, and ligaments. No significant excess of new cancers was observed following cancers of the cervix and corpus uteri. However, after second cancers of both the cervix and corpus uteri were eliminated from the analysis (because it was likely they were surgically removed or not recorded due to conservative coding practices), 6 and 4% excess risks of borderline significance were found among women with cancer of the cervix and uterus, respectively. A significant 25% excess of all second primary cancers was observed following cancer of the ovary (relative risk = 1.25; 95% CI = 1.14-1.37). Significant excesses of colon and breast cancers followed cancers of the ovary and corpus uteri. Subsequent to cervical cancer, the risk of cancers of the lung, esophagus, bladder, and kidney occurred significantly above expectation. These associations may be explained by common risk factors related to reproduction and possibly diet for cancers of the breast, colon, ovary, and corpus uteri; and to cigarette smoking for cancers of the lung, esophagus, bladder, and cervix uteri. The significant deficit of breast cancer after cervical cancer could be due to different patterns of risk factor (i.e., reproductive and socioeconomic variables) and loss of functioning ovaries as a part of the treatment for cervical cancer. Each of the female genital sites showed significant excesses of second bladder cancers, and the risk increased significantly with time, which indicate a relation to radiotherapy. The pattern of risk of leukemia observed following cancer of the ovary was also compatible with effects of treatment, especially chemotherapy.","['Storm, H H', 'Ewertz, M']","['Storm HH', 'Ewertz M']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Denmark', 'Female', 'Genital Neoplasms, Female/*epidemiology', 'Humans', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Ovarian Neoplasms/epidemiology', 'Registries', 'Risk', 'Uterine Neoplasms/epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:331-40.,,,,,,,,,,,,
4088306,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the female breast in Denmark, 1943-80.",325-9,"The risk of a person developing a second primary cancer was evaluated in approximately 55,000 women diagnosed with breast cancer in Denmark between 1943 and 1980. Excluding second cancers of the contralateral breast, 2,480 new cancers were observed compared with 2,398 expected (relative risk = 1.03; 95% CI = 0.99-1.08). Breast cancer patients followed for 10 years or more showed a significant 13% excess of all second primary tumors. Significant excesses of cancers of the lung, bone, and connective tissue were observed. Although some misclassification of metastases may have occurred, the risk of second cancers at these sites (as well as the salivary gland and esophagus) increased significantly with time and was especially high among women followed for 10 years or more. These observations suggest that radiation, as a part of the initial treatment, may have been involved. Radiation or chemotherapy, or both, may also have influenced the risk of acute nonlymphocytic leukemia (51 cases observed vs. 20.7 expected), which remained significantly elevated after the first year of follow-up. Common risk factors, related to reproductive experience and nutrition, may have contributed to the excess risk of cancers of the ovary and colon. On the other hand, an anticipated excess of cancer of the corpus uteri was not found, although cancer of the uterus not otherwise specified was significantly increased. Significant deficits were observed for second cancers of the liver and biliary tract, due perhaps to underreporting or conservative coding practices, or both. A significant excess of malignant melanoma was not easily explained but might indicate a common hormonal etiology with breast cancer.(ABSTRACT TRUNCATED AT 250 WORDS)","['Ewertz, M', 'Mouridsen, H T']","['Ewertz M', 'Mouridsen HT']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Breast Neoplasms/*epidemiology', 'Denmark', 'Female', 'Humans', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:325-9.,,,,,,,,,,,,
4088298,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82.",191-217,"The risk of developing a second primary cancer was evaluated in approximately 19,000 persons with initial cancers of the lymphatic and hematopoietic system in Connecticut between 1935 and 1982. Significant excesses for all second cancers were observed among patients with leukemia (34%), Hodgkin's disease (70%), non-Hodgkin's lymphoma (25%), and multiple myeloma (24%). In general, the risk of second cancers was greater in males than in females, even for cohorts not showing an excess of surveillance-related prostate cancer. Among patients with leukemia, significant excesses of cancers of the lung, kidney/ureter, and prostate were noted; cutaneous melanoma was elevated only in males. These excesses did not persist in the small number of long-term survivors. Possible etiologic factors included tobacco smoking for lung and kidney cancers, medical surveillance artifact for prostate cancer, and immunosuppression for malignant melanoma and lung cancer. The large number and good prognoses of patients with chronic lymphocytic leukemia strongly influenced the pattern of second cancers when all leukemias were analyzed together; no evidence was found for an increased risk of second cancer in patients with acute lymphocytic leukemia. A disproportionate number of subsequent cancers, particularly those of the kidney and ureter, were diagnosed incidentally at autopsy. Patients with Hodgkin's disease displayed significant excesses of cancers of the buccal cavity and pharynx, lung, female breast, and thyroid. The latter 3 sites remained significantly elevated in long-term survivors (10 yr or more postdiagnosis), so that radiation therapy may have contributed to their development. Among persons with non-Hodgkin's lymphoma, cancers of the stomach, lung, brain, and connective tissue occurred excessively. The first 3 sites, plus cancers of the urinary bladder, remained elevated among long-term survivors. The brain cancer excess, not previously reported, may represent misclassification of central nervous system lymphoma. The risk of gastric cancer is reminiscent of similar findings in patients with both acquired and genetically determined immunodeficiency disorders. The alkylating agent, cyclophosphamide, used extensively in the treatment of non-Hodgkin's lymphoma, is known to cause bladder cancer in man.(ABSTRACT TRUNCATED AT 400 WORDS)","['Greene, M H', 'Wilson, J']","['Greene MH', 'Wilson J']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Connecticut', 'Female', 'Hodgkin Disease/epidemiology', 'Humans', 'Leukemia/*epidemiology', 'Lymphoma/*epidemiology', 'Male', 'Multiple Myeloma/epidemiology', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Sex Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:191-217.,,,,,,,,,,,,
4088297,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82.",161-89,"The risk of second primary cancers developing was evaluated in individuals with 6 rare tumors in Connecticut between 1935 and 1982. Small but significant excesses of all second cancers occurred in patients with cutaneous melanoma (42%), and cancers of the brain (59%), thyroid (49%), connective tissue (23%), bone (66%), and eye (40%). In individuals with cutaneous melanoma, the highest risks were for subsequent cutaneous melanomas [relative risk (RR) = 8.5] that persisted throughout all intervals of observation. The risk for second melanomas was higher in persons under age 40, consistent with a heritable component. Connective tissue tumors and breast cancers also occurred in excess. Among patients with brain cancer, an increase of melanoma was observed that may represent an underlying neural crest abnormality, although no excess of brain cancer was seen after melanoma. Reciprocal increases of bone cancer after connective tissue cancer and connective tissue cancer after bone cancer point to shared risk factors, such as high dose radiotherapy or genetic susceptibility states. An anticipated high risk of osteogenic sarcoma following Ewing's sarcoma was not seen. An excess of breast cancer (RR = 1.9) after thyroid cancer indicates common etiologic factors. Expected excesses of bilateral retinoblastoma and bone cancer after retinoblastoma were seen. Tumors commonly treated with alkylating agents or nitrosoureas (melanoma, brain, connective tissue) showed slightly elevated risks of acute nonlymphocytic leukemia. Prostate cancer was frequently found to be in excess, but this is likely an artifact due to ascertainment bias.","['Tucker, M A', 'Boice, J D Jr', 'Hoffman, D A']","['Tucker MA', 'Boice JD Jr', 'Hoffman DA']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Bone Neoplasms/*epidemiology', 'Brain Neoplasms/*epidemiology', 'Connecticut', 'Connective Tissue Diseases/*epidemiology', 'Eye Neoplasms/*epidemiology', 'Female', 'Humans', 'Male', 'Melanoma/*epidemiology', 'Neoplasms/*epidemiology', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Skin Neoplasms/*epidemiology', 'Thyroid Neoplasms/*epidemiology']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:161-89.,,,,,,,,,,,,
4088296,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the urinary system in Connecticut, 1935-82.",149-59,"The risk of second primary cancer was assessed in persons who developed cancer of the urinary tract in Connecticut during 1935-82. Among 12,384 patients with a first primary tumor of the bladder or urethra, a second cancer was reported in 1,151 (or 9%). A significantly elevated relative risk (RR) of 1.23 was due to excess cancers of the lung, larynx, prostate, and kidney, and acute nonlymphocytic leukemia. Among 5,115 persons with a first primary tumor of the kidney, renal pelvis or ureter, a second cancer was reported in 374 (or 7%) that yielded a significantly elevated RR of 1.54 due to excess tumors of the bladder and prostate and second primary kidney neoplasms. The role of common etiologic factors, such as cigarette smoking, the multifocal tendency of tumors of the urinary tract, and heightened medical surveillance are discussed in relation to these findings.","['Kantor, A F', 'McLaughlin, J K']","['Kantor AF', 'McLaughlin JK']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Connecticut', 'Female', 'Humans', 'Kidney Neoplasms/epidemiology', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Sex Factors', 'Ureteral Neoplasms/epidemiology', 'Urogenital Neoplasms/*epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:149-59.,,,,,,,,,,,,
4088295,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the male genital system in Connecticut, 1935-82.",139-47,"The risk of a second primary cancer developing was evaluated in nearly 20,000 men with cancers of the prostate or testis in Connecticut, 1935-82. Among 18,135 men with prostate cancer, a significant 15% deficit of all second cancers was observed [1,053 vs. 1,241; relative risk (RR) = 0.85; 95% CI = 0.80-0.90], most notably for respiratory (RR = 0.7) and digestive cancers (RR = 0.8). The absence of a colon cancer risk lends little support to the idea of common risk factors such as dietary fat consumption. Only the risk for salivary gland cancer was significantly increased, possibly due to chance. Leukemia was significantly elevated among men observed for 10 and more years (RR = 2.2). In contrast to most other index tumors, the prostate stands out as being associated with an overall low risk of second cancer development. The reasons for these deficiencies have not been explained. Among 1,446 men with testis cancer, a significant twofold risk of second cancers was seen (104 vs. 50.1). A fivefold risk of leukemia (8 vs. 1.5) was not related to treatment or age. Contralateral testis cancer (6 vs. 0.5) was elevated in men treated with and without radiation. Risks for kidney cancer (5 vs. 1.5), bladder cancer (9 vs. 3.4), pancreatic cancer (6 vs. 1.5), non-Hodgkin's lymphoma (6 vs. 1.5), and prostate cancer (12 vs. 5.9) were significantly increased. No trends over time were noted for any cancer. Overall risk of second cancer development tended to be higher in younger men with testis cancer. The relationship of leukemia to testis and prostate cancers should be investigated in future research.","['Kleinerman, R A', 'Liebermann, J V', 'Li, F P']","['Kleinerman RA', 'Liebermann JV', 'Li FP']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Connecticut', 'Female', 'Genital Neoplasms, Male/*epidemiology', 'Humans', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Registries', 'Risk', 'Testicular Neoplasms/epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:139-47.,,,,,,,,,,,,
4088294,NLM,MEDLINE,19860307,20041117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Cancer registration in Connecticut and the study of multiple primary cancers, 1935-82.",13-24,"The Connecticut Tumor Registry (CTR) was established in 1941 and is the oldest population-based cancer registry in the world. Since 1935, all malignant tumors have been registered, and cancer patients are followed annually for vital status. Reporting by hospitals of all cancers diagnosed in Connecticut residents became mandatory in 1971. The reporting physician or hospital makes the initial determination as to whether a tumor is an independent primary cancer, recurrent tumor, or metastatic lesion. In addition, the Registry maintains stringent quality control procedures to avoid duplication of cancer reports. The Registry reviews reports of new cancers developing in patients with a previous primary cancer to rule out the possibility of misdiagnosed metastases. Microscopic confirmation of the diagnosis has improved from 49% in 1935-39 to 94% in 1980-82. Cancers reported only from death certificates currently account for only 1% of all registrations. Between 1935 and 1979, cancer rates in Connecticut almost doubled among males and increased by more than one-third among females; notable increases were seen for cancers of the lung and prostate in males and cancers of the lung and breast in females. In recent years, rates for malignant melanoma of the skin have increased dramatically among both sexes. Stomach cancer has decreased over time in both sexes, as has cervical cancer in females. Although the CTR has used several revisions of the International Classification of Diseases to code the primary site of cancers, rules for the coding of multiple primary cancers have remained essentially the same. Among 253,536 individuals diagnosed between 1935 and 1982 with an invasive cancer, 16,727 (6.6%) nonsimultaneous second cancers were evaluated and are discussed in subsequent chapters of this monograph. Simultaneous cancers were diagnosed in 4,107 individuals and accounted for approximately 20% of all multiple cancers reported in Connecticut. The most frequent simultaneous tumors were cancers of the colon, rectum, prostate, lung, breast, and bladder. Some simultaneous cancers (chronic lymphocytic leukemia, testis, prostate, rectum, uterine corpus, and liver and biliary tract) occurred almost as frequently as the number of subsequent nonsimultaneous tumors, which suggests that the patterns of risk over time for certain sites may be distorted when diagnoses are advanced in time and removed from analysis.(ABSTRACT TRUNCATED AT 400 WORDS)","['Flannery, J T', 'Boice, J D Jr', 'Devesa, S S', 'Kleinerman, R A', 'Curtis, R E', 'Fraumeni, J F Jr']","['Flannery JT', 'Boice JD Jr', 'Devesa SS', 'Kleinerman RA', 'Curtis RE', 'Fraumeni JF Jr']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Age Factors', 'Connecticut', 'Demography', 'Female', 'Humans', 'Male', 'Neoplasms/diagnosis/epidemiology', 'Neoplasms, Multiple Primary/diagnosis/*epidemiology', 'Registries']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:13-24.,,,,,,,,,,,,
4088293,NLM,MEDLINE,19860307,20051117,0083-1921 (Print) 0083-1921 (Linking),68,,1985 Dec,"Second cancer following cancer of the female genital system in Connecticut, 1935-82.",113-37,"The risk of second primary cancer was evaluated in more than 25,000 women with cancer of the genital organs diagnosed between 1935 and 1982 in Connecticut. Significant excesses of subsequent cancers were observed following cancers of the cervix (35%, n = 656), uterine corpus (16%, n = 1,060), and ovary (58%, n = 366). When observed and expected second cancers of the female genital tract were excluded, these excesses became 40%, 30%, and 59% after cervix, uterine corpus, and ovary, respectively. Among women with either cancer of the cervix or uterine corpus, the risk of developing a second cancer rose with increasing duration of follow-up, reaching an excess of 61 and 34%, respectively, after 20 years. In contrast, among patients with ovarian cancer, the second cancer risk decreased over time to 41% after 10 years. Cancers related to smoking, i.e., oral cavity and pharynx, esophagus, and respiratory system, were notably increased among cervical cancer patients. The twofold to threefold risks observed for these second cancers are consistent with recent evidence linking cervical cancer to cigarette smoking and seem too large to be artifacts of confounding by low socioeconomic status. An increased incidence of second cancer of the abdominal organs (colon, rectum, kidney, bladder, ovaries) was generally observed for each gynecologic site. However, only rectal cancer was consistently linked with radiation treatment for the first primary cancer. Leukemia occurred in excess after cancers of the uterine corpus and ovary, but not after cervical cancer. The predominant cell type was acute nonlymphocytic leukemia, and the excess was associated with radiotherapy for uterine corpus cancer and with chemotherapy for ovarian cancer. Cancers of the breast and colon were increased following uterine corpus and ovarian cancer and vice versa, which supports the notion that these sites share a common etiology, perhaps related to dietary or hormonal factors. Cervical cancer patients experienced a deficit of subsequent breast cancer, possibly due to ovarian removal or ablation by radiation. Investigators need to explore further the association between the smoking-related cancer sites and cervical cancer, to clarify the role of radiotherapy and chemotherapy in relation to excess cancers, and to define more fully the etiologic factors that link cancers of the breast, colon, uterine corpus, and ovary.","['Curtis, R E', 'Hoover, R N', 'Kleinerman, R A', 'Harvey, E B']","['Curtis RE', 'Hoover RN', 'Kleinerman RA', 'Harvey EB']",['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Breast Neoplasms/*epidemiology', 'Connecticut', 'Fallopian Tube Neoplasms/epidemiology', 'Female', 'Humans', 'Male', 'Neoplasms, Multiple Primary/*epidemiology', 'Ovarian Neoplasms/epidemiology', 'Registries', 'Risk', 'Uterine Cervical Neoplasms/epidemiology', 'Uterine Neoplasms/epidemiology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 Dec;68:113-37.,,,,,,,,,,,,
4088090,NLM,MEDLINE,19860314,20190711,0076-6879 (Print) 0076-6879 (Linking),116,,1985,Immunoglobulin E (IgE).,76-94,,"['Ishizaka, K']",['Ishizaka K'],['eng'],['Journal Article'],United States,Methods Enzymol,Methods in enzymology,0212271,IM,"['Animals', 'Basophils/immunology', 'Chromatography, Affinity/methods', 'Chromatography, DEAE-Cellulose/methods', 'Chromatography, Gel/methods', 'Humans', 'Immunoglobulin E/*isolation & purification', 'Immunoglobulin Fragments/analysis', 'Indicators and Reagents', 'Leukemia, Experimental/immunology', 'Mast Cells/immunology', 'Mice', 'Molecular Weight', 'Passive Cutaneous Anaphylaxis', 'Radioimmunoassay', 'Rats', 'Species Specificity', 'Terminology as Topic']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/s0076-6879(85)16006-4 [doi]'],ppublish,Methods Enzymol. 1985;116:76-94. doi: 10.1016/s0076-6879(85)16006-4.,"['0 (Immunoglobulin Fragments)', '0 (Indicators and Reagents)', '37341-29-0 (Immunoglobulin E)']",,,,,,,,,,,
4087824,NLM,MEDLINE,19860320,20061115,0300-8630 (Print) 0300-8630 (Linking),197,6,1985 Nov-Dec,[Delayed-type skin reaction in children with malignant diseases].,447-52,"The delayed type hypersensitivity reaction has been employed in order to study the cell-mediated immunity in 103 children and adolescents with malignant tumors, using the Multitest system (Merieux). This skin test allows the simultaneous application of seven various recall-antigens in a standardized fashion and proved to be very predicative in normal children and adolescents at the age of 1-30 years, since beyond infancy no major variations of the test results has been observed in older age groups and a complete anergy has only been seen in 1.8%. The tumor patients were divided in three groups (50 patients with leukemia and malignant lymphoma, 23 patients with malignant bone tumors and 30 patients with other malignant diseases) and studied at the beginning or under chemotherapy. A significant decrease of skin reactions or a total anergy were found in all tumor groups compared to the normal control group and regardless the duration of chemotherapy. This was more pronounced in patients with systemic malignancies than in solid tumors. The largest group of the ALL- and NHL-patients showed a severely depressed cell-mediated immunity or complete anergy at the beginning of chemotherapy and subsequently improved already during the induction phase of chemotherapy. If improvement was missing, it was highly suspicious for relapse. In addition, such an increase of skin reactivity could not be demonstrated in few relapse patients during reinduction therapy. Patients with malignant bone tumors did not show such a dramatic depression of cell-mediated immunity at the beginning of chemotherapy and the results correlated with the course of the intervall chemotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)","['Ebell, W', 'Schmidt, C', 'Wahn, V', 'Gobel, U']","['Ebell W', 'Schmidt C', 'Wahn V', 'Gobel U']",['ger'],"['Comparative Study', 'English Abstract', 'Journal Article']",Germany,Klin Padiatr,Klinische Padiatrie,0326144,IM,"['Adolescent', 'Adult', 'Bone Neoplasms/immunology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Hypersensitivity, Delayed/*immunology', 'Immunity, Cellular', 'Infant', 'Leukemia/immunology', 'Lymphoma/immunology', 'Male', 'Neoplasms/*immunology', 'Prognosis', 'Skin/*immunology', 'Skin Tests/methods']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1055/s-2008-1034020 [doi]'],ppublish,Klin Padiatr. 1985 Nov-Dec;197(6):447-52. doi: 10.1055/s-2008-1034020.,,,Die Hautreaktion vom verzogerten Typ bei Kindern mit malignen Erkrankungen.,,,,,,,,,
4087437,NLM,MEDLINE,19860326,20041117,0047-1860 (Print) 0047-1860 (Linking),33,10,1985 Oct,[Circulating immune complexes in human leukemia].,1119-23,,"['Takamura, T', 'Senda, Y', 'Yamagishi, K', 'Fujita, S', 'Matsubara, F']","['Takamura T', 'Senda Y', 'Yamagishi K', 'Fujita S', 'Matsubara F']",['jpn'],['Journal Article'],Japan,Rinsho Byori,Rinsho byori. The Japanese journal of clinical pathology,2984781R,IM,"['Antigen-Antibody Complex/*analysis', 'Antineoplastic Agents/pharmacology', 'Enzyme-Linked Immunosorbent Assay', 'Humans', 'Leukemia/*immunology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Rinsho Byori. 1985 Oct;33(10):1119-23.,"['0 (Antigen-Antibody Complex)', '0 (Antineoplastic Agents)']",,,,,,,,,,,
4087033,NLM,MEDLINE,19860324,20201221,0732-6580 (Print) 0732-6580 (Linking),4,6,1985 Dec,"Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].",621-7,"Polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC] significantly augmented natural killer (NK) cell activity in several tissues. Macrophage (M phi) tumoricidal activity was also markedly increased. Both effector cells were active for 9 days. Poly(I,C)-LC also increased effector cell response in vitro. Injections of poly(I,C)-LC resulted in elevated effector cell responses in four of five routes tested. Treatment with poly(I,C)-LC led to an earlier reconstitution of bone marrow cells, NK cell activity, and M phi effector cell activity in mice pretreated with cyclophosphamide (Cytoxan). Combined treatment of MBL-2 tumor cells with cytoreductive chemotherapy and poly(I,C)-LC resulted in an enhanced therapeutic response.","['Chirigos, M A', 'Schlick, E', 'Ruffmann, R', 'Budzynski, W', 'Sinibaldi, P', 'Gruys, E']","['Chirigos MA', 'Schlick E', 'Ruffmann R', 'Budzynski W', 'Sinibaldi P', 'Gruys E']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Biol Response Mod,Journal of biological response modifiers,8219656,IM,"['Animals', 'Antineoplastic Agents/metabolism/therapeutic use', 'Carboxymethylcellulose Sodium/administration & dosage/*metabolism/therapeutic use', 'Cyclophosphamide/administration & dosage', 'Drug Therapy, Combination', 'Female', 'In Vitro Techniques', 'Killer Cells, Natural/drug effects/immunology', 'Kinetics', 'Leukemia, Experimental/drug therapy', 'Macrophages/drug effects/immunology', 'Methylcellulose/*analogs & derivatives', 'Mice', 'Poly I-C/administration & dosage/*metabolism/therapeutic use', 'Polylysine/administration & dosage/*metabolism/therapeutic use']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,J Biol Response Mod. 1985 Dec;4(6):621-7.,"['0 (Antineoplastic Agents)', '25104-18-1 (Polylysine)', '7KYP9TKT70 (poly ICLC)', '8N3DW7272P (Cyclophosphamide)', '9004-67-5 (Methylcellulose)', 'K679OBS311 (Carboxymethylcellulose Sodium)', 'O84C90HH2L (Poly I-C)']",,,,,,,,,,,
4086829,NLM,MEDLINE,19860318,20041117,0019-5847 (Print) 0019-5847 (Linking),83,7,1985 Jul,Hairy cell leukaemia.,239-40,,"['Chugh, S N', 'Rajapal, K', 'Singh, U', 'Malhotra, K C', 'Yadav, M S']","['Chugh SN', 'Rajapal K', 'Singh U', 'Malhotra KC', 'Yadav MS']",['eng'],"['Case Reports', 'Journal Article']",India,J Indian Med Assoc,Journal of the Indian Medical Association,7505608,IM,"['Aged', 'Bone Marrow/pathology', 'Humans', 'Leukemia, Hairy Cell/*diagnosis/pathology', 'Male', 'Monocytes/pathology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,J Indian Med Assoc. 1985 Jul;83(7):239-40.,,,,,,,,,,,,
4086140,NLM,MEDLINE,19860318,20190511,0300-5771 (Print) 0300-5771 (Linking),14,4,1985 Dec,Geographical variation of cancer mortality in Italy.,538-48,"The distribution of death certification rates from various cancers or groups of cancers in broad Italian geographical areas (north/centre/south) was analysed. In both sexes, total cancer mortality was considerably elevated in the north of the country compared to southern regions (around 70% for males and 30% for females in the truncated 35-64 rate), and generally intermediate in central areas. Northern mortality rates were higher for respiratory cancers and other tobacco related neoplasms (excluding bladder), with a north/south ratio ranging from 1.5 for lung and most respiratory sites to about 4.0 for oesophageal cancer in males. There was little tendency towards a leveling of these differences in younger (40-49 year old) males. Northern areas showed higher death certification rates for cancers of the stomach, large bowel, liver and most other digestive sites. The lower gastric cancer mortality registered in southern Italy is curious, since this is the poorest part of the country. Death certification rates from all other common neoplasms (uterus apart) were also elevated in the north. The geographical variation, however, appeared more limited for non-epithelial neoplasms. The substantial differences in cancer mortality between various Italian geographical areas can hardly be dismissed as due to lower death certification accuracy in the south. Some of the differences can be explained in terms of available knowledge of the causes of cancer (eg reproductive factors for breast and ovarian neoplasms, alcohol plus tobacco for oesophageal cancer). However, the lower mortality from respiratory cancers in southern areas can only with some difficulty be totally explained in terms of tobacco consumption. Likewise, the north/south variation cannot be related to non-specific consequences of industrialization, since cancer mortality was similarly elevated in highly industrialized and chiefly rural northern areas. It is conceivable that dietary factors may also explain some of the differences. However, at present, there is no obvious general explanation for this quite peculiar geographical distribution of cancer mortality within a single country.","['Facchini, U', 'Camnasio, M', 'Cantaboni, A', 'Decarli, A', 'La Vecchia, C']","['Facchini U', 'Camnasio M', 'Cantaboni A', 'Decarli A', 'La Vecchia C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Int J Epidemiol,International journal of epidemiology,7802871,IM,"['Adult', 'Age Factors', 'Breast Neoplasms/mortality', 'Diet', 'Ethanol', 'Female', 'Gastrointestinal Neoplasms/mortality', 'Humans', 'Italy', 'Leukemia/mortality', 'Male', 'Middle Aged', 'Neoplasms/*mortality', 'Nervous System Neoplasms/mortality', 'Ovarian Neoplasms/mortality', 'Plants, Toxic', 'Respiratory Tract Neoplasms/mortality', 'Sarcoma/mortality', 'Sex Factors', 'Skin Neoplasms/mortality', 'Tobacco', 'Urogenital Neoplasms/mortality', 'Uterine Neoplasms/mortality']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1093/ije/14.4.538 [doi]'],ppublish,Int J Epidemiol. 1985 Dec;14(4):538-48. doi: 10.1093/ije/14.4.538.,['3K9958V90M (Ethanol)'],,,,"['IND: 9014676', 'POP: 00154653']","['The authors examine variations in mortality due to cancer among the northern,', 'central, and southern regions of Italy. Using data from official death records', 'for the years 1969-1978, the authors calculate age-standardized mortality rates', 'for all ages and for ages 35-64, and age-specific mortality rates for men and', 'women aged 40-49. The results are presented by sex and region for 29 categories', 'of cancer. The analysis shows a clear north-south gradient with consistently', 'higher mortality rates in the north, lower rates in the south, and intermediate', 'values in the central region. More detailed findings according to sex, age, and', 'type of cancer are discussed, and possible reasons for the geographical', 'variations, including regional patterns concerning diet, alcohol consumption, and', 'smoking, are considered.']",['eng'],['PIP'],"['*Age Factors', '*Age Specific Death Rate', 'Alcohol Drinking', '*Causes Of Death', 'Death Rate', 'Demographic Factors', 'Developed Countries', '*Differential Mortality', 'Europe', '*Geographic Factors', 'Italy', 'Mediterranean Countries', '*Mortality--changes', 'Nutrition', 'Population', 'Population Characteristics', 'Population Dynamics', '*Sex Factors', 'Smoking', '*Southern Europe']",['PIP: TJ: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY'],,
4086079,NLM,MEDLINE,19860305,20071115,0300-5038 (Print) 0300-5038 (Linking),,65,1985,Interpretation of negative epidemiological evidence for carcinogenicity. Statistical considerations.,13-27,,"['Day, N E']",['Day NE'],['eng'],['Journal Article'],France,IARC Sci Publ,IARC scientific publications,8009542,IM,"['Adolescent', 'Adult', 'Asbestos/adverse effects', 'Bone Marrow/radiation effects', 'Dose-Response Relationship, Drug', 'Dose-Response Relationship, Radiation', '*Epidemiologic Methods', 'Female', 'Humans', 'Leukemia, Radiation-Induced/epidemiology', 'Lung Neoplasms/chemically induced/epidemiology/etiology', 'Male', 'Neoplasms/*epidemiology/etiology', 'Neoplasms, Radiation-Induced/epidemiology/etiology', 'Occupational Diseases/chemically induced/epidemiology/etiology', 'Radiotherapy/adverse effects', 'Risk', 'Statistics as Topic', 'Stomach Neoplasms/epidemiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,IARC Sci Publ. 1985;(65):13-27.,['1332-21-4 (Asbestos)'],,,,,,,,,,,
4085970,NLM,MEDLINE,19860228,20061115,0367-6102 (Print) 0367-6102 (Linking),60,6,1985 Nov,[Immunogenicity of viable tumor cells--comparison of immunogenicity between xenogenized tumor cells and BCG-tumor cell vaccine].,908-15,"We compared the immunogenicity of FV-KMT-17 (fibrosarcoma, KMT-17 cells which had been xenogenized by infection with Friend leukemia virus (FV] and BCG + KMT-17 (KMT-17 cells which had been admixed with BCG), both of which can be used as viable tumor cell vaccines. The strength of immunogenicity shown by ETD50 (50% effective tumor dose), the number of immunizing cells required for a 50% suppression of growth of 10(7) KMT-17 cells, was 2.1 X 10(3) in FV-KMT-17 and 36.3 X 10(3) in BCG + KMT-17. The LTD50 (50% lethal tumor dose) which was required to kill 50% of rats immunized with 10(5) FV-KMT-17 was more than 10,000 times as high as the amount of LTD50 in normal rats. The LTD50 in rats immunized with the same number of BCG + KMT-17 was only 3,680 times higher than the amount in normal rats. These results indicate that the immunogenicity of FV-KMT-17 is much stronger than that of BCG + KMT-17. The difference in immunogenicity between the two vaccines was also observed in the tumor -neutralizing activities of spleen cells obtained from rats which had been immunized with them, as measured by Winn assay. Moreover, the antitumor activity of spleen cells from rats immunized with FV-KMT-17 concentrated in the carrageenan-non-sensitive and plastic nonadherent cells, while that of spleen cells from rats immunized with BCG + KMT-17 was observed in both carrageenan-sensitive and plastic adherent cells as well as nonadherent cells.(ABSTRACT TRUNCATED AT 250 WORDS)","['Suzuki, Y']",['Suzuki Y'],['jpn'],"['English Abstract', 'Journal Article']",Japan,Hokkaido Igaku Zasshi,[Hokkaido igaku zasshi] The Hokkaido journal of medical science,17410290R,IM,"['Animals', 'BCG Vaccine/*immunology', 'Cell Division', 'Female', 'Fibrosarcoma/*immunology', 'Immunity, Cellular', 'Rats', 'Rats, Inbred Strains', 'Retroviridae/*immunology', 'Sarcoma, Experimental/immunology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Hokkaido Igaku Zasshi. 1985 Nov;60(6):908-15.,['0 (BCG Vaccine)'],,,,,,,,,,,
4085778,NLM,MEDLINE,19860324,20200713,0234-5730 (Print) 0234-5730 (Linking),30,12,1985 Dec,[Free-radical lipid oxidation in the erythrocyte membranes and the dynamics of endogenous alpha-tocopherol in the blood plasma of acute leukemia patients].,28-31,,"['Karagezian, K G', 'Bilian, L F', 'Osipova, E N', 'Pogosian, A S']","['Karagezian KG', 'Bilian LF', 'Osipova EN', 'Pogosian AS']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Gematol Transfuziol,Gematologiia i transfuziologiia,8301796,IM,"['Acute Disease', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Erythrocyte Membrane/*metabolism', 'Female', 'Free Radicals', 'Humans', 'Leukemia/*blood/drug therapy', 'Male', 'Membrane Lipids/*blood', 'Oxidation-Reduction/drug effects', 'Vitamin E/*blood']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Gematol Transfuziol. 1985 Dec;30(12):28-31.,"['0 (Free Radicals)', '0 (Membrane Lipids)', '1406-18-4 (Vitamin E)']",,Svobodnoradikal'noe okislenie lipidov v membranakh eritrotsitov i dinamika endogennogo al'fa-tokoferola v plazme krovi bol'nykh ostrym leikozom.,,,,,,,,,
4085767,NLM,MEDLINE,19860305,20200713,0234-5730 (Print) 0234-5730 (Linking),30,11,1985 Nov,[Characteristics of the formation of the immunologic response to hepatitis B virus in patients with leukemia].,21-4,,"['Golosova, T V', 'Fainshtein, F E', 'Pobedinskaia, I N', 'Liubimova, L S']","['Golosova TV', 'Fainshtein FE', 'Pobedinskaia IN', 'Liubimova LS']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Gematol Transfuziol,Gematologiia i transfuziologiia,8301796,IM,"['Carrier State/*immunology', 'Hepatitis B/*immunology', 'Hepatitis B Surface Antigens/analysis', 'Hepatitis B virus/*immunology', 'Humans', 'Leukemia/complications/*immunology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Gematol Transfuziol. 1985 Nov;30(11):21-4.,['0 (Hepatitis B Surface Antigens)'],,Osobennosti formirovaniia immunologicheskogo otveta k virusu gepatita B u bol'nykh leikozami.,,,,,,,,,
4085446,NLM,MEDLINE,19860226,20181113,0091-6765 (Print) 0091-6765 (Linking),62,,1985 Oct,"Formaldehyde, cancer, and social class.",465-6,,"['Levine, R J']",['Levine RJ'],['eng'],"['Comparative Study', 'Letter']",United States,Environ Health Perspect,Environmental health perspectives,0330411,IM,"['Adult', 'Aged', 'Brain Neoplasms/chemically induced/*mortality', 'Formaldehyde/*toxicity', 'Humans', 'Leukemia/chemically induced/*mortality', 'Male', 'Middle Aged', '*Socioeconomic Factors', 'United Kingdom', 'United States']",PMC1568717,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1289/ehp.8562465 [doi]'],ppublish,Environ Health Perspect. 1985 Oct;62:465-6. doi: 10.1289/ehp.8562465.,['1HG84L3525 (Formaldehyde)'],,,,,,,,,,,
4085433,NLM,MEDLINE,19860226,20181113,0091-6765 (Print) 0091-6765 (Linking),62,,1985 Oct,Mortality in workers exposed to electromagnetic fields.,297-300,"In an occupational mortality analysis of 486,000 adult male death records filed in Washington State in the years 1950-1982, leukemia and the non-Hodgkin's lymphomas show increased proportionate mortality ratios (PMRs) in workers employed in occupations with intuitive exposures to electromagnetic fields. Nine occupations of 219 were considered to have electric or magnetic field exposures. These were: electrical and electronic technicians, radio and telegraph operators, radio and television repairmen, telephone and power linemen, power station operators, welders, aluminum reduction workers, motion picture projectionists and electricians. There were 12,714 total deaths in these occupations. Eight of the nine occupations had PMR increases for leukemia [International Classification of Diseases (ICD), seventh revision 204] and seven of the nine occupations had PMR increases for the other lymphoma category (7th ICD 200.2, 202). The highest PMRs were seen for acute leukemia: (67 deaths observed, 41 deaths expected; PMR 162), and in the other lymphomas (51 deaths observed, 31 deaths expected; PMR 164). No increase in mortality was seen for Hodgkin's disease or multiple myeloma. These findings offer some support for the hypothesis that electric and magnetic fields may be carcinogenic.","['Milham, S Jr']",['Milham S Jr'],['eng'],['Journal Article'],United States,Environ Health Perspect,Environmental health perspectives,0330411,IM,"['Adult', 'Electromagnetic Fields/*adverse effects', 'Electromagnetic Phenomena/*adverse effects', 'Humans', 'Leukemia/mortality', 'Leukemia, Radiation-Induced/*etiology/mortality', 'Lymphoma/*etiology/mortality', 'Male', 'Neoplasms, Radiation-Induced/*etiology/mortality', 'Washington']",PMC1568699,1985/10/01 00:00,2001/03/28 10:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1289/ehp.8562297 [doi]'],ppublish,Environ Health Perspect. 1985 Oct;62:297-300. doi: 10.1289/ehp.8562297.,,,,,,,,,,,,
4085398,NLM,MEDLINE,19860307,20061115,0204-3564 (Print) 0204-3564 (Linking),7,6,1985,[Effect of a substance isolated from the regenerating spleen on the chromatin structural organization and the leukosogenic activity of transplanted cells].,44-7,"When leukemic cells in vitro are treated with the substance isolated from the regenerating calf spleen, incorporation of 3H-thymidine into DNA is rapidly inhibited. The completeness of DNA synthesis restoration after washing off cells from the substance depends on the duration of the previous contact with the substance. It is the change in the structural organization of chromatin but not the very fact of inhibition of the ability of the cells to the DNA synthesis that is important for a decrease of transplantability of mice cells treated by the substance. The quicker the stability of the DNA/protein interaction in chromatin weakens due to the effect of the substance, the earlier the leukosogenic potential of the treated cells decreases.","['Svirnovskii, A I', 'Shimanskaia, T V', 'Tsygankov, V G', 'Ageichik, V M', 'Bakun, A V']","['Svirnovskii AI', 'Shimanskaia TV', 'Tsygankov VG', 'Ageichik VM', 'Bakun AV']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Ukraine,Eksp Onkol,Eksperimental'naia onkologiia,8406659,IM,"['Animals', 'Cattle', 'Cells, Cultured', 'Chromatin/*drug effects/ultrastructure', 'DNA, Neoplasm/antagonists & inhibitors', 'Leukemia, Experimental/etiology/metabolism/*pathology', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred C57BL', 'Neoplasm Transplantation', '*Regeneration', 'Spleen/*physiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Eksp Onkol. 1985;7(6):44-7.,"['0 (Chromatin)', '0 (DNA, Neoplasm)']",,"Vliianie veshchestva, vydelennogo iz regeneriruiushchei selezenki, na strukturnuiu organizatsiiu khromatina i leikozogennuiu aktivnost' transplantirovannykh kletok.",,,,,,,,,
4085312,NLM,MEDLINE,19860320,20131121,0253-3766 (Print) 0253-3766 (Linking),7,4,1985 Jul,[Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].,250-3,"Ara-c entrapped into multilamella vesicles (MLV's) composed of PC:C (2:1) (phosphotidylcholine, cholesterol) or PC:SM (1:4) (sphingomyelin) was incubated in the simple salt medium at 37 degrees C for one hour. Its leakage from the liposomes was 5.6-17.6% but, in the presence of serum, the leakage was 35.7-49.1%. Having been incubated at 37 degrees C overnight, the leakage significantly increased but the leakage rate was the highest within the 1st hour. When ara-c entrapped into reverse evaporation vesicles (REV's) composed of PC:C (2:1) or PC:SM (1:4) was incubated in the simple salt medium at 37 degrees C for one hour, its leakage was 2.4-4.1% but, in the presence of serum, the leakage was 10.9-8.2%. When the liposomes were incubated at 37 degrees C overnight, the leakage gradually increased. Whether in the presence of serum or not, the leakage from REV's was much less than that from MLV's. There was no effect on the survival of L1210 leukemia mice when free ara-c was injected intraperitoneally once at the dose of 10 mg/kg, but when the same dose was given for five times, the increase rate in life span was 43.2--51.3%. When ara-c, entrapped into MLV's or REV's composed of PC:C (2:1) and PC:SM (1:4), was given at the dose of 10 mg/kg only once, the effect of intraperitoneal injection was more marked than that of intravenous injection. No effect was observed when free ara-c was continuously infused at the dose of 2 mg/kg once everyday for five days.(ABSTRACT TRUNCATED AT 250 WORDS)","['Fu, N W']",['Fu NW'],['chi'],"['English Abstract', 'Journal Article']",China,Zhonghua Zhong Liu Za Zhi,Zhonghua zhong liu za zhi [Chinese journal of oncology],7910681,IM,"['Animals', 'Cytarabine/*therapeutic use', 'Female', 'Leukemia L1210/*drug therapy', 'Liposomes/*administration & dosage', 'Mice', 'Mice, Inbred Strains']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Zhonghua Zhong Liu Za Zhi. 1985 Jul;7(4):250-3.,"['0 (Liposomes)', '04079A1RDZ (Cytarabine)']",,,,,,,,,,,
4085042,NLM,MEDLINE,19860305,20190705,0009-2363 (Print) 0009-2363 (Linking),33,7,1985 Jul,5-Fluorouracil derivatives. IX. Synthesis and antitumor activities of (alkylthio)carbonyl-5-fluorouracils.,2832-7,,"['Hoshiko, T', 'Ozaki, S', 'Watanabe, Y', 'Ogasawara, T', 'Yamauchi, S', 'Fujiwara, K', 'Hoshi, A', 'Iigo, M']","['Hoshiko T', 'Ozaki S', 'Watanabe Y', 'Ogasawara T', 'Yamauchi S', 'Fujiwara K', 'Hoshi A', 'Iigo M']",['eng'],['Journal Article'],Japan,Chem Pharm Bull (Tokyo),Chemical & pharmaceutical bulletin,0377775,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Fluorouracil/*analogs & derivatives', 'Leukemia L1210/drug therapy', 'Mice']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1248/cpb.33.2832 [doi]'],ppublish,Chem Pharm Bull (Tokyo). 1985 Jul;33(7):2832-7. doi: 10.1248/cpb.33.2832.,"['0 (Antineoplastic Agents)', 'U3P01618RT (Fluorouracil)']",,,,,,,,,,,
4084905,NLM,MEDLINE,19860221,20031114,0305-7232 (Print) 0305-7232 (Linking),8,2,1985 Dec,Migration and colonization of leukemic lymphoblasts in AKR and HSS inbred mice followed by serial enzyme determinations.,119-27,"After transplantation of AKR and HSS leukemic cells into AKR and HSS inbred mice as well as into their hybrids, the distribution and proliferation of the cells depend on the host organism. The energy production and glycolytic enzyme activity of the settled cells differ from that of the injected leukemic cells. It may be supposed that either the cell transplantation was carried out with a heterogeneous cell population or the cells of the host organism started to dedifferentiate.","['Arany, I', 'Kertai, P']","['Arany I', 'Kertai P']",['eng'],['Journal Article'],England,Cancer Biochem Biophys,Cancer biochemistry biophysics,7506524,IM,"['Animals', 'Cell Division', 'Glycolysis', 'Leukemia/*blood', 'Lymphocytes/*cytology/enzymology', 'Mice', 'Mice, Inbred Strains/*blood', 'Neoplasm Transplantation', 'Oxygen Consumption']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Biochem Biophys. 1985 Dec;8(2):119-27.,,,,,,,,,,,,
4084671,NLM,MEDLINE,19860305,20190606,0144-8463 (Print) 0144-8463 (Linking),5,9,1985 Sep,The calmodulin content of normal and leukaemic lymphocytes.,721-7,Normal human peripheral blood mononuclear cells (PBMC) and leukaemic cell lines (three of human and one of gibbon origin) were found to contain similar levels of calmodulin (CaM) when expressed relative to the total cell protein. Two of the cell lines examined further were found to contain much higher amounts of CaM per cell (up to 5-fold) than PBMC but this was readily explained by their much greater cell size. Variations in CaM levels were noted during culture of both PBMC and leukaemic cells which were apparently independent of the percentage of cells undergoing active division in these cultures. These results do not support the contention that transformed cells contain a higher proportion of CaM than normal cells.,"['Mac Neil, S', 'Dawson, R', 'Tucker, W F', 'Clegg, A', 'Platts, A', 'Rees, R C']","['Mac Neil S', 'Dawson R', 'Tucker WF', 'Clegg A', 'Platts A', 'Rees RC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Biosci Rep,Bioscience reports,8102797,IM,"['Calmodulin/*blood', 'Cell Cycle', 'Cell Line', 'Humans', 'Leukemia/*blood', 'Lymphocyte Activation', 'Lymphocytes/*metabolism', 'Radioimmunoassay']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1007/BF01119869 [doi]'],ppublish,Biosci Rep. 1985 Sep;5(9):721-7. doi: 10.1007/BF01119869.,['0 (Calmodulin)'],,,,,,,,,,,
4084659,NLM,MEDLINE,19860324,20061115,0753-3322 (Print) 0753-3322 (Linking),39,5,1985,Lymphocyte subpopulations and cell mediated cytotoxicity in acute non-lymphoid leukemia (ANLL) patients in complete remission (CR) and off-therapy.,245-7,"An assessment of the lymphocyte sub-populations and cell mediated cytotoxicity was made in 12 adults with acute non-lymphoid leukemia after stopping chemotherapy. No significant differences were found between ANLL and controls, for absolute lymphocyte count, %SIg/+ cells, Fc gamma + cells and ERFC. The OKT4+/OKT8+ was reduced in ANLL. Leu-7+ cells were significantly higher in ANLL. Moreover it appears that in ANLL lymphocyte function is restored early after stopping chemotherapy.","['De Rossi, G', 'Fontana, L', 'de Sanctis, G', 'Petti, M C', 'Pasqualetti, D', 'Guglielmi, C', 'Vitale, A', 'Mandelli, F']","['De Rossi G', 'Fontana L', 'de Sanctis G', 'Petti MC', 'Pasqualetti D', 'Guglielmi C', 'Vitale A', 'Mandelli F']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",France,Biomed Pharmacother,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,8213295,IM,"['Acute Disease', 'Adult', 'Antibody-Dependent Cell Cytotoxicity', 'Cytotoxicity, Immunologic', 'Humans', 'Leukemia/*immunology', 'Leukocyte Count', 'Lymphocytes/*immunology', 'Middle Aged']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Biomed Pharmacother. 1985;39(5):245-7.,,,,,,,,,,,,
4084517,NLM,MEDLINE,19860317,20190613,0006-2960 (Print) 0006-2960 (Linking),24,22,1985 Oct 22,Structural mapping of Fc receptor bound immunoglobulin E: proximity to the membrane surface of the antibody combining site and another site in the Fab segments.,6252-9,"Resonance energy-transfer methods have been used to investigate the structure of immunoglobulin E (IgE) bound to its high-affinity receptor on plasma membrane vesicles derived from rat basophilic leukemia cells. The structural mapping of receptor-bound IgE was initiated in an earlier study [Holowka, D., & Baird, B. (1983) Biochemistry 22, 3475], and it is based on measuring the minimal distance from IgE sites that are selectively labeled with donor probes to a plane of amphipathic acceptors at the membrane surface. This paper describes the use of monoclonal IgE specific for 5-(dimethylamino)naphthalene-1-sulfonyl (DNS) to place a donor probe, DNS-L-Lys, in the antibody combining sites. The distance from these sites to the membrane surface was determined to be greater than 100 A with two different amphipathic acceptor probes. Another site in the Fab segments of monoclonal IgE (anti-dinitrophenyl) could be labeled selectively with N-[4-[7-(diethylamino)-4-methylcoumarin-3-yl]phenyl]maleimide (CPM) in the absence of reducing agents [CPM(-)], and the reaction could not be blocked by prereaction with N-ethylmaleimide. The pattern of CPM(-)-labeled proteolytic fragments and the lack of fluorescence quenching by (trinitrophenyl)lysine in the antibody combining sites suggested the CPM(-)-labeled site to be in the C epsilon 1 domain of IgE. The distance between this site on receptor-bound IgE and the membrane surface was determined to be 75-87 A with two different amphipathic acceptors.(ABSTRACT TRUNCATED AT 250 WORDS)","['Baird, B', 'Holowka, D']","['Baird B', 'Holowka D']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Biochemistry,Biochemistry,0370623,IM,"['Animals', 'Antibodies, Monoclonal', 'Basophils/enzymology', 'Cell Membrane/immunology', 'Energy Transfer', 'Immunoglobulin E/*metabolism', 'Immunoglobulin Fab Fragments/immunology', 'Kinetics', 'Leukemia, Experimental/immunology', 'Rats', 'Receptors, Fc/*metabolism', 'Spectrometry, Fluorescence']",,1985/10/22 00:00,1985/10/22 00:01,['1985/10/22 00:00'],"['1985/10/22 00:00 [pubmed]', '1985/10/22 00:01 [medline]', '1985/10/22 00:00 [entrez]']",['10.1021/bi00343a032 [doi]'],ppublish,Biochemistry. 1985 Oct 22;24(22):6252-9. doi: 10.1021/bi00343a032.,"['0 (Antibodies, Monoclonal)', '0 (Immunoglobulin Fab Fragments)', '0 (Receptors, Fc)', '37341-29-0 (Immunoglobulin E)']",,,"['AI18306/AI/NIAID NIH HHS/United States', 'AI18610/AI/NIAID NIH HHS/United States']",,,,,,,,
4084458,NLM,MEDLINE,19860228,20190704,0007-1048 (Print) 0007-1048 (Linking),61,4,1985 Dec,Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF?,687-94,"A patient with acute megakaryoblastic leukaemia is described in whom exactly the same paracentric inversion of 3q was detected as in three previously documented cases. The patient's serum thrombopoietin (TSF) was significantly raised. Based on these findings we postulate a role for a gene (? oncogene) on chromosome 3q in thrombopoietin production. Abnormalities of 3q may assist in delineating a subgroup of acute nonlymphocytic leukaemia, namely acute megakaryoblastic leukaemia.","['Pinto, M R', 'King, M A', 'Goss, G D', 'Bezwoda, W R', 'Fernandes-Costa, F', 'Mendelow, B', 'McDonald, T P', 'Dowdle, E', 'Bernstein, R']","['Pinto MR', 'King MA', 'Goss GD', 'Bezwoda WR', 'Fernandes-Costa F', 'Mendelow B', 'McDonald TP', 'Dowdle E', 'Bernstein R']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Br J Haematol,British journal of haematology,0372544,IM,"['Bone Marrow/ultrastructure', 'Chromosome Aberrations/*genetics', 'Chromosome Disorders', '*Chromosome Inversion', 'Chromosomes, Human, 1-3/*ultrastructure', 'Female', 'Glycoproteins/*genetics', 'Humans', 'Karyotyping', 'Microscopy, Electron', 'Middle Aged', 'Thrombocythemia, Essential/*genetics', 'Thrombopoietin/*genetics']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02883.x [doi]'],ppublish,Br J Haematol. 1985 Dec;61(4):687-94. doi: 10.1111/j.1365-2141.1985.tb02883.x.,"['0 (Glycoproteins)', '9014-42-0 (Thrombopoietin)']",,,['HL14637/HL/NHLBI NIH HHS/United States'],,,,,,,,
4084455,NLM,MEDLINE,19860228,20190704,0007-1048 (Print) 0007-1048 (Linking),61,4,1985 Dec,Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre.,657-66,"Sixty-five patients with primary proliferative polycythaemia (polycythaemia rubra vera) were followed during the period 1962-83 and analysed retrospectively. Primary control of PCV was by venesection only with low dose busulphan solely as required to keep the platelet count below 400 X 10(9)/l. Median survival was 11.1 years from diagnosis which is equal to or marginally better than with other reported regimens. Vascular causes of death were only a little higher than expected in a comparable normal population. Only deaths from acute leukaemia and myelofibrosis were significantly increased above the normal population incidence. There was no evidence to suggest that these transformations were busulphan induced. Analysis of the incidence of occlusive vascular lesions lends support to an earlier recommendation that the PCV level be maintained below 0.45. No support was found for the possible disadvantages of a predominantly venesection regimen, such as iron deficiency and reactive thrombocytosis. The case is put for this use of low dose busulphan. The data presented would warrant the future inclusion of this therapeutic regime as one limb of a controlled trial.","['Messinezy, M', 'Pearson, T C', 'Prochazka, A', 'Wetherley-Mein, G']","['Messinezy M', 'Pearson TC', 'Prochazka A', 'Wetherley-Mein G']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Br J Haematol,British journal of haematology,0372544,IM,"['Adult', 'Aged', '*Bloodletting/adverse effects', 'Busulfan/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Polycythemia Vera/mortality/*therapy', 'Primary Myelofibrosis/etiology', 'Prognosis', 'Retrospective Studies']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02880.x [doi]'],ppublish,Br J Haematol. 1985 Dec;61(4):657-66. doi: 10.1111/j.1365-2141.1985.tb02880.x.,['G1LN9045DK (Busulfan)'],,,,,,,,,,,
4084239,NLM,MEDLINE,19860218,20190919,0006-2944 (Print) 0006-2944 (Linking),34,2,1985 Oct,Amino acid content of L5178Y and L5178Y/L-ASE cells after L-asparaginase treatment.,135-50,"The amino acid contents of tumor cells that are either sensitive or resistant to treatment with L-asparaginase were measured. These amino acid concentrations were measured as a function of incubation time with L-asparaginase or as a function of the L-asparaginase dose. The cell types compared were the mouse leukemia lines L5178Y (sensitive to L-asparaginase treatment) and L5178Y/L-ASE (resistant to L-asparaginase treatment). Upon L-asparaginase treatment both cell lines lost most of their cellular asparagine but, whereas the resistant cells exhibited the ability to rebound to about 50% of initial values, the sensitive cells did not. While previous work had suggested that asparagine-dependent glycine synthesis was essential for sensitive cells (but not in resistant cells), we found no difference in the glycine content of either of the two cell lines as a function of either time or dose that would support this hypothesis. Major differences between the two cell lines were seen in the content of the essential amino acids before treatment with L-asparaginase. After incubation without L-asparaginase the contents of the two cell lines became similar. These results are discussed in terms of possible mechanisms of L-asparaginase sensitivity and resistance.","['Keefer, J F', 'Moraga, D A', 'Schuster, S M']","['Keefer JF', 'Moraga DA', 'Schuster SM']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Biochem Med,Biochemical medicine,0151424,IM,"['Amino Acids/*metabolism', 'Animals', 'Asparaginase/*pharmacology', 'Chromatography, High Pressure Liquid', 'Drug Resistance', 'Indicators and Reagents', 'Leukemia L5178/*metabolism', 'Leukemia, Experimental/*metabolism', 'Male', 'Mice', 'Mice, Inbred DBA', 'Solvents']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1016/0006-2944(85)90105-x [doi]'],ppublish,Biochem Med. 1985 Oct;34(2):135-50. doi: 10.1016/0006-2944(85)90105-x.,"['0 (Amino Acids)', '0 (Indicators and Reagents)', '0 (Solvents)', 'EC 3.5.1.1 (Asparaginase)']",,,"['CA 00628/CA/NCI NIH HHS/United States', 'CA 28725/CA/NCI NIH HHS/United States']",,,,,,,,
4084022,NLM,MEDLINE,19860212,20190903,0365-6233 (Print) 0365-6233 (Linking),318,10,1985 Oct,Xanthone analogue of geiparvarin.,923-6,,"['Valenti, P', 'Recanatini, M', 'Da Re, P', 'Galimbeni, W', 'Avanzi, N', 'Filippeschi, S']","['Valenti P', 'Recanatini M', 'Da Re P', 'Galimbeni W', 'Avanzi N', 'Filippeschi S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Arch Pharm (Weinheim),Archiv der Pharmazie,0330167,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Leukemia P388/drug therapy', 'Mice', 'Mice, Inbred Strains', 'Xanthenes/*chemical synthesis/pharmacology', '*Xanthones']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/ardp.19853181012 [doi]'],ppublish,Arch Pharm (Weinheim). 1985 Oct;318(10):923-6. doi: 10.1002/ardp.19853181012.,"['0 (Antineoplastic Agents)', '0 (Xanthenes)', '0 (Xanthones)', '102275-60-5', '(3-((3-(4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl)-2-butenyl)oxy)-9H-xanthen-9-one', ')']",,,,,,,,,,,
4084015,NLM,MEDLINE,19860205,20061115,0004-069X (Print) 0004-069X (Linking),33,4,1985,Decrease of lymphatic mast cells in response to syngeneic WAMIB tumor cells.,539-42,"In response to the syngeneic carcinoma cells the regional lymph nodes are enlarged, but their lymphatic Mast Cell content was reduced in both, relative and absolute terms. This result confirms our earlier data on the depletion of lymphatic Mast Cells in the lymph nodes stimulated by various antigens.","['Wlodarski, K', 'Rychlik, G', 'Mazur, S', 'Dolowy, J', 'Jakobisiak, M']","['Wlodarski K', 'Rychlik G', 'Mazur S', 'Dolowy J', 'Jakobisiak M']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Switzerland,Arch Immunol Ther Exp (Warsz),Archivum immunologiae et therapiae experimentalis,0114365,IM,"['Animals', 'Carcinoma/*immunology', 'Cell Line', 'Crosses, Genetic', 'Leukemia L1210/immunology', 'Lymph Nodes/*immunology', 'Lymphocyte Transfusion', 'Lymphocytes/*immunology', 'Mast Cells/*immunology', 'Mice', 'Mice, Inbred Strains', 'Transplantation, Isogeneic']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arch Immunol Ther Exp (Warsz). 1985;33(4):539-42.,,,,,,,,,,,,
4084011,NLM,MEDLINE,19860207,20121115,0004-069X (Print) 0004-069X (Linking),33,2,1985,"Biological activity of 1,4-dihydropyridine derivatives.",345-52,"Six new 1,4-dihydropyridine derivatives were evaluated in vitro for antimicrobial and cytotoxic effects and in vivo for antineoplastic activity. These compounds inhibited the growth of most of Gram-positive and Gram-negative bacteria at concentrations of 50 and 100 micrograms/ml. Concentrations effective against fungi were somewhat lower (25-50 micrograms/ml). The growth of mycobacteria was inhibited at concentrations of 3.1-25 micrograms/ml. Compound IV inhibited the growth of pathogenic mycobacteria including M. tuberculosis resistant to SM and INH at 3.1 or 6.2 micrograms/ml. In cytotoxicity assays, compound II, IV and V appeared the most active. However, none of the 1,4-dihydropyridine derivatives affected the survival time of mice with P388 and L1210 leukemias or melanoma B16. The growth of subcutaneous tumors of sarcoma 180 was inhibited by compounds I, III, IV and V. The effect was dose related.","['Fiszer-Maliszewska, L', 'Wieczorek, J', 'Mordarski, M', 'Balicki, R', 'Kaczmarek, L', 'Nantka-Namirski, P']","['Fiszer-Maliszewska L', 'Wieczorek J', 'Mordarski M', 'Balicki R', 'Kaczmarek L', 'Nantka-Namirski P']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Switzerland,Arch Immunol Ther Exp (Warsz),Archivum immunologiae et therapiae experimentalis,0114365,IM,"['Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents/*pharmacology', 'Antineoplastic Agents/*therapeutic use', 'Bacteria/drug effects', '*Dihydropyridines', 'Drug Evaluation, Preclinical/methods', 'Fungi/drug effects', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Melanoma/drug therapy', 'Mice', 'Pyridines/*pharmacology/therapeutic use/toxicity', 'Species Specificity', 'Structure-Activity Relationship']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arch Immunol Ther Exp (Warsz). 1985;33(2):345-52.,"['0 (Anti-Bacterial Agents)', '0 (Anti-Infective Agents)', '0 (Antineoplastic Agents)', '0 (Dihydropyridines)', '0 (Pyridines)', '7M8K3P6I89 (1,4-dihydropyridine)']",,,,,,,,,,,
4084010,NLM,MEDLINE,19860207,20131121,0004-069X (Print) 0004-069X (Linking),33,2,1985,Biological properties of dipyridyl sulphides and related compounds.,331-8,"Antibacterial, antifungal and antitumor activity of 15 newly synthetized compounds were investigated in vitro. These compounds were mainly 1-[4-pyridyl]-pyridinium salts, dipyridyl sulphides and corresponding sulphones. Antitumor activity was evaluated in a model of leukemia L1210, P388, Sarcoma 180, Ehrlich carcinoma, NK-lymphoma and melanoma B16. None of the compounds investigated, even at the concentration of 100 micrograms/ml, appeared to influence Gram-negative bacteria. However, at the concentration as low as 1.0 microgram/ml, three of them (No. III, VI and VII) strongly inhibited the growth of Gram positive bacteria and fungi. The compounds did not prolong the survival time of Sarcoma 880 leukemia L1210 or P388--bearing mice. Few of the compounds examined exerted marked antitumor effect on Ehrlich carcinoma and NK-lymphoma--compounds No. I and XV inhibited the growth of these tumors by ca. 70%. The strongest inhibitory effect on melanoma B16 was observed with compound No. XV, the effect being dose-dependent.","['Boduszek, B', 'Wieczorek, J S', 'Mordarski, M', 'Wieczorek, J']","['Boduszek B', 'Wieczorek JS', 'Mordarski M', 'Wieczorek J']",['eng'],['Journal Article'],Switzerland,Arch Immunol Ther Exp (Warsz),Archivum immunologiae et therapiae experimentalis,0114365,IM,"[""2,2'-Dipyridyl/analogs & derivatives/pharmacology/therapeutic use"", 'Animals', 'Anti-Bacterial Agents', 'Anti-Infective Agents/*pharmacology', 'Antineoplastic Agents/*therapeutic use', 'Cell Division/drug effects', 'Drug Evaluation, Preclinical', 'Fungi/drug effects', 'Gram-Negative Bacteria/drug effects', 'Mice', 'Mice, Inbred BALB C', 'Microbial Sensitivity Tests', 'Neoplasms, Experimental/*drug therapy', 'Pyridinium Compounds/pharmacology/*therapeutic use', 'Structure-Activity Relationship', 'Sulfides/pharmacology/therapeutic use']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arch Immunol Ther Exp (Warsz). 1985;33(2):331-8.,"['0 (Anti-Bacterial Agents)', '0 (Anti-Infective Agents)', '0 (Antineoplastic Agents)', '0 (Pyridinium Compounds)', '0 (Sulfides)', ""551W113ZEP (2,2'-Dipyridyl)""]",,,,,,,,,,,
4083909,NLM,MEDLINE,19860210,20190824,0003-9896 (Print) 0003-9896 (Linking),40,6,1985 Nov-Dec,"The role of tobacco smoke, iron ore mine dusts, viruses, and chemicals in experimental cancer.",296-300,"Assessment of long-term studies on the carcinogenic potential of certain environmental agents has indicated that all of the following appear to activate and/or promote the inherent tumors of the host strains of the animals used irrespective of the extent of additional immunological modulation accompanying the agents: tobacco smoke inhalation, the implantation and inhalation of the respirable fraction of iron ore mine dusts, acute neonatal reovirus 3 infection, urethane, and tobacco smoke inhalation following urethane treatment. It is proposed that these environmental agents function at the onc-gene level as promoters/activators rather than carcinogens, and that this now requires an understanding of the means by which certain environmental agents function at the onc-gene level.","['Keast, D', 'Tam, N', 'Sheppard, N', 'Papadimitriou, J M']","['Keast D', 'Tam N', 'Sheppard N', 'Papadimitriou JM']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Arch Environ Health,Archives of environmental health,0212627,IM,"['Adenoma/*etiology/immunology', 'Animals', '*Carcinogens', 'Dust/adverse effects', 'Environmental Exposure', 'Female', 'Iron/*adverse effects', 'Leukemia, Experimental/*etiology/immunology', 'Lung Neoplasms/*etiology/immunology', 'Male', 'Mammalian orthoreovirus 3/*immunology', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mining', 'Models, Biological', 'Neoplasms, Experimental/*etiology/immunology', '*Plants, Toxic', 'Reoviridae/*immunology', 'Smoke/adverse effects', 'Species Specificity', '*Tobacco']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1080/00039896.1985.10545936 [doi]'],ppublish,Arch Environ Health. 1985 Nov-Dec;40(6):296-300. doi: 10.1080/00039896.1985.10545936.,"['0 (Carcinogens)', '0 (Dust)', '0 (Smoke)', 'E1UOL152H7 (Iron)']",,,,,,,,,,,
4083694,NLM,MEDLINE,19860218,20061115,0003-4509 (Print) 0003-4509 (Linking),43,3,1985,"[Ochrolifuanines, alkaloid analogs of emetine and tubulosine: hemisynthesis and research on cytotoxic and antitumor properties].",301-10,,"['Seguin, E', 'Trinh Minh Chau', 'Koch, M', 'Andre, S', 'Farjaudon, N', 'Pareyre, C', 'Tempete, C', 'Robert-Gero, M', 'Bourut, C', 'Chenu, E']","['Seguin E', 'Trinh Minh Chau', 'Koch M', 'Andre S', 'Farjaudon N', 'Pareyre C', 'Tempete C', 'Robert-Gero M', 'Bourut C', 'Chenu E', 'et al.']",['fre'],"['English Abstract', 'Journal Article']",France,Ann Pharm Fr,Annales pharmaceutiques francaises,2985176R,IM,"['Alkaloids/*chemical synthesis/pharmacology', 'Animals', 'Antineoplastic Agents/*chemical synthesis', 'Cell Division/drug effects', 'Leukemia P388/drug therapy', 'Mice', 'Mice, Inbred Strains']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ann Pharm Fr. 1985;43(3):301-10.,"['0 (Alkaloids)', '0 (Antineoplastic Agents)']",,"Ochrolifuanines, alcaloides analogues de l'emetine et de la tubulosine: hemisynthese et recherche de proprietes cytotoxiques et antitumorales.",,,,,,,,,
4083405,NLM,MEDLINE,19860213,20041117,0192-8562 (Print) 0192-8562 (Linking),7,4,1985 Winter,Pediatric hematology/oncology in Turkey.,399-400,,"['Cavdar, A O']",['Cavdar AO'],['eng'],['Journal Article'],United States,Am J Pediatr Hematol Oncol,The American journal of pediatric hematology/oncology,7908071,IM,"['Anemia/epidemiology', 'Anemia, Sickle Cell/epidemiology', 'Child', '*Hematology', 'Humans', 'Leukemia/epidemiology', '*Medical Oncology', 'Thalassemia/epidemiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Am J Pediatr Hematol Oncol. 1985 Winter;7(4):399-400.,,,,,,,,,,,,
4083404,NLM,MEDLINE,19860213,20041117,0192-8562 (Print) 0192-8562 (Linking),7,4,1985 Winter,Pediatric hematology/oncology in Taiwan.,398-9,,"['Yang, Y M']",['Yang YM'],['eng'],['Journal Article'],United States,Am J Pediatr Hematol Oncol,The American journal of pediatric hematology/oncology,7908071,IM,"['Child', 'Glucosephosphate Dehydrogenase Deficiency/epidemiology', '*Hematology', 'Humans', 'Insurance, Health', 'Leukemia/epidemiology', '*Medical Oncology', 'Taiwan', 'Thalassemia/epidemiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Am J Pediatr Hematol Oncol. 1985 Winter;7(4):398-9.,,,,,,,,,,,,
4082758,NLM,MEDLINE,19860217,20061115,0002-3027 (Print) 0002-3027 (Linking),,10,1985,"[Co-leukemogenic activity of protein preparations, isolated from cells of Mycoplasma arthritidis].",62-6,,"['Rakovskaia, I V', 'Gorina, L G']","['Rakovskaia IV', 'Gorina LG']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Vestn Akad Med Nauk SSSR,Vestnik Akademii meditsinskikh nauk SSSR,7506153,IM,"['Animals', 'Bacterial Outer Membrane Proteins/*adverse effects', '*Cocarcinogenesis', 'Leukemia, Experimental/*etiology', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', '*Mycoplasma', 'Rauscher Virus']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vestn Akad Med Nauk SSSR. 1985;(10):62-6.,['0 (Bacterial Outer Membrane Proteins)'],,"Koleikemogennaia aktivnost' belkovykh preparatov, vydelennykh iz kletok Mycoplasma arthritidis.",,,,,,,,,
4082287,NLM,MEDLINE,19860207,20171213,0300-8916 (Print) 0300-8916 (Linking),71,6,1985 Dec 31,Immunological reactivity of serum ferritin in patients with malignancy.,547-54,"Serum ferritin has been suggested as a tumor marker in the diagnosis of certain malignancies and for following the activity or dissemination of the malignant process. Since neoplastic tissues generally contain more acidic isoferritins than their normal tissue counterparts, it has also been suggested that the specific assay of such isoferritins in serum may be of particular value in the diagnosis of malignancy. In this work, we have evaluated ferritin concentration in the serum of normal subjects and patients with acute nonlymphocytic leukemia, Hodgkin's disease, breast cancer and lung cancer by simultaneously using three different immunoassays: an immunoradiometric assay based on polyclonal antibodies against human liver (basic, L-subunit rich) ferritin, a radioimmunoassay based on polyclonad antibodies against HeLa cell (acidic, H-subunit rich) ferritin, and an immunoradiometric assay based on the monoclonal antibody 2A4 raised against human heart (acidic, H-subunit rich) ferritin. Most of the patients studied had increased values for liver-type ferritin in the absence of increased iron stores. Binding of serum ferritin to concanavalin A did not prove to be useful in distinguishing a tumor-specific basic isoferritin. The HeLa ferritin assay was found to be less specific than the heart ferritin assay in the detection of acidic isoferritins, and did not provide any advantage over the liver assay in detecting the increased levels of serum ferritin associated with malignant disease. Heart-type ferritin was found in one-fifth of normal sera and 64% of sera from patients with malignancy. Values were very low compared with those for basic ferritin, ranging from less than 0.1 to 17% of total serum ferritin (geometric mean value 1.3%) in patients with malignancy. These findings indicate that at present there is little application for serum ferritin immunoassays based on antibodies to HeLa cell or heart ferritin in the diagnosis or monitoring of malignant disease. This seems to be due to the presence in human serum of biding factors which are responsible for the rapid clearance of acidic isoferritins from the circulation. The serum concentration of basic ferritin, however, can be useful in the diagnosis and management of some malignancies, and it is possible that studies on cell isoferritins can be important in biologic monitoring of neoplastic disorders. It should also be noted that the increased levels of serum ferritin found in patients with malignancy can exert adverse effects on the host immune response and perhaps an inhibitory effect on hematopoiesis.","['Cazzola, M', 'Arosio, P', 'Bellotti, V', 'Bergamaschi, G', 'Dezza, L', 'Iacobello, C', 'Ruggeri, G', 'Zappone, E', 'Albertini, A', 'Ascari, E']","['Cazzola M', 'Arosio P', 'Bellotti V', 'Bergamaschi G', 'Dezza L', 'Iacobello C', 'Ruggeri G', 'Zappone E', 'Albertini A', 'Ascari E']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Tumori,Tumori,0111356,IM,"['Antibodies, Monoclonal', 'Concanavalin A/metabolism', 'Ferritins/*blood/immunology', 'HeLa Cells', 'Humans', 'Immunoassay/*methods', 'Liver/metabolism', 'Myocardium/metabolism', 'Neoplasms/*blood']",,1985/12/31 00:00,1985/12/31 00:01,['1985/12/31 00:00'],"['1985/12/31 00:00 [pubmed]', '1985/12/31 00:01 [medline]', '1985/12/31 00:00 [entrez]']",,ppublish,Tumori. 1985 Dec 31;71(6):547-54.,"['0 (Antibodies, Monoclonal)', '11028-71-0 (Concanavalin A)', '9007-73-2 (Ferritins)']",,,,,,,,,,,
4082151,NLM,MEDLINE,19860220,20080716,0029-2001 (Print) 0029-2001 (Linking),105,33,1985 Nov 30,[Leukemia among electricians. An epidemiologic screening].,2371-3,,"['Lund, E']",['Lund E'],['nor'],"['English Abstract', 'Journal Article']",Norway,Tidsskr Nor Laegeforen,"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",0413423,IM,"['Adolescent', 'Adult', 'Aged', 'Electricity', 'Humans', 'Leukemia/*epidemiology', 'Male', 'Middle Aged', 'Norway', 'Occupational Diseases/*epidemiology', 'Risk']",,1985/11/30 00:00,1985/11/30 00:01,['1985/11/30 00:00'],"['1985/11/30 00:00 [pubmed]', '1985/11/30 00:01 [medline]', '1985/11/30 00:00 [entrez]']",,ppublish,Tidsskr Nor Laegeforen. 1985 Nov 30;105(33):2371-3.,,,Leukemi blant elektrikere. En epidemiologisk screening.,,,,,,,,,
4082003,NLM,MEDLINE,19860213,20061115,0040-3660 (Print) 0040-3660 (Linking),57,10,1985,[Characteristics of the correction of the blood aggregate condition during extracorporeal hemosorption in hematologic patients].,80-5,"The authors described experience in the use of the method of extracorporal hemosorption in patients with grave hemoblastoses. Nineteen of them were given 24 hemosorptions. Though severe disorders of the blood aggregate condition, thrombocytopenia (65%) and signs of disorder of thrombocyte function were present, no hemorrhagic complications during hemosorption were observed. Mean doses of heparin taking account of its consumption for sorbent treatment were 200 I.U./kg of body mass in thrombocytopenia and 300 I.U./kg of body mass with the normal level of thrombocytes. The refusal of protamine-sulfate administration to neutralize residual heparin at the end of operation for fear of possible complications made it possible to restore the initial indices of homeostasis 20 hrs. after sorption. This scheme for examination of the homeostasis system made it possible to control the adequacy of patient's heparinization and to avoid complications of the blood coagulation system.","['Katsadze, Iu L', 'Ganapiev, A A']","['Katsadze IuL', 'Ganapiev AA']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Blood Coagulation/*drug effects', '*Hemoperfusion', 'Hemorrhage/prevention & control', 'Heparin/*administration & dosage', 'Humans', 'Leukemia/blood/*therapy', 'Multiple Myeloma/blood/*therapy', 'Platelet Aggregation/*drug effects', 'Thrombosis/prevention & control']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(10):80-5.,['9005-49-6 (Heparin)'],,Osobennosti korrektsii agregatnogo sostoianiia krovi pri ekstrakorporal'noi gemosorbtsii u gematologicheskikh bol'nykh.,,,,,,,,,
4081642,NLM,MEDLINE,19860213,20190908,0036-553X (Print) 0036-553X (Linking),35,4,1985 Oct,Characterisation of a new cell line (CJ18) from a patient with 'hairy' cell leukaemia.,430-6,"A cell line (CJ18) has been established from the peripheral blood of a patient with hairy cell leukaemia (HCL) in a leukaemic phase. They grow slowly in large clumps with a doubling time of 3-4 d. 8% show positivity for surface immunoglobulin G and a small percentage (5%) are positive for intracytoplasmic immunoglobulin. They are B1,Ia1 positive and CALL, TdT and OKM1 negative. Although they are Epstein Barr Virus Nuclear Antigen (EBNA) positive they have several features not found in other EBNA positive B lymphoblastoid cell lines which suggest they may be derived from the patient's leukaemic hairy cells. They are strongly positive for tartrate resistant acid phosphatase, esterase positive, contain numerous lysosomes and are able to phagocytose sheep red blood cells after exposure to tetradecanoyl-12, 13-phorbol acetate (TPA). Following exposure to retinoic acid and TPA they adhere to plastic with numerous slender processes, a feature seen in HCL cells.","['Skinnider, L F', 'Ha, T', 'Bergen, S', 'Wang, H C']","['Skinnider LF', 'Ha T', 'Bergen S', 'Wang HC']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Antibodies, Monoclonal/immunology', 'Antigens, Neoplasm/analysis', 'Antigens, Surface/analysis', 'Antigens, Viral/analysis', 'Cell Differentiation/drug effects', '*Cell Line', 'Dimethyl Sulfoxide/pharmacology', 'Epstein-Barr Virus Nuclear Antigens', 'Humans', 'Karyotyping', 'Leukemia, Hairy Cell/immunology/*pathology', 'Male', 'Microscopy, Electron', 'Middle Aged', 'Phagocytosis', 'Receptors, Antigen, B-Cell/analysis', 'Tetradecanoylphorbol Acetate/pharmacology', 'Tretinoin/pharmacology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb02267.x [doi]'],ppublish,Scand J Haematol. 1985 Oct;35(4):430-6. doi: 10.1111/j.1600-0609.1985.tb02267.x.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)', '0 (Antigens, Viral)', '0 (Epstein-Barr Virus Nuclear Antigens)', '0 (Receptors, Antigen, B-Cell)', '5688UTC01R (Tretinoin)', 'NI40JAQ945 (Tetradecanoylphorbol Acetate)', 'YOW8V9698H (Dimethyl Sulfoxide)']",,,,,,,,,,,
4081640,NLM,MEDLINE,19860213,20190908,0036-553X (Print) 0036-553X (Linking),35,4,1985 Oct,Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells.,408-17,"A monoclonal antibody (SA-1) has been characterized. The antibody was derived from the fusion of the X-63 myeloma cell-line with splenocytes from a mouse immunized with human acute megakaryoblastic leukaemia cells. The antibody reacted with blast cells from 65% of patients with AML without correlation to morphologic classification. The antibody further reacted with a subset of myeloid cells from normal bone marrow, and with peripheral neutrophil granulocytes. In lymph nodes the antibody showed reactivity with subsets of dendritic reticulum cells. In skin biopsies the antibody reacted with subsets of Langerhans cells, subsets of indeterminate cells and activated T-lymphocytes. The antigen was not expressed on non-activated T-lymphocytes. Neither was it expressed on B-lymphocytes, erythrocytes, platelets nor blast cells from patients with ALL. The antigenic target for the antibody SA-1 was a surface exposed polypeptide (mol. wt. 15 000 D).","['Avnstrom, S', 'Plesner, T', 'Ralfkier, E', 'Wilken, M', 'Griffin, J D', 'Nissen, N I']","['Avnstrom S', 'Plesner T', 'Ralfkier E', 'Wilken M', 'Griffin JD', 'Nissen NI']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Antibodies, Monoclonal/*immunology', 'Antibody Specificity', 'Antigen-Presenting Cells/immunology', 'Antigens, Neoplasm/*analysis', 'Antigens, Surface/*immunology', 'Bone Marrow/immunology', 'Bone Marrow Cells', 'Cell Differentiation', 'Granulocytes/immunology', 'Humans', 'Leukemia/immunology', 'Lymph Nodes/immunology', 'Lymphocytes/immunology', 'Macrophages/immunology', 'Megakaryocytes/immunology', 'Neutrophils/*immunology', 'Palatine Tonsil/immunology', 'Skin/immunology', 'Thymus Gland/immunology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb02264.x [doi]'],ppublish,Scand J Haematol. 1985 Oct;35(4):408-17. doi: 10.1111/j.1600-0609.1985.tb02264.x.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)']",,,,,,,,,,,
4081624,NLM,MEDLINE,19860220,20190820,0036-5513 (Print) 0036-5513 (Linking),45,8,1985 Dec,Separation of erythropoietic stimulators in severe anaemia using high performance gel permeation chromatography.,753-8,"Patients with various types of anaemia, but with comparable haemoglobin levels, show a wide range of serum erythropoietic activity. We have developed a method for the fractionation of serum by HPLC followed by bioassay of the individual fractions, using the mouse spleen cell microassay. Up to three distinct peaks of erythropoietic activity corresponding to molecular weights (MW) greater than 300,000, 250,000-300,000 and 40,000 have been found in serum from both normal and anaemic subjects. The erythropoietic profiles of the sera examined differ markedly in anaemias of different aetiology. The chemical nature and the physiological significance of the stimulators remain to be investigated.","['Lappin, T R', 'Elder, G E', 'Madden, M', 'Bridges, J M']","['Lappin TR', 'Elder GE', 'Madden M', 'Bridges JM']",['eng'],"['Case Reports', 'Journal Article']",England,Scand J Clin Lab Invest,Scandinavian journal of clinical and laboratory investigation,0404375,IM,"['Adolescent', 'Aged', 'Anemia/*blood', 'Anemia, Aplastic/blood', 'Anemia, Megaloblastic/blood', 'Animals', 'Biological Assay', 'Chromatography, High Pressure Liquid', 'Erythropoietin/*blood', 'Female', 'Hemoglobins/analysis', 'Humans', 'Leukemia/blood', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Middle Aged', 'Spleen/cytology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.3109/00365518509155290 [doi]'],ppublish,Scand J Clin Lab Invest. 1985 Dec;45(8):753-8. doi: 10.3109/00365518509155290.,"['0 (Hemoglobins)', '11096-26-7 (Erythropoietin)']",,,,,,,,,,,
4081370,NLM,MEDLINE,19860207,20151119,0034-8376 (Print) 0034-8376 (Linking),37,3,1985 Jul-Sep,[Treatment of chronic lymphocytic leukemia in advanced stages].,237-40,,"['Aviles-Miranda, A', 'Chavez-Sanchez, G', 'Ambriz-Fernandez, R', 'Herrera Gomez, J', 'Pizzuto, J']","['Aviles-Miranda A', 'Chavez-Sanchez G', 'Ambriz-Fernandez R', 'Herrera Gomez J', 'Pizzuto J']",['spa'],"['English Abstract', 'Journal Article']",Mexico,Rev Invest Clin,Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,9421552,IM,"['Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Cyclophosphamide/administration & dosage', 'Female', 'Humans', 'Leukemia, Lymphoid/*drug therapy/pathology', 'Male', 'Middle Aged', 'Prednisone/administration & dosage', 'Vincristine/administration & dosage']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Rev Invest Clin. 1985 Jul-Sep;37(3):237-40.,"['5J49Q6B70F (Vincristine)', '8N3DW7272P (Cyclophosphamide)', 'VB0R961HZT (Prednisone)', 'COP protocol 2']",,Tratamiento de la leucemia linfocitica cronica en estadios avanzados.,,,,,,,,,
4081326,NLM,MEDLINE,19860205,20141120,0034-5164 (Print) 0034-5164 (Linking),50,3,1985 Dec,Methylthio-capping of selenocysteamine: preliminary studies on selective toxicity for cancer chemotherapy.,447-50,"Dimethyl disulfide markedly increased the cytotoxicity of selenocystamine by 2 orders of magnitude, from 40 microM to 0.5 microM for 50% inhibition of growth in 45 hr. When mice were injected ip with 22 microMole/Kg of selenocystamine on Day 0, all were dead on Day 4. If dimethyl disulfide (500 microMole/Kg) was either mixed with the selenocystamine or injected immediately prior to it, the mice survived treatment for at least 21 days afterwards, suggesting that methylthio-capping of selenocysteamine reduced host toxicity. Such combined treatment may be of value in chemotherapy.","['Pierson, H F', 'Fisher, J M', 'Rabinovitz, M']","['Pierson HF', 'Fisher JM', 'Rabinovitz M']",['eng'],['Journal Article'],United States,Res Commun Chem Pathol Pharmacol,Research communications in chemical pathology and pharmacology,0244734,IM,"['Animals', 'Cell Survival/*drug effects', 'Cystamine/*analogs & derivatives/metabolism/toxicity', 'Disulfides/metabolism/*pharmacology', 'Drug Evaluation, Preclinical', 'Drug Synergism', 'Female', 'In Vitro Techniques', 'Leukemia L1210/metabolism/*pathology', 'Mice', '*Organoselenium Compounds', 'Selenium/metabolism/*toxicity']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):447-50.,"['0 (Disulfides)', '0 (Organoselenium Compounds)', '2697-61-2 (selenocystamine)', '3P8D642K5E (dimethyl disulfide)', 'H6241UJ22B (Selenium)', 'R110LV8L02 (Cystamine)']",,,,,,,,,,,
4080853,NLM,MEDLINE,19860219,20031114,0032-0943 (Print) 0032-0943 (Linking),,5,1985 Oct,The cytotoxic principle of Scutellariae radix against L1210 cell.,462,,"['Ryu, S H', 'Ahn, B Z', 'Pack, M Y']","['Ryu SH', 'Ahn BZ', 'Pack MY']",['eng'],['Journal Article'],Germany,Planta Med,Planta medica,0066751,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/isolation & purification/*pharmacology', 'Flavonoids/isolation & purification/*pharmacology', 'Leukemia L1210/*drug therapy', 'Mice']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Planta Med. 1985 Oct;(5):462.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Flavonoids)', '55084-08-7 (skullcapflavone II)']",,,,,,,,,,,
4080815,NLM,MEDLINE,19860207,20070129,0031-7144 (Print) 0031-7144 (Linking),40,8,1985 Aug,Cytotoxic saponins from Asparagus and Agave.,586,,"['Sati, O P', 'Pant, G', 'Nohara, T', 'Sato, A']","['Sati OP', 'Pant G', 'Nohara T', 'Sato A']",['eng'],['Journal Article'],Germany,Pharmazie,Die Pharmazie,9800766,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*pharmacology', 'Cell Line', 'Humans', 'Leukemia P388/drug therapy', 'Mice', 'Mice, Inbred Strains', 'Plants, Medicinal/*analysis', 'Saponins/*pharmacology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Pharmazie. 1985 Aug;40(8):586.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Saponins)']",,,,,,,,,,,
4080797,NLM,MEDLINE,19860207,20131121,0031-7144 (Print) 0031-7144 (Linking),40,8,1985 Aug,"[Synthesis and biological activity of 1,4-benzoquinone-guanylhydrazone-thiosemicarbazone analogs. 1. Substitution at the S atom].",540-1,"The synthesis of S-substituted derivatives of 1,4-benzoquinone-guanylhydrazone-thiosemicarbazone is described. The obtained 1,4-benzoquinone-guanylhydrazone-S-alkyl (resp. aralkyl)-isothiosemicarbazones, in comparison with the unsubstituted standard compound, showed a significantly decreased biological activity against the murine leukemias L 1210 and P 388 as well as against the growth of several kinds of bacteria. Therefore the S-substitution seems not to be useful for reaching a maximum activity.","['Schulze, W', 'Gutsche, W', 'Wohlrabe, K', 'Fleck, W', 'Tresselt, D']","['Schulze W', 'Gutsche W', 'Wohlrabe K', 'Fleck W', 'Tresselt D']",['ger'],"['English Abstract', 'Journal Article']",Germany,Pharmazie,Die Pharmazie,9800766,IM,"['Animals', '*Anti-Bacterial Agents/chemical synthesis/pharmacology', '*Antineoplastic Agents/chemical synthesis/pharmacology', 'Bacteria/drug effects', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Mice', 'Microbial Sensitivity Tests', 'Mitoguazone/*analogs & derivatives/chemical synthesis/pharmacology', 'Structure-Activity Relationship']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Pharmazie. 1985 Aug;40(8):540-1.,"['0 (Anti-Bacterial Agents)', '0 (Antineoplastic Agents)', 'BYK4592A3Q (1,4-benzoquinone guanylhydrazone thiosemicarbazone)', 'OD5Q0L447W (Mitoguazone)']",,"Zur Synthese und biologischen Wirksamkeit von Analogen des 1,4-Benzochinon-guanylhydrazon-thiosemicarbazons. 1. Mitteilung: Substitution am S-Atom.",,,,,,,,,
4080300,NLM,MEDLINE,19860128,20180216,0030-2414 (Print) 0030-2414 (Linking),42 Suppl 1,,1985,Interferon-alpha-2C in the treatment of advanced hairy cell leukaemia. Results of a phase II trial.,7-9,The efficacy of recombinant interferon-alpha 2 in the treatment of advanced hairy cell leukaemia is investigated in 31 patients. Preliminary results show a complete and partial response rate of 69%. An optimal dose study utilizing maximal stimulation of an interferon-dependent pathway was carried out in 5 patients. The optimal dose of the order of 5 X 10(5) IU/day is effective and without side-effects. Interferon treatment did not enhance natural killer cell activity and therefore a direct mode of action upon tumour cells is proposed.,"['Huber, C', 'Flener, R', 'Gastl, G']","['Huber C', 'Flener R', 'Gastl G']",['eng'],['Journal Article'],Switzerland,Oncology,Oncology,0135054,IM,"['Dose-Response Relationship, Drug', 'Drug Evaluation', 'Humans', 'Interferon Type I/*therapeutic use', 'Killer Cells, Natural/immunology', 'Leukemia, Hairy Cell/*therapy', 'Recombinant Proteins/*therapeutic use']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000226076 [doi]'],ppublish,Oncology. 1985;42 Suppl 1:7-9. doi: 10.1159/000226076.,"['0 (Interferon Type I)', '0 (Recombinant Proteins)']",,,,,,,,,,,
4080299,NLM,MEDLINE,19860128,20180216,0030-2414 (Print) 0030-2414 (Linking),42 Suppl 1,,1985,Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies.,3-6,"Twenty-two patients with advanced haemopoietic and other malignancies were treated intramuscularly with recombinant interferon-alpha 2C in a daily escalating dose. The most common side-effects were flu-like symptoms. Two patients showed severe neurotoxicity, which was completely reversible in 1 case. Doses above 30 X 10(6) IU/day were poorly tolerated and could only be achieved in a minority of the patients. Objective tumour responses were documented in malignant lymphomas, hairy cell leukaemia, and renal cell carcinoma.","['Janssen, J T', 'Ludwig, H', 'Scheithauer, W', 'de Pauw, B E', 'Keyser, A', 'van Tol, R', 'Flener, R']","['Janssen JT', 'Ludwig H', 'Scheithauer W', 'de Pauw BE', 'Keyser A', 'van Tol R', 'Flener R']",['eng'],['Journal Article'],Switzerland,Oncology,Oncology,0135054,IM,"['Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Drug Resistance', 'Female', 'Humans', 'Interferon Type I/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Neoplasms/*therapy', 'Nervous System Physiological Phenomena', 'Recombinant Proteins/*therapeutic use']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000226075 [doi]'],ppublish,Oncology. 1985;42 Suppl 1:3-6. doi: 10.1159/000226075.,"['0 (Interferon Type I)', '0 (Recombinant Proteins)']",,,,,,,,,,,
4080297,NLM,MEDLINE,19860128,20180216,0030-2414 (Print) 0030-2414 (Linking),42 Suppl 1,,1985,Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.,19-25,"Forty-two patients with multiple myeloma were allocated to two groups to receive either polychemotherapy with vincristine, melphalan, cyclophosphamide and prednisolone, or recombinant interferon-alpha 2C monotherapy. The response rate of 43% in the interferon group was significantly lower than that in the chemotherapy group (89%). Patients with stage I disease showed better response rates than those with stage II or stage III disease. Eleven patients with thrombocythaemia due to polycythaemia vera, chronic myeloid leukaemia or essential thrombocythaemia were treated with recombinant interferon-alpha 2C and complete remissions were achieved in 7 of the 8 evaluable patients. Side-effects were common on interferon therapy, but could be reduced by dose reduction and were reversed by cessation of treatment.","['Ludwig, H', 'Cortelezzi, A', 'Van Camp, B G', 'Polli, E', 'Scheithauer, W', 'Kuzmits, R', 'Linkesch, W', 'Gisslinger, H', 'Sinzinger, H', 'Fritz, E']","['Ludwig H', 'Cortelezzi A', 'Van Camp BG', 'Polli E', 'Scheithauer W', 'Kuzmits R', 'Linkesch W', 'Gisslinger H', 'Sinzinger H', 'Fritz E', 'et al.']",['eng'],"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial', ""Research Support, Non-U.S. Gov't""]",Switzerland,Oncology,Oncology,0135054,IM,"['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Female', 'Humans', 'Interferon Type I/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Multiple Myeloma/drug therapy/*therapy', 'Myeloproliferative Disorders/*complications', 'Platelet Count', 'Recombinant Proteins/adverse effects/*therapeutic use', 'Thrombocythemia, Essential/complications/*therapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000226080 [doi]'],ppublish,Oncology. 1985;42 Suppl 1:19-25. doi: 10.1159/000226080.,"['0 (Interferon Type I)', '0 (Recombinant Proteins)']",,,,,,,,,,,
4080277,NLM,MEDLINE,19860130,20151119,0361-1817 (Print) 0361-1817 (Linking),10,12,1985 Dec,Radiation risks for patients having X rays.,"16, 19, 22 passim","In addition to radiation from naturally occurring radioactive materials and cosmic rays, individuals in developed countries receive radiation doses to bone marrow and gonads from the medical diagnostic use of X rays. A brief discussion of radiation epidemiology shows that deleterious effects are low even when doses are high. The concept of ""acceptable risk"" is introduced to help evaluate the small, but still existent, risks of radiation dose. Examples of bone marrow and gonadal doses for representative X-ray examinations are presented along with the current best estimates, per unit of X-ray dose, of the induction of leukemia or of genetic harm. The risk to the patient from an examination can then be compared with the normal risk of mortality from leukemia or of the occurrence of genetic defects. The risk increase is found to be very low. The risks to unborn children from radiographic examinations are also discussed. The benefit to the patient from information obtained from the examination must be balanced against the small risks.","['Hale, J', 'Thomas, J W']","['Hale J', 'Thomas JW']",['eng'],['Journal Article'],United States,Nurse Pract,The Nurse practitioner,7603663,IM,"['Abnormalities, Radiation-Induced/etiology', 'Barium Sulfate', 'Enema', 'Female', 'Fetus/radiation effects', 'Humans', 'Leukemia, Radiation-Induced/etiology', 'Male', 'Pregnancy', 'Radiation Dosage', 'Radiography/*adverse effects', 'Risk']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,"Nurse Pract. 1985 Dec;10(12):16, 19, 22 passim.",['25BB7EKE2E (Barium Sulfate)'],,,,,,,,,,,
4079719,NLM,MEDLINE,19860205,20041117,0374-9320 (Print) 0374-9320 (Linking),26,3,1985 Jul-Sep,[Physician-patient-family relational implications in informing of an illness with a fatal outcome].,231-5,,"['Pierantonelli, P', 'Mondaini, F', 'Messi, R']","['Pierantonelli P', 'Mondaini F', 'Messi R']",['ita'],['Journal Article'],Italy,Minerva Psichiatr,Minerva psichiatrica,7707981,IM,"['*Death', '*Family', 'Humans', 'Leukemia/*psychology', '*Physician-Patient Relations']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Minerva Psichiatr. 1985 Jul-Sep;26(3):231-5.,,,Implicazioni relazionali medico-paziente-famiglia nell'informazione di malattia ad esito mortale.,,,,,,,,,
4079518,NLM,MEDLINE,19860212,20071115,0025-7753 (Print) 0025-7753 (Linking),85,13,1985 Oct 26,[Structural pathology: apropos of the prognosis of chronic lymphatic leukemia].,537-8,,"['Moragas, A']",['Moragas A'],['spa'],['Journal Article'],Spain,Med Clin (Barc),Medicina clinica,0376377,IM,"['Bone Marrow/pathology', 'Cell Transformation, Neoplastic/pathology', 'Humans', 'Leukemia, Lymphoid/*pathology', 'Prognosis']",,1985/10/26 00:00,1985/10/26 00:01,['1985/10/26 00:00'],"['1985/10/26 00:00 [pubmed]', '1985/10/26 00:01 [medline]', '1985/10/26 00:00 [entrez]']",,ppublish,Med Clin (Barc). 1985 Oct 26;85(13):537-8.,,,Patologia estructural: a proposito del pronostico de la leucemia linfatica cronica.,,,,,,,,,
4079515,NLM,MEDLINE,19860212,20071115,0025-7753 (Print) 0025-7753 (Linking),85,13,1985 Oct 26,[Prognosis of chronic lymphatic leukemia: clinical stage or bone marrow histopathology?].,521-4,,"['Rozman, C', 'Montserrat, E', 'Rodriguez Fernandez, J M', 'Ayats, R', 'Vallespi, T', 'Parody, R', 'Rios, A', 'Prados, D', 'Morey, M', 'Gomis, F']","['Rozman C', 'Montserrat E', 'Rodriguez Fernandez JM', 'Ayats R', 'Vallespi T', 'Parody R', 'Rios A', 'Prados D', 'Morey M', 'Gomis F', 'et al.']",['spa'],"['Comparative Study', 'English Abstract', 'Journal Article']",Spain,Med Clin (Barc),Medicina clinica,0376377,IM,"['Biopsy', 'Bone Marrow/*pathology', 'Humans', 'Leukemia, Lymphoid/mortality/*pathology', 'Neoplasm Staging', 'Prognosis']",,1985/10/26 00:00,1985/10/26 00:01,['1985/10/26 00:00'],"['1985/10/26 00:00 [pubmed]', '1985/10/26 00:01 [medline]', '1985/10/26 00:00 [entrez]']",,ppublish,Med Clin (Barc). 1985 Oct 26;85(13):521-4.,,,Pronostico de la leucemia linfatica cronica: estadios clinicos o histopatologia medular?,,,,,,,,,
4079455,NLM,MEDLINE,19860207,20190824,0145-2126 (Print) 0145-2126 (Linking),9,12,1985,11;19 translocation in a congenital leukemia with two cell populations of lymphoblasts and monoblasts.,1467-73,"This report describes a case of a female infant of congenital leukemia with a chromosomal translocation t(11;19) (q23;p13) which presented initially with lymphoid features and at relapse with monocytic ones. The clinical course and the results of sequential cytochemical, cytogenetic and immunological studies are considered to be consistent with the interpretation of leukemogenesis of the myelo-monocytoid progenitor cell which still retains the capability of exhibiting lymphoid features to a limited extent. Although leukemia with t(11;19) has been classified as ANLL, most commonly M5 of FAB classification, the patient with this chromosomal abnormality may have a mixed leukemia in which cells with lymphoid features and those with monocytic ones exist.","['Hayashi, Y', 'Sakurai, M', 'Kaneko, Y', 'Abe, T', 'Mori, T', 'Nakazawa, S']","['Hayashi Y', 'Sakurai M', 'Kaneko Y', 'Abe T', 'Mori T', 'Nakazawa S']",['eng'],"['Case Reports', 'Journal Article']",England,Leuk Res,Leukemia research,7706787,IM,"['Cell Differentiation', '*Chromosomes, Human, 19-20', '*Chromosomes, Human, 6-12 and X', 'Female', 'Humans', 'Infant, Newborn', 'Leukemia/congenital/*genetics/pathology', 'Lymphocytes/*pathology', 'Monocytes/*pathology', '*Translocation, Genetic']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90038-4 [doi]'],ppublish,Leuk Res. 1985;9(12):1467-73. doi: 10.1016/0145-2126(85)90038-4.,,,,,,,,,,,,
4079454,NLM,MEDLINE,19860207,20190824,0145-2126 (Print) 0145-2126 (Linking),9,12,1985,Tyrosine protein kinases and their substrates in human leukemia cells.,1443-50,"We have quantitated tyrosine protein kinase (TPK) activity in particulate and cytosolic fractions from human leukemic cells. Slowly proliferating cells from patients with chronic lymphocytic leukemia (CLL) had levels of TPK similar to those of quiescent normal lymphocytes. Cells from patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic granulocytic leukemia (CGL) contained markedly lower levels of TPK activity, similar to the levels in phytohaemagglutinin-stimulated (proliferating) normal lymphocytes and in bone marrow cells. This suggested that TPK is part of a mechanism for transducing growth signals and is down-regulated following signal transmission. We also identified endogenous substrates for TPK in leukemic cells. Particulate fractions from ALL, CLL and AML cells contained substrates identical to those previously detected in normal lymphocytes. In particular, a 38kD substrate thought to be involved in early stages of growth signal transduction in normal lymphocytes was found in all samples of these groups examined. Cytosolic fractions from these groups of leukemia cells contained higher molecular weight substrates not found in resting or proliferating normal lymphocytes or bone marrow cells. In contrast, TPK substrates in both particulate and cytosolic fractions from CGL cells resembled those of normal bone marrow cells in that only proteins with molecular weight below 40kD were labelled on tyrosine. We conclude that leukemic cells do not contain higher levels of TPK than do normal hemopoietic cells. Qualitative differences in TPK species or in their substrates may result in aberrant regulation of proliferation in leukemic cells. However, we cannot exclude the possibility that additional TPK substrates detected in leukemic cells were a feature of the normal equivalent hematopoietic cells from which the leukemia cells were derived.","['Wickremasinghe, R G', 'Piga, A', 'Mire, A R', 'Taheri, M R', 'Yaxley, J C', 'Hoffbrand, A V']","['Wickremasinghe RG', 'Piga A', 'Mire AR', 'Taheri MR', 'Yaxley JC', 'Hoffbrand AV']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Leuk Res,Leukemia research,7706787,IM,"['Bone Marrow/enzymology', 'Cell Division', 'Cytosol/enzymology', 'Humans', 'Leukemia/*enzymology', 'Lymphocytes/enzymology', 'Phosphorylation', 'Protein-Tyrosine Kinases/*analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90034-7 [doi]'],ppublish,Leuk Res. 1985;9(12):1443-50. doi: 10.1016/0145-2126(85)90034-7.,['EC 2.7.10.1 (Protein-Tyrosine Kinases)'],,,,,,,,,,,
4079453,NLM,MEDLINE,19860207,20190824,0145-2126 (Print) 0145-2126 (Linking),9,12,1985,Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.,1437-42,"The c-mos and c-myc proto-oncogenes have been assigned to bands q22 and q24, respectively, of human chromosome No. 8. A gain of chromosome No. 8 is the most common abnormality observed in myeloproliferative diseases. By using probes specific for the c-mos and c-myc genes, we have analysed the genomic DNA from peripheral blood and bone marrow samples from 15 patients with various malignant myeloid diseases, including leukemia and myelodysplasia, and from one patient with non-Hodgkin's lymphoma, all of whom have trisomy for chromosome No. 8. Except for one patient, the c-mos and c-myc genes were found in restriction fragments of germline size. In one patient with myelodysplasia, one c-myc allele was rearranged in a Hind III fragment, the other allele being normal. Thus, trisomy 8 associated with human hematologic neoplasia is generally not related to gross rearrangements of the c-mos or c-myc genes.","['Diaz, M O', 'Le Beau, M M', 'Harden, A', 'Rowley, J D']","['Diaz MO', 'Le Beau MM', 'Harden A', 'Rowley JD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",England,Leuk Res,Leukemia research,7706787,IM,"['Anemia, Refractory/genetics', 'Base Sequence', '*Chromosomes, Human, 6-12 and X', 'Humans', 'Leukemia/*genetics', '*Proto-Oncogenes', '*Trisomy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90033-5 [doi]'],ppublish,Leuk Res. 1985;9(12):1437-42. doi: 10.1016/0145-2126(85)90033-5.,,,,"['CA-16910/CA/NCI NIH HHS/United States', 'CA-25568/CA/NCI NIH HHS/United States']",,,,,,,,
4079452,NLM,MEDLINE,19860129,20190824,0145-2126 (Print) 0145-2126 (Linking),9,11,1985,Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines.,1373-8,"Estrogen receptors (ER) and androgen receptors (AR) were determined in a series of 23 leukemia or lymphoma cell lines including 8 T-cell lines, 12 B-cell lines, and 3 non lymphoid cell lines. The phenotypic characterization of these cells by currently available immunological markers provides an estimate of their stage of differentiation. The result indicate that none of the investigated cell lines bear simultaneously ER and AR. Four were found to bear ER: U266, RPMI 8226, HL60, IARC/310/LT2, and four to express AR: RAJI, IARC/301/LTI, U937, REH6. The presence of cytosolic receptors was always associated with that of nuclear receptors. The expression of either ER or AR is restricted to discrete maturation stages of different haemopoietic cell lineages. Thus AR were found among the most immature lines of the T, B or monocytic lineage but they could be detected neither in the promyelocytic line HL60, nor in the pluripotential K562. The present results are in keeping with the demonstration of AR in some leukaemic blasts or in non Hodgkin's lymphomas. In contrast with AR, ER are present in two myeloma cell lines, in the promyelocytic cell line, HL60 and in a T-cell line bearing the phenotype of mature suppressor/cytotoxic T cells.","['Danel, L', 'Menouni, M', 'Cohen, J H', 'Magaud, J P', 'Lenoir, G', 'Revillard, J P', 'Saez, S']","['Danel L', 'Menouni M', 'Cohen JH', 'Magaud JP', 'Lenoir G', 'Revillard JP', 'Saez S']",['eng'],['Journal Article'],England,Leuk Res,Leukemia research,7706787,IM,"['Cell Line', 'Female', 'Humans', 'Leukemia/immunology/*metabolism', 'Lymphoma/*analysis/immunology', 'Male', 'Receptors, Androgen/*analysis', 'Receptors, Estrogen/*analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0145-2126(85)90125-0 [pii]', '10.1016/0145-2126(85)90125-0 [doi]']",ppublish,Leuk Res. 1985;9(11):1373-8. doi: 10.1016/0145-2126(85)90125-0.,"['0 (Receptors, Androgen)', '0 (Receptors, Estrogen)']",,,,,,,,,,,
4079441,NLM,MEDLINE,19860211,20190820,0022-4790 (Print) 0022-4790 (Linking),30,4,1985 Dec,Cancer in young adults between the ages of 15 and 34 years in Greater Bombay.,245-51,"An attempt has been made in this study to examine the nature and magnitude of the cancer problem in young adults between the ages of 15 and 34 years living in Greater Bombay. The morbidity data utilised for this exercise were obtained from the Bombay Cancer Registry and the mortality analysis was made from the death records maintained by the Bombay Municipal Corporation. In Greater Bombay, the ratio of cancer incidence in this specific group as compared with the total incidence of the disease in the general population was very high in comparison with the Western incidence. The site most commonly affected by cancer in young adults seems to be the lymphatic and haematopoietic tissues in males and breast and cervix in females. The morbidity and mortality rates of the disease in the general population and in children reveal an overall male preponderance, but the situation is found to be totally reversed in young adults. Then again, the incidence as well as the mortality rates appear to decrease with advancing age in children, but in young adults the incidence increases with age. Leukaemia is the most commonly encountered malignancy in the young adult male, followed by cancers of the testes and bones, Hodgkin's disease, and cancers of the brain and connective tissues, in descending order of frequency. In females, breast cancer has the highest incidence followed by cancer of the cervix, leukaemia, and cancers of the ovary and thyroid. When the various registers are ranked according to age-adjusted incidence rates, the figures for Greater Bombay are seen to be at the lowest levels in both sexes.","['Jussawalla, D J', 'Yeole, B B']","['Jussawalla DJ', 'Yeole BB']",['eng'],"['Comparative Study', 'Journal Article']",United States,J Surg Oncol,Journal of surgical oncology,0222643,IM,"['Adolescent', 'Adult', 'Age Factors', 'Female', 'Humans', 'India', 'Male', 'Neoplasms/*epidemiology/mortality', 'Sex Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1002/jso.2930300412 [doi]'],ppublish,J Surg Oncol. 1985 Dec;30(4):245-51. doi: 10.1002/jso.2930300412.,,,,,,,,,,,,
4079070,NLM,MEDLINE,19860214,20041117,0047-1860 (Print) 0047-1860 (Linking),33,9,1985 Sep,[Determination of TdT positive cells using flow cytometry].,1020-4,,"['Tazawa, H', 'Mizukoshi, M', 'Ishigami, T', 'Sato, S', 'Funato, T', 'Hayashi, M', 'Saito, M']","['Tazawa H', 'Mizukoshi M', 'Ishigami T', 'Sato S', 'Funato T', 'Hayashi M', 'Saito M']",['jpn'],['Journal Article'],Japan,Rinsho Byori,Rinsho byori. The Japanese journal of clinical pathology,2984781R,IM,"['Cell Separation', 'DNA Nucleotidylexotransferase/*metabolism', 'DNA Nucleotidyltransferases/*metabolism', '*Flow Cytometry', 'Humans', 'Leukemia/diagnosis', 'Leukocyte Count', 'Lymphocyte Activation', 'Lymphocytes/*enzymology']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Rinsho Byori. 1985 Sep;33(9):1020-4.,"['EC 2.7.7.- (DNA Nucleotidyltransferases)', 'EC 2.7.7.31 (DNA Nucleotidylexotransferase)']",,,,,,,,,,,
4079067,NLM,MEDLINE,19860212,20041117,0047-1860 (Print) 0047-1860 (Linking),33,8,1985 Aug,[Tumor specific antigen].,839-46,,"['Nakayama, E']",['Nakayama E'],['jpn'],['Journal Article'],Japan,Rinsho Byori,Rinsho byori. The Japanese journal of clinical pathology,2984781R,IM,"['Animals', 'Antibodies, Monoclonal/immunology', 'Antigens, Neoplasm/*analysis', 'Antigens, Surface/*analysis', 'Cytotoxicity, Immunologic', 'Female', 'Humans', 'Hybridomas', 'Leukemia, Radiation-Induced/*immunology', 'Male', 'Methylcholanthrene', 'Mice', 'Mice, Inbred BALB C', 'Sarcoma, Experimental/chemically induced/*immunology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Rinsho Byori. 1985 Aug;33(8):839-46.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)', '56-49-5 (Methylcholanthrene)']",,,,,,,,,,,
4079021,NLM,MEDLINE,19860130,20161116,0368-2781 (Print) 0368-2781 (Linking),38,9,1985 Sep,[The use of SM-4300 against severe infections complicated with hematological diseases].,2559-63,"The intravenous human gamma-globulin (SM-4300) was used with antibiotics for 9 patients who had severe bacterial infections resisted to the antibiotics. All of these patients had underlying hematological diseases, acute leukemia, aplastic anemia, malignant lymphoma and pure red cell aplasia. In many of the cases the leukocyte counts were extremely decreased. In 11 episodes of the infections, 4 cases were successfully treated by SM-4300 and 4 cases were not. No adverse reaction was found. It seems that the use of SM-4300 is effective for the treatment of these severe infections.","['Ikeda, S', 'Ichimaru, M']","['Ikeda S', 'Ichimaru M']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,Jpn J Antibiot,The Japanese journal of antibiotics,0154402,IM,"['Adult', 'Aged', 'Anti-Bacterial Agents/administration & dosage', 'Bacteria/immunology', 'Bacterial Infections/etiology/*therapy', 'Drug Evaluation', 'Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Female', 'Hematologic Diseases/*complications', 'Humans', '*Immunization, Passive', 'Immunoglobulins/administration & dosage', 'Male', 'Middle Aged']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Jpn J Antibiot. 1985 Sep;38(9):2559-63.,"['0 (Anti-Bacterial Agents)', '0 (Immunoglobulins)', '0 (SM-4300)']",,,,,,,,,,,
4079019,NLM,MEDLINE,19860130,20161116,0368-2781 (Print) 0368-2781 (Linking),38,9,1985 Sep,[Clinical studies on SM-4300].,2535-41,"Use of SM-4300, which is a newly developed human immunoglobulin preparation for intravenous administration, has clinically been evaluated in the patients with severe or intractable bacterial infections. Of total 13 cases of the admitted patients at the 1st department of internal medicine, faculty of medicine, Kyushu university, 10-pneumonia case were associated with blood diseases like acute myelocytic leukemia (AML) and multiple myeloma (MM), and in addition, with other underlying diseases like lung cancer and bronchiectasis, 1 was prosthetic valve endocarditis, 1 cholecystitis associated with pericarditis and 1 fever of undetermined origin (FUO). SM-4300 of 5 g single bolus or 3 daily doses of 2.5 g per day were infused with chemotherapy drugs preceedingly administered for more than 3 days and the results were evaluated; good in 4, fair 4, poor 2 and unknown 3, and the efficacy rate was 40%. Bacteriologically, the results were decreased in 1, persisted 1 and the majority was unknown. Observed were no side reactions nor the changes in clinical examination variables incurred by this drug. It is therefore considered that SM-4300 is of use for the treatment of intractable bacterial infections when used with antibiotics.","['Sawae, Y', 'Nagafuchi, S']","['Sawae Y', 'Nagafuchi S']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Jpn J Antibiot,The Japanese journal of antibiotics,0154402,IM,"['Adult', 'Aged', 'Anti-Bacterial Agents/administration & dosage', 'Bacteria/immunology', 'Bacterial Infections/*therapy', 'Drug Evaluation', 'Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Female', 'Humans', '*Immunization, Passive', 'Immunoglobulins/administration & dosage', 'Male', 'Middle Aged']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Jpn J Antibiot. 1985 Sep;38(9):2535-41.,"['0 (Anti-Bacterial Agents)', '0 (Immunoglobulins)', '0 (SM-4300)']",,,,,,,,,,,
4079014,NLM,MEDLINE,19860130,20161116,0368-2781 (Print) 0368-2781 (Linking),38,9,1985 Sep,[Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group].,2402-12,"One hundred and nine patients with infection accompanying hematologic disorders including leukemia and lymphoma were treated with aztreonam (AZT). Of the 90 patients in whom the efficacy could be evaluated, 17 (18.9%) responded markedly and 29 (32.2%) moderately, the effective rate being 51.1%. The efficacy rate classified according to infections was 25% in septicemia, 46.3% in suspected septicemia, 57.1% in pneumonia and 100% in urinary tract infection. The efficacy rate to the Gram-negative bacteria was 78.9% and to the Gram-positive bacteria was 20.0%. In 4 (66.7%) out of 6 patients in whom P. aeruginosa was the causative organism, AZT was effective. The efficacy rate was 52.2% in the 23 patients whose causative organisms were identified and 50.7% in 67 patients whose causative organisms were not identified. There was no significant difference in the efficacy rate between the patients who failed to respond to prior antibiotic therapy (53.6%) and those treated with AZT from the beginning. The initial neutrophil count did not affect the efficacy rate. Side effects which might have been caused by AZT were eruption and fever in 4 patients. Hepatic disorders and eosinophilia were observed in 7 patients. However, the relationship between AZT and these abnormal findings was not established. These results indicate that AZT is an effective and safe antibiotic for the treatment of infections accompanying hematologic disorders.","['Hirayama, F', 'Masaoka, T', 'Shibata, H', 'Nagai, K', 'Kitani, T', 'Horiuchi, A', 'Kawagoe, H', 'Yasunaga, K', 'Okamoto, Y', 'Yonezawa, T']","['Hirayama F', 'Masaoka T', 'Shibata H', 'Nagai K', 'Kitani T', 'Horiuchi A', 'Kawagoe H', 'Yasunaga K', 'Okamoto Y', 'Yonezawa T', 'et al.']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,Jpn J Antibiot,The Japanese journal of antibiotics,0154402,IM,"['Adolescent', 'Adult', 'Aged', 'Aztreonam/pharmacology/*therapeutic use', 'Bacterial Infections/*drug therapy/etiology', 'Drug Evaluation', 'Drug Resistance, Microbial', 'Female', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Hematologic Diseases/complications', 'Humans', 'Infusions, Parenteral', 'Leukemia/*complications', 'Lymphoma/*complications', 'Male', 'Middle Aged', 'Multiple Myeloma/complications']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Jpn J Antibiot. 1985 Sep;38(9):2402-12.,['G2B4VE5GH8 (Aztreonam)'],,,,,,,,,,,
4079002,NLM,MEDLINE,19860128,20161116,0368-2781 (Print) 0368-2781 (Linking),38,8,1985 Aug,[Clinical evaluation of amikacin by intravenous drip infusion for infections in the field of internal medicine].,2108-18,"Amikacin (AMK) by intravenous drip infusion was given to patients with infections in the field of internal medicine and the results were followings: AMK was administered to 19 patients. Diagnosis included sepsis or suspected sepsis (11 cases), pneumonia (2 cases), chronic respiratory tract infections (3 cases) and urinary tract infections (3 cases). Underlying disease included hematologic disease (13 cases), lung fibrosis (1 case), chronic respiratory insufficiency (1 case), diabetes mellitus (1 case), hepatic coma and bronchial asthma (1 case) and prostatic hypertrophy (1 case). Nineteen episodes responded to single therapy (2 cases) or combined therapy with other antibiotics (17 cases). AMK by intravenous drip infusion (dissolved in not less than 100 ml of saline or glucose) was administered at the dose of 200 mg/day to 600 mg/day divided into 2 or 3 times, over 1 hour to 2 hours. The mean duration of therapy was 10 days and the mean total dose was 4.3 g. Clinical effects: Excellent in 7 cases, good in 7 cases, fair in 3 cases and poor in 2 cases, and efficacy rate was 74%. Bacteriological effects: Disappeared in 3 cases, partly disappeared and unchanged in 3 cases, superinfection in 1 case and newly appeared in 1 case. Four strains out of 7 cases of which were detected the causative bacteria were disappeared. GM resistant bacteria (S. marcescens in 2 strains and C. diversus in 1 strain) were disappeared by the administration of AMK, also some clinical symptoms and signs were improved. No side effects and no abnormalities in laboratory findings were noted in any cases attributed to AMK. In conclusion, high efficacy rate was obtained without any side effects, intravenous drip infusion of AMK seemed to be useful for infections in patients with bleeding tendency (e.g. leukemia) or malignant disease.","['Ito, A', 'Maruta, I', 'Ogawa, K', 'Asada, H', 'Matsuzaki, M']","['Ito A', 'Maruta I', 'Ogawa K', 'Asada H', 'Matsuzaki M']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,Jpn J Antibiot,The Japanese journal of antibiotics,0154402,IM,"['Acinetobacter Infections/drug therapy', 'Adult', 'Aged', 'Amikacin/administration & dosage/adverse effects/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Cystitis/drug therapy', 'Female', 'Humans', 'Infusions, Parenteral', 'Kanamycin/*analogs & derivatives', 'Leukemia/complications', 'Male', 'Middle Aged', 'Pneumonia/drug therapy', 'Respiratory Tract Infections/drug therapy', 'Sepsis/drug therapy']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Jpn J Antibiot. 1985 Aug;38(8):2108-18.,"['59-01-8 (Kanamycin)', '84319SGC3C (Amikacin)']",,,,,,,,,,,
4078915,NLM,MEDLINE,19860130,20181113,0027-9684 (Print) 0027-9684 (Linking),77,11,1985 Nov,Normoblasts in peripheral blood of Nigerians: their clinical significance.,899-903,"The clinical conditions associated with peripheral blood nucleated red blood cells (NRBC) in Nigerians were investigated prospectively to define them and establish their mortality. Of the 4,565 differential counts carried out within ten months, NRBC were detected in 120 cases (2.6 percent). Of these, severe nutritional anemia was seen in 64.4 percent, sickle cell anemia in 23.8 percent, neonatal status in 7.6 percent; and malignant diseases in 4.2 percent. Leukoerythroblastosis occurred in 11 percent. The overall mortality was 4.2 percent, and among those with congestive cardiac failure, there was no fatality. These results show that malignancy is not a major cause of normoblasts in peripheral blood in this environment and that the prognosis is not as poor as has been reported in some North American and European literature.","['Okpara, R A']",['Okpara RA'],['eng'],['Journal Article'],United States,J Natl Med Assoc,Journal of the National Medical Association,7503090,IM,"['Adolescent', 'Adult', 'Anemia/blood/complications/mortality', 'Anemia, Myelophthisic/blood/mortality', 'Anemia, Sickle Cell/blood/mortality', 'Child', 'Child, Preschool', 'Erythrocytes/*pathology', 'Female', 'Heart Failure/etiology', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/blood/mortality', 'Male', 'Middle Aged', 'Nigeria', 'Prospective Studies']",PMC2571209,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,J Natl Med Assoc. 1985 Nov;77(11):899-903.,,,,,,,,,,,,
4078697,NLM,MEDLINE,19860131,20041117,0731-8898 (Print) 0731-8898 (Linking),6,2,1985 Nov-Dec,Mortality patterns among professional artists: a preliminary report.,303-13,"Causes of death among 1598 professional artists were compared with an expected distribution based on the general U.S. population to determine if there were unusual patterns of fatal disease that might be indicative of exposure to hazardous substances in their work environment. Deaths among men and women in the arts were identified from obituaries in Who's Who in American Art published between 1940 and 1969. Among 1253 white male artists, PMRs were significantly elevated for arteriosclerotic heart disease, leukemia and cancers of the bladder, colon, rectum, kidney, and brain. The significant excesses of bladder cancer and leukemia deaths were limited to painters. Proportions of deaths due to colon cancer were significantly elevated among male painters and sculptors. Prostate cancer mortality was slightly higher than expected among painters and significantly elevated among sculptors. Among 345 female artists, painters represented the only specialty category large enough to analyze and excess numbers of deaths due to cancers of the rectum, lung, and breast were noted.","['Miller, B A', 'Blair, A', 'McCann, M']","['Miller BA', 'Blair A', 'McCann M']",['eng'],['Journal Article'],United States,J Environ Pathol Toxicol Oncol,"Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer",8501420,IM,"['Aged', '*Art', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/chemically induced/mortality', 'Occupational Diseases/chemically induced/*mortality', 'United States']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,J Environ Pathol Toxicol Oncol. 1985 Nov-Dec;6(2):303-13.,,,,,,,,,,,,
4078644,NLM,MEDLINE,19860210,20190829,0301-4800 (Print) 0301-4800 (Linking),31,5,1985 Oct,Evaluation of a new assay kit for intrinsic factor blocking antibody (type I) as an aid in the diagnosis of pernicious anemia.,491-8,"Sera from 39 patients with pernicious anemia and 251 patients with various other diseases and 42 healthy normal subjects were tested for intrinsic factor blocking antibody by a Corning commercial kit. Twenty-five (64%) out of 39 pernicious anemia patients showed a positive reaction to the intrinsic factor blocking antibody. The positive incidence of intrinsic factor blocking antibody by this method agreed well with the results obtained in this laboratory over the past 10 years using the charcoal method. No sera from normal subjects tested were positive for the intrinsic factor blocking antibody. All 226 sera with vitamin B12 levels less than 3,500 pg/ml which came from patients without pernicious anemia, were negative for the intrinsic factor blocking antibody. In 15 sera with B12 levels greater than 3,500 pg/ml from patients who received recent B12 medications, 11 sera showed false positive results. On the other hand, no false positive results were obtained by this method in 10 sera with endogenous serum B12 levels greater than 3,500 pg/ml collected from patients with chronic myelogenous leukemia. It is reasonable to presume that this assay is clinically useful for detection of intrinsic factor blocking antibody in the diagnosis of pernicious anemia, if false positive results due to B12 medication are excluded.","['Chen, W L', 'Morishita, R', 'Eguchi, T', 'Kawai, T', 'Uchino, H']","['Chen WL', 'Morishita R', 'Eguchi T', 'Kawai T', 'Uchino H']",['eng'],['Journal Article'],Japan,J Nutr Sci Vitaminol (Tokyo),Journal of nutritional science and vitaminology,0402640,IM,"['Adolescent', 'Adult', 'Aged', 'Anemia, Pernicious/*diagnosis', 'Antibodies/*analysis', 'Female', 'Humans', 'Intrinsic Factor/*immunology', 'Male', 'Middle Aged', '*Reagent Kits, Diagnostic', 'Vitamin B 12/blood']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.3177/jnsv.31.491 [doi]'],ppublish,J Nutr Sci Vitaminol (Tokyo). 1985 Oct;31(5):491-8. doi: 10.3177/jnsv.31.491.,"['0 (Antibodies)', '0 (Reagent Kits, Diagnostic)', '9008-12-2 (Intrinsic Factor)', 'P6YC3EG204 (Vitamin B 12)']",,,,,,,,,,,
4078569,NLM,MEDLINE,19860219,20190908,0162-0134 (Print) 0162-0134 (Linking),25,4,1985 Dec,"The antitumor activity of di-n-butyltin(IV) glycylglycinate, and the correlation with the structure of dialkyltin(IV) glycylglycinates in solution studied by conductivity measurements and by infrared, nuclear magnetic resonance, and Mossbauer spectroscopic methods.",229-45,"The in vivo activity of Bu2nSnGlyGly, Na(Cl2GaGlyGly), and ClGaGlyGly (GlyGly2- = glycylglycinate) has been investigated in connection with a number of tumors. Positive results have been obtained only for the Bu2nSnIV complex in the case of leukemia P-388. In order to try to interpret the pharmacological data on a molecular basis, the nature of the species present in solutions of AlK2Sn GlyGly complexes, as well as the reactivity of aqueous Me2SnGlyGly, have been studied. The presence of chelated species (I), Figure 1, in organic solvents, and the equilibrium (I) in equilibrium (II), Figure 1, in water and mixed water-organic solvent systems, have been inferred from conductance measurements, as well as from studies by Mossbauer (in frozen solution), 1H, 13C, and 119Sn NMR, and ir spectroscopy. Moreover, solvated (II) would release AlK2SnIV moieties, as evidenced by the slow formation of (Me2SnO)n from aqueous Me2Sn GlyGly. The involvement of (I) and (II) in the transportation of these drugs across cell membranes is discussed.","['Ruisi, G', 'Silvestri, A', 'Lo Guidice, M T', 'Barbieri, R', 'Atassi, G', 'Huber, F', 'Gratz, K', 'Lamartina, L']","['Ruisi G', 'Silvestri A', 'Lo Guidice MT', 'Barbieri R', 'Atassi G', 'Huber F', 'Gratz K', 'Lamartina L']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Inorg Biochem,Journal of inorganic biochemistry,7905788,IM,"['Animals', 'Breast Neoplasms/drug therapy', 'Chemical Phenomena', 'Chemistry', 'Colonic Neoplasms/drug therapy', 'Drug Evaluation, Preclinical', 'Female', 'Humans', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Magnetic Resonance Spectroscopy/methods', 'Mammary Neoplasms, Experimental/drug therapy', 'Melanoma/drug therapy', 'Mice', 'Mice, Inbred Strains', 'Neoplasm Transplantation', 'Neoplasms, Experimental/*drug therapy', '*Organotin Compounds/*therapeutic use', 'Spectrophotometry, Infrared/methods', 'Spectrum Analysis/methods', 'Structure-Activity Relationship', 'Transplantation, Heterologous']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0162-0134(85)80023-4 [pii]', '10.1016/0162-0134(85)80023-4 [doi]']",ppublish,J Inorg Biochem. 1985 Dec;25(4):229-45. doi: 10.1016/0162-0134(85)80023-4.,"['0 (Organotin Compounds)', '59592-90-4 (di-n-butyltin glycylglycinate)']",,,,,,,,,,,
4077516,NLM,MEDLINE,19860124,20190722,0017-9078 (Print) 0017-9078 (Linking),49,6,1985 Dec,Effective dose equivalent and associated risks from mass chest radiography in Kuwait.,1147-54,"The number of x-ray examinations performed on persons undergoing mass chest radiography in Kuwait reached a maximum of 1.858 X 10(5) in 1982 with miniature radiography (70 mm) claiming more than 90% of the total number and the rest done with the large film technique. The annual prevalence of asymptomatic tuberculosis patients diagnosed by x rays, as reported by the project statistics, does not, in our opinion, justify exposing such a large population. In this paper, the effective dose equivalent is calculated from both miniature and large film mass chest radiography as applied in Kuwait. The values obtained are 283 mu Sv and 35.5 mu Sv, respectively. These figures yield calculated risks of fatal malignancies per examination of 3.37 X 10(-6) and 0.422 X 10(-6), respectively. The annual collective effective dose equivalent to the population undergoing mass chest radiography in Kuwait during the 7 y 1977-1983 is found to vary between 38-48 man-Sv. These figures are used to calculate an average of 0.5 additional cases of fatal malignancies per year, or about 12 excess fatalities in the forthcoming 25-y period if the number of mass chest x-ray examinations stays at its existing level. A total of 98% of these calculated excess fatalities result from the predominant technique, miniature radiography.","['Mustafa, A A', 'Kouris, K']","['Mustafa AA', 'Kouris K']",['eng'],['Journal Article'],United States,Health Phys,Health physics,2985093R,IM,"['Adolescent', 'Adult', 'Female', 'Humans', 'Kuwait', 'Leukemia, Radiation-Induced/etiology', 'Male', '*Mass Chest X-Ray', 'Middle Aged', 'Neoplasms, Radiation-Induced/etiology', '*Radiation Dosage', 'Risk', 'Tuberculosis, Pulmonary/*prevention & control']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1097/00004032-198512000-00009 [doi]'],ppublish,Health Phys. 1985 Dec;49(6):1147-54. doi: 10.1097/00004032-198512000-00009.,,,,,,,,,,,,
4077272,NLM,MEDLINE,19860219,20190829,0300-8126 (Print) 0300-8126 (Linking),13,6,1985 Nov-Dec,Septicaemia with a dysgonic fermenter-2 (DF-2) bacterium in a compromised host.,286-7,"Dysgonic fermenter-2 (DF-2) is a newly described gram-negative bacterium that can produce serious infections in the compromised host. We are reporting a case of DF-2 septicaemia in a splenectomized patient with chronic lymphocytic leukaemia. The clinical spectrum of infections due to the DF-2 bacterium, the difficulties in establishing the diagnosis and the preferential treatment are discussed.","['Fibbe, W', 'Ligthart, G', 'van den Broek, P', 'Lampe, A', 'van der Meer, J']","['Fibbe W', 'Ligthart G', 'van den Broek P', 'Lampe A', 'van der Meer J']",['eng'],"['Case Reports', 'Journal Article']",Germany,Infection,Infection,0365307,IM,"['Agammaglobulinemia/complications', 'Bacterial Infections/complications/*microbiology', '*Gram-Negative Bacteria', 'Humans', 'Leukemia, Lymphoid/complications', 'Male', 'Middle Aged', 'Splenectomy']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1007/BF01645441 [doi]'],ppublish,Infection. 1985 Nov-Dec;13(6):286-7. doi: 10.1007/BF01645441.,,,,,,,,,,,,
4077135,NLM,MEDLINE,19860220,20151119,0019-5189 (Print) 0019-5189 (Linking),23,7,1985 Jul,Antiviral activity of liposome-encapsulated cupric complex of isonicotinic acid hydrazide against avian myeloblastosis virus infection.,393-6,,"['Vasudevachari, M B', 'Antony, A']","['Vasudevachari MB', 'Antony A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",India,Indian J Exp Biol,Indian journal of experimental biology,0233411,IM,"['Animals', 'Avian Leukosis/*drug therapy', 'Avian Myeloblastosis Virus', 'Chickens', 'Copper/*administration & dosage', 'Isoniazid/*administration & dosage', 'Liposomes', 'Metabolic Clearance Rate']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Indian J Exp Biol. 1985 Jul;23(7):393-6.,"['0 (Liposomes)', '789U1901C5 (Copper)', 'V83O1VOZ8L (Isoniazid)']",,,,,,,,,,,
4076886,NLM,MEDLINE,19860128,20061115,0017-7768 (Print) 0017-7768 (Linking),109,1-2,1985 Jul,[Hairy cell leukemia in Israel].,1-3,,"['Lishner, M', 'Lang, R', 'Sorek, M', 'Ravid, M']","['Lishner M', 'Lang R', 'Sorek M', 'Ravid M']",['heb'],"['English Abstract', 'Journal Article']",Israel,Harefuah,Harefuah,0034351,IM,"['Actuarial Analysis', 'Antineoplastic Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Combined Modality Therapy', 'Humans', 'Leukemia, Hairy Cell/mortality/*therapy', 'Splenectomy']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Harefuah. 1985 Jul;109(1-2):1-3.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4076498,NLM,MEDLINE,19860217,20190903,0011-9075 (Print) 0011-9075 (Linking),171,4,1985,Skin involvement in hemopathies: specific cutaneous manifestations of acute nonlymphoid leukemias and non-Hodgkin lymphomas.,250-4,"The course of a hemopathy may be characterized by the appearance of cutaneous lesions. In such cases a correct histological investigation is needed, especially when the lesions have an aspecific appearance. It is important, therefore, to recognize the cases characterized by cutaneous involvement of typical systemic disease cells. Lymphomas and leukemias are the hemopathies which more frequently present specific and nonspecific cutaneous manifestations (with an approximate incidence of 3-40 and 6-50%, respectively). In the period 1977-1983 we examined 337 patients affected with acute nonlymphoblastic leukemia and 243 patients affected with non-Hodgkin lymphoma, in order to verify the incidence of specific cutaneous manifestations.","['Ricevuti, G', 'Mazzone, A', 'Rossini, S', 'Rizzo, S C', 'Ricevuti, G', 'Bosatra, M', 'Jucci, A', ""Dell'Acqua, R"", 'Sacchi, S']","['Ricevuti G', 'Mazzone A', 'Rossini S', 'Rizzo SC', 'Ricevuti G', 'Bosatra M', 'Jucci A', ""Dell'Acqua R"", 'Sacchi S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Switzerland,Dermatologica,Dermatologica,0211607,IM,"['Acute Disease', 'Humans', 'Leukemia/*pathology', 'Lymphoma/*pathology', 'Skin/*pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000249432 [doi]'],ppublish,Dermatologica. 1985;171(4):250-4. doi: 10.1159/000249432.,,,,,,,,,,,,
4076429,NLM,MEDLINE,19860130,20090605,0430-0920 (Print) 0430-0920 (Linking),40,9,1985 Sep,[Tridentate N-N-N chelating systems as potential antitumor agents].,645-54,"Tridentate chelating agents, as potential antitumor agents, were prepared by condensing 2-quinolylhydrazines, 2-pyridylhydrazine and 2-benzothiazolylhydrazine with pyridine-2-aldehyde, 6-methylpyridine-2-aldehyde, 2-acetylpyridine and 2-benzoylpyridine. All compounds were tested against Lymphocytic leukemia P388. The active pyridine-2-aldehyde-4-methyl-2-quinolylhydrazone [1-(4'-methyl-2'-quinolyl)-3-(2'-pyridyl)-1,2-diaza-2-propene] (I d) was also tested against other experimental tumors and proved inactive.","['Pellerano, C', 'Savini, L', 'Massarelli, P']","['Pellerano C', 'Savini L', 'Massarelli P']",['ita'],"['English Abstract', 'Journal Article']",Italy,Farmaco Sci,Il Farmaco; edizione scientifica,0370716,IM,"['Animals', '*Antineoplastic Agents/administration & dosage/chemical synthesis', 'Cell Line', '*Chelating Agents/administration & dosage/chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Female', 'Hydrazones/pharmacology', 'Leukemia P388/drug therapy', 'Male', 'Mice']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Farmaco Sci. 1985 Sep;40(9):645-54.,"['0 (Antineoplastic Agents)', '0 (Chelating Agents)', '0 (Hydrazones)']",,Sistemi chelanti tridentati N-N-N quali potenziali agenti antitumorali.,,,,,,,,,
4076286,NLM,MEDLINE,19860210,20190908,0277-5379 (Print) 0277-5379 (Linking),21,10,1985 Oct,Stage IV non-Hodgkin's lymphoma in children.,1191-4,"Twenty-five children with previously untreated stage IV non-Hodgkin's lymphoma (NHL) were studied. At the time of evaluation 16 patients were disease-free (64%), with a median observation time of 23 months. Intensive chemotherapy for childhood NHL provides a better outlook for these patients, including those who would be considered high-risk acute lymphoblastic leukemia (ALL).","['Sumer, T', 'Al-Awamy, B', 'Al-Mouzan, M']","['Sumer T', 'Al-Awamy B', 'Al-Mouzan M']",['eng'],['Journal Article'],England,Eur J Cancer Clin Oncol,European journal of cancer & clinical oncology,8112045,IM,"['Antineoplastic Agents/therapeutic use', 'Bone Marrow/pathology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Leukocyte Count', 'Lymph Nodes/pathology', 'Lymphoma/drug therapy/mortality/*pathology', 'Male', 'Prognosis']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1016/0277-5379(85)90014-8 [doi]'],ppublish,Eur J Cancer Clin Oncol. 1985 Oct;21(10):1191-4. doi: 10.1016/0277-5379(85)90014-8.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4076283,NLM,MEDLINE,19860210,20190908,0277-5379 (Print) 0277-5379 (Linking),21,10,1985 Oct,Clostridium difficile colitis in leukemia patients.,1159-63,"Leukemia patients with diarrhea or other abdominal symptoms have been investigated for the presence of Clostridium difficile and its cytotoxin in stools. Of the patients studied 19% had C. difficile, in most cases together with cytotoxin. All patients but one had received antibiotics, while one had been treated with cytotoxic agents only. Symptoms of colitis were most often abdominal pain and distension rather than diarrhea. Owing to the not infrequent fatal evolution, it is recommended that routine search for C. difficile in leukemia patients with abdominal symptoms be performed and appropriate therapy started immediately.","['Panichi, G', 'Pantosti, A', 'Gentile, G', 'Testore, G P', 'Venditti, M', 'Martino, P', 'Serra, P']","['Panichi G', 'Pantosti A', 'Gentile G', 'Testore GP', 'Venditti M', 'Martino P', 'Serra P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Eur J Cancer Clin Oncol,European journal of cancer & clinical oncology,8112045,IM,"['Adolescent', 'Adult', 'Anti-Bacterial Agents/therapeutic use', 'Child, Preschool', 'Clostridium/isolation & purification', 'Clostridium Infections/*complications/drug therapy', 'Colitis/complications/drug therapy/*microbiology', 'Feces/microbiology', 'Female', 'Humans', 'Leukemia/*complications/drug therapy', 'Male', 'Middle Aged']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1016/0277-5379(85)90008-2 [doi]'],ppublish,Eur J Cancer Clin Oncol. 1985 Oct;21(10):1159-63. doi: 10.1016/0277-5379(85)90008-2.,['0 (Anti-Bacterial Agents)'],,,,,,,,,,,
4075859,NLM,MEDLINE,19860219,20180216,0009-3157 (Print) 0009-3157 (Linking),31,6,1985,Antitumour activity of chlorimidazine on transplantable mouse tumour systems.,472-5,"The antitumour activity of the newly synthesized compound, chlorimidazine (1-chlorethyl-2-chlormethyl-2-imidazoline hydrochloride), has been investigated on mouse tumour systems including L 1210 and P 388 leukaemias and Lewis lung carcinoma. It has been found that optimum treatment schedules resulted in 153% T/C in mice with L 1210 leukaemia, 159% T/C in mice bearing P 388 leukaemia and 68% TWI for Lewis lung carcinoma. Due to the results obtained the compound acts as a novel potential antitumour agent that warrants further evaluation.","['Mircheva, J J', 'Pantev, T P']","['Mircheva JJ', 'Pantev TP']",['eng'],['Journal Article'],Switzerland,Chemotherapy,Chemotherapy,0144731,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Drug Evaluation, Preclinical', 'Female', 'Imidazoles/*pharmacology', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Lung Neoplasms/drug therapy', 'Male', 'Mice', 'Neoplasm Transplantation', 'Neoplasms, Experimental/*drug therapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000238376 [doi]'],ppublish,Chemotherapy. 1985;31(6):472-5. doi: 10.1159/000238376.,"['0 (Antineoplastic Agents)', '0 (Imidazoles)', '99103-36-3 (chlorimidazine)']",,,,,,,,,,,
4075840,NLM,MEDLINE,19860129,20130912,0011-4162 (Print) 0011-4162 (Linking),36,6,1985 Dec,Multiple cutaneous squamous cell carcinomas in a patient with chronic lymphocytic leukemia.,467-9,"A 79-year-old white woman had stasis dermatitis and multiple cutaneous squamous cell carcinomas not only in the exposed areas of the face, neck, and arms, but also on the lower legs in the area of dermatitis. Further evaluation revealed early chronic lymphocytic leukemia. This case illustrates the need to search for an underlying abnormality in patients with multiple or unusual skin cancers and to examine biopsy specimens from suspicious skin lesions in immunocompromised patients.","['Fowler, J F Jr', 'Knuckles, M L']","['Fowler JF Jr', 'Knuckles ML']",['eng'],"['Case Reports', 'Journal Article']",United States,Cutis,Cutis,0006440,IM,"['Aged', 'Arm', 'Carcinoma, Squamous Cell/*complications', 'Face', 'Female', 'Humans', 'Keratosis/complications', 'Leg', 'Leukemia, Lymphoid/*complications', 'Neck', '*Neoplasms, Multiple Primary', 'Skin Neoplasms/*complications']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cutis. 1985 Dec;36(6):467-9.,,,,,,,,,,,,
4075320,NLM,MEDLINE,19860131,20061115,0361-5960 (Print) 0361-5960 (Linking),69,12,1985 Dec,Use of protein A-Sepharose-treated sera in human acute nonlymphocytic leukemia: lack of toxicity.,1449-50,,"['Spitzer, T R', 'Lazarus, H M', 'Biblo, L A']","['Spitzer TR', 'Lazarus HM', 'Biblo LA']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer Treat Rep,Cancer treatment reports,7607107,IM,"['Acute Disease', 'Adult', '*Blood', 'Bone Marrow/immunology', 'Female', 'Humans', 'Immunoglobulin G/analysis', 'Leukemia/immunology/*therapy', 'Male', 'Middle Aged', 'Receptors, Antigen, B-Cell/analysis', 'Staphylococcal Protein A/adverse effects/*immunology']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Treat Rep. 1985 Dec;69(12):1449-50.,"['0 (Immunoglobulin G)', '0 (Receptors, Antigen, B-Cell)', '0 (Staphylococcal Protein A)']",,,,,,,,,,,
4075311,NLM,MEDLINE,19860131,20161123,0361-5960 (Print) 0361-5960 (Linking),69,12,1985 Dec,Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.,1359-63,"Cisplatin plus 5-FU appears to have significant additive activity in various tumors, such as head and neck carcinoma and esophageal cancer. A partial explanation for this may be drug synergism, which has been noted in the L1210 leukemia model. Based on these data, a prospective trial of weekly bolus 5-FU (15 mg/kg) and cisplatin (60 mg/m2) given every 3 weeks was initiated at Indiana University. Forty-one patients, of whom 38 are fully evaluable for response, were treated with these two drugs. Ten partial and one complete response (complete + partial response rate = 29%) were observed in the 38 evaluable patients. Thirteen additional patients had stable disease for greater than or equal to 3 months. The median durations of remission and survival time were 6 and 10.3 months, respectively. Myelosuppression was unusually severe, with granulocyte counts less than 1000/mm3 in 65% of patients, including four patients with granulocyte count nadirs less than 100/mm3. Three patients developed granulocytopenic fever, with two drug-related deaths (sepsis, hyperosmolar coma). Nearly all patients had nausea and vomiting, but this was not a treatment-limiting toxic effect in any patient. Although this combination suggests a higher response rate than usually seen with bolus iv 5-FU in colon cancer, a trial comparing 5-FU alone or with cisplatin to determine whether true synergy exists is currently underway.","['Loehrer, P J Sr', 'Einhorn, L H', 'Williams, S D', 'Hui, S L', 'Estes, N C', 'Pennington, K']","['Loehrer PJ Sr', 'Einhorn LH', 'Williams SD', 'Hui SL', 'Estes NC', 'Pennington K']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Treat Rep,Cancer treatment reports,7607107,IM,"['Adenocarcinoma/diagnostic imaging/*drug therapy', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoembryonic Antigen/analysis', 'Cisplatin/administration & dosage', 'Colonic Neoplasms/diagnostic imaging/*drug therapy', 'Drug Evaluation', 'Female', 'Fluorouracil/administration & dosage', 'Gastrointestinal Diseases/chemically induced', 'Hematologic Diseases/chemically induced', 'Humans', 'Liver Neoplasms/secondary', 'Lung Neoplasms/secondary', 'Male', 'Middle Aged', 'Radionuclide Imaging', 'Rectal Neoplasms/drug therapy', 'Tomography, X-Ray Computed']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Treat Rep. 1985 Dec;69(12):1359-63.,"['0 (Carcinoembryonic Antigen)', 'Q20Q21Q62J (Cisplatin)', 'U3P01618RT (Fluorouracil)']",,,['RR-00750/RR/NCRR NIH HHS/United States'],,,,,,,,
4075300,NLM,MEDLINE,19860210,20190720,0304-3835 (Print) 0304-3835 (Linking),29,3,1985 Dec,"In the search for new anticancer drugs. XV. Various aliphatic and aromatic hydrazones containing the N,N;N',N'-bis(1,2-ethanediyl)phosphoric diamide moiety.",309-22,"The scope of the structure-anticancer activity relationship among various aliphatic and aromatic hydrazones containing the N,N,N',N'-bis(1,2-ethanediyl)-phosphoric diamide moiety was studied. A total of 19 compounds were tested in vivo, using murine lymphocytic leukemia P388. At optimum dose all these compounds were active. The highest activity was exhibited by the N,N;N',N'-bis(1,2-ethanediyl)-[N2-(p-chlorobenzylidene)-N1- hydrazin-1-yl]phosphoric triamide, N,N;N',N'-bis(1,2-ethanediyl)-N2-(p-chlorobenzylidene)-N1- methylhydrazin-1-yl]phosphoric triamide and N,N;N',N'-bis(1,2-ethanediyl)-[N2-(p-chlorobenzylidene)-N1- phenylhydrazin-1-yl]phosphoric triamide as is evidenced by the percent T/C of 212, 194 and 192, respectively. An attempt was made to correlate the anticancer activities with the corresponding lipophilicities. On the basis of the activity-lipophilicity results, it is concluded that, in general, the activity scale follows the lipophilicity scale in the reverse order, i.e. the more active compounds possess lower lipophilicity than the less active compounds.","['Sosnovsky, G', 'Rao, N U']","['Sosnovsky G', 'Rao NU']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Ireland,Cancer Lett,Cancer letters,7600053,IM,"['Animals', 'Antineoplastic Agents/chemical synthesis/*pharmacology/toxicity', 'Hydrazones/chemical synthesis/*pharmacology/toxicity', 'Male', 'Mice', 'Mice, Inbred Strains', 'Rats', 'Rats, Inbred Strains', 'Solubility', 'Structure-Activity Relationship']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0304-3835(85)90142-9 [pii]', '10.1016/0304-3835(85)90142-9 [doi]']",ppublish,Cancer Lett. 1985 Dec;29(3):309-22. doi: 10.1016/0304-3835(85)90142-9.,"['0 (Antineoplastic Agents)', '0 (Hydrazones)']",,,,,,,,,,['Cancer Lett 1986 Mar;30(3):337'],
4075296,NLM,MEDLINE,19860210,20190720,0304-3835 (Print) 0304-3835 (Linking),29,3,1985 Dec,"Timing- and sequence-dependent synergism between etoposide and methotrexate or etoposide, methotrexate and 5-fluorouracil in advanced leukemia L1210.",277-82,"The optimal synergism in combination therapy of leukemia L1210 depends on the sequence and the timing of the agents used. Etoposide (20 mg/kg applied intravenously) 3 h before methotrexate (50 mg/kg administered subcutaneously) results in significantly improved therapeutic action. Simultaneous application of these drugs, or an exceeding of that interval, do not entail synergism. Similar to the results obtained with other transplantable murine tumors, the optimal interval between methotrexate and 5-fluorouracil treatments of leukemia L1210 amounts to 6 h. Sequential treatment with etoposide (20 mg/kg given intravenously) significantly improves the efficacy of combined methotrexate (50 mg/kg applied subcutaneously) and 5-fluorouracil (80 mg/kg administered subcutaneously). The optimal synergism combining etoposide, methotrexate and 5-fluorouracil is achieved when the interval between etoposide and methotrexate amounts to 3 h followed 6 h later by 5-fluorouracil.","['Osswald, H', 'Herrmann, R', 'Youssef, M']","['Osswald H', 'Herrmann R', 'Youssef M']",['eng'],['Journal Article'],Ireland,Cancer Lett,Cancer letters,7600053,IM,"['Animals', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Drug Synergism', 'Etoposide/*administration & dosage', 'Female', 'Fluorouracil/*administration & dosage', 'Leukemia L1210/*drug therapy', 'Methotrexate/*administration & dosage/metabolism', 'Mice', 'Mice, Inbred Strains', 'Podophyllotoxin/*analogs & derivatives', 'Time Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0304-3835(85)90137-5 [pii]', '10.1016/0304-3835(85)90137-5 [doi]']",ppublish,Cancer Lett. 1985 Dec;29(3):277-82. doi: 10.1016/0304-3835(85)90137-5.,"['6PLQ3CP4P3 (Etoposide)', 'L36H50F353 (Podophyllotoxin)', 'U3P01618RT (Fluorouracil)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4074887,NLM,MEDLINE,19860131,20071115,0340-4684 (Print) 0340-4684 (Linking),11,1,1985,Use of mean platelet volume improves detection of platelet disorders.,127-35,"Classification of platelet disorders has been based on the platelet count. Addition of a second variable, mean platelet volume (MPV), to the routine blood count allows classification of patients into 9 categories: high, low, or normal MPV, and high, low or normal platelet count. We studied 1,244 adult inpatients. 1,134 had both platelet values normal. 11 patients had high MPV and low platelet count: all had hyperdestructive causes. 15 patients had high MPV and normal platelet count: 12 had heterozygous thalassemia, and three had iron deficiency. Seven patients had high MPV and high platelet count: causes included myeloproliferative disorders, inflammation, iron deficiency, and splenectomy, 25 patients had high platelet counts and normal MPV: the causes were inflammation, infection, sickle cell anemia, iron deficiency, or chronic myelogenous leukemia. 52 patients had an MPV that was inappropriately low for the platelet count (high, normal, or low). All had sepsis, splenomegaly, aplastic anemia, chronic renal failure, or a disease being treated with myelosuppressive drugs. High MPV thus appears correlated with myeloproliferative disease or thalassemia; and low MPV, with cytotoxic drugs or marrow hypoplasia. Addition of MPV to the platelet count allows subtler disorders to be detected (when the platelet count is normal), and allows distinction of the cause of thrombocytopenia.","['Bessman, J D', 'Gilmer, P R', 'Gardner, F H']","['Bessman JD', 'Gilmer PR', 'Gardner FH']",['eng'],['Journal Article'],United States,Blood Cells,Blood cells,7513567,IM,"['Blood Cell Count/*methods', 'Blood Platelet Disorders/*diagnosis', '*Blood Platelets', 'Humans', 'Statistics as Topic']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Blood Cells. 1985;11(1):127-35.,,,,,,,,,,,,
4074871,NLM,MEDLINE,19860213,20081008,0365-9615 (Print) 0365-9615 (Linking),100,12,1985 Dec,[Acid glycosidases of normal cattle lymphocytes and in chronic lympholeukemia].,698-701,"The activity of five acid glycosidases was determined in lymphocytes from normal animals and animals with chronic lymphocytic leukemia. It was shown that alpha-D-mannosidase activity in leukemic lymphocytes was 5 times lower (p less than less than 0.001) and alpha-D-glucosidase activity was 2 times lower (p less than 0.01) than in normal controls. The progress of the disease and the increase in leukocyte count were accompanied by the decrease in alpha-D-mannosidase activity. No differences have been found in alpha-D-mannosidase properties (thermostability, Km values, ZnSl2 activation) in normal and leukemic lymphocytes.","['Preobrazhenskaia, M E', 'Gevorkian, N M']","['Preobrazhenskaia ME', 'Gevorkian NM']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Biull Eksp Biol Med,Biulleten' eksperimental'noi biologii i meditsiny,0370627,IM,"['Animals', 'Cattle', 'Cell Separation', 'Glycoside Hydrolases/*blood', 'Hydrogen-Ion Concentration', 'Leukemia, Lymphoid/enzymology/*veterinary', 'Lymphocytes/*enzymology', 'Substrate Specificity']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Biull Eksp Biol Med. 1985 Dec;100(12):698-701.,['EC 3.2.1.- (Glycoside Hydrolases)'],,Kislye glikozidazy limfotsitov krupnogo rogatogo skota v norme i pri khronicheskom limfoleikoze.,,,,,,,,,
4074781,NLM,MEDLINE,19860220,20070723,0320-9725 (Print) 0320-9725 (Linking),50,12,1985 Dec,[Polynucleotide sequences in the DNA from leukemic cells forming RNAse-resistant complexes with polyuridylic acid].,1953-6,"RNAase-resistant complexes of poly(U): poly (dA) were obtained by hybridization of [3H] poly (U) with cellular DNA. Depending on the mode by hybrids treatment with RNAase, two types of (dA)-sites i. el, dA and poly (dA) sites with different homogeneity were identified. The amount of these sequences in the DNA isolated from normal cells of intact animals and from several types of leukemic cells was determined. Full identity of the dA-sites in normal tissue DNAs of the same animals and a statistically significant increase in their content in leukemic cells were demonstrated. Differences between DNAs of normal and leukemic cells vary widely, depending on the leukemia type.","['Smirnova, I A']",['Smirnova IA'],['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Biokhimiia,"Biokhimiia (Moscow, Russia)",0372667,IM,"['Animals', 'Base Sequence', 'Cattle', 'DNA, Neoplasm/genetics/*metabolism', 'Leukemia, Experimental/genetics/*metabolism', 'Mice', 'Nucleic Acid Hybridization', 'Poly A/*metabolism', 'Poly U/*metabolism', 'Rats']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Biokhimiia. 1985 Dec;50(12):1953-6.,"['0 (DNA, Neoplasm)', '24937-83-5 (Poly A)', '25191-20-2 (poly(dA))', '27416-86-0 (Poly U)']",,"Polinukleotidnye posledovatel'nosti v DNK leikoznykh kletok, obrazuiushchie RNKaza-ustoichivye kompleksy s poliuridilovoi kislotoi.",,,,,,,,,
4074742,NLM,MEDLINE,19860210,20190609,0006-3002 (Print) 0006-3002 (Linking),821,3,1985 Dec 19,Transport of folates at maternal and fetal sides of the placenta: lack of inhibition by methotrexate.,497-501,"Folate (pteroylglutamate) and methotrexate rapid (seconds) uptake by the trophoblast was investigated from either the maternal or fetal circulations of the isolated dually-perfused guinea-pig placenta. Tissue uptake was measured by using a single-circulation paired-tracer (3H-test and 14C-extracellular marker) technique. [3H]Folate uptakes were 80 and 52% (mean) in perfusates without unlabelled folate, on maternal and fetal sides, respectively. There was negligible 3H-tracer backflux into the circulation up to 6 min probably due to metabolic sequestration. [3H]Methotrexate uptakes were about 85 and 22% on maternal and fetal sides, respectively; however these uptakes were followed by rapid and complete backflux of the label. Specific transplacental transfer of [3H]folate or [3H]methotrexate in either direction was not detectable within 5-6 min. At the brush-border side (maternal) uptake of [3H]folate was highly inhibited by 100 nM unlabelled folate or its reduced form, methyltetrahydrofolate (the main form in plasma); however, equimolar methotrexate (an antifolate chemotherapeutic agent) failed to produce any inhibition of folate uptake. Our findings demonstrate that on both sides of the placenta a high-affinity transport system exists for trophoblast uptake of folate compounds. For methotrexate, either a separate transport system may exist or methotrexate may have a very low affinity for the folate system. These results are distinct from the findings reported in mouse L1210 leukemia cells.","['Sweiry, J H', 'Yudilevich, D L']","['Sweiry JH', 'Yudilevich DL']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Biochim Biophys Acta,Biochimica et biophysica acta,0217513,IM,"['Animals', 'Biological Transport/drug effects', 'Carbon Radioisotopes', 'Female', 'Folic Acid/blood/*metabolism', 'Guinea Pigs', 'Kinetics', 'Methotrexate/*pharmacology', 'Placenta/drug effects/*metabolism', 'Pregnancy', 'Tritium', 'Trophoblasts/drug effects/*metabolism']",,1985/12/19 00:00,1985/12/19 00:01,['1985/12/19 00:00'],"['1985/12/19 00:00 [pubmed]', '1985/12/19 00:01 [medline]', '1985/12/19 00:00 [entrez]']","['0005-2736(85)90055-0 [pii]', '10.1016/0005-2736(85)90055-0 [doi]']",ppublish,Biochim Biophys Acta. 1985 Dec 19;821(3):497-501. doi: 10.1016/0005-2736(85)90055-0.,"['0 (Carbon Radioisotopes)', '10028-17-8 (Tritium)', '935E97BOY8 (Folic Acid)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4074714,NLM,MEDLINE,19860207,20190613,0006-2960 (Print) 0006-2960 (Linking),24,20,1985 Sep 24,DNA methylation in mammalian nuclei.,5575-81,"A novel system to study the methylation of newly synthesized DNA in isolated nuclei was developed. Approximately 2.5% of cytosine residues incorporated into nascent DNA became methylated by endogenous methylase(s), and the level of DNA modification was reduced by methylation inhibitors. DNA synthesis and methylation were dependent on separate cytosol factors. The cytosol factor or factors required for DNA methylation were sensitive to trypsin digestion and were precipitable by (NH4)2SO4, suggesting that they were proteinaceous. Time-course experiments revealed a short lag of approximately 20 s between synthesis and methylation in nuclei. The DNAs produced in these nuclei were a mixed population of low molecular weight fragments and higher molecular weight fragments shown to be short extension of existing replicons. The methylation level found in low molecular weight DNA was lower than that found in bulk L1210 DNA, indicating that further methylation events might take place after ligation of small fragments. These data suggest that newly synthesized DNA is a good substrate for methylase enzymes and that nuclear cytoplasmic interactions may be important in controlling inheritance of methylation patterns.","['Kautiainen, T L', 'Jones, P A']","['Kautiainen TL', 'Jones PA']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Biochemistry,Biochemistry,0370623,IM,"['Animals', 'Cell Nucleus/*metabolism', 'DNA (Cytosine-5-)-Methyltransferases/*metabolism', '*DNA Replication', 'DNA, Neoplasm/genetics/*isolation & purification', 'Kinetics', 'Leukemia L1210/*metabolism', 'Male', 'Methylation', 'Mice', 'Mice, Inbred Strains']",,1985/09/24 00:00,1985/09/24 00:01,['1985/09/24 00:00'],"['1985/09/24 00:00 [pubmed]', '1985/09/24 00:01 [medline]', '1985/09/24 00:00 [entrez]']",['10.1021/bi00341a043 [doi]'],ppublish,Biochemistry. 1985 Sep 24;24(20):5575-81. doi: 10.1021/bi00341a043.,"['0 (DNA, Neoplasm)', 'EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)']",,,['CA39913/CA/NCI NIH HHS/United States'],,,,,,,,
4074528,NLM,MEDLINE,19860124,20131121,0037-8771 (Print) 0037-8771 (Linking),61,7,1985 Jul 30,[Damage to DNA by tritiated thymidine and its development in normal human (PHA-stimulated lymphocytes) and leukemic (Molt-3) lymphoblasts].,1075-81,,"['Catena, C', 'Mattoni, A']","['Catena C', 'Mattoni A']",['ita'],"['English Abstract', 'Journal Article']",Italy,Boll Soc Ital Biol Sper,Bollettino della Societa italiana di biologia sperimentale,7506962,IM,"['Cell Cycle', 'Cell Line', 'DNA/*radiation effects', 'Dose-Response Relationship, Drug', 'Humans', 'Leukemia/*genetics', 'Lymphocyte Activation', 'Lymphocytes/*radiation effects', 'Phytohemagglutinins/*pharmacology', 'Thymidine/*pharmacology', 'Time Factors', '*Tritium']",,1985/07/30 00:00,1985/07/30 00:01,['1985/07/30 00:00'],"['1985/07/30 00:00 [pubmed]', '1985/07/30 00:01 [medline]', '1985/07/30 00:00 [entrez]']",,ppublish,Boll Soc Ital Biol Sper. 1985 Jul 30;61(7):1075-81.,"['0 (Phytohemagglutinins)', '10028-17-8 (Tritium)', '9007-49-2 (DNA)', 'VC2W18DGKR (Thymidine)']",,Danno al DNA da timidina tritiata e sua evoluzione in linfoblasti umani normali (linfociti PHA stimolati) e leucemici (Molt-3).,,,,,,,,,
4074416,NLM,MEDLINE,19860117,20031114,0004-4172 (Print) 0004-4172 (Linking),35,10,1985,Inhibitory effect of nocardia rubra cell wall skeleton on splenomegaly induced by Friend leukemia virus in mice.,1563-4,Antitumorigenic effect of Nocardia rubra cell wall skeleton (N-CWS) was evaluated by its ability to prevent splenomegaly induced by Friend leukemia virus (FLV) in C3H/HeN mice. Pretreatment with N-CWS significantly inhibited the splenomegaly as evidenced by the lack of increase in spleen weight but N-CWS given after FLV inoculation had no effect.,"['Mine, Y', 'Yokota, Y', 'Kikuchi, H']","['Mine Y', 'Yokota Y', 'Kikuchi H']",['eng'],['Journal Article'],Germany,Arzneimittelforschung,Arzneimittel-Forschung,0372660,IM,"['Animals', 'Cell Wall/physiology', 'Friend murine leukemia virus', 'Leukemia, Experimental/*complications/therapy', 'Male', 'Mice', 'Mice, Inbred C3H', 'Nocardia/*physiology', 'Splenomegaly/etiology/*prevention & control']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arzneimittelforschung. 1985;35(10):1563-4.,,,,,,,,,,,,
4074375,NLM,MEDLINE,19860115,20190612,0006-291X (Print) 0006-291X (Linking),133,1,1985 Nov 27,Kinetics of the reaction of cis-platinum compounds with DNA in vitro.,347-53,"The kinetics of the reaction of a series of cis-platinum(II) compounds with DNA in vitro has been studied using their ability to disturb the secondary structure of the macromolecule. The complexation modifies the stacking of the base pairs and causes an inhibition of the intercalation of ethidium bromide which is correlated with the number of platinum atoms bound per nucleotide. The compounds fall into three groups which react in a few minutes, in a few hours or in several days. The inhibition of the complexation by chloride and carboxylato ions indicates that the interaction occurs through hydrolysed species and that hydrolysis is the rate limiting step. In addition the results indicate that the carboxylato entities are able to react with DNA in vitro without enzymatic activation and that there is no correlation between the antitumoral activity of these compounds against L1210 Leukemia cells and their in vitro reactivity towards DNA.","['Butour, J L', 'Mazard, A M', 'Macquet, J P']","['Butour JL', 'Mazard AM', 'Macquet JP']",['eng'],['Journal Article'],United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,IM,"['Chemical Phenomena', 'Chemistry', '*Cisplatin/pharmacology', '*DNA', 'Kinetics']",,1985/11/27 00:00,1985/11/27 00:01,['1985/11/27 00:00'],"['1985/11/27 00:00 [pubmed]', '1985/11/27 00:01 [medline]', '1985/11/27 00:00 [entrez]']","['0006-291X(85)91882-0 [pii]', '10.1016/0006-291x(85)91882-0 [doi]']",ppublish,Biochem Biophys Res Commun. 1985 Nov 27;133(1):347-53. doi: 10.1016/0006-291x(85)91882-0.,"['9007-49-2 (DNA)', 'Q20Q21Q62J (Cisplatin)']",,,,,,,,,,,
4073928,NLM,MEDLINE,19860114,20131121,0385-0684 (Print) 0385-0684 (Linking),12,12,1985 Dec,[The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency].,2331-7,"The antitumor activity of etoposide against a wide variety of transplantable tumors in mice and rats was examined. Etoposide exhibited antitumor activity by both i.p. and p.o. administrations but a much larger effect was obtained in the former case. In addition, the effective dose of etoposide was much less in i.p. administration. In order to further investigate this large difference of etoposide effect the level of etoposide in the blood was followed after administration of 3H-etoposide via i.p. and p.o. routes. Although the maximum levels for both were seen 10 to 20 min after administration, the level in i.p. administration was much higher than that in p.o. administration. For instance, the level seen for i.p. administration at 8 mg/kg was comparable to that for p.o. administration at a much higher dose of 128 mg/kg. The administration schedule dependency of etoposide antitumor activity was examined using L1210 leukemia as the target tumor. When etoposide was administered alone on day, 1, the effect was the smallest obtained in i.p. as well as in p.o. administrations among the schedules examined in this study. Under other schedules where etoposide was administered i.p. and p.o. once a day for 3, 5 and 9 consecutive days from day 1 and on every other day, that is, days 1, 3 and 5, higher antitumor effects were seen.","['Okamoto, K', 'Nishikawa, K', 'Seki, T', 'Shibasaki, C', 'Uchida, T', 'Takahashi, K']","['Okamoto K', 'Nishikawa K', 'Seki T', 'Shibasaki C', 'Uchida T', 'Takahashi K']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Adenocarcinoma/drug therapy', 'Administration, Oral', 'Animals', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Colonic Neoplasms/drug therapy', 'Drug Administration Schedule', 'Etoposide/*administration & dosage/blood', 'Female', 'Leukemia, Experimental/drug therapy', 'Liver Neoplasms, Experimental/drug therapy', 'Lung Neoplasms/drug therapy', 'Male', 'Mice', 'Neoplasms, Experimental/blood/*drug therapy/pathology', 'Podophyllotoxin/*analogs & derivatives']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Dec;12(12):2331-7.,"['6PLQ3CP4P3 (Etoposide)', 'L36H50F353 (Podophyllotoxin)']",,,,,,,,,,,
4073927,NLM,MEDLINE,19860114,20131121,0385-0684 (Print) 0385-0684 (Linking),12,12,1985 Dec,[Effect of ethyl-O-[N-(p-carboxyphenyl) carbamoyl]-mycophenolate against L1210 leukemia].,2327-30,"Ethyl-O-[N-(p-carboxyphenyl) carbamoyl]-mycophenolate (CAM), a mycophenolic acid (MPA) derivative, has been evaluated in terms of influence of treatment schedule and route of administration on antitumor activity in mice bearing L 1210 leukemia and cross-resistance to 6-MP was studied. The results obtained were as follows; The effect of oral administration of CAM was identical to that of MPA or FT-207. Both CAM and MPA were most effective when given on day 1, 5 and 9 following tumor inoculation. Intraperitoneal administration with MPA was marginally effective, while the activity obtained with intraperitoneal administration of CAM was superior to that for oral administration. CAM did not show any cross-resistance to 6-MP.","['Kato, T', 'Ota, K']","['Kato T', 'Ota K']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Administration, Oral', 'Animals', 'Antineoplastic Agents/administration & dosage/*therapeutic use', 'Leukemia L1210/*drug therapy', 'Mice', 'Mice, Inbred DBA', 'Mycophenolic Acid/administration & dosage/*analogs & derivatives/therapeutic use']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Dec;12(12):2327-30.,"['0 (Antineoplastic Agents)', '82970-82-9 (ethyl O-(N-(4-carboxyphenyl)carbamoyl)mycophenolate)', 'HU9DX48N0T (Mycophenolic Acid)']",,,,,,,,,,,
4073494,NLM,MEDLINE,19860108,20190628,0003-2697 (Print) 0003-2697 (Linking),149,2,1985 Sep,Measurement of DNA-protein crosslinks in mammalian cells without X-irradiation.,365-8,"To study the mechanisms of formation and repair of DNA-protein crosslinks in mammalian cells, the best general method to assay these lesions is the Kohn membrane alkaline elution procedure. Use of this sensitive technique requires the introduction of random strand breaks in the DNA by X-irradiation to reduce the very high molecular weight so that it elutes off the filter at an appropriate rate. This report describes an alternative method for fragmenting the DNA in the absence of X-irradiation equipment. Convenient reproducible elution rates of DNA from various mouse and human cells in culture without X-irradiation result from elution through polyvinyl chloride filters with 75 mM sodium hydroxide (0.33 ml/min) instead of the standard 20 mM EDTA-tetrapropylammonium hydroxide, pH 12.2 (0.03 to 0.04 ml/min). Dose-dependent retardation of the DNA elution was observed over the range 0 to 30 microM trans-platinum(II)diamminedichloride, and proteinase K treatment during cell lysis restored the elution rate to that of the untreated control cell DNA. In the absence of X-irradiation, this elution method measures DNA-protein crosslinks with higher sensitivity and equivalent reproducibility as the air-burst procedure.","['Gantt, R', 'Stephens, E V', 'Davis, S R']","['Gantt R', 'Stephens EV', 'Davis SR']",['eng'],['Journal Article'],United States,Anal Biochem,Analytical biochemistry,0370535,IM,"['Animals', 'Cells, Cultured', 'Cisplatin', 'DNA/*analysis/radiation effects', 'DNA, Neoplasm/analysis', 'Humans', 'Hydrogen-Ion Concentration', 'Leukemia L1210/metabolism', 'Mice', 'Molecular Weight', '*Protein Binding', 'Sodium Hydroxide']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['0003-2697(85)90584-6 [pii]', '10.1016/0003-2697(85)90584-6 [doi]']",ppublish,Anal Biochem. 1985 Sep;149(2):365-8. doi: 10.1016/0003-2697(85)90584-6.,"['0 (DNA, Neoplasm)', '14913-33-8 (transplatin)', '55X04QC32I (Sodium Hydroxide)', '9007-49-2 (DNA)', 'Q20Q21Q62J (Cisplatin)']",,,,,,,,,,,
4073355,NLM,MEDLINE,19851227,20190820,0147-5185 (Print) 0147-5185 (Linking),9,11,1985 Nov,Cutaneous Thorotrast granulomas and chronic lymphocytic leukemia following Thorotrast angiography.,835-41,"A patient underwent cerebral angiography with thorium dioxide (Thorotrast). Six years later, an acne-like eruption of the face and scalp occurred which persisted despite aggressive treatment. Twenty-six years after the angiography he developed chronic lymphocytic leukemia with massive lymphadenopathy. Review of three facial biopsies revealed collections of Thorotrast-laden histiocytes and free thorium dioxide within a background of chronic inflammation and dermal fibrosis. These changes are of the same type described in Thorotrast granulomas of the subcutaneous tissues. There is an increased incidence of myelogenous leukemia in Thorotrast-treated patients; lymphoproliferative disorders, however, are only rarely observed.","['Wargotz, E S']",['Wargotz ES'],['eng'],"['Case Reports', 'Journal Article']",United States,Am J Surg Pathol,The American journal of surgical pathology,7707904,IM,"['Cerebral Angiography/adverse effects', 'Facial Dermatoses/*chemically induced/pathology', 'Granuloma/*chemically induced/pathology', 'Humans', 'Leukemia, Lymphoid/*chemically induced/pathology', 'Male', 'Middle Aged', 'Multiple Sclerosis/diagnostic imaging', 'Thorium Dioxide/*adverse effects']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1097/00000478-198511000-00007 [doi]'],ppublish,Am J Surg Pathol. 1985 Nov;9(11):835-41. doi: 10.1097/00000478-198511000-00007.,['9XA7X17UQC (Thorium Dioxide)'],,,,,,,,,,,
4073113,NLM,MEDLINE,19851223,20190716,0002-9629 (Print) 0002-9629 (Linking),290,4,1985 Oct,Myelomatous ascites.,159-64,"Ascites is an unusual feature of multiple myeloma. We report a case of ascites occurring early in the course of a patient with myeloma in whom there was no evidence of intra-abdominal plasmacytoma, and the skeleton was relatively spared. The serum contained predominantly polymeric IgA, a feature not investigated in previous cases. We reviewed the relevant literature and will discuss the suggestion that human myelomas presenting with the triad of ascites, relative or absolute sparing of the skeleton, and an IgA paraprotein bear an analogy to mouse myelomas induced by intraperitoneal instillation of irritants. The relevance of polymeric IgA is discussed with respect to tissue origin of the paraprotein. Seventeen cases were identified consistent with a definition of ""myelomatous ascites"" (malignant myeloma in which plasma cells and/or monoclonal immunoglobulin can be demonstrated in ascitic fluid). IgA immunoglobulin class was present at three times the incidence seen in myelomas in general (five of seven cases were specified). In twelve patients there was no identifiable intra-abdominal plasmacytoma although liver infiltration was common. Amyloidosis was reported in only one case, and no cases of uncomplicated plasma cell leukemia were noted. Ascites was a presenting feature in five cases. In each of these five there was absolute or relative sparing of the skeleton, four had no evidence of plasmacytoma, and the paraprotein was IgA in three, IgG in one, and unreported in one. In no case was there a known history of chronic intra-abdominal irritation.","['Morgan, D', 'Cieplinski, W']","['Morgan D', 'Cieplinski W']",['eng'],"['Case Reports', 'Journal Article']",United States,Am J Med Sci,The American journal of the medical sciences,0370506,IM,"['Aged', 'Ascites/*etiology/immunology', 'Ascitic Fluid/metabolism', 'Electrophoresis, Starch Gel', 'Female', 'Humans', 'Immunoglobulin A/metabolism', 'Male', 'Middle Aged', 'Multiple Myeloma/*complications/immunology', 'Plasma Cells/*metabolism']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']","['S0002-9629(15)37075-0 [pii]', '10.1097/00000441-198510000-00005 [doi]']",ppublish,Am J Med Sci. 1985 Oct;290(4):159-64. doi: 10.1097/00000441-198510000-00005.,['0 (Immunoglobulin A)'],,,,,,,,,,,
4073096,NLM,MEDLINE,19860122,20170908,0002-9343 (Print) 0002-9343 (Linking),79,5B,1985 Nov 29,Ticarcillin plus clavulanic acid in the treatment of patients with cancer.,62-6,"Since the combination of ticarcillin with clavulanic acid is active against many otherwise resistant organisms that commonly affect patients with cancer, a therapeutic trial with ticarcillin disodium plus clavulanate potassium for treating infections in cancer patients was conducted. A total of 127 evaluable patients were treated with this antibiotic. Of these, 63 percent were women with breast carcinoma, 28 percent were patients with leukemia, and the remainder were patients with sarcomas and lung cancer. The median duration of therapy was 7.7 days. There were 63 documented infections, with bacteriologic documentation in 39 episodes. Because of the high incidence of gram-positive infections and after the failure of ticarcillin plus clavulanate potassium in two of these episodes, vancomycin was added to the regimen. The overall response rate was 75 percent. In microbiologically proved infections, the response rate was 79 percent. Thirteen of 17 gram-negative infections responded (76 percent), including four of four episodes caused by Pseudomonas aeruginosa. The only failures in this group were two episodes with Klebsiella species, one episode with Escherichia coli, and one episode with Enterobacter species. Of the gram-positive infections treated without vancomycin, five of eight (63 percent) responded and only two episodes due to Staphylococcus aureus and one due to JK diphtheroid bacteria failed. All episodes treated with the combination of ticarcillin plus clavulanate potassium and vancomycin responded. Seven of eight (88 percent) polymicrobial infections and 73 percent of those infections without identified organisms responded as well. The overall response rates for septicemia, pneumonia, soft tissue infections, and urinary tract infections were 71, 50, 71, and 83 percent, respectively. Of five microbiologically proved superinfections, three were fungal, and one each was due to Klebsiella species and S. aureus. No toxicity was observed. For 12 organisms, the minimal inhibitory concentration was lower for ticarcillin plus clavulanate potassium than for ticarcillin alone; in six it was identical. Five organisms were resistant to both, and three that were resistant to ticarcillin were sensitive to ticarcillin plus clavulanate potassium. Ticarcillin plus clavulanate potassium is a safe drug with an expanded spectrum of activity. More therapeutic trials need to be conducted to better define its role in the therapy of serious infections in cancer patients.","['Fainstein, V', 'Elting, L', 'Pitlik, S', 'Hortobagyi, G', 'Keating, M', 'Bodey, G P']","['Fainstein V', 'Elting L', 'Pitlik S', 'Hortobagyi G', 'Keating M', 'Bodey GP']",['eng'],['Journal Article'],United States,Am J Med,The American journal of medicine,0267200,IM,"['Adolescent', 'Adult', 'Aged', 'Bacterial Infections/*drug therapy', 'Clavulanic Acid', 'Clavulanic Acids/*administration & dosage', 'Drug Combinations', 'Humans', 'Middle Aged', 'Neoplasms/*complications', 'Penicillins/*administration & dosage', 'Ticarcillin/*administration & dosage']",,1985/11/29 00:00,1985/11/29 00:01,['1985/11/29 00:00'],"['1985/11/29 00:00 [pubmed]', '1985/11/29 00:01 [medline]', '1985/11/29 00:00 [entrez]']",['0002-9343(85)90130-5 [pii]'],ppublish,Am J Med. 1985 Nov 29;79(5B):62-6.,"['0 (Clavulanic Acids)', '0 (Drug Combinations)', '0 (Penicillins)', '23521W1S24 (Clavulanic Acid)', 'F93UJX4SWT (Ticarcillin)']",,,,,,,,,,,
4073051,NLM,MEDLINE,19860116,20190829,0271-3586 (Print) 0271-3586 (Linking),8,6,1985,Mortality among rubber workers: IX. Curing workers.,537-44,"This research examined mortality among 1,152 white male production workers employed in the tire-curing department of a large rubber manufacturing plant. To determine whether these men had any cause-specific mortality excesses, their experience was compared with that of both the U.S. white male general population and a group of production workers at the same plant who had not worked in the curing division. Both types of comparisons indicated that the curing workers experienced excess mortality from lung cancer. There were 45 deaths from lung cancer among curing workers compared to 24.6 expected based on the age- and calendar period-specific rates of other rubber workers. In addition, the mortality rate ratio for pneumonia was 2.2 for curing relative to noncuring workers. These findings are consistent with the results of other studies and suggest that occupational exposures may have contributed to the development of pulmonary disease among curing workers.","['Delzell, E', 'Monson, R R']","['Delzell E', 'Monson RR']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Am J Ind Med,American journal of industrial medicine,8101110,IM,"['Age Factors', 'Humans', 'Leukemia/mortality', 'Lung Neoplasms/mortality', 'Male', 'Occupational Diseases/*mortality', 'Pancreatic Neoplasms/mortality', 'Pneumonia/mortality', 'Rubber']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1002/ajim.4700080605 [doi]'],ppublish,Am J Ind Med. 1985;8(6):537-44. doi: 10.1002/ajim.4700080605.,['9006-04-6 (Rubber)'],,,['5 T15 OHO 7096/OH/NIOSH CDC HHS/United States'],,,,,,,,
4072799,NLM,MEDLINE,19860107,20191022,0065-2571 (Print) 0065-2571 (Linking),23,,1985,Polymorphism of dihydrofolate reductase from a methotrexate-resistant subline of L1210 cells.,3-12,"Dihydrofolate reductase, purified to homogeneity (as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis), from a subline of L1210 murine leukemia cells resistant to 10(-6) M methotrexate, was resolved into two principal forms (1 and 2) by polyacrylamide gel electrophoresis at pH 8.3 or isoelectric focusing. In the latter procedure, these forms had pI values of 7.4 and 8.2, respectively; both stained for protein and catalytic activity. Form 1 appears to be a single component, comprising ca. 10% of the total protein and at least 20% of the total catalytic activity. It is also more sensitive to inhibition by MTX, more heat-stable, and less susceptible to activation than form 2. Multiple components of 2 were observed by narrowing the pH range in isoelectric focusing, and further resolution was achieved by urea denaturation. Substrate and inhibitor complexes of 1 and 2, differentiated by polyacrylamide gel electrophoresis or isoelectric focusing, provided information about the ability of the enzyme to undergo conformational changes. Interconversion of 1 with one of the components of 2 may also involve conformational isomerism. These conclusions are consistent with the well-known ability of eukaryotic dihydrofolate reductases to exhibit increased catalytic activity (attributed to transformations to more open conformations) when treated with salts, chaotropes, or cysteine-modifying agents. Treatment of the L1210/R6 enzyme preparation with one of these activating agents, 5,5'-dithiobis(2-nitrobenzoic acid), derivatized both 1 and 2 (changing their pI values to 7.3 and 6.9, respectively) and altered the enzyme such that stoichiometric inhibition for MTX was observed.","['Duffy, T H', 'Beckman, S B', 'Sato, J K', 'Nagae, H', 'Vitols, K S', 'Huennekens, F M']","['Duffy TH', 'Beckman SB', 'Sato JK', 'Nagae H', 'Vitols KS', 'Huennekens FM']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Adv Enzyme Regul,Advances in enzyme regulation,0044263,IM,"['Animals', 'Cell Line', 'Dithionitrobenzoic Acid/pharmacology', 'Drug Resistance', 'Electrophoresis, Polyacrylamide Gel', 'Enzyme Activation/drug effects', 'Isoelectric Focusing', 'Isoenzymes/*metabolism', 'Leukemia L1210/*enzymology/pathology', 'Macromolecular Substances', 'Methotrexate/*pharmacology', 'Mice', 'Protein Conformation', 'Tetrahydrofolate Dehydrogenase/*metabolism']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0065-2571(85)90037-8 [doi]'],ppublish,Adv Enzyme Regul. 1985;23:3-12. doi: 10.1016/0065-2571(85)90037-8.,"['0 (Isoenzymes)', '0 (Macromolecular Substances)', '9BZQ3U62JX (Dithionitrobenzoic Acid)', 'EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)', 'YL5FZ2Y5U1 (Methotrexate)']",,,"['CA00964/CA/NCI NIH HHS/United States', 'CA06522/CA/NCI NIH HHS/United States']",,,,,,,,
4072768,NLM,MEDLINE,19860117,20121115,0375-8338 (Print) 0375-8338 (Linking),39,4,1985,Autoimmune hemolytic anemia in chronic lymphocytic leukemia.,293-9,,"['Stojcevski, T', 'Saso, R', 'Stojanoski, R', 'Karanfilski, O']","['Stojcevski T', 'Saso R', 'Stojanoski R', 'Karanfilski O']",['eng'],['Journal Article'],Croatia,Acta Med Iugosl,Acta medica Iugoslavica,0370324,IM,"['Anemia, Hemolytic, Autoimmune/blood/*etiology', 'Coombs Test', 'Female', 'Humans', 'Leukemia, Lymphoid/*complications/mortality', 'Male', 'Middle Aged']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Acta Med Iugosl. 1985;39(4):293-9.,,,,,,,,,,,,
4072694,NLM,MEDLINE,19860110,20061115,0513-4870 (Print) 0513-4870 (Linking),20,4,1985 Apr,[Studies on the antineoplastic action of N-methylisoindigotin].,247-51,,"['Ji, X J', 'Zhang, F R', 'Liu, Y', 'Gu, Q M']","['Ji XJ', 'Zhang FR', 'Liu Y', 'Gu QM']",['chi'],"['English Abstract', 'Journal Article']",China,Yao Xue Xue Bao,Yao xue xue bao = Acta pharmaceutica Sinica,21710340R,IM,"['Animals', '*Antineoplastic Agents', 'Carcinoma 256, Walker/drug therapy', 'DNA, Neoplasm/biosynthesis', 'Dogs', 'Indoles/therapeutic use/toxicity', 'Leukemia L1210/drug therapy', 'Lung Neoplasms/drug therapy', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Neoplasms, Experimental/*drug therapy', 'Rats']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",,ppublish,Yao Xue Xue Bao. 1985 Apr;20(4):247-51.,"['0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (Indoles)', '97207-47-1 (N-methylisoindigotin)']",,,,,,,,,,,
4072200,NLM,MEDLINE,19860115,20061115,0043-5147 (Print) 0043-5147 (Linking),38,15,1985 Aug 1,[Psychotherapeutic management of children with acute leukemia].,1067-70,,"['Franiczek, W', 'Sonta-Jakimczyk, D']","['Franiczek W', 'Sonta-Jakimczyk D']",['pol'],"['English Abstract', 'Journal Article']",Poland,Wiad Lek,"Wiadomosci lekarskie (Warsaw, Poland : 1960)",9705467,IM,"['Acute Disease', 'Child', '*Family Therapy', 'Humans', 'Leukemia/*psychology/therapy']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Wiad Lek. 1985 Aug 1;38(15):1067-70.,,,Postepowanie psychoterapeutyczne z dziecmi chorymi na ostra bialaczke.,,,,,,,,,
4072090,NLM,MEDLINE,19860116,20041117,0507-3758 (Print) 0507-3758 (Linking),31,11,1985,[Failures and prospects for therapy of leukemia].,93-7,,"['Shabalin, V N', 'Abdulkadyrov, K M']","['Shabalin VN', 'Abdulkadyrov KM']",['rus'],['Journal Article'],Russia (Federation),Vopr Onkol,Voprosy onkologii,0413775,IM,"['Antineoplastic Agents/adverse effects/therapeutic use', 'Drug Resistance', 'Humans', 'Immunotherapy', 'Leukemia/*therapy', 'Plasmapheresis', 'Prognosis', 'Tumor Stem Cell Assay']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vopr Onkol. 1985;31(11):93-7.,['0 (Antineoplastic Agents)'],,Neudachi i perspektivy terapii leikozov.,,,,,,,,,
4072085,NLM,MEDLINE,19860116,20061115,0507-3758 (Print) 0507-3758 (Linking),31,11,1985,[Damage to the supramolecular DNA complex in the mechanism of action of antitumor drugs].,60-6,"The report deals with damaging effects on the structure of a supramolecular DNA complex of leukemic cells in P388 mice, susceptible to most antitumor preparations, following treatment with therapeutic doses of sarcolysin, methylnitrosourea, actinomycin D and adriamycin. Capillary elastoviscosimetry and nucleoid sedimentation procedure showed that damage to supramolecular DNA complex structure became apparent as quickly as 15-60 min after injection of the said preparations and persisted for several days. The said damage consisted in DNA's filaments rupture and alterations in higher-order chromatin structures. The role of conformational changes of supramolecular DNA complex in the course of the cytotoxic action of antitumor agents is discussed.","['Blokhin, D Iu']",['Blokhin DIu'],['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Vopr Onkol,Voprosy onkologii,0413775,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'DNA, Neoplasm/*analysis', 'DNA, Single-Stranded/analysis', 'DNA, Superhelical/*analysis', 'Leukemia P388/drug therapy', 'Macromolecular Substances', 'Mice', 'Nucleic Acid Conformation/*drug effects', 'Viscosity']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vopr Onkol. 1985;31(11):60-6.,"['0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (DNA, Single-Stranded)', '0 (DNA, Superhelical)', '0 (Macromolecular Substances)']",,Povrezhdenie nadmolekuliarnogo kompleksa DNK v mekhanizme deistviia protivoopukholevykh preparatov.,,,,,,,,,
4072034,NLM,MEDLINE,19860114,20061115,0042-773X (Print) 0042-773X (Linking),31,11,1985 Nov,[Central nervous system involvement in hemoblastoses in adults].,1111-9,,"['Cermak, J', 'Sedlackova, M', 'Lukasova, M']","['Cermak J', 'Sedlackova M', 'Lukasova M']",['cze'],"['English Abstract', 'Journal Article']",Czech Republic,Vnitr Lek,Vnitrni lekarstvi,0413602,IM,"['Adult', 'Central Nervous System Diseases/drug therapy/*pathology/prevention & control', 'Humans', 'Leukemia/*pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Vnitr Lek. 1985 Nov;31(11):1111-9.,,,Problematika postizeni centralniho nervoveho systemu u hemoblastoz dospelych.,,,,,,,,,
4072028,NLM,MEDLINE,19860114,20061115,0042-773X (Print) 0042-773X (Linking),31,11,1985 Nov,[Experience with the treatment of central nervous system involvement in leukemia in adults].,1075-80,,"['Sedlackova, M', 'Cermak, J', 'Lukasova, M', 'Chudomel, V']","['Sedlackova M', 'Cermak J', 'Lukasova M', 'Chudomel V']",['cze'],"['English Abstract', 'Journal Article']",Czech Republic,Vnitr Lek,Vnitrni lekarstvi,0413602,IM,"['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Central Nervous System Diseases/*drug therapy/prevention & control', 'Female', 'Humans', 'Leukemia/*drug therapy', 'Lymphoma/drug therapy', 'Male', 'Meningeal Neoplasms/drug therapy', 'Middle Aged']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Vnitr Lek. 1985 Nov;31(11):1075-80.,,,Zkusenosti s lecbou postizeni centralniho nervoveho systemu u leukemii dospelych.,,,,,,,,,
4071853,NLM,MEDLINE,19860114,20180217,0042-1138 (Print) 0042-1138 (Linking),40,5,1985,Chronic lymphatic leukemia diagnosed through histological evaluation of resected prostatic tissue.,292-3,Chronic lymphatic leukemia was diagnosed through routine histological evaluation of resected prostatic tissue. Two cases are presented.,"['Worning, A M', 'Dragsted, J']","['Worning AM', 'Dragsted J']",['eng'],"['Case Reports', 'Journal Article']",Switzerland,Urol Int,Urologia internationalis,0417373,IM,"['Aged', 'Bone Marrow Examination', 'Humans', 'Leukemia, Lymphoid/complications/*diagnosis', 'Male', 'Prostate/*pathology', 'Urination Disorders/complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000281103 [doi]'],ppublish,Urol Int. 1985;40(5):292-3. doi: 10.1159/000281103.,,,,,,,,,,,,
4071712,NLM,MEDLINE,19851227,20061115,0041-5782 (Print) 0041-5782 (Linking),147,35,1985 Aug 26,[A central venous catheter of the Hickman type used in patients with hematological diseases].,2753-5,,"['Worning, A M', 'Petersen, F B', 'Frimodt-Moller, C', 'Hippe, E']","['Worning AM', 'Petersen FB', 'Frimodt-Moller C', 'Hippe E']",['dan'],"['English Abstract', 'Journal Article']",Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,IM,"['Adolescent', 'Adult', 'Antineoplastic Agents/*administration & dosage', '*Catheters, Indwelling', 'Female', 'Humans', 'Injections, Intravenous/methods', 'Leukemia/*drug therapy', 'Male', 'Middle Aged']",,1985/08/26 00:00,1985/08/26 00:01,['1985/08/26 00:00'],"['1985/08/26 00:00 [pubmed]', '1985/08/26 00:01 [medline]', '1985/08/26 00:00 [entrez]']",,ppublish,Ugeskr Laeger. 1985 Aug 26;147(35):2753-5.,['0 (Antineoplastic Agents)'],,Centralt venekateter af Hickman-typen anvendt hos haematologiske patienter.,,,,,,,,,
4071704,NLM,MEDLINE,19851227,20061115,0041-5782 (Print) 0041-5782 (Linking),147,34,1985 Aug 19,[A completely implanted system with permanent intravenous access].,2667-70,,"['Husegaard, H C', 'Wernberg, M', 'Petersen, E L', 'Olsen, K H']","['Husegaard HC', 'Wernberg M', 'Petersen EL', 'Olsen KH']",['dan'],"['English Abstract', 'Journal Article']",Denmark,Ugeskr Laeger,Ugeskrift for laeger,0141730,IM,"['Adult', 'Aged', '*Arteriovenous Shunt, Surgical', '*Catheters, Indwelling', 'Humans', '*Injections, Intravenous', 'Leukemia/drug therapy', 'Middle Aged']",,1985/08/19 00:00,1985/08/19 00:01,['1985/08/19 00:00'],"['1985/08/19 00:00 [pubmed]', '1985/08/19 00:01 [medline]', '1985/08/19 00:00 [entrez]']",,ppublish,Ugeskr Laeger. 1985 Aug 19;147(34):2667-70.,,,Et totalt implanteret system med permanent intravenos adgang.,,,,,,,,,
4071685,NLM,MEDLINE,19860121,20150505,0201-8470 (Print) 0201-8470 (Linking),57,6,1985 Nov-Dec,[Polyamine levels in polyribosomes from the rat liver in Shvets leukemia].,74-6,The content of spermidine in the liver polyribosomes of rats with the subcutaneously transplanted Svets leucosis is found to increase that evidences for qualitative changes in ribosomes of the liver of tumour-bearing animals.,"['Berdinskikh, N K', 'Lialiushko, N M']","['Berdinskikh NK', 'Lialiushko NM']",['rus'],"['English Abstract', 'Journal Article']",Ukraine,Ukr Biokhim Zh (1978),Ukrainskii biokhimicheskii zhurnal (1978),7804246,IM,"['Animals', 'Leukemia, Experimental/*metabolism', 'Liver/*metabolism', 'Neoplasm Transplantation', 'Polyamines/*metabolism', 'Polyribosomes/*metabolism', 'Rats']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Ukr Biokhim Zh (1978). 1985 Nov-Dec;57(6):74-6.,['0 (Polyamines)'],,Soderzhanie poliaminov v poliribosomakh pecheni krys pri leikoze Shvetsa.,,,,,,,,,
4071498,NLM,MEDLINE,19860103,20080716,0029-2001 (Print) 0029-2001 (Linking),105,29,1985 Oct 20,[Chronic lymphocytic leukemia. Is staging or prognostic grouping of chronic lymphocytic leukemia relevant to the choice of treatment?].,2066-9,,"['Ly, B']",['Ly B'],['nor'],"['English Abstract', 'Journal Article']",Norway,Tidsskr Nor Laegeforen,"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",0413423,IM,"['Humans', 'Leukemia, Lymphoid/*diagnosis/therapy', 'Prognosis']",,1985/10/20 00:00,1985/10/20 00:01,['1985/10/20 00:00'],"['1985/10/20 00:00 [pubmed]', '1985/10/20 00:01 [medline]', '1985/10/20 00:00 [entrez]']",,ppublish,Tidsskr Nor Laegeforen. 1985 Oct 20;105(29):2066-9.,,,Kronisk lymfatisk leukemi. Hvilken relevans har stadieinndeling og prognostisk gruppering for valg av terapi?,,,,,,,,,
4071061,NLM,MEDLINE,19851226,20061115,0094-6176 (Print) 0094-6176 (Linking),11,4,1985 Oct,A contribution to the pathology of acquired plasma factor XIII deficiency.,357-61,"The biologic activity of Factor XIII was measured in four groups of patients: 20 with liver cirrhosis, ten with acute DIC, 30 with acute leukemia with DIC, and 20 with acute leukemia without DIC. In all groups, the plasma Factor XIII transamidating activity was reduced, but this deficiency was more evident in patients with DIC alone or with leukemia and DIC. The immunologic determination of the a and b subunits of Factor XIII was also performed. Both subunits were below the normal range in the groups of patients studied, except for subunit b, which was normal in patients with leukemia without coagulopathy. Acute DIC patients showed an equally reduced level of both subunits, whereas in patients with leukemia, even in the presence of a complicating coagulopathy, a lesser decrease of subunit b than subunit a was found. Both subunits were equally reduced in patients with cirrhosis, suggesting an impaired synthesis of these proteins. In conclusion, our findings do not support the use of Factor XIII subunit measurements in distinguishing between thrombin- or protease-mediated consumption coagulopathy, and they seem to suggest that the deficiency pattern of the subunits is not accounted for by a simple pathogenetic mechanism.","['Ballerini, G', 'Guerra, S', 'Rodeghiero, F', 'Castaman, G']","['Ballerini G', 'Guerra S', 'Rodeghiero F', 'Castaman G']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Semin Thromb Hemost,Seminars in thrombosis and hemostasis,0431155,IM,"['Acute Disease', 'Disseminated Intravascular Coagulation/complications', 'Factor XII Deficiency/*blood/complications', 'Factor XIII/analysis', 'Humans', 'Leukemia/complications', 'Liver Cirrhosis/complications', 'Macromolecular Substances', 'Platelet Count']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1055/s-2007-1004394 [doi]'],ppublish,Semin Thromb Hemost. 1985 Oct;11(4):357-61. doi: 10.1055/s-2007-1004394.,"['0 (Macromolecular Substances)', '9013-56-3 (Factor XIII)']",,,,,,,,,,,
4070999,NLM,MEDLINE,19860114,20190908,0355-3140 (Print) 0355-3140 (Linking),11,5,1985 Oct,"Mortality of styrene production, polymerization and processing workers at a site in northwest England.",347-52,"The mortality of 622 men who worked for at least one year in the production, polymerization, and processing of styrene at a chemical site in the United Kingdom during the period 1945-1974 was surveyed up to the end of 1978; 3 072 male manual workers at the same site but unexposed to styrene were also studied. A statistically significant excess of lymphoma deaths was found in the exposed population, and two of the three deaths observed occurred in men less than 40 years of age. The small number of deaths and the lack of any evidence for an association with duration or level of exposure to styrene are reasons for interpreting this result cautiously. However, the otherwise normal pattern of mortality in the exposed population and the absence of any excess of lymphomas in the reference group lend some support to suggestions that exposure to styrene may be associated with lymphomas in man. An analysis of cancer registrations for the exposed population revealed no further cases of lymphoma but identified one case of lymphatic leukemia. An excess of laryngeal cancer registrations was found. As this effect has not been previously postulated and because of the small number of registrations, too much weight should not be attached to this one observation.","['Hodgson, J T', 'Jones, R D']","['Hodgson JT', 'Jones RD']",['eng'],['Journal Article'],Finland,Scand J Work Environ Health,"Scandinavian journal of work, environment & health",7511540,IM,"['Adult', 'England', 'Humans', 'Leukemia/*chemically induced/mortality', 'Lymphoma/*chemically induced/mortality/pathology', 'Male', 'Middle Aged', 'Occupational Diseases/chemically induced/*mortality', 'Polymers/*poisoning', 'Risk', 'Styrenes/*poisoning']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']","['2214 [pii]', '10.5271/sjweh.2214 [doi]']",ppublish,Scand J Work Environ Health. 1985 Oct;11(5):347-52. doi: 10.5271/sjweh.2214.,"['0 (Polymers)', '0 (Styrenes)']",,,,,,,,,,,
4070451,NLM,MEDLINE,19860109,20031114,0032-0943 (Print) 0032-0943 (Linking),,4,1985 Aug,The cytotoxic principle of Scutellariae radix against L1210 cell.,355,,"['Ryu, S H', 'Ahn, B Z', 'Pack, M Y']","['Ryu SH', 'Ahn BZ', 'Pack MY']",['eng'],['Journal Article'],Germany,Planta Med,Planta medica,0066751,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*isolation & purification', 'Flavonoids/*isolation & purification/pharmacology', 'Leukemia L1210/*drug therapy', 'Mice', 'Plants, Medicinal/*analysis']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Planta Med. 1985 Aug;(4):355.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Flavonoids)', '55084-08-7 (skullcapflavone II)']",,,,,,,,,,,
4070449,NLM,MEDLINE,19860109,20071114,0032-0943 (Print) 0032-0943 (Linking),,4,1985 Aug,Plant anticancer agents XXXVII. Constituents of Amanoa oblongifolia.,346-7,,"['Fang, X D', 'Dhammika, N P', 'Phoebe, C H Jr', 'Pezzuto, J M', 'Kinghorn, A D', 'Farnsworth, N R']","['Fang XD', 'Dhammika NP', 'Phoebe CH Jr', 'Pezzuto JM', 'Kinghorn AD', 'Farnsworth NR']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Germany,Planta Med,Planta medica,0066751,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*isolation & purification/pharmacology', 'Humans', 'KB Cells/drug effects', 'Leukemia P388/drug therapy', 'Mice', 'Plants, Medicinal/*analysis']",,1985/08/01 00:00,2001/03/28 10:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Planta Med. 1985 Aug;(4):346-7.,"['0 (Antineoplastic Agents, Phytogenic)']",,,"['CA-33047/CA/NCI NIH HHS/United States', 'CM-97295/CM/NCI NIH HHS/United States']",,,,,,,,
4070035,NLM,MEDLINE,19860108,20131121,0108-9684 (Print) 0108-9684 (Linking),2,5,1985 Oct,Use of photoactivated chlorpromazine in avian leukemia.,334-5,,"['Carraz, G']",['Carraz G'],['eng'],['Letter'],Denmark,Photodermatol,Photo-dermatology,8407997,IM,"['Animals', 'Avian Leukosis/*drug therapy', 'Chlorpromazine/*therapeutic use', 'Extracorporeal Circulation', 'Female', 'Photochemistry']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Photodermatol. 1985 Oct;2(5):334-5.,['U42B7VYA4P (Chlorpromazine)'],,,,,,,,,,,
4069549,NLM,MEDLINE,19860115,20180216,0030-2414 (Print) 0030-2414 (Linking),42,6,1985,"Combination chemotherapy with the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for chronic lymphocytic leukemia (stages III and IV).",350-3,"The M-2 protocol was administered every 5 weeks to 25 patients with stage III and IV chronic lymphocytic leukemia (CLL). Complete remission (CR; absence of all clinical and bone marrow evidence of leukemia including normal immune markers for monoclonal disease) and partial remission (PR; greater than 50% decrease in organ enlargement and reduction of WBC count to below 15,000 X 10(6)/l) were achieved in 20 and 48%, respectively. A median number of 24 cycles of therapy was required to produce a CR. The median duration of unmaintained remission was 12 months. All CR patients are still surviving. The median survival of the PR patients and the overall groups is 21 months. To improve the CR rate and survival in patients with advanced CLL, more effective methods of determining residual leukemic cells and different treatment strategies will be needed.","['Case, D C Jr', 'Porensky, R S', 'Fanning, J P']","['Case DC Jr', 'Porensky RS', 'Fanning JP']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Switzerland,Oncology,Oncology,0135054,IM,"['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carmustine/administration & dosage', 'Cyclophosphamide/administration & dosage', 'Humans', 'Leukemia, Lymphoid/*drug therapy/pathology', 'Melphalan/administration & dosage', 'Middle Aged', 'Neoplasm Staging', 'Prednisone/administration & dosage', 'Prognosis', 'Vincristine/administration & dosage']",,1985/01/01 00:00,2001/03/28 10:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000226062 [doi]'],ppublish,Oncology. 1985;42(6):350-3. doi: 10.1159/000226062.,"['5J49Q6B70F (Vincristine)', '8N3DW7272P (Cyclophosphamide)', 'Q41OR9510P (Melphalan)', 'U68WG3173Y (Carmustine)', 'VB0R961HZT (Prednisone)']",,,,,,,,,,,
4069288,NLM,MEDLINE,19851227,20061115,0028-2685 (Print) 0028-2685 (Linking),32,5,1985,Comparison of the effectivity of two diaminocyclohexane Pt-complexes.,537-42,"A group of Pt-complexes was tested in various in vitro and in vivo systems. Murine P388 leukemia for the in vivo testing and three sublines of L1210 leukemia for the in vitro testing of two 1,2-diaminocyclohexane (DACH) derivatives of platinum were used. The effectivity of DACH-Pt(II) citrate and DACH-Pt(II) isocitrate with different ratio of trans- and/or cis-DACH was compared on the sensitive strain of L1210 and two resistant sublines: L1210 resistant to cis-diammine-dichloroplatinum(II) (cis-DDP) and L1210 resistant to trans-DACH-Pt(II) citrate. No cross-resistance was found between the DACH derivatives and cis-DDP. Slightly higher activity of citrate and trans-DACH in comparison with isocitrate and cis-DACH was found both in suspension culture and in vivo testing.","['Balazova, E', 'Hrubisko, M', 'Ujhazy, V']","['Balazova E', 'Hrubisko M', 'Ujhazy V']",['eng'],"['Comparative Study', 'Journal Article']",Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Female', 'Isomerism', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Male', 'Mice', 'Mice, Inbred DBA', 'Organoplatinum Compounds/*therapeutic use']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1985;32(5):537-42.,"['0 (1,2-diaminocyclohexaneplatinum II isocitrate)', '0 (Antineoplastic Agents)', '0 (Organoplatinum Compounds)', '52691-24-4 (dichloro-1,2-diaminocyclohexane platinum complex)', '96081-74-2 (1,2-diaminocyclohexaneplatinum II citrate)']",,,,,,,,,,,
4069238,NLM,MEDLINE,19851226,20061115,0028-2162 (Print) 0028-2162 (Linking),129,37,1985 Sep 14,[A Dutch chromosome abnormality in myelodysplasia?].,1783-7,,"['Scheres, J M', 'Hustinx, T W', 'Geraedts, J P', 'Leeksma, C H', 'Holdrinet, R S']","['Scheres JM', 'Hustinx TW', 'Geraedts JP', 'Leeksma CH', 'Holdrinet RS']",['dut'],"['English Abstract', 'Journal Article']",Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,IM,"['Adult', 'Aged', 'Child', 'Child, Preschool', 'Chromosome Aberrations/*genetics', 'Chromosome Disorders', '*Chromosomes, Human, 1-3', '*Chromosomes, Human, 6-12 and X', 'Female', 'Humans', 'Leukemia/*genetics', 'Male', 'Middle Aged', 'Myeloproliferative Disorders/*genetics', 'Netherlands', 'Translocation, Genetic']",,1985/09/14 00:00,1985/09/14 00:01,['1985/09/14 00:00'],"['1985/09/14 00:00 [pubmed]', '1985/09/14 00:01 [medline]', '1985/09/14 00:00 [entrez]']",,ppublish,Ned Tijdschr Geneeskd. 1985 Sep 14;129(37):1783-7.,,,"Een ""Nederlandse"" chromosomenafwijking bij myelodysplasie?",,,,,,,,,
4069211,NLM,MEDLINE,19851231,20211203,0028-0836 (Print) 0028-0836 (Linking),318,6044,1985 Nov 28-Dec 4,The human met oncogene is related to the tyrosine kinase oncogenes.,385-8,"The met oncogene was previously isolated from a chemically transformed human cell line, MNNG-HOS. Recent evidence has demonstrated that two classes of transcripts are expressed from the met proto-oncogene locus. The met oncogene, however, expresses an aberrant RNA which has sequences in common with both transcripts. We now report partial nucleotide sequencing of the human met oncogene and show that met is related to the protein kinase oncogenes and growth factor receptors. The met nucleotide sequence is not identical to that of any published gene, and it is more closely homologous to the tyrosine kinases than to the serine/threonine kinases. Within the tyrosine kinase family, the sequenced met domains are most closely related to the human insulin receptor and the viral abl gene. In situ chromosome hybridization has mapped met to human chromosome 7 band 7q21-q31, a location distinct from that of other kinases. This is also a region associated with nonrandom chromosomal deletions observed in a portion of patients with acute nonlymphocytic leukaemia. The accompanying paper shows that this chromosomal locus is also tightly linked with the human heredity disease cystic fibrosis.","['Dean, M', 'Park, M', 'Le Beau, M M', 'Robins, T S', 'Diaz, M O', 'Rowley, J D', 'Blair, D G', 'Vande Woude, G F']","['Dean M', 'Park M', 'Le Beau MM', 'Robins TS', 'Diaz MO', 'Rowley JD', 'Blair DG', 'Vande Woude GF']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",England,Nature,Nature,0410462,IM,"['Base Sequence', 'Chromosome Mapping', '*Chromosomes, Human, 6-12 and X', 'Humans', 'Oncogene Proteins, Viral/*genetics', '*Oncogenes', 'Protein-Tyrosine Kinases/*genetics', 'Proto-Oncogene Mas', 'Receptor, Insulin/genetics', 'Sequence Homology, Nucleic Acid']",,1985/11/04 00:00,1985/11/04 00:01,['1985/11/04 00:00'],"['1985/11/04 00:00 [pubmed]', '1985/11/04 00:01 [medline]', '1985/11/04 00:00 [entrez]']",['10.1038/318385a0 [doi]'],ppublish,Nature. 1985 Nov 28-Dec 4;318(6044):385-8. doi: 10.1038/318385a0.,"['0 (MAS1 protein, human)', '0 (Oncogene Proteins, Viral)', '0 (Proto-Oncogene Mas)', 'EC 2.7.10.1 (Protein-Tyrosine Kinases)', 'EC 2.7.10.1 (Receptor, Insulin)']",,,"['CA 23954/CA/NCI NIH HHS/United States', 'N01-CO-23909/CO/NCI NIH HHS/United States']",,,,,,,,
4069122,NLM,MEDLINE,19851231,20031114,0254-7600 (Print) 0254-7600 (Linking),4,4,1985,Leukemogenesis by methylnitrosourea in BDF1 mice. The origin of transplantable cells and the activity of the natural killer cells during the preleukemic period.,193-201,"BDF1 mice injected with methylnitrosourea (MNU, 50 mg/kg) developed T cell leukemias within 9-35 weeks (median induction time 18 weeks). Leukemic cells, determined by transplantation, were found 2-5 weeks before the death of the animals. Natural killer (NK) cell activity in the spleen and peritoneal exudate cells was studied using YAC-1 cells as targets. MNU-treated mice showed reduced lytic activity with or without stimulation by Corynebacterium parvum. NK activity was essentially the same in mice with and without transplantable leukemic cells. No correlation could be demonstrated between the degree of NK cell depression, as studied in the spleen after splenectomy, and the survival time of individual mice.","['Seidel, H J', 'Kreja, L']","['Seidel HJ', 'Kreja L']",['eng'],['Journal Article'],Switzerland,Nat Immun Cell Growth Regul,Natural immunity and cell growth regulation,8407979,IM,"['Animals', 'Cell Transformation, Neoplastic/drug effects/immunology/pathology', '*Cytotoxicity, Immunologic', 'Female', 'Killer Cells, Natural/*immunology/pathology', 'Leukemia/chemically induced/immunology/mortality/*pathology', 'Lymph Nodes/pathology', '*Methylnitrosourea', 'Mice', 'Neoplasm Transplantation', 'Preleukemia/chemically induced/immunology/mortality/*pathology', 'Spleen/pathology', 'Thymoma/immunology', 'Thymus Gland/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Nat Immun Cell Growth Regul. 1985;4(4):193-201.,['684-93-5 (Methylnitrosourea)'],,,,,,,,,,,
4069121,NLM,MEDLINE,19851231,20071114,0254-7600 (Print) 0254-7600 (Linking),4,4,1985,Murine NK cell heterogeneity: subpopulations of C57BL/6 splenic NK cells detected by NK-1.1 and NK-2.1 antisera.,169-77,"NK-1.1 antiserum - (BALB/c X C3H)F1 anti-CE - and NK-2.1 antiserum - NZB anti-BALB/c - detect genetically distinct alloantigens on C57BL/6 natural killer (NK) cells. We have analyzed whether these two alloantigens are associated with functional subsets of NK cells. For this study, nylon wool nonadherent C57BL/6 spleen cells (SC) were treated with complement (C) and NK-1.1 or NK-2.1 antisera and then tested for NK activity against a panel of tumor targets in 6- and 19-hour 51Cr release assays. The NK activity against the prototype NK target YAC-1 was reduced equally by both antisera. Similar reductions by both antisera were also observed when SC were tested against another murine lymphoma target, L5178c127v, against the C57BL/6 melanoma B16, and against the human liver cell line Chang. In contrast, NK activity to the lymphoma FBL-3 and the human erythroleukemia K562 was significantly reduced in SC treated with NK-2.1 antiserum and C, whereas SC treated with NK-1.1 antiserum and C showed either less reduction or no reduction in activity against these two cell lines. With two other targets, E male G2 and RBL-5, neither serum produced significant depletion of activity, Analysis of SC indirectly labeled with either NK-1.1 or NK-2.1 antiserum and fluorescein-labeled goat anti-mouse Ig, however, did not detect significant differences between NK-1+ and NK-2+ cell populations.","['Emmons, S L', 'Pollack, S B']","['Emmons SL', 'Pollack SB']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",Switzerland,Nat Immun Cell Growth Regul,Natural immunity and cell growth regulation,8407979,IM,"['Animals', 'Antigen-Antibody Reactions', '*Antilymphocyte Serum/pharmacology', 'Cell Line', 'Complement System Proteins/physiology', 'Cytotoxicity Tests, Immunologic', 'Flow Cytometry', 'Humans', 'Killer Cells, Natural/*classification/immunology', 'Leukemia L5178/immunology', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mice, Inbred NZB', 'Phenotype', 'Spleen/*cytology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Nat Immun Cell Growth Regul. 1985;4(4):169-77.,"['0 (Antilymphocyte Serum)', '9007-36-7 (Complement System Proteins)']",,,['CA-32553/CA/NCI NIH HHS/United States'],,,,,,,,
4068805,NLM,MEDLINE,19860116,20191030,0736-0118 (Print) 0736-0118 (Linking),2,3,1985,Folate and iron metabolism in patients with tumors and inflammations.,189-93,"Reduced serum concentrations of nutrients like iron, zinc and folates and of albumin and cholesterol are found, as well as emaciation, both in malnutrition and in cancer. In patients with leukemia, a depletion of intracellular potassium and hypo-potassemia are found in addition. The use of hyperalimentation in cancer was originally based on the concept that too little food is the cause of these disturbances in the nutrition state. However, there is also a disturbed metabolism of nutrients in patients with tumors and inflammatory disease. In the case of folic acid, the disturbed metabolism could not be normalized by hyperalimentation. The more advanced the disease, the more pronounced is the disturbed nutrient metabolism, and this disturbance is related to the macrophage activity. It is not self-evident, therefore, that hyperalimentation can normalize the nutritional state in cancer. Emaciation in cancer patients is not caused exclusively by malnutrition.","['Reizenstein, P']",['Reizenstein P'],['eng'],['Journal Article'],England,Med Oncol Tumor Pharmacother,Medical oncology and tumor pharmacotherapy,8405039,IM,"['Anorexia/complications', 'Body Composition', 'Folic Acid/*blood', 'Humans', 'Inflammation/*blood', 'Iron/*blood', 'Macrophage Activation', 'Macrophages/physiology', 'Models, Biological', 'Neoplasms/blood/complications/*metabolism']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF02934547 [doi]'],ppublish,Med Oncol Tumor Pharmacother. 1985;2(3):189-93. doi: 10.1007/BF02934547.,"['935E97BOY8 (Folic Acid)', 'E1UOL152H7 (Iron)']",,,,,,,,,,,
4068801,NLM,MEDLINE,19860116,20191030,0736-0118 (Print) 0736-0118 (Linking),2,3,1985,Hypocholesterolemia in cancer patients may be caused by elevated LDL receptor activities in malignant cells.,143-7,"Several epidemiological studies indicate an inverse relation between plasma cholesterol and the occurrence of cancer. Since we in previous studies have found that certain malignant cell types have an elevated LDL receptor activity, the aim of the present study was to further explore the possibility that an elevated LDL consumption by tumor cells causes hypocholesterolemia. The plasma cholesterol concentrations in patients with acute leukemia were inversely correlated with the rate of receptor-mediated degradation of 125I-LDL by the leukemic cells. During chemotherapy, the total plasma and the LDL cholesterol levels increased concomitantly with the reduction in the leukemic cell count in a patient whose leukemic cells exhibited a high rate at receptor-mediated degradation of 125I-LDL. In certain patients with inoperable urinary bladder carcinoma, the plasma cholesterol concentration fell as the disease progressed. Studies in breast cancer patients indicate that the number of LDL receptors in the tumor tissue may have prognostic significance. The results are in agreement with the hypothesis that an elevated LDL receptor activity in malignant cells may lead to hypocholesterolemia.","['Peterson, C', 'Vitols, S', 'Rudling, M', 'Blomgren, H', 'Edsmyr, F', 'Skoog, L']","['Peterson C', 'Vitols S', 'Rudling M', 'Blomgren H', 'Edsmyr F', 'Skoog L']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Med Oncol Tumor Pharmacother,Medical oncology and tumor pharmacotherapy,8405039,IM,"['Blood Donors', 'Breast Neoplasms/blood/*metabolism', 'Cholesterol/*blood', 'Female', 'Humans', 'Kinetics', 'Leukemia/blood/*metabolism', 'Lipoproteins, LDL/*metabolism', 'Receptors, LDL/*metabolism', 'Reference Values']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF02934541 [doi]'],ppublish,Med Oncol Tumor Pharmacother. 1985;2(3):143-7. doi: 10.1007/BF02934541.,"['0 (Lipoproteins, LDL)', '0 (Receptors, LDL)', '97C5T2UQ7J (Cholesterol)']",,,,,,,,,,,
4068758,NLM,MEDLINE,19851226,20190516,0025-6196 (Print) 0025-6196 (Linking),60,12,1985 Dec,Magnetic resonance imaging for neurotoxicity in long-term survivors of carcinoma.,803-12,"Neurotoxicity is a potential complication of combined chemotherapy and whole-brain radiotherapy in long-term survivors of carcinoma. Clinical features of this neurotoxicity are similar to those manifested in the leukoencephalopathy of pediatric patients with leukemia who have been treated prophylactically with whole-brain radiotherapy and chemotherapy. Magnetic resonance imaging, because of its ability to distinguish cortical gray matter and white matter and its utility for studying demyelinating diseases, was used in the assessment of five long-term survivors of carcinoma who had clinical evidence of neurotoxicity. On magnetic resonance examinations, all five patients had profound abnormalities in the periventricular white matter. These changes were considerably more pronounced than those seen on computed tomographic scanning. Thus, magnetic resonance imaging may serve as a useful procedure for early detection of neurotoxicity in patients with carcinoma who have received cerebral radiotherapy and chemotherapy.","['Frytak, S', 'Earnest, F 4th', ""O'Neill, B P"", 'Lee, R E', 'Creagan, E T', 'Trautmann, J C']","['Frytak S', 'Earnest F 4th', ""O'Neill BP"", 'Lee RE', 'Creagan ET', 'Trautmann JC']",['eng'],"['Case Reports', 'Journal Article']",England,Mayo Clin Proc,Mayo Clinic proceedings,0405543,IM,"['Aged', 'Antineoplastic Agents/*adverse effects', 'Brain/drug effects/*pathology/radiation effects', 'Female', 'Humans', '*Magnetic Resonance Spectroscopy', 'Male', 'Middle Aged', 'Neoplasms/*therapy', 'Radiotherapy/*adverse effects', 'Tomography, X-Ray Computed']",,1985/12/01 00:00,2001/03/28 10:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/01 00:00 [entrez]']","['S0025-6196(12)64785-5 [pii]', '10.1016/s0025-6196(12)64785-5 [doi]']",ppublish,Mayo Clin Proc. 1985 Dec;60(12):803-12. doi: 10.1016/s0025-6196(12)64785-5.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4068751,NLM,MEDLINE,19860108,20190824,0145-2126 (Print) 0145-2126 (Linking),9,9,1985,Leukemia in patients following radiotherapy for malignant neoplasms in the pelvic region.,1201-8,"A prospective study of 1572 women treated with radiotherapy for cervical (1478 women) and ovarian cancer (94 women) was done. Patients had been followed clinically and especially by blood tests between 1961 and 1981, comprising 8990 woman-years (WY). Following radiotherapy, 5 patients developed non-lymphocytic leukemia [2 acute myeloblastic leukemia (AML), 1 acute monocytic leukemia (AMoL), and 2 chronic myeloid leukemia (CML)]. Based on rates for the general population, 0.45 case would be expected and, therefore, the relative risk was 11.2. The average mean marrow dose for all our subjects was calculated to be 1177 rad, the risk of radiation-induced leukemia was 0.43 excess case per year per one million women exposed to 1 rad of radiation to the bone marrow. Four patients with cervical cancer who developed leukemia were in a high-dose-rate group treated with both a linear accelerator (Linac) and remote afterloading system (RALS), and 1 patient with ovarian cancer who developed leukemia was treated with a Linac alone. This is the first report of a statistically significant increased risk of leukemia for patients treated with large doses of radiation for malignant neoplasms in the pelvic region.","['Murohashi, I']",['Murohashi I'],['eng'],"['Case Reports', 'Journal Article']",England,Leuk Res,Leukemia research,7706787,IM,"['Adolescent', 'Adult', 'Aged', 'Female', 'Humans', 'Leukemia/*etiology', 'Middle Aged', 'Neoplasms, Radiation-Induced/*etiology', 'Ovarian Neoplasms/*diagnostic imaging', 'Prospective Studies', 'Radiography', 'Radiotherapy/*adverse effects', 'Radiotherapy Dosage', 'Uterine Cervical Neoplasms/*diagnostic imaging']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90112-2 [doi]'],ppublish,Leuk Res. 1985;9(9):1201-8. doi: 10.1016/0145-2126(85)90112-2.,,,,,,,,,,,,
4068750,NLM,MEDLINE,19860108,20190824,0145-2126 (Print) 0145-2126 (Linking),9,9,1985,Proliferation in liquid culture of megakaryocytes from the blood of patients with primary myelofibrosis and other myeloproliferative disorders.,1171-9,"Using a short term liquid system we have shown that blood from some patients with primary myelofibrosis (PMF) and chronic granulocytic leukaemia (CGL) in megakaryoblastic transformation (CGL-Mk) gives rise to large numbers of progenitor cells committed to the megakaryocyte (Mk) lineage. As assessed by indirect immunofluorescence the number of cells reacting with three antiplatelet monoclonal antibodies, C17, J15 and AN51, increases during the culture period. There is no equivalent increase in cultures from the blood of normal individuals or patients with essential thrombocythaemia (ET). Furthermore plasma-free supernatants from cultures of the cells from patients with PMF and CGL-Mk stimulate the rate of proliferation of fibroblasts from normal bone marrow. These data provide further evidence for the involvement of the Mk lineage in PMF and CGL and suggest that the excess fibrosis seen in these conditions may be caused by a factor emanating from Mks.","['Hibbin, J A', 'Matutes, E', 'Goldman, J M']","['Hibbin JA', 'Matutes E', 'Goldman JM']",['eng'],"['Historical Article', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Leuk Res,Leukemia research,7706787,IM,"['Antibodies, Monoclonal', 'Bone Marrow Cells', 'Cell Division', 'Cells, Cultured', 'Colony-Forming Units Assay', '*Culture Media', 'Female', 'Fibroblasts/cytology', 'History, 16th Century', 'History, 17th Century', 'History, 18th Century', 'Humans', 'Male', 'Megakaryocytes/*cytology', 'Myeloproliferative Disorders/*blood', 'Primary Myelofibrosis/*blood']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90108-0 [doi]'],ppublish,Leuk Res. 1985;9(9):1171-9. doi: 10.1016/0145-2126(85)90108-0.,"['0 (Antibodies, Monoclonal)', '0 (Culture Media)']",,,,,,,,,,,
4068748,NLM,MEDLINE,19860110,20190824,0145-2126 (Print) 0145-2126 (Linking),9,10,1985,Enhanced production of intracellular ara-CTP after sequential use of methotrexate and 1-beta-D-arabinofuranosylcytosine.,1263-5,"Synergistic antiproliferative effect has been proven in vitro when mouse leukemic cells were sequentially treated with MTX and ara-C. The mechanism of this combination effect not well elucidated but the intracellular uptake of ara-C was higher when cells were pre-exposed to MTX. In this experiment, the intracellular ara-CTP was measured by HPLC after MTX and ara-C were sequentially administered to BDF1 mice bearing L1210 leukemic cell, either being sensitive or resistant to MTX. When MTX at the dose of 12 mg/kg was preceded 6 h and 3 h to ara-C at the dose of 25 mg/kg, the intracellular levels of ara-CTP were found to be significantly higher as compared with those of ara-C alone as control group. At 1 h after ara-C, ara-CTP was measured about 165 and 130% of the control levels, respectively, and at 12 h, ara-CTP was over 4 times higher of control level with group of mice to which MTX was preceded 6 h prior to MTX. On the contrary, the enhancement of ara-CTP production was definitely diminished with MTX-resistant cells in the same administrative model. From our present experiment, the time sequential modulation of intracellular ara-CTP production by MTX was reconfirmed in vivo, and this modulation might depend upon the sensitivity of MTX of leukemic cells.","['Nobori, T', 'Okubo, T', 'Shimizu, N', 'Kawasaki, H', 'Sako, T', 'Komada, M', 'Hirota, H', 'Kamiya, H', 'Sakurai, M']","['Nobori T', 'Okubo T', 'Shimizu N', 'Kawasaki H', 'Sako T', 'Komada M', 'Hirota H', 'Kamiya H', 'Sakurai M']",['eng'],['Journal Article'],England,Leuk Res,Leukemia research,7706787,IM,"['Animals', 'Antineoplastic Combined Chemotherapy Protocols/*pharmacology', 'Arabinofuranosylcytosine Triphosphate/*biosynthesis', 'Arabinonucleotides/*biosynthesis', 'Cytarabine/*administration & dosage', 'Deoxycytosine Nucleotides/analysis', 'Drug Administration Schedule', 'Leukemia L1210/metabolism', 'Male', 'Methotrexate/*administration & dosage', 'Mice', 'Mice, Inbred Strains']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90154-7 [doi]'],ppublish,Leuk Res. 1985;9(10):1263-5. doi: 10.1016/0145-2126(85)90154-7.,"['0 (Arabinonucleotides)', '0 (Deoxycytosine Nucleotides)', '04079A1RDZ (Cytarabine)', '13191-15-6 (Arabinofuranosylcytosine Triphosphate)', ""2056-98-6 (2'-deoxycytidine 5'-triphosphate)"", 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4068747,NLM,MEDLINE,19860110,20190824,0145-2126 (Print) 0145-2126 (Linking),9,10,1985,Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia.,1231-5,"We performed cytogenetic analyses using banding techniques on 89 adults with acute nonlymphoblastic leukemia prior to receiving protocol chemotherapy. The relationships of cytogenetic findings both to outcome and to other pretreatment variables (particularly the presence or absence of Auer rods) were analyzed. Patients were followed up to 90+ months. When patients were grouped according to cytogenetic findings (NN: all normal metaphases; AA: all abnormal metaphases; AN: both normal and abnormal metaphases; F: no evaluable metaphases; I: insufficient (less than three) metaphases) no significant differences were noted with regard to age, sex, terminal transferase positivity, complete remission rate, remission duration or survival. The marrow aspirates of patients with only normal (69%) metaphases or no evaluable metaphases (64%) were more likely to display Auer rods than specimens from individuals with only abnormal (26%) or a mixture of normal and abnormal (42%) metaphases (p = 0.03). The presence of Auer rods in the pretreatment marrow aspirate was associated with an increased complete remission rate (71% vs 41%, p = 0.004), median remission duration (12 months vs 9 months, p = 0.02), and median survival (13 months vs 4 months, p = 0.01). Using multivariable analyses, the presence or absence of Auer rods was the pretreatment factor that most significantly predicted response and survival in this group of patients. The presence of a normal karyotype in the initial cytogenetic preparation is associated with the presence of Auer rods. The finding of Auer rods in the initial bone marrow predicts greater response and longer survival in acute nonlymphoblastic leukemia.","['Kris, M G', 'Mertelsmann, R', 'Jhanwar, S', 'Chaganti, R', 'Szatrowski, T H', 'Gee, T S', 'Arlin, Z', 'Kempin, S', 'Benedetto, P', 'Clarkson, B']","['Kris MG', 'Mertelsmann R', 'Jhanwar S', 'Chaganti R', 'Szatrowski TH', 'Gee TS', 'Arlin Z', 'Kempin S', 'Benedetto P', 'Clarkson B']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Leuk Res,Leukemia research,7706787,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', '*Chromosome Aberrations', 'Female', 'Humans', 'Karyotyping', 'Leukemia/*genetics/mortality/pathology', 'Male', 'Metaphase', 'Middle Aged']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0145-2126(85)90150-X [pii]', '10.1016/0145-2126(85)90150-x [doi]']",ppublish,Leuk Res. 1985;9(10):1231-5. doi: 10.1016/0145-2126(85)90150-x.,,,,"['CA-04110/CA/NCI NIH HHS/United States', 'CA-08748/CA/NCI NIH HHS/United States', 'CA-19267/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4068603,NLM,MEDLINE,19860121,20061115,0300-8630 (Print) 0300-8630 (Linking),197,5,1985 Sep-Oct,[Ocular findings in leukemia in childhood].,437-40,"A 6 1/2 years old boy got completely blind within 3 days. Ophthalmoscopically regular findings suggested a retrobulbar opticus infiltration in a pediatric-diagnosed acute myeloic leukemia FAB-M2. A quick diagnosis and prompt cytostatic therapy combined with irradiation of the retrobulbar space opened the way for complete remission with bilateral optic atrophy. The ophthalmoscopic examination of 12 other leukemic children showed once more the involvement of the central nervous system with bilateral papilloedema, 2 times retinal hemorrhages and one vitreous bleeding; 8 children had no ocular symptoms. Comparing these findings to those described in literature, the authors point out the value of ophthalmoscopy to exclude ophthalmologic damages and to avoid side-effects of cytostatic therapy, fortunately not observed till now.","['Mayer, U M', 'Beck, J D', 'Gromball, J']","['Mayer UM', 'Beck JD', 'Gromball J']",['ger'],"['Case Reports', 'English Abstract', 'Journal Article']",Germany,Klin Padiatr,Klinische Padiatrie,0326144,IM,"['Adolescent', 'Child', 'Eye Diseases/*diagnosis/etiology/pathology', 'Female', 'Humans', 'Leukemia/complications/*diagnosis/pathology', 'Male', 'Nervous System Diseases/diagnosis/etiology/pathology', 'Ophthalmoscopy']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Klin Padiatr. 1985 Sep-Oct;197(5):437-40.,,,Augenbefunde bei Leukamie im Kindesalter.,,,,,,,,,
4068253,NLM,MEDLINE,19851231,20061115,0485-1439 (Print) 0485-1439 (Linking),26,6,1985 Jun,[Remission induction failures in adult acute non-lymphocytic leukemia].,924-8,,"['Yoshida, M', 'Furukawa, Y', 'Akashi, M', 'Komatsu, N', 'Takeda, K', 'Muroi, K', 'Ikeda, K', 'Ohsaka, A', 'Ohta, M', 'Takagi, S']","['Yoshida M', 'Furukawa Y', 'Akashi M', 'Komatsu N', 'Takeda K', 'Muroi K', 'Ikeda K', 'Ohsaka A', 'Ohta M', 'Takagi S', 'et al.']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Age Factors', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Female', 'Humans', 'Leukemia/*drug therapy/mortality', 'Male', 'Middle Aged']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Jun;26(6):924-8.,,,,,,,,,,,,
4068250,NLM,MEDLINE,19851231,20061115,0485-1439 (Print) 0485-1439 (Linking),26,6,1985 Jun,[Treatment of minimal residual leukemia].,880-5,,"['Ohshima, T']",['Ohshima T'],['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Drug Administration Schedule', 'Humans', 'Leukemia/*drug therapy/mortality', 'Middle Aged']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Jun;26(6):880-5.,,,,,,,,,,,,
4068249,NLM,MEDLINE,19851231,20041117,0485-1439 (Print) 0485-1439 (Linking),26,6,1985 Jun,[Possible modality for overcoming drug resistance].,877-9,,"['Tsuruo, T']",['Tsuruo T'],['jpn'],['Journal Article'],Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Animals', 'Antineoplastic Agents/*therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Drug Evaluation, Preclinical', 'Drug Resistance', 'Humans', 'Leukemia/*drug therapy', 'Leukemia P388/drug therapy', 'Mice']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Jun;26(6):877-9.,"['0 (Antineoplastic Agents)', '0 (Calcium Channel Blockers)']",,,,,,,,,,,
4068142,NLM,MEDLINE,19860102,20200724,0022-538X (Print) 0022-538X (Linking),56,3,1985 Dec,Mouse chromosomal mapping of a murine leukemia virus integration region (Mis-1) first identified in rat thymic leukemia.,1045-8,"We have previously identified a region of genomic DNA which constitutes the site of frequent provirus integration in rat thymomas induced by Moloney murine leukemia virus (Lemay and Jolicoeur, Proc. Natl. Acad. Sci. USA 81:38-42, 1984). This genetic locus is now designated Mis-1 (Moloney integration site). Cellular sequences homologous to Mis-1 are present in mouse DNA. Using a series of hamster-mouse somatic cell hybrids, we mapped the Mis-1 locus to mouse chromosome 15. Frequent chromosome 15 aberrations have been described in mouse thymomas. Mis-1 represents a putative new oncogene which might be involved in the initiation or maintenance or both of these neoplasms.","['Jolicoeur, P', 'Villeneuve, L', 'Rassart, E', 'Kozak, C']","['Jolicoeur P', 'Villeneuve L', 'Rassart E', 'Kozak C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Cell Transformation, Viral', 'Chromosome Mapping', 'Mice/*genetics/microbiology', 'Moloney murine leukemia virus/*genetics', '*Proto-Oncogenes', 'Recombination, Genetic']",PMC252684,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1128/JVI.56.3.1045-1048.1985 [doi]'],ppublish,J Virol. 1985 Dec;56(3):1045-8. doi: 10.1128/JVI.56.3.1045-1048.1985.,,,,,,,,,,,,
4068136,NLM,MEDLINE,19851226,20190829,0022-5320 (Print) 0022-5320 (Linking),90,1,1985 Jan,Structural changes induced in rat leukemic basophils by immunological stimulus.,105-13,"We have examined morphological events in RBL-2H3 basophilic leukocyte-derived cells following stimulation to secrete with specific antigen. Following stimulation, the cell surface undergoes a rapid and pronounced ruffling concomitant with an overall flattening. Secretory granules which are located in one area before stimulation becomes rapidly dispersed throughout the cytoplasm. Since secretion has been shown to be a relatively slow process in the RBL-2H3 cell line our observations suggest that ruffling and flattening precede the secretion process.","['Phillips, D M', 'Bashkin, P', 'Pecht, I']","['Phillips DM', 'Bashkin P', 'Pecht I']",['eng'],['Journal Article'],United States,J Ultrastruct Res,Journal of ultrastructure research,0376344,IM,"['Animals', 'Antigens/immunology', 'Basophils/ultrastructure', 'Cells, Cultured', 'Culture Media', 'Cytoplasmic Granules/ultrastructure', 'Leukemia, Experimental/immunology/*pathology', 'Microscopy, Electron, Scanning', 'Rats']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0889-1605(85)90120-x [doi]'],ppublish,J Ultrastruct Res. 1985 Jan;90(1):105-13. doi: 10.1016/0889-1605(85)90120-x.,"['0 (Antigens)', '0 (Culture Media)']",,,,,,,,,,,
4068000,NLM,MEDLINE,19851227,20190709,0022-2623 (Print) 0022-2623 (Linking),28,11,1985 Nov,2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.,1740-2,"Syntheses of 2-fluoroformycin [7-amino-5-fluoro-3-(beta-D-ribofuranosyl)pyrazolo[4,3-d]pyrimidine] (2b) and 2-aminoformycin [5,7-diamino-3-(beta-D-ribofuranosyl)pyrazolo[4,3-d]pyrimidine] (2c) are described. Cytotoxicity data are given for 2b and 2c alone as well as with added pentostatin. Kinetic parameters for adenosine deaminase are also provided. 2-Fluoroformycin, although a much poorer substrate for adenosine deaminase than formycin A, is not nearly as cytotoxic to cells in culture.","['Secrist, J A 3rd', 'Shortnacy, A T', 'Montgomery, J A']","['Secrist JA 3rd', 'Shortnacy AT', 'Montgomery JA']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Adenosine/metabolism', 'Adenosine Deaminase/metabolism', 'Animals', 'Antibiotics, Antineoplastic/*therapeutic use', 'Formycins/chemical synthesis/metabolism/*therapeutic use', 'Kinetics', 'Leukemia L1210/*drug therapy/metabolism', 'Nucleotides/metabolism', 'Phosphates/metabolism', 'Substrate Specificity']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1021/jm00149a033 [doi]'],ppublish,J Med Chem. 1985 Nov;28(11):1740-2. doi: 10.1021/jm00149a033.,"['0 (Antibiotics, Antineoplastic)', '0 (Formycins)', '0 (Nucleotides)', '0 (Phosphates)', '6742-12-7 (formycin)', '97782-03-1 (2-aminoformycin)', '97782-08-6 (2-fluoroformycin)', 'EC 3.5.4.4 (Adenosine Deaminase)', 'K72T3FS567 (Adenosine)']",,,"['P01 CA34200/CA/NCI NIH HHS/United States', 'R01 CA24975/CA/NCI NIH HHS/United States']",,,,,,,,
4067995,NLM,MEDLINE,19851227,20190709,0022-2623 (Print) 0022-2623 (Linking),28,11,1985 Nov,"Synthesis and properties of bis(2,2-dimethylaziridinyl)phosphinic amides: a series of new antineoplastic agents.",1685-91,"In continuation of efforts to improve the antitumor selectivity of the 2,2-dimethylaziridine class of alkylating agents, a series of N-substituted bis(2,2-dimethyl-1-aziridinyl)phosphinic amides has been synthesized and evaluated. All of these compounds (3-15) were tested in vivo against leukemia P-388 in mice, where most of them caused significant increase of survival time at nontoxic dose levels. Some of the most active compounds were also tested against leukemia L1210, B16 melanoma, and colon 26 carcinoma; in the latter tests, the parent unsubstituted amide 3 appeared to show the highest antitumor activity. Since the dose-limiting toxicity of the clinically tested prototypes of this class of anticancer agents AB-132 (1) and AB-163 (2) had been found to be CNS toxicity attributable mainly to the inhibition of cholinesterase, the compounds were tested in vitro against the cholinesterases from horse serum, electric eel, and bovine erythrocytes, as well as in vivo for the inhibition of the cholinesterase present in the whole blood of mice. In all of these assays, the various members of the present series showed a wide range of anticholinesterase activities, ranging from almost zero (for 3) to even higher potency than that of the prototype 2. A similarly wide range of stability was observed toward hydrolytic ring opening of the 2,2-dimethylaziridine moieties. Several of the compounds, particularly 3, deserve further study.","['MacDiarmid, J E', 'Rose, W C', 'Biddle, W C', 'Perlman, M E', 'Breiner, R G', 'Ambrus, J L', 'Bardos, T J']","['MacDiarmid JE', 'Rose WC', 'Biddle WC', 'Perlman ME', 'Breiner RG', 'Ambrus JL', 'Bardos TJ']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Aziridines/chemical synthesis/pharmacology/*therapeutic use', 'Azirines/*therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Chlorambucil/therapeutic use', 'Cholinesterase Inhibitors/pharmacology', 'Colonic Neoplasms/drug therapy', 'Cyclophosphamide/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Hydrolysis', 'Kinetics', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Male', 'Melanoma/drug therapy', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred DBA', 'Neoplasms, Experimental/*drug therapy', 'Organophosphorus Compounds/chemical synthesis/pharmacology/*therapeutic use']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1021/jm00149a025 [doi]'],ppublish,J Med Chem. 1985 Nov;28(11):1685-91. doi: 10.1021/jm00149a025.,"['0 (Aziridines)', '0 (Azirines)', '0 (Cholinesterase Inhibitors)', '0 (Organophosphorus Compounds)', '18D0SL7309 (Chlorambucil)', '8N3DW7272P (Cyclophosphamide)']",,,['R01-CA06695/CA/NCI NIH HHS/United States'],,,,,,,,
4067986,NLM,MEDLINE,19851227,20190709,0022-2623 (Print) 0022-2623 (Linking),28,11,1985 Nov,Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity.,1568-74,"Four classes of diacridines, joined at the 9-position by linker chains of varying length, rigidity, and polarity, were evaluated for DNA-binding properties and antitumor activity. Diacridines linked by flexible chains of varying polarity show relatively fast chromophore exchange kinetics among DNA binding sites but slower dissociation rates, suggesting the potential for considerable ""creeping"" of the drug along the helix, and are inactive in vivo. The exchange kinetics can be slowed dramatically by inclusion of positive charges in the side chain, but the resulting polycationic drugs are inactive in vivo, possibly due to poor distribution. Diacridines linked by a rigid, polar but neutral dicarbamoylpyrazole chain retain slow exchange kinetics, have a greatly reduced potential ""creep rate"", and possess good in vitro potency and significant in vivo antileukemic activity.","['Denny, W A', 'Atwell, G J', 'Baguley, B C', 'Wakelin, L P']","['Denny WA', 'Atwell GJ', 'Baguley BC', 'Wakelin LP']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Acridines/chemical synthesis/*metabolism/therapeutic use', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Chemistry, Physical', 'DNA/*metabolism', 'Kinetics', 'Leukemia P388/drug therapy', 'Poly A/metabolism', 'Poly dA-dT/metabolism', 'Polydeoxyribonucleotides/metabolism', 'Structure-Activity Relationship']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1021/jm00149a005 [doi]'],ppublish,J Med Chem. 1985 Nov;28(11):1568-74. doi: 10.1021/jm00149a005.,"['0 (Acridines)', '0 (Polydeoxyribonucleotides)', '24937-83-5 (Poly A)', '25191-20-2 (poly(dA))', '26966-61-0 (Poly dA-dT)', '29855-95-6 (poly(dC-dG))', '9007-49-2 (DNA)']",,,,,,,,,,,
4067680,NLM,MEDLINE,19860110,20131121,0096-1736 (Print) 0096-1736 (Linking),27,10,1985 Oct,"Mortality of aluminum reduction plant workers, 1950 through 1977.",761-70,"The mortality experience of 5,406 men (cohort I) employed at one aluminum smelter on Jan. 1, 1950, and 485 men employed at a second plant (cohort II) on Jan. 1, 1951, is reported. For each man, the total number of years of exposure to tars, the number of years since first exposure to tars, and an index of exposure to tars expressed in tar-years were calculated. More than 99% of the men in the first cohort and 98% of the men in the second cohort were traced. Of the 1,539 men in cohort I who were deceased as of December 31, 1977, death certificates were obtained for 1,432 (93%). Of the 92 men in cohort II who were deceased as of December 31, 1977, death certificates were obtained for 80 (87%). The results showed that men in cohort I died of the following causes at approximately the same rate as or less frequently than men of similar age in the Province of Quebec: tuberculosis; circulatory disease; hypertensive heart disease; trauma; leukemia and aleukemia; and malignant neoplasms of the pancreas, genital organs, brain, intestine, and rectum and other abdominal areas. There were no deaths from pneumoconiosis or Alzheimer's disease. Although the observed and expected numbers of deaths in some of the cause-of-death categories were small, men in cohort I died of the following causes more frequently than did men of similar age in the Province of Quebec: respiratory disease; pneumonia and bronchitis; malignant neoplasms (all sites); malignant neoplasms of the stomach and esophagus, bladder, and lung; other malignant neoplasms; Hodgkin's disease; and other hypertensive disease. Mortality from malignant neoplasms of the bladder and lung was meaningfully related to numbers of tar-years and of years of exposure. Exposure-response relationships were less clear for malignant neoplasms of the esophagus and stomach and for other malignancies. Mortality from respiratory disease for men with 21 or more tar-years of exposure was approximately twice that of persons never exposed to tars. The apparent excess of other hypertensive disease was restricted to men never exposed to tars. Malignant neoplasm of the lung was the only cause of death in cohort II that was in excess of that expected at Quebec provincial rates.","['Gibbs, G W']",['Gibbs GW'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Occup Med,Journal of occupational medicine. : official publication of the Industrial Medical Association,7502807,IM,"['Aluminum', 'Environmental Exposure', 'Humans', '*Metallurgy', '*Mortality', 'Neoplasms/mortality', 'Occupational Diseases/chemically induced/epidemiology', '*Occupational Medicine', 'Respiratory Tract Diseases/mortality', 'Tars/*adverse effects']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,J Occup Med. 1985 Oct;27(10):761-70.,"['0 (Tars)', 'CPD4NFA903 (Aluminum)']",,,,,,,,,,,
4067615,NLM,MEDLINE,19860116,20170210,0732-183X (Print) 0732-183X (Linking),3,12,1985 Dec,Tetracycline sclerosis in the management of malignant pericardial effusion.,1678-82,"Twenty-two patients with malignant pericardial effusion were seen at the Toronto General Hospital between 1979 and 1984. Under ECG monitoring, an indwelling Kifa catheter was inserted into the pericardial sac and then connected to a Hemovac system and allowed to drain for 12 to 24 hours. Xylocaine hydrochloride, 100 mg, was first instilled intrapericardially, followed by tetracycline hydrochloride, 500 to 1,000 mg, dissolved in 20 mL normal saline. The catheter was clamped for one to two hours and then allowed to drain into the Hemovac. This procedure was repeated every 24 to 48 hours until the net drainage was less than 25 mL/24 hours. Nine men and 13 women were treated (median age, 55 years). The primary malignancy included lung in 15 patients, breast in two patients, and carcinoma of the stomach, ovary, pleural mesothelioma, chronic granulocytic leukemia, and adenocarcinoma of unknown primary in one patient each. Twenty patients received one to five instillations of tetracycline. In one patient the catheter could not be inserted into the pericardial sac, and in one patient the catheter clotted before tetracycline instillation. Minor complications included transient arrhythmia in two patients, postinjection pain in four patients, and self-limited temperature elevation greater than 38.5 degrees C in two patients. fifteen patients had good control of their malignant pericardial effusion for more than 30 days (median survival, 160 days; range, 38 to 275 days). Three patients died before 30 days without evidence of effusion, and no patient surviving longer than 30 days developed recurrent effusion or pericardial constriction. Intrapericardial tetracycline instillation is a safe and efficacious treatment for malignant pericardial effusion and should be considered the first treatment modality in this situation.","['Shepherd, F A', 'Ginsberg, J S', 'Evans, W K', 'Scott, J G', 'Oleksiuk, F']","['Shepherd FA', 'Ginsberg JS', 'Evans WK', 'Scott JG', 'Oleksiuk F']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Clin Oncol,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,8309333,IM,"['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Cardiac Catheterization/adverse effects', 'Drainage/methods', 'Echocardiography', 'Electrocardiography', 'Female', 'Heart Neoplasms/pathology/secondary', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/pathology/radiotherapy', 'Pericardial Effusion/diagnosis/*drug therapy/pathology', 'Pericardium/drug effects/pathology', 'Prognosis', 'Sclerosis', 'Tetracycline/*administration & dosage/therapeutic use']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1200/JCO.1985.3.12.1678 [doi]'],ppublish,J Clin Oncol. 1985 Dec;3(12):1678-82. doi: 10.1200/JCO.1985.3.12.1678.,['F8VB5M810T (Tetracycline)'],,,,,,,,,,,
4067607,NLM,MEDLINE,19860121,20190908,0162-0134 (Print) 0162-0134 (Linking),25,3,1985 Nov,"Some mixed-ligand palladium(II) complexes of 2,2'-bipyridine and amino acids as potential anticancer agents.",207-15,"Eight new palladium complexes of the formula [Pd(bipy)(AA)]Cl 1 or 2 H2O (where bipy is 2,2'-bipyridine and AA is an anion of glycine, L-alanine, L-leucine, L-proline, L-serine, L-lysine, L-asparagine, or L-glutamine) have been synthesized by reaction of [Pd(bipy)Cl2] with an appropriate mono sodium salt of amino acid in water. These complexes have been characterized by chemical analysis and by visible, infrared, and 1H NMR spectroscopy. The detailed 1H NMR and infrared spectral studies of these complexes ascertain the mode of binding of amino acids to palladium through nitrogen of terminal -NH2 group and oxygen of terminal -COO- group. The molar conductance values of these complexes in water suggest them to be 1:1 electrolytes. These complexes have also shown growth inhibition against L1210 lymphoid leukemic, P388 lymphocytic leukemic, Sarcoma 180, and Ehrlich ascitic tumor cells. Some of these complexes show better 50% inhibitory dose values than cis-diamminedichloroplatinum(II).","['Puthraya, K H', 'Srivastava, T S', 'Amonkar, A J', 'Adwankar, M K', 'Chitnis, M P']","['Puthraya KH', 'Srivastava TS', 'Amonkar AJ', 'Adwankar MK', 'Chitnis MP']",['eng'],['Journal Article'],United States,J Inorg Biochem,Journal of inorganic biochemistry,7905788,IM,"[""2,2'-Dipyridyl/analogs & derivatives/*chemical synthesis/pharmacology"", 'Amino Acids/*chemical synthesis/pharmacology', 'Animals', 'Antineoplastic Agents/*chemical synthesis', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Chemical Phenomena', 'Chemistry', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice', 'Palladium/*analysis/pharmacology', 'Pyridines/*chemical synthesis', 'Sarcoma 180/drug therapy']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0162-0134(85)80014-3 [pii]', '10.1016/0162-0134(85)80014-3 [doi]']",ppublish,J Inorg Biochem. 1985 Nov;25(3):207-15. doi: 10.1016/0162-0134(85)80014-3.,"['0 (Amino Acids)', '0 (Antineoplastic Agents)', '0 (Pyridines)', ""551W113ZEP (2,2'-Dipyridyl)"", '5TWQ1V240M (Palladium)']",,,,,,,,,,,
4067359,NLM,MEDLINE,19860116,20061115,0737-1454 (Print) 0737-1454 (Linking),3,6,1985 Nov,"CFU-gm assay, cytochemical and electron microscopic studies in agar in patients with preleukemic syndrome and aplastic anemia.",367-87,"Thirty-seven patients with chronic cytopenia were studied using a CFU-gm assay in agar. Cell proliferation was evaluated on days 2, 3, 5, 7, and 10 of incubation. Growth patterns were different in cultures of hematologically healthy persons versus patients with preleukemic syndrome (PL) and aplastic anemia (AA). Three types of PL syndrome and two types of AA (C1 and C2) were distinguished. Bone marrow dysfunction was evaluated further using cytochemistry and electron microscopy to morphologically study cell proliferation in vitro. Cytochemical staining performed in agar demonstrated well-defined maturation defects in myelopoietic precursor cells from the bone marrow of PL patients. Electron microscopic findings of Auer-body-like inclusions in ""statu nascendi"" in the vacuoles of preleukemic cells supported our results. PL patient groups at high risk for development of overt leukemia and patients with grave prognosis in AA were distinguished. Our results are relevant for the clinical diagnosis and prognosis of patients with cytopenia.","['Konwalinka, G', 'Peschel, C', 'Schmalzl, F', 'Schaefer, H E', 'Geissler, D', 'Schuler, G', 'Huber, H', 'Tomaschek, B', 'Odavic, R', 'Braunsteiner, H']","['Konwalinka G', 'Peschel C', 'Schmalzl F', 'Schaefer HE', 'Geissler D', 'Schuler G', 'Huber H', 'Tomaschek B', 'Odavic R', 'Braunsteiner H']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Int J Cell Cloning,International journal of cell cloning,8308172,IM,"['Aged', 'Anemia, Aplastic/*pathology', 'Bone Marrow/*pathology', 'Cell Cycle', 'Colony-Forming Units Assay', 'Erythropoiesis', 'Granulocytes', 'Hematopoietic Stem Cells/*pathology', 'Humans', 'Megakaryocytes/pathology', 'Microscopy, Electron', 'Middle Aged', 'Monocytes', 'Preleukemia/*pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1002/stem.5530030603 [doi]'],ppublish,Int J Cell Cloning. 1985 Nov;3(6):367-87. doi: 10.1002/stem.5530030603.,,,,,,,,,,,,
4067029,NLM,MEDLINE,19860117,20190709,0190-9622 (Print) 0190-9622 (Linking),13,5 Pt 2,1985 Nov,Pyoderma gangrenosum and chronic persistent hepatitis.,892-7,"Pyoderma gangrenosum is a diagnosis of exclusion. A 36-year-old woman was clinically diagnosed as having pyoderma gangrenosum and appropriate exclusion tests were performed. Pyoderma gangrenosum may occur in association with underlying diseases such as leukemia, monoclonal gammopathy, inflammatory bowel disease, arthritis, and chronic active hepatitis. However, these diseases were excluded in this patient who did have chronic persistent hepatitis. To our knowledge, this is the first reported case of chronic persistent hepatitis and pyoderma gangrenosum.","['Green, L K', 'Hebert, A A', 'Jorizzo, J L', 'Solomon, A R Jr', 'Subramanyam, K']","['Green LK', 'Hebert AA', 'Jorizzo JL', 'Solomon AR Jr', 'Subramanyam K']",['eng'],"['Case Reports', 'Journal Article']",United States,J Am Acad Dermatol,Journal of the American Academy of Dermatology,7907132,IM,"['Adult', 'Female', 'Hepatitis B Surface Antigens/analysis', 'Hepatitis, Chronic/*complications/immunology', 'Humans', 'Pyoderma/drug therapy/*etiology/pathology', 'Skin/pathology']",,1985/11/01 00:00,2001/03/28 10:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/11/01 00:00 [entrez]']","['S0190-9622(85)70236-8 [pii]', '10.1016/s0190-9622(85)70236-8 [doi]']",ppublish,J Am Acad Dermatol. 1985 Nov;13(5 Pt 2):892-7. doi: 10.1016/s0190-9622(85)70236-8.,['0 (Hepatitis B Surface Antigens)'],,,,,,,,,,,
4066981,NLM,MEDLINE,19860117,20190501,0021-9746 (Print) 0021-9746 (Linking),38,11,1985 Nov,"Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features.",1218-24,"In a retrospective study of 111 patients with aplastic anaemia iliac crest biopsies were evaluated for the presence of morphological features statistically related to the evolution of the disease. Prognostic variables for a transition to acute non-lymphatic leukaemia were: cellular atypias of the three haemopoietic lineages, as observed in the myelodysplastic syndrome, and especially ""micromegakaryocytes""; high numbers or irregular distribution of megakaryocytes, or both; and (slight) marrow fibrosis. Clinical variables did not influence these prognostic correlations. Prognosis in relation to death from bone marrow failure without leukaemia might well have been influenced by a strong plasma cell reaction, but this correlation was weakened by clinical factors. On the basis of this study aplastic anaemia can thus be subdivided morphologically into two disease entities--namely, hypocellular myelodysplastic syndrome with a 23-82% risk of acute non-lymphatic leukaemia developing within three years, depending on how many variables associated with acute non-lymphatic leukaemia are present, and non-dysplastic myelohypoplasia.","['Fohlmeister, I', 'Fischer, R', 'Modder, B', 'Rister, M', 'Schaefer, H E']","['Fohlmeister I', 'Fischer R', 'Modder B', 'Rister M', 'Schaefer HE']",['eng'],['Journal Article'],England,J Clin Pathol,Journal of clinical pathology,0376601,IM,"['Adolescent', 'Adult', 'Aged', 'Anemia, Aplastic/*pathology', 'Bone Marrow/*pathology', 'Cell Count', 'Cell Transformation, Neoplastic', 'Child', 'Hematopoietic Stem Cells/pathology', 'Humans', 'Leukemia/*etiology', 'Megakaryocytes/pathology', 'Middle Aged', 'Prognosis', 'Reticulin', 'Retrospective Studies', 'Time Factors']",PMC499416,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1136/jcp.38.11.1218 [doi]'],ppublish,J Clin Pathol. 1985 Nov;38(11):1218-24. doi: 10.1136/jcp.38.11.1218.,['0 (Reticulin)'],,,,,,,,,,,
4066762,NLM,MEDLINE,19860103,20190508,0021-9525 (Print) 0021-9525 (Linking),101,6,1985 Dec,"Cell surface tubulin in leukemic cells: molecular structure, surface binding, turnover, cell cycle expression, and origin.",2345-54,"We report here new characteristics of cell surface tubulin from a human leukemia cell line. These cells (CEM cells) possess tubulin that is readily iodinated on the surface of living cells, turns over at a rate identical to that of other surface proteins, and is present throughout the cell cycle. When removed with trypsin, it rapidly returns to the surface. Peptide mapping of iodinated surface tubulin indicates that it possesses a similar, but not identical, primary structure to total CEM and rat brain tubulin. Living CEM cells are able to bind specifically a subfraction of CEM tubulin from metabolically labeled high speed supernatants of lysed CEM cells. Surface tubulin is more basic than the total tubulin pool. The binding, which is saturable, is inhibited by unlabeled CEM high speed supernatants but not by excess thrice-cycled rat or bovine brain tubulin. Surface tubulin is also shown to bind to living nontransformed normal rat kidney cells but not to normal, circulating, mononuclear white cells. Activated lymphocytes produce a tubulin that binds to CEM cells. Since CEM tubulin was detected in the media of 6-h cultures of CEM cells, we must conclude that at least some of the surface tubulin comes from the media. We further conclude that these leukemic cells produce an unusual tubulin that may bind specifically to any membrane. The presence of iodinatable surface tubulin, however, appears to require both the production of a unique tubulin and the presence of a ""receptor-like"" surface binding component.","['Quillen, M', 'Castello, C', 'Krishan, A', 'Rubin, R W']","['Quillen M', 'Castello C', 'Krishan A', 'Rubin RW']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Cell Biol,The Journal of cell biology,0375356,IM,"['Animals', 'Binding, Competitive', 'Cell Cycle', 'Cell Line', 'Cell Membrane/*metabolism', 'Humans', 'Isoelectric Point', 'Leukemia/metabolism/*pathology', 'Leukemia L1210/metabolism', 'Mice', 'Protein Binding', 'Tubulin/*metabolism']",PMC2114015,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1083/jcb.101.6.2345 [doi]'],ppublish,J Cell Biol. 1985 Dec;101(6):2345-54. doi: 10.1083/jcb.101.6.2345.,['0 (Tubulin)'],,,['CA-23960/CA/NCI NIH HHS/United States'],,,,,,,,
4066509,NLM,MEDLINE,19851224,20190723,0021-8820 (Print) 0021-8820 (Linking),38,9,1985 Sep,Synthesis and antitumor activity of optically active (+)-9-O-alpha-L-daunosaminyl-4-demethoxydaunorubicin.,1277-9,,"['Kimura, Y', 'Matsumoto, T', 'Suzuki, M', 'Terashima, S']","['Kimura Y', 'Matsumoto T', 'Suzuki M', 'Terashima S']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Antibiotics, Antineoplastic/*chemical synthesis/pharmacology', 'Daunorubicin/*analogs & derivatives/chemical synthesis/pharmacology', '*Idarubicin/*analogs & derivatives', 'Leukemia P388/drug therapy', 'Mice']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.7164/antibiotics.38.1277 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Sep;38(9):1277-9. doi: 10.7164/antibiotics.38.1277.,"['0 (Antibiotics, Antineoplastic)', '99457-12-2 (9-O-daunosaminyl-4-demethoxydaunorubicin)', 'ZRP63D75JW (Idarubicin)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4066496,NLM,MEDLINE,19860108,20190723,0021-8820 (Print) 0021-8820 (Linking),38,10,1985 Oct,Biological properties of streptonigrin derivatives. I. Antimicrobial and cytocidal activities.,1429-32,,"['Inouye, Y', 'Okada, H', 'Roy, S K', 'Miyasaka, T', 'Hibino, S', 'Tanaka, N', 'Nakamura, S']","['Inouye Y', 'Okada H', 'Roy SK', 'Miyasaka T', 'Hibino S', 'Tanaka N', 'Nakamura S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Bacteria/*drug effects', 'Cell Line', 'Doxorubicin/pharmacology', 'Leukemia P388/pathology', 'Mice', 'Microbial Sensitivity Tests', 'Streptonigrin/analogs & derivatives/*pharmacology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.7164/antibiotics.38.1429 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Oct;38(10):1429-32. doi: 10.7164/antibiotics.38.1429.,"['261Q3JB310 (Streptonigrin)', '80168379AG (Doxorubicin)']",,,,,,,,,,,
4066493,NLM,MEDLINE,19860108,20190723,0021-8820 (Print) 0021-8820 (Linking),38,10,1985 Oct,"Antitumor activities of (2""R)-4'-O-tetrahydropyranyl-adriamycin (THP) and its combination with other antitumor agents on murine tumors.",1408-19,"(2''R)-4'-O-Tetrahydropyranyladriamycin (THP) is a new derivative of doxorubicin (adriamycin, ADM). The concentrations of THP and ADM required to inhibit by 50% the growth of a cultured L1210 cells was 0.003 microgram/ml and 0.016 microgram/ml, respectively. Various therapeutic designs of combinations of THP with other antitumor agents were investigated in vivo using the L1210 murine leukemia. The combination of THP with cytosine arabinoside (Ara-C), cyclocytidine hydrochloride (Cyclo-C), 6-mercaptopurine (6-MP) and cyclophosphamide (EX) showed a great effectiveness following daily intraperitoneal treatment from days 1 to 10. High therapeutic effects were also obtained with the combinations of THP with Ara-C, Cyclo-C, vincristine (VCR) and EX following intravenous combination therapy one day following implantation of L1210 leukemia. Schedule dependency and its therapeutic efficacy of THP were examined. THP showed almost the same antitumor activity on the solid-type sarcoma-180 or solid-type Ehrlich carcinoma as ADM by intraperitoneal or intravenous treatment. THP showed some superior activity to ADM in the advanced stage of L1210 leukemia. High antitumor activity of THP on murine leukemia L1210 has been reported by Tsuruo et al. (Cancer Res. 42: 1462-1467, 1982) and was also confirmed. THP gave many mice cures, especially in the intravenous treatment.","['Matsushita, Y', 'Kumagai, H', 'Yoshimoto, A', 'Tone, H', 'Ishikura, T', 'Takeuchi, T', 'Umezawa, H']","['Matsushita Y', 'Kumagai H', 'Yoshimoto A', 'Tone H', 'Ishikura T', 'Takeuchi T', 'Umezawa H']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Antibiotics, Antineoplastic/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Cells, Cultured', 'Doxorubicin/administration & dosage/*analogs & derivatives/therapeutic use', 'Drug Administration Schedule', 'Leukemia L1210/drug therapy', 'Male', 'Mice', 'Mice, Inbred ICR', 'Neoplasms, Experimental/*drug therapy', 'Sarcoma 180/drug therapy']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.7164/antibiotics.38.1408 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Oct;38(10):1408-19. doi: 10.7164/antibiotics.38.1408.,"['0 (Antibiotics, Antineoplastic)', '80168379AG (Doxorubicin)', 'D58G680W0G (pirarubicin)']",,,,,,,,,,,
4066460,NLM,MEDLINE,19860116,20031114,0003-1488 (Print) 0003-1488 (Linking),187,10,1985 Nov 15,Myelodysplastic syndrome in two dogs.,1038-40,"Two cases of myelodysplastic syndrome in the dog are described. Both cases were characterized by hepatomegaly, cytopenias, macrocytosis, cellular bone marrow, and dysplastic changes in all hematopoietic cell lines. Serum vitamin B12 and folic acid concentrations were within reference ranges in one dog, but vitamin B12 was slightly decreased in the other. Vitamin B12 therapy did not result in amelioration of the hematologic disorder. The duration of illness was approximately 5 months. Necropsy of one dog revealed an acute undifferentiated leukemia.","['Weiss, D J', 'Raskin, R', 'Zerbe, C']","['Weiss DJ', 'Raskin R', 'Zerbe C']",['eng'],"['Case Reports', 'Journal Article']",United States,J Am Vet Med Assoc,Journal of the American Veterinary Medical Association,7503067,IM,"['Anemia/therapy/veterinary', 'Animals', 'Biopsy', 'Blood Transfusion', 'Bone Marrow/pathology', 'Dog Diseases/*pathology/therapy', 'Dogs', 'Female', 'Male', 'Myelodysplastic Syndromes/pathology/therapy/*veterinary']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",,ppublish,J Am Vet Med Assoc. 1985 Nov 15;187(10):1038-40.,,,,,,,,,,,,
4066436,NLM,MEDLINE,19860115,20190708,0360-3016 (Print) 0360-3016 (Linking),11,12,1985 Dec,Results of radiation treatment of medulloblastoma in adults.,2051-6,"From 1961 to 1982, 20 adults (greater than 16 years of age) were treated with radiation therapy following surgery for medulloblastoma. All patients received neuro-axis irradiation. Five patients received adjuvant chemotherapy. A 5- and 10-year survival rate of 78 and 55%, respectively, were achieved. Treatment failures were mainly a result of local recurrences, but also of metastases. One patient died of acute myeloid leukemia. One patient developed paraplegia. The survival rate was better in males (2 deaths out of 14) than in females (5 deaths out of 6). All the survivors are free of deficit or sequelae, except the patient with paraplegia.","['Haie, C', 'Schlienger, M', 'Constans, J P', 'Meder, J F', 'Reynaud, A', 'Ghenim, C']","['Haie C', 'Schlienger M', 'Constans JP', 'Meder JF', 'Reynaud A', 'Ghenim C']",['eng'],['Journal Article'],United States,Int J Radiat Oncol Biol Phys,"International journal of radiation oncology, biology, physics",7603616,IM,"['Adolescent', 'Adult', 'Bone Neoplasms/secondary', 'Brain Neoplasms/mortality/*radiotherapy', 'Female', 'Humans', 'Liver Neoplasms/secondary', 'Male', 'Medulloblastoma/mortality/*radiotherapy', 'Retrospective Studies', 'Sex Factors', 'Spinal Cord Neoplasms/secondary', 'Time Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0360-3016(85)90083-5 [pii]', '10.1016/0360-3016(85)90083-5 [doi]']",ppublish,Int J Radiat Oncol Biol Phys. 1985 Dec;11(12):2051-6. doi: 10.1016/0360-3016(85)90083-5.,,,,,,,,,,,,
4066221,NLM,MEDLINE,19860103,20191022,0167-6997 (Print) 0167-6997 (Linking),3,3,1985,Homoharringtonine: a phase I evaluation.,279-86,"Homoharringtonine is one of several Cephalotaxine esters which have shown experimental antineoplastic activity as well as anti-leukemia effects in patients in China. In a Phase I trial of homoharringtonine administered daily X 5 by bolus intravenous injection, the dose limiting toxicity was hypotension and the maximum tolerated dose was 3.5 mg/m2/d X 5. Evidence of drug induced cardiac irritability with resulting ventricular and atrial dysrhythmias was seen. Minimal myelosuppression was seen at this dose. Treatment of patients by 5 day continuous intravenous (rather than bolus) infusion resulted in more pronounced myelosuppression and clinically significant but tolerable hypotension. Significant reduction of white blood cell and platelet counts occurred at a dose of 3.5 mg/m2/day. Further investigations of the hypotensive and cardiac effects of homoharringtonine and Phase II trials using continuous infusion are indicated.","['Stewart, J A', 'Krakoff, I H']","['Stewart JA', 'Krakoff IH']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Invest New Drugs,Investigational new drugs,8309330,IM,"['Aged', 'Alkaloids/*therapeutic use', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Drug Evaluation', 'Female', 'Harringtonines/administration & dosage/adverse effects/*therapeutic use', 'Heart/drug effects', 'Homoharringtonine', 'Humans', 'Infusions, Parenteral', 'Leukocyte Count/drug effects', 'Male', 'Middle Aged', 'Neoplasms/*drug therapy', 'Platelet Count/drug effects', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00179432 [doi]'],ppublish,Invest New Drugs. 1985;3(3):279-86. doi: 10.1007/BF00179432.,"['0 (Alkaloids)', '0 (Antineoplastic Agents)', '0 (Harringtonines)', '6FG8041S5B (Homoharringtonine)']",,,"['CA 22435/CA/NCI NIH HHS/United States', 'GCRC-RR109/RR/NCRR NIH HHS/United States', 'N01 CM27547/CM/NCI NIH HHS/United States']",,,,,,,,
4066218,NLM,MEDLINE,19860103,20191022,0167-6997 (Print) 0167-6997 (Linking),3,3,1985,Dezaguanine mesylate: a new antipurine antimetabolite.,223-31,"3-Deazaguanine (dezaguanine, USAN; CI-908) is a new antipurine antimetabolite which is entering Phase I studies in the USA. This compound differs from guanine only in the substitution of a carbon for the 3-nitrogen of guanine. Dezaguanine has an unusual spectrum of activity against experimental rodent tumors; its activity against transplantable rodent leukemias is only modest, but it has significant activity against transplantable rodent solid tumors, particularly mammary adenocarcinomas. Mammary adenocarcinoma models against which this compound is active include slow and fast-growing tumors, hormone sensitive and hormone insensitive tumors, and the subrenal capsule implanted human breast cancer xenograft, MX-1. Dezaguanine must be converted to its nucleotides to be active. Dezaguanine nucleotides inhibit synthesis of guanine nucleotides, and can be incorporated into nucleic acids in place of guanine nucleotides; incorporation into DNA may be particularly important in the cytotoxicity of this compound. Addition of certain purines or purine nucleosides can prevent dezaguanine cytotoxicity in vitro. Preclinical studies suggest that dezaguanine does not undergo deamination to 3-deazaxanthine, and is not metabolized by xanthine oxidase. Therefore, this compound may not be subject to metabolic inactivation in vivo, and active metabolites may have a prolonged half-life. This concept is supported by the prolonged half-life of radiolabelled dezaguanine in rats. Finally, dezaguanine can cross the blood-brain barrier. In summary, the novel biochemical and experimental antitumor properties of dezaguanine indicate that this compound could have better activity against some human solid tumors than currently used purine antimetabolites.(ABSTRACT TRUNCATED AT 250 WORDS)","['Leopold, W R', 'Fry, D W', 'Boritzki, T J', 'Besserer, J A', 'Pattison, I C', 'Jackson, R C']","['Leopold WR', 'Fry DW', 'Boritzki TJ', 'Besserer JA', 'Pattison IC', 'Jackson RC']",['eng'],['Journal Article'],United States,Invest New Drugs,Investigational new drugs,8309330,IM,"['Adenocarcinoma/metabolism/pathology', 'Animals', 'Antimetabolites, Antineoplastic/*pharmacology', 'Cell Survival/drug effects', 'Cells, Cultured', 'DNA, Neoplasm/biosynthesis', 'Drug Evaluation', 'Guanine/*analogs & derivatives/pharmacology', 'Humans', 'Kinetics', 'Leukemia L1210/metabolism/pathology', 'Mammary Neoplasms, Experimental/metabolism/pathology', 'Mice', 'Purines/*antagonists & inhibitors', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00179426 [doi]'],ppublish,Invest New Drugs. 1985;3(3):223-31. doi: 10.1007/BF00179426.,"['0 (Antimetabolites, Antineoplastic)', '0 (DNA, Neoplasm)', '0 (Purines)', '5Z93L87A1R (Guanine)', '9DRB973HUI (3-deazaguanine)']",,,,,,,,,,,
4066104,NLM,MEDLINE,19860121,20190722,0011-9059 (Print) 0011-9059 (Linking),24,9,1985 Nov,Leukemia cutis masquerading as chronic paronychia.,595-7,,"['High, D A', 'Luscombe, H A', 'Kauh, Y C']","['High DA', 'Luscombe HA', 'Kauh YC']",['eng'],"['Case Reports', 'Journal Article']",England,Int J Dermatol,International journal of dermatology,0243704,IM,"['Aged', 'Biopsy', 'Chronic Disease', 'Diagnosis, Differential', 'Female', 'Humans', 'Leukemia, Lymphoid/*diagnosis/pathology', 'Paronychia/*diagnosis', 'Skin Neoplasms/*diagnosis/pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1365-4362.1985.tb05859.x [doi]'],ppublish,Int J Dermatol. 1985 Nov;24(9):595-7. doi: 10.1111/j.1365-4362.1985.tb05859.x.,,,,,,,,,,,,
4065882,NLM,MEDLINE,19860121,20190722,0046-8177 (Print) 0046-8177 (Linking),16,12,1985 Dec,Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha 2-interferon.,1200-5,"Bone marrow specimens from 21 patients with hairy cell leukemia (HCL) who were entered into a program to study the efficacy of treatment with recombinant alpha 2-interferon were evaluated. Patients were treated with the interferon, 2 X 10(6) U/m2 subcutaneously three times weekly, and were scheduled to undergo bone marrow aspiration and biopsy at study entry and after three (21 patients) and six (16 patients) months of treatment. Bone marrow samples after three months of treatment showed an overall decline in cellularity, from an average of 77 +/- 20 to 57 +/- 22 per cent, with a marked decrease in the percentage of neoplastic mass (from 87 +/- 9 to 59 +/- 24 per cent). The bone marrow changes were associated with significant improvement in hematologic values, including hemoglobin levels and granulocyte and platelet counts. The bone marrow changes and improved hematologic values remained stable with continuation of interferon therapy. However complete bone marrow remission did not occur in any of the patients after three or six months of interferon therapy. The HCL cell mass in more than 60 per cent of the patients remained at or above 50 per cent of the marrow cellularity and dropped to less than 25 per cent in 14 per cent of the patients. In all of the patients increased amounts of reticulin fibers were identified in the bone marrow prior to therapy, and 89 per cent of bone marrow aspirations failed (dry tap). The amounts of reticulin fibers remained increased in most of the patients (91 per cent), with a high incidence of dry taps (73 per cent), after therapy. Interferon therapy also changed the tartrate-resistant acid phosphatase(TRAP)-positive HCL cells to TRAP-negative, suggesting inhibition of activity and/or production of TRAP in HCL cells.","['Naeim, F', 'Jacobs, A D']","['Naeim F', 'Jacobs AD']",['eng'],['Journal Article'],United States,Hum Pathol,Human pathology,9421547,IM,"['Acid Phosphatase/analysis', 'Adult', 'Aged', 'Bone Marrow/*drug effects/pathology', 'Cell Count/drug effects', 'Female', 'Hematopoiesis/drug effects', 'Humans', 'Interferon Type I/*therapeutic use', 'Leukemia, Hairy Cell/enzymology/pathology/*therapy', 'Male', 'Middle Aged', 'Recombinant Proteins/*therapeutic use', 'Reticulin/biosynthesis', 'Tartrates/pharmacology', 'Time Factors']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['S0046-8177(85)80031-9 [pii]', '10.1016/s0046-8177(85)80031-9 [doi]']",ppublish,Hum Pathol. 1985 Dec;16(12):1200-5. doi: 10.1016/s0046-8177(85)80031-9.,"['0 (Interferon Type I)', '0 (Recombinant Proteins)', '0 (Reticulin)', '0 (Tartrates)', 'EC 3.1.3.2 (Acid Phosphatase)']",,,,,,,,,,,
4065523,NLM,MEDLINE,19860122,20200713,0234-5730 (Print) 0234-5730 (Linking),30,10,1985 Oct,[Reaction of hematopoietic tissue to the administration of an antileukemic substance isolated from splenic tissue].,34-7,,"['Svirnovskii, A I', 'Shimanskaia, T V', 'Bakun, A V', 'Levin, V I']","['Svirnovskii AI', 'Shimanskaia TV', 'Bakun AV', 'Levin VI']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Gematol Transfuziol,Gematologiia i transfuziologiia,8301796,IM,"['Animals', 'Cattle', 'Erythrocyte Count', 'Hematopoietic Stem Cells/*pathology', 'Leukemia, Experimental/blood/*therapy', 'Leukocyte Count', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred C57BL', '*Spleen', 'Tissue Extracts/*therapeutic use']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Gematol Transfuziol. 1985 Oct;30(10):34-7.,['0 (Tissue Extracts)'],,Reaktsiia krovetvornoi tkani na vvedenie vydelennogo iz tkani selezenki veshchestva s protivoleikoznoi aktivnost'iu.,,,,,,,,,
4065085,NLM,MEDLINE,19860110,20190919,0013-9432 (Print) 0013-9432 (Linking),33,4,1985,A radioimmunoassay for the measurement of aminopeptidase (microsomal) in human serum.,181-7,"A radioimmunoassay for the measurement of aminopeptidase (microsomal) (AP) in human serum was developed by using antiserum to human kidney AP. AP purified from kidney and AP present in normal serum and in serum from a patient with obstructive jaundice gave parallel logit-log transformation lines, suggesting immunological identity. The mean concentration of AP in normal serum (n = 104) was 1.33 +/- 0.30 (mean +/- SD) micrograms/ml. Men had significantly higher serum AP levels (1.41 +/- 0.30 micrograms/ml) (p less than 0.005) than women (1.24 +/- 0.28 micrograms/ml). Serum AP levels of patients with hepatoma (2.26 +/- 0.87 micrograms/ml) and cancer of the pancreas or the biliary tract (2.90 +/- 0.67 micrograms/ml) were significantly higher (p less than 0.005) than those of normal subjects. Patients with acute and chronic hepatitis (2.06 +/- 0.66 micrograms/ml) also had significantly higher serum AP levels (p less than 0.005) than normal subjects. In pregnant women, however, the increase in AP activity without the increase in AP concentration showed that the increased AP activity was due to an enzyme other than AP. The enzyme levels and activities in normal serum as well as in patients' sera were significantly correlated (normal, r = 0.77; patients, r = 0.95). Based on the specific activity of AP purified from human plasma, the enzyme activity splitting L-alanyl-beta-naphthylamide is due almost completely to AP in normal subjects and in patients with hepatobiliary diseases.","['Tokioka-Terao, M', 'Hiwada, K', 'Kokubu, T']","['Tokioka-Terao M', 'Hiwada K', 'Kokubu T']",['eng'],['Journal Article'],Switzerland,Enzyme,Enzyme,1262265,IM,"['Adult', 'Aged', 'Aminopeptidases/*blood', 'Female', 'Hepatitis/enzymology', 'Humans', 'Leukemia/enzymology', 'Male', 'Microsomes/enzymology', 'Middle Aged', 'Neoplasms/enzymology', 'Pregnancy', 'Radioimmunoassay', 'Regression Analysis', 'Sex Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000469432 [doi]'],ppublish,Enzyme. 1985;33(4):181-7. doi: 10.1159/000469432.,['EC 3.4.11.- (Aminopeptidases)'],,,,,,,,,,,
4064845,NLM,MEDLINE,19860121,20151119,0196-4763 (Print) 0196-4763 (Linking),6,6,1985 Nov,Detection of cytosine arabinoside resistant cells at low frequency using the bromodeoxyuridine/DNA assay.,657-62,This report describes a rapid and sensitive procedure for detection of cytosine arabinoside- (Ara-C) resistant mouse leukemia cells (L1210) in a predominantly Ara-C-sensitive population. L1210 cell lines sensitive or resistant to Ara-C were grown and treated with Ara-C in vitro or in vivo. Ara-C-resistant cells were detected as those cells with S-phase DNA content retaining the ability to incorporate bromodeoxyuridine (BrdUrd) after treatment with Ara-C. The BrdUrd incorporation ability of the S-phase cells was assessed by simultaneous flow cytometric measurement of cellular DNA content and amount of incorporated BrdUrd. The proportion of Ara-C-resistant cells was accurately estimated at frequencies approaching 10(-3).,"['Waldman, F M', 'Dolbeare, F', 'Gray, J W']","['Waldman FM', 'Dolbeare F', 'Gray JW']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cytometry,Cytometry,8102328,IM,"['Animals', 'Antibodies, Monoclonal', 'Bromodeoxyuridine', 'Cell Cycle', 'Cytarabine/*pharmacology', 'DNA, Neoplasm/analysis', 'Drug Resistance', 'Flow Cytometry', 'Leukemia L1210/pathology/*physiopathology', 'Mice']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1002/cyto.990060623 [doi]'],ppublish,Cytometry. 1985 Nov;6(6):657-62. doi: 10.1002/cyto.990060623.,"['0 (Antibodies, Monoclonal)', '0 (DNA, Neoplasm)', '04079A1RDZ (Cytarabine)', 'G34N38R2N1 (Bromodeoxyuridine)']",,,['CA 14533/CA/NCI NIH HHS/United States'],,,,,,,,
4064442,NLM,MEDLINE,19860115,20190720,0363-9762 (Print) 0363-9762 (Linking),10,9,1985 Sep,Spontaneous rupture of the spleen in primary plasma cell leukemia. Scintigraphic-pathologic correlation.,639-41,A rare case of spontaneous rupture of the spleen occurring in a patient with primary plasma cell leukemia is presented. The scintigraphic-pathologic correlation is presented together with a review of the literature.,"['Kienzle, G D', 'Stern, J', 'Cooperberg, A', 'Osborne, C A']","['Kienzle GD', 'Stern J', 'Cooperberg A', 'Osborne CA']",['eng'],"['Case Reports', 'Journal Article']",United States,Clin Nucl Med,Clinical nuclear medicine,7611109,IM,"['Female', 'Humans', 'Leukemia, Plasma Cell/*complications/pathology', 'Middle Aged', '*Organotechnetium Compounds', 'Phytic Acid', 'Radionuclide Imaging', 'Rupture, Spontaneous', 'Spleen/diagnostic imaging/*pathology', 'Splenic Rupture/diagnostic imaging/*etiology/pathology', 'Technetium']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1097/00003072-198509000-00009 [doi]'],ppublish,Clin Nucl Med. 1985 Sep;10(9):639-41. doi: 10.1097/00003072-198509000-00009.,"['0 (Organotechnetium Compounds)', '0 (technetium phytate)', '7440-26-8 (Technetium)', '7IGF0S7R8I (Phytic Acid)']",,,,,,,,,,,
4064351,NLM,MEDLINE,19860103,20191030,0300-595X (Print) 0300-595X (Linking),14,2,1985 May,Radio-iodine treatment of hyperthyroidism--a more liberal policy?,467-89,"The main and most valid evidence we have is that on direct follow-up of treated patients. This has been well done in thousands of patients in two countries with very good medical care and over long periods--10 to 15 years or more. On the other hand there is no doubt about radiation carcinogenesis, and thyroid cancer has been caused in children by low-dose x-ray therapy. The possibility of other cancer and of leukaemogenesis is also real. The evidence for this is reviewed and risk estimates given. Experimental work and radiation biology is reviewed and it is suggested that the risk of thyroid cancer from the usual radio-iodine doses given for treatment is low because of cell killing or sterilization, and animal evidence is discussed that supports this. The final position appears to be that no risk has yet been demonstrated in man and evidence in general suggests that if there is indeed a cancer risk it will be less than about 0.1%. It is suggested that this is not dissimilar to surgical risks, except that these are more immediate as compared with the long latent period for development of radiation-induced cancer. Genetic risks are also discussed and again have not been demonstrated in man from this treatment and should in any case be low. The risk to children is also considered; there is no direct evidence of risk but only small numbers have been treated--nevertheless the hypothetical risk may be counterbalanced by the benefits. Administration of radio-iodine therapy to pregnant or lactating women must be scrupulously avoided; both cause significant risks. Finally, if a more liberal policy be accepted it is worth while giving optimum treatment, and evidence is given suggesting low-dose treatment similar in effect to surgical thyroidectomy and followed temporarily if need be by anti-thyroid drug treatment.","['Halnan, K E']",['Halnan KE'],['eng'],['Journal Article'],England,Clin Endocrinol Metab,Clinics in endocrinology and metabolism,0357424,IM,"['Abnormalities, Radiation-Induced/etiology', 'Adult', 'Animals', 'Cell Survival/radiation effects', 'Child', 'Female', 'Follow-Up Studies', 'Humans', 'Hyperthyroidism/*radiotherapy', 'Iodine/metabolism', 'Iodine Radioisotopes/adverse effects/*therapeutic use', 'Leukemia, Radiation-Induced/etiology', 'Male', 'Neoplasms, Radiation-Induced/etiology', 'Pregnancy', 'Radiation Genetics', 'Radiotherapy Dosage', 'Risk', 'Thyroid Neoplasms/etiology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1016/s0300-595x(85)80043-8 [doi]'],ppublish,Clin Endocrinol Metab. 1985 May;14(2):467-89. doi: 10.1016/s0300-595x(85)80043-8.,"['0 (Iodine Radioisotopes)', '9679TC07X4 (Iodine)']",,,,,,,,,,,
4064208,NLM,MEDLINE,19860110,20190705,0009-2363 (Print) 0009-2363 (Linking),33,6,1985 Jun,Antitumor effect of implanted ethylene-vinyl alcohol copolymer matrices containing anticancer agents on Ehrlich ascites carcinoma and P388 leukemia in mice.,2490-8,,"['Miyazaki, S', 'Takeuchi, S', 'Hou, W M', 'Hashiguchi, N', 'Yokouchi, C', 'Takada, M', 'Hosokawa, M', 'Koga, Y', 'Kobayashi, H']","['Miyazaki S', 'Takeuchi S', 'Hou WM', 'Hashiguchi N', 'Yokouchi C', 'Takada M', 'Hosokawa M', 'Koga Y', 'Kobayashi H']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Chem Pharm Bull (Tokyo),Chemical & pharmaceutical bulletin,0377775,IM,"['Animals', 'Antineoplastic Agents/administration & dosage/*therapeutic use', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Drug Implants', 'Leukemia P388/drug therapy', 'Male', 'Mice', 'Polyvinyls']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1248/cpb.33.2490 [doi]'],ppublish,Chem Pharm Bull (Tokyo). 1985 Jun;33(6):2490-8. doi: 10.1248/cpb.33.2490.,"['0 (Antineoplastic Agents)', '0 (Drug Implants)', '0 (Polyvinyls)', '25067-34-9 (ethylene-vinyl alcohol copolymer)']",,,,,,,,,,,
4064198,NLM,MEDLINE,19860110,20190705,0009-2363 (Print) 0009-2363 (Linking),33,6,1985 Jun,Syntheses and biological activities of N1-(2-formylethyl)-5-fluorouracil and related compounds.,2395-402,,"['Kawase, M', 'Samejima, K', 'Okada, M', 'Ochi, K', 'Matsunaga, I']","['Kawase M', 'Samejima K', 'Okada M', 'Ochi K', 'Matsunaga I']",['eng'],['Journal Article'],Japan,Chem Pharm Bull (Tokyo),Chemical & pharmaceutical bulletin,0377775,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Cell Line', 'Cell Survival/drug effects', 'Chemical Phenomena', 'Chemistry', 'Chemistry, Physical', 'Fluorouracil/*analogs & derivatives/chemical synthesis/pharmacology', 'Leukemia P388/drug therapy/pathology', 'Mice']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1248/cpb.33.2395 [doi]'],ppublish,Chem Pharm Bull (Tokyo). 1985 Jun;33(6):2395-402. doi: 10.1248/cpb.33.2395.,"['0 (Antineoplastic Agents)', '56058-99-2 (N(1)-(2-formylethyl)-5-fluorouracil)', 'U3P01618RT (Fluorouracil)']",,,,,,,,,,,
4064088,NLM,MEDLINE,19860114,20201209,0008-7335 (Print) 0008-7335 (Linking),124,46,1985 Nov 15,[Effective pharmacotherapy of candidiasis in hemoblastoses].,1419-22,,"['Jezkova, Z', 'Chudomel, V', 'Lepsik, J', 'Lukasova, M']","['Jezkova Z', 'Chudomel V', 'Lepsik J', 'Lukasova M']",['cze'],['Journal Article'],Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,IM,"['Antibodies, Fungal/*analysis', 'Candida/*immunology', 'Candidiasis/complications/diagnosis/*drug therapy', 'Humans', 'Leukemia/*complications/immunology']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",,ppublish,Cas Lek Cesk. 1985 Nov 15;124(46):1419-22.,"['0 (Antibodies, Fungal)']",,Ucelna farmakoterapie kandidoz u hemoblastoz.,,,,,,,,,
4064049,NLM,MEDLINE,19860123,20061115,0361-090X (Print) 0361-090X (Linking),8,1-2,1985,Aneuploidy as a marker of minimal residual disease in leukemia.,303-15,"Aneuploidy as an indication of abnormal cellular DNA content has recently been confirmed to be a reliable marker of malignant cells in human solid tumors and hematologic malignancies. Flow cytometry (FCM), measuring cellular DNA content in thousands of cells within seconds, is able to safely detect the ""rare event cell,"" the rare aneuploid cell in a diploid cell population. This very fast and sensitive technique was combined with a newly developed cell separation technique. Cell separation prior to FCM enabled us to detect malignant cells at concentrations of 0.05% in blood, bone marrow, and lymph node cell suspensions of patients with leukemia. An illustration of this method is presented in conjunction with first clinical applications demonstrating that patients with minimal residual disease in clinically complete remission had significantly shorter survival times than patients in whom no minimal residual disease was detected with this new method.","['Walle, A J', 'Niedermayer, W']","['Walle AJ', 'Niedermayer W']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Cancer Detect Prev,Cancer detection and prevention,7704778,IM,"['*Aneuploidy', 'Cell Separation', 'Centrifugation, Density Gradient', 'DNA, Neoplasm/analysis', 'Flow Cytometry', 'Humans', 'Leukemia/*diagnosis/genetics/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Cancer Detect Prev. 1985;8(1-2):303-15.,"['0 (DNA, Neoplasm)']",,,,,,,,,,,
4064012,NLM,MEDLINE,19860109,20041117,0147-4006 (Print) 0147-4006 (Linking),10,,1985,Chromosome abnormalities in human leukemia as indicators of mutagenic exposure.,409-18,"It is from an analysis of these data that I proposed that losses of all or part of the long arm of chromosomes 5 and/or 7 may be indicators of exposure to mutagenic agents (8). Moreover, our analysis of the regions of chromosomes 5 and 7 that are consistently missing can define the critical region of each chromosome with some precision. Looked at from another perspective, the frequency of losses of chromosomes 5 and/or 7 may be an indicator of the proportion of ANLL in each particular population that is related to some mutagenic exposure. These aberrations are most frequent in cells of patients who were previously exposed to various cytotoxic regimens for treatment of a primary (usually malignant) disease; these patients are considered to have 2 degrees ANLL. Among patients with ANLL de novo, abnormalities of chromosomes 5 and 7 are much more frequent in older than younger patients. Finally, among adult patients with ANLL de novo, -5 and -7 are more common in those whose occupations could potentially expose them to mutagenic agents such as chemicals, pesticides, or petroleum products. With regard to chromosome 5, most of these deletions are interstitial and always include 5q23 through q31, which I have called the critical region. Although I am less certain with regard to chromosome 7, it appears that the critical region that is consistently deleted may be 7q32 or 7q34-35.","['Rowley, J D']",['Rowley JD'],['eng'],['Journal Article'],United States,Carcinog Compr Surv,Carcinogenesis; a comprehensive survey,7704086,IM,"['Adult', 'Age Factors', 'Antibiotics, Antineoplastic/adverse effects', 'Bone Marrow/pathology', 'Child', 'Chromosome Aberrations/*etiology/genetics', 'Chromosome Deletion', 'Chromosome Disorders', 'Chromosome Mapping', '*Chromosomes, Human, 4-5', '*Chromosomes, Human, 6-12 and X', 'Humans', 'Karyotyping', 'Leukemia/chemically induced/*genetics', 'Mutagens', 'Occupational Diseases/genetics']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Carcinog Compr Surv. 1985;10:409-18.,"['0 (Antibiotics, Antineoplastic)', '0 (Mutagens)']",,,,,,,,,,,
4064010,NLM,MEDLINE,19860109,20071114,0147-4006 (Print) 0147-4006 (Linking),10,,1985,Cellular responses in chronic radiation leukemogenesis.,363-79,,"['Seed, T M', 'Kaspar, L V', 'Fritz, T E', 'Tolle, D V']","['Seed TM', 'Kaspar LV', 'Fritz TE', 'Tolle DV']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Carcinog Compr Surv,Carcinogenesis; a comprehensive survey,7704086,IM,"['Animals', 'Bone Marrow/radiation effects', 'Cell Division/radiation effects', 'Cell Survival/radiation effects', 'Dogs', 'Dose-Response Relationship, Radiation', 'Gamma Rays', 'Granulocytes/radiation effects', 'Hematopoiesis/radiation effects', 'Hematopoietic Stem Cells/radiation effects', 'Leukemia, Radiation-Induced/*pathology', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Carcinog Compr Surv. 1985;10:363-79.,,,,['Y01-CO-00320/CO/NCI NIH HHS/United States'],,,,,,,,
4063995,NLM,MEDLINE,19851230,20131121,0008-5472 (Print) 0008-5472 (Linking),45,12 Pt 1,1985 Dec,Relationship of dehydroascorbic acid transport to cell lineage in lymphocytes from normal subjects and patients with chronic lymphocytic leukemia.,6507-12,"Dehydroascorbic acid is the principal form for the cellular uptake by blood cells of vitamin C. Since previous studies from this laboratory had shown a higher content of ascorbic acid and dehydroascorbic acid (DHA) in chronic lymphocytic leukemia (CLL) lymphocytes when compared to their normal counterparts, DHA uptake was characterized using these cells. The affinities of CLL and normal lymphocytes for DHA uptake were similar, as demonstrated by the Km values of 3.7 and 3.5 mM, respectively. Differences were found in other kinetic constants of DHA uptake. The Vmax for normal lymphocytes, 634 mumol/liter cell H2O/min, was approximately twice that of CLL cells, 392 mumol/liter cell H2O/min. In addition, the initial velocity and the maximal DHA uptake by normal lymphocytes were greater than that of CLL lymphocytes. These differences were not simply a reflection of lymphocyte subsets since CLL B-cells demonstrated lower uptake rates than did normal B-cells whereas CLL T-cells were similar to their normal counterparts. The alterations appear to be specific for the leukemic B-cell since they were not shared by neoplastic cells from two patients with T-cell CLL. When analyzed in light of the 3-fold greater cellular DHA and ascorbic acid content in B-cell CLL as compared to normal lymphocytes, these kinetic parameters support the occurrence of a concentration-dependent transport system for DHA. We conclude that the DHA uptake properties of CLL lymphocytes of B-cell origin serves to distinguish this lineage from T-cell CLL or normal lymphocytes.","['Stahl, R L', 'Farber, C M', 'Liebes, L F', 'Silber, R']","['Stahl RL', 'Farber CM', 'Liebes LF', 'Silber R']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Ascorbic Acid/*analogs & derivatives/metabolism', 'Biological Transport', 'Cytosol/metabolism', 'Dehydroascorbic Acid/*metabolism', 'Humans', 'Kinetics', 'Leukemia, Lymphoid/*metabolism', 'Lymphocytes/*metabolism']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Dec;45(12 Pt 1):6507-12.,"['PQ6CK8PD0R (Ascorbic Acid)', 'Y2Z3ZTP9UM (Dehydroascorbic Acid)']",,,"['CA28376/CA/NCI NIH HHS/United States', 'T32HL07151/HL/NHLBI NIH HHS/United States']",,,,,,,,
4063986,NLM,MEDLINE,19851230,20141120,0008-5472 (Print) 0008-5472 (Linking),45,12 Pt 1,1985 Dec,"Effects of the tricyclic nucleoside 6-amino-4-methyl-8-(beta-D-ribofuranosyl)- pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine on the viability and cell cycle distribution of L1210 cells in vitro.",6355-61,"TCN (1 microM) totally inhibited the growth of L1210 cells in culture and caused progressive loss of cellular viability, as indicated by a decreased clonogenicity and nigrosin dye exclusion. After 24 h or more of TCN treatment, a significant fraction of the cells had shrunk in size but did not fragment into dye-impermeable vesicles as reported previously for N1S1-67 hepatoma cells (P. G. W. Plagemann, J. Natl. Cancer Inst., 57: 1283-1295, 1976). TCN-induced growth inhibition was accompanied by a block of cell cycle progression in G1 or at the G1-S boundary. At all TCN concentrations studied, progression of cells out from behind this block was evident as a depletion of the early S-phase population in comparison to controls, while increasing the concentration of TCN (0.1 to 1 microM) led to a progressive retention of cells in S phase, suggesting a slowing of progression through S phase. The fraction of S-phase cells incorporating [methyl-3H]thymidine and the amount of [methyl-3H]thymidine incorporated per labeled cell were both decreased by TCN treatment. Increasing the concentration of TCN (0.1 to 1 microM) progressively decreased DNA synthesis and increased cell lethality. Thus it appeared that inhibition of DNA synthesis might cause the retention of cells in S phase which is associated with TCN lethality.","['Wotring, L L', 'Passiatore, J E', 'Roti Roti, J L', 'Hudson, J L', 'Townsend, L B']","['Wotring LL', 'Passiatore JE', 'Roti Roti JL', 'Hudson JL', 'Townsend LB']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Cell Cycle/drug effects', 'Cell Survival/drug effects', 'Cells, Cultured', 'DNA, Neoplasm/analysis', 'Leukemia L1210/*drug therapy/pathology', 'Mice', 'Mitotic Index/drug effects', 'Ribonucleosides/*pharmacology/therapeutic use']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Dec;45(12 Pt 1):6355-61.,"['0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (Ribonucleosides)', '2421HMY9N6 (triciribine)']",,,['CA 28756/CA/NCI NIH HHS/United States'],,,,,,,,
4063977,NLM,MEDLINE,19851230,20131121,0008-5472 (Print) 0008-5472 (Linking),45,12 Pt 1,1985 Dec,Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.,6273-9,"The effects of N-benzyladriamycin-14-valerate (AD198) and N,N-dimethyladriamycin-14-valerate (AD199), two novel lipophilic N-alkyl derivatives of Adriamycin (ADR), on cell growth and cell cycle distribution were investigated in L1210 cells grown in suspension. Following a 1-h exposure to the drug levels selected, growth inhibition was noticeable in all cultures for most or all of the observation period of 96 h. With flow cytometry, an asynchronous cell population was measured with respect to cellular DNA, RNA, and light scatter (size) properties following a 1-h incubation with the various ADR analogues. In addition, flow cytometric techniques were utilized to determine whether drug treatment altered the sensitivity of DNA in situ to acid-induced denaturation or to binding by small DNA-intercalating dyes. Unlike the parent compound ADR or its DNA-nonbinding derivative N-trifluoroacetyladriamycin-14-O-hemiadipate (AD143), the N-alkyl derivatives AD198 and AD199 only slightly affected L1210 cell cycle traverse over the first 5 h posttreatment. However, by 24 h, AD199 (0.62 micrograms/ml) caused an S- and G2 + M-phase accumulation which became more dramatic at 48 and 72 h. AD198 (3.27 micrograms/ml) also caused an accumulation of cells predominantly in G2 + M phase at longer culture times (48 to 96 h). The two half-substituted congeners N-benzyladriamycin (AD288) and N,N-dimethyladriamycin (AD280) affected L1210 cell cycle traverse over a similar time scale at concentrations of 12.3 and 4.17 micrograms/ml, respectively. AD280 blocked cells in G1 and G2 + M whereas AD288 caused predominantly a G2 + M accumulation. While neither ADR nor AD143 interfered appreciably with binding and fluorescence of the intercalating dye acridine orange, all of the N-alkyl analogues tested reduced the fluorescence signal of acridine orange-stained L1210 cells by 26 to 60%. This effect lasted, with decreasing intensity, for at least 48 h following a 1-h exposure to the drugs. In addition, while ADR appeared to stabilize DNA in situ against acid-induced denaturation, all N-alkyl derivatives, to varying degrees, tended to increase DNA denaturability. Thus alkylation at the glycoside amine combined with the lipophilic 14-valerate side chain function accounts for several new biochemical and biological properties of AD198 and AD199, relative to ADR.(ABSTRACT TRUNCATED AT 400 WORDS)","['Traganos, F', 'Israel, M', 'Silber, R', 'Seshadri, R', 'Kirschenbaum, S', 'Potmesil, M']","['Traganos F', 'Israel M', 'Silber R', 'Seshadri R', 'Kirschenbaum S', 'Potmesil M']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Cell Cycle/drug effects', 'Cell Survival/drug effects', 'Cells, Cultured', 'Chromatin/ultrastructure', 'Doxorubicin/*analogs & derivatives/pharmacology/therapeutic use', 'Hydrogen-Ion Concentration', 'Leukemia L1210/*drug therapy/pathology', 'Mice', 'Nucleic Acid Denaturation', 'Structure-Activity Relationship']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Dec;45(12 Pt 1):6273-9.,"['0 (Chromatin)', '80168379AG (Doxorubicin)']",,,"['CA32055/CA/NCI NIH HHS/United States', 'CA37082/CA/NCI NIH HHS/United States', 'CA37209/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4063971,NLM,MEDLINE,19851230,20131121,0008-5472 (Print) 0008-5472 (Linking),45,12 Pt 1,1985 Dec,Radical dimer rescue of toxicity and improved therapeutic index of adriamycin in tumor-bearing mice.,6200-4,"The product of adriamycin (ADR) reductive glycosidic cleavage is the pharmacologically inactive 7-deoxyadriamycin aglycone. Bi(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl) (DHM3) is a radical dimer which reacts with ADR in vitro to produce this aglycone. We utilized DHM3 to prevent ADR toxicity in mice. CD2F1 male mice were given a single dose of ADR, 25 mg/kg i.p., which was acutely lethal as indicated by a median survival time of 7 days. DHM3 administered as a single i.p. dose of 50 mg/kg 15 or 30 min following ADR provided significant protection with median survival times greater than 9 wk. Mice bearing ascitic L1210 leukemic cells were given ADR, 0, 6.6, 15, or 25 mg/kg i.p. 1 day following inoculation of tumor. DHM3 administered as a single 50 mg/kg i.p. dose 20 min after ADR had no significant effect on ADR efficacy at the lower dose range (% treated versus control = 171 and 285 for 6.6 and 15.0 mg/kg, respectively). Less than 15% of the animals in these treatment groups were long-term survivors. However, following high doses of ADR (25 mg/kg), DHM3 protected mice from ADR lethality and over 70% of animals were long-term survivors. The determination of parent ADR and ADR aglycone content in several tissues indicated that the concentration of ADR was reduced in those animals that received DHM3 15 min after ADR. Correspondingly an increase in ADR aglycone concentration in each tissue resulted from DHM3 treatment. DHM3 represents a novel class of compounds that can ameliorate ADR toxicity and has potential use as a rescue agent.","['Averbuch, S D', 'Gaudiano, G', 'Koch, T H', 'Bachur, N R']","['Averbuch SD', 'Gaudiano G', 'Koch TH', 'Bachur NR']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', '*Doxorubicin/antagonists & inhibitors/therapeutic use/toxicity', 'Free Radicals', 'Leukemia L1210/drug therapy', 'Male', 'Mice', 'Morpholines/*therapeutic use', 'Naphthacenes/metabolism']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Dec;45(12 Pt 1):6200-4.,"['0 (Free Radicals)', '0 (Morpholines)', '0 (Naphthacenes)', '24385-10-2 (adriamycin aglycone)', '80168379AG (Doxorubicin)', '99634-12-5 (bis(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl))']",,,['CA-24665/CA/NCI NIH HHS/United States'],,,,,,,,
4063954,NLM,MEDLINE,19860116,20190816,0165-4608 (Print) 0165-4608 (Linking),18,4,1985 Dec,Chromosome 1 heterochromatin variants and cancer: a reassessment.,325-31,"Evidence for a relationship between chromosome #1 heterochromatin polymorphisms and cancer has been reviewed. Eighty-four of 135 (62%) patients with epithelial malignancies were heteromorphic for C-band size compared with 38 of 107 (36%) controls (significant at the 0.1% level). However, only 33 of 67 (49%) patients with nonepithelial malignancies were heteromorphic (not significantly different from controls). Similarly, the incidence of partial inversions of the C-band region in one or both homologs was significantly greater than controls [28 of 107 (26%)] for patients with epithelial [66 of 135 (49%)] but not nonepithelial [25 of 67 (37%)] malignancies. However, when the presence of either or both size heteromorphism and inversions were assessed, the incidence was significantly higher in patients with nonepithelial [46 of 67 (69%), including 11 of 11 patients with leukemia or myeloproliferative disorders] as well as epithelial [112 of 135 (83%)] malignancies compared with controls [52 of 107 (49%)]. Forty-seven of the patients did not differ significantly from controls with respect to the incidence of chromosome #1 heteromorphism as revealed by the Giemsa-11 technique. However, 26 patients assessed for their chromosome #1 lateral asymmetry pattern differed significantly from controls, having a higher incidence of compound asymmetry with a large proximal and small distal block and a lower incidence of simple asymmetry.","['Atkin, N B', 'Brito-Babapulle, V']","['Atkin NB', 'Brito-Babapulle V']",['eng'],['Journal Article'],United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Chromatin/*genetics', 'Chromosome Banding', 'Chromosome Inversion', '*Chromosomes, Human, 1-3', 'Humans', 'Karyotyping', 'Neoplasms/*genetics', 'Oncogenes', '*Polymorphism, Genetic']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0165-4608(85)90154-2 [pii]', '10.1016/0165-4608(85)90154-2 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Dec;18(4):325-31. doi: 10.1016/0165-4608(85)90154-2.,['0 (Chromatin)'],,,,,,,,,,,
4063953,NLM,MEDLINE,19860116,20190816,0165-4608 (Print) 0165-4608 (Linking),18,4,1985 Dec,Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia: three new cases.,303-6,"Several recent reports have described cases of acute nonlymphocytic leukemia with a unique chromosome translocation, t(6;9)(p23;q34). We have studied three additional patients who have acute nonlymphocytic leukemia and t(6;9)(p23;q34). Our findings provide additional support for the suggestion that this translocation is yet another distinct cytogenetic abnormality associated with myeloproliferative disorders.","['Carroll, A J', 'Castleberry, R P', 'Prchal, J T', 'Finley, W H']","['Carroll AJ', 'Castleberry RP', 'Prchal JT', 'Finley WH']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Acute Disease', 'Adult', 'Child', '*Chromosomes, Human, 6-12 and X', 'Female', 'Humans', 'Karyotyping', 'Leukemia/*genetics', 'Male', '*Translocation, Genetic']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']","['0165-4608(85)90151-7 [pii]', '10.1016/0165-4608(85)90151-7 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Dec;18(4):303-6. doi: 10.1016/0165-4608(85)90151-7.,,,,['CA-13148/CA/NCI NIH HHS/United States'],,,,,,,,
4063529,NLM,MEDLINE,19860121,20210216,0006-4971 (Print) 0006-4971 (Linking),66,6,1985 Dec,"Quantitation of apo-, mono-, and diferric transferrin by polyacrylamide gradient gel electrophoresis in patients with disorders of iron metabolism.",1445-51,"We have developed a polyacrylamide gradient gel electrophoretic method to quantitate apo-, mono-, and diferric transferrin based upon differences in their molecular size. Purified transferrin saturated to different extents (3% to 98%) with iron showed proportions of the three forms as predicted from an approximately random distribution of iron between the two metal-binding sites. The iron distributions in sera of 14 normal individuals similarly correlated with the predicted values. In contrast, 22 of 43 patients with diseases associated with abnormalities in iron or transferrin metabolism had a disproportionate increase in monoferric transferrin. This abnormality occurred in seven of nine patients who had received bone marrow transplants, seven of 14 with chronic liver disease, and eight of nine menstruating women with probable iron deficiency anemia. Interestingly, 11 patients with malabsorption or chronic renal disease had normal iron distributions. The finding of abnormal distributions of iron on transferrin suggests that gradient gel analysis may be a useful tool for studying the physiologic mechanisms controlling iron utilization.","['DiRusso, S C', 'Check, I J', 'Hunter, R L']","['DiRusso SC', 'Check IJ', 'Hunter RL']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Blood,Blood,7603509,IM,"['Anemia, Hypochromic/*blood', '*Apoproteins', 'Electrophoresis, Polyacrylamide Gel', 'Female', 'Humans', 'Iron/blood', 'Kidney Diseases/blood', 'Leukemia/blood', 'Liver Diseases/blood', 'Male', 'Nutrition Disorders/blood', 'Transferrin/*analysis']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['S0006-4971(20)80984-7 [pii]'],ppublish,Blood. 1985 Dec;66(6):1445-51.,"['0 (Apoproteins)', '0 (Transferrin)', '0 (apotransferrin)', '0 (diferric transferrin)', 'E1UOL152H7 (Iron)']",,,,,,,,,,,
4063527,NLM,MEDLINE,19860121,20210216,0006-4971 (Print) 0006-4971 (Linking),66,6,1985 Dec,t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association.,1409-13,"A number of specific chromosomal abnormalities have been associated with distinctive clinical and/or morphological subtypes of acute nonlymphocytic leukemia (ANLL) in recent years. We have studied three patients with ANLL and t(1;3)(p36;q21). Each had weakness as their major complaint, a moderately severe anemia and, for ANLL, a relatively high platelet count. All three demonstrated abnormalities of the megakaryocytic, erythroid and granulocytic lineages. Most striking was the dysmegakaryocytopoiesis. The blasts in all three patients showed relatively few azurophilic granules, one to four prominent nucleoli, and rare peroxidase positivity. No patient had Auer rods. No patient responded to standard chemotherapy regimens. The data suggest that t(1;3)(p36;q21) identifies a new cytogenetic-clinicopathologic subtype of ANLL.","['Bloomfield, C D', 'Garson, O M', 'Volin, L', 'Knuutila, S', 'de la Chapelle, A']","['Bloomfield CD', 'Garson OM', 'Volin L', 'Knuutila S', 'de la Chapelle A']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Blood,Blood,7603509,IM,"['Acute Disease', 'Adult', 'Anemia/etiology', 'Cell Nucleus', 'Chromosome Banding', 'Chromosomes, Human, 1-3', 'Erythrocytes, Abnormal', 'Female', 'Humans', 'Karyotyping', 'Leukemia/complications/*genetics', 'Male', 'Megakaryocytes/cytology', 'Middle Aged', '*Translocation, Genetic']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['S0006-4971(20)80979-3 [pii]'],ppublish,Blood. 1985 Dec;66(6):1409-13.,,,,,,,,,,,,
4063525,NLM,MEDLINE,19860121,20210216,0006-4971 (Print) 0006-4971 (Linking),66,6,1985 Dec,Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia.,1362-70,"Fourteen patients with acute nonlymphocytic leukemia (ANLL) or dysmyelopoietic syndromes were found to have abnormalities involving the long arm of chromosome 3. In eight patients, the structural rearrangements involved both bands 3q21 and 3q26 and included t(3;3) (four patients), inv(3) (three patients), and ins(5;3) (one patient). Before treatment, seven of these eight patients had platelet counts above 100,000 per microliter, five had normal or elevated platelet counts, and four had significantly elevated platelet counts (600,000 to 1,731,000 per microliter). In each of the eight cases, normal or elevated platelet counts were associated with marked abnormalities of megakaryocytopoiesis, including increased numbers of megakaryocytes and numerous micromegakaryocytes. Classification within the French-American-British system was difficult in most of these cases; however, the leukemia in five of the eight patients with abnormalities of chromosome 3 that involved both bands 3q21 and 3q26 was classified as M4. The remaining six of the 14 patients had translocations between chromosome 3 and another chromosome. None involved both bands 3q21 and 3q26, and a break in either q21 or q26 was noted in only two patients. One of the six, who had ANLL (M4) with a normal platelet count, had a 3;5 translocation which involved band 3q25. These data suggest that in patients with ANLL, abnormalities of chromosome 3 which simultaneously involve bands 3q21 and 3q26 are associated with unusually high platelet counts.","['Bitter, M A', 'Neilly, M E', 'Le Beau, M M', 'Pearson, M G', 'Rowley, J D']","['Bitter MA', 'Neilly ME', 'Le Beau MM', 'Pearson MG', 'Rowley JD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Blood,Blood,7603509,IM,"['Adult', 'Aged', 'Chromosome Aberrations', 'Chromosomes, Human, 1-3', 'Erythrocytes, Abnormal', 'Female', 'Humans', 'Karyotyping', 'Leukemia/*genetics', 'Male', 'Megakaryocytes', 'Middle Aged', 'Myelodysplastic Syndromes/*genetics', 'Platelet Count', 'Translocation, Genetic']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['S0006-4971(20)80972-0 [pii]'],ppublish,Blood. 1985 Dec;66(6):1362-70.,,,,"['CA16910/CA/NCI NIH HHS/United States', 'CA25568/CA/NCI NIH HHS/United States']",,,,,,,,
4063466,NLM,MEDLINE,19860117,20061115,0753-3322 (Print) 0753-3322 (Linking),39,4,1985,[A case of septicemia by a Corynebacterium of the J. K. group].,173-6,"We have reported a case of septicaemia caused by ""Corynebacterium of group J. K."" in a patient with acute myeloblastic leukaemia. Recent studies by Riley (1978) have shown that the corynebacteria, saprophytes of the skin and mucosa have a resistance to common antibiotics. Corynebacteria that are only sensitive to virginiamycin and vancomycin are a potential danger for immunosuppressed patients and patients with artificial heart valves, the appropriate choice of antibiotic can be difficult in these patients.","['Mathieu, D', 'Misset, J L', 'Chardans, B', 'Machover, D', 'Goldschmidt, E', 'Jacques, L']","['Mathieu D', 'Misset JL', 'Chardans B', 'Machover D', 'Goldschmidt E', 'Jacques L']",['fre'],"['Case Reports', 'English Abstract', 'Journal Article']",France,Biomed Pharmacother,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,8213295,IM,"['Alcoholism/complications', 'Anti-Bacterial Agents/pharmacology', 'Corynebacterium/drug effects/isolation & purification', 'Corynebacterium Infections/*diagnosis', 'Diagnosis, Differential', 'Humans', 'Male', 'Middle Aged', 'Sepsis/*diagnosis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Biomed Pharmacother. 1985;39(4):173-6.,['0 (Anti-Bacterial Agents)'],,A propos d'un cas de septicemie a Corynebacterium du groupe J. K.,,,,,,,,,
4063213,NLM,MEDLINE,19860121,20190704,0007-1048 (Print) 0007-1048 (Linking),61,3,1985 Nov,Erythrocyte fragmentation in disseminated intravascular coagulation (DIC) in acute leukaemia.,593-4,,"['Rodeghiero, F', 'Castaman, G', 'Tonellato, L', 'Dini, E']","['Rodeghiero F', 'Castaman G', 'Tonellato L', 'Dini E']",['eng'],['Letter'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Acute Disease', 'Disseminated Intravascular Coagulation/*blood', 'Erythrocytes/*pathology', 'Humans', 'Leukemia/*blood']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02871.x [doi]'],ppublish,Br J Haematol. 1985 Nov;61(3):593-4. doi: 10.1111/j.1365-2141.1985.tb02871.x.,,,,,,,,,,,,
4063211,NLM,MEDLINE,19860121,20190704,0007-1048 (Print) 0007-1048 (Linking),61,3,1985 Nov,Low-dose Ara-C in treatment of overt acute leukaemia.,584-6,,"['Ruiz-Arguelles, G J']",['Ruiz-Arguelles GJ'],['eng'],['Letter'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Acute Disease', 'Cytarabine/*administration & dosage', 'Humans', 'Leukemia/*drug therapy']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02866.x [doi]'],ppublish,Br J Haematol. 1985 Nov;61(3):584-6. doi: 10.1111/j.1365-2141.1985.tb02866.x.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4063210,NLM,MEDLINE,19860121,20190704,0007-1048 (Print) 0007-1048 (Linking),61,3,1985 Nov,Collection of circulating haemopoietic cells after chemotherapy in acute non-lymphocytic leukaemia.,577-8,,"['Bernard, P', 'Reiffers, J', 'Vezon, G', 'Sarrat, A', 'Marit, G', 'David, B', 'Broustet, A']","['Bernard P', 'Reiffers J', 'Vezon G', 'Sarrat A', 'Marit G', 'David B', 'Broustet A']",['eng'],['Letter'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Adolescent', 'Adult', 'Blood Component Removal', 'Hematopoietic Stem Cells/*pathology', 'Humans', 'Leukemia/*drug therapy']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02861.x [doi]'],ppublish,Br J Haematol. 1985 Nov;61(3):577-8. doi: 10.1111/j.1365-2141.1985.tb02861.x.,,,,,,,,,,,,
4063012,NLM,MEDLINE,19850909,20061115,0042-8809 (Print) 0042-8809 (Linking),31,3,1985 May-Jun,[Platelet adenosine desaminase in various hematological diseases].,26-30,"Activity of adenosine deaminase (EC 3.5.4.4) was studied in thrombocytes of donors and patients with various hematological diseases. The enzymatic activity was decreased in acute leukemia, chronic myeloleukemia, chronic leukemia and blast transformation myeloma, microspherocytic and hypoplastic anemias. Variable level of the activity was observed in chronic lympholeukemia and non-Hodgkin disease. In all the diseases studied functions of thrombocytes were altered after treatment with various aggregating agents (ADP, thrombin, collagen, adrenaline, ristomycin).","['Sokovnina, Ia M', 'Pestina, T I', 'Chizhova, A I', 'Tentsova, I A', 'Lagutina, N Ia']","['Sokovnina IaM', 'Pestina TI', 'Chizhova AI', 'Tentsova IA', 'Lagutina NIa']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Vopr Med Khim,Voprosy meditsinskoi khimii,0416601,IM,"['Adenosine Deaminase/*blood', 'Anemia/blood/enzymology', 'Blood Platelets/*enzymology', 'Hematologic Diseases/blood/*enzymology', 'Humans', 'Lymphoproliferative Disorders/blood/enzymology', 'Myeloproliferative Disorders/blood/enzymology', 'Nucleoside Deaminases/*blood', 'Platelet Aggregation']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Vopr Med Khim. 1985 May-Jun;31(3):26-30.,"['EC 3.5.4.- (Nucleoside Deaminases)', 'EC 3.5.4.4 (Adenosine Deaminase)']",,Adenozindezaminaza trombotsitov krovi pri razlichnykh gematologicheskikh zabolevaniiakh.,,,,,,,,,
4063011,NLM,MEDLINE,19850919,20131121,0361-7742 (Print) 0361-7742 (Linking),181,,1985,Effect of biological response modifier-streptococcal preparation OK-432 on NK/K cell system of gnotobiotic miniature swine.,337-41,,"['Kim, Y B']",['Kim YB'],['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Prog Clin Biol Res,Progress in clinical and biological research,7605701,IM,"['Animals', 'Antibody-Dependent Cell Cytotoxicity/*drug effects', 'Biological Products/*pharmacology', 'Cell Line', '*Germ-Free Life', 'Humans', 'Killer Cells, Natural/drug effects/*immunology', 'Leukemia, Lymphoid', 'Picibanil/*pharmacology', 'Swine', 'Swine, Miniature']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Prog Clin Biol Res. 1985;181:337-41.,"['0 (Biological Products)', '39325-01-4 (Picibanil)']",,,"['CA-38336/CA/NCI NIH HHS/United States', 'HD-19420/HD/NICHD NIH HHS/United States']",,,,,,,,
4062971,NLM,MEDLINE,19851218,20190623,0006-2952 (Print) 0006-2952 (Linking),34,22,1985 Nov 15,Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists.,3973-8,"We have characterized the antiproliferative effects of the phenothiazines, a group of antipsychotic drugs possessing a wide range of pharmacological actions. The phenothiazines inhibited both the proliferation and clonogenicity of L1210 leukemic lymphocytes. This effect was dependent on both time of exposure and concentration of drug. Clonogenicity of cells in the logarithmic phase of growth was inhibited by greater than 99% at a concentration of drug that had no effect on cells in the plateau phase of growth. Human and murine cell lines, grown either in suspension or in monolayers, were equally susceptible. Calmodulin (CaM), purified from L1210 cells by preparative polyacrylamide gel electrophoresis, had sensitivity to inhibition by phenothiazines similar to that reported for CaM prepared from brain. The order of potency was trifluoperazine greater than or equal to fluphenazine greater than chlorpromazine greater than chlorpromazine-sulfoxide. As a class, these drugs were less potent antagonists of CaM than was the bee venom polypeptide, melittin. The antiproliferative effects of phenothiazines were similar to the anticalmodulin effects. Thus, the same order of potencies was seen for both effects; the shapes of the dose-response curves were similarly steep and the effects of excess calcium on the inhibition of both were identical. These studies add pharmacological support for CaM being a potential intracellular target for the antiproliferative effect of the phenothiazines.","['Hait, W N', 'Lee, G L']","['Hait WN', 'Lee GL']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Biochem Pharmacol,Biochemical pharmacology,0101032,IM,"['Animals', 'Calcium/pharmacology', 'Calmodulin/*antagonists & inhibitors', 'Cell Division/drug effects', 'Cell Line', 'Dose-Response Relationship, Drug', 'Humans', 'Leukemia L1210/pathology', 'Mice', 'Phenothiazines/*pharmacology', 'Protein Kinase C/analysis']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']","['0006-2952(85)90374-0 [pii]', '10.1016/0006-2952(85)90374-0 [doi]']",ppublish,Biochem Pharmacol. 1985 Nov 15;34(22):3973-8. doi: 10.1016/0006-2952(85)90374-0.,"['0 (Calmodulin)', '0 (Phenothiazines)', 'EC 2.7.11.13 (Protein Kinase C)', 'SY7Q814VUP (Calcium)']",,,['CA-08341-19/CA/NCI NIH HHS/United States'],,,,,,,,
4062941,NLM,MEDLINE,19851220,20190612,0006-291X (Print) 0006-291X (Linking),132,2,1985 Oct 30,Restorative effects of defective autologous lymphocyte cytotoxicity by calmodulin antagonists.,620-7,"Reactivity of lymphocytes from paired living patients with ovarian carcinoma on autologous cancer cells was examined using six established cell lines. Although allogeneic lymphocytes had the capacity to lyse other cultured cancer cells, autologous lymphocytes were found to be unable to lyse their own cultured cancer cells. The defective activity of autologous lymphocytes was restored by preincubation of autologous target cells but not autologous effector cells with the calmodulin inhibitors W-5 or W-7.","['Kikuchi, Y', 'Oomori, K', 'Kizawa, I', 'Kato, K']","['Kikuchi Y', 'Oomori K', 'Kizawa I', 'Kato K']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,IM,"['Adenocarcinoma/immunology', 'Adult', 'Animals', 'Calmodulin/*antagonists & inhibitors/physiology', 'Cell Line', 'Cystadenocarcinoma/immunology', 'Cytotoxicity, Immunologic/drug effects', 'Female', 'Humans', 'Killer Cells, Natural/drug effects/*immunology', 'Leukemia/immunology', 'Mice', 'Mice, Inbred BALB C', 'Middle Aged', 'Ovarian Neoplasms/immunology', 'Sulfonamides/*pharmacology', 'Uterine Neoplasms/immunology']",,1985/10/30 00:00,1985/10/30 00:01,['1985/10/30 00:00'],"['1985/10/30 00:00 [pubmed]', '1985/10/30 00:01 [medline]', '1985/10/30 00:00 [entrez]']","['0006-291X(85)91178-7 [pii]', '10.1016/0006-291x(85)91178-7 [doi]']",ppublish,Biochem Biophys Res Commun. 1985 Oct 30;132(2):620-7. doi: 10.1016/0006-291x(85)91178-7.,"['0 (Calmodulin)', '0 (Sulfonamides)', '65595-90-6 (W 7)', '7B979CWO03 (N-(6-aminohexyl)-1-naphthalenesulfonamide)']",,,,,,,,,,,
4062886,NLM,MEDLINE,19851204,20190501,0264-6021 (Print) 0264-6021 (Linking),231,1,1985 Oct 1,Effects of bis(guanylhydrazones) on the activity and expression of ornithine decarboxylase.,213-6,"Derivatives of glyoxal bis(guanylhydrazone) (GBG), such as methylglyoxal bis(guanylhydrazone) and ethylglyoxal bis(guanylhydrazone), are potent inhibitors of S-adenosylmethionine decarboxylase (EC 4.1.1.50), the key enzyme required for the synthesis of spermidine and spermine. These compounds, but not the parent compound, induce a massive accumulation of putrescine, partly by blocking the conversion of putrescine into spermidine, but also by strikingly stimulating ornithine decarboxylase (ODC; EC 4.1.1.17) activity. The mechanism of the stimulation of ODC activity and enhanced accumulation of the enzyme protein apparently involved a distinct stabilization of the enzyme against intracellular degradation. However, although the parent compound GBG also stabilized ODC, it powerfully inhibited the enzyme activity and the accumulation of immunoreactive protein in cultured L1210 leukaemia cells. Kinetic considerations indicated that, in addition to the stabilization, all three compounds, GBG in particular, inhibited the expression of ODC. It is unlikely that the decreased rate of synthesis of ODC was attributable to almost unaltered amounts of mRNA in drug-treated cells, thus supporting the view that especially GBG apparently depressed the expression of ODC at some post-transcriptional level.","['Nikula, P', 'Alhonen-Hongisto, L', 'Janne, J']","['Nikula P', 'Alhonen-Hongisto L', 'Janne J']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Biochem J,The Biochemical journal,2984726R,IM,"['Animals', 'Cells, Cultured', 'Enzyme Activation/drug effects', 'Half-Life', 'Kinetics', 'Leukemia L1210/enzymology', 'Mice', 'Mitoguazone/*analogs & derivatives/*pharmacology', 'Ornithine Decarboxylase/*metabolism', 'Ornithine Decarboxylase Inhibitors', 'RNA, Messenger/metabolism']",PMC1152727,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1042/bj2310213 [doi]'],ppublish,Biochem J. 1985 Oct 1;231(1):213-6. doi: 10.1042/bj2310213.,"['0 (Ornithine Decarboxylase Inhibitors)', '0 (RNA, Messenger)', '14358-42-0 (glyoxal bis(guanylhydrazone))', '1945-68-2 (ethylglyoxal bis(guanylhydrazone))', 'EC 4.1.1.17 (Ornithine Decarboxylase)', 'OD5Q0L447W (Mitoguazone)']",,,['1 RO1 CA37695/CA/NCI NIH HHS/United States'],,,,,,,,
4062507,NLM,MEDLINE,19851219,20131121,0004-069X (Print) 0004-069X (Linking),33,3,1985,Phospholipids and cholesterol in the liver mitochondrial fraction in mice with transplantable leukemia P 388.,429-34,"BDF1 hybrid mice, were given 10(4) lymphatic leukemia cells P 388 intraperitoneally. They were killed on 5th day and 11th day of the experiment. In the plasma the level of cholesterol was determined. Inner organs, i.e. liver, spleen, lymph nodes and thymus were verified histopathologically. Mitochondrial fraction lipids were extracted from liver and separated by thin layer chromatography. It was proved that the amount of mitochondrial fraction lipids of leukemic mice was considerably higher than in healthy mice and it increased together with the process of the neoplasma. In the group of leukemic animals the level of phosphatidylcholine, phosphatidylethanolamine, cholesterol and sphingomyelin increased in comparison with healthy mice. The results concerning phospholipids and cholesterol level in leukemic animals were interpreted in the aspect of the interaction of these compounds with vitamin E, polyunsaturated fatty acids and free radicals.","['Madej, J A', 'Berezecka, J', 'Sobiech, K A', 'Kaszubkiewicz, C', 'Jopek, Z', 'Klimentowski, S']","['Madej JA', 'Berezecka J', 'Sobiech KA', 'Kaszubkiewicz C', 'Jopek Z', 'Klimentowski S']",['eng'],['Journal Article'],Switzerland,Arch Immunol Ther Exp (Warsz),Archivum immunologiae et therapiae experimentalis,0114365,IM,"['Animals', 'Cholesterol/analysis/blood', 'Female', 'Intracellular Membranes/analysis', 'Leukemia P388/*metabolism', 'Leukemia, Experimental/*metabolism', 'Membrane Lipids/analysis', 'Mice', 'Mitochondria, Liver/*analysis', 'Phospholipids/analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Arch Immunol Ther Exp (Warsz). 1985;33(3):429-34.,"['0 (Membrane Lipids)', '0 (Phospholipids)', '97C5T2UQ7J (Cholesterol)']",,,,,,,,,,,
4062460,NLM,MEDLINE,19851125,20071114,0003-9926 (Print) 0003-9926 (Linking),145,11,1985 Nov,Ten-year survival in multiple myeloma.,2073-4,"Of 305 consecutive patients with symptomatic multiple myeloma treated between 1965 and 1974, a total of 4% survived ten years. Virtually all were less than 65 years old, presented with low or intermediate stage disease, and responded well to chemotherapy. Prolonged unmaintained remissions, slow tumor growth, and recontrol of relapsing disease were common. Acute leukemia caused the death of two of six long-term survivors. Patients treated since 1974 lived longer than those seen previously, a finding attributed to better control of complications and more effective combination chemotherapy.","['Alexanian, R']",['Alexanian R'],['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Arch Intern Med,Archives of internal medicine,0372440,IM,"['Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Female', 'Humans', 'Longevity', 'Male', 'Middle Aged', 'Multiple Myeloma/drug therapy/*mortality', 'Recurrence', 'Texas']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Arch Intern Med. 1985 Nov;145(11):2073-4.,,,,['CA-03195/CA/NCI NIH HHS/United States'],,,,,,,,
4062396,NLM,MEDLINE,19851220,20190628,0003-4975 (Print) 0003-4975 (Linking),40,5,1985 Nov,Prospective randomized study of open lung biopsy versus empirical antibiotic therapy for acute pneumonitis in nonneutropenic cancer patients.,422-8,"Diffuse pulmonary infiltrates and acute respiratory compromise frequently occur in patients with cancer who are undergoing chemotherapy, and treatment remains controversial. We initiated a prospective randomized trial in 22 nonneutropenic patients to compare the efficacy of immediate open lung biopsy with that of empirical trimethoprim-sulfamethoxazole and erythromycin therapy with delayed open lung biopsy if no clinical improvement occurred after 4 days of therapy. Diagnoses included non-Hodgkin's lymphoma (15 patients), T-cell lymphoma (2), acute lymphoblastic leukemia (3), Hodgkin's disease (1), and breast cancer (1). The median age was 40 years, and fever (18) and tachypnea (13) were the most frequent signs. Median room air arterial oxygen tension in 18 hypoxic patients was 53 mm Hg; 19 patients had diffuse pulmonary infiltrates. Eight of the 10 patients randomized to empirical antibiotic therapy showed improvement after 4 days. The 2 patients whose condition did not improve and who underwent delayed open lung biopsy had Pneumocystis carinii pneumonia. One of them did show improvement, and the other died of respiratory failure. Time to clinical resolution in the 9 surviving patients was 14 days; 4 required prolonged ventilation (longer than 24 hours). Findings for the 12 patients randomized to immediate open lung biopsy were P. carinii pneumonia in 7 and nonspecific pneumonitis in 5; there were 3 deaths related to open lung biopsy. Time to resolution in the surviving patients was 13 days for those with P. carinii pneumonia and 5 days for those with nonspecific pneumonitis; 7 required prolonged ventilation.(ABSTRACT TRUNCATED AT 250 WORDS)","['Potter, D', 'Pass, H I', 'Brower, S', 'Macher, A', 'Browne, M', 'Thaler, M', 'Cotton, D', 'Hathorn, J', 'Wesley, R', 'Longo, D']","['Potter D', 'Pass HI', 'Brower S', 'Macher A', 'Browne M', 'Thaler M', 'Cotton D', 'Hathorn J', 'Wesley R', 'Longo D', 'et al.']",['eng'],"['Clinical Trial', 'Comparative Study', 'Journal Article', 'Randomized Controlled Trial']",Netherlands,Ann Thorac Surg,The Annals of thoracic surgery,15030100R,IM,"['Acute Disease', 'Adult', 'Aged', 'Anti-Bacterial Agents/*therapeutic use', 'Biopsy/methods', 'Child', 'Child, Preschool', 'Humans', 'Lung/*pathology', 'Middle Aged', 'Neoplasms/*complications', 'Pneumonia/*complications/drug therapy/pathology', 'Prospective Studies', 'Random Allocation']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['S0003-4975(10)60096-3 [pii]', '10.1016/s0003-4975(10)60096-3 [doi]']",ppublish,Ann Thorac Surg. 1985 Nov;40(5):422-8. doi: 10.1016/s0003-4975(10)60096-3.,['0 (Anti-Bacterial Agents)'],,,,,,,,,,,
4062319,NLM,MEDLINE,19851213,20131121,0385-0684 (Print) 0385-0684 (Linking),12,11,1985 Nov,[Antitumor effect of etoposide and its analogs].,2196-201,"The antitumor activity of etoposide and its nine analogs including podophyllotoxin, the mother compound of etoposide, against Hela cells and mouse leukemia L1210 was investigated in vitro and in vivo, respectively. Etoposide showed antitumor effect against HeLa cells. Against mouse leukemia L1210, etoposide showed an excellent antitumor effect and about 80% of treated animals survived beyond the test period of 2 months. Podophyllotoxin, 4'-demethylpodophyllotoxin and 4'-demethylepipodophyllotoxin excluding an ethylidene glucose group had more anti-HeLa, but much less anti-L1210 activity than etoposide. 3'-Demethyletoposide showed only 1/25 of the anti-HeLa activity of etoposide, while the anti-L1210 activity was almost the same as that of etoposide. The anti-HeLa activity of 4'-demethylepipodophyllotoxin beta-D-glucoside excluding on ethylidene group and 4'-demethylepipodophyllotoxin ethylidene alpha-D-glucoside were only 1/180 and 1/26 that of etoposide, respectively. Their anti-L1210 activities were also low and the maximum T/C values were 154 and 135%, respectively. Both of two picro compounds, picroetoposide and 4'-demethylepipicropodophyllotoxin beta-D-glucoside, hardly showed any antitumor activity. 4'-O-glucuronyletoposide, the main metabolite of etoposide in humans and dogs, had little anti-HeLa activity.","['Kuramochi, H', 'Okamoto, K', 'Nishikawa, K', 'Nagamine, S', 'Takahashi, K']","['Kuramochi H', 'Okamoto K', 'Nishikawa K', 'Nagamine S', 'Takahashi K']",['jpn'],"['Comparative Study', 'English Abstract', 'Journal Article']",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Animals', 'Cell Division/drug effects', 'Dogs', 'Etoposide/analogs & derivatives/*pharmacology', 'HeLa Cells/drug effects', 'Humans', 'Leukemia L1210/*drug therapy', 'Male', 'Mice', 'Podophyllotoxin/*analogs & derivatives/pharmacology', 'Structure-Activity Relationship']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Nov;12(11):2196-201.,"['6PLQ3CP4P3 (Etoposide)', 'L36H50F353 (Podophyllotoxin)']",,,,,,,,,,,
4062318,NLM,MEDLINE,19851213,20061115,0385-0684 (Print) 0385-0684 (Linking),12,11,1985 Nov,[Antitumor effect of the tumor necrosis factor against various types of human cancer cells].,2185-9,"The antitumor activity of tumor necrosis factor (TNA) against various human cancer cells (32 cases) was investigated by 51Cr cytotoxic release assay and tumor stem cell assay. Over 50% sensitivity (the ratio of cytotoxicity for L929 cells) was shown by 4 of 14 cases of gastric cancer (28.6%), 7 of 9 cases of leukemic cells (77.8%), and 1 case each of pancreatic carcinoma and ovarian cancer. However, scarcely any sensitivity was shown by APL, a portion of the gastric cancer cells, normal lymphocytes or colony-forming cells tested. No correspondence was observed between the histological type of the cancer and TNF sensitivity. The above results seem to confirm the significant antitumor activity of TNF against human cancer cells.","['Watanabe, N', 'Niitsu, Y', 'Neda, H', 'Sone, H', 'Yamauchi, N', 'Umetsu, T', 'Urushizaki, I']","['Watanabe N', 'Niitsu Y', 'Neda H', 'Sone H', 'Yamauchi N', 'Umetsu T', 'Urushizaki I']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Adenocarcinoma/pathology', 'Adult', 'Aged', '*Colony-Forming Units Assay', 'Cytotoxicity, Immunologic', 'Female', 'Glycoproteins/*pharmacology', 'Humans', 'Leukemia/pathology', 'Lung Neoplasms/pathology', 'Male', 'Middle Aged', 'Ovarian Neoplasms/pathology', 'Pancreatic Neoplasms/pathology', 'Stomach Neoplasms/pathology', 'Tumor Necrosis Factor-alpha', '*Tumor Stem Cell Assay']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Nov;12(11):2185-9.,"['0 (Glycoproteins)', '0 (Tumor Necrosis Factor-alpha)']",,,,,,,,,,,
4062310,NLM,MEDLINE,19851213,20211203,0385-0684 (Print) 0385-0684 (Linking),12,11,1985 Nov,[Suppression of tumor growth by peritoneal macrophages isolated from mice treated with carboxyethylgermanium sesquioxide (Ge-132)].,2122-8,"In a murine model it has been shown that the antitumor activity of carboxyethylgermanium sesquioxide (Ge-132) can be depleted by administration of macrophage (M phi) blockers. In the present study, the role that M phi play in the antitumor activity of the compound was investigated. Oral administration of Ge-132 in mice was demonstrated to be effective in activating M phi (Ge-132-cytotoxic M phi), and the cytotoxic activity of these M phi appeared in the peritoneal cavity of mice 48 hours after the oral administration of the compound. Co-cultivation of RL male-1 leukemia or Ehrlich carcinoma cells with Ge-132-cytotoxic M phi in vitro resulted in marked suppression of the growth of tumor cells. The transfer of peritoneal exudate cells (PEC), or purified M phi fractions of PEC from Ge-132-treated mice to mice bearing Ehrlich or RL male-1 ascites tumors resulted in significant protection. However, when the cytotoxic M phi were depleted by carbonyl-iron treatment in vitro, no antitumor effect was demonstrated in mice bearing Ehrlich or RL male-1 ascites tumors. Macrophage fractions obtained from PEC of Ge-132-treated mice exhibited an inhibitory effect against certain tumors both in vivo and in vitro suggesting that the antitumor effect of Ge-132 observed in vivo resulted from the activation of M phi.","['Suzuki, F']",['Suzuki F'],['jpn'],['Journal Article'],Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Administration, Oral', 'Animals', 'Antineoplastic Agents/administration & dosage/*pharmacology', 'Carcinoma, Ehrlich Tumor/*immunology/pathology', '*Cytotoxicity, Immunologic', 'Germanium/administration & dosage/*pharmacology', 'Leukemia, Experimental/*immunology/pathology', 'Liver Neoplasms, Experimental/*immunology/pathology', 'Macrophage Activation/drug effects', 'Macrophages/*immunology', 'Mice', 'Organometallic Compounds/administration & dosage/*pharmacology', 'Peritoneal Cavity/cytology', 'Propionates']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Nov;12(11):2122-8.,"['0 (Antineoplastic Agents)', '0 (Organometallic Compounds)', '0 (Propionates)', '00072J7XWS (Germanium)', '1Q2P9TO9Q7 (propagermanium)']",,,,,,,,,,,
4060979,NLM,MEDLINE,19851218,20131121,0001-5806 (Print) 0001-5806 (Linking),48,4,1985 Jul,Antileukemic effect of cimetidine in vitro.,1100-3,,"['Takahashi, T', 'Miura, I', 'Takatsu, H', 'Fukushima, Y', 'Fukuda, M', 'Yoshida, K', 'Yamaguchi, A', 'Miura, A B']","['Takahashi T', 'Miura I', 'Takatsu H', 'Fukushima Y', 'Fukuda M', 'Yoshida K', 'Yamaguchi A', 'Miura AB']",['eng'],['Journal Article'],Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Cells, Cultured', 'Cimetidine/*pharmacology', '*Colony-Forming Units Assay', 'Humans', 'Leukemia/*pathology', 'Neoplastic Stem Cells/*drug effects', '*Tumor Stem Cell Assay']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 Jul;48(4):1100-3.,['80061L1WGD (Cimetidine)'],,,,,,,,,,,
4060976,NLM,MEDLINE,19851218,20141120,0001-5806 (Print) 0001-5806 (Linking),48,4,1985 Jul,"Mitogenic response of neoplastic ""hairy cells"" to Staphylococcus aureus Cowan I.",1042-52,,"['Tamaki, T', 'Yonezawa, T', 'Kanayama, Y', 'Inoue, R', 'Kanakura, Y', 'Katagiri, S', 'Machii, T', 'Kitani, T', 'Tarui, S']","['Tamaki T', 'Yonezawa T', 'Kanayama Y', 'Inoue R', 'Kanakura Y', 'Katagiri S', 'Machii T', 'Kitani T', 'Tarui S']",['eng'],['Journal Article'],Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Adult', 'Aged', 'Female', 'Humans', 'In Vitro Techniques', 'Leukemia, Hairy Cell/*immunology', 'Lymphocyte Activation', 'Male', 'Middle Aged', '*Mitogens', 'Staphylococcal Protein A/*pharmacology', '*Staphylococcus aureus']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 Jul;48(4):1042-52.,"['0 (Mitogens)', '0 (Staphylococcal Protein A)']",,,,,,,,,,,
4060961,NLM,MEDLINE,19851216,20191030,0302-4369 (Print) 0302-4369 (Linking),39,6,1985,5-Hydroxymethyl-2'-deoxyuridine. Cytotoxicity and DNA incorporation studied by using a novel [2-14C]-derivative with normal and leukemic human hematopoietic cells.,477-84,"5-Hydroxymethyl-2'-deoxyuridine is a biologically active thymidine analogue. This investigation was aimed at characterizing the cytotoxicity of 5-hydroxymethyl-2'-deoxyuridine and its incorporation into DNA. Fifty percent inhibition of cellular proliferation, assessed by incorporation of [U-14C]-L-leucine in vitro, was caused by 1.7-5.8 X 10(-5) incorporation of [U-14C]-L-leucine in vitro, was caused by 1.7-5.8 X 10(-5) M 5-hydroxymethyl-2'-deoxyuridine in seven human leukemia cell lines. Higher concentrations of 5-hydroxymethyl-2'-deoxyuridine, i.e. 6-8 X 10(-5) M, were required for a comparable inhibition in human PHA-stimulated peripheral blood lymphocytes. A new synthesis procedure for [2-14C]5-hydroxymethyl-2'-deoxyuridine was developed. The net incorporation of [2-14C]5-hydroxymethyl-2'-deoxyuridine into DNA of hematopoietic cells was low. The possibility of a repair mechanism for 5-hydroxymethyluracil bound to DNA is discussed.","['Kahilainen, L I', 'Bergstrom, D E', 'Vilpo, J A']","['Kahilainen LI', 'Bergstrom DE', 'Vilpo JA']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",Denmark,Acta Chem Scand B,Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,0421265,IM,"['Carbon Radioisotopes', 'Cell Division/drug effects', 'Cell Line', 'DNA/*biosynthesis', 'DNA, Neoplasm/*biosynthesis', 'Humans', 'Kinetics', 'Leukemia/*metabolism/pathology', 'Lymphoma/*metabolism/pathology', 'Thymidine/*analogs & derivatives/metabolism/toxicity']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.3891/acta.chem.scand.39b-0477 [doi]'],ppublish,Acta Chem Scand B. 1985;39(6):477-84. doi: 10.3891/acta.chem.scand.39b-0477.,"['0 (Carbon Radioisotopes)', '0 (DNA, Neoplasm)', ""5116-24-5 (5-hydroxymethyl-2'-deoxyuridine)"", '9007-49-2 (DNA)', 'VC2W18DGKR (Thymidine)']",,,['CA 30050/CA/NCI NIH HHS/United States'],,,,,,,,
4060695,NLM,MEDLINE,19851213,20190819,0042-9007 (Print) 0042-9007 (Linking),49,4,1985,Antiglycolipid antibodies in normal and pathologic human sera and synovial fluids.,292-300,"Antiglycolipid antibodies were measured in normal and pathologic sera and synovial fluids by means of a modified microplate method of complement-mediated immune lysis of fluorescent dye-trapped liposomes. All sera of normal subjects had antibodies against globopentaosylceramide (IV3 GalNAcGbOse4Cer), ganglioside GM1, gangliotriaosylceramide, gangliotetraosylceramide, and galactosylneolactotetraosylceramide antigens. Most sera of normal subjects had antibodies against lactotriaosylceramide, N-glycolylneuraminosyl-neolactotetraosylceramide (NeuGcnLcOse4Cer), GM3 ganglioside with N-glycolylneuraminic acid (NeuGcGM3) and GD1a antigens. Differences of titers against IV3GalNAcGbOse4Cer, neolactotetraosylceramide, NeuGcGM3 and NeuGcnLcOse4Cer antigens were observed between sera of normal subjects and pathologic sera from cases of leukemias, lymphomas, several autoimmune diseases and liver diseases.","['Kaise, S', 'Yasuda, T', 'Kasukawa, R', 'Nishimaki, T', 'Watarai, S', 'Tsumita, T']","['Kaise S', 'Yasuda T', 'Kasukawa R', 'Nishimaki T', 'Watarai S', 'Tsumita T']",['eng'],['Journal Article'],England,Vox Sang,Vox sanguinis,0413606,IM,"['Adult', 'Autoantibodies/*analysis', 'Collagen Diseases/immunology', 'Complement System Proteins', 'Female', 'Fetal Blood/immunology', 'Glycolipids/*immunology', 'Humans', 'Leukemia/immunology', 'Liposomes', 'Liver Diseases/immunology', 'Lupus Erythematosus, Systemic/immunology', 'Lymphoma/immunology', 'Male', 'Middle Aged', 'Purpura, Thrombocytopenic/immunology', 'Synovial Fluid/*immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1111/j.1423-0410.1985.tb01124.x [doi]'],ppublish,Vox Sang. 1985;49(4):292-300. doi: 10.1111/j.1423-0410.1985.tb01124.x.,"['0 (Autoantibodies)', '0 (Glycolipids)', '0 (Liposomes)', '9007-36-7 (Complement System Proteins)']",,,,,,,,,,,
4060594,NLM,MEDLINE,19851218,20190714,0042-6822 (Print) 0042-6822 (Linking),144,2,1985 Jul 30,Comparison of the transcriptional properties of the Friend and Moloney retrovirus long terminal repeats: importance of tandem duplications and of the core enhancer sequence.,481-94,"The effects of sequence differences within the long terminal repeats (LTRs) of various murine retroviruses on transcription are examined by linking genetically engineered recombinant LTRs to the protein coding region of the herpes simplex virus thymidine kinase (TK) gene and assaying TK expression in tissue culture fibroblasts. The Goldberg/Hogness box region and the enhancer region are examined independently. We find that the Friend and Moloney Goldberg/Hogness boxes (TATAAAA and AATAAAA, respectively) give similar results in this assay, whereas differences between the sequences in the enhancer region have a marked effect. Tandem duplications increase the transcription level of the LTR. A single nucleotide transition in the core enhancer sequence has as large an effect on transcription as the presence of a tandem duplication: thymidine in the fifth position of the core enhancer (TCTGTGGTAAG) leads to a much higher transcriptional activity than cytidine. The LTRs have been implicated by others in the oncogenic potential of murine retroviruses, which is perhaps dependent on the transcriptional properties endowed in part by the core enhancer and tandem duplications.","['Clark, S P', 'Kaufhold, R', 'Chan, A', 'Mak, T W']","['Clark SP', 'Kaufhold R', 'Chan A', 'Mak TW']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Virology,Virology,0110674,IM,"['Base Sequence', 'Cloning, Molecular', '*Enhancer Elements, Genetic', 'Friend murine leukemia virus/*genetics', 'Gene Expression Regulation', '*Genes, Regulator', 'Moloney murine leukemia virus/*genetics', 'Promoter Regions, Genetic', '*Repetitive Sequences, Nucleic Acid', 'Structure-Activity Relationship', '*Transcription, Genetic']",,1985/07/30 00:00,1985/07/30 00:01,['1985/07/30 00:00'],"['1985/07/30 00:00 [pubmed]', '1985/07/30 00:01 [medline]', '1985/07/30 00:00 [entrez]']",['10.1016/0042-6822(85)90288-0 [doi]'],ppublish,Virology. 1985 Jul 30;144(2):481-94. doi: 10.1016/0042-6822(85)90288-0.,,,,,,,,,,,,"['GENBANK/M10168', 'GENBANK/M10169']"
4060571,NLM,MEDLINE,19851213,20190714,0042-6822 (Print) 0042-6822 (Linking),142,1,1985 Apr 15,Generation of thymotropic envelope gene recombinant virus and induction of lymphoma by ecotropic Moloney murine leukemia virus.,197-205,"Biologically cloned pure ecotropic Moloney MuLV was used to infect Balb/c and AKR mice to determine the replication of ecotropic virus, the possible generation of recombinant viruses, and the induction of disease. Infectious cell center (ICC) experiments carried out with lymphoid cells of individual Balb/c mice showed that e-M-MuLV rapidly infected up to 30% of lymphoid cells in liver, spleen, and especially in the thymus. No recombinant virus was seen until about Day 35 when a burst of RM-MuLV was observed only in the thymus. New RM-MuLV was found in all 32 preleukemic and leukemic mice tested and persisted at low levels until death. The RM-MuLV recovered early in the preleukemic phase had an env-related M-MuLV but grew very poorly. Cells from a late tumor which grew and cloned readily were examined to see whether the new RM-MuLV was present in every clone. Overtly, most tumor cells did not seem to contain RM-MuLV, but when ""unmasking"" was performed, every tumor cell contained identical RM-MuLV. In AKR mice, both e-M-MuLV and recombinant M-MuLV caused an acceleration of lymphoma. De novo appearance of a thymotropic RM-MuLV, which was of the Moloney RM-MuLV type and the absence of early detectable endogenous AKR-MCF-type recombinants, suggested that the early lymphoma was due to the induction of a new disease. Several theoretical approaches dealing with viral env-gene permutations are discussed.","['Fischinger, P J', 'Dunlop, N M', 'Robey, W G', 'Schafer, W']","['Fischinger PJ', 'Dunlop NM', 'Robey WG', 'Schafer W']",['eng'],['Journal Article'],United States,Virology,Virology,0110674,IM,"['Animals', 'Cloning, Molecular', 'DNA Replication', '*Genes', '*Genes, Viral', 'Lymphoma/*microbiology', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Moloney murine leukemia virus/*genetics', 'Recombination, Genetic', 'Viral Envelope Proteins/*genetics', 'Virus Replication']",,1985/04/15 00:00,1985/04/15 00:01,['1985/04/15 00:00'],"['1985/04/15 00:00 [pubmed]', '1985/04/15 00:01 [medline]', '1985/04/15 00:00 [entrez]']",['10.1016/0042-6822(85)90433-7 [doi]'],ppublish,Virology. 1985 Apr 15;142(1):197-205. doi: 10.1016/0042-6822(85)90433-7.,['0 (Viral Envelope Proteins)'],,,,,,,,,,,
4060229,NLM,MEDLINE,19851220,20191210,0041-3771 (Print) 0041-3771 (Linking),27,9,1985 Sep,[Effect of serotonin on proliferating and resting cells in culture].,1043-8,"The influence of exogenous serotonin on cell division of L929 and L-41 cell strains has been investigated under various conditions of cell growth in culture (the incubation either in 10% serum medium without changing the medium, or in the medium with 0.5% serum). The data obtained show that serotonin in physiological concentration (10(-7) M) stimulates proliferation of resting cells. In proliferating cells, compared to resting ones, the sensitivity to exogenous amine appeared statistically non-significant. Exogenous serotonin is suggested to be a proliferating stimulus for resting cells.","['Nefedov, V P', 'Kulinskii, V I', 'Andreeva, T V']","['Nefedov VP', 'Kulinskii VI', 'Andreeva TV']",['rus'],"['Comparative Study', 'Journal Article']",Russia (Federation),Tsitologiia,Tsitologiia,0417363,IM,"['Animals', 'Autoradiography', 'Cell Division/drug effects', 'Cell Line', 'Cells, Cultured/*drug effects', 'HeLa Cells/drug effects', 'Humans', 'Interphase/*drug effects', 'L Cells/drug effects', 'Leukemia/pathology', 'Leukocytes/drug effects', 'Mice', 'Serotonin/*pharmacology', 'Stimulation, Chemical']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Tsitologiia. 1985 Sep;27(9):1043-8.,['333DO1RDJY (Serotonin)'],,Vliianie serotonina na proliferiruiushchie i pokoiashchiesia kletki v kul'ture.,,,,,,,,,
4060193,NLM,MEDLINE,19851209,20190819,0378-4274 (Print) 0378-4274 (Linking),28,1,1985 Oct,"Genotoxicity of ochratoxin A in mice: DNA single-strand break evaluation in spleen, liver and kidney.",29-35,"Ochratoxin A, a natural contaminant of feed and food, has been shown to induce experimental liver and kidney tumours. In vitro experiments on mice spleen cells showed evidence of DNA single-strand breaks induced by ochratoxin A. We measured single-strand breaks in the DNA of spleen, liver and kidney of ochratoxin A-treated animals. Ochratoxin A induced DNA damage in vivo. This damage reversed with time. The appearance and extent of the damage varied in different tissues. Except for spleen our data correlate with the tumours induced by ochratoxin in mouse liver and kidney. With regard to the spleen, there has been no report to date of experimental leukemia induced by ochratoxin A. Thus our results indicate that this possibility has to be considered.","['Creppy, E E', 'Kane, A', 'Dirheimer, G', 'Lafarge-Frayssinet, C', 'Mousset, S', 'Frayssinet, C']","['Creppy EE', 'Kane A', 'Dirheimer G', 'Lafarge-Frayssinet C', 'Mousset S', 'Frayssinet C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Toxicol Lett,Toxicology letters,7709027,IM,"['Animals', '*DNA, Single-Stranded', 'Kidney/*drug effects', 'Liver/*drug effects', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Ochratoxins/*toxicity', 'Spleen/*drug effects']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']","['0378-4274(85)90006-2 [pii]', '10.1016/0378-4274(85)90006-2 [doi]']",ppublish,Toxicol Lett. 1985 Oct;28(1):29-35. doi: 10.1016/0378-4274(85)90006-2.,"['0 (DNA, Single-Stranded)', '0 (Ochratoxins)', '1779SX6LUY (ochratoxin A)']",,,,,,,,,,,
4059888,NLM,MEDLINE,19851220,20190908,0355-3140 (Print) 0355-3140 (Linking),11,4,1985 Aug,"The mortality of boot and shoe makers, with special reference to cancer.",249-55,"The study describes the mortality of 5 017 men known to have been employed in the boot and shoe manufacturing industry in three towns in Great Britain in 1939. At the end of 1982, 97.5% of the men were traced, and 3 434 (68.4%) were known to be dead. Expected numbers were calculated according to the person-years method and were adjusted according to the standardized mortality ratios of the counties in which the towns were situated. The mortality experience of the men for all causes, all cancers combined, and all other causes was favorable. The anticipated excess of deaths from nasal cancer (10 observed, 1.87 expected) was found, and the excess was significant for workers in the finishing room. Deficits were found for other types of respiratory cancer. An excess mortality from leukemia was found for workers in one town (7 observed, 3.0 expected), and the excess was significant for workers in the lasting and making room, where glues and solvents, including benzene, were known to have been used. An excess mortality from rectal cancer was found for workers in two towns (61 observed, 47.6 expected), and it was significant for workers in the lasting and making rooms (25 observed, 12.4 expected). Some supporting evidence for a risk of rectal cancer in this industry was found in the literature.","['Pippard, E C', 'Acheson, E D']","['Pippard EC', 'Acheson ED']",['eng'],"['Comparative Study', 'Journal Article']",Finland,Scand J Work Environ Health,"Scandinavian journal of work, environment & health",7511540,IM,"['Adhesives/adverse effects', 'Adult', 'Chlorophenols/adverse effects', 'Gastrointestinal Neoplasms/chemically induced/mortality', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/chemically induced/*mortality', 'Occupational Diseases/chemically induced/*mortality', 'Respiratory Tract Neoplasms/chemically induced/mortality', '*Shoes', 'Solvents/adverse effects', 'United Kingdom']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['2223 [pii]', '10.5271/sjweh.2223 [doi]']",ppublish,Scand J Work Environ Health. 1985 Aug;11(4):249-55. doi: 10.5271/sjweh.2223.,"['0 (Adhesives)', '0 (Chlorophenols)', '0 (Solvents)']",,,,,,,,,,,
4059870,NLM,MEDLINE,19851219,20190824,0036-5548 (Print) 0036-5548 (Linking),17,3,1985,Characteristic manifestations of clostridium induced spontaneous gangrenous myositis.,291-4,"Spontaneous clostridial myonecrosis occurred in 30- and 69-year-old patients with pancytopenia (after treatment of acute myelogenous leukemia) and diabetes with neutropenia respectively. They presented with fever and sudden onset of pain plus tenderness in involved muscles. They rapidly deteriorated and died within hours after admission. A review of the literature for previous reports of this condition disclosed 31 additional cases. Mean age of patients was 50 years, male to female ratio was 2.2:1, and an underlying condition was present in all of them. Presenting manifestations were spontaneously occurring excruciating pain in the involved muscle (67%), generalized sepsis and shock (24%), nonpainful swelling in the involved muscles (6%) and pain, swelling and shock (3%). Mortality rate was 91% (30/33). The clostridial strains associated with this condition were identified in 31 cases, with Clostridium perfringens and C. septicum causing 28 of them. Bacteremia was described in 10 cases. Awareness of this rare catastrophe may aid in early recognition and surgical intervention which are essential for patient survival.","['Narula, A', 'Khatib, R']","['Narula A', 'Khatib R']",['eng'],"['Case Reports', 'Journal Article']",England,Scand J Infect Dis,Scandinavian journal of infectious diseases,0215333,IM,"['Adult', 'Aged', 'Clostridium Infections/*etiology/microbiology', 'Gangrene/etiology/*microbiology', 'Humans', 'Male', 'Myositis/*etiology/microbiology', 'Neutropenia/complications', 'Pancytopenia/complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.3109/inf.1985.17.issue-3.08 [doi]'],ppublish,Scand J Infect Dis. 1985;17(3):291-4. doi: 10.3109/inf.1985.17.issue-3.08.,,,,,,,,,,,,
4059861,NLM,MEDLINE,19851220,20190908,0036-553X (Print) 0036-553X (Linking),35,3,1985 Sep,Response to oxymetholone in hairy cell leukaemia.,374-5,,"['Lenner, P', 'Osterman, B', 'Roos, G']","['Lenner P', 'Osterman B', 'Roos G']",['eng'],"['Case Reports', 'Letter']",Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Humans', 'Leukemia, Hairy Cell/*drug therapy', 'Male', 'Middle Aged', 'Oxymetholone/*therapeutic use']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb01723.x [doi]'],ppublish,Scand J Haematol. 1985 Sep;35(3):374-5. doi: 10.1111/j.1600-0609.1985.tb01723.x.,['L76T0ZCA8K (Oxymetholone)'],,,,,,,,,,,
4059858,NLM,MEDLINE,19851220,20190908,0036-553X (Print) 0036-553X (Linking),35,3,1985 Sep,Aseptic bone/bone marrow necrosis in leukaemia.,354-7,"Aseptic (avascular) bone/bone marrow necrosis (ABN) was found in 21 leukaemic patients during a period of 14 yr, with a frequency of 6.5% in autopsied leukaemic patients, and with the highest frequency in ALL. 8 patients (38%) complained of bone pain. X-ray examination was carried out in 7 of these with a positive result in 3 (43%). Only 1 patient had elevated S-Alkaline phosphatase. Leucocytosis was found in 12 patients. Only 1 patient (ALL) received steroid in a rather high dose during 6 weeks. At autopsy ABN was found localized to the femur in all patients and 2 patients also had ABN in other bones. Post-mortem X-ray examination demonstrated changes in 8 of 15 cases (53%), with osteolysis in 6 and sclerosis in 2. 19 patients had had recent ABN with some fibroblast proliferation. In 4 of these, appositional bone formation had started. 2 patients had sclerosis as the only change. The pathogenesis of ABN is not known; an important factor, however, may be ischaemia due to vascular obstruction.","['Vesterby, A', 'Myhre Jensen, O']","['Vesterby A', 'Myhre Jensen O']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Adolescent', 'Adult', 'Aged', 'Autopsy', 'Bone Diseases/*etiology', 'Bone Marrow Diseases/*etiology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Leukemia/*complications/drug therapy', 'Middle Aged', 'Necrosis', 'Pain/etiology', 'Prednisone/therapeutic use']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb01719.x [doi]'],ppublish,Scand J Haematol. 1985 Sep;35(3):354-7. doi: 10.1111/j.1600-0609.1985.tb01719.x.,['VB0R961HZT (Prednisone)'],,,,,,,,,,,
4059800,NLM,MEDLINE,19851219,20191030,0390-5748 (Print) 0390-5748 (Linking),15,2,1985 Apr-Jun,Paraproteinemia and neoplasia.,99-104,"According to the various case series, both myelomatous and non-myelomatous paraproteinemias are associated with a second malignant neoplasia in a frequency that ranges between 10 and 22%. This association, with a frequency higher than that statistically expected, is 2 to 4 times higher when compared to the association between two tumors of other origin. The association paraproteinemia-neoplasia was found in 10% of cases of our series of 311 paraproteinemias. In this series epithelial neoplasias are associated with paraproteinemias more frequently than lymphoreticular neoplasias. As far as the Ig class is concerned, there appears to be a prevalence of IgM paraproteinemias, which accounts for 22.5%, while it is only 9% in the general survey of paraproteinemias. The prevalence of the IgM class should be related to the high degree of association (approximately 50%) between the IgM paraproteinemias and lymphoreticular neoplasias. The frequent association with a second neoplasia, common to other malignancies of the B-cell line (chronic lymphocytic leukemia, myeloma), must be considered a greater risk in the prognostic evaluation of a paraproteinemia. This should make us more cautious in affirming the 'benignancy' of every non-myelomatous paraproteinemia.","['Bonomo, L', 'Dammacco, F', 'Miglietta, A']","['Bonomo L', 'Dammacco F', 'Miglietta A']",['eng'],['Journal Article'],Italy,Ric Clin Lab,La Ricerca in clinica e in laboratorio,7613947,IM,"['Adult', 'Aged', 'Female', 'Humans', 'Immunoglobulin A/analysis', 'Immunoglobulin G/analysis', 'Immunoglobulin M/analysis', 'Male', 'Middle Aged', 'Neoplasms/*complications', 'Paraproteinemias/*complications']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",['10.1007/BF03029826 [doi]'],ppublish,Ric Clin Lab. 1985 Apr-Jun;15(2):99-104. doi: 10.1007/BF03029826.,"['0 (Immunoglobulin A)', '0 (Immunoglobulin G)', '0 (Immunoglobulin M)']",,,,,,,,,,,
4059756,NLM,MEDLINE,19851209,20190829,0162-0886 (Print) 0162-0886 (Linking),7,5,1985 Sep-Oct,"Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.",646-55,"Two hundred episodes of fungemia that occurred at Memorial Sloan-Kettering Cancer Center between January 1, 1978, and June 30, 1982, are reviewed and compared with those seen from 1974 through 1977. The total number of episodes of fungemia per year increased by 30.6%, episodes per 100 new lymphoma and solid tumor patients increased by 73% and 95%, respectively, and episodes per 100 new leukemia patients decreased by 50%. Fungemia also occurred earlier during hospitalization, and embolic skin lesions were a common early sign of Candida tropicalis fungemia. Mortality was not significantly different with and without amphotericin B therapy in fungemic patients with leukemia, lymphoma, or aplastic anemia (51 of 70 vs. 21 of 24) or solid tumors (29 of 36 vs. 29 of 43); however, some patients appeared to benefit from combination therapy with amphotericin B and flucytosine. The prevalence of disseminated candidiasis at autopsy was the same in treated (11 of 15) and untreated (8 of 11) patients with leukemia, lymphoma, and aplastic anemia, but it was significantly lower in treated (none of 8) than in untreated (5 of 11) patients with solid tumors.","['Horn, R', 'Wong, B', 'Kiehn, T E', 'Armstrong, D']","['Horn R', 'Wong B', 'Kiehn TE', 'Armstrong D']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Rev Infect Dis,Reviews of infectious diseases,7905878,IM,"['Adult', 'Amphotericin B/administration & dosage', 'Cancer Care Facilities', 'Candidiasis/drug therapy/etiology/mortality', 'Dermatomycoses/diagnosis/etiology', 'Drug Therapy, Combination', 'Female', 'Flucytosine/administration & dosage', 'Humans', 'Male', 'Middle Aged', 'Mycoses/drug therapy/*etiology/mortality', 'Neoplasms/*complications', 'New York City', 'Retrospective Studies']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1093/clinids/7.5.646 [doi]'],ppublish,Rev Infect Dis. 1985 Sep-Oct;7(5):646-55. doi: 10.1093/clinids/7.5.646.,"['7XU7A7DROE (Amphotericin B)', 'D83282DT06 (Flucytosine)']",,,,,,,,,,,
4059730,NLM,MEDLINE,19851204,20150826,0370-629X (Print) 0370-629X (Linking),40,17,1985 Sep 1,[Five cases of tricholeukocyte leukemia].,586-92,,"['Malherbe, R', 'Bury, J', 'Fillet, G', 'Andrien, J M', 'Borlee, M']","['Malherbe R', 'Bury J', 'Fillet G', 'Andrien JM', 'Borlee M']",['fre'],"['Case Reports', 'Journal Article']",Belgium,Rev Med Liege,Revue medicale de Liege,0404317,IM,"['Aged', 'Cyclophosphamide/therapeutic use', 'Cytarabine/therapeutic use', 'Erythropoiesis', 'Female', 'Humans', 'Leukemia, Hairy Cell/*diagnosis/surgery/therapy', 'Male', 'Middle Aged', 'Splenectomy']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Rev Med Liege. 1985 Sep 1;40(17):586-92.,"['04079A1RDZ (Cytarabine)', '8N3DW7272P (Cyclophosphamide)']",,Etude de cinq cas de leucemie a tricholeucocyte.,,,,,,,,,
4059627,NLM,MEDLINE,19851209,20061115,0034-1193 (Print) 0034-1193 (Linking),76,6,1985 Jun,[New implantable systems in intensive long-term chemotherapy of leukemias and lymphomas].,316-8,,"['Agolini, G', 'Lipartiti, T', 'Milani, A', 'Paparazzo, R']","['Agolini G', 'Lipartiti T', 'Milani A', 'Paparazzo R']",['ita'],"['English Abstract', 'Journal Article']",Italy,Recenti Prog Med,Recenti progressi in medicina,0401271,IM,"['Antineoplastic Agents/administration & dosage', '*Catheters, Indwelling', 'Humans', 'Injections, Intravenous', 'Leukemia/*drug therapy', 'Lymphoma/*drug therapy']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Recenti Prog Med. 1985 Jun;76(6):316-8.,['0 (Antineoplastic Agents)'],,I nuovi sistemi impiantabili nella chemioterapia intensiva a lungo termine delle leucemie e dei linfomi.,,,,,,,,,
4059547,NLM,MEDLINE,19851218,20161123,0033-8419 (Print) 0033-8419 (Linking),157,3,1985 Dec,Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign.,605-10,"The air crescent sign is regarded as an important diagnostic finding in invasive pulmonary aspergillosis (IPA). This study examined the incidence, clinical importance, and natural history of air crescents in 25 patients with acute leukemia and IPA. Twelve (50%) of the patients had cavities (ten with an air crescent) that appeared an average of 15 days after the initial infiltrate. The diagnostic utility of the air crescent sign was relatively minor; cavities developed after the diagnosis was established in 50% of cases and after therapy was started in 75% of cases. In each case, the pneumonia improved at the time of cavitation. In six patients (50%), the cavities resolved over 2-8 months. Three patients (25%), however, experienced massive hemoptysis. Air crescent formation, previously shown to be dependent on granulocyte recovery, was associated with improved survival (67%) compared with the group without cavitation (8%). In the latter group, the pneumonia in ten (77%) of 13 patients progressed to diffuse disease. In patients with leukemia, the diagnostic value of the air crescent sign is limited by cavities that develop relatively late, as the infection improves after white blood cell recovery; cavities that do not occur in patients who remain neutropenic; and associated hemorrhage, at times life-threatening, that obscures the air crescent. The diagnosis of IPA should not await observation of air crescents in these patients.","['Gefter, W B', 'Albelda, S M', 'Talbot, G H', 'Gerson, S L', 'Cassileth, P A', 'Miller, W T']","['Gefter WB', 'Albelda SM', 'Talbot GH', 'Gerson SL', 'Cassileth PA', 'Miller WT']",['eng'],['Journal Article'],United States,Radiology,Radiology,0401260,IM,"['Acute Disease', 'Aspergillosis/complications/*diagnostic imaging/pathology', 'Humans', 'Leukemia/*complications', 'Lung/*diagnostic imaging/pathology', 'Lung Diseases, Fungal/complications/*diagnostic imaging/pathology', 'Prognosis', 'Radiography']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1148/radiology.157.3.4059547 [doi]'],ppublish,Radiology. 1985 Dec;157(3):605-10. doi: 10.1148/radiology.157.3.4059547.,,,,,,,,,,,,
4058553,NLM,MEDLINE,19851219,20190824,0028-4793 (Print) 0028-4793 (Linking),313,23,1985 Dec 5,Leukemia in occupational groups with presumed exposure to electrical and magnetic fields.,1476-7,,"['Calle, E E', 'Savitz, D A']","['Calle EE', 'Savitz DA']",['eng'],['Letter'],United States,N Engl J Med,The New England journal of medicine,0255562,IM,"['Acute Disease', 'Adult', 'Electricity/*adverse effects', 'Electromagnetic Fields/adverse effects', 'Humans', 'Leukemia/*mortality', 'Leukemia, Radiation-Induced/mortality', 'Magnetics/*adverse effects', 'Male', 'Occupational Diseases/*mortality', 'Wisconsin']",,1985/12/05 00:00,1985/12/05 00:01,['1985/12/05 00:00'],"['1985/12/05 00:00 [pubmed]', '1985/12/05 00:01 [medline]', '1985/12/05 00:00 [entrez]']",['10.1056/nejm198512053132312 [doi]'],ppublish,N Engl J Med. 1985 Dec 5;313(23):1476-7. doi: 10.1056/nejm198512053132312.,,,,,,,,,,,,
4058136,NLM,MEDLINE,19851218,20071115,0023-7205 (Print) 0023-7205 (Linking),82,42,1985 Oct 16,[Vasculitis associated with malignancy--a rarity].,"3609, 3611",,"['Irving, P']",['Irving P'],['swe'],"['Case Reports', 'Journal Article']",Sweden,Lakartidningen,Lakartidningen,0027707,IM,"['Diagnosis, Differential', 'Female', 'Humans', 'Leukemia, Lymphoid/*complications', 'Middle Aged', 'Vasculitis/*complications/diagnosis']",,1985/10/16 00:00,1985/10/16 00:01,['1985/10/16 00:00'],"['1985/10/16 00:00 [pubmed]', '1985/10/16 00:01 [medline]', '1985/10/16 00:00 [entrez]']",,ppublish,"Lakartidningen. 1985 Oct 16;82(42):3609, 3611.",,,Malignitetsassocierad vaskulit--en sallsynthet.,,,,,,,,,
4058079,NLM,MEDLINE,19851219,20191030,0736-0118 (Print) 0736-0118 (Linking),2,2,1985,Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside.,87-91,Eight patients with inaspiratable bone marrows due to significant degrees of fibrosis were treated with high dose cytosine arabinoside because of either documented or suspected coexistent acute leukemia. The peripheral blood counts returned to normal in 7 patients. Remissions were short lived and bone marrow abnormalities persisted suggesting that consolidation therapy should be administered to these patients as soon as their peripheral blood counts are normalized.,"['Preisler, H D', 'Raza, A', 'Barcos, M']","['Preisler HD', 'Raza A', 'Barcos M']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",England,Med Oncol Tumor Pharmacother,Medical oncology and tumor pharmacotherapy,8405039,IM,"['Acute Disease', 'Adult', 'Aged', 'Biopsy', 'Blood Cell Count', 'Bone Marrow/pathology', 'Cytarabine/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Hyperplasia', 'Leukemia/*drug therapy', 'Male', '*Megakaryocytes/drug effects', 'Middle Aged', 'Myelodysplastic Syndromes/*drug therapy', 'Pancytopenia/drug therapy', 'Primary Myelofibrosis/*drug therapy', 'Thrombocythemia, Essential/drug therapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF02934853 [doi]'],ppublish,Med Oncol Tumor Pharmacother. 1985;2(2):87-91. doi: 10.1007/BF02934853.,['04079A1RDZ (Cytarabine)'],,,['CA-5834/CA/NCI NIH HHS/United States'],,,,,,,,
4057913,NLM,MEDLINE,19851209,20190711,0023-2173 (Print) 0023-2173 (Linking),63,17,1985 Sep 2,[Septicemia in leukemia and malignant lymphoma. Incidence pathogens--causes].,821-6,"Septicemia occurred in 81 (= 23.9%) of 339 patients with leukemias an malignant lymphomas during 1979-1984/VI. In leukemias the acute forms and in malignant lymphomas the high malignant forms were mostly affected. The frequency of gramnegative bacterias (46 = 56.8%) was higher than that of gram-positive bacterias (32 = 39.5%) and of fungus (3 = 3.7%). The frequency of septicemia in leukemias (alone) between 1966-1977 was 13.9%, between 1979-1984/VI 30%. In this comparison septicemias caused by gram-negative bacterias and fungus decreased, whereas gram-positive septicemias increased. The focus of septicemia remained unknown in 30 cases, Pneumonias and the urinary tract were the most common source, followed by the skin. All patients were under cytostatics and therefore leukopenic, most of them received corticosteroids simultaneously and were thus immunosuppressed. A combination of granulocytopenia less than 1,000 mm3 with hypogammaglobulinemia less than 10 rel.% were mostly found in acute leukemias and in chronic lymphatic leukemia. 41.5% of febrile episodes from all groups of these diseases were of non-microbic origin (local or septic) an thus possibly symptom of activity of the underlying disease.","['Hennemann, H H']",['Hennemann HH'],['ger'],"['English Abstract', 'Journal Article']",Germany,Klin Wochenschr,Klinische Wochenschrift,2985205R,IM,"['Acute Disease', 'Bacteria/isolation & purification', 'Hodgkin Disease/complications', 'Humans', 'Immunologic Deficiency Syndromes/complications', 'Leukemia/*complications', 'Leukopenia/complications', 'Lymphoma/*complications', 'Sepsis/*etiology']",,1985/09/02 00:00,1985/09/02 00:01,['1985/09/02 00:00'],"['1985/09/02 00:00 [pubmed]', '1985/09/02 00:01 [medline]', '1985/09/02 00:00 [entrez]']",['10.1007/BF01732287 [doi]'],ppublish,Klin Wochenschr. 1985 Sep 2;63(17):821-6. doi: 10.1007/BF01732287.,,,Septikamien bei Leukamien und malignen Lymphomen. Haufigkeit--Erreger--Ursachen.,,,,,,,,,
4057586,NLM,MEDLINE,19851127,20151119,0485-1439 (Print) 0485-1439 (Linking),26,5,1985 May,[Surface marker analysis with monoclonal antibodies in acute non-lymphocytic leukemia in childhood. Children's Cancer and Leukemia Study group].,731-6,,"['Kawai, S', 'Fujimoto, T', 'Yatabe, M', 'Mimaya, J', 'Koizumi, S', 'Ohta, S', 'Komazawa, M', 'Tanaka, K', 'Yanai, M', 'Hiyoshi, Y']","['Kawai S', 'Fujimoto T', 'Yatabe M', 'Mimaya J', 'Koizumi S', 'Ohta S', 'Komazawa M', 'Tanaka K', 'Yanai M', 'Hiyoshi Y', 'et al.']",['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Acute Disease', 'Adolescent', '*Antibodies, Monoclonal', 'Antigens, Surface/*analysis', 'Humans', 'Leukemia/drug therapy/*immunology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 May;26(5):731-6.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Surface)']",,,,,,,,,,,
4057356,NLM,MEDLINE,19851127,20200724,0022-538X (Print) 0022-538X (Linking),56,2,1985 Nov,Individual adenovirus type 5 early region 1A gene products elicit distinct alterations of cellular morphology and gene expression.,404-13,"Adenovirus early region 1A (E1A), which gives rise to three overlapping transcripts, was inserted into a murine leukemia virus-derived vector, and recombinant viruses were used to prepare permanent cell lines of NIH 3T3 cells containing DNA copies of the individual 13S, 12S, and 9S mRNAs. Integrated proviral copies of the recombinant genomes were rescued as bacterial plasmids from each of the cell lines, and the DNA sequence of E1A was demonstrated to be a precise copy of the individual transcripts. The DNA copies were shown to be expressed as part of the full-length retroviral transcript by S1 nuclease analysis, and the synthesis of their encoded polypeptides was demonstrated by immunoprecipitation. Those cell lines expressing the polypeptide encoded by the 13S transcript were shown to contain that function required for regulating the accumulation of mRNAs from adenovirus early genes by their ability to complement the adenovirus type 5 E1A deletion mutant dl312. Cell lines expressing polypeptides encoded by the 13S, 12S, and 9S transcripts showed characteristic alterations in morphology. Two-dimensional gel electrophoresis of total cellular protein derived from the three cell lines demonstrated that each E1A gene product elicits specific alterations in the patterns of proteins expressed. Studies of the expression of two specific genes, those encoding fibronectin and collagen type 1, indicated that the observed alteration in levels of the two proteins results from a reduction in RNA levels induced by E1A functions.","['Roberts, B E', 'Miller, J S', 'Kimelman, D', 'Cepko, C L', 'Lemischka, I R', 'Mulligan, R C']","['Roberts BE', 'Miller JS', 'Kimelman D', 'Cepko CL', 'Lemischka IR', 'Mulligan RC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Virol,Journal of virology,0113724,IM,"['Adenoviruses, Human/*genetics', 'Animals', 'Cell Line', '*Cell Transformation, Viral', 'Collagen/genetics', 'Fibronectins/genetics', 'Gene Expression Regulation', 'Genes, Viral', 'Mice', 'Molecular Weight', 'RNA, Messenger/genetics', 'RNA, Viral/genetics', 'Transfection', 'Tubulin/genetics', 'Viral Proteins/*genetics']",PMC252593,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1128/JVI.56.2.404-413.1985 [doi]'],ppublish,J Virol. 1985 Nov;56(2):404-13. doi: 10.1128/JVI.56.2.404-413.1985.,"['0 (Fibronectins)', '0 (RNA, Messenger)', '0 (RNA, Viral)', '0 (Tubulin)', '0 (Viral Proteins)', '9007-34-5 (Collagen)']",,,,,,,,,,,
4056659,NLM,MEDLINE,19851211,20190508,0022-1007 (Print) 0022-1007 (Linking),162,5,1985 Nov 1,Establishment of the DU.528 human lymphohemopoietic stem cell line.,1561-78,"We have established the DU.528 cell line from the pretreatment leukemia cells of a patient who underwent a T lymphoblastic-to-promyelocytic phenotype conversion during treatment with the adenosine deaminase inhibitor, deoxycoformycin. The cell line and clones obtained from it by limiting dilution have the same karyotype previously found in the patient's pretreatment T lymphoblasts and post-deoxycoformycin treatment promyelocytes. DU.528 cells in continuous culture for greater than 2 yr display a predominant undifferentiated T lymphoblastoid phenotype. These cells spontaneously generate progeny of at least three lineages, T lymphoid, granulocytic/monocytic, and erythroid. The surface marker most consistently expressed by DU.528 cells in the undifferentiated state is the 3A1 antigen, which has been found on prothymocytes in the embryonic thymus. Some undifferentiated DU.528 cells also expressed the IL-2 receptor, but no other T cell differentiation antigens. Exposure of DU.528 cells to a variety of agents induced myeloid maturation; adenosine and deoxyadenosine, in the presence of deoxycoformycin, induced expression of myeloid differentiation antigens. Our results suggest that DU.528 is a lymphohematopoietic stem cell line and support the hypothesis that differentiation of pluripotent stem cells may be altered by genetic deficiency of adenosine deaminase. DU.528 cells may provide a useful model for examining factors that regulate stem cell proliferation and differentiation.","['Kurtzberg, J', 'Bigner, S H', 'Hershfield, M S']","['Kurtzberg J', 'Bigner SH', 'Hershfield MS']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Exp Med,The Journal of experimental medicine,2985109R,IM,"['Antibodies, Monoclonal', 'Cell Division', 'Cell Line', 'Culture Techniques/methods', 'Hematopoietic Stem Cells/*cytology', 'Humans', 'Karyotyping', 'Kinetics', 'Lymphocytes/*cytology', 'Time Factors']",PMC2187926,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1084/jem.162.5.1561 [doi]'],ppublish,J Exp Med. 1985 Nov 1;162(5):1561-78. doi: 10.1084/jem.162.5.1561.,"['0 (Antibodies, Monoclonal)']",,,"['5T32 AM 07015/AM/NIADDK NIH HHS/United States', 'AM 00434/AM/NIADDK NIH HHS/United States', 'AM 20902/AM/NIADDK NIH HHS/United States']",,,,,,,,
4056453,NLM,MEDLINE,19851209,20190903,0163-4453 (Print) 0163-4453 (Linking),11,2,1985 Sep,Legionnaires' disease and hairy cell leukaemia.,173-5,,"['Bevan, P C', 'Wreghitt, T G', 'King, M']","['Bevan PC', 'Wreghitt TG', 'King M']",['eng'],"['Letter', ""Research Support, Non-U.S. Gov't""]",England,J Infect,The Journal of infection,7908424,IM,"[""Legionnaires' Disease/*complications/diagnosis/drug therapy"", 'Leukemia, Hairy Cell/*complications']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['S0163-4453(85)92195-4 [pii]', '10.1016/s0163-4453(85)92195-4 [doi]']",ppublish,J Infect. 1985 Sep;11(2):173-5. doi: 10.1016/s0163-4453(85)92195-4.,,,,,,,,,,,,
4055210,NLM,MEDLINE,19851203,20211203,0300-5771 (Print) 0300-5771 (Linking),14,3,1985 Sep,Proportionate mortality among male corn wet-milling workers.,432-7,"Workers in the corn wet-milling industry are exposed to grain dusts, pesticides and fumigants, acids, solvents, sulphur dioxide, and other chemicals used in the manufacture of starch, oil, syrup, and dextrins. In a preliminary investigation of the long-term health effects of occupational exposures in this industry, deaths among active and retired corn wet-milling workers were identified from records of a trade union. Underlying cause of death for workers who died between 1947 and 1981 was determined from death certificates. Cause-specific Proportionate Mortality Ratios (PMR's) were computed for white and black males using US males as a comparison with adjustments for age, race, and calendar year of death. There were deficits of deaths from respiratory and digestive diseases. Among whites, mortality from chronic nephritis, bladder cancer, and lymphatic and haematopoietic malignancies was elevated. There was an elevated frequency of deaths due to diabetes and a threefold excess of pancreatic cancer deaths among blacks. Crude work history information indicated a small cluster of pancreatic cancer deaths among whites and blacks who had worked in production processes that convert corn starch to syrup and dextrins. An elevated frequency of deaths from leukaemia was seen among white maintenance workers.","['Thomas, T L', 'Krekel, S', 'Heid, M']","['Thomas TL', 'Krekel S', 'Heid M']",['eng'],['Journal Article'],England,Int J Epidemiol,International journal of epidemiology,7802871,IM,"['Blacks', 'Digestive System Neoplasms/mortality', '*Food Technology/instrumentation', 'Humans', 'Leukemia/mortality', '*Mortality', 'Nephritis/mortality', 'Occupational Diseases/*mortality', '*Occupations', 'Respiratory Tract Diseases/mortality', 'United States', 'Whites', '*Zea mays']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1093/ije/14.3.432 [doi]'],ppublish,Int J Epidemiol. 1985 Sep;14(3):432-7. doi: 10.1093/ije/14.3.432.,,,,,,,,,,,,
4055128,NLM,MEDLINE,19851216,20190708,0020-7136 (Print) 0020-7136 (Linking),36,5,1985 Nov 15,Detection of a retrovirus-related glycoprotein in immune complexes from patients with hematopoietic disorders.,535-9,"Human sera from normal and leukemic individuals were found to contain various amounts of an antigen with determinants related to p15E and reverse transcriptase of retroviruses. Using a specific monoclonal antibody and the immuno-affinity purified antigen, we surveyed a series of sera and plasmas from normal individuals and hematological patients by competition radioimmunoassays and binding assays directed against this specific protein. It was detected in all the samples at various levels. The level of this 74-kd glycoprotein appeared to be related to a stimulation of the hematopoietic system. No free antibodies were found that could recognized the labelled purified antigen. Only immune complexes prepared from the blood of some hematological patients contained the specific antigen, but complexes prepared from the blood of normal individuals did not.","['Jacquemin, P C', 'Strijckmans, P']","['Jacquemin PC', 'Strijckmans P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Int J Cancer,International journal of cancer,0042124,IM,"['Antigen-Antibody Complex/*analysis', 'Glycoproteins/*blood', 'Humans', 'Leukemia/*blood', 'Radioimmunoassay', 'Retroviridae Proteins/*blood']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",['10.1002/ijc.2910360503 [doi]'],ppublish,Int J Cancer. 1985 Nov 15;36(5):535-9. doi: 10.1002/ijc.2910360503.,"['0 (Antigen-Antibody Complex)', '0 (Glycoproteins)', '0 (Retroviridae Proteins)']",,,,,,,,,,,
4055041,NLM,MEDLINE,19851212,20190829,0300-8126 (Print) 0300-8126 (Linking),13 Suppl 1,,1985,Superinfections during antimicrobial treatment with betalactam-aminoglycoside combinations in neutropenic patients with hematologic malignancies.,S115-22,"The frequency, etiology and risk factors of superinfections during and/or within one week after antibiotic therapy with betalactam-aminoglycoside combinations were evaluated in 631 patients with hematologic malignancies admitted to the Institute of Hematology of Rome from January 1982 to December 1984. 356 patients (56%) developed 402 episodes of proven or presumed infection. Of these patients, 78 developed 102 superinfections. Overall, superinfections responded less satisfactorily to antibiotic therapy than the primary febrile episodes (63% vs. 85%). The distribution of etiologic agents of superinfections differed from those responsible for primary infections, since fungi and anaerobes (especially Clostridium difficile) were mostly isolated after antibiotic therapy had begun. Moreover, among aerobic bacteria, frequently antibiotic-resistant species, such as Pseudomonas aeruginosa, Streptococcus faecalis and Staphylococcus epidermidis were the leading etiologic agents of superinfection. The risk of superinfection appeared to increase with the depth and persistence of granulocytopenia. On the other hand, the length of hospitalization, length of previous antibiotic therapy, previous chemoprophylaxis and presence of indwelling venous catheter did not affect the risk of superinfection.","['Serra, P', 'Santini, C', 'Venditti, M', 'Mandelli, F', 'Martino, P']","['Serra P', 'Santini C', 'Venditti M', 'Mandelli F', 'Martino P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Infection,Infection,0365307,IM,"['Adolescent', 'Adult', 'Aged', 'Agranulocytosis/*complications', 'Aminoglycosides/administration & dosage/adverse effects', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Bacteria/isolation & purification', 'Bacterial Infections/*etiology', 'Child', 'Child, Preschool', 'Drug Therapy, Combination', 'Female', 'Humans', 'Infant', 'Lactams', 'Leukemia/*complications', 'Male', 'Middle Aged', 'Neutropenia/*complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF01644231 [doi]'],ppublish,Infection. 1985;13 Suppl 1:S115-22. doi: 10.1007/BF01644231.,"['0 (Aminoglycosides)', '0 (Anti-Bacterial Agents)', '0 (Lactams)']",,,,,,,,,,,
4054976,NLM,MEDLINE,19851213,20130418,0971-5916 (Print) 0971-5916 (Linking),82,,1985 Aug,Estimation of serum cholinesterase & lactate dehydrogenase levels for diagnosis & prognosis in lymphoreticular malignancy.,141-5,,"['Khan, N', 'Tyagi, S P', 'Sibghatullah']","['Khan N', 'Tyagi SP', 'Sibghatullah']",['eng'],['Journal Article'],India,Indian J Med Res,The Indian journal of medical research,0374701,IM,"['Cholinesterases/*blood', 'Female', 'Humans', 'L-Lactate Dehydrogenase/*blood', 'Leukemia/diagnosis/*enzymology', 'Lymphoma/diagnosis/*enzymology', 'Male', 'Prognosis']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Indian J Med Res. 1985 Aug;82:141-5.,"['EC 1.1.1.27 (L-Lactate Dehydrogenase)', 'EC 3.1.1.8 (Cholinesterases)']",,,,,,,,,,,
4054246,NLM,MEDLINE,19851218,20131121,0301-472X (Print) 0301-472X (Linking),13,10,1985 Nov,Erythroid progenitor cells (CFU-E*) from Friend virus-infected mice undergo 55Fe suicide in vitro in the absence of added erythropoietin.,1055-61,"We have investigated the effect of 55Fe on the survival in suspension of erythropoietin (epo)-independent erythroid progenitor cells (CFU-E*) induced by Friend polycythemia virus (FV). Spleen cells from C3Hf/Bi mice previously infected with FV were exposed to carrier-free 55Fe, and the survival of CFU-E* as a function of time in liquid medium was determined from the number of erythroid colonies that developed from these cells seeded in plasma cultures without added epo. The results showed that spleen CFU-E* were highly vulnerable to 55Fe: Do approximately equal to 1 h exposure to 100 microCi/ml. Marrow CFU-E* behaved in a similar manner. The 55Fe responsible for their suicide had been presented to the progenitor cells only during the 4-h period of incubation, after which they were washed and plated in excess nonradioactive iron. We therefore conclude that CFU-E* themselves, and not only their progeny, are capable of actively incorporating iron. Under the same conditions in the absence of added epo, the effect of 55Fe on the survival of normal spleen or marrow CFU-E could not be assessed because two few normal CFU-E survived the incubation period. Normal bone marrow cells incubated in complete medium containing epo retained their capacity for erythrocytic colony formation, and CFU-E could then be shown to be vulnerable to 55Fe. Thus, either the iron-incorporating system of normal CFU-E was inducible by epo, or else epo permitted survival of the CFU-E so that the activity of a constitutive iron-incorporating system could be recognized.","['Del Rizzo, D F', 'Axelrad, A A']","['Del Rizzo DF', 'Axelrad AA']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Exp Hematol,Experimental hematology,0402313,IM,"['Animals', 'Bone Marrow/pathology', 'Cell Survival/drug effects/radiation effects', 'Erythropoietin/*pharmacology', 'Female', 'Friend murine leukemia virus/pathogenicity', 'Hematopoietic Stem Cells/*cytology/drug effects/radiation effects', 'Iron/*toxicity', 'Iron Radioisotopes', 'Leukemia, Experimental/*pathology', 'Male', 'Mice', 'Mice, Inbred C3H', 'Spleen/pathology']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Exp Hematol. 1985 Nov;13(10):1055-61.,"['0 (Iron Radioisotopes)', '11096-26-7 (Erythropoietin)', 'E1UOL152H7 (Iron)']",,,,,,,,,,,
4054243,NLM,MEDLINE,19851218,20161123,0301-472X (Print) 0301-472X (Linking),13,10,1985 Nov,Comparison of the supravital DNA dyes Hoechst 33342 and DAPI for flow cytometry and clonogenicity studies of human leukemic marrow cells.,1039-43,"Human leukemic bone marrow cells were studied by flow cytometry and a colony-forming assay. Two supravital DNA dyes, Hoechst 33342 (H33342) and 4',6-diamidino-2-phenyl indole dihydrochloride (DAPI), were compared in terms of DNA histograms by flow cytometry and toxicity to cells by colony-forming assay. Initially, Chinese hamster ovary (CHO) cells were used, and the optimal staining conditions for the two dyes were determined: 30 min exposure to 10 micrograms/ml at 37 degrees C for H33342 and at 23 degrees C for DAPI. DAPI demonstrated DNA profiles with better coefficients of variation for Go/G1 cells than did H33342. This difference was consistently shown in four additional mammalian cell lines and bone marrows freshly obtained from five patients, four of which were leukemic. Both dyes, in the optimal staining conditions, can suppress the growth of CHO cells with H33342 more toxic than DAPI. In experiments on three leukemic bone marrows, H33342 was shown to be more toxic than DAPI in terms of colony-forming capability. Although there is considerable variation in the degree of the toxicity between different cases, more than 50% of leukemic colony-forming cells can survive after DAPI staining. These data indicate that DAPI is preferable to H33342 for use with human leukemic cells because the staining technique required is less stringent; there is a more homogenous staining of the DNA, and there is less cytotoxicity induced. Supravital staining of DNA with DAPI and viable sorting by flow cytometry should be reasonably possible for functional studies such as colony formation after sorting.","['Park, C H', 'Kimler, B F', 'Smith, T K']","['Park CH', 'Kimler BF', 'Smith TK']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,Exp Hematol,Experimental hematology,0402313,IM,"['Acute Disease', 'Animals', 'Benzimidazoles/toxicity', 'Bone Marrow/*pathology', 'Breast Neoplasms', 'Cell Line', 'Cell Survival/drug effects', 'Clone Cells', 'Cricetinae', 'Cricetulus', 'DNA/analysis', 'DNA, Neoplasm/*analysis', 'Female', 'Flow Cytometry/methods', 'Fluorescent Dyes/toxicity', 'Humans', 'Indoles/toxicity', 'Leukemia/*pathology', 'Ovary', 'Tumor Stem Cell Assay']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Exp Hematol. 1985 Nov;13(10):1039-43.,"['0 (Benzimidazoles)', '0 (DNA, Neoplasm)', '0 (Fluorescent Dyes)', '0 (Indoles)', '47165-04-8 (DAPI)', '9007-49-2 (DNA)', 'P976261J69 (bisbenzimide ethoxide trihydrochloride)']",,,"['BRSGS07RR05373/RR/NCRR NIH HHS/United States', 'K04CA00534/CA/NCI NIH HHS/United States', 'R01CA20717/CA/NCI NIH HHS/United States']",,,,,,,,
4054202,NLM,MEDLINE,19851213,20190813,0031-6970 (Print) 0031-6970 (Linking),29,1,1985,Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.,127-9,"In 6 patients with acute myeloblastic leukaemia, daunorubicin was assayed in leukaemic cells from peripheral blood or bone marrow. The cells were separated from red blood cells and granulocytes by centrifugation on a Ficoll-Isopac gradient. The assay was performed by high performance liquid chromatography. Daunorubicin concentrations in peripheral leukaemic cells, 2 hours after the end of the infusion, were much higher than in plasma, the cell/plasma concentration ratio reaching about 350 and rising to almost 700 at 24 h. At that time, drug concentrations were even higher in the bone marrow leukaemic cells. The value of the assay of daunorubicin in cells as method for monitoring therapy is discussed.","['Trillet, V', 'Lakhal, M', 'Lang, J', 'Perrin-Fayolle, E', 'Timour Chah, Q', 'Fiere, D', 'Faucon, G']","['Trillet V', 'Lakhal M', 'Lang J', 'Perrin-Fayolle E', 'Timour Chah Q', 'Fiere D', 'Faucon G']",['eng'],['Journal Article'],Germany,Eur J Clin Pharmacol,European journal of clinical pharmacology,1256165,IM,"['Adult', 'Aged', 'Daunorubicin/*metabolism', 'Female', 'Humans', 'Kinetics', 'Leukemia/*metabolism', 'Male', 'Middle Aged']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00547382 [doi]'],ppublish,Eur J Clin Pharmacol. 1985;29(1):127-9. doi: 10.1007/BF00547382.,['ZS7284E0ZP (Daunorubicin)'],,,,,,,,,,,
4054163,NLM,MEDLINE,19851218,20190813,0340-6199 (Print) 0340-6199 (Linking),144,3,1985 Sep,Increased prevalence of minor anomalies in childhood malignancy.,243-54,"Body measurements were taken and the prevalence of major malformations and of 57 minor anomalies was determined in 106 children with malignant disease, in 81 of their sibs, and in 106 control subjects matched to the patients according to sex, age and ethnic origin. Leukaemic children had a significantly smaller head circumference than the corresponding control children, but no significant differences in height, weight, anthropometric and syndromologic indices were found. No differences were observed in the frequency of associated major malformations including renal malformations detectable by sonography. The prevalence of minor anomalies was significantly higher in the patients with malignant disease and their sibs than in the control children: 69.2% of the patients, 63.0% of the sibs and 34.6% of the control subjects had at least one minor anomaly. When two and more minor anomalies were considered, the prevalence figures were 36.5%, 29.6% and 12.5%, respectively. Among the single minor anomalies only the Sydney line was significantly more frequent in patients with solid tumours. No specific association of an individual dysplasia or a pattern of minor anomalies with a given tumour could be established.","['Mehes, K', 'Signer, E', 'Pluss, H J', 'Muller, H J', 'Stalder, G']","['Mehes K', 'Signer E', 'Pluss HJ', 'Muller HJ', 'Stalder G']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Eur J Pediatr,European journal of pediatrics,7603873,IM,"['Adolescent', 'Adult', 'Body Height', 'Body Weight', 'Child', 'Child, Preschool', 'Congenital Abnormalities/complications/*epidemiology/genetics', 'Female', 'Head/anatomy & histology', 'Humans', 'Infant', 'Leukemia/complications/genetics', 'Male', 'Neoplasms/*complications/genetics', 'Switzerland']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1007/BF00451951 [doi]'],ppublish,Eur J Pediatr. 1985 Sep;144(3):243-54. doi: 10.1007/BF00451951.,,,,,,,,,,,,
4054099,NLM,MEDLINE,19851218,20181113,0261-4189 (Print) 0261-4189 (Linking),4,10,1985 Oct,DNA sequences responsible for tissue-specific expression of a chicken alpha-crystallin gene in mouse lens cells.,2589-95,"We have studied the DNA sequences required for high-level expression of a cloned chicken alpha-crystallin gene by introducing a hybrid alpha/delta-crystallin gene into nuclei of mouse lens epithelial cells in primary culture. The level of transient expression of the hybrid gene consisting of the 5' upstream promoter region of the alpha-crystallin gene fused to the structural portion of the delta-crystallin gene was determined by Western blot analysis using anti-delta-crystallin serum. The hybrid gene appears to be expressed in a tissue-specific manner, since it is active in mouse lens cells but not in fibroblasts or in L cells. The DNA sequences located 242-189 bp upstream from the transcription initiation site are required for high-level expression in lens cells. They are active when their orientation is reversed at the original site or when placed approximately 1.7 kbp downstream from the cap site in the second intron of the hybrid gene in either orientation. When these DNA sequences were replaced by the enhancer sequences of Moloney murine leukemia virus, the hybrid gene was expressed in both lens cells and fibroblasts.","['Okazaki, K', 'Yasuda, K', 'Kondoh, H', 'Okada, T S']","['Okazaki K', 'Yasuda K', 'Kondoh H', 'Okada TS']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,EMBO J,The EMBO journal,8208664,IM,"['Animals', 'Cells, Cultured', 'Chickens', 'Chromosome Mapping', 'Crystallins/*genetics', 'DNA, Recombinant', '*Enhancer Elements, Genetic', 'Epithelium/physiology', 'Fibroblasts/physiology', '*Gene Expression Regulation', '*Genes, Regulator', 'Genetic Linkage', 'Lens, Crystalline/*physiology', 'Mice', 'Transcription, Genetic']",PMC554548,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,EMBO J. 1985 Oct;4(10):2589-95.,"['0 (Crystallins)', '0 (DNA, Recombinant)']",,,,,,,,,,,['GENBANK/X03005']
4054094,NLM,MEDLINE,19851218,20181113,0261-4189 (Print) 0261-4189 (Linking),4,10,1985 Oct,LDL-mediated targeting of liposomes to leukemic lymphocytes in vitro.,2461-7,"We describe a method for the covalent coupling of low-density lipoproteins (LDL) to the surface of small unilamellar vesicles, and the delivery of the liposome content to leukemic L2C lymphocytes in vitro. We demonstrate the stability of the linkage between LDL and liposomes, the preservation of vesicle integrity and the affinity of the LDL for their specific receptors after the coupling reaction. Hygromycin B, an impermeant inhibitor of protein synthesis, was encapsulated in the targeted liposomes, and delivered into the cytoplasm of leukemic L2C lymphocytes by the LDL pathway, as demonstrated by the lethal effect on cells measured by 51chromium-release assay.","['Vidal, M', 'Sainte-Marie, J', 'Philippot, J R', 'Bienvenue, A']","['Vidal M', 'Sainte-Marie J', 'Philippot JR', 'Bienvenue A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,EMBO J,The EMBO journal,8208664,IM,"['Animals', 'Dose-Response Relationship, Drug', 'Endocytosis', 'Guinea Pigs', 'Hygromycin B/administration & dosage', 'Leukemia, Experimental/*metabolism', 'Lipoproteins, LDL/*metabolism', 'Liposomes/*administration & dosage', 'Lymphocytes/metabolism', 'Temperature']",PMC554530,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,EMBO J. 1985 Oct;4(10):2461-7.,"['0 (Lipoproteins, LDL)', '0 (Liposomes)', '3XQ2233B0B (Hygromycin B)']",,,,,,,,,,,
4053444,NLM,MEDLINE,19851219,20170112,0392-856X (Print) 0392-856X (Linking),3,3,1985 Jul-Sep,Pseudo-leukocytosis in essential mixed cryoglobulinemia may simulate chronic lymphocytic leukemia.,278-9,,"['Montecucco, C', 'Cherie-Ligniere, E L', 'Ascari, E']","['Montecucco C', 'Cherie-Ligniere EL', 'Ascari E']",['eng'],"['Case Reports', 'Letter']",Italy,Clin Exp Rheumatol,Clinical and experimental rheumatology,8308521,IM,"['Adult', 'Cryoglobulinemia/*diagnosis', 'Female', 'Humans', 'Leukemia, Lymphoid/*diagnosis', 'Leukocytosis/*diagnosis']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Clin Exp Rheumatol. 1985 Jul-Sep;3(3):278-9.,,,,,,,,,,,,
4053283,NLM,MEDLINE,19851211,20190511,0143-3334 (Print) 0143-3334 (Linking),6,11,1985 Nov,Survival curves and incidence of neoplastic and non-neoplastic disease in SENCAR mice.,1649-52,"The survival curves and the incidence of spontaneous diseases were studied in a population of SENCAR mice, a stock derived by a selected breeding protocol for enhanced susceptibility to chemical carcinogenesis in the skin. SENCAR mice proved to be as long-lived as other mouse strains or stocks, including one of their parental lines, Charles River CD-1. The most frequently occurring neoplasias in SENCAR mice were lymphoma, myeloid leukemia and reticulum cell sarcoma. Other frequently occurring neoplastic diseases included lung adenomas and carcinoma and mammary gland carcinoma. However, the incidence of these tumors was not higher than the incidence in CD-1 mice or other mouse strains or stocks. A variety of non-neoplastic diseases, both inflammatory and degenerative, were also observed in old mice. The most common were liver, spleen and kidney amyloidosis, pyelonephritis and papillary necrosis. These data indicate that selective breeding for susceptibility to chemical carcinogenesis has not produced a concomitant increase in the incidence of spontaneous neoplastic and non-neoplastic disease.","['Conti, C J', 'Clapp, N', 'Klein-Szanto, A J', 'Nesnow, S', 'Slaga, T J']","['Conti CJ', 'Clapp N', 'Klein-Szanto AJ', 'Nesnow S', 'Slaga TJ']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S.""]",England,Carcinogenesis,Carcinogenesis,8008055,IM,"['Animals', 'Female', 'Male', 'Mice', '*Mice, Inbred Strains', 'Mortality', 'Neoplasms/epidemiology/*veterinary', 'Rodent Diseases/*epidemiology', 'Sex Factors']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1093/carcin/6.11.1649 [doi]'],ppublish,Carcinogenesis. 1985 Nov;6(11):1649-52. doi: 10.1093/carcin/6.11.1649.,,,,,,,,,,,,
4053267,NLM,MEDLINE,19851202,20190829,0344-5704 (Print) 0344-5704 (Linking),15,3,1985,A low density lipoprotein-methotrexate covalent complex and its activity against L1210 cells in vitro.,223-7,"Low-density lipoprotein particles are potential drug carriers, but only lipophilic drug species partition into the core of the system. In this paper the polar drug methotrexate has been coupled to the exterior protein of low density lipoprotein (LDL) particles using the reagent 1-ethyl-3(3'-dimethylaminopropyl) carbodiimide HCl. The coupled system was sized by photon correlation spectroscopy and the in vitro activity of the complex determined against L1210 cells maintained in medium supplemented with fetal calf serum. The reaction between methotrexate and low density lipoprotein is variable but quantifiable, about ten drug molecules being attached to each LDL particle, resulting in an increase in the radius and polydispersity of the particles. The activity of the complex against L1210 murine leukaemia cells has been demonstrated in vitro, but it is 30 times less active than free drug.","['Halbert, G W', 'Stuart, J F', 'Florence, A T']","['Halbert GW', 'Stuart JF', 'Florence AT']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Cancer Chemother Pharmacol,Cancer chemotherapy and pharmacology,7806519,IM,"['Animals', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Kinetics', 'Leukemia L1210/*pathology', 'Lipoproteins, LDL/blood/chemical synthesis/isolation & purification/*toxicity', 'Methotrexate/chemical synthesis/*toxicity', 'Mice']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00263890 [doi]'],ppublish,Cancer Chemother Pharmacol. 1985;15(3):223-7. doi: 10.1007/BF00263890.,"['0 (Lipoproteins, LDL)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4053215,NLM,MEDLINE,19851218,20131121,0392-906X (Print) 0392-906X (Linking),4,4,1985 Aug,Limits of antifungal prophylaxis by ketoconazole in leukemic patients.,299-302,"Serum ketoconazole levels in leukemic patients, subjected to ketoconazole prophylaxis, were determined by an agar diffusion assay. High individual variability of drug concentration was noted. In addition, the highest drug concentration observed was less than 1 microgram/ml in 5 out of 6 patients studied. The reliability of prophylaxis of airborne opportunistic fungal infections by ketoconazole seems, therefore, to be hampered, at least in leukemics, by the too low serum concentrations of the drug. The bioassay proved to be highly reproducible and accurate as well as easy and safe to perform.","['Mazzoni, A', 'Fiorentini, C', 'Cevenini, R', 'Nanetti, A']","['Mazzoni A', 'Fiorentini C', 'Cevenini R', 'Nanetti A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Italy,Chemioterapia,Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,8401667,IM,"['Adult', 'Biological Assay', 'Female', 'Humans', 'Ketoconazole/blood/*therapeutic use', 'Leukemia/blood/*complications', 'Male', 'Mycoses/etiology/*prevention & control']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Chemioterapia. 1985 Aug;4(4):299-302.,['R9400W927I (Ketoconazole)'],,,,,,,,,,,
4053157,NLM,MEDLINE,19851213,20131121,0008-7335 (Print) 0008-7335 (Linking),124,38-39,1985 Sep 27,[Modern aspects of using chronopharmacology in hematology. II. Biorhythms in drug effects].,1220-2,,"['Berger, J', 'Mikeska, J']","['Berger J', 'Mikeska J']",['cze'],"['English Abstract', 'Journal Article']",Czech Republic,Cas Lek Cesk,Casopis lekaru ceskych,0004743,IM,"['Animals', '*Circadian Rhythm', 'Cytarabine/*administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Hematopoiesis/drug effects', 'Humans', 'Leukemia L1210/*pathology/physiopathology', 'Mice']",,1985/09/27 00:00,1985/09/27 00:01,['1985/09/27 00:00'],"['1985/09/27 00:00 [pubmed]', '1985/09/27 00:01 [medline]', '1985/09/27 00:00 [entrez]']",,ppublish,Cas Lek Cesk. 1985 Sep 27;124(38-39):1220-2.,['04079A1RDZ (Cytarabine)'],,Soucasne aspekty aplikace chronofarmakologie v hematologii. II. Biorytmy ucinku leku.,,,,,,,,,
4053085,NLM,MEDLINE,19851127,20061115,0147-4006 (Print) 0147-4006 (Linking),9,,1985,Comparative evaluation of three mammalian cell transformation assay systems.,399-410,"One cellular transformation assay system (Syrian hamster embryo (SHE) primary cells) and two viral mediated transformation systems (primary Syrian hamster embryo cells infected with Simian adenovirus type 7 (SHE/SA7), and a rat fibroblast cell line (2FR450) infected with Rauscher leukemia virus (Rat/RLV] were evaluated using a group of nine ""model"" and five coded chemicals. The purpose of the project was to establish the intra- and interlaboratory reproducibility of the assays and to provide a basis for objective comparisons between the systems. This is a preliminary evaluation of the assay systems using the results for these chemicals tested in eight collaborating laboratories under the auspices of the National Toxicology Program (NTP). The endpoint measured in each system is very different and a positive response in each had to be separately defined. The assay systems all produced a response to carcinogens and in most instances the responses could be qualitatively reproduced in the different laboratories. However, the assays differed significantly in their ability to demonstrate dose-related effects. In addition, multiple tests or modified assay procedures were required with every system in order to insure that chemicals had been adequately tested. In each system, technical or procedural limitations exist that preclude the application of these assays to routine chemical testing at this time. Among these limitations were ambiguity in scoring morphological transformation, significant but poorly defined influence of reagents such as serum or metabolic activation systems on test performance, and difficulty in repeating responses to a given chemical. Additional efforts to overcome these limitations will be necessary in order to make these test systems of use in routine testing of unknown chemicals for genetic toxicity.","['Tennant, R W', 'Stasiewicz, S', 'Spalding, J W']","['Tennant RW', 'Stasiewicz S', 'Spalding JW']",['eng'],"['Comparative Study', 'Journal Article']",United States,Carcinog Compr Surv,Carcinogenesis; a comprehensive survey,7704086,IM,"['Animals', '*Carcinogens', 'Cell Survival/drug effects', '*Cell Transformation, Neoplastic', 'Cells, Cultured', 'Cricetinae', 'Dose-Response Relationship, Drug', 'Drug Evaluation, Preclinical/*methods', 'Female', 'Male', 'Mesocricetus']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Carcinog Compr Surv. 1985;9:399-410.,['0 (Carcinogens)'],,,,,,,,,,,
4053067,NLM,MEDLINE,19851129,20131121,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 2,1985 Nov,Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.,5952-7,"The pharmacokinetic values of 1-beta-D-arabinofuranosylcytosine (ara-C) in plasma and its active metabolite 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) in circulating blast cells were studied in 11 patients with acute leukemia. ara-C was administered as a 2-h infusion (3 g/m2) followed in 12 to 24 h by a continuous infusion for 4 days in 10 patients and for 7 days in one. A steady-state concentration of ara-C in plasma (94 +/- 32 microM) was reached by the end of the 2-h infusion. Its elimination was biphasic with an initial and terminal t1/2 of 0.44 +/- 0.10 h and 2.8 +/- 0.9 h, respectively. The accumulation of ara-CTP in leukemic cells was linear and continued for up to 2 h after the bolus infusion. ara-CTP elimination was monophasic with a median t1/2 of 3.4 h (range, 1.25 to 18.9 h). The disposition of ara-C and 1-beta-D-arabinofuranosyluracil during continuous infusion was linear with dose rate over the dose range of 70 to 3000 mg/m2/day. The area under the concentration versus time curve for ara-CTP in leukemic cells was not related to the dose infused, but rather appeared to be intrinsic to the cells of each individual. As a general finding, the pharmacokinetic values of ara-CTP in circulating blasts were more heterogeneous than those of ara-C in plasma. There were marked differences in the absolute concentrations of ara-C in plasma and ara-CTP in leukemic cells at different times after the bolus infusion and also during continuous infusion. No correlation was evident between the determinants of ara-C pharmacokinetic values and those of ara-CTP. Thus, it is concluded that the pharmacokinetics of ara-C in plasma cannot predict for the metabolism of ara-CTP in leukemic cells.","['Liliemark, J O', 'Plunkett, W', 'Dixon, D O']","['Liliemark JO', 'Plunkett W', 'Dixon DO']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Arabinofuranosylcytosine Triphosphate/*blood', 'Arabinonucleotides/*blood', 'Cytarabine/administration & dosage/*blood', 'Humans', 'Kinetics', 'Leukemia/drug therapy/*metabolism']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 2):5952-7.,"['0 (Arabinonucleotides)', '04079A1RDZ (Cytarabine)', '13191-15-6 (Arabinofuranosylcytosine Triphosphate)']",,,"['CA 28153/CA/NCI NIH HHS/United States', 'CA 32839/CA/NCI NIH HHS/United States']",,,,,,,,
4053066,NLM,MEDLINE,19851129,20071114,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 2,1985 Nov,Circulating membrane vesicles in leukemic blood.,5944-51,"Ultramicroscopic membrane vesicles were found in the plasma of 17 patients with certain types of leukemia (acute promyelocytic leukemia, acute monocytic leukemia, acute myelomonocytic leukemia, and chronic myelogenous leukemia) and in guinea pigs with the L2C leukemia. Labeled vesicles were cleared from normal guinea pig plasma according to a two exponential function with a half-life for the second exponent of greater than 11 h. By immunofluorescence, vesicles shared antigens with the L2C leukemic cells. Attempts to elucidate the cellular origin of the circulating vesicles in human leukemias were less definitive. However, vesicles did not react with the platelet membrane antigen GP IIb/IIIa nor did the presence of circulating vesicles or vesicle-associated procoagulant activity correlate with the platelet count. In three patients studied serially, circulating vesicles paralleled disease activity. Vesicles were not detected in 16 other patients with leukemias including acute myelogenous leukemia and most lymphoid leukemias. Similarly, vesicles were not present in 29 normal plasmas or in 10 plasmas from patients with solid tumors or nonmalignant hematological disorders. In contrast to vesicles of similar appearance shed by a variety of solid and ascites tumor cells in vitro and in vivo, the vesicles circulating in leukemia patients and guinea pigs expressed variable and generally weak procoagulant activity and no tissue factor activity. Thus, although many of the patients with circulating vesicles expressed abnormal coagulation, we were not able to establish a close pathogenetic relationship between the procoagulant activity of circulating vesicles and clinical coagulopathies.","['Carr, J M', 'Dvorak, A M', 'Dvorak, H F']","['Carr JM', 'Dvorak AM', 'Dvorak HF']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Blood Coagulation', 'Cell Membrane/*ultrastructure', 'Cells, Cultured', 'Guinea Pigs', 'Half-Life', 'Humans', 'Leukemia/*blood/pathology', 'Platelet Count']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 2):5944-51.,,,,"['CA-28471/CA/NCI NIH HHS/United States', 'HL-07516/HL/NHLBI NIH HHS/United States']",,,,,,,,
4053063,NLM,MEDLINE,19851129,20141120,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 2,1985 Nov,In vitro hematopoiesis following induction chemotherapy for acute leukemia.,5921-5,"The treatment of acute nonlymphocytic leukemia results in predictable bone marrow hypoplasia and eventual cellular repopulation. In order to study this postchemotherapy repopulation, assays for hematopoietic progenitor cells were performed on bone marrow samples obtained from seven patients with acute nonlymphocytic leukemia who had received similar chemotherapeutic induction regimens. Burst-forming units (erythrocyte), colony-forming units (megakaryocyte), colony-forming units (granulocyte-macrophage), and colony-forming units (granulocyte-erythrocyte-megakaryocyte-macrophage) were cloned from human bone marrow mononuclear cells 5 and/or 10 days following completion of chemotherapy. All patients were pancytopenic and had hypocellular marrows when studied. Assays were performed 7 to 30 days prior to complete remission. Colony-forming units (granulocyte-macrophage) were equivalent to control values 5 days following chemotherapy, while burst-forming units (erythrocyte) and colony-forming units (granulocyte-erythrocyte-megakaryocyte-macrophage) were not assayable at that time. Ten days following chemotherapy, colony-forming units (granulocyte-erythrocyte-megakaryocyte-macrophage) and colony-forming units (granulocyte-macrophage) were 200 and 250% of normal controls, respectively, while burst-forming units (erythrocyte) were 29% of control values. Colony-forming units (macrophage) were 10 to 15 times normal values 10 days following chemotherapy. In contrast to colonies from normal individuals, those grown from marrow obtained following chemotherapy were frequently macroscopic and were composed of thousands of cells. Patient marrow had larger proportions of progenitor cells in S phase of the cell cycle than did normal controls. These studies suggest the presence of a stem cell in human bone marrow which is resistant to chemotherapeutic agents and has a high capacity to regenerate hematopoietic progenitor cells. The period following completion of chemotherapy for acute nonlymphocytic leukemia appears suitable for the study of the hierarchical nature of human hematopoiesis.","['Beyer, G S', 'Bruno, E', 'Hoffman, R']","['Beyer GS', 'Bruno E', 'Hoffman R']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Acute Disease', 'Adult', 'Antineoplastic Agents/*pharmacology', 'Bone Marrow/drug effects', 'Female', 'Hematopoiesis/*drug effects', 'Hematopoietic Stem Cells/drug effects', 'Humans', 'In Vitro Techniques', 'Leukemia/*drug therapy', 'Male', 'Middle Aged']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 2):5921-5.,['0 (Antineoplastic Agents)'],,,['T32 AM 7519-01/AM/NIADDK NIH HHS/United States'],,,,,,,,
4053030,NLM,MEDLINE,19851202,20121115,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 1,1985 Nov,"Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.",5563-8,"A novel, substituted 4-quinolinecarboxylic acid (NSC 339768) demonstrated antitumor activity against L1210 leukemia and B16 melanoma in the National Cancer Institute's Developmental Therapeutics Program. An extensive analogue synthesis program was initiated; over 200 derivatives were synthesized and tested for anticancer activity. One of these compounds, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt, NSC 368390 (DuP-785), was selected for further investigation because of its efficacy against a spectrum of human solid tumors and its water solubility. In initial studies with L1210 leukemia, the compound caused an increase in life span of greater than 80%. The activity was schedule dependent, and the compound was equally efficacious when administered i.p., i.v., s.c., or p.o. In tests against human tumors xenografted under the renal capsule of nude mice, NSC 368390 when injected i.p. in doses of 20-40 mg/kg daily for 9 days inhibited the growth of the MX-1 breast, LX-1 lung, BL/STX-1 stomach, and CX-1 colon carcinomas by greater than 90%. NSC 368390 also inhibited the growth of three distinct human colon carcinomas, the HCT-15, clone A, and DLD-2 tumors, growing s.c. in nude mice. An i.p. dose of 25 mg/kg given daily for 9 days inhibited the growth of the DLD-2 colon cancer by 98%. 1-beta-D-Arabinofuranosylcytosine and Adriamycin were ineffective, and fluorouracil was only moderately effective against these colon tumors. Because of its good activity against human colon tumors and other human carcinomas and its water solubility, NSC 368390 (DuP-785) is being developed as a Phase 1 anticancer agent.","['Dexter, D L', 'Hesson, D P', 'Ardecky, R J', 'Rao, G V', 'Tippett, D L', 'Dusak, B A', 'Paull, K D', 'Plowman, J', 'DeLarco, B M', 'Narayanan, V L']","['Dexter DL', 'Hesson DP', 'Ardecky RJ', 'Rao GV', 'Tippett DL', 'Dusak BA', 'Paull KD', 'Plowman J', 'DeLarco BM', 'Narayanan VL', 'et al.']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antimetabolites/pharmacology', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Biphenyl Compounds/*therapeutic use', 'Colonic Neoplasms/drug therapy', 'Female', 'Lung Neoplasms/drug therapy', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred DBA', 'Neoplasm Transplantation', 'Neoplasms, Experimental/*drug therapy', 'Transplantation, Heterologous']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 1):5563-8.,"['0 (Antimetabolites)', '0 (Antineoplastic Agents)', '0 (Biphenyl Compounds)', '5XL19F49H6 (brequinar)']",,,,,,,,,,,
4053027,NLM,MEDLINE,19851202,20131121,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 1,1985 Nov,"Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.",5532-9,"A series of 5-[(aminoalkyl)amino]-substituted anthra[1,9-cd] pyrazol-6(2H)ones (anthrapyrazoles) were synthesized. These compounds, which differ from the anthracenediones in that an additional pyrazole ring has been fused to the anthracene system in place of one carbonyl group, were evaluated in vivo for their anticancer activity in eight different mouse tumor systems. Compounds were selected for testing primarily on the basis of their high levels of activity P388 leukemia and occasionally for structural considerations. Sixty-seven % of the 21 analogues studied were curative in the National Cancer Institute P388 screen. Many of the compounds tested were highly active against each of the tumors of the National Cancer Institute panel. Thus 82, 73, 45, and 80% of the compounds tested were curative for L1210 leukemia, B16 melanoma, M5076 sarcoma, and the MX-1 mammary xenograft, respectively. Several of the compounds studied were curative against every tumor of the above panel. Because of the high activity of the anthrapyrazole series as a class in the National Cancer Institute tumor panel, additional testing was necessary to allow selection of clinical candidates. Twenty-one anthrapyrazoles were tested against mammary adenocarcinoma 16C, colon adenocarcinoma 11a, and the Ridgway osteogenic sarcoma. Four compounds, PD 113,309 (Cl-937), PD 113,785 (Cl-941), PD 111,815 (Cl-942), and PD 115,593, were judged superior to the rest on the basis of the expanded panel testing. The preclinical data to date suggest that these anthrapyrazoles are similar to doxorubicin in both degree and spectrum of activity. Each of these anthrapyrazoles were significantly more active than were the other synthetic intercalating agents, the anthracenediones mitoxantrone and ametantrone, against the tumors of the expanded panel. On the basis of their high level of broad spectrum activity in preclinical systems, ease of formulation, possible lack of cross-resistance with doxorubicin, and potential lack of cardiotoxicity, Cl-937, Cl-941, and Cl-942 have been selected for further preclinical evaluation and possible clinical development.","['Leopold, W R', 'Nelson, J M', 'Plowman, J', 'Jackson, R C']","['Leopold WR', 'Nelson JM', 'Plowman J', 'Jackson RC']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Anthracenes/*therapeutic use/toxicity', 'Antineoplastic Agents/*therapeutic use/toxicity', 'Doxorubicin/therapeutic use', 'Drug Resistance', 'Female', 'Intercalating Agents/*therapeutic use/toxicity', 'Male', 'Mice', 'Mice, Inbred Strains', 'Neoplasms, Experimental/*drug therapy', 'Pyrazoles/*therapeutic use/toxicity', 'Structure-Activity Relationship']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 1):5532-9.,"['0 (Anthracenes)', '0 (Antineoplastic Agents)', '0 (Intercalating Agents)', '0 (Pyrazoles)', '80168379AG (Doxorubicin)']",,,,,,,,,,,
4053006,NLM,MEDLINE,19851202,20131121,0008-5472 (Print) 0008-5472 (Linking),45,11 Pt 1,1985 Nov,Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.,5299-303,"A panel of murine monoclonal antibodies (MAbs) was produced by fusing NS-0 myeloma cells with spleen cells of a BALB/c X DBA/2 F1 mouse hyperimmunized against a highly immunogenic subline of the L1210 leukemia obtained by in vivo treatment of the L1210 parental line with the antitumor drug 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Among the 52 MAbs produced 16 (anti-D) were specifically cytotoxic in a complement-dependent cytotoxicity assay for the drug-altered subline and the others (anti-L) also cross-reacted with the L1210 parental leukemia. Six anti-D and three anti-L MAbs were selected for detailed studies of tissue specificity. In quantitative absorption experiments the antigens defined by these antibodies could not be detected on cells from normal mouse tissues (lung, liver, kidney, heart, spleen, and thymus). The reactivities of both anti-D and anti-L MAbs against a panel of L1210/DTIC sublines obtained at different times were assayed. The results showed that the antigenic specificities defined by anti-L MAbs were expressed on almost every L1210/DTIC subline while the anti-D MAbs detected antigenic structures specific for the L1210/DTIC used for the immunization. None of the MAbs tested cross-reacted with the L5178Y lymphoma or with its DTIC-altered sublines. The failure of anti-D MAbs to cross-react with cells from other L1210/DTIC sublines supports the hypothesis that the immunological alterations induced by the DTIC treatment are the consequence of mutagenic activity of the drug. On the other hand the presence of anti-L antigens on the cells of every L1210 subline indicates that the DTIC alteration is not accompanied by a loss of the tumor-associated antigen from the L1210 leukemia.","['Testorelli, C', 'Archetti, Y L', 'Aresca, P', 'Del Vecchio, L']","['Testorelli C', 'Archetti YL', 'Aresca P', 'Del Vecchio L']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antibodies, Monoclonal/*immunology', 'Antibody Specificity', 'Cell Line', 'Complement System Proteins/immunology', 'Cross Reactions', 'Cytotoxicity Tests, Immunologic', 'Dacarbazine/*pharmacology', 'Leukemia L1210/*immunology', 'Lymphoma/immunology', 'Male', 'Mice', 'Mice, Inbred BALB C']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Nov;45(11 Pt 1):5299-303.,"['0 (Antibodies, Monoclonal)', '7GR28W0FJI (Dacarbazine)', '9007-36-7 (Complement System Proteins)']",,,,,,,,,,,
4052984,NLM,MEDLINE,19851206,20190816,0165-4608 (Print) 0165-4608 (Linking),18,3,1985 Nov,Deletion of chromosome band 13q14: a primary event in preleukemia and leukemia.,243-9,"Chromosome abnormalities were analyzed in 200 consecutive patients with preleukemia and leukemia, and four patients were found with a deletion of 13q14 for an incidence of 2%. Together with data on chromosome aberrations in cancer from the literature, our results indicate clearly that deletion of band 13q14 is a nonrandom chromosome anomaly in premalignant and malignant blood disorders. Deletion of 13q14 appears specifically to constitute a primary event in the initiation of preleukemia. An additional rearrangement involving another chromosome must occur for progression of the preleukemia to acute nonlymphocytic leukemia.","['Morgan, R', 'Hecht, F']","['Morgan R', 'Hecht F']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Acute Disease', 'Aged', 'Chromosome Banding', '*Chromosome Deletion', '*Chromosomes, Human, 13-15', 'Humans', 'Infant', 'Karyotyping', 'Leukemia/*genetics', 'Male', 'Middle Aged', 'Preleukemia/*genetics']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0165-4608(85)90089-5 [pii]', '10.1016/0165-4608(85)90089-5 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Nov;18(3):243-9. doi: 10.1016/0165-4608(85)90089-5.,,,,['CA 25055/CA/NCI NIH HHS/United States'],,,,,,,,
4052983,NLM,MEDLINE,19851206,20190816,0165-4608 (Print) 0165-4608 (Linking),18,3,1985 Nov,Deletions of chromosome 13 in malignant hematologic disorders.,235-41,"Thirteen patients with a hematologic disorder and an interstitial deletion of part of a chromosome #13 were evaluated to determine if any specific clinical manifestations are associated with these cytogenetic anomalies. Our results suggest that these anomalies occur in approximately 1.7% of patients with a chromosomally abnormal clone and a hematologic disorder. They may occur as the sole chromosome anomaly (8 of our patients) or with other abnormalities (5 of our patients). The breakpoints are not always the same, but band 13q14 always seems to be lost. At the time of chromosome analysis, 5 patients had a history of myelofibrosis or agnogenic myeloid metaplasia, 2 had acute nonlymphocytic leukemia, 2 had a myelodysplastic syndrome, one had polycythemia vera, one had sideroblastic anemia, one had acute lymphocytic leukemia, and one had an undifferentiated myeloproliferative disorder.","['Johnson, D D', 'Dewald, G W', 'Pierre, R V', 'Letendre, L', 'Silverstein, M N']","['Johnson DD', 'Dewald GW', 'Pierre RV', 'Letendre L', 'Silverstein MN']",['eng'],['Journal Article'],United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Adult', 'Aged', 'Chromosome Banding', '*Chromosome Deletion', '*Chromosomes, Human, 13-15', 'Female', 'Hematologic Diseases/*genetics', 'Humans', 'Karyotyping', 'Leukemia/genetics', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/genetics', 'Myeloproliferative Disorders/genetics']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0165-4608(85)90088-3 [pii]', '10.1016/0165-4608(85)90088-3 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Nov;18(3):235-41. doi: 10.1016/0165-4608(85)90088-3.,,,,,,,,,,,,
4052982,NLM,MEDLINE,19851206,20190816,0165-4608 (Print) 0165-4608 (Linking),18,3,1985 Nov,Translocation 1;7 in hematologic disorders: a brief review of 22 cases.,207-13,"A translocation t(1;7)(p11;p11), previously reported in patients with myelodysplasia or leukemia has been found in seven new cases. The present report briefly reviews the cytogenetic and clinical features of 22 patients with this translocation. The majority of these patients had a history of occupational or therapeutic exposure to toxic substances or radiation. Trisomy 8 or 21 were the most common additional abnormalities, especially in leukemic patients. The t(1;7) should be added to the group of specific cytogenetic abnormalities observed frequently in secondary myelodysplasia and leukemia.","['Scheres, J M', 'Hustinx, T W', 'Geraedts, J P', 'Leeksma, C H', 'Meltzer, P S']","['Scheres JM', 'Hustinx TW', 'Geraedts JP', 'Leeksma CH', 'Meltzer PS']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Adolescent', 'Adult', 'Aged', 'Child', '*Chromosomes, Human, 1-3', '*Chromosomes, Human, 6-12 and X', 'Female', 'Hematologic Diseases/chemically induced/*genetics', 'Humans', 'Karyotyping', 'Male', 'Middle Aged', 'Occupational Diseases/chemically induced/genetics', 'Radiation Injuries/genetics', '*Translocation, Genetic/drug effects/radiation effects']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0165-4608(85)90085-8 [pii]', '10.1016/0165-4608(85)90085-8 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Nov;18(3):207-13. doi: 10.1016/0165-4608(85)90085-8.,,,,,,,,,,,,
4052981,NLM,MEDLINE,19851206,20190816,0165-4608 (Print) 0165-4608 (Linking),18,3,1985 Nov,Translocation (1;7)(p11;p11): a new myeloproliferative hematologic entity.,199-206,"Four cases with myeloproliferative syndromes or acute nonlymphocytic leukemia associated with t(1;7)(p11;p11) are presented. In each case, as in all cases published in the literature, the karyotypes of the affected cells contained two normal chromosomes #1, but only one chromosome #7, with the result that the basic karyotype was 46, -7, +t(1;7). This chromosome change is not geographically restricted, and appears to characterize a group of patients with myeloproliferative disorders and acute nonlymphocytic leukemia, including myeloproliferative syndromes, in whom exposure to previous chemotherapy, x-rays, or drugs is in the background history. The t(1;7) in secondary leukemia and myeloproliferative syndromes serves to duplicate the long arm of a chromosome #1 and to rescue the short arm of a chromosome #7.","['Sandberg, A A', 'Morgan, R', 'Hecht, B K', 'Hecht, F']","['Sandberg AA', 'Morgan R', 'Hecht BK', 'Hecht F']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Acute Disease', 'Aged', 'Chromosome Banding', '*Chromosomes, Human, 1-3', '*Chromosomes, Human, 6-12 and X', 'Female', 'Humans', 'Karyotyping', 'Leukemia/*genetics', 'Male', 'Middle Aged', 'Myelodysplastic Syndromes/*genetics', '*Translocation, Genetic']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']","['0165-4608(85)90084-6 [pii]', '10.1016/0165-4608(85)90084-6 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Nov;18(3):199-206. doi: 10.1016/0165-4608(85)90084-6.,,,,['CA-25055/CA/NCI NIH HHS/United States'],,,,,,,,
4052964,NLM,MEDLINE,19851211,20190619,0008-543X (Print) 0008-543X (Linking),56,9,1985 Nov 1,Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia.,2181-4,"Seventy-four adult patients with acute leukemia in relapse were studied. They received high-dose intravenous boluses of cytosine arabinoside (Ara-C) according to the following schedules: 3 g/m2 over 2 hours, every 12 hours for 4 to 12 consecutive doses, or a continuous infusion over 5 days at 200, 400, or 800 mg/m2/day. The patients' ages ranged from 16 to 68 years (median, 35). Subacute pulmonary failure attributable to Ara-C was observed in 16 of 72 evaluable patients (22%) and appeared 2 to 21 days (median, 6) after the first dose. None of the 28 patients who received up to six doses experienced any toxicity. With repeated courses or more than six doses in the first course there was a sharp increase in the incidence of toxicity. Thus, subacute pulmonary failure developed in 6 of 24 patients who received 9 doses and 6 of 19 patients who received 12 doses. The increase in toxicity with increasing number of doses is significant (P = 0.03). This suggests that the high-dose Ara-C regimen should be used with awareness of possible drug-induced pulmonary toxicity.","['Andersson, B S', 'Cogan, B M', 'Keating, M J', 'Estey, E H', 'McCredie, K B', 'Freireich, E J']","['Andersson BS', 'Cogan BM', 'Keating MJ', 'Estey EH', 'McCredie KB', 'Freireich EJ']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer,Cancer,0374236,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Cytarabine/administration & dosage/*adverse effects', 'Drug Evaluation', 'Female', 'Humans', 'Leukemia/*drug therapy', 'Lung Diseases/*chemically induced', 'Male', 'Middle Aged', 'Pulmonary Edema/chemically induced', 'Respiratory Insufficiency/chemically induced']",,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.1002/1097-0142(19851101)56:9<2181::aid-cncr2820560907>3.0.co;2-b [doi]'],ppublish,Cancer. 1985 Nov 1;56(9):2181-4. doi: 10.1002/1097-0142(19851101)56:9<2181::aid-cncr2820560907>3.0.co;2-b.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4052961,NLM,MEDLINE,19851219,20190619,0008-543X (Print) 0008-543X (Linking),56,12,1985 Dec 15,Extraintestinal cancers in inflammatory bowel disease.,2914-21,"The case histories of 1961 patients with inflammatory bowel disease (IBD), 1227 with Crohn's disease (CD) and 734 with ulcerative colitis (UC), have been studied for the incidence of extraintestinal malignant neoplasms. There were 54 extraintestinal cancers in 51 patients: 28 patients with CD and 23 with UC; 25 men and 26 women. There were 9 breast, 7 skin, 15 reticuloendothelial, 11 genitourinary, 3 lung, 3 perianal, 2 pancreatic islet cell, and several miscellaneous cancers. The number of patient-years from the onset of disease to the last date of follow-up was calculated for men and women with each form of IBD. The observed number (O) of neoplasms was recorded. The expected number (E) of neoplasms was derived from the Department of Health, Education, and Welfare (DHEW) incidence figures for the same neoplasms that occurred in a standard age- and sex-matched population. The O/E ratio was then calculated for each type of cancer as well as for the entire series. There were no statistically significant increases in overall O/E ratios of extraintestinal cancers for either CD (0.76) or UC (1.32). On the other hand, several specific types of cancer did appear to occur with a frequency that was significantly greater than expected. These cancers were classified into two groups. The first group included reticuloendothelial neoplasms. There was an excess of leukemias in UC (P less than 0.005) and an excess of lymphomas in both UC and CD (P less than 0.005). The second group included three squamous cell cancers of the perianal region, an incidence 30 times greater than expected, and two squamous cell cancers of the vagina, also in excess of the expected number. Lymphoma, leukemia, and squamous cell cancers have been reported to occur in excess in immunosuppressed or irradiated patients. It may therefore be speculated that the apparently increased incidence of these neoplasms in the patients with ileitis and colitis might be related to immunologic deficiencies associated with IBD, to the long-term administration of steroids or other immunosuppressive medications that were given to most of the patients or, possibly, to increased exposure to ionizing radiation. The apparently increased incidence of perianal and vaginal cancers of the squamous variety might be a consequence of the combined effects of chronic inflammatory disease involving these areas and primary immune suppression.","['Greenstein, A J', 'Gennuso, R', 'Sachar, D B', 'Heimann, T', 'Smith, H', 'Janowitz, H D', 'Aufses, A H Jr']","['Greenstein AJ', 'Gennuso R', 'Sachar DB', 'Heimann T', 'Smith H', 'Janowitz HD', 'Aufses AH Jr']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Adult', 'Aged', 'Colitis, Ulcerative/*complications', 'Crohn Disease/*complications', 'Female', 'Hodgkin Disease/complications', 'Humans', 'Leukemia/complications', 'Lymphoma/complications', 'Male', 'Middle Aged', 'Neoplasms/*complications', 'Retrospective Studies', 'Risk', 'Skin Neoplasms/complications']",,1985/12/15 00:00,2001/03/28 10:01,['1985/12/15 00:00'],"['1985/12/15 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/12/15 00:00 [entrez]']",['10.1002/1097-0142(19851215)56:12<2914::aid-cncr2820561232>3.0.co;2-j [doi]'],ppublish,Cancer. 1985 Dec 15;56(12):2914-21. doi: 10.1002/1097-0142(19851215)56:12<2914::aid-cncr2820561232>3.0.co;2-j.,,,,,,,,,,,,
4052958,NLM,MEDLINE,19851219,20190619,0008-543X (Print) 0008-543X (Linking),56,12,1985 Dec 15,Chronic lymphocytic leukemia with hyperleukocytosis. The hyperviscosity syndrome.,2865-9,"A 47-year-old man with hyperleukocytic chronic lymphocytic leukemia progressively developed retinal hemorrhages, headache, diplopia, dysequilibrium, slurred speech, nystagmus, ataxic gait, and hearing loss as his leukocyte count rose to a maximum of 968,000/mm3. All of these symptoms and signs resolved promptly after leukapheresis. The authors reviewed records of 210 patients with chronic lymphocytic leukemia seen at our institution over a 12-year period, and found 16 patients with sustained hyperleukocytosis above 500,000/mm3, 3 of whom had features of the hyperviscosity syndrome. No laboratory values consistently predicted the occurrence or lack of occurrence of the hyperviscosity syndrome. The key to the management of hyperviscosity syndrome in the setting of hyperleukocytic chronic lymphocytic leukemia is to consider the diagnosis and to rapidly lower the lymphocyte count.","['Baer, M R', 'Stein, R S', 'Dessypris, E N']","['Baer MR', 'Stein RS', 'Dessypris EN']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S.""]",United States,Cancer,Cancer,0374236,IM,"['Adult', 'Aged', '*Blood Viscosity', 'Female', 'Humans', 'Leukapheresis', 'Leukemia, Lymphoid/*blood/complications/therapy', 'Leukocytosis/blood/*etiology/therapy', 'Male', 'Middle Aged', 'Syndrome']",,1985/12/15 00:00,1985/12/15 00:01,['1985/12/15 00:00'],"['1985/12/15 00:00 [pubmed]', '1985/12/15 00:01 [medline]', '1985/12/15 00:00 [entrez]']",['10.1002/1097-0142(19851215)56:12<2865::aid-cncr2820561225>3.0.co;2-6 [doi]'],ppublish,Cancer. 1985 Dec 15;56(12):2865-9. doi: 10.1002/1097-0142(19851215)56:12<2865::aid-cncr2820561225>3.0.co;2-6.,,,,,,,,,,,,
4052936,NLM,MEDLINE,19851209,20190619,0008-543X (Print) 0008-543X (Linking),56,11,1985 Dec 1,Treatment of acute nonlymphocytic leukemia in young and elderly patients.,2587-92,"Among 95 consecutive patients with acute nonlymphocytic leukemia (ANLL), 61 were treated with a high-dose chemotherapeutic induction regimen consisting of daunorubicin, vincristine, and cytosine arabinoside (DOA). The complete remission (CR) rate was 66%. Although young patients responded better than older patients, only sex was found to be of prognostic significance for achieving CR (84% CR in men versus 47% in women, P less than 0.005, independent of age). Patients in CR received consolidation, monthly maintenance therapy, and late intensification for a period of 2 years. Median remission duration was 57 weeks and median survival, 93 weeks. Projected CR rate at 5 years was 30%. CR and survival duration were significantly longer in patients 40 to 60 years old when compared with younger and older patients (P = 0.023). They were also longer in male than in female patients (P = 0.018), but this may be due to an effect of age. In the 34 patients who did not receive DOA treatment because of age or poor clinical conditions, there was no survival beyond 57 weeks, except in a 73-year-old woman who reached a spontaneous remission during acute infection. ANLL characteristics at presentation revealed a tendency toward a smaller tumor mass (P less than 0.05) and rarer Auer rods present (P = 0.03) with increasing age. Features and treatment of ANLL in elderly patients are discussed in view of the poor results obtained with conservative management.","['Beguin, Y', 'Bury, J', 'Fillet, G', 'Lennes, G']","['Beguin Y', 'Bury J', 'Fillet G', 'Lennes G']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Age Factors', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Child', 'Cytarabine/administration & dosage/adverse effects', 'Daunorubicin/administration & dosage/adverse effects', 'Female', 'Humans', 'Leukemia/*drug therapy', 'Male', 'Middle Aged', 'Prognosis', 'Recurrence', 'Sex Factors', 'Vincristine/administration & dosage/adverse effects']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1002/1097-0142(19851201)56:11<2587::aid-cncr2820561109>3.0.co;2-8 [doi]'],ppublish,Cancer. 1985 Dec 1;56(11):2587-92. doi: 10.1002/1097-0142(19851201)56:11<2587::aid-cncr2820561109>3.0.co;2-8.,"['04079A1RDZ (Cytarabine)', '5J49Q6B70F (Vincristine)', 'ZS7284E0ZP (Daunorubicin)', 'DOA protocol']",,,,,,,,,,,
4052933,NLM,MEDLINE,19851209,20190619,0008-543X (Print) 0008-543X (Linking),56,11,1985 Dec 1,Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients.,2557-62,"Twenty-three of 26 patients with hairy cell leukemia evaluable for response to splenectomy had significant improvement in anemia, thrombocytopenia, and/or neutropenia. Eight of the 23 had a recurrence of cytopenia after a median response duration of 4 to 5 months (range, 1-22). The remaining 15 patients did not have a recurrence of cytopenia at 20 months median follow-up (range, 1-76). Six patients with postsplenectomy cytopenia were given androgenic steroids. Two of the six had an improvement in anemia and thrombocytopenia, and a third patient had an improvement in neutropenia. It was concluded that, although most patients with hairy cell leukemia have initial improvement in cytopenia with splenectomy, a significant number of them either fail to respond or have recurrent cytopenia after initial response to splenectomy. A trial of androgenic steroids is a reasonable therapeutic option in these patients. Alternative therapies are reviewed and recommendations made.","['Magee, M J', 'McKenzie, S', 'Filippa, D A', 'Arlin, Z A', 'Gee, T S', 'Clarkson, B D']","['Magee MJ', 'McKenzie S', 'Filippa DA', 'Arlin ZA', 'Gee TS', 'Clarkson BD']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Adult', 'Aged', 'Anabolic Agents/*therapeutic use', 'Female', 'Fluoxymesterone/therapeutic use', 'Hemoglobins/analysis', 'Humans', 'Leukemia, Hairy Cell/blood/drug therapy/*therapy', 'Leukocyte Count', 'Male', 'Middle Aged', 'Neutrophils', 'Oxymetholone/therapeutic use', 'Platelet Count', 'Recurrence', '*Splenectomy']",,1985/12/01 00:00,1985/12/01 00:01,['1985/12/01 00:00'],"['1985/12/01 00:00 [pubmed]', '1985/12/01 00:01 [medline]', '1985/12/01 00:00 [entrez]']",['10.1002/1097-0142(19851201)56:11<2557::aid-cncr2820561103>3.0.co;2-t [doi]'],ppublish,Cancer. 1985 Dec 1;56(11):2557-62. doi: 10.1002/1097-0142(19851201)56:11<2557::aid-cncr2820561103>3.0.co;2-t.,"['0 (Anabolic Agents)', '0 (Hemoglobins)', '9JU12S4YFY (Fluoxymesterone)', 'L76T0ZCA8K (Oxymetholone)']",,,,,,,,,,,
4052928,NLM,MEDLINE,19851210,20191030,0732-9482 (Print) 0732-9482 (Linking),2,2,1985 Spring,Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.,133-8,"Dihydrofolate reductase (DHFR), the main target for methotrexate and other antifolate compounds was found to be present in 100-200 times higher concentration in human cell lines grown in vitro than in human tumors or cells obtained in situ. The DHFR content of human cell lines in vitro however were equivalent to rodent tumor lines also measured in vitro. The enzyme was quantitated by [3H]methotrexate binding, [3H]dihydrofolate reduction to [3H]tetrahydrofolate, and immunoprecipitation with a monospecific anti-serum to DHFR. Additional studies revealed only a liver sample to contain significant amounts of an inhibitor of DHFR activity. It is postulated either that low levels of DHFR in fresh human tissue reflect low cell turnover or conversely that high levels in vitro and in animal tissues reflect high levels of enzyme due to selection because of high levels of folic acid in culture medium and prepared feeds.","['Kamen, B A', 'Nylen, P A', 'Whitehead, V M', 'Abelson, H T', 'Dolnick, B J', 'Peterson, D W']","['Kamen BA', 'Nylen PA', 'Whitehead VM', 'Abelson HT', 'Dolnick BJ', 'Peterson DW']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer Drug Deliv,Cancer drug delivery,8409965,IM,"['Animals', 'Cattle', 'Cell Line', 'Cells, Cultured', 'Chickens', 'Humans', 'Leukemia, Experimental/*enzymology', 'Liver/enzymology', 'Methotrexate/metabolism', 'NADP/metabolism', 'Neoplasms/*enzymology', 'Tetrahydrofolate Dehydrogenase/*deficiency', 'Tissue Distribution']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1089/cdd.1985.2.133 [doi]'],ppublish,Cancer Drug Deliv. 1985 Spring;2(2):133-8. doi: 10.1089/cdd.1985.2.133.,"['53-59-8 (NADP)', 'EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4052923,NLM,MEDLINE,19851218,20191030,0732-9482 (Print) 0732-9482 (Linking),2,1,1985 Winter,Comparison of cytotoxicity of single dose and infusion of alkylating agents.,11-8,"Both cytotoxicity and host toxicity were examined for the alkylating agents HN2, BCNU and L-PAM administered intravenously (IV) either as a single bolus injection or a 24-hour infusion. The bolus injection was more effective than the infusion schedule at a given dose for BCNU and L-PAM. Unexpectedly, the HN2 infusion schedule was more effective than bolus injection at a given dose. When host survival was the endpoint, both HN2 and L-PAM were shown to be more effective by the infusion schedule.","['Valeriote, F', 'Vietti, T']","['Valeriote F', 'Vietti T']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Drug Deliv,Cancer drug delivery,8409965,IM,"['Alkylating Agents/*administration & dosage/toxicity', 'Animals', 'Carmustine/administration & dosage/toxicity', 'Cell Survival/drug effects', 'Colony-Forming Units Assay', 'Infusions, Parenteral', 'Injections, Intravenous', 'Lethal Dose 50', 'Leukemia L1210/*drug therapy/pathology', 'Male', 'Melphalan/administration & dosage/toxicity', 'Mice', 'Mice, Inbred DBA', 'Nitrogen Mustard Compounds/administration & dosage/toxicity']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1089/cdd.1985.2.11 [doi]'],ppublish,Cancer Drug Deliv. 1985 Winter;2(1):11-8. doi: 10.1089/cdd.1985.2.11.,"['0 (Alkylating Agents)', '0 (Nitrogen Mustard Compounds)', 'Q41OR9510P (Melphalan)', 'U68WG3173Y (Carmustine)']",,,['CA34144/CA/NCI NIH HHS/United States'],,,,,,,,
4052832,NLM,MEDLINE,19851210,20190912,0735-7907 (Print) 0735-7907 (Linking),3,5,1985,Lymphoid colony growth with phorbol myristate acetate and lymphocyte-conditioned media in chronic lymphocytic leukemia and malignant lymphomas.,427-33,"Cell preparations from 49 cases of lymphoid malignancy were cultured to determine optimal culture conditions (in semisolid media). Colony growth was obtained in the majority of cases (73%) using the combination of phorbol myristate acetate (PMA) and lymphocyte-conditioned medium (L-CM). Cell surface marker studies of plated cells in 36 cases identified 31 to be B-cell type, 1 to be T-cell type, and 4 null-cell type. The morphology and markers of harvested cells were similar to plated cells, suggesting proliferation of neoplastic cells predominantly. A relationship was found between the degree of colony growth and the clinical course of the disease in lymphomas but not in chronic lymphocytic leukemia (CLL). The use of PMA in combination with other mitogens deserves further investigation as a colony growth stimulator in hemopoietic malignancies.","['Maksymiuk, A W', 'Skinnider, L F']","['Maksymiuk AW', 'Skinnider LF']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Cancer Invest,Cancer investigation,8307154,IM,"['Cell Division/drug effects', 'Cells, Cultured', 'Chronic Disease', 'Culture Media', 'Humans', 'Leukemia, Lymphoid/*pathology', 'Lymph Nodes/*pathology', 'Lymphocytes/drug effects/*immunology', 'Lymphoma/*pathology', 'Phorbols/*pharmacology', 'Phytohemagglutinins/pharmacology', 'Prognosis', 'Tetradecanoylphorbol Acetate/*pharmacology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.3109/07357908509039803 [doi]'],ppublish,Cancer Invest. 1985;3(5):427-33. doi: 10.3109/07357908509039803.,"['0 (Culture Media)', '0 (Phorbols)', '0 (Phytohemagglutinins)', 'NI40JAQ945 (Tetradecanoylphorbol Acetate)']",,,,,,,,,,,
4052488,NLM,MEDLINE,19851127,20151119,0006-3029 (Print) 0006-3029 (Linking),30,5,1985 Sep-Oct,[Levels of labile phosphorus-containing metabolites].,905-10,The work deals with the investigation of possible use of 31P-NMR for revealing metabolism changes in the mouse liver during the development of leukemia. This method was shown to permit observation of the extreme pattern of relative concentrations of sugar phosphate and bioorganic phosphate in the latent period. This observed increase in the metabolic activity of hepatocytes correlates with biophysical shifts found by other methods.,"['Khristianovich, D S', 'Knubovets, T L', ""Sibel'dina, L A"", 'Dronova, L M']","['Khristianovich DS', 'Knubovets TL', ""Sibel'dina LA"", 'Dronova LM']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Biofizika,Biofizika,0372666,IM,"['Animals', 'Leukemia, Experimental/drug therapy/*metabolism', 'Liver/*metabolism', 'Magnetic Resonance Spectroscopy', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Molecular Weight', 'Phosphates/metabolism', 'Phosphorus/*metabolism', 'Time Factors', 'Vincristine/therapeutic use']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Biofizika. 1985 Sep-Oct;30(5):905-10.,"['0 (Phosphates)', '27YLU75U4W (Phosphorus)', '5J49Q6B70F (Vincristine)']",,Soderzhanie labil'nykh fosforsoderzhashchikh metabolitov.,,,,,,,,,
4052328,NLM,MEDLINE,19851126,20190704,0007-1048 (Print) 0007-1048 (Linking),61,1,1985 Sep,Favourable remission rate by repeating low dose ARA-C treatment in ANLL and RAEB.,187-90,,"['Izumi, Y', 'Sawada, H', 'Okazaki, T', 'Mochizuki, T', 'Ishikura, H', 'Tashima, M', 'Yamagishi, M', 'Uchino, H']","['Izumi Y', 'Sawada H', 'Okazaki T', 'Mochizuki T', 'Ishikura H', 'Tashima M', 'Yamagishi M', 'Uchino H']",['eng'],['Letter'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Anemia, Aplastic/*drug therapy', 'Bone Marrow/pathology', 'Cytarabine/*therapeutic use', 'Female', 'Humans', 'Leukemia/*drug therapy', 'Male', 'Middle Aged']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb04077.x [doi]'],ppublish,Br J Haematol. 1985 Sep;61(1):187-90. doi: 10.1111/j.1365-2141.1985.tb04077.x.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4052321,NLM,MEDLINE,19851126,20190704,0007-1048 (Print) 0007-1048 (Linking),61,1,1985 Sep,Myeloid progenitor surface antigen identified by monoclonal antibody.,11-20,"A mouse monoclonal antibody, WM-15, has been developed which reacts with a human myeloid lineage-restricted cell surface antigen. WM-15, an IgG1 antibody, reacts with a mean of 3.8% of normal bone marrow mononuclear cells, identifying predominantly promyelocytes and myeloblasts, and in fluorescence-activated cell sorting experiments produces enrichment of bone marrow granulocyte-macrophage progenitor cells. Normal mature monocytes and granulocytes are weakly labelled by WM-15, but other haemopoietic cells including erythroblasts and all lymphoid cells are unreactive. The myeloid specificity of this antibody is highlighted by its reactivity with myeloid leukaemia cell lines and 65% of cases of acute myeloid leukaemia, while lymphoid cell lines and leukaemias are WM-15 negative. WM-15 appears to be a useful reagent for further investigation of normal and abnormal myelopoiesis.","['Bradstock, K F', 'Favaloro, E J', 'Kabral, A', 'Kerr, A', 'Hughes, W G', 'Musgrove, E']","['Bradstock KF', 'Favaloro EJ', 'Kabral A', 'Kerr A', 'Hughes WG', 'Musgrove E']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Br J Haematol,British journal of haematology,0372544,IM,"['Animals', 'Antibodies, Monoclonal/*immunology', 'Antibody Specificity', 'Antigens, Neoplasm/analysis', 'Antigens, Surface/*analysis', 'Blood Cells/immunology', 'Bone Marrow/*immunology', 'Cell Line', 'Hematopoietic Stem Cells/*immunology', 'Humans', 'Leukemia/immunology', 'Mice', 'Mice, Inbred BALB C']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb04055.x [doi]'],ppublish,Br J Haematol. 1985 Sep;61(1):11-20. doi: 10.1111/j.1365-2141.1985.tb04055.x.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Antigens, Surface)']",,,,,,,,,,,
4052311,NLM,MEDLINE,19851213,20191022,0007-0971 (Print) 0007-0971 (Linking),79,4,1985 Oct,Hairy cell leukaemia and Legionnaires' disease.,393-5,"A 69-year-old man who had recently returned from a holiday in Majorca, presented with haemoptysis and fever. Chest radiograph showed right lower lobe consolidation. A diagnosis of Legionnaires' disease was made. He was treated with erythromycin and made an uneventful recovery.","['Chowdhury, V J', 'Oscier, D G', 'Mufti, G J', 'Hamblin, T J']","['Chowdhury VJ', 'Oscier DG', 'Mufti GJ', 'Hamblin TJ']",['eng'],"['Case Reports', 'Journal Article']",England,Br J Dis Chest,British journal of diseases of the chest,7511123,IM,"['Aged', 'Erythromycin/therapeutic use', 'Humans', ""Legionnaires' Disease/*complications/drug therapy"", 'Leukemia, Hairy Cell/*complications', 'Male']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1016/0007-0971(85)90075-0 [doi]'],ppublish,Br J Dis Chest. 1985 Oct;79(4):393-5. doi: 10.1016/0007-0971(85)90075-0.,['63937KV33D (Erythromycin)'],,,,,,,,,,,
4052259,NLM,MEDLINE,19851205,20191022,0814-9763 (Print) 0814-9763 (Linking),13,2,1985 May,Influence of neural retina on lens fibre differentiation in rats.,103-11,"Lens epithelial explants grown in retina-conditioned medium (RCM) undergo structural and molecular changes characteristic of fibre differentiation in the intact lens. We suggest that in vivo neural retina releases a fibre differentiation factor (FDF) that interacts with equatorial lens epithelial cells and stimulates them to undergo fibre cell differentiation. According to this model, interaction with neural retina is essential for normal lens formation in embryos and for normal lens growth throughout life. Preliminary work on purification of the factor indicates that FDF activity is associated with a high molecular weight complex of 500 kd. The active component of this complex appears to be an 80 kd molecule.","['McAvoy, J W', 'Campbell, M T', 'Walton, J']","['McAvoy JW', 'Campbell MT', 'Walton J']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",Australia,Aust N Z J Ophthalmol,Australian and New Zealand journal of ophthalmology,8505423,IM,"['Animals', 'Animals, Newborn/physiology', 'Cell Differentiation', 'Cells, Cultured', 'Chemical Phenomena', 'Chemistry', 'Crystallins/metabolism', 'Culture Media', 'Epithelial Cells', 'Epithelium/ultrastructure', 'Glycoproteins/metabolism', '*Growth Inhibitors', '*Interleukin-6', 'Lens, Crystalline/cytology/metabolism/*physiology/ultrastructure', 'Leukemia Inhibitory Factor', '*Lymphokines', 'Rats', 'Retina/*physiology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1111/j.1442-9071.1985.tb00411.x [doi]'],ppublish,Aust N Z J Ophthalmol. 1985 May;13(2):103-11. doi: 10.1111/j.1442-9071.1985.tb00411.x.,"['0 (Crystallins)', '0 (Culture Media)', '0 (Glycoproteins)', '0 (Growth Inhibitors)', '0 (Interleukin-6)', '0 (Leukemia Inhibitory Factor)', '0 (Lymphokines)']",,,['R01 EY03177/EY/NEI NIH HHS/United States'],,,,,,,,
4052102,NLM,MEDLINE,19851113,20190623,0006-2952 (Print) 0006-2952 (Linking),34,19,1985 Oct 1,Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay.,3603-5,,"['Lacey, E', 'Watson, T R']","['Lacey E', 'Watson TR']",['eng'],"['Comparative Study', 'Journal Article']",England,Biochem Pharmacol,Biochemical pharmacology,0101032,IM,"['Animals', 'Benzimidazoles/pharmacology/*therapeutic use', 'Carbamates/pharmacology/*therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Leukemia L1210/*drug therapy', 'Macromolecular Substances', 'Mice', 'Nocodazole', 'Sheep', 'Structure-Activity Relationship', '*Tubulin Modulators']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']","['0006-2952(85)90742-7 [pii]', '10.1016/0006-2952(85)90742-7 [doi]']",ppublish,Biochem Pharmacol. 1985 Oct 1;34(19):3603-5. doi: 10.1016/0006-2952(85)90742-7.,"['0 (Benzimidazoles)', '0 (Carbamates)', '0 (Macromolecular Substances)', '0 (Tubulin Modulators)', 'SH1WY3R615 (Nocodazole)']",,,,,,,,,,,
4051924,NLM,MEDLINE,19851115,20190829,0005-7967 (Print) 0005-7967 (Linking),23,5,1985,Behavioral management of children's distress during painful medical procedures.,513-20,,"['Jay, S M', 'Elliott, C H', 'Ozolins, M', 'Olson, R A', 'Pruitt, S D']","['Jay SM', 'Elliott CH', 'Ozolins M', 'Olson RA', 'Pruitt SD']",['eng'],['Journal Article'],England,Behav Res Ther,Behaviour research and therapy,0372477,IM,"['*Adaptation, Psychological', 'Adolescent', 'Behavior Therapy/*methods', 'Biopsy, Needle', 'Bone Marrow/*pathology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Leukemia/psychology/*therapy', 'Male', 'Spinal Puncture/*psychology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0005-7967(85)90098-1 [pii]', '10.1016/0005-7967(85)90098-1 [doi]']",ppublish,Behav Res Ther. 1985;23(5):513-20. doi: 10.1016/0005-7967(85)90098-1.,,,,,,,,,,,,
4051667,NLM,MEDLINE,19851119,20061115,0003-9055 (Print) 0003-9055 (Linking),39,4,1985 Jul,[Cell electrophoretic studies of cattle lymphocytes].,545-50,,"['Gallien, P', 'Perlberg, K W', 'Miko, A', 'Kruger, K']","['Gallien P', 'Perlberg KW', 'Miko A', 'Kruger K']",['ger'],"['English Abstract', 'Journal Article']",Germany,Arch Exp Veterinarmed,Archiv fur experimentelle Veterinarmedizin,0372410,IM,"['Animals', 'Cattle/*blood', 'Culture Media', 'Electrophoresis/methods', 'Heparin/pharmacology', 'Immune Sera/pharmacology', 'Leukemia/*veterinary', 'Lymphocytes/drug effects/*physiology', 'Neuraminidase/pharmacology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Arch Exp Veterinarmed. 1985 Jul;39(4):545-50.,"['0 (Culture Media)', '0 (Immune Sera)', '9005-49-6 (Heparin)', 'EC 3.2.1.18 (Neuraminidase)']",,Zellelektrophoretische Untersuchungen an Lymphozyten des Rindes.,,,,,,,,,
4051656,NLM,MEDLINE,19851106,20061115,0003-9055 (Print) 0003-9055 (Linking),39,3,1985 May,[Determination of cytotoxic antibodies against BL-3 cells in cattle with enzootic leukosis].,408-13,,"['Ristau, E', 'Weppe, C', 'Schon, R']","['Ristau E', 'Weppe C', 'Schon R']",['ger'],"['English Abstract', 'Journal Article']",Germany,Arch Exp Veterinarmed,Archiv fur experimentelle Veterinarmedizin,0372410,IM,"['Animals', 'Antilymphocyte Serum/*analysis', 'Cattle', 'Cattle Diseases/*immunology', 'Cell Line', 'Complement System Proteins/immunology', 'Cytotoxicity, Immunologic', 'Female', 'Leukemia/immunology/*veterinary', 'Lymphocytes']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Arch Exp Veterinarmed. 1985 May;39(3):408-13.,"['0 (Antilymphocyte Serum)', '9007-36-7 (Complement System Proteins)']",,Nachweis zytotoxischer Antikorper gegen BL-3-Zellen bei Rindern mit enzootischer Leukose.,,,,,,,,,
4051654,NLM,MEDLINE,19851106,20061115,0003-9055 (Print) 0003-9055 (Linking),39,3,1985 May,[Determination of tumor-associated antigen activity in plasma membrane preparations from tumorous lymph nodes of cattle with enzootic leukosis].,375-86,,"['Ristau, E', 'Klima, F']","['Ristau E', 'Klima F']",['ger'],"['English Abstract', 'Journal Article']",Germany,Arch Exp Veterinarmed,Archiv fur experimentelle Veterinarmedizin,0372410,IM,"['Animals', 'Antigens, Neoplasm/*analysis', 'Cattle', 'Cattle Diseases/*immunology', 'Enzyme-Linked Immunosorbent Assay', 'Immunoelectrophoresis, Two-Dimensional', 'Intracellular Membranes/immunology', 'Leukemia/immunology/*veterinary', 'Lymph Nodes/*immunology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Arch Exp Veterinarmed. 1985 May;39(3):375-86.,"['0 (Antigens, Neoplasm)']",,Nachweis einer tumorassoziierten Antigenaktivitat in Plasmamembranpraparaten aus tumorosen Lymphknoten von Rindern mit enzootischer Leukose.,,,,,,,,,
4051575,NLM,MEDLINE,19851104,20190824,0003-9896 (Print) 0003-9896 (Linking),40,4,1985 Jul-Aug,Leukemia cell types and agricultural practices in Nebraska.,211-4,"The risk of specific histologic types of leukemia among farmers was investigated using mortality records from Nebraska for the years 1957-1974. The frequency of farming as an occupation listed on the death certificates among 1,084 leukemia deaths was compared to the corresponding frequency for 2,168 controls for calculation of odds ratios (OR). The elevated OR for chronic lymphatic leukemia among farmers was statistically significant (OR = 1.67), while elevated ORs for acute lymphatic leukemia (OR = 1.34), acute monocytic leukemia (OR = 1.94), and acute unspecified leukemia (OR = 2.36) were not. Farmers who died at younger ages or who were born in more recent years were at greater risk of acute lymphatic, acute myeloid, chronic myeloid, acute unspecified, and unspecified leukemia than other farmers. Certain cell types were related to agricultural characteristics of the subject's county of residence, although few were statistically significant. Farmers from counties with large cattle inventories and significant dairy activity were at higher risk of chronic lymphatic leukemia. Farmers from major corn-producing, hog- and chicken-raising, and pesticide- and fertilizer-using counties tended to be at higher risk of acute lymphatic, acute myeloid, chronic myeloid, and acute unspecified leukemia than farmers from counties less involved in the production or use of these agricultural factors.","['Blair, A', 'White, D W']","['Blair A', 'White DW']",['eng'],['Journal Article'],United States,Arch Environ Health,Archives of environmental health,0212627,IM,"['Adult', 'Age Factors', 'Aged', ""Agricultural Workers' Diseases/*epidemiology"", 'Humans', 'Leukemia/*epidemiology', 'Male', 'Middle Aged', 'Nebraska', 'Smoking', 'Time Factors']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1080/00039896.1985.10545920 [doi]'],ppublish,Arch Environ Health. 1985 Jul-Aug;40(4):211-4. doi: 10.1080/00039896.1985.10545920.,,,,,,,,,,,,
4051519,NLM,MEDLINE,19851107,20161123,0385-0684 (Print) 0385-0684 (Linking),12,10,1985 Oct,[Antitumor activities of orally administered 4-carbamoylimidazolium-5-olate (SM-108)].,2030-6,"We investigated the antitumor effect of orally administered SM-108. The drug showed strong antitumor activities against Ehrlich carcinoma, sarcoma 180, P388 leukemia, L1210 leukemia, colon 26 adenocarcinoma, colon 38 adenocarcinoma, and Lewis lung carcinoma. The antitumor activity of SM-108 against Ehrlich carcinoma was so remarkable, in fact, that all mice in a group survived for a long time. The antitumor effect of SM-108 depends on its administration schedule. Treatment involving a schedule of one dose every 6 h for 24 h at intervals of 3 days brought about a much stronger effect than daily single treatment. The maintenance of a high serum level of SM-108 for 24 h by the former treatment is responsible for the strong therapeutic effects, because the action of SM-108 is time-dependent. The antitumor activities of SM-108 administered orally are excellent enough to be comparable with those obtained by intraperitoneal administration as previously reported.","['Nakamura, M', 'Fukui, M', 'Morisada, S', 'Inaba, M', 'Tsukagoshi, S', 'Sakurai, Y']","['Nakamura M', 'Fukui M', 'Morisada S', 'Inaba M', 'Tsukagoshi S', 'Sakurai Y']",['jpn'],['Journal Article'],Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Administration, Oral', 'Animals', '*Antineoplastic Agents', 'Body Weight/drug effects', 'Carcinoma, Ehrlich Tumor/drug therapy', 'Colonic Neoplasms/drug therapy', 'Drug Administration Schedule', 'Imidazoles/administration & dosage/*therapeutic use', 'Leukemia P388/drug therapy', 'Lung Neoplasms/drug therapy', 'Male', 'Mice', 'Mice, Inbred ICR', 'Neoplasms, Experimental/*drug therapy/metabolism', 'Sarcoma 180/drug therapy']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Oct;12(10):2030-6.,"['0 (Antineoplastic Agents)', '0 (Imidazoles)', 'U6IZ97918F (4-carbamoylimidazolium 5-olate)']",,,,,,,,,,,
4051335,NLM,MEDLINE,19851112,20041117,0003-1348 (Print) 0003-1348 (Linking),51,10,1985 Oct,Incidence of malignancy in peripheral lymph node biopsy.,587-90,"A review was made of 62 lymph node biopsy procedures during a 12-month period, from January 1, 1982, to December 31, 1982. The overall diagnostic yield was 56.5 per cent. Malignant lymph nodes were found in 53.2 per cent of cases. Seventy-two and two-tenths per cent (72.2%) of all malignant lymph nodes were metastatic carcinoma, including 6.1 per cent of metastatic lymph nodes with unknown primary. Twenty-seven and three-tenths per cent (27.3%) of all malignant lymph nodes belonged to the lymphoma-leukemia group. Among all the superficial lymph node regions, enlarged supraclavicular lymph nodes are associated with the highest incidence (75%) of malignancy. Clinical features associated with high incidence malignancy were: age greater than 55 years (75.8%), duration of less than 1 month (66.6%)--particularly, with a history of previous malignancy (91.7%). The anatomic knowledge of regional lymphatic drainage is essential in localizing the primary lesion of a metastatic lymph node.","['Sriwatanawongsa, V', 'Cardoso, R', 'Chang, P']","['Sriwatanawongsa V', 'Cardoso R', 'Chang P']",['eng'],['Journal Article'],United States,Am Surg,The American surgeon,0370522,IM,"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Axilla', 'Biopsy', 'Child', 'Clavicle', 'Female', 'Humans', 'Leukemia/*epidemiology/pathology', 'Lymph Nodes/*pathology', 'Lymphatic Metastasis/*epidemiology', 'Lymphoma/*epidemiology/pathology', 'Male', 'Middle Aged', 'Neck', 'Probability']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Am Surg. 1985 Oct;51(10):587-90.,,,,,,,,,,,,
4051064,NLM,MEDLINE,19851118,20190514,0090-0036 (Print) 0090-0036 (Linking),75,11,1985 Nov,Mortality among workers exposed to coal tar pitch volatiles and welding emissions: an exercise in epidemiologic triage.,1283-7,"The United Automobile Workers International Union has established a system of epidemiologic triage to evaluate patterns of mortality among groups of union members. In response to worker concerns, the Union examined mortality at a metal stamping plant, using a method which linked pension records with the State of Michigan computerized death registry. The observed proportion of malignant neoplasms was nearly twice that expected (95% Confidence Limits 1.36, 2.62). Two- to five-fold excess proportional mortality from cancer of the digestive organs, lung cancer, and leukemia accounted for most of the overall excess. Strong associations were found between lung and digestive organ cancer and employment as maintenance welders or millwrights in the plant (odds ratios greater than 10). High levels of six polycyclic aromatic hydrocarbons with mutagenic and carcinogenic properties were found during hot coal tar application to wood block floors, work conducted by the high-risk groups. These levels were substantially reduced following the purchase of new tar pots. The example demonstrates that epidemiologic tools can play a valuable role in occupational health decision making, but care must be taken to avoid mechanical reliance on quantitative testing and to acknowledge the important role of social and political value judgments in the establishment of responsible public policy.","['Silverstein, M', 'Maizlish, N', 'Park, R', 'Mirer, F']","['Silverstein M', 'Maizlish N', 'Park R', 'Mirer F']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Am J Public Health,American journal of public health,1254074,IM,"['Adult', 'Coal Tar/*poisoning', 'Death Certificates', 'Epidemiologic Methods', 'Female', 'Humans', 'Male', 'Michigan', 'Middle Aged', 'Neoplasms/chemically induced/*mortality', 'Occupational Diseases/chemically induced/*mortality', 'Occupations', 'Polycyclic Compounds/*poisoning', 'Welding']",PMC1646700,1985/11/01 00:00,1985/11/01 00:01,['1985/11/01 00:00'],"['1985/11/01 00:00 [pubmed]', '1985/11/01 00:01 [medline]', '1985/11/01 00:00 [entrez]']",['10.2105/ajph.75.11.1283 [doi]'],ppublish,Am J Public Health. 1985 Nov;75(11):1283-7. doi: 10.2105/ajph.75.11.1283.,"['0 (Polycyclic Compounds)', '8007-45-2 (Coal Tar)']",,,['210-81-5104/PHS HHS/United States'],,,,,,,,
4050802,NLM,MEDLINE,19851025,20190829,0271-3586 (Print) 0271-3586 (Linking),8,3,1985,Mortality patterns among styrene-exposed boatbuilders.,193-205,"In order to test the hypothesis that leukemia and lymphoma may be associated with exposure to styrene, cause-of-death patterns were studied at two reinforced plastic boatbuilding facilities. There were 5,021 workers who met the criterion of having worked at the two plants between 1959 and 1978. Based on industrial hygiene surveys conducted at the two plants, 2,060 individuals were determined to have worked in departments classified as having high exposure to styrene. There were 176 deaths observed among the total cohort, in comparison to 195.3 deaths expected (standardized mortality ratio [SMR] = 90). Among the high styrene exposure group, 47 deaths were observed in comparison to 41.5 deaths expected (SMR = 113). No leukemia or lymphoma deaths were observed in either the high exposure group or the total cohort. An excess of accidental deaths among the high exposure group (18 observed vs 12.4 expected) did not appear to be due to styrene's acute central nervous system effects, since none of the individuals were employed at the facilities at the time of their death. However, the possibility of a chronic effect could not be dismissed. While leukemia and lymphoma did not appear to be related to styrene exposure, the study had little statistical power to detect excesses of these diseases, due to the short length of observation and the young age of most cohort members. It was concluded that the cohort should provide increasingly useful information on chronic styrene toxicity as the population ages and the observation period increases.","['Okun, A H', 'Beaumont, J J', 'Meinhardt, T J', 'Crandall, M S']","['Okun AH', 'Beaumont JJ', 'Meinhardt TJ', 'Crandall MS']",['eng'],['Journal Article'],United States,Am J Ind Med,American journal of industrial medicine,8101110,IM,"['Adolescent', 'Adult', 'Aged', 'Female', 'Glass', 'Humans', 'Leukemia/chemically induced/*mortality', 'Lymphoma/chemically induced/*mortality', 'Male', 'Maximum Allowable Concentration', 'Middle Aged', 'Occupational Diseases/chemically induced/*mortality', 'Occupations', 'Resins, Synthetic/toxicity', 'Risk', '*Ships', 'Styrene', 'Styrenes/*toxicity', 'United States']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1002/ajim.4700080305 [doi]'],ppublish,Am J Ind Med. 1985;8(3):193-205. doi: 10.1002/ajim.4700080305.,"['0 (Resins, Synthetic)', '0 (Styrenes)', '0 (fiberglass)', '44LJ2U959V (Styrene)']",,,,,,,,,,,
4050746,NLM,MEDLINE,19851114,20190903,0277-3732 (Print) 0277-3732 (Linking),8,3,1985 Jun,Mitogenic inhibition and effect on survival of mice bearing L1210 leukemia using a combination of dehydroascorbic acid and hydroxycobalamin.,266-9,The present study was designed to test the effect of a combination of dehydroascorbic acid (DHA) and hydroxycobalamin (vitamin B12) on the survival of mice bearing L1210 leukemia. Results showed a significant increase in survival of treated mice compared with controls (p less than or equal to 0.0001) (Student's t-test). This positive effect was significantly lost when DHA was substituted by ascorbic acid (AA) in the same experimental conditions. In vitro findings also revealed that the DHA-B12 combination specifically inhibited mitoses of L1210 cells while non-neoplastic L929 cells were not affected.,"['Poydock, M E', 'Harguindey, S', 'Hart, T', 'Takita, H', 'Kelly, D']","['Poydock ME', 'Harguindey S', 'Hart T', 'Takita H', 'Kelly D']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Am J Clin Oncol,American journal of clinical oncology,8207754,IM,"['Animals', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Cell Division/*drug effects', 'Cells, Cultured', 'Dehydroascorbic Acid/administration & dosage', 'Drug Evaluation, Preclinical', 'Female', 'Hydroxocobalamin/administration & dosage', 'Leukemia L1210/*drug therapy/mortality', 'Mice', 'Mice, Inbred DBA']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1097/00000421-198506000-00013 [doi]'],ppublish,Am J Clin Oncol. 1985 Jun;8(3):266-9. doi: 10.1097/00000421-198506000-00013.,"['Q40X8H422O (Hydroxocobalamin)', 'Y2Z3ZTP9UM (Dehydroascorbic Acid)']",,,,,,,,,,,
4050602,NLM,MEDLINE,19851105,20190622,0065-2598 (Print) 0065-2598 (Linking),186,,1985,Two monoclonal antibodies raised against a Burkitt lymphoma cell line recognise separate components of lymphoid follicles.,971-8,,"['Murray, L J', 'Habeshaw, J A']","['Murray LJ', 'Habeshaw JA']",['eng'],['Journal Article'],United States,Adv Exp Med Biol,Advances in experimental medicine and biology,0121103,IM,"['Antibodies, Monoclonal/*immunology', 'Antigen-Presenting Cells/*immunology', 'Burkitt Lymphoma/*immunology', 'Hematopoietic Stem Cells/immunology', 'Humans', 'Leukemia, Lymphoid/immunology', 'Lymphoid Tissue/*cytology/immunology', 'Lymphoma/immunology/pathology', 'Palatine Tonsil/cytology/immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-1-4613-2463-8_117 [doi]'],ppublish,Adv Exp Med Biol. 1985;186:971-8. doi: 10.1007/978-1-4613-2463-8_117.,"['0 (Antibodies, Monoclonal)']",,,,,,,,,,,
4050146,NLM,MEDLINE,19851119,20161123,0340-1855 (Print) 0340-1855 (Linking),44,2,1985 Mar-Apr,Association of ankylosing spondylitis with hairy cell leukemia: a previously once reported case.,93-6,We report a case of ankylosing spondylitis associated with hairy cell leukemia. This is the second observed case (I3) of ankylosing spondylitis with a B-type lymphoproliferative disorder which allows us to make some observations about the pathogenesis of these rare diseases.,"['Manna, R', 'Perri, F', 'Ghirlanda, G', 'Zeppilli, P', 'Carughi, S', 'Annese, V', 'Uccioli, L', 'Mango, G']","['Manna R', 'Perri F', 'Ghirlanda G', 'Zeppilli P', 'Carughi S', 'Annese V', 'Uccioli L', 'Mango G']",['eng'],"['Case Reports', 'Journal Article']",Germany,Z Rheumatol,Zeitschrift fur Rheumatologie,0414162,IM,"['Adult', 'Humans', 'Leukemia, Hairy Cell/*complications/pathology/therapy', 'Male', 'Radiography', 'Splenectomy', 'Spondylitis, Ankylosing/*complications/diagnostic imaging']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",,ppublish,Z Rheumatol. 1985 Mar-Apr;44(2):93-6.,,,,,,,,,,,,
4050078,NLM,MEDLINE,19851105,20061115,0002-3027 (Print) 0002-3027 (Linking),,7,1985,[Expression of structural proteins of Retroviruses type C on the membrane of normal and leukemic cells in mice].,44-51,,"['Lezhneva, O M', 'Abelev, G I']","['Lezhneva OM', 'Abelev GI']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Vestn Akad Med Nauk SSSR,Vestnik Akademii meditsinskikh nauk SSSR,7506153,IM,"['Animals', 'Antigens, Neoplasm/analysis', 'Antigens, Viral/analysis', 'Leukemia, Experimental/*immunology', 'Membrane Proteins/*immunology', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Retroviridae/*immunology', 'Viral Proteins/*immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vestn Akad Med Nauk SSSR. 1985;(7):44-51.,"['0 (Antigens, Neoplasm)', '0 (Antigens, Viral)', '0 (Membrane Proteins)', '0 (Viral Proteins)']",,Ekspressiia strukturnykh belkov retrovirusov tipa C na membrane normal'nykh i leikemicheskikh kletok myshei.,,,,,,,,,
4049523,NLM,MEDLINE,19851121,20071115,0041-3771 (Print) 0041-3771 (Linking),27,7,1985 Jul,[Alkaline phosphatase activity of normal and transformed cultured human cells].,775-9,A study was made of the relationship between the activity of alkaline phosphatase and the proliferation of cultured human cells with different replicative potentials. It is shown that alkaline phosphatase plays a role as one of endogenic stimulators of cellular proliferation. The ageing of diploid cells is accompanied by a decrease in the enzyme activity. Maximum activity was observed during a period of logarithmic cell growth. Addition of placental alkaline phosphatase to the synchronized diploid cells stimulated DNA synthesis in the S-phase of the cell cycle. Heteroploid cells with a high growth rate possessed a 30-100 times higher alkaline phosphatase activity than in the diploid cells. Under certain conditions alkaline phosphatase may presumably function as a proteinkinase.,"['Zgurskii, A A', 'Alekseev, S B', 'Stepanova, L G']","['Zgurskii AA', 'Alekseev SB', 'Stepanova LG']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Tsitologiia,Tsitologiia,0417363,IM,"['Alkaline Phosphatase/*metabolism/pharmacology', 'Cell Survival', 'Cell Transformation, Neoplastic/*metabolism', 'Cells, Cultured', 'Chromosome Aberrations', 'DNA Replication/drug effects', 'Diploidy', 'Embryo, Mammalian', 'Humans', 'Leukemia/blood', 'Lung/cytology/*enzymology', 'Ploidies', 'Time Factors']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Tsitologiia. 1985 Jul;27(7):775-9.,['EC 3.1.3.1 (Alkaline Phosphatase)'],,Aktivnost' shchelochnoi fosfatazy v kul'tiviruemykh normal'nykh i transformirovannykh kletkakh cheloveka.,,,,,,,,,
4049471,NLM,MEDLINE,19851121,20190903,0163-4356 (Print) 0163-4356 (Linking),7,3,1985,Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography.,315-20,"The analysis of 6-mercaptopurine (6-MP) by a rapid, sensitive, and specific high performance liquid chromatographic assay is described. This method does not require any derivatization and allows for direct quantitation of the drug. Only 200 microliters of serum or plasma is needed, and concentrations as low as 10 ng/ml can be reliably quantitated. Analytical recoveries of 83% for 6-MP and 71% for the internal standard, 6-thioguanine, are obtained. Between-day precision studies at three plasma concentrations of 6-MP produce a mean coefficient of variation of 7.2%. This assay will be clinically useful for pharmacokinetic studies of 6-MP in patients in remission of acute lymphoblastic leukemia.","['Whalen, C E', 'Tamary, H', 'Greenberg, M', 'Zipursky, A', 'Soldin, S J']","['Whalen CE', 'Tamary H', 'Greenberg M', 'Zipursky A', 'Soldin SJ']",['eng'],['Journal Article'],United States,Ther Drug Monit,Therapeutic drug monitoring,7909660,IM,"['Child', 'Child, Preschool', 'Chromatography, High Pressure Liquid', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Mercaptopurine/*blood', 'Phenylmercuric Acetate', 'Plasma/analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1097/00007691-198507030-00015 [doi]'],ppublish,Ther Drug Monit. 1985;7(3):315-20. doi: 10.1097/00007691-198507030-00015.,"['E7WED276I5 (Mercaptopurine)', 'OSX88361UX (Phenylmercuric Acetate)']",,,,,,,,,,,
4049331,NLM,MEDLINE,19851107,20080716,0029-2001 (Print) 0029-2001 (Linking),105,22,1985 Aug 10,[Monoclonal antibodies. A new tool in the diagnosis of leukemia and lymphoma].,1379-82,,"['Melsom, H', 'Kvaloy, S', 'Beiske, K', 'Funderud, S', 'Marton, P F', 'Godal, T', 'Lie, S O']","['Melsom H', 'Kvaloy S', 'Beiske K', 'Funderud S', 'Marton PF', 'Godal T', 'Lie SO']",['nor'],['Journal Article'],Norway,Tidsskr Nor Laegeforen,"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke",0413423,IM,"['Antibodies, Monoclonal/*analysis', 'Antibodies, Neoplasm/analysis', 'Child', 'Humans', 'Leukemia/diagnosis/*immunology', 'Lymphoma/diagnosis/*immunology']",,1985/08/10 00:00,1985/08/10 00:01,['1985/08/10 00:00'],"['1985/08/10 00:00 [pubmed]', '1985/08/10 00:01 [medline]', '1985/08/10 00:00 [entrez]']",,ppublish,Tidsskr Nor Laegeforen. 1985 Aug 10;105(22):1379-82.,"['0 (Antibodies, Monoclonal)', '0 (Antibodies, Neoplasm)']",,Monoklonale antistoffer. Et nytt hjelpemiddel ved utredningen av leukemier og lymfomer.,,,,,,,,,
4049268,NLM,MEDLINE,19851112,20161123,0040-3660 (Print) 0040-3660 (Linking),57,7,1985,[Secondary erythrocytoses].,49-54,"The author provides data pertinent to the modern classification of erythrocytosis, which rests on the pathogenetic principle. The difference in the pathogenesis of erythremia and secondary erythrocytoses was proved with the help of an erythroid culture and by examination of erythropoietins, which can be thus used for diagnostic purposes. Analysis of so-called ""pure"" erythrocytosis has shown that this term implies different patterns of erythrocytosis from the standpoint of the pathogenesis: erythremia, secondary erythrocytoses that are difficult to diagnose, and hereditary erythrocytosis associated with erythropoietin hyperproduction. There is no evidence for the existence of the ""pure"" erythroid leukemia and thus the author doubts this disease entity. Analysing the different patterns of secondary absolute erythrocytosis the author discusses specific problems of their pathogenesis. Attention is paid to erythrocytosis of a tobacco smoker, to the role of obesity and concomitant action of some factors on the development of hypoxic erythrocytosis. The data are presented on the new types of erythrocytosis, on the post-transplantation one, in particular, which occurs after kidney transplantation, and finally on erythrocytosis that develops occasionally in patients on hemodialysis. Attention is paid as well to relative erythrocytoses, risk factor in the development of thrombotic complications. The problems of etiologically and pathogenetically valid therapy of secondary erythrocytoses are reviewed.","['Demidova, A V']",['Demidova AV'],['rus'],['Journal Article'],Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Erythropoiesis', 'Hemoglobinopathies/blood', 'Humans', 'Hypoxia/blood', 'Kidney Diseases/blood', 'Neoplasms/blood', 'Polycythemia/classification/*etiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(7):49-54.,,,Vtorichnye eritrotsitozy.,,,,,,,,,
4049267,NLM,MEDLINE,19851112,20141120,0040-3660 (Print) 0040-3660 (Linking),57,7,1985,[Effect of stromal cells of the bone marrow on hematopoiesis in culture].,33-40,"The authors studied the effect of medullary fibroblasts on granulomonocytopoiesis in a semi-solid agar gel. Seventy-three untreated patients with the blood system diseases and 18 hematologically healthy subjects were entered into the study. The medium conditioned with fibroblasts and fibroblasts themselves are capable of stimulating granulomonocytopoiesis. In addition, fibroblasts can exert an inhibitory effect on granulomonocytopoiesis, with the degree of this effect being dependent on the agar layer thickness. Patients with chronic lympholeukemia and acute lymphoblastic leukemia showed a decrease in the stimulating activity of fibroblasts, whereas in patients with chronic myeloleukemia, that activity was elevated. In patients with neutropenic conditions, the stimulating activity of fibroblasts depended on a factor that produced neutropenia. The role of the alterations in question in the pathogenesis of the blood system diseases and other possible influences of fibroblasts on myelopoiesis are discussed.","['Almazov, V A', 'Zaritskii, A Iu', 'Kulik, M A', 'Borgest, O V', 'Dallmann, Kh']","['Almazov VA', 'Zaritskii AIu', 'Kulik MA', 'Borgest OV', 'Dallmann Kh']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Agar', 'Bone Marrow/*pathology', 'Colony-Forming Units Assay', 'Culture Media', 'Fibroblasts/pathology', 'Hematologic Diseases/*blood', '*Hematopoiesis', 'Hematopoietic Stem Cells/*pathology', 'Humans', 'In Vitro Techniques']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(7):33-40.,"['0 (Culture Media)', '9002-18-0 (Agar)']",,Vliianie stromal'nykh kletok kostnogo mozga na gemopoez v kul'ture.,,,,,,,,,
4049265,NLM,MEDLINE,19851112,20041117,0040-3660 (Print) 0040-3660 (Linking),57,7,1985,[Basophilic leukemia].,139-41,,"[""Al'nikov, G P"", 'Podgurskaia, R A', 'Beliakova, T A', 'Sarkisian, A P', ""Rugal', V I""]","[""Al'nikov GP"", 'Podgurskaia RA', 'Beliakova TA', 'Sarkisian AP', ""Rugal' VI""]",['rus'],"['Case Reports', 'Journal Article']",Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Basophils/pathology', 'Humans', 'Leukemia/classification/*diagnosis/pathology', 'Male', 'Middle Aged']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(7):139-41.,,,O bazofil'nom leikoze.,,,,,,,,,
4049264,NLM,MEDLINE,19851112,20191210,0040-3660 (Print) 0040-3660 (Linking),57,7,1985,[Plasma fibronectin level in patients with depression of hematopoiesis].,119-24,"Plasma fibronectin is regarded to play an important part in a decrease of the resistance to infections. To specify the role of fibronectin in the pathogenesis of infectious complications in patients with depressions of hemopoiesis, the content of this opsonin was measured by ELISA in 113 patients with different patterns of hemoblastoses, lymphoproliferative diseases and with an aplastic syndrome. In 42 patients, the concentration of opsonin was measured in the presence of the superimposed infection of varying gravity. The fibronectin content was examined in 39 patients before, during and after completion of the cytostatic polychemotherapy. It turned out that in patients with paraproteinemic hemoblastoses, lymphogranulomatosis, aplastic anemia, chronic lympholeukemia, acute lympho- and myelo(mono)blastic leukemias, cyclic neutropenia, chronic myelosis and hematosarcomas, the concentration of fibronectin remained normal in the absence of infections. The computation of the linear correlation ratio did not reveal any association between the opsonin level and the concentration of neoplastic elements in the peripheral blood. Repeated measurements of the fibronectin level in patients whose underlying disease ran its course in association with marked neoplastic fever failed to detect any deficiency of the glycoprotein. The lowering of the fibronectin level was recorded in patients with a grave concomitant infection of the type of sepsis, necrotic enteropathy and lobar pneumonia. The degree of opsonin deficiency correlated with the patients' disease gravity. Prolonged reduction in the blood fibronectin level was of unfavourable prognostic importance. Cytostatic polychemotherapy, myelotoxic agranulocytosis as well as infectious complications of low gravity did not influence the concentration of fibronectin.(ABSTRACT TRUNCATED AT 250 WORDS)","[""Vasil'ev, S A"", 'Savchenko, V G', 'Margulis, E Ia', 'Ermolin, G A', 'Kotelianskii, V E']","[""Vasil'ev SA"", 'Savchenko VG', 'Margulis EIa', 'Ermolin GA', 'Kotelianskii VE']",['rus'],"['Comparative Study', 'Journal Article']",Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Adolescent', 'Adult', 'Aged', 'Agranulocytosis/*blood', 'Female', 'Fibronectins/*blood/deficiency', 'Hodgkin Disease/blood', 'Humans', 'Infections/blood', 'Leukemia/blood', 'Male', 'Middle Aged', 'Neutropenia/*blood', 'Paraproteinemias/blood']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(7):119-24.,['0 (Fibronectins)'],,Kontsentratsiia plazmennogo fibronektina u bol'nykh s depressiiami krovetvoreniia.,,,,,,,,,
4049080,NLM,MEDLINE,19851104,20041117,0038-5077 (Print) 0038-5077 (Linking),,5,1985,[Splenectomy in hairy cell leukemia].,114-6,,"['Golenkov, A K', 'Zlatkina, A R', 'Lobakov, A I', 'Dzhafarov, R A', 'Ostrun, Iu Z']","['Golenkov AK', 'Zlatkina AR', 'Lobakov AI', 'Dzhafarov RA', 'Ostrun IuZ']",['rus'],['Journal Article'],Russia (Federation),Sov Med,Sovetskaia meditsina,0404525,IM,"['Adult', 'Female', 'Humans', 'Leukemia, Hairy Cell/*therapy', '*Splenectomy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Sov Med. 1985;(5):114-6.,,,Splenektomiia pri volosatokletochnom leikoze.,,,,,,,,,
4049047,NLM,MEDLINE,19851119,20190702,0038-4348 (Print) 0038-4348 (Linking),78,10,1985 Oct,Invasive candidal balanitis due to a condom catheter in a neutropenic patient.,1247-9,A 58-year-old man with acute leukemia had balanitis and penile ulceration due to Candida tropicalis after a condom catheter was used because of urinary incontinence. This case illustrates that condom catheters can be associated with serious complications in neutropenic patients and should be used only when absolutely necessary.,"['Morrissey, R', 'Xavier, A', 'Nguyen, N', 'Webb, D W']","['Morrissey R', 'Xavier A', 'Nguyen N', 'Webb DW']",['eng'],"['Case Reports', 'Journal Article']",United States,South Med J,Southern medical journal,0404522,IM,"['Agranulocytosis/*complications', 'Balanitis/*etiology', 'Candidiasis/*etiology', 'Humans', 'Male', 'Middle Aged', 'Neutropenia/*complications', 'Urinary Catheterization/*adverse effects/instrumentation']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1097/00007611-198510000-00025 [doi]'],ppublish,South Med J. 1985 Oct;78(10):1247-9. doi: 10.1097/00007611-198510000-00025.,,,,,,,,,,,,
4048868,NLM,MEDLINE,19851120,20190908,0036-553X (Print) 0036-553X (Linking),35,2,1985 Aug,Evaluation of neutrophil alkaline phosphatase (NAP) activity in untreated myeloproliferative syndromes and in leukaemoid reactions.,219-24,"Neutrophil alkaline phosphatase activity was estimated in 194 patients; 59 cases of chronic myeloid leukaemia (CML), 42 cases of polycythaemia vera (PV), 24 cases of primary myelofibrosis, 7 cases of idiopathic thrombocythaemia, 6 cases of leukaemoid reaction, 19 cases of secondary polycythaemia (PS) and 37 cases of the primary myelodysplastic syndrome (MDS). According to NAP activities the groups proved to be separate entities (p less than 0.00025). The incidence of decreased NAP score in the CML group was 85% and differed significantly from the other groups as a whole, as well as separately (p less than 0.001). The MDS group, the only group besides CML that showed decreased scores, also differed significantly from the others (p less than 0.001). The PS group, nearly always showing normal scores, differed significantly from the PV group (p less than 0.0052). A method evaluating single cell NAP activity proved superior to the score method in discriminating between the different groups. Thus, the incidence of decreased activity in the CML group was 93% compared with 85% by the score method and the incidences of increased activity in the PV, MP, IT, and LR groups were 79% to 100% compared with 25% to 67% by the score method. The latter difference was statistically significant (p = 0.029).","['Bendix-Hansen, K', 'Bergmann, O J']","['Bendix-Hansen K', 'Bergmann OJ']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Alkaline Phosphatase/*blood', 'Humans', 'Leukemoid Reaction/*enzymology', 'Myeloproliferative Disorders/classification/*enzymology', 'Neutrophils/*enzymology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb01576.x [doi]'],ppublish,Scand J Haematol. 1985 Aug;35(2):219-24. doi: 10.1111/j.1600-0609.1985.tb01576.x.,['EC 3.1.3.1 (Alkaline Phosphatase)'],,,,,,,,,,,
4048862,NLM,MEDLINE,19851106,20190908,0036-553X (Print) 0036-553X (Linking),35,1,1985 Jul,Alpha interferon treatment of patients with hairy-cell leukaemia.,66-70,"We have treated 10 patients with hairy-cell, or hairy-cell-like leukaemia, for more than 6 months, with alpha interferon 3 X 10(6) IV/day I.M. or subcutaneously. All patients were severely pancytopenic before treatment. 7 patients had a typical hairy-cell leukaemia, whereas 3 lacked hairy cells but had the characteristic bone-marrow infiltration. The peripheral blood counts improved in all patients during treatment and the lymphoid infiltration of the bone-marrow was shown to decrease. 1 patient obtained complete remission, 6 partial remission and 3 had a minor response. It is concluded that alpha interferon is effective in the treatment of patients suffering from hairy-cell leukaemia.","['Hagberg, H', 'Alm, G', 'Bjorkholm, M', 'Glimelius, B', 'Killander, A', 'Simonsson, B', 'Sundstrom, C', 'Ahre, A']","['Hagberg H', 'Alm G', 'Bjorkholm M', 'Glimelius B', 'Killander A', 'Simonsson B', 'Sundstrom C', 'Ahre A']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Aged', 'Bone Marrow/pathology', 'Female', 'Hematopoiesis/drug effects', 'Humans', 'Interferon Type I/adverse effects/*therapeutic use', 'Leukemia, Hairy Cell/complications/pathology/*therapy', 'Leukopenia/etiology', 'Male', 'Middle Aged', 'Primary Myelofibrosis/complications/pathology/therapy', 'Thrombocytopenia/etiology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb00802.x [doi]'],ppublish,Scand J Haematol. 1985 Jul;35(1):66-70. doi: 10.1111/j.1600-0609.1985.tb00802.x.,['0 (Interferon Type I)'],,,,,,,,,,,
4048861,NLM,MEDLINE,19851106,20190908,0036-553X (Print) 0036-553X (Linking),35,1,1985 Jul,Development of acute nonlymphocytic leukaemia (ANLL) in myelomatosis.,35-7,"On the basis of the literature, so-called secondary acute nonlymphocytic leukaemia (S-ANLL) in myelomatosis is reviewed. Using the banding technique, cytogenetic changes including hypodiploidy and partially or totally missing chromosomes # 5 and # 7 are recorded. The findings are in accordance with the cytogenetic changes seen in S-ANLL in other malignancies which have been treated with cytostatics, especially alkylating agents. So, S-ANLL in myelomatosis seems to be a result of treatment with cytostatics, though a causal relationship has to be documented.","['Drivsholm, A', 'Lisse, I', 'Philip, P']","['Drivsholm A', 'Lisse I', 'Philip P']",['eng'],['Journal Article'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Acute Disease', 'Alkylating Agents/adverse effects', 'Humans', 'Leukemia/chemically induced/*etiology/genetics', 'Multiple Myeloma/*complications', 'Neoplasms, Radiation-Induced']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb00796.x [doi]'],ppublish,Scand J Haematol. 1985 Jul;35(1):35-7. doi: 10.1111/j.1600-0609.1985.tb00796.x.,['0 (Alkylating Agents)'],,,,,,,,,,,
4048857,NLM,MEDLINE,19851106,20190908,0036-553X (Print) 0036-553X (Linking),35,1,1985 Jul,HLA and chronic lymphocytic leukaemia.,116-7,,"['Kilpatrick, D C', 'Dewar, A E', 'Hoyle, C', 'Lawson, A', 'Stockdill, G']","['Kilpatrick DC', 'Dewar AE', 'Hoyle C', 'Lawson A', 'Stockdill G']",['eng'],['Letter'],Denmark,Scand J Haematol,Scandinavian journal of haematology,0404507,IM,"['Female', 'HLA Antigens/*classification', 'Humans', 'Leukemia, Lymphoid/*immunology', 'Male', 'Prospective Studies', 'Retrospective Studies']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1111/j.1600-0609.1985.tb00811.x [doi]'],ppublish,Scand J Haematol. 1985 Jul;35(1):116-7. doi: 10.1111/j.1600-0609.1985.tb00811.x.,['0 (HLA Antigens)'],,,,,,,,,,,
4048194,NLM,MEDLINE,19851105,20151119,0361-7742 (Print) 0361-7742 (Linking),184,,1985,Neoplasms of the hematopoietic stem cell.,393-402,,"['Adamson, J W']",['Adamson JW'],['eng'],['Journal Article'],United States,Prog Clin Biol Res,Progress in clinical and biological research,7605701,IM,"['Anemia, Aplastic/pathology', 'Animals', 'Cats', 'Clone Cells/pathology', 'Disease Models, Animal', 'Glucosephosphate Dehydrogenase/*metabolism', 'Hematopoietic Stem Cells/*cytology/enzymology', 'Humans', 'Leukemia/enzymology/pathology', 'Lymphoma/enzymology/pathology', 'Myeloproliferative Disorders/enzymology/pathology', 'Neoplasms/*pathology', 'Neoplastic Stem Cells/*cytology/enzymology', 'Sarcoma/enzymology/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Prog Clin Biol Res. 1985;184:393-402.,['EC 1.1.1.49 (Glucosephosphate Dehydrogenase)'],,,,,,,,,,,
4047857,NLM,MEDLINE,19851112,20160523,0031-403X (Print) 0031-403X (Linking),,7,1985 Jul,"[""Internal image of the disease"" in children with acute leukemia].",42-4,,"['Isaev, D N', 'Shats, I K']","['Isaev DN', 'Shats IK']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Pediatriia,Pediatriia,0405563,IM,"['Acute Disease', 'Adolescent', 'Child', 'Humans', 'Leukemia/*psychology', '*Self Concept']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Pediatriia. 1985 Jul;(7):42-4.,,,"""Vnutrenniaia kartina bolezni"" u detei s ostrym leikozom.",,,,,,,,,
4047641,NLM,MEDLINE,19851115,20091021,0030-6002 (Print) 0030-6002 (Linking),126,39,1985 Sep 29,[Secondary malignant tumor associated with melanoma].,2387-9,,"['Korom, I', 'Szekeres, L', 'Bertenyi, C', 'Morvay, M']","['Korom I', 'Szekeres L', 'Bertenyi C', 'Morvay M']",['hun'],"['English Abstract', 'Journal Article']",Hungary,Orv Hetil,Orvosi hetilap,0376412,IM,"['Adult', 'Aged', 'Carcinoma/*pathology', 'Female', 'Humans', 'Leukemia/*pathology', 'Lymphoma/*pathology', 'Male', 'Melanoma/*pathology', 'Middle Aged', '*Neoplasms, Multiple Primary']",,1985/09/29 00:00,1985/09/29 00:01,['1985/09/29 00:00'],"['1985/09/29 00:00 [pubmed]', '1985/09/29 00:01 [medline]', '1985/09/29 00:00 [entrez]']",,ppublish,Orv Hetil. 1985 Sep 29;126(39):2387-9.,,,A melanomahoz tarsulo masodik malignus tumor.,,,,,,,,,
4047251,NLM,MEDLINE,19851106,20151119,0028-2685 (Print) 0028-2685 (Linking),32,4,1985,A simple technique for cell surface radioactive labeling of human and animal neoplastic cells: reductive methylation with formaldehyde and tritiated borohydride.,393-9,"Avian sarcoma virus-, or 3,4-benzopyrene-transformed cultured rat cells and human leukemia or lymphoblastoid cell lines were radiolabeled by reductive methylation with formaldehyde and tritiated sodium borohydride--an application of a known technique for radiolabeling of soluble proteins. Optimal conditions for tritium incorporation into cell proteins with the aid of this technique were ascertained. Analysis of cell proteins tritium radiolabeled with the aid of this technique by acrylamide electrophoresis or by two-dimensional electrophoretic analysis allowed to disclose typical transformation-associated alterations in oncovirus-, or chemical carcinogen-transformed cells, as well as cell type-associated protein patterns in examined lymphoid cell lines. An individual protein (class II MHC antigen) radiolabeled by this technique has been identified as bimolecular complex p30,35 by immunoprecipitation with a monoclonal antibody recognizing this antigen; electrophoretic properties of immunoprecipitated antigen were identical to those observed after immunoprecipitation of the same antigen radiolabeled by sodium periodate/tritiated borohydride glycoprotein radiolabeling.","['Chorvath, B', 'Duraj, J', 'Sedlak, J']","['Chorvath B', 'Duraj J', 'Sedlak J']",['eng'],['Journal Article'],Slovakia,Neoplasma,Neoplasma,0377266,IM,"['Animals', '*Borohydrides', 'Cell Line', 'Cell Transformation, Neoplastic', 'Cells, Cultured', 'Electrophoresis', '*Formaldehyde', 'Humans', '*Isotope Labeling', 'Methylation', 'Neoplasm Proteins/*analysis', 'Neoplasms/*analysis', 'Rats', 'Tritium']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Neoplasma. 1985;32(4):393-9.,"['0 (Borohydrides)', '0 (Neoplasm Proteins)', '10028-17-8 (Tritium)', '1HG84L3525 (Formaldehyde)']",,,,,,,,,,,
4047206,NLM,MEDLINE,19851115,20041117,0028-2162 (Print) 0028-2162 (Linking),129,33,1985 Aug 17,[Unknown is unrecognized].,1569-71,,"['Westerhof, P W']",['Westerhof PW'],['dut'],"['Case Reports', 'Journal Article']",Netherlands,Ned Tijdschr Geneeskd,Nederlands tijdschrift voor geneeskunde,0400770,IM,"['Adult', 'Cardiac Tamponade/*diagnosis/etiology', 'Diagnosis, Differential', 'Humans', 'Leukemia/*diagnosis', 'Male', 'Pericarditis/complications', 'Pleurisy/complications']",,1985/08/17 00:00,1985/08/17 00:01,['1985/08/17 00:00'],"['1985/08/17 00:00 [pubmed]', '1985/08/17 00:01 [medline]', '1985/08/17 00:00 [entrez]']",,ppublish,Ned Tijdschr Geneeskd. 1985 Aug 17;129(33):1569-71.,,,Onbekend maakt onherkend.,,,,,,,,,
4047151,NLM,MEDLINE,19851119,20061115,0083-1921 (Print) 0083-1921 (Linking),67,,1985 May,"Selection, follow-up, and analysis in the Atomic Bomb Casualty Commission Study.",53-8,"More is known about ionizing radiation as a cause of human cancer than about any other carcinogen. Most of this knowledge is derived from the studies conducted by the Atomic Bomb Casualty Commission and Radiation Effects Research Foundation on about 100,000 Japanese survivors of the atomic bombing in 1945. The importance of these studies is based on the large size of the exposed population and the fact that individual estimates of radiation dose were possible. These factors and the combined excellence of the centralized vital statistics reporting and population registration systems in Japan have made feasible the continuing longitudinal studies of cancer mortality by site in relation to radiation dose over a span of more than 30 years. Excellent voluntary cooperation by the survivors has enabled the continuation of a biennial physical examination program which has made possible the acquisition of blood for studies of radiation-induced chromosomal aberrations and mutations at the level of specific genes. Similarly, with the cooperation of local universities, hospitals, and physicians, tumor and tissue registries necessary for the study of cancer incidence have been developed. An autopsy pathology program has enabled study of the accuracy of cause of death certification.","['Jablon, S']",['Jablon S'],['eng'],"['Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S.""]",United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Aged', 'Female', 'Follow-Up Studies', 'Humans', 'Japan', 'Leukemia, Radiation-Induced/*mortality', 'Male', 'Middle Aged', 'Neoplasms, Radiation-Induced/*mortality', '*Nuclear Warfare', 'Radiation Dosage', 'Registries', 'Risk', 'United States']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 May;67:53-8.,,,,,,,,,,,,
4047139,NLM,MEDLINE,19851119,20071115,0083-1921 (Print) 0083-1921 (Linking),67,,1985 May,Selection factors in cohort studies.,111-5,"Cohort studies play an important role in the quantitation of cancer risk among occupationally exposed individuals. Properly conducted cohort studies can develop important data on the age, time, and exposure dependence of cancer risk. Such information allows identification of possible selection effects which may be present and allows generalization of risk estimates to other exposure circumstances.","['Nicholson, W J']",['Nicholson WJ'],['eng'],['Journal Article'],United States,Natl Cancer Inst Monogr,National Cancer Institute monograph,0216026,IM,"['Adult', 'Aged', 'Asbestos/*adverse effects', 'Female', 'Humans', 'Leukemia, Radiation-Induced/*epidemiology', 'Lung Neoplasms/*epidemiology', 'Male', 'Mesothelioma/*epidemiology', 'Middle Aged', 'Occupational Diseases/*epidemiology', 'Prospective Studies', 'Risk', 'Statistics as Topic']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Natl Cancer Inst Monogr. 1985 May;67:111-5.,['1332-21-4 (Asbestos)'],,,,,,,,,,,
4046634,NLM,MEDLINE,19851115,20190824,0145-2126 (Print) 0145-2126 (Linking),9,8,1985,Glucocorticoid receptors in chronic lymphocytic leukemia.,993-9,"Glucocorticoid receptor (GR) levels have not been extensively studied in untreated patients with chronic lymphocytic leukemia (CLL). We have measured tumor GR levels using a whole cell assay in 18 untreated patients with CLL and correlated these levels with various in-vitro and in-vivo data. In 12 of these patients, tumor cells from more than one tissue were simultaneously studied. Measurable GR levels were found in all 36 specimens studied with median total GR levels in blood, bone marrow, and lymph nodes being 3018 (n = 17), 3524 (n = 12) and 3102 (n = 7) sites/cell respectively. GR levels did not correlate with in-vitro sensitivity, as measured by inhibition by dexamethasone of radiolabelled leucine, uridine, and thymidine uptake, nor with the clinical or laboratory features examined. Nine patients were treated with dexamethasone as a single agent; blood GR levels were not predictive of antitumor response. We conclude that in patients with CLL, malignant cells from all involved tissues have measurable numbers of GRs, but these are not correlated with in-vitro sensitivity to glucocorticoid. Blood GR levels do not correlate with antitumor response; further studies are required to see if bone marrow or lymph node receptor levels correlate with antitumor response to steroids.","['Levine, E G', 'Peterson, B A', 'Smith, K A', 'Hurd, D D', 'Bloomfield, C D']","['Levine EG', 'Peterson BA', 'Smith KA', 'Hurd DD', 'Bloomfield CD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Leuk Res,Leukemia research,7706787,IM,"['Dexamethasone/therapeutic use', 'Female', 'Humans', 'Leukemia, Lymphoid/drug therapy/*metabolism', 'Lymph Nodes/analysis', 'Male', 'Middle Aged', 'Prednisone/therapeutic use', 'Receptors, Glucocorticoid/*analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0145-2126(85)90069-4 [pii]', '10.1016/0145-2126(85)90069-4 [doi]']",ppublish,Leuk Res. 1985;9(8):993-9. doi: 10.1016/0145-2126(85)90069-4.,"['0 (Receptors, Glucocorticoid)', '7S5I7G3JQL (Dexamethasone)', 'VB0R961HZT (Prednisone)']",,,['CA 26273/CA/NCI NIH HHS/United States'],,,,,,,,
4046633,NLM,MEDLINE,19851115,20190824,0145-2126 (Print) 0145-2126 (Linking),9,8,1985,"Wilsede Meeting on Modern Trends in Human Leukaemia VI. June 17-21, 1984. Differentiation: Paradigm and paradox at Wilsede.",951-4,,"['Francis, G E']",['Francis GE'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Leuk Res,Leukemia research,7706787,IM,"['Bromodeoxyuridine/pharmacology', '*Cell Differentiation/drug effects', 'DNA, Neoplasm/metabolism', 'Humans', 'Leukemia/metabolism/*pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90065-7 [doi]'],ppublish,Leuk Res. 1985;9(8):951-4. doi: 10.1016/0145-2126(85)90065-7.,"['0 (DNA, Neoplasm)', 'G34N38R2N1 (Bromodeoxyuridine)']",,,,,,,,,,,
4046632,NLM,MEDLINE,19851115,20190824,0145-2126 (Print) 0145-2126 (Linking),9,8,1985,4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells.,1017-21,"Despite its considerable toxicity to haemopoietic colony-forming cells, 4-hydroperoxycyclophosphamide (4-HC) has successfully been used to purge marrow of leukaemic cells before it is used to rescue patients from high-dose chemoradiotherapy. These conflicting observations indicate that haemopoietic progenitor cells that are not detected by the established colony-forming assays survive exposure to 4-HC and repopulate the marrow. The recent finding that murine spleen colony-forming cells (CFU-S) are resistant to 4-HC [Porcellini A, et al. (1983) Expl Hemat. 11 (suppl 14) 331 (abstract)] [14] also indicates that sensitivity to 4-HC can be used to distinguish primitive progenitor cells from committed progenitor cells. As part of a study on the nature of a population of blast colony-forming cells in human bone marrow, we tested their sensitivity to 4-HC to see whether they also are spared by the drug. We found that 4-HC had much less effect on the blast colony-forming cells than on the granulocyte-macrophage colony-forming cells (GM-CFC). This result suggests that the blast-colony-forming cells may be early human haemopoietic progenitor cells.","['Gordon, M Y', 'Goldman, J M', 'Gordon-Smith, E C']","['Gordon MY', 'Goldman JM', 'Gordon-Smith EC']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Leuk Res,Leukemia research,7706787,IM,"['Anemia, Aplastic/therapy', 'Bone Marrow Cells', 'Cell Differentiation/drug effects', 'Cell Division/drug effects', 'Cell Survival', 'Colony-Forming Units Assay', 'Cyclophosphamide/*analogs & derivatives/pharmacology', 'Drug Resistance', 'Granulocytes/*cytology', 'Hematopoietic Stem Cells/cytology/*drug effects', 'Humans', 'Leukemia/therapy', 'Macrophages/*cytology', 'Transplantation, Autologous']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90072-4 [doi]'],ppublish,Leuk Res. 1985;9(8):1017-21. doi: 10.1016/0145-2126(85)90072-4.,"['8N3DW7272P (Cyclophosphamide)', 'U880A4FUDA (perfosfamide)']",,,,,,,,,,,
4046631,NLM,MEDLINE,19851115,20190824,0145-2126 (Print) 0145-2126 (Linking),9,8,1985,New possibilities of research in chronic lymphatic leukemia by means of Fourier transform-infrared spectroscopy--II.,1001-8,"Ten samples of lymphocytes coming from patients affected by chronic lymphatic leukemia and ten samples from normal subjects were studied by FT-IR spectroscopy. Spectral differences observed between the two kinds of cells correspond to an increase of the intensities, in the leukemic samples with respect to the normal ones, of the bands corresponding mainly to PO2- symmetrical and asymmetrical stretching vibrations of DNA. The ratios of the integrated areas of the band at 1080 cm-1 mainly involving the symmetrical stretching vibration of the O-P-O linkages of DNA, and of the band at 1540 cm-1, due to the proteic components of the lymphocytes, assume different values for the two kinds of cells. These ratios can constitute an additional marker to diagnose chronic lymphatic leukemia and may be usefully employed to evidence the early phases of the disease.","['Benedetti, E', 'Palatresi, M P', 'Vergamini, P', 'Papineschi, F', 'Spremolla, G']","['Benedetti E', 'Palatresi MP', 'Vergamini P', 'Papineschi F', 'Spremolla G']",['eng'],['Journal Article'],England,Leuk Res,Leukemia research,7706787,IM,"['Chronic Disease', 'DNA, Neoplasm/analysis', 'Fourier Analysis', 'Humans', 'Leukemia/*blood/genetics', 'Lymphocytes/*pathology', 'RNA, Neoplasm/analysis', 'Spectrophotometry, Infrared']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0145-2126(85)90070-0 [pii]', '10.1016/0145-2126(85)90070-0 [doi]']",ppublish,Leuk Res. 1985;9(8):1001-8. doi: 10.1016/0145-2126(85)90070-0.,"['0 (DNA, Neoplasm)', '0 (RNA, Neoplasm)']",,,,,,,,,,,
4046450,NLM,MEDLINE,19851115,20091111,0023-2165 (Print) 0023-2165 (Linking),186,6,1985 Jun,[Pathology of the lacrimal apparatus].,434-5,"Following a brief survey of the subjects covered in this paper the author discusses the problem of lacrimal gland tumefactions. These can be divided into five groups: malignant lymphoma and leukemias, proliferative reactions of the lymphatic tissues, dacryoadenitis, secondary and metastatic tumors, and finally miscellaneous conditions; the main nosological characteristics are described.","['Ducrey, N']",['Ducrey N'],['fre'],"['English Abstract', 'Journal Article']",Germany,Klin Monbl Augenheilkd,Klinische Monatsblatter fur Augenheilkunde,0014133,IM,"['Dacryocystitis/*diagnosis', 'Diagnosis, Differential', 'Humans', 'Lacrimal Apparatus Diseases/*diagnosis', 'Leukemia/*diagnosis', 'Lymphoma/*diagnosis']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1055/s-2008-1050952 [doi]'],ppublish,Klin Monbl Augenheilkd. 1985 Jun;186(6):434-5. doi: 10.1055/s-2008-1050952.,,,Pathologie de l'appareil lacrymal.,,,,,,,,,
4046331,NLM,MEDLINE,19851029,20061115,0023-1495 (Print) 0023-1495 (Linking),53,6,1985 Jun,"[The Ommaya reservoir as a therapeutic aid in the treatment of malignant diseases in childhood. Indications, technic, results].",283-9,,"['Roosen, K', 'Havers, W', 'Meusers, P', 'Schaaf, J']","['Roosen K', 'Havers W', 'Meusers P', 'Schaaf J']",['ger'],"['English Abstract', 'Journal Article']",Germany,Kinderarztl Prax,Kinderarztliche Praxis,0376356,IM,"['Acute Disease', 'Adolescent', 'Brain Neoplasms/*therapy', '*Catheters, Indwelling', 'Cerebrospinal Fluid Shunts/*instrumentation', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Injections, Intraventricular/*instrumentation', 'Leukemia/therapy', 'Lymphoma/therapy', 'Male', 'Meningeal Neoplasms/therapy']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Kinderarztl Prax. 1985 Jun;53(6):283-9.,,,"Das Ommaya-Reservoir als therapeutische Hilfe bei der Behandlung von malignen Erkrankungen im Kindesalter. Indikationen, Technik, Ergebnisse.",,,,,,,,,
4046183,NLM,MEDLINE,19851031,20071115,0485-1439 (Print) 0485-1439 (Linking),26,4,1985 Apr,[Chronic lymphocytic leukemia associated with multiple myeloma].,515-21,,"['Kizaki, M', 'Kamiya, T', 'Okawa, H', 'Kiryu, Y', 'Yamamoto, Y', 'Yokomizo, M', 'Handa, M', 'Ogawa, T', 'Toyama, K', 'Osamura, Y']","['Kizaki M', 'Kamiya T', 'Okawa H', 'Kiryu Y', 'Yamamoto Y', 'Yokomizo M', 'Handa M', 'Ogawa T', 'Toyama K', 'Osamura Y']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Aged', 'Bence Jones Protein/analysis', 'Humans', 'Leukemia, Lymphoid/*pathology', 'Male', 'Multiple Myeloma/*pathology']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Apr;26(4):515-21.,['9006-99-9 (Bence Jones Protein)'],,,,,,,,,,,
4046182,NLM,MEDLINE,19851031,20071115,0485-1439 (Print) 0485-1439 (Linking),26,4,1985 Apr,[Plasma cell leukemia of Bence-Jones (lambda) type].,509-14,,"['Tsumoto, S', 'Oyabu, H', 'Kageyama, T', 'Takano, A', 'Nakata, K']","['Tsumoto S', 'Oyabu H', 'Kageyama T', 'Takano A', 'Nakata K']",['jpn'],"['Case Reports', 'English Abstract', 'Journal Article']",Japan,Rinsho Ketsueki,[Rinsho ketsueki] The Japanese journal of clinical hematology,2984782R,IM,"['Bence Jones Protein/*analysis', 'Female', 'Humans', 'Leukemia, Plasma Cell/*pathology', 'Middle Aged', 'Multiple Myeloma/*pathology']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",,ppublish,Rinsho Ketsueki. 1985 Apr;26(4):509-14.,['9006-99-9 (Bence Jones Protein)'],,,,,,,,,,,
4045930,NLM,MEDLINE,19851107,20190709,0022-2623 (Print) 0022-2623 (Linking),28,10,1985 Oct,"Antimicrobial and cytotoxic properties of 9,10-dihydrophenanthrenes: structure-activity studies on juncusol.",1543-7,"The antimicrobial and cytotoxic properties of a series of 9,10-dihydrophenanthrenes structurally related to juncusol (1a), a postulated phytoalexin with confirmed cytotoxic properties, are detailed. Two simple 9,10-dihydrophenanthrenes, 2,7-dihydroxy-3,8-dimethyl-9,10-dihydrophenanthrene (2h, desvinyljuncusol) and 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h), were found to possess in vitro antimicrobial activity comparable with that of the natural product. Two 9,10-dihydrophenanthrenes substituted with quaternary ammonium salts, 2d and 3d, each containing a reactive benzylic dimethyl[(phenylthio)methyl]ammonio group, were found to be 10-20 times more potent than juncusol (1a). Confirmed in vitro cytotoxic activity that parallels antimicrobial activity was found for juncusol (1a), desvinyljuncusol (2h), 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h), and the quaternary dimethyl[(phenylthio)methyl]ammonium salts 2d and 3d in a human lymphoblastic leukemia cell culture (CCRF-CEM, IC50 = nt, 9.3, nt, 0.9 and 1.4 microgram/mL, respectively), B-16 mouse melanoma cell culture (IC50 = 12.5, 17.5, 27.7, 0.3, and 0.5 microgram/mL, respectively), and L-1210 mouse lymphocytic leukemia cell culture (IC50 = 13.8, 10.2, 24.5, 1.3, and 3.7 micrograms/mL, respectively). The comparable potency and spectrum of activity of juncusol (1a), desvinyljuncusol (2h), and 2-hydroxy-3-methyl-9,10-dihydrophenanthrene (3h) suggest that the agents are acting as simple phenols in exerting their antimicrobial and cytotoxic effects.","['Boger, D L', 'Mitscher, L A', 'Mullican, M D', 'Drake, S D', 'Kitos, P']","['Boger DL', 'Mitscher LA', 'Mullican MD', 'Drake SD', 'Kitos P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', '*Anti-Bacterial Agents', '*Antineoplastic Agents, Phytogenic', 'Bacteria/drug effects', 'Cell Survival/drug effects', 'Cells, Cultured', 'Mice', 'Microbial Sensitivity Tests', 'Neoplasms, Experimental/drug therapy', 'Phenanthrenes/*pharmacology/therapeutic use', 'Structure-Activity Relationship']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1021/jm00148a031 [doi]'],ppublish,J Med Chem. 1985 Oct;28(10):1543-7. doi: 10.1021/jm00148a031.,"['0 (Anti-Bacterial Agents)', '0 (Antineoplastic Agents, Phytogenic)', '0 (Phenanthrenes)', '62023-90-9 (juncusol)']",,,"['AI 13155/AI/NIAID NIH HHS/United States', 'CA 33668/42056/CA/NCI NIH HHS/United States', 'ES 02046/ES/NIEHS NIH HHS/United States']",,,,,,,,
4045922,NLM,MEDLINE,19851107,20190709,0022-2623 (Print) 0022-2623 (Linking),28,10,1985 Oct,Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent.,1468-76,"The synthesis of 12 new 5,8-dideazafolates with isopropyl, cyclopropylmethyl, 2-fluoroethyl, carbamoylmethyl, phenacyl, 3-fluorobenzyl, 5-uracilylmethyl, carboxymethyl, 2-carboxyethyl, 3-cyanopropyl, 3-hydroxypropyl, and cyanomethyl substituents at N10 is described. In general, the synthetic route involved monoalkylation of diethyl N-(4-amino-benzoyl)-L-glutamate, coupling of the resulting secondary amine with 2-amino-6-(bromomethyl)-4-hydroxyquinazoline hydrobromide in N,N-dimethylacetamide with calcium carbonate as the base, and deprotection using mild alkali. The cyanomethyl derivatives was found to be unexpectedly base labile and was therefore prepared by mild acid deprotection of a di-tert-butyl ester. The compounds were tested as inhibitors of purified L1210 thymidylate synthase (TS). Four members of the series were more potent that the N10-hydrogen compound, but none was superior to the previously described N10-propargyl-5,8-dideazafolic acid. Selected compounds were examined as inhibitors of purified L1210 dihydrofolate reductase (DHFR). As desired, N10 substitution in general reduced DHFR inhibitory activity; these results are discussed. As a measure of cytotoxicity, the compounds were examined for their inhibition of the growth of L1210 cells in culture. None of the new substituents conferred enhanced potency relative to N10-propargyl-5,8-dideazafolic acid (ID50 = 5 microM), which, as the best TS inhibitor and a relatively poor DHFR inhibitor, continues to lead this series.","['Jones, T R', 'Calvert, A H', 'Jackman, A L', 'Eakin, M A', 'Smithers, M J', 'Betteridge, R F', 'Newell, D R', 'Hayter, A J', 'Stocker, A', 'Harland, S J']","['Jones TR', 'Calvert AH', 'Jackman AL', 'Eakin MA', 'Smithers MJ', 'Betteridge RF', 'Newell DR', 'Hayter AJ', 'Stocker A', 'Harland SJ', 'et al.']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Alkylation', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Folic Acid Antagonists', 'Leukemia L1210/enzymology', 'Mice', 'Quinazolines/chemical synthesis/*pharmacology', 'Structure-Activity Relationship', 'Thymidylate Synthase/*antagonists & inhibitors']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1021/jm00148a016 [doi]'],ppublish,J Med Chem. 1985 Oct;28(10):1468-76. doi: 10.1021/jm00148a016.,"['0 (Folic Acid Antagonists)', '0 (Quinazolines)', 'EC 2.1.1.45 (Thymidylate Synthase)']",,,,,,,,,,,
4045901,NLM,MEDLINE,19851112,20200611,0141-0768 (Print) 0141-0768 (Linking),78,9,1985 Sep,Anaesthesia for minor procedures in children with malignant disease.,715-20,"Minor invasive procedures in children with leukaemia can be very distressing for patients, parents and staff. In Nottingham a combined clinic has been established with an anaesthetist as an integral member of the team. General anaesthesia, usually by inhalation, is frequently employed. From May 1980 to September 1984, 515 anaesthetics were given to 97 patients. Records are kept to allow analysis of the clinic's function. With close personal contact, induction of anaesthesia becomes increasingly a matter of cooperation between patient and anaesthetist, removing much of the fear of these procedures. The development of this service is described and the reasons for its success are discussed.","['Hain, W R', 'Tomlinson, J H', 'Barbor, P R']","['Hain WR', 'Tomlinson JH', 'Barbor PR']",['eng'],['Journal Article'],England,J R Soc Med,Journal of the Royal Society of Medicine,7802879,IM,"['Adolescent', 'Anesthesia, General/methods/*psychology', 'Child', 'Child, Preschool', 'Emotions', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*therapy', 'Patient Care Team', 'Patient Compliance']",PMC1289890,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1177/014107688507800905 [doi]'],ppublish,J R Soc Med. 1985 Sep;78(9):715-20. doi: 10.1177/014107688507800905.,,,,,,,,,,,,
4045795,NLM,MEDLINE,19851119,20161123,0221-0363 (Print) 0221-0363 (Linking),66,6-7,1985 Jun-Jul,[Chronic lymphoid leukemia of the colon. Apropos of a case].,469-72,The authors describe a rare case of chronic lymphocytic leukemia of the colon which they observed. Particular emphasis is placed upon the problem of differential diagnosis as presented by this affection.,"['Romano, A', 'Nocera, V', 'Esposito, S', 'Calvino, G', 'Schioppa, A', 'Navarro, D', 'Ragozzino, A']","['Romano A', 'Nocera V', 'Esposito S', 'Calvino G', 'Schioppa A', 'Navarro D', 'Ragozzino A']",['fre'],"['Case Reports', 'Journal Article']",France,J Radiol,Journal de radiologie,7906266,IM,"['Colonic Neoplasms/*diagnostic imaging', 'Colonic Polyps/diagnostic imaging', 'Diagnosis, Differential', 'Humans', 'Leukemia, Lymphoid/*diagnostic imaging', 'Male', 'Middle Aged', 'Radiography']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,J Radiol. 1985 Jun-Jul;66(6-7):469-72.,,,Leucemie lymphoide chronique du colon. A propos d'un cas.,,,,,,,,,
4045577,NLM,MEDLINE,19851106,20081121,0096-1736 (Print) 0096-1736 (Linking),27,9,1985 Sep,Leukemia risk among U.S. white male coal miners. A case-control study.,669-71,"The relevance of occupational exposure to electrical and magnetic fields (EMF) in the etiology of leukemia has been raised in several studies. Underground coal miners represent an occupational group with situationally determined EMF exposure, as high-voltage power distribution lines are strung overhead in the mines and converters and step-down transformers provide power to mining equipment. Risk in occupational exposure to EMF was examined in a case-control study of 40 leukemia decedents and 160 control subjects who died of causes other than cancer or accident and who were matched on age at death. The control subjects were selected from a group of 6,066 persons whose deaths were reported in four National Institute for Occupational Safety and Health cohort mortality follow-up studies. Based on these data, 25 or more years of underground mining, a surrogate of EMF exposure, was found to pose a statistically significant risk for leukemia (International Classification of Diseases [ICD] codes 204 through 207, eighth revision), myelogenous leukemia (ICD 205), and chronic lymphocytic leukemia (CLL) (ICD 204.1). Accumulative exposure to chemical agents probably poses a risk for acute myelogenous leukemia, although this relationship fell short of being statistically significant. Although CLL has not previously been attributed to environmental agents, these data suggest a possible CLL risk from prolonged exposure to EMF.","['Gilman, P A', 'Ames, R G', 'McCawley, M A']","['Gilman PA', 'Ames RG', 'McCawley MA']",['eng'],['Journal Article'],United States,J Occup Med,Journal of occupational medicine. : official publication of the Industrial Medical Association,7502807,IM,"['Adult', '*Coal Mining', '*Electricity', '*Electromagnetic Fields', '*Electromagnetic Phenomena', 'Humans', 'Leukemia/*etiology', 'Male', 'Occupational Diseases/*etiology', 'Risk', 'Time Factors', 'United States']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,J Occup Med. 1985 Sep;27(9):669-71.,,,,,,,,,,,,
4044956,NLM,MEDLINE,19851107,20190709,0190-9622 (Print) 0190-9622 (Linking),13,2 Pt 1,1985 Aug,Hairy cell leukemia and pyoderma gangrenosum.,300-2,,"['Rustin, M H', 'Staughton, R C', 'Coomes, E N']","['Rustin MH', 'Staughton RC', 'Coomes EN']",['eng'],"['Case Reports', 'Letter']",United States,J Am Acad Dermatol,Journal of the American Academy of Dermatology,7907132,IM,"['Biopsy/adverse effects', 'Female', 'Humans', 'Leukemia, Hairy Cell/*complications', 'Liver/pathology', 'Middle Aged', 'Pyoderma/*etiology/pathology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['S0190-9622(85)80287-5 [pii]', '10.1016/s0190-9622(85)80287-5 [doi]']",ppublish,J Am Acad Dermatol. 1985 Aug;13(2 Pt 1):300-2. doi: 10.1016/s0190-9622(85)80287-5.,,,,,,,,,,,,
4044805,NLM,MEDLINE,19851031,20210526,0095-1137 (Print) 0095-1137 (Linking),22,3,1985 Sep,Meningitis caused by Gordona aurantiaca (Rhodococcus aurantiacus).,472-4,"In a case of hairy cell leukemia, Gordona aurantiaca (Rhodococcus aurantiacus) was isolated from cerebrospinal fluid as the pathogen responsible for lethal infection of the central nervous system. The pathogen had been isolated previously from one case of pulmonary infection process only.","['Prinz, G', 'Ban, E', 'Fekete, S', 'Szabo, Z']","['Prinz G', 'Ban E', 'Fekete S', 'Szabo Z']",['eng'],"['Case Reports', 'Journal Article']",United States,J Clin Microbiol,Journal of clinical microbiology,7505564,IM,"['Actinomycetales Infections/*cerebrospinal fluid/complications/microbiology', 'Adult', 'Agranulocytosis', 'Brain/microbiology', 'Humans', 'Leukemia, Hairy Cell/*complications', 'Male', 'Meningitis/*cerebrospinal fluid/complications/microbiology/pathology', 'Nocardiaceae/*isolation & purification', 'Sputum/microbiology']",PMC268441,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1128/jcm.22.3.472-474.1985 [doi]'],ppublish,J Clin Microbiol. 1985 Sep;22(3):472-4. doi: 10.1128/jcm.22.3.472-474.1985.,,,,,,,,,,,,
4044742,NLM,MEDLINE,19851106,20190629,,342,1,1985 Jul 12,High-performance liquid chromatographic assay for the antitumor glycoside phyllanthoside and its stability in plasma of several species.,129-34,"Phyllanthoside is a glycoside isolated from the roots of the Central American tree Phyllanthus acuminatus Vahl with antitumor activity against murine B-16 melanoma and P-388 leukemia. We report a reversed-phase high-performance liquid chromatographic assay for phyllanthoside in plasma using a 25-cm RP-18, 5-micron column with a linear 10-min gradient of 50% to 100% methanol in 0.3 M sodium acetate, pH 4.0, at a flow-rate of 1.5 ml/min. Eluting peaks were detected at 270 nm. The lower limit of sensitivity of the assay for phyllanthoside in 0.5 ml plasma following ethyl acetate extraction at pH 7.0 was 0.25 micrograms/ml and the coefficient of variation at 1 microgram/ml was +/- 7.4%. Phyllanthoside was very rapidly broken down by mouse and rat plasma in vitro to an unidentified less polar metabolite. Formation of this metabolite was completely inhibited by preheating mouse plasma to 100 degrees C for 10 min. When mouse plasma was diluted 1:50 with water the half-life of phyllanthoside disappearance at 37 degrees C was 2.0 min. Breakdown of phyllanthoside in plasma from other species was slower than in mouse and the initial half-life at 37 degrees C in dog plasma was 30 min, in monkey plasma 33 min and in human plasma 38 min. The same less polar metabolite as in mouse plasma was formed slowly by plasma of monkey and dog. Phyllanthoside did not accumulate in human red blood cells. Binding of phyllanthoside to human plasma protein determined by ultrafiltration at 4 degrees C was 70%.","['Powis, G', 'Moore, D J']","['Powis G', 'Moore DJ']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,J Chromatogr,Journal of chromatography,0427043,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*blood', '*Benzofurans', 'Chromatography, High Pressure Liquid', 'Dogs', 'Drug Stability', 'Glycosides/*blood', 'Humans', 'Macaca fascicularis', 'Mice', 'Mice, Inbred Strains', 'Rats', 'Rats, Inbred Strains', '*Sesquiterpenes', 'Species Specificity', 'Spiro Compounds']",,1985/07/12 00:00,1985/07/12 00:01,['1985/07/12 00:00'],"['1985/07/12 00:00 [pubmed]', '1985/07/12 00:01 [medline]', '1985/07/12 00:00 [entrez]']",['10.1016/s0378-4347(00)84495-3 [doi]'],ppublish,J Chromatogr. 1985 Jul 12;342(1):129-34. doi: 10.1016/s0378-4347(00)84495-3.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Benzofurans)', '0 (Glycosides)', '0 (Sesquiterpenes)', '0 (Spiro Compounds)', '63166-73-4 (phyllanthoside)']",,,['N01-CM-37601/CM/NCI NIH HHS/United States'],,,,,,,,
4044667,NLM,MEDLINE,19851120,20131121,0021-9541 (Print) 0021-9541 (Linking),125,1,1985 Oct,The synergistic action of the copper chelator bathocuproine sulphonate and cysteine in enhancing growth of L1210 cells in vitro.,151-5,"The growth stimulating effect of a copper-specific chelator, 2,9-dimethyl-4,7-diphenyl-1,10-phenonthroline-sulfonic acid on mouse lymphoma L1210 cells in vitro has been studied. Since they are defective in cystine transport, these cells require cysteine for their growth in vitro. However, addition of cysteine does not greatly enhance cell growth because it is rapidly oxidized to cystine. We have observed that the copper chelator potently inhibited oxidation of cysteine in culture medium and that simultaneous addition of cysteine and the chelator greatly enhanced cell growth. The chelator alone stimulated cell growth slightly by stabilizing a small amount of cysteine effluxed from the cells to the medium. The chelator also enhanced the growth promoting activity of 2-mercaptoethanol by stabilizing cysteine produced in the medium during culture. These results suggest that the chelator stimulates cell growth by inhibiting copper mediated oxidation of cysteine in culture medium.","['Ishii, T', 'Bannai, S']","['Ishii T', 'Bannai S']",['eng'],['Journal Article'],United States,J Cell Physiol,Journal of cellular physiology,0050222,IM,"['Animals', 'Blood', 'Cell Count', 'Cell Division/drug effects', 'Cysteine/*pharmacology', 'Drug Synergism', 'Leukemia L1210/*pathology', 'Mercaptoethanol/pharmacology', 'Mice', 'Phenanthrolines/*pharmacology', 'Sulfhydryl Compounds/metabolism']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/jcp.1041250119 [doi]'],ppublish,J Cell Physiol. 1985 Oct;125(1):151-5. doi: 10.1002/jcp.1041250119.,"['0 (Phenanthrolines)', '0 (Sulfhydryl Compounds)', '60-24-2 (Mercaptoethanol)', '73348-75-1 (bathocuproine sulfonate)', 'K848JZ4886 (Cysteine)']",,,,,,,,,,,
4044626,NLM,MEDLINE,19851120,20190903,0171-5216 (Print) 0171-5216 (Linking),110,2,1985,Atypical mycosis fungoides with cerebral involvement.,123-6,This report concerns a 17-year-old male patient with atypical mycosis fungoides (m.f.). Initial examination revealed generalized lymphoma and uncharacteristic livid skin efflorescence. The patient developed bone marrow involvement and meningeal leukaemia 6 months later. Diagnosis was confirmed by immunohistochemistry and electron microscopy. Aggressive chemotherapy yielded no response.,"['Gorg, C', 'Gorg, K', 'Bepler, G', 'Adler, G', 'Gropp, C', 'Havemann, K']","['Gorg C', 'Gorg K', 'Bepler G', 'Adler G', 'Gropp C', 'Havemann K']",['eng'],"['Case Reports', 'Journal Article']",Germany,J Cancer Res Clin Oncol,Journal of cancer research and clinical oncology,7902060,IM,"['Adolescent', 'Humans', 'Lymphoma/pathology', 'Male', 'Meningeal Neoplasms/pathology/*secondary', 'Mycosis Fungoides/*pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00402724 [doi]'],ppublish,J Cancer Res Clin Oncol. 1985;110(2):123-6. doi: 10.1007/BF00402724.,,,,,,,,,,,,
4044624,NLM,MEDLINE,19851120,20190903,0171-5216 (Print) 0171-5216 (Linking),110,2,1985,In vitro and in vivo investigations for the development of cytostatic methylhydrazones.,110-4,"In in vitro short-term (3 h) assays, the beta-chloroethyl-methyl-hydrazones B 1 and B 2 inhibit the uptake of 3H-thymidine by EAC and L 1210 leukemia cells, B 2 being 5 to 10 times more effective than B 1. The growth inhibitory effect of both compounds was also confirmed in long-term (7 days) clonal assays using agar-containing glass capillaries, B 2 again being more effective than B 1. In contrast to these differences in vitro, in vivo both substances showed remission to the same degree in EAC- and complete resistance in L 1210-bearing mice. The diverging in vitro/in vivo sensitivities were thought to result from differences in the affinity of the methylhydrazones to the tumor cells: using short exposure periods (3 h) B 1 was more inhibitory than B 2 on both EAC and L 1210 colony growth; i.e., the more hydrophilic B 2 could more easily be washed off. To further test the idea of different cell membrane affinities, the methylhydrazones ZB 1 and P 1 with increasing lipophilic properties were synthesized. In vitro, after both pulse and continuous exposure ZB 1 and P 1 showed enforced inhibitory effects on colony growth. In vivo, ZB 1 and P 1 reduced the tumor weight of EAC mice, while only P 1 increased the survival time of L 1210 mice. The results suggest that from the combination of in vitro/in vivo assays mechanistic conclusions can be derived that are valuable for further development of these cystostatics.","['Dittmar, W', 'Klitschka, G', 'Braun, R', 'Ali-Osman, F', 'Meckert, C', 'Maurer, H R']","['Dittmar W', 'Klitschka G', 'Braun R', 'Ali-Osman F', 'Meckert C', 'Maurer HR']",['eng'],"['Comparative Study', 'Journal Article']",Germany,J Cancer Res Clin Oncol,Journal of cancer research and clinical oncology,7902060,IM,"['Animals', 'Carcinoma, Ehrlich Tumor/*drug therapy', 'Cell Division/*drug effects', 'Cell Membrane/metabolism', 'Cells, Cultured', 'Hydrazones/*pharmacology', 'Leukemia L1210/*drug therapy', 'Male', 'Mice', 'Mice, Inbred DBA', 'Mice, Inbred Strains', 'Tumor Stem Cell Assay']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00402721 [doi]'],ppublish,J Cancer Res Clin Oncol. 1985;110(2):110-4. doi: 10.1007/BF00402721.,['0 (Hydrazones)'],,,,,,,,,,,
4044476,NLM,MEDLINE,19851120,20171116,0004-5772 (Print) 0004-5772 (Linking),33,3,1985 Mar,Outcome of aggressive induction therapy in acute non-lymphocytic leukaemia.,203-6,,"['Saikia, T K', 'Ahuja, H G', 'Gopal, R', 'Nair, C N', 'Kamat, D M', 'Pai, M R', 'Advani, S H']","['Saikia TK', 'Ahuja HG', 'Gopal R', 'Nair CN', 'Kamat DM', 'Pai MR', 'Advani SH']",['eng'],['Journal Article'],India,J Assoc Physicians India,The Journal of the Association of Physicians of India,7505585,IM,"['Acute Disease', 'Adolescent', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Cytarabine/administration & dosage', 'Daunorubicin/administration & dosage', 'Female', 'Humans', 'Leukemia/*drug therapy/mortality', 'Male', 'Mercaptopurine/administration & dosage', 'Prednisolone/administration & dosage', 'Vincristine/administration & dosage']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",,ppublish,J Assoc Physicians India. 1985 Mar;33(3):203-6.,"['04079A1RDZ (Cytarabine)', '5J49Q6B70F (Vincristine)', '9PHQ9Y1OLM (Prednisolone)', 'E7WED276I5 (Mercaptopurine)', 'ZS7284E0ZP (Daunorubicin)', 'DAP protocol', 'DOAPP protocol']",,,,,,,,,,,
4044234,NLM,MEDLINE,19851113,20071115,0021-2180 (Print) 0021-2180 (Linking),21,8,1985 Aug,High-output cardiac failure as a presenting symptom of plasma cell leukemia.,679-82,"A patient presented with high-output cardiac failure and was found to have plasma-cell leukemia. No cause for the cardiac failure was found, and there was no response to treatment with diuretics and thiamine. Chemotherapy for the leukemia resulted in resolution of the cardiac failure, suggesting that the latter was caused by the leukemia--a hitherto unreported association.","['Tamir, R', 'Lewin, R F', 'Inbal, A', 'Heller, I', 'Theodor, E']","['Tamir R', 'Lewin RF', 'Inbal A', 'Heller I', 'Theodor E']",['eng'],"['Case Reports', 'Journal Article']",Israel,Isr J Med Sci,Israel journal of medical sciences,0013105,IM,"['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Cardiac Output', 'Heart Failure/drug therapy/*etiology/physiopathology', 'Humans', 'Leukemia, Plasma Cell/*complications/drug therapy/physiopathology', 'Male', 'Middle Aged']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Isr J Med Sci. 1985 Aug;21(8):679-82.,,,,,,,,,,,,
4044089,NLM,MEDLINE,19851104,20190908,0192-0561 (Print) 0192-0561 (Linking),7,4,1985,The immunological activity of plant toxins used in the preparation of immunotoxins--II. The immunodepressive activity of gelonin.,455-63,"The immunological activity of Gelonin, a 30,000 dalton plant protein possessing close similarity to Ricin chain A as a protein synthesis inhibitor which may be of interest for the preparation of antibody-toxin conjugates, was studied in mice. At in vitro concentrations not affecting baseline radioactivity uptake, this substance reduced mitogen responses with the following order of sensitivity PHA less than ConA less than LPS. In microgram/ml concentrations it also markedly reduced macrophage-dependent cytotoxicity while not affecting NK activity. Macrophagic (but not NK) cytotoxicity and mitogen responses were similarly depressed after in vivo treatment. When given before (but not after) stimulus, Gelonin also reduced the primary responses to a T-dependent and, although to a lower degree, to a T-independent antigen, and decreased resistance to allogeneic tumor grafts and L. monocytogenes challenges. The immunopharmacological activity of this and similar substances should be considered in the design of antibody-toxin conjugates and in the evaluation of their therapeutic activity.","['Descotes, G', 'Romano, M', 'Stirpe, F', 'Spreafico, F']","['Descotes G', 'Romano M', 'Stirpe F', 'Spreafico F']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Int J Immunopharmacol,International journal of immunopharmacology,7904799,IM,"['Animals', 'Antibody Formation/drug effects', 'Antineoplastic Agents/pharmacology', 'Immunity, Innate/drug effects', '*Immunosuppressive Agents', 'Killer Cells, Natural/drug effects', 'Leukemia L1210/drug therapy', 'Listeriosis/drug therapy', 'Lymphocyte Activation/drug effects', 'Male', 'Mice', 'Mice, Inbred C3H', 'Mice, Inbred C57BL', 'Neoplasm Transplantation', 'Plant Proteins/*pharmacology', 'Ribosome Inactivating Proteins, Type 1', 'Spleen/cytology', 'Toxins, Biological/*pharmacology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0192-0561(85)90064-5 [pii]', '10.1016/0192-0561(85)90064-5 [doi]']",ppublish,Int J Immunopharmacol. 1985;7(4):455-63. doi: 10.1016/0192-0561(85)90064-5.,"['0 (Antineoplastic Agents)', '0 (Immunosuppressive Agents)', '0 (Plant Proteins)', '0 (Ribosome Inactivating Proteins, Type 1)', '0 (Toxins, Biological)', '75037-46-6 (GEL protein, Gelonium multiflorum)']",,,,,,,,,,,
4043994,NLM,MEDLINE,19851112,20181113,0019-2805 (Print) 0019-2805 (Linking),56,1,1985 Sep,Differences in surface antigen expression of human fibroblasts cultured from bone marrow compared with those obtained from skin and embryo lung tissue.,189-94,"We have described the optimal conditions for the culture of human fibroblast cells from whole bone marrow aspirates and have shown that these fibroblasts differ in surface markers from those obtained from the skin and embryo lung tissue. All three fibroblast types express HLA class 1 antigens, together with an antigen found on T cells, granulocytes, white matter of brain and breast epithelial cells, but none of them expressed HLA class 2 antigens. In addition, skin fibroblasts expressed an antigen found on common acute lymphoblastic leukaemia cells, while bone marrow fibroblasts expressed an antigen found on human natural killer cells. Hence, all three types of fibroblasts can be separated on the basis of their surface markers, thereby suggesting a difference in maturation pathways.","['Ndumbe, P M', 'Levinsky, R J']","['Ndumbe PM', 'Levinsky RJ']",['eng'],['Journal Article'],England,Immunology,Immunology,0374672,IM,"['Antigens, Surface/*analysis', 'Bone Marrow/*immunology', 'Cell Differentiation', 'Cells, Cultured', 'Fibroblasts/cytology/*immunology', 'Humans', 'Lung/embryology/*immunology', 'Skin/*immunology', 'Time Factors']",PMC1453658,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Immunology. 1985 Sep;56(1):189-94.,"['0 (Antigens, Surface)']",,,,,,,,,,,
4043734,NLM,MEDLINE,19851025,20190707,0378-1119 (Print) 0378-1119 (Linking),35,3,1985,Polyadenylation of a human mitochondrial ribosomal RNA transcript detected by molecular cloning.,305-12,"We have identified by molecular cloning a polyadenylated RNA transcript in the human leukemia cell line, K562, which is complementary to a portion of the gene-encoding mitochondrial 16S ribosomal RNA (mt 16S rRNA). The cloned portion of the transcript corresponds to positions 2191-2395 of the human mt genome. The clone represents a cDNA copy of an RNA transcript from the H strand and carries an additional poly(A) tail 21 residues long at its 3'-end. Our data provide direct evidence for polyadenylation of some mt 16S rRNA transcripts.","['Baserga, S J', 'Linnenbach, A J', 'Malcolm, S', 'Ghosh, P', 'Malcolm, A D', 'Takeshita, K', 'Forget, B G', 'Benz, E J Jr']","['Baserga SJ', 'Linnenbach AJ', 'Malcolm S', 'Ghosh P', 'Malcolm AD', 'Takeshita K', 'Forget BG', 'Benz EJ Jr']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,Gene,Gene,7706761,IM,"['Base Sequence', 'Cell Line', 'Humans', 'Leukemia', 'Mitochondria/*physiology', 'Poly A/*genetics', 'RNA Processing, Post-Transcriptional', 'RNA, Ribosomal/*genetics']",,1985/01/01 00:00,2001/03/28 10:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/01/01 00:00 [entrez]']","['0378-1119(85)90009-5 [pii]', '10.1016/0378-1119(85)90009-5 [doi]']",ppublish,Gene. 1985;35(3):305-12. doi: 10.1016/0378-1119(85)90009-5.,"['0 (RNA, Ribosomal)', '24937-83-5 (Poly A)']",,,,,,,,,,,
4043729,NLM,MEDLINE,19851105,20071115,0016-6758 (Print) 0016-6758 (Linking),21,7,1985 Jul,[Cytogenetic characteristics of the cells of different organs in AKR mice during the development of transplanted lympholeukemia].,1168-76,"The process of cell generalization of lymphatic leukemia transplanted clone of AKR mice was studied by the routine and differential methods of metaphase chromosome staining. In 99.5% cases, the cells have an additional small chromosome specific for this type of leukemia, the chromosome being comparable in size with 18-19 pairs of chromosomes of mouse karyotype. Generalization process within 7 days' experiment (from the moment of transplantation up to the moment of animals' death from lymphatic leukemia) appeared to be slower in thymus and bone marrow of AKR mice than in spleen, lymphatic nodes and liver of the same animals with nearly the same generalization rate. A change in the frequency of marked leukemic cells in various organs at different time intervals after transplantation of lymphatic leukemia correlated with intensive cell division of an undulating character in all organs. The data obtained show that hyperdiploid cells carrying the specific additional small chromosome are responsible for the generalization process, this chromosome being also present in spontaneous strain of AKR mice, from which this clone was obtained.","['Ronichevskaia, G M', 'Zvereva, L I']","['Ronichevskaia GM', 'Zvereva LI']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Genetika,Genetika,0047354,IM,"['Animals', '*Chromosome Aberrations', 'Chromosome Banding', 'Female', 'Guinea Pigs', 'Leukemia, Lymphoid/*genetics', 'Metaphase', 'Mice', 'Mice, Inbred AKR/*genetics', 'Neoplasm Metastasis', 'Neoplasm Transplantation', 'Time Factors']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Genetika. 1985 Jul;21(7):1168-76.,,,O tsitogeneticheskoi kharakteristike kletok raznykh organov myshei AKR v protsesse razvitiia perevivnogo limfoleikoza.,,,,,,,,,
4043437,NLM,MEDLINE,19851115,20161020,0239-8508 (Print) 0239-8508 (Linking),23,1-2,1985,The role of the BCG dose and the mouse strain in the inhibition of development of neoplasms susceptible and nonsusceptible to the action of natural cytotoxic cells.,3-10,"The susceptibility of Ehrlich Ascites Carcinoma (EAC) cells to the action of natural cytotoxic cells of DBA/2 and Balb/c mice in vitro was established. Leukaemia L 1210 cells proved insensitive to the in vitro action of natural cytotoxic cells of DBA/2 mice, but not to those of Balb/c ones. BCG, one of the inductors of cytotoxic NK cells, when administered to DBA/2 or Balb/c mice before introduction of EAC cells inhibited the growth of this tumour but did not retard the development of leukaemia L 1210 in DBA/2 mice. The change in the number of peritoneal exsudate cells (PEC) in DBA/2 mice after intraperitoneal injection of BCG was demonstrated to be dependent on the dose and the time elapsed after bacilli introduction. The antitumour action of BCG does not depend on changes in the number of PEC caused by the bacilli. Both large (3.0 mg) and small (0.02 mg) doses of BCG inhibit the development of EAC in Balb/c mice (""sensitive"" to BCG), notwithstanding the time of administration of the bacilli. In DBA/2 mice (""resistant"" to BCG) development of EAC can be inhibited only by the large dose of BCG since small one is sometimes ineffective.","['Skorski, T']",['Skorski T'],['eng'],['Journal Article'],Poland,Folia Histochem Cytobiol,Folia histochemica et cytobiologica,8502651,IM,"['Animals', 'BCG Vaccine/*administration & dosage', 'Carcinoma, Ehrlich Tumor/*immunology/therapy', 'Cell Survival', 'Cytotoxicity, Immunologic', 'Disease Susceptibility', 'Dose-Response Relationship, Immunologic', 'Injections, Intraperitoneal', 'Killer Cells, Natural/*immunology', 'Leukemia L1210/*immunology/therapy', 'Macrophages', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred DBA', 'Neutrophils', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Folia Histochem Cytobiol. 1985;23(1-2):3-10.,['0 (BCG Vaccine)'],,,,,,,,,,,
4043397,NLM,MEDLINE,19851113,20190621,0014-5793 (Print) 0014-5793 (Linking),190,1,1985 Oct 7,Rapid down-regulation of protein kinase C and membrane association in phorbol ester-treated leukemia cells.,50-4,"Peripheral blood lymphocytes from patients with chronic lymphocytic leukemia (CLL) acquire after several days of exposure to 12-O-tetradecanoylphorbol-13-acetate (TPA) several morphological, immunological and histochemical features of hairy cell leukemia. We have investigated the short term effects of TPA treatment on protein kinase C and its subcellular distribution. Within minutes of addition of TPA to CLL cells 20% of the cytosolic protein kinase C had associated with the particulate fraction. The remaining 80% of protein kinase C activity was down-regulated. The association with the membrane dramatically increased the resistance of the enzyme to inhibition by the non-ionic detergent, Triton X-100. These results suggest that activation of protein kinase C causes multiple biological changes in CLL cells.","['Wickremasinghe, R G', 'Piga, A', 'Campana, D', 'Yaxley, J C', 'Hoffbrand, A V']","['Wickremasinghe RG', 'Piga A', 'Campana D', 'Yaxley JC', 'Hoffbrand AV']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,FEBS Lett,FEBS letters,0155157,IM,"['Cell Differentiation/drug effects', 'Cell Membrane/enzymology', 'Cytosol/enzymology', 'Humans', 'Leukemia, Lymphoid/blood/*enzymology', 'Lymphocytes/enzymology', 'Octoxynol', 'Phorbol Esters/*pharmacology', 'Polyethylene Glycols/pharmacology', 'Protein Kinase C/*antagonists & inhibitors', 'Subcellular Fractions/enzymology', 'Tetradecanoylphorbol Acetate/pharmacology']",,1985/10/07 00:00,1985/10/07 00:01,['1985/10/07 00:00'],"['1985/10/07 00:00 [pubmed]', '1985/10/07 00:01 [medline]', '1985/10/07 00:00 [entrez]']","['0014-5793(85)80425-7 [pii]', '10.1016/0014-5793(85)80425-7 [doi]']",ppublish,FEBS Lett. 1985 Oct 7;190(1):50-4. doi: 10.1016/0014-5793(85)80425-7.,"['0 (Phorbol Esters)', '3WJQ0SDW1A (Polyethylene Glycols)', '9002-93-1 (Octoxynol)', 'EC 2.7.11.13 (Protein Kinase C)', 'NI40JAQ945 (Tetradecanoylphorbol Acetate)']",,,,,,,,,,,
4043348,NLM,MEDLINE,19851115,20190919,0014-7370 (Print) 0014-7370 (Linking),24,3,1985 Sep,"Feed-forward: future questions, future maps.",299-310,"""Feed-forward"" is a technique that encourages families to imagine the pattern of their relationships at some future point in time. Questions about the future, in conjunction with positive connotation, put families in a metaposition to their own dilemmas and thus facilitate change by opening up new solutions for old problems.","['Penn, P']",['Penn P'],['eng'],"['Case Reports', 'Journal Article']",United States,Fam Process,Family process,0400666,IM,"['Adolescent', 'Aged', 'Anorexia Nervosa/therapy', 'Chronic Disease', 'Family Therapy/*methods', 'Female', 'Humans', 'Imagination', 'Learning', 'Leukemia/psychology', 'Male', 'Models, Psychological', 'Problem Solving']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1111/j.1545-5300.1985.00299.x [doi]'],ppublish,Fam Process. 1985 Sep;24(3):299-310. doi: 10.1111/j.1545-5300.1985.00299.x.,,,,,,,,,,,,
4043259,NLM,MEDLINE,19851115,20061115,0301-472X (Print) 0301-472X (Linking),13,8,1985 Sep,Stimulation of normal rat bone marrow fibroblast proliferation by sera from leukemic Fischer rats.,750-9,"Fibroblast hyperplasia and accumulation of fibrous material in the bone marrow of patients with idiopathic (primary) or secondary myelofibrosis (MF) is believed to result from a reaction by marrow fibroblasts to an altered marrow microenvironment, the alteration being potentiated by abnormal hemic cells. We investigated the hypothesis that humoral factors might contribute to fibroblast overgrowth in MF by using an animal model, aged Fischer rats, where MF frequently occurs with leukemia. Sera from leukemic rats and leukemic cell conditioned media (CM) were assayed for enhancement of normal rat marrow fibroblast proliferation in a culture system where fibroblasts form discrete, adherent colonies. Our results demonstrated that: leukemic sera induced a 170% increase in total fibroblast colony numbers and a 325% increase in colonies containing more than 80 cells, stimulation of fibroblast growth was leukemia related since sera from rats with transplanted leukemia enhanced marrow fibroblast proliferation, leukemic cell CM did not contain a growth factor for marrow fibroblasts, sera from leukemic rats and 2-mercaptoethanol were additive in enhancing marrow fibroblast proliferation and probably act by different mechanisms, and leukemic rat sera was less effective as a colony-stimulating factor than normal rat sera, a condition mimicked when leukemic and normal spleen CM were compared. This is the first time that a serum component has been implicated in the pathogenesis of MF; our work may contribute to understanding the mechanism involved when MF occurs as a complication of leukemia.","['Bauldry, S A', 'Wilson, F D', 'Stromberg, P C', 'Ackerman, G A']","['Bauldry SA', 'Wilson FD', 'Stromberg PC', 'Ackerman GA']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Exp Hematol,Experimental hematology,0402313,IM,"['Animals', '*Bone Marrow Cells', 'Cell Division/drug effects', 'Cells, Cultured', 'Colony-Forming Units Assay', 'Culture Media', 'Fibroblasts/cytology', 'Hematopoietic Stem Cells/drug effects', 'Leukemia/*blood/pathology', 'Mercaptoethanol/pharmacology', 'Neoplasm Transplantation', 'Rats', 'Rats, Inbred F344', 'Spleen/pathology', 'Time Factors']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Exp Hematol. 1985 Sep;13(8):750-9.,"['0 (Culture Media)', '60-24-2 (Mercaptoethanol)']",,,,,,,,,,,
4043257,NLM,MEDLINE,19851115,20071114,0301-472X (Print) 0301-472X (Linking),13,8,1985 Sep,Erythroid progenitors in Rauscher leukemia virus variant-A-induced erythropoietic dysplasia in mice.,719-21,"In vitro erythropoiesis by bone marrow and spleen cells was assessed in normal mice and during progression of Rauscher leukemia virus, variant-A (RLV-A) disease in mice. As RLV-A disease progressed from early through terminal stages, there was a marked increase in the numbers of in vitro splenic CFU-E and BFU-E. Conversely, bone marrow CFU-E and BFU-E demonstrated a concomitant decrease in numbers with disease progression. At no time were erythropoietin-independent (endogenous) erythroid colonies generated. The results suggest that compartmental alterations in erythroid precursors occur during progression of RLV-A.","['Ferdinand, P M', 'LoBue, J', 'Lutton, J D', 'Weitz-Hamburger, A', 'Fredrickson, T N']","['Ferdinand PM', 'LoBue J', 'Lutton JD', 'Weitz-Hamburger A', 'Fredrickson TN']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,Exp Hematol,Experimental hematology,0402313,IM,"['Animals', 'Bone Marrow/pathology', 'Colony-Forming Units Assay', 'Erythrocytes/*pathology', '*Erythropoiesis', 'Leukemia, Experimental/blood/*pathology/physiopathology', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Rauscher Virus', 'Spleen/pathology', 'Stem Cells/*pathology']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Exp Hematol. 1985 Sep;13(8):719-21.,,,,['CA12815/CA/NCI NIH HHS/United States'],,,,,,,,
4043127,NLM,MEDLINE,19851105,20190813,0340-6199 (Print) 0340-6199 (Linking),144,2,1985 Jul,Hepatitis B vaccination and immune response in children with malignant diseases.,160-3,"Fifty children with malignant diseases were vaccinated against hepatitis B. Twenty-nine children suffered from leukaemia or non-Hodgkin's lymphoma; 14 of these were on intensive chemotherapy (group I) and 15 were without intensive therapy (group II). The other 21 children had various forms of solid tumours, 14 of them were on intensive therapy (group III) and 7 were without intensive therapy (group IV). To evaluate the immune response, we determined antibody titres over a period of more than 14 weeks after the first vaccination. As 22 out of 50 patients had received passive immunisation together with either the first or the first and second vaccination, antibody titres at the 14th and 18th week (i.e. more than 10 weeks after passive immunisation) were used to evaluate the vaccination results. An antibody titre of greater than or equal to 10 mIU/ml was considered to be a positive response. All patients of group IV, but only 4 out of 14 in group III, 4 out of 15 in group II, and 0 out of 14 in group I produced antibody titres higher than 50 mIU/ml. In contrast to the full response in group IV, two-thirds of all other patients had no immune response (less than 10 mIU/ml). Based on our experience we recommend vaccinating patients suffering from solid tumours and receiving no intensive therapy (group IV) against hepatitis B and protecting all the other children with malignant diseases by passive immunisation, if necessary.","['Entacher, U', 'Jurgenssen, O', 'Thun-Hohenstein, L', 'Simbruner, G', 'Khoss, A', 'Wank, H', 'Neuwirth, G', 'Gadner, H', 'Frisch-Niggemeyer, W']","['Entacher U', 'Jurgenssen O', 'Thun-Hohenstein L', 'Simbruner G', 'Khoss A', 'Wank H', 'Neuwirth G', 'Gadner H', 'Frisch-Niggemeyer W']",['eng'],"['Comparative Study', 'Journal Article']",Germany,Eur J Pediatr,European journal of pediatrics,7603873,IM,"['Adolescent', 'Antibodies, Viral/*analysis', 'Antineoplastic Agents/therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Hepatitis B/immunology/*prevention & control', 'Hepatitis B virus/*immunology', 'Humans', 'Immunization, Passive', 'Infant', 'Male', 'Neoplasms/complications/drug therapy/*therapy', 'Viral Hepatitis Vaccines/*therapeutic use']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1007/BF00451904 [doi]'],ppublish,Eur J Pediatr. 1985 Jul;144(2):160-3. doi: 10.1007/BF00451904.,"['0 (Antibodies, Viral)', '0 (Antineoplastic Agents)', '0 (Viral Hepatitis Vaccines)']",,,,,,,,,,,
4043025,NLM,MEDLINE,19851119,20191030,0192-2521 (Print) 0192-2521 (Linking),7,5,1985,Chemical enhancement of survival in aggregation of retrovirus-infected rat cells: an interlaboratory comparison.,727-46,"This study provides a comparative evaluation among three independent laboratories of the responses to 16 chemicals in the retrovirus (Rauscher leukemia) infected Fischer rat embryo (RIFRE) cell-survival-in-aggregation assay. When suspended in liquid media above an agar base, control cells showed a rapid decline in cell survival, whereas cells that had previously been treated with chemical carcinogen survive in suspension longer than control cells. The endpoint, survival in aggregation, is measured by counting viable cells dissociated from aggregates in suspension for 4 days. By modifying previously reported procedures, we have improved the system so that a clear differential (positive or negative) response is achieved by cells treated with either a known carcinogen or known noncarcinogen. Using procedures designed to minimize assay variability, replicate assays were performed and the data analyzed for inter- and intralaboratory concordance. The RIFRE cell-survival-in-aggregation assay demonstrated a high degree of interlaboratory reproducibility in assessing the overall positive or negative responses of known carcinogens and noncarcinogens, and good qualitative reproducibility in assessing compounds tested under code. The assay could discriminate between known carcinogens and noncarcinogens. All chemicals were tested without the addition of a metabolic activation system. Cells exhibiting carcinogen-induced enhancement of survival in aggregation, when plated back onto a solid substrate and carried in culture, subsequently expressed transformation-associated changes in their cellular morphology, growth in semisolid media, and tumorigenicity in nude mice. These results indicate that retrovirus-infected Fischer rat embryo cells detect a carcinogen-mediated early event that progresses to neoplastic phenotypes. Survival in aggregation appears to require the presence of the exogenous retrovirus, since uninfected cells did not show a differential survival response when carcinogen-treated, noncarcinogen-treated, or control cells were compared. This system provides a reproducible method of detecting carcinogenic chemicals based on their ability to induce enhanced survival in aggregation of treated cells.","['Suk, W A', 'Poiley, J A', 'Raineri, R', 'Steuer, A F', 'Tennant, R W']","['Suk WA', 'Poiley JA', 'Raineri R', 'Steuer AF', 'Tennant RW']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Environ Mutagen,Environmental mutagenesis,7909737,IM,"['Animals', 'Carcinogens/*pharmacology', 'Cell Aggregation/drug effects', 'Cell Survival/*drug effects', 'Cell Transformation, Neoplastic/drug effects', 'Cell Transformation, Viral/drug effects', 'Dose-Response Relationship, Drug', 'Leukemia, Experimental/*pathology', 'Rats', 'Rauscher Virus']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1002/em.2860070511 [doi]'],ppublish,Environ Mutagen. 1985;7(5):727-46. doi: 10.1002/em.2860070511.,['0 (Carcinogens)'],,,"['N01-ES-15797/ES/NIEHS NIH HHS/United States', 'N01-ES-15798/ES/NIEHS NIH HHS/United States', 'N01-ES-15807/ES/NIEHS NIH HHS/United States']",,,,,,,,
4042959,NLM,MEDLINE,19851112,20131121,0204-3564 (Print) 0204-3564 (Linking),7,4,1985,[Cytological characteristics of carminomycin-resistant P-388 lymphoid leukosis].,"60-4, 76","The carminomycin-resistant strain (P-388/c) of P-388 lymphoid leukemia is obtained. Resistance development is accompanied by higher sensitivity to cytostatics, rise of hyperploidy, replacement of the stem line, presence of definite markers in leukemic cells as well as by the appearance of a clone of cells with higher dry mass. At the level of CFUs after the carminomycin administration more remote terms of cell restoration than in case of P-388/c lymphoid leukemia are determined. The P-388/c lymphoid leukemia cells lost their sensitivity to carminomycin at the stage of the DNA synthesis. Accumulation of cells is observed in phase G2 of the mitotic cycle.","['Kozinets, G I', 'Ivanova, E', 'Kuznetsova, T V', 'Khanykova, O K', 'Levina, N V']","['Kozinets GI', 'Ivanova E', 'Kuznetsova TV', 'Khanykova OK', 'Levina NV']",['rus'],"['English Abstract', 'Journal Article']",Ukraine,Eksp Onkol,Eksperimental'naia onkologiia,8406659,IM,"['Animals', 'Antineoplastic Agents/pharmacology', 'Carubicin/*pharmacology', 'Cell Survival/drug effects', 'Daunorubicin/*analogs & derivatives', 'Drug Resistance', 'Female', 'Hematopoietic Stem Cells/drug effects', 'Leukemia P388/*pathology', 'Leukemia, Experimental/*pathology', 'Mice', 'Mitosis/drug effects', 'Neoplasm Transplantation']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,"Eksp Onkol. 1985;7(4):60-4, 76.","['0 (Antineoplastic Agents)', 'E7437K3983 (Carubicin)', 'ZS7284E0ZP (Daunorubicin)']",,"Tsitologicheskaia kharakteristika limfoleikoza P-388, rezistentnogo k karminomitsinu.",,,,,,,,,
4042705,NLM,MEDLINE,19851028,20211203,0012-3692 (Print) 0012-3692 (Linking),88,4,1985 Oct,Transbronchial biopsy in the thrombocytopenic patient.,549-52,"Twenty-five flexible fiberoptic bronchoscopic procedures with transbronchial lung biopsies were performed in 24 severely thrombocytopenic immunocompromised patients (mean platelet count of 30,000/cu mm, with a range of 7,000/cu mm to 60,000/cu mm) during the diagnostic evaluation of pulmonary infiltrates. Three patients had self-limited endobronchial bleeding. A single death was attributable to massive hemorrhage after transbronchial biopsy and brushing. Specific etiologic diagnoses were established by bronchoscopy in nine cases.","['Papin, T A', 'Lynch, J P 3rd', 'Weg, J G']","['Papin TA', 'Lynch JP 3rd', 'Weg JG']",['eng'],['Journal Article'],United States,Chest,Chest,0231335,IM,"['Biopsy/*adverse effects', 'Bronchoscopy', 'Hemorrhage/*etiology', 'Humans', 'Immune Tolerance', 'Immunosuppression Therapy', 'Leukemia/complications', 'Lung/*pathology', 'Lymphoproliferative Disorders/complications', 'Thrombocytopenia/etiology/*pathology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']","['S0012-3692(15)34238-0 [pii]', '10.1378/chest.88.4.549 [doi]']",ppublish,Chest. 1985 Oct;88(4):549-52. doi: 10.1378/chest.88.4.549.,,,,,,,,,,,,
4042680,NLM,MEDLINE,19851119,20190829,0070-217X (Print) 0070-217X (Linking),122,,1985,Characteristics of the wm substrain of BALB/c mice.,38-42,,"['Murphy, W H', 'Bolgos, G L']","['Murphy WH', 'Bolgos GL']",['eng'],['Journal Article'],Germany,Curr Top Microbiol Immunol,Current topics in microbiology and immunology,0110513,IM,"['Animals', 'Bacterial Infections', 'Immunity, Innate', 'Leukemia, Experimental/immunology', 'Mice', 'Mice, Inbred BALB C/*physiology', 'Virus Diseases']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70740-7_5 [doi]'],ppublish,Curr Top Microbiol Immunol. 1985;122:38-42. doi: 10.1007/978-3-642-70740-7_5.,,,,,,,,,,,,
4042674,NLM,MEDLINE,19851119,20190829,0070-217X (Print) 0070-217X (Linking),122,,1985,Susceptibility to Abelson or Moloney murine leukemia viruses.,162-8,,"['Risser, R', 'Kaehler, D']","['Risser R', 'Kaehler D']",['eng'],['Journal Article'],Germany,Curr Top Microbiol Immunol,Current topics in microbiology and immunology,0110513,IM,"['Abelson murine leukemia virus', 'Animals', 'Antigens, Neoplasm/analysis', 'Immunity, Innate', 'Leukemia, Experimental/genetics/*immunology', 'Lymphoma/immunology', 'Mice', 'Mice, Inbred Strains/genetics/*immunology', 'Moloney murine leukemia virus', 'Thymoma/immunology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70740-7_24 [doi]'],ppublish,Curr Top Microbiol Immunol. 1985;122:162-8. doi: 10.1007/978-3-642-70740-7_24.,"['0 (Antigens, Neoplasm)']",,,,,,,,,,,
4042596,NLM,MEDLINE,19851107,20041117,0098-8243 (Print) 0098-8243 (Linking),11,9,1985 Sep,Psychosocial considerations in the treatment of leukemia.,44-9,,"['Gonda, T A', 'Ruark, J E']","['Gonda TA', 'Ruark JE']",['eng'],"['Case Reports', 'Journal Article']",United States,Compr Ther,Comprehensive therapy,7605837,IM,"['Adult', 'Age Factors', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Humans', 'Informed Consent', 'Leukemia/drug therapy/*psychology/therapy', 'Male', 'Middle Aged']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Compr Ther. 1985 Sep;11(9):44-9.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4042567,NLM,MEDLINE,19851114,20190919,0141-9854 (Print) 0141-9854 (Linking),7,2,1985,An assessment of the Ortho ELT-800 WBC and three-part WBC screen.,151-6,"The ELT-800 WBC and three-part WBC screen have been evaluated. Technical assessment showed each to be satisfactory but in a small number of samples, the total WBC was found to be incorrect. Discrepancies were found in some cases of chronic lymphatic leukaemia, sickle cell disease and paraproteinaemia. The reasons for these differences are discussed. In the population studied, an accurate WBC screen was obtained on 87.3% of samples. Initial instrument WBC screen rejection occurred on 12.7% but in only 2.1% could no explanation be found to account for this.","['Strange, C A', 'Mackie, M J', 'Marnell, J H', 'McEvoy, P']","['Strange CA', 'Mackie MJ', 'Marnell JH', 'McEvoy P']",['eng'],"['Comparative Study', 'Journal Article']",England,Clin Lab Haematol,Clinical and laboratory haematology,7907061,IM,"['Evaluation Studies as Topic', 'Granulocytes/cytology', 'Hematologic Diseases/*blood', 'Humans', 'Leukocyte Count/instrumentation/*methods', 'Leukocytes/*cytology', 'Lymphocytes/cytology', 'Monocytes/cytology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1111/j.1365-2257.1985.tb00019.x [doi]'],ppublish,Clin Lab Haematol. 1985;7(2):151-6. doi: 10.1111/j.1365-2257.1985.tb00019.x.,,,,,,,,,,,,
4042463,NLM,MEDLINE,19851113,20191022,0262-0898 (Print) 0262-0898 (Linking),3,2,1985 Apr-Jun,Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma.,77-86,"The role of oncogene expression in tumor metastasis was examined using the Abelson leukemia virus-transformed murine large cell lymphoma RAW117. Cell sublines of low and high metastatic potential expressed equally abl oncogene-coded mRNA and its phosphoprotein product p160, and the capacity of p160 to become autophosphorylated with gamma-[32P]ATP was the same among low and high metastatic cells. The expression of other oncogene-coded mRNAs (fos, myc, myb), if present, was also similar in low and high metastatic RAW117 cells. Although oncogene expression is thought to be important in initiating, and in some cases maintaining, the transformed phenotype, its expression in RAW117 lymphoma cells appears to be unrelated to metastatic phenotype.","['Rotter, V', 'Wolf, D', 'Blick, M', 'Nicolson, G L']","['Rotter V', 'Wolf D', 'Blick M', 'Nicolson GL']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",Netherlands,Clin Exp Metastasis,Clinical & experimental metastasis,8409970,IM,"['Abelson murine leukemia virus', 'Animals', 'Cell Line', 'Cell Transformation, Neoplastic', 'Electrophoresis, Polyacrylamide Gel', 'Female', '*Gene Expression Regulation', 'Leukemia, Experimental/*pathology', 'Lymphoma/*pathology', 'Mice', 'Mice, Inbred BALB C', '*Neoplasm Metastasis', '*Oncogenes', 'Phenotype', 'Phosphoproteins/biosynthesis', 'RNA, Messenger/analysis', 'RNA, Neoplasm/metabolism']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",['10.1007/BF01758957 [doi]'],ppublish,Clin Exp Metastasis. 1985 Apr-Jun;3(2):77-86. doi: 10.1007/BF01758957.,"['0 (Phosphoproteins)', '0 (RNA, Messenger)', '0 (RNA, Neoplasm)']",,,['R01-CA29571/CA/NCI NIH HHS/United States'],,,,,,,,
4042077,NLM,MEDLINE,19851121,20190619,0008-543X (Print) 0008-543X (Linking),56,10,1985 Nov 15,The human B-cell lineage cell line ARH-77.,2544-5,,"['Ralph, P']",['Ralph P'],['eng'],"['Comparative Study', 'Letter']",United States,Cancer,Cancer,0374236,IM,"['Antibody-Producing Cells', '*Cell Line', 'Humans', 'Leukemia, Plasma Cell', 'Multiple Myeloma', 'Plasmacytoma']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",['10.1002/1097-0142(19851115)56:10<2544::aid-cncr2820561039>3.0.co;2-g [doi]'],ppublish,Cancer. 1985 Nov 15;56(10):2544-5. doi: 10.1002/1097-0142(19851115)56:10<2544::aid-cncr2820561039>3.0.co;2-g.,,,,,,,,,,,,
4042076,NLM,MEDLINE,19851121,20190619,0008-543X (Print) 0008-543X (Linking),56,10,1985 Nov 15,Burkitt's lymphoma in the Middle East. A study of 34 cases.,2539-43,"The clinical features of 34 patients with Burkitt's lymphoma diagnosed at the American University Medical Center (AUMC) are described. Ages ranged between 3 and 20 years (median, 7 years). Seventy-three percent of the patients were younger than 8 years. Three cases occurred among siblings. The primary site of disease at presentation was the abdomen, 23 patients; jaw, 6; jaw and abdomen, 2; Waldeyer's ring, 2; and mediastinum, 1. Of those who had abdominal disease, the involvement was diffuse and extensive in abdomen and pelvis in 9, apparently confined to the ileocecal region in 5, mesenteric nodes and small intestine in 5, large intestine in 1, and ovary in 3. One patient presented with paraplegia. The bone marrow was studied in 19 patients; it was positive in 5 and suspicious in 2. None had frank leukemia. CSF was studied in 4 patients at presentation and was negative. Eight patients developed meningeal lymphoma during the course of the disease. Liver involvement was documented in 3 patients. Peripheral lymphadenopathy was observed at presentation in 11 patients (9, neck; 2, inguinal + axillary). In contrast to African Burkitt's, the majority of our patients presented with abdominal disease, and in contrast to the American form, our patients were younger with a median age similar to that of African Burkitt's. Thirty percent of the patients had jaw tumor at presentation--a figure intermediate between the African and the American Burkitt's.","['Anaissie, E', 'Geha, S', 'Allam, C', 'Jabbour, J', 'Khalyl, M', 'Salem, P']","['Anaissie E', 'Geha S', 'Allam C', 'Jabbour J', 'Khalyl M', 'Salem P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer,Cancer,0374236,IM,"['Abdominal Neoplasms/pathology', 'Adolescent', 'Adult', 'Burkitt Lymphoma/*epidemiology/genetics/pathology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Jaw Neoplasms/pathology', 'Male', 'Middle East', 'Neoplasm Staging/methods', 'Pelvic Neoplasms/pathology', 'Retrospective Studies']",,1985/11/15 00:00,1985/11/15 00:01,['1985/11/15 00:00'],"['1985/11/15 00:00 [pubmed]', '1985/11/15 00:01 [medline]', '1985/11/15 00:00 [entrez]']",['10.1002/1097-0142(19851115)56:10<2539::aid-cncr2820561038>3.0.co;2-5 [doi]'],ppublish,Cancer. 1985 Nov 15;56(10):2539-43. doi: 10.1002/1097-0142(19851115)56:10<2539::aid-cncr2820561038>3.0.co;2-5.,,,,,,,,,,,,
4041970,NLM,MEDLINE,19851112,20181113,0008-4050 (Print) 0008-4050 (Linking),49,3,1985 Jul,Hypereosinophilic syndrome in cats: a report of three cases.,248-53,"The clinical, clinicopathological and pathological findings in three cats with hypereosinophilic syndrome are described. The cats chosen for the study had marked eosinophilia and evidence of tissue infiltration by eosinophils. Necropsies were performed on two cats, biopsy and blood samples were provided for the third cat. At necropsy, there was diffuse reddening of femoral bone marrow with ulceration and thickening of the duodenum. The livers had an enhanced lobular pattern with multiple, white, 1-3 mm nodules throughout the parenchyma. One cat had splenomegaly and the other had several enlarged, white, firm lymph nodes. Histopathologically, there was eosinophil infiltration of intestine, lymph nodes, liver, spleen, adrenal medulla and beneath the endocardium. Ultrastructurally, the eosinophils from lymph node and bone marrow of cat II were morphologically normal. The rigid criteria for eosinophilic leukemia were not fulfilled by these cases and the etiology of the eosinophilia in each case is not known. Possible pathogenic mechanisms are discussed.","['McEwen, S A', 'Valli, V E', 'Hulland, T J']","['McEwen SA', 'Valli VE', 'Hulland TJ']",['eng'],"['Case Reports', 'Journal Article']",Canada,Can J Comp Med,Canadian journal of comparative medicine : Revue canadienne de medecine comparee,0151747,IM,"['Adrenal Medulla/pathology', 'Animals', 'Bone Marrow/pathology', 'Cat Diseases/*pathology', 'Cats', 'Eosinophilia/pathology/*veterinary', 'Eosinophils/cytology/ultrastructure', 'Female', 'Intestines/pathology', 'Leukocyte Count/veterinary', 'Liver/pathology', 'Lymph Nodes/pathology', 'Male', 'Microscopy, Electron', 'Spleen/pathology', 'Syndrome/veterinary']",PMC1236165,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Can J Comp Med. 1985 Jul;49(3):248-53.,,,,,,,,,,,,
4041378,NLM,MEDLINE,19851119,20190704,0007-1048 (Print) 0007-1048 (Linking),61,2,1985 Oct,Autoimmune disease in hairy-cell leukaemia: clinical syndromes and treatment.,349-56,"Thirty-seven patients with hairy-cell leukaemia were retrospectively reviewed for the presence of autoimmune disease. Ten definite and two probable cases were identified; these patients had positive serologies (immune complexes, antinuclear antibodies or rheumatoid factor) or biopsy-proven vasculitis. Clinically, two distinct syndromes were recognized. Six patients had joint symptoms, usually associated with nodular skin lesions; all responded promptly to therapy. Four additional cases had a more severe disease consisting of fevers, malaise, weight loss, skin rash, and variable visceral involvement; there was one death in this group. There appeared to be no relationship between presence of vasculitis and the severity or progression of the underlying malignant disease. We conclude that autoimmune disease is much more frequent in hairy-cell leukaemia than has previously been recognized, and that the outcome in these syndromes is usually good. Although the autoimmune syndrome generally responds promptly to splenectomy, corticosteroids, or cytotoxic therapy, failure to recognize this complication may lead to increased morbidity and occasional mortality.","['Westbrook, C A', 'Golde, D W']","['Westbrook CA', 'Golde DW']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",England,Br J Haematol,British journal of haematology,0372544,IM,"['Autoimmune Diseases/*etiology', 'Granuloma/etiology', 'Humans', 'Joint Diseases/etiology', 'Leukemia, Hairy Cell/*complications', 'Liver Diseases/etiology', 'Lung Diseases/etiology', 'Male', 'Middle Aged', 'Retrospective Studies', 'Syndrome', 'Vasculitis/etiology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02835.x [doi]'],ppublish,Br J Haematol. 1985 Oct;61(2):349-56. doi: 10.1111/j.1365-2141.1985.tb02835.x.,,,,['CA327-37/CA/NCI NIH HHS/United States'],,,,,,,,
4041369,NLM,MEDLINE,19851119,20190704,0007-1048 (Print) 0007-1048 (Linking),61,2,1985 Oct,Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia.,261-5,"Anthracyclines given by continuous infusion, as opposed to bolus administration, are associated with a reduced incidence of cardiac and gastrointestinal toxicity. Our study was developed to test the antileukaemic effect of anthracyclines given as a continuous infusion. Nineteen sequential patients admitted for treatment of acute nonlymphocytic leukaemia (ANLL) were managed with a regimen utilizing a 3 d continuous intravenous infusion of daunomycin (DNM), and the complete response rate was similar to this institution's past experience with antileukaemic regimens employing 3 d bolus DNM. In our studies, infusion DNM was at least as myelotoxic and antileukaemic as bolus DNM; thus this method of administration should be explored further in remission-induction regimens for ANLL.","['Lewis, J P', 'Meyers, F J', 'Tanaka, L']","['Lewis JP', 'Meyers FJ', 'Tanaka L']",['eng'],['Journal Article'],England,Br J Haematol,British journal of haematology,0372544,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Cytarabine/administration & dosage', 'Daunorubicin/*administration & dosage', 'Drug Administration Schedule', 'Humans', 'Infusions, Parenteral', 'Leukemia/*drug therapy', 'Middle Aged', 'Thioguanine/administration & dosage', 'Time Factors']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb02824.x [doi]'],ppublish,Br J Haematol. 1985 Oct;61(2):261-5. doi: 10.1111/j.1365-2141.1985.tb02824.x.,"['04079A1RDZ (Cytarabine)', 'FTK8U1GZNX (Thioguanine)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4041112,NLM,MEDLINE,19851002,20131121,0001-5806 (Print) 0001-5806 (Linking),48,3,1985 May,[Immunological and hematological changes in the preleukemic stage of leukemia in Donryu rats induced by N-ethylnitrosourea].,724-33,,"['Soh, S', 'Shiomi, Z', 'Saitoh, M', 'Kuroyanagi, T']","['Soh S', 'Shiomi Z', 'Saitoh M', 'Kuroyanagi T']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Animals', 'Antibody-Producing Cells/immunology', 'Erythroblasts/pathology', 'Ethylnitrosourea', 'Female', 'Leukemia, Experimental/chemically induced/*immunology/pathology', 'Preleukemia/*immunology/pathology', 'Rats', 'Rats, Inbred Strains']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 May;48(3):724-33.,['P8M1T4190R (Ethylnitrosourea)'],,,,,,,,,,,
4040956,NLM,MEDLINE,19851017,20190903,0163-3864 (Print) 0163-3864 (Linking),48,3,1985 May-Jun,"Studies on cytotoxic constituents in pericarps of Mallotus japonicus, Part I.",455-9,"Two new phloroglucinol derivatives, named mallotophenone and mallotochromene, were isolated from the pericarps of Mallotus japonicus together with two known compounds, 3-(3,3-dimethylallyl)-5-(3-acetyl-2,4-dihydroxy-5-methyl-6- methoxybenzyl)-phloracetophenone and 2,6-dihydroxy-3-methyl-4-methoxyacetophenone. The new derivatives were confirmed to be 5-methylene-bis-2,6-dihydroxy-3-methyl-4-methoxyacetophenone and 8-acetyl-5,7-dihydroxy-6-(3-acetyl-2,4-dihydroxy-5-methyl-6- methoxybenzyl)2,2-dimethylchromene by their respective chemical and spectral data. Several of the phloroglucinol derivatives isolated from this tree were cytotoxic against the KB system and L-5178Y in cell culture.","['Arisawa, M', 'Fujita, A', 'Suzuki, R', 'Hayashi, T', 'Morita, N', 'Kawano, N', 'Koshimura, S']","['Arisawa M', 'Fujita A', 'Suzuki R', 'Hayashi T', 'Morita N', 'Kawano N', 'Koshimura S']",['eng'],['Journal Article'],United States,J Nat Prod,Journal of natural products,7906882,IM,"['Acetylation', 'Animals', 'Antineoplastic Agents, Phytogenic/*analysis/pharmacology', 'Chemical Phenomena', 'Chemistry', 'Humans', 'KB Cells/drug effects', 'Leukemia, Experimental/drug therapy', 'Plants, Medicinal/*analysis']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1021/np50039a014 [doi]'],ppublish,J Nat Prod. 1985 May-Jun;48(3):455-9. doi: 10.1021/np50039a014.,"['0 (Antineoplastic Agents, Phytogenic)']",,,,,,,,,,,
4040806,NLM,MEDLINE,19851023,20131121,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,"Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.",4748-53,"Dichloro-1,2-diaminocyclohexane (DACH):platinum(II), the prototype DACH:platinum complex, had good antitumor activity, was not cross-resistant with cis-dichlorodiammineplatinum(II) (DDP), but was, unfortunately, virtually insoluble in water and was, therefore, not evaluated clinically. This paper summarizes some of the chemical and biological attributes of a series of cis-bisascorbato-DACH:platinum(II) complexes (DAP). Although the primary emphasis has been placed on the DAP complex consisting of the isomeric mixture DACH, a series of complexes using the isomers of either DACH or ascorbic acid have also been synthesized. The synthetic procedure entailed reacting the water-soluble sulfato-DACH:platinum(II) with barium ascorbate, and the water-soluble product DAP was removed from the BaSO4 precipitate by filtration. Based upon elemental analysis, all the complexes had stoichiometric composition of one DACH:one platinum and two ascorbate monoanions. High-pressure liquid chromatography of cis-bisascorbato (mixed-isomer DACH):platinum revealed a series of platinum-containing, ultraviolet-absorbing peaks. All the DAP complexes had significant in vitro cytotoxicity against L1210 leukemia cells (L1210/0) with 50%-inhibitory dose values ranging from 2 to 5 micrograms/ml. None of the complexes was cross-resistant with DDP when tested in vitro against L1210 cells 50-fold resistant to DDP (L1210/DDP). The cis-bisascorbato (mixed-isomer DACH):platinum (DAP-1) was administered i.p. to C57BL X DBA/2 F1 mice inoculated i.p. with 10(6) L1210/0 cells. When administered on Days 1, 5, and 9, the DAP-1 complex consistently produced treated:control values in excess of 200% with several long-term survivors (alive 60 days after tumor inoculation). Further, the DAP-1 complex was totally non-cross-resistant with DDP when tested in vivo against a DDP-resistant L1210 line. Toxicological investigations revealed that DAP-1 was relatively nonnephrotoxic but did cause the expected bone marrow and gastrointestinal toxicity. In summary, the DAP complexes are highly water-soluble, nonnephrotoxic platinum complexes with sufficient antitumor activity to warrant further pharmacological, biochemical, and chemical investigations.","['Hacker, M P', 'Khokhar, A R', 'Brown, D B', 'McCormack, J J', 'Krakoff, I H']","['Hacker MP', 'Khokhar AR', 'Brown DB', 'McCormack JJ', 'Krakoff IH']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antineoplastic Agents/*pharmacology/toxicity', 'Chemical Phenomena', 'Chemistry', 'Cisplatin/pharmacology', 'Drug Resistance', 'Male', 'Mice', 'Mice, Inbred Strains', 'Organoplatinum Compounds/*pharmacology/toxicity', 'Solubility']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):4748-53.,"['0 (Antineoplastic Agents)', '0 (Organoplatinum Compounds)', '52691-24-4 (dichloro-1,2-diaminocyclohexane platinum complex)', '92784-30-0 (ARK 62-62)', 'Q20Q21Q62J (Cisplatin)']",,,"['CA23545/CA/NCI NIH HHS/United States', 'CA32244/CA/NCI NIH HHS/United States']",,,,,,,,
4040753,NLM,MEDLINE,19850903,20190612,0006-291X (Print) 0006-291X (Linking),130,1,1985 Jul 16,Microinjection of macromolecules into leukemic cells by cell fusion technique: search for intracellular growth-suppressive factors.,257-63,"To investigate the intracellular molecular events during leukemic cell proliferation, we have examined the method of ghost-mediated microinjection of macromolecules into leukemic cell line cells (HL-60). Samples were packed into red cell ghosts. Microinjection was performed by the fusion of ghosts and HL-60 cells using the hemagglutinating virus of Japan (HVJ). Fusion rate was about 80-90%, when determined by the injection of FITC-labeled globulins (IgG) or diphtheria toxin fragment A into HL-60 cells. When the nuclear protein extract from normal granulocytes was injected into HL-60 cells, their growth was significantly suppressed. The injection of the nuclear protein extract from HL-60 itself into HL-60 cells did not inhibit their growth. This finding suggests that leukemic cells may be deficient in intracellular regulatory factors which have suppressive activity on cell growth.","['Ozawa, K', 'Hosoi, T', 'Tsao, C J', 'Urabe, A', 'Uchida, T', 'Takaku, F']","['Ozawa K', 'Hosoi T', 'Tsao CJ', 'Urabe A', 'Uchida T', 'Takaku F']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Biochem Biophys Res Commun,Biochemical and biophysical research communications,0372516,IM,"['Animals', '*Cell Fusion', 'Erythrocyte Membrane', 'Growth Inhibitors/administration & dosage', 'Humans', 'Immunoglobulin G/administration & dosage', 'Leukemia, Experimental/drug therapy/*pathology', 'Microinjections/*methods', 'Nucleoproteins/administration & dosage']",,1985/07/16 00:00,1985/07/16 00:01,['1985/07/16 00:00'],"['1985/07/16 00:00 [pubmed]', '1985/07/16 00:01 [medline]', '1985/07/16 00:00 [entrez]']","['0006-291X(85)90410-3 [pii]', '10.1016/0006-291x(85)90410-3 [doi]']",ppublish,Biochem Biophys Res Commun. 1985 Jul 16;130(1):257-63. doi: 10.1016/0006-291x(85)90410-3.,"['0 (Growth Inhibitors)', '0 (Immunoglobulin G)', '0 (Nucleoproteins)']",,,,,,,,,,,
4040724,NLM,MEDLINE,19850909,20190619,0003-4819 (Print) 0003-4819 (Linking),103,3,1985 Sep,FAB M7: acute megakaryoblastic leukemia--beyond morphology.,450-2,,"['Bloomfield, C D', 'Brunning, R D']","['Bloomfield CD', 'Brunning RD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Ann Intern Med,Annals of internal medicine,0372351,IM,"['Acute Disease', 'Bone Marrow/pathology', 'Diagnosis, Differential', 'Humans', 'International Cooperation', 'Leukemia/*classification/pathology', 'Thrombocythemia, Essential/*classification/pathology']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.7326/0003-4819-103-3-450 [doi]'],ppublish,Ann Intern Med. 1985 Sep;103(3):450-2. doi: 10.7326/0003-4819-103-3-450.,,,,,,,,,,,,
4040700,NLM,MEDLINE,19850916,20201209,0513-4870 (Print) 0513-4870 (Linking),20,1,1985 Jan,[Effects of hematoporphyrin derivatives--photoirradiation on DNA and RNA synthesis in L1210 cells].,17-20,,"['Li, Z R', 'Feng, J B', 'Han, R']","['Li ZR', 'Feng JB', 'Han R']",['chi'],"['Comparative Study', 'Journal Article']",China,Yao Xue Xue Bao,Yao xue xue bao = Acta pharmaceutica Sinica,21710340R,IM,"['Animals', 'DNA Polymerase II/metabolism', 'DNA, Neoplasm/*biosynthesis', 'Hematoporphyrins/*pharmacology', 'In Vitro Techniques', 'Leukemia L1210/*metabolism', 'Light', 'Photochemotherapy', 'RNA, Neoplasm/*biosynthesis', 'Radiation-Sensitizing Agents/*pharmacology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Yao Xue Xue Bao. 1985 Jan;20(1):17-20.,"['0 (DNA, Neoplasm)', '0 (Hematoporphyrins)', '0 (RNA, Neoplasm)', '0 (Radiation-Sensitizing Agents)', 'EC 2.7.7.7 (DNA Polymerase II)']",,,,,,,,,,,
4040505,NLM,MEDLINE,19850905,20191022,0167-6997 (Print) 0167-6997 (Linking),3,2,1985,Pharmacology of mitoxantrone: mode of action and pharmacokinetics.,101-7,"Although a number of investigators have established that mitoxantrone (Novantrone; dihydroxyanthracenedione) inhibits RNA and DNA synthesis and intercalates with DNA in vitro, its exact mechanism of action is unclear. Mitoxantrone is structurally related to a series of substituted anthraquinones and has features known to be essential for DNA intercalation; however, we have determined recently that mitoxantrone binds DNA in intact L1210 leukemia cells by a non-intercalative, electrostatic interaction and induces both protein associated and non-protein associated DNA strand scissions. The difference between mitoxantrone and doxorubicin with respect to their interactions with DNA could account for their relative lack of cross-resistance in the treatment of lymphoma and acute leukemia. Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule. Considerable evidence exists to suggest that mitoxantrone undergoes extensive metabolism, probably in the liver. Preliminary data show that abnormal liver function leads to decreased rates of total body mitoxantrone clearance, suggesting a possible need for dose reduction in patients with severe liver dysfunction. The most important route of mitoxantrone elimination appears to be fecal. Because of the relatively low urinary excretion it is unlikely that the standard drug dose must be reduced in the presence of compromised renal function.","['Alberts, D S', 'Peng, Y M', 'Bowden, G T', 'Dalton, W S', 'Mackel, C']","['Alberts DS', 'Peng YM', 'Bowden GT', 'Dalton WS', 'Mackel C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Invest New Drugs,Investigational new drugs,8309330,IM,"['Animals', 'Anthraquinones/administration & dosage/*metabolism/therapeutic use', 'Antineoplastic Agents/*metabolism', 'Bone Marrow/analysis', 'Bone Neoplasms/drug therapy/secondary', 'Chromatography, High Pressure Liquid', 'Colonic Neoplasms/drug therapy', 'DNA/metabolism', 'Female', 'Half-Life', 'Humans', 'Injections, Intraperitoneal', 'Kidney Neoplasms/pathology', 'Kinetics', 'Leukemia L1210/metabolism', 'Mice', 'Mitoxantrone', 'Ovarian Neoplasms/drug therapy', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00174156 [doi]'],ppublish,Invest New Drugs. 1985;3(2):101-7. doi: 10.1007/BF00174156.,"['0 (Anthraquinones)', '0 (Antineoplastic Agents)', '9007-49-2 (DNA)', 'BZ114NVM5P (Mitoxantrone)']",,,"['CA 17094/CA/NCI NIH HHS/United States', 'CA 21839/CA/NCI NIH HHS/United States', 'CA 23014/CA/NCI NIH HHS/United States']",,,,,,,,
4040435,NLM,MEDLINE,19850919,20190912,0309-1651 (Print) 0309-1651 (Linking),9,5,1985 May,Ultrastructural evidence for contacts between migrating L5222 rat leukemia cells and extracellular matrix components of the rat mesentery.,447-61,"The nature of interactions between cells migrating through tissues and their structural surroundings are largely unknown. We have therefore examined the ultrastructural relationship between L5222 rat leukemia cells, moving through the loose connective tissue of the mesentery, and components of the extracellular matrix (ECM). Ultrathin tissue sections, fixed in the presence of ruthenium hexammine trichloride (RHT), revealed the following: Constitutents of fibrillar and nonfibrillar elements of the ECM are in contact with the plasma membrane of L5222 cells. Linear nonfibrillar ECM elements contact the plasma membrane at point-like sites, often associated with root-like structures present within the submembraneous microfilament mesh. Aggregates of ECM material are connected to patch-like cell membrane sites, associated with a condensed, plate-like part of the microfilament mesh. Point-like and patch-like contacts are more numerous at the anterior part of polarized migrating L5222 cells than on the posterior end. In round resting leukemia cells they are evenly distributed around the cell periphery. We suggest that the ECM-cell membrane contacts represent tissue adhesion sites. We therefore hypothesize that in migrating cells a coordinate interaction occurs between the contact sites and the continuous microfilament meshwork which results in a simultaneous backward movement of ECM-membrane contacts on the cell body and in a net forward movement of the whole cell. Since Dembo et al. (1981) present a similar mechanism for in vitro locomotion of granulocytes, we assume that blood cell locomotion in vivo and in vitro depends on similar molecular mechanisms: force generation by the cell, transmembraneous linkage between cytoskeletal and ECM elements, and membrane fluidity. The major difference in blood cell locomotion through a three-dimensional tissue or on a plane substratum would then be given by the distribution of contact sites, occurring around the cell periphery or limited to the ventral cell surface, respectively.","['Muller-Glauser, W', 'Haemmerli, G', 'Strauli, P']","['Muller-Glauser W', 'Haemmerli G', 'Strauli P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Cell Biol Int Rep,Cell biology international reports,7708050,IM,"['Animals', 'Cell Adhesion', 'Cell Membrane/ultrastructure', 'Cell Movement', 'Connective Tissue/ultrastructure', 'Cytoskeleton/ultrastructure', 'Extracellular Matrix/*ultrastructure', 'Leukemia, Experimental/*pathology', 'Mesentery/ultrastructure', 'Microscopy, Electron', 'Rats', 'Rats, Inbred Strains']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1016/0309-1651(85)90153-5 [doi]'],ppublish,Cell Biol Int Rep. 1985 May;9(5):447-61. doi: 10.1016/0309-1651(85)90153-5.,,,,,['NASA: 85254988'],,,,,,,
4040366,NLM,MEDLINE,19850815,20190623,0006-2952 (Print) 0006-2952 (Linking),34,13,1985 Jul 1,"PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.",2347-54,"PTT.119 [p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl], a new synthetic tripeptide, was highly effective against the L-phenylalanine mustard (L-PAM) resistant (L1210/L-PAM and P388/L-PAM) tumor lines, as well as the sensitive L1210 leukemia. Cytolytic activity of PTT.119 against all three leukemias was significantly greater than equimolar doses of L-PAM. These in vitro results paralleled the significant increases in mean survival times of hosts and, in some cases, abrogations of tumor formation observed in the in vivo bioassays of PTT.119-treated L1210 and L1210/L-PAM cells. Dose-response studies failed to demonstrate cross-resistance to the tripeptide by L-PAM resistant cells. Doses of PTT.119 required to reduce the viable fraction by 50% (tissue culture dose 50, TCD50) or 100% (TCD100) were 1.3- to 3-fold lower for the L-PAM resistant cells than for the L1210 leukemia. In comparison, L-PAM was unable to completely eliminate cell survival; 0.2 to 3% of the cells in all three leukemias remained viable even at doses of 75 and 163 microM. In similar studies, L1210 leukemia cells made resistant to methotrexate (L1210 MTX) and cisplatin (L1210DDP) were also completely susceptible to PTT.119; TCD50 values of the two resistant lines were 1.94 microM for L1210 MTX and 0.525 microM for L1210DDP compared to 2.38 microM for the susceptible parent L1210S leukemia. Continuous low-dose PTT.119 treatment of MJY-alpha mammary tumor cells for 8 months and exposure of L1210 leukemia to escalating levels of tripeptide for over 100 passages failed to select or induce drug-resistant phenotypes in either cell line. PTT.119 appears to be a poor mutagen and is unlikely to readily increase the probability of drug-resistant mutants in the tumor cell populations.","['Yagi, M J', 'Chin, S E', 'Scanlon, K J', 'Holland, J F', 'Bekesi, J G']","['Yagi MJ', 'Chin SE', 'Scanlon KJ', 'Holland JF', 'Bekesi JG']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Biochem Pharmacol,Biochemical pharmacology,0101032,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Cell Line', 'Cell Survival/drug effects', 'Cisplatin/pharmacology', 'Dose-Response Relationship, Drug', 'Drug Resistance', 'Leukemia L1210/drug therapy', 'Melphalan/pharmacology', 'Mice', 'Mice, Inbred Strains', 'Neoplasms, Experimental/*drug therapy/pathology', 'Nitrogen Mustard Compounds/*pharmacology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']","['0006-2952(85)90793-2 [pii]', '10.1016/0006-2952(85)90793-2 [doi]']",ppublish,Biochem Pharmacol. 1985 Jul 1;34(13):2347-54. doi: 10.1016/0006-2952(85)90793-2.,"['0 (Antineoplastic Agents)', '0 (Nitrogen Mustard Compounds)', 'IB1H345F24 (ambamustine)', 'Q20Q21Q62J (Cisplatin)', 'Q41OR9510P (Melphalan)']",,,,,,,,,,,
4040298,NLM,MEDLINE,19850801,20190824,0364-2313 (Print) 0364-2313 (Linking),9,3,1985 Jun,Splenectomy for thrombocytopenia.,416-21,,"['Schwartz, S I']",['Schwartz SI'],['eng'],['Journal Article'],United States,World J Surg,World journal of surgery,7704052,IM,"['Adolescent', 'Adult', 'Aged', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Leukemia, Hairy Cell/complications', 'Leukemia, Lymphoid/complications', 'Male', 'Middle Aged', 'Myeloproliferative Disorders/complications', 'Postoperative Complications', 'Purpura, Thrombocytopenic/surgery', 'Purpura, Thrombotic Thrombocytopenic/surgery', '*Splenectomy', 'Thrombocytopenia/etiology/mortality/*surgery']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1007/BF01655276 [doi]'],ppublish,World J Surg. 1985 Jun;9(3):416-21. doi: 10.1007/BF01655276.,,,,,,,,,,,,
4040193,NLM,MEDLINE,19850809,20190824,0145-2126 (Print) 0145-2126 (Linking),9,6,1985,Inherited factors in leukaemia and lymphoma.,705-7,,"['Harnden, D G']",['Harnden DG'],['eng'],['Journal Article'],England,Leuk Res,Leukemia research,7706787,IM,"['Animals', 'Diseases in Twins', 'Female', 'H-2 Antigens/analysis', 'HLA Antigens/analysis', 'Humans', 'Leukemia/*genetics', 'Leukemia, Experimental/immunology', 'Lymphoma/*genetics', 'Pregnancy', 'Syndrome', 'Twins, Monozygotic']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0145-2126(85)90279-6 [pii]', '10.1016/0145-2126(85)90279-6 [doi]']",ppublish,Leuk Res. 1985;9(6):705-7. doi: 10.1016/0145-2126(85)90279-6.,"['0 (H-2 Antigens)', '0 (HLA Antigens)']",,,,,,,,,,,
4040103,NLM,MEDLINE,19850821,20190829,0278-6915 (Print) 0278-6915 (Linking),23,6,1985 Jun,Tumorigenicity study of butyl and isobutyl p-hydroxybenzoates administered orally to mice.,575-8,"Butyl p-hydroxybenzoate (n-BHB) and isobutyl p-hydroxybenzoate (i-BHB) were administered orally to ICR/Jcl mice at concentrations of 0.6 (maximum tolerated dose), 0.3 or 0.15% in the diet for up to 102 wk. Tumours were observed at various sites including the haematopoietic system, the lung and the soft tissue. However, at none of the sites did the tumour incidence or the time to death with tumours differ significantly from that in the untreated control group.","['Inai, K', 'Aoki, Y', 'Akamizu, H', 'Eto, R', 'Nishida, T', 'Tokuoka, S']","['Inai K', 'Aoki Y', 'Akamizu H', 'Eto R', 'Nishida T', 'Tokuoka S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Food Chem Toxicol,Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,8207483,IM,"['Administration, Oral', 'Amyloidosis/chemically induced', 'Animals', 'Dose-Response Relationship, Drug', 'Female', 'Food Preservatives/*toxicity', 'Leukemia, Experimental/chemically induced', 'Male', 'Mice', 'Mice, Inbred ICR', 'Mutagenicity Tests', 'Neoplasms, Experimental/*chemically induced', 'Parabens/*toxicity']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']","['0278-6915(85)90181-4 [pii]', '10.1016/0278-6915(85)90181-4 [doi]']",ppublish,Food Chem Toxicol. 1985 Jun;23(6):575-8. doi: 10.1016/0278-6915(85)90181-4.,"['0 (Food Preservatives)', '0 (Parabens)', '3QPI1U3FV8 (butylparaben)', '4247-02-3 (isobutyl-4-hydroxybenzoate)']",,,,,,,,,,,
4039973,NLM,MEDLINE,19850821,20190720,0304-3835 (Print) 0304-3835 (Linking),27,2,1985 Jun,Antitumor activity of l-OHP in mice.,135-43,"The isomeric mixtures of platinum complexes of diaminocyclohexane (DACH) had been found active on several murine tumors. A recent separation of the oxalato-platinum complex of trans-l-DACH isomer allowed more precise screening studies and permitted the selection of one compound: l-OHP was submitted to our murine tumor screening system. The drug was given: (a) at doses of 1-12 mg/kg i.p. or i.v. on day 1, 5 and 9 compared to identical doses of cis-dichlorodiamine platinum II (CDDP) in L1210 bearing mice and (b) to AkR leukemia, LGC lymphoma, glioma 26, B16 melanoma, MA 16-C mammary carcinoma and Lewis lung carcinoma bearing mice at 2 dosages: 5 mg/kg (minimal effective dose on L1210), and 8 mg/kg (subtoxic dose in L1210). Acute LD10 and LD50 appeared similar to CDDP and l-OHP. l-OHP administered i.p. was more active on L1210 than CDDP. On L1210 grafted intracerebrally and on LGC lymphoma l-OHP increased significantly the lifespan while CDDP was inactive. On AkR leukemia, both drugs were active but l-OHP was less toxic. Both drugs were inactive on murine solid tumors. No renal toxicity was observed with l-OHP as compared to CDDP.","['Mathe, G', 'Kidani, Y', 'Noji, M', 'Maral, R', 'Bourut, C', 'Chenu, E']","['Mathe G', 'Kidani Y', 'Noji M', 'Maral R', 'Bourut C', 'Chenu E']",['eng'],['Journal Article'],Ireland,Cancer Lett,Cancer letters,7600053,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Cisplatin/pharmacology/toxicity', 'Kidney/drug effects', 'Leukemia L1210/drug therapy', 'Male', 'Mice', 'Mice, Inbred Strains', 'Neoplasms, Experimental/drug therapy', 'Organoplatinum Compounds/*pharmacology/toxicity']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']","['0304-3835(85)90102-8 [pii]', '10.1016/0304-3835(85)90102-8 [doi]']",ppublish,Cancer Lett. 1985 Jun;27(2):135-43. doi: 10.1016/0304-3835(85)90102-8.,"['0 (Antineoplastic Agents)', '0 (Organoplatinum Compounds)', '52691-24-4 (dichloro-1,2-diaminocyclohexane platinum complex)', 'Q20Q21Q62J (Cisplatin)']",,,,,,,,,,,
4039917,NLM,MEDLINE,19850625,20131121,0385-0684 (Print) 0385-0684 (Linking),12,3 Pt 1,1985 Mar,[The effect of methotrexate on intracellular nucleotide pools].,485-92,"In a previous study, we showed that methotrexate (MTX) enhanced the intracellular production of ara-CTP. The study described in the present paper has elucidated the mechanism of this MTX-enhanced ara-CTP production, which occurs as a result of MTX reducing the intracellular dCTP pool, and the decreased dCTP pool then allowing activation of deoxycytidine Kinase. One of the mechanisms of synergistic interaction between 1-beta-D-arabinofuranosylcytosine (ara-C) and MTX might therefore be the stimulated phosphorylation of ara-C with MTX-activated deoxy-cytidine kinase. Using high-pressure liquid chromatography, the sequential changes occurring in the acid-soluble intracellular nucleotide pools of L1210 mouse leukemic cells were analysed after treatment with MTX (12mg/kg). At 3 hr after treatment with MTX a reduction of the dTTP pool to 46% of the control level was observed. The dCTP pool was also reduced to 36% of the control level after treatment with MTX. The levels of the dATP and dGTP pools were not significantly changed, at least during the observation period. Pyrimidine ribonucleotide pools were almost unchanged at 3 hr, but in the sequential changes observed in purine ribonucleotide pools after treatment with MTX, both diphosphate and triphosphate pools were seen to be on the decline, the reduction of triphosphate pools being especially marked. A decline in ATP and GPT to 24-30% of control levels was observed at 3 hr after treatment with MTX.","['Kawasaki, H', 'Okubo, T', 'Shimizu, N', 'Komada, M', 'Sako, T', 'Hirota, H', 'Noboru, T', 'Kamiya, H', 'Sakurai, M', 'Izawa, T']","['Kawasaki H', 'Okubo T', 'Shimizu N', 'Komada M', 'Sako T', 'Hirota H', 'Noboru T', 'Kamiya H', 'Sakurai M', 'Izawa T']",['jpn'],"['English Abstract', 'Journal Article']",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Adenosine Triphosphate/metabolism', 'Animals', 'Cells, Cultured', 'Chromatography, High Pressure Liquid', 'Cytarabine/pharmacology', 'Drug Synergism', 'Guanosine Triphosphate/metabolism', 'Leukemia L1210/metabolism', 'Male', 'Methotrexate/*pharmacology', 'Mice', 'Mice, Inbred Strains', 'Nucleotides/*metabolism', 'Purine Nucleotides/metabolism', 'Pyrimidine Nucleotides/metabolism']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 1):485-92.,"['0 (Nucleotides)', '0 (Purine Nucleotides)', '0 (Pyrimidine Nucleotides)', '04079A1RDZ (Cytarabine)', '86-01-1 (Guanosine Triphosphate)', '8L70Q75FXE (Adenosine Triphosphate)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4039684,NLM,MEDLINE,19850725,20190621,0014-5793 (Print) 0014-5793 (Linking),185,2,1985 Jun 17,Purification of antineoplastic factor from eggs of a sea hare.,295-8,"An antineoplastic factor inducing tumor lysis was purified to apparent homogeneity from the supernatant of a homogenate of eggs of the sea hare Aplysia kurodai. On gel filtration, the purified substance gave a single band of material of 250 kDa containing 3 different subunits and this band coincided with cytolytic activity. The purified factor was half-maximally active at 10-60 ng protein/ml and lysed all tumor cells tested, but not normal cells.","['Yamazaki, M', 'Kisugi, J', 'Kimura, K', 'Kamiya, H', 'Mizuno, D']","['Yamazaki M', 'Kisugi J', 'Kimura K', 'Kamiya H', 'Mizuno D']",['eng'],['Journal Article'],England,FEBS Lett,FEBS letters,0155157,IM,"['Animals', 'Antineoplastic Agents/*isolation & purification/pharmacology', 'Aplysia/*analysis', 'Carbohydrates/analysis', 'Cell Line', 'Chemical Phenomena', 'Chemistry', 'Chromatography, Gel', 'Electrophoresis, Polyacrylamide Gel', 'Female', 'Humans', 'Leukemia L1210/drug therapy', 'Male', 'Mice', 'Mice, Inbred Strains', 'Neoplasms, Experimental/drug therapy', 'Ovum/analysis', 'Proteins/analysis']",,1985/06/17 00:00,1985/06/17 00:01,['1985/06/17 00:00'],"['1985/06/17 00:00 [pubmed]', '1985/06/17 00:01 [medline]', '1985/06/17 00:00 [entrez]']","['0014-5793(85)80926-1 [pii]', '10.1016/0014-5793(85)80926-1 [doi]']",ppublish,FEBS Lett. 1985 Jun 17;185(2):295-8. doi: 10.1016/0014-5793(85)80926-1.,"['0 (Antineoplastic Agents)', '0 (Carbohydrates)', '0 (Proteins)']",,,,,,,,,,,
4039607,NLM,MEDLINE,19850717,20190609,0006-3002 (Print) 0006-3002 (Linking),825,1,1985 May 24,The quantitative determination of metabolites of 6-mercaptopurine in biological materials. VI. Evidence for posttranscriptional modification of 6-thioguanosine residues in RNA from L5178Y cells treated with 6-mercaptopurine.,39-44,"Mammalian cells incorporate 6-thioguanosine into their nucleic acids when grown in the presence of 6-mercaptopurine. 35S-labeled total RNA was prepared from L5178Y murine lymphoma cells grown in vitro in the presence of 6-[35S]mercaptopurine. Base analyses of this RNA suggested that 6-thioguanosine residues in RNA molecules undergo posttranscriptional modification. Thus, enzymatic peak-shifting analyses using anion-exchange high-performance liquid chromatography were applied to the hydrolysis products released from total RNA preparations by digestion with nuclease P1 or nuclease P1 plus nucleotide pyrophosphatase. At least eight 35S-labeled, phosphatase-sensitive compounds structurally different from [35S]6thioGMP were found in nuclease P1 digests. Four of these compounds were susceptible to cleavage with nucleotide pyrophosphatase, thus indicating that they contained phosphoric acid anhydride bonds. Individual RNA species were not separately examined, the radiochromatographic data, however, which were obtained from digests of total RNA preparations, present evidence that 6-thioguanosine 5'-diphosphate and 6-thioguanosine 5'-triphosphate exist as 5'-terminal starting nucleotides (in tRNA and rRNA) and that 6-thioguanosine becomes incorporated into the highly modified dinucleoside triphosphate structures (caps) which commonly block the 5'-termini of eukaryotic poly(A)+ mRNA-molecules.","['Breter, H J']",['Breter HJ'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Biochim Biophys Acta,Biochimica et biophysica acta,0217513,IM,"['Animals', 'Chromatography, High Pressure Liquid', 'Guanosine/*analogs & derivatives/metabolism', 'Leukemia L5178/*metabolism', 'Leukemia, Experimental/*metabolism', 'Mercaptopurine/*pharmacology', 'Mice', 'RNA Processing, Post-Transcriptional/*drug effects', 'RNA, Neoplasm/*genetics/isolation & purification/metabolism', 'Ribonucleosides/analysis', 'Sulfur Radioisotopes', 'Thionucleosides/*metabolism']",,1985/05/24 00:00,1985/05/24 00:01,['1985/05/24 00:00'],"['1985/05/24 00:00 [pubmed]', '1985/05/24 00:01 [medline]', '1985/05/24 00:00 [entrez]']","['0167-4781(85)90077-6 [pii]', '10.1016/0167-4781(85)90077-6 [doi]']",ppublish,Biochim Biophys Acta. 1985 May 24;825(1):39-44. doi: 10.1016/0167-4781(85)90077-6.,"['0 (RNA, Neoplasm)', '0 (Ribonucleosides)', '0 (Sulfur Radioisotopes)', '0 (Thionucleosides)', '12133JR80S (Guanosine)', 'C558LI0K8P (6-thioguanosine)', 'E7WED276I5 (Mercaptopurine)']",,,,,,,,,,,
4039541,NLM,MEDLINE,19850619,20190628,0003-2697 (Print) 0003-2697 (Linking),144,2,1985 Feb 1,A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells.,514-21,"A highly sensitive and rapid assay for the detection of 6-mercaptopurine metabolites in the red blood cells of leukemic patients receiving the drug has been developed. The method employs a batch-chromatographic procedure using a mercurial cellulose resin to selectively absorb thiol compounds combined with separation by high-performance liquid chromatography using a Partisil-SAX column and uv detection. This method permits detection of 6-thioinosine monophosphate, 6-thiouric acid, and 6-thioguanosine mono-, di-, and triphosphates in patient samples with a sensitivity of 5-10 pmol. No 6-thioinosine di- or triphosphates were detected in patient samples. The results of our study indicate that 6-thioguanosine triphosphate is the major metabolite of 6-mercaptopurine retained by red blood cells after oral or iv administration of the drug.","['Lavi, L E', 'Holcenberg, J S']","['Lavi LE', 'Holcenberg JS']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Anal Biochem,Analytical biochemistry,0370535,IM,"['Biotransformation', 'Cellulose/analogs & derivatives', 'Chromatography, High Pressure Liquid', 'Erythrocytes/*analysis', 'Humans', 'Leukemia/blood', 'Mercaptoethanol/analysis', 'Mercaptopurine/*blood', 'Methylthioinosine/analysis', 'Organomercury Compounds', 'Thioguanine/analysis']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']","['0003-2697(85)90148-4 [pii]', '10.1016/0003-2697(85)90148-4 [doi]']",ppublish,Anal Biochem. 1985 Feb 1;144(2):514-21. doi: 10.1016/0003-2697(85)90148-4.,"['0 (Organomercury Compounds)', '342-69-8 (Methylthioinosine)', '60-24-2 (Mercaptoethanol)', '9004-34-6 (Cellulose)', 'E7WED276I5 (Mercaptopurine)', 'FTK8U1GZNX (Thioguanine)']",,,,,,,,,,,
4039236,NLM,MEDLINE,19850617,20190829,0307-6938 (Print) 0307-6938 (Linking),10,1,1985 Jan,Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease.,3-12,,"['Farthing, C F', 'Staughton, R C', 'Rowland Payne, C M']","['Farthing CF', 'Staughton RC', 'Rowland Payne CM']",['eng'],"['Case Reports', 'Journal Article']",England,Clin Exp Dermatol,Clinical and experimental dermatology,7606847,IM,"['Acquired Immunodeficiency Syndrome/*complications', 'Adult', 'Animals', 'Homosexuality', 'Humans', 'Male', 'Middle Aged', 'Sarcoma, Kaposi/etiology', 'Skin Diseases/*etiology', 'Skin Neoplasms/etiology', 'Tumor Virus Infections/*complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1111/j.1365-2230.1985.tb02545.x [doi]'],ppublish,Clin Exp Dermatol. 1985 Jan;10(1):3-12. doi: 10.1111/j.1365-2230.1985.tb02545.x.,,,,,,,,,,,,
4039125,NLM,MEDLINE,19850510,20141120,0385-0684 (Print) 0385-0684 (Linking),12,4,1985 Apr,[Effects of calcium influx blocker on the cellular transport of Adriamycin].,966-8,"Effects of the calcium influx blocker, verapamil, on the cellular transport of adriamycin (ADR) were studied using the technique of flow cytometry. A marked increase in intracellular ADR accumulation was brought about by verapamil treatment. Flow cytometric analysis suggested that this augmentation of cellular ADR content was due to the inhibition of active ADR efflux from the cells. This inhibitory effect of verapamil was dependent on the concentration of the calcium influx blocker in the culture medium.","['Sasaki, K', 'Nagaoka, S', 'Murakami, T', 'Kawasaki, S', 'Takahashi, M']","['Sasaki K', 'Nagaoka S', 'Murakami T', 'Kawasaki S', 'Takahashi M']",['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Gan To Kagaku Ryoho,Gan to kagaku ryoho. Cancer & chemotherapy,7810034,IM,"['Animals', 'Biological Transport', 'Calcium Channel Blockers/*pharmacology', 'Cell Line', 'Culture Media', 'Doxorubicin/*metabolism', 'Flow Cytometry', 'In Vitro Techniques', 'Leukemia L5178/*metabolism/pathology', 'Leukemia, Experimental/*metabolism', 'Verapamil/*pharmacology']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",,ppublish,Gan To Kagaku Ryoho. 1985 Apr;12(4):966-8.,"['0 (Calcium Channel Blockers)', '0 (Culture Media)', '80168379AG (Doxorubicin)', 'CJ0O37KU29 (Verapamil)']",,,,,,,,,,,
4039028,NLM,MEDLINE,19850502,20210526,0270-7306 (Print) 0270-7306 (Linking),5,1,1985 Jan,Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.,204-13,"The v-abl protein of Abelson murine leukemia virus is a tyrosine-specific kinase. Its normal cellular homolog, murine c-abl, does not possess detectable tyrosine kinase activity in vitro. Previously, we have detected tyrosine kinase activity in vitro for an altered c-abl gene product (c-abl P210) in the K562 human chronic myelogenous leukemia cell line. The expression of this variant c-abl gene product correlates with chromosomal translocation and amplification of the c-abl gene in K562 cells. Like v-abl, c-abl P210 is a fusion protein containing non-abl sequences near the amino terminus of c-abl. We compared the in vitro tyrosine kinase activity of c-abl P210 with that of wild-type murine v-abl. The remarkable similarities of these two proteins with respect to cis-acting autophosphorylation, trans-acting phosphorylation of exogenous substrates, and kinase inhibition, using site-directed abl-specific antisera, suggested that c-abl P210 could function similarly to v-abl in vivo. In addition, c-abl P210 possessed an associated serine kinase activity in immunoprecipitates. The serine kinase activity was not inhibited by site-directed, abl-specific antisera that inhibit the tyrosine kinase activity, suggesting that the serine kinase activity is not an intrinsic property of c-abl P210. Thus, the activation of the c-abl gene in a human leukemia cell line may have functional consequences analogous to activation of the c-abl gene in Abelson murine leukemia virus.","['Davis, R L', 'Konopka, J B', 'Witte, O N']","['Davis RL', 'Konopka JB', 'Witte ON']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Mol Cell Biol,Molecular and cellular biology,8109087,IM,"['Abelson murine leukemia virus', 'Angiotensin I/metabolism', 'Gene Expression Regulation', 'Molecular Weight', '*Oncogenes', 'Phosphoproteins/*genetics/metabolism', 'Phosphorylation', 'Phosphoserine/metabolism', 'Protein Kinases/*genetics/metabolism', 'Protein-Tyrosine Kinases', 'Substrate Specificity', 'Transduction, Genetic', 'Translocation, Genetic']",PMC366695,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1128/mcb.5.1.204-213.1985 [doi]'],ppublish,Mol Cell Biol. 1985 Jan;5(1):204-13. doi: 10.1128/mcb.5.1.204-213.1985.,"['0 (Phosphoproteins)', '17885-08-4 (Phosphoserine)', '9041-90-1 (Angiotensin I)', 'EC 2.7.- (Protein Kinases)', 'EC 2.7.10.1 (Protein-Tyrosine Kinases)']",,,,,,,,,,,
4038980,NLM,MEDLINE,19850507,20190903,0171-5216 (Print) 0171-5216 (Linking),109,2,1985,Susceptibility of mice reconstituted with trisomy 19 hematopoietic cells to infection with Rauscher leukemia virus.,107-14,"Radiation chimeras with trisomy 19 hematopoietic cells were constructed to test the sensitivity of the trisomic hematopoietic system to infection with Rauscher leukemia virus: Hematopoietic cells from livers of trisomic fetuses were rescued by transplantation into lethally irradiated adult mice. These Ts 19 radiation chimeras show a stable and sufficiently long-lived trisomic hematopoiesis to allow experimental induction of Rauscher leukemia. Rauscher leukemia virus (RLV) induced a marked proliferation of erythroblasts in the spleens of Ts 19 mice and control chimeras within 3 weeks. The onset of erythroblast proliferation was significantly delayed in the Ts 19 mice, suggesting a smaller number of target cells for the RLV and/or reduced susceptibility of the target cells to RLV. Both Ts 19 and control chimeras developed nonlymphocytic leukemia 2-4 months after RLV injection. The course of leukemogenesis was similar in the two experimental groups. No numerical chromosome abnormalities associated with leukemogenesis were detectable in Ts 19 or control cells. The numbers of chromosomal sister chromatid exchanges 2 weeks after RLV injection were elevated to the same degree in both Ts 19 and control cells. Thus, cells with constitutional trisomy do not show increased chromosomal instability due to leukemogenesis.","['Herbst, E W', 'Gropp, A', 'Pluznik, D H']","['Herbst EW', 'Gropp A', 'Pluznik DH']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,J Cancer Res Clin Oncol,Journal of cancer research and clinical oncology,7902060,IM,"['Animals', '*Chromosomes, Human, 19-20', 'Female', 'Hematocrit', 'Hematopoietic System/*pathology', 'Humans', 'Leukemia, Experimental/*genetics/pathology', 'Mice', 'Mice, Inbred C3H', 'Organ Size', 'Radiation Chimera', 'Rauscher Virus', 'Sister Chromatid Exchange', 'Spleen/pathology', '*Trisomy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00391884 [doi]'],ppublish,J Cancer Res Clin Oncol. 1985;109(2):107-14. doi: 10.1007/BF00391884.,,,,,,,,,,,,
4038675,NLM,MEDLINE,19850329,20190829,0278-6915 (Print) 0278-6915 (Linking),23,1,1985 Jan,Suitability of the P388F mouse lymphoma system for detecting potential carcinogens and mutagens.,115-8,"The P388F mouse lymphoma (TK +/-) system has been evaluated further for use as a primary mammalian-cell test and as a complementary assay to the Ames Salmonella reverse-mutation assay. The system showed a clear dose response with three alkylating agents of previously demonstrated genotoxic potential and gave the anticipated positive result with benzo[a]pyrene in the presence of S-9 mix. In addition, while giving the expected negative result with sugar, the assay detected genotoxic activity in hexamethylphosphoramide, acrylonitrile and formaldehyde, all of which are known to give negative results in the Ames test.","['Anderson, D', 'Cross, M F']","['Anderson D', 'Cross MF']",['eng'],['Journal Article'],England,Food Chem Toxicol,Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,8207483,IM,"['Animals', 'Carcinogens/*toxicity', 'Cell Survival/drug effects', 'Leukemia P388/*enzymology/genetics', 'Leukemia, Experimental/*enzymology', 'Lymphoma/*enzymology/genetics', 'Mice', 'Mutagenicity Tests/*methods', 'Thymidine Kinase/genetics']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']","['0278-6915(85)90229-7 [pii]', '10.1016/0278-6915(85)90229-7 [doi]']",ppublish,Food Chem Toxicol. 1985 Jan;23(1):115-8. doi: 10.1016/0278-6915(85)90229-7.,"['0 (Carcinogens)', 'EC 2.7.1.21 (Thymidine Kinase)']",,,,,,,,,,,
4038655,NLM,MEDLINE,19850425,20190908,0277-5379 (Print) 0277-5379 (Linking),21,1,1985 Jan,Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.,23-30,"Bone marrow cells were obtained from patients with acute non-lymphocytic leukemia immediately prior to the administration of cytosine arabinoside/anthracycline antibiotic remission induction therapy. The ability of the leukemic cells to take up and phosphorylate cytosine arabinoside (araC) and to retain cytosine arabinoside triphosphate (araCTP) was measured and compared to the outcome of remission induction therapy and the duration of remission. While the outcome of remission induction therapy was unrelated to cellular metabolism of araC, the duration of remission was highly correlated with araCTP retention. A comparison of the remission durations of patients treated on successive chemotherapeutic protocols suggests that the benefits of intensive remission consolidation therapy may be limited to patients whose leukemic cell retention of araCTP is low and that aggressive consolidation chemotherapy may reduce the prognostic significance of araCTP retention.","['Preisler, H D', 'Rustum, Y', 'Priore, R L']","['Preisler HD', 'Rustum Y', 'Priore RL']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",England,Eur J Cancer Clin Oncol,European journal of cancer & clinical oncology,8112045,IM,"['Acute Disease', 'Adult', 'Arabinofuranosylcytosine Triphosphate/*metabolism', 'Arabinonucleotides/*metabolism', 'Cytarabine/metabolism/therapeutic use', 'Female', 'Humans', 'Leukemia/drug therapy/*metabolism', 'Male', 'Middle Aged', 'Phosphorylation', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0277-5379(85)90196-8 [doi]'],ppublish,Eur J Cancer Clin Oncol. 1985 Jan;21(1):23-30. doi: 10.1016/0277-5379(85)90196-8.,"['0 (Arabinonucleotides)', '04079A1RDZ (Cytarabine)', '13191-15-6 (Arabinofuranosylcytosine Triphosphate)']",,,"['CA-21071/CA/NCI NIH HHS/United States', 'CA-24162/CA/NCI NIH HHS/United States', 'CA-5834/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4038625,NLM,MEDLINE,19850327,20131121,0008-5472 (Print) 0008-5472 (Linking),45,3,1985 Mar,Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines.,1046-51,"Phenothiazines (chlorpromazine and trifluoperazine) enhance the cellular retention and cytotoxicity of adriamycin in P388/S and P388/R cells. Effects on the resistant cells are more pronounced than those on the sensitive cells. Multiparametric flow-cytometric determination of cellular Adriamycin fluorescence shows that the phenothiazine effects are not uniform in a cell population, and cells in later part of the cell cycle traverse (S and G2/M), mitogen-stimulated lymphocytes (as compared to nonstimulated lymphocytes), and ascites (as compared to splenocytes) have greater sensitivity to phenothiazine effects on Adriamycin retention.","['Krishan, A', 'Sauerteig, A', 'Wellham, L L']","['Krishan A', 'Sauerteig A', 'Wellham LL']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Calmodulin/physiology', 'Cell Cycle', 'Cell Line', 'Doxorubicin/*metabolism/pharmacology', '*Flow Cytometry', 'Fluorometry', 'Humans', 'Leukemia P388/metabolism', 'Lymphocyte Activation', 'Phenothiazines/*pharmacology', 'Tumor Stem Cell Assay']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Mar;45(3):1046-51.,"['0 (Calmodulin)', '0 (Phenothiazines)', '80168379AG (Doxorubicin)']",,,['CA-23960/CA/NCI NIH HHS/United States'],,,,,,,,
4038588,NLM,MEDLINE,19850315,20171213,0002-9513 (Print) 0002-9513 (Linking),248,2 Pt 2,1985 Feb,Kinetic model for disposition of 6-mercaptopurine in monkey plasma and cerebrospinal fluid.,R147-56,The antipurine 6-mercaptopurine (6-MP) is effective in the induction and maintenance of remission in patients with acute lymphocytic leukemia. This report presents a compartmental model that describes the kinetics of 6-MP in the plasma and cerebrospinal fluid (CSF) of the monkey. Analysis is based on simultaneously measured plasma and CSF 6-MP concentrations after intravenous and intraventricular bolus administration. Results indicate that 6-MP administered intraventricularly remains largely in the CSF. Disappearance of 6-MP from CSF is principally due to convective losses at a rate equivalent to CSF turnover. Diffusion of 6-MP across the ependymal surface accounts for only 7% of the 6-MP appearing in the plasma. Conversely the dominant route for entry of 6-MP into the CSF from the plasma is entrainment in choroidally formed CSF. Only 12% of 6-MP in the CSF after intravenous administration can be accounted for by permeation of cerebral capillaries and diffusion through brain parenchyma and across the ependymal surface into CSF. These results indicate that the choroid plexus is not a significant barrier for the transfer of molecules like 6-MP from plasma to CSF.,"['Covell, D G', 'Narang, P K', 'Poplack, D G']","['Covell DG', 'Narang PK', 'Poplack DG']",['eng'],['Journal Article'],United States,Am J Physiol,The American journal of physiology,0370511,IM,"['Animals', 'Kinetics', 'Macaca mulatta', 'Male', 'Mercaptopurine/*blood/cerebrospinal fluid', '*Models, Biological', 'Time Factors']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']",['10.1152/ajpregu.1985.248.2.R147 [doi]'],ppublish,Am J Physiol. 1985 Feb;248(2 Pt 2):R147-56. doi: 10.1152/ajpregu.1985.248.2.R147.,['E7WED276I5 (Mercaptopurine)'],,,,['NASA: 85119679'],,,,,,,
4038404,NLM,MEDLINE,19850221,20181113,0021-9738 (Print) 0021-9738 (Linking),75,1,1985 Jan,Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.,141-6,"Pretreatment of L5178Y murine leukemia cells with uracil arabinoside (ara-U) enhances the cytotoxicity of cytosine arabinoside (ara-C). This effect is mediated by the cytostatic effect of ara-U, which causes a delay of cell progression through S-phase. Consequently, the specific activity of enzymes that peak during S-phase increases, and deoxycytidine kinase increases 3.6-fold over untreated controls. This allows enhanced anabolism of ara-C to nucleotides, as well as increased incorporation into DNA with ultimate synergistic cytotoxicity. It is postulated that the systemic metabolism of high-dose ara-C to sustained high levels of ara-U in patients with acute leukemia may enhance the activity of subsequent doses of ara-C, and thus contribute to a means for pharmacologic self-potentiation, contributing to the unique therapeutic activity of high-dose ara-C.","['Yang, J L', 'Cheng, E H', 'Capizzi, R L', 'Cheng, Y C', 'Kute, T']","['Yang JL', 'Cheng EH', 'Capizzi RL', 'Cheng YC', 'Kute T']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Clin Invest,The Journal of clinical investigation,7802877,IM,"['Animals', 'Arabinofuranosyluracil/blood/*pharmacology', 'Cytarabine/immunology/metabolism/*therapeutic use', 'Cytotoxicity, Immunologic/drug effects', 'Drug Interactions', 'Humans', 'Kinetics', 'Leukemia L5178/blood/*drug therapy', 'Leukemia, Experimental/*drug therapy', 'Tumor Stem Cell Assay', 'Uridine/*analogs & derivatives']",PMC423419,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1172/JCI111666 [doi]'],ppublish,J Clin Invest. 1985 Jan;75(1):141-6. doi: 10.1172/JCI111666.,"['04079A1RDZ (Cytarabine)', '3083-77-0 (Arabinofuranosyluracil)', 'WHI7HQ7H85 (Uridine)']",,,['CA-12197/CA/NCI NIH HHS/United States'],,,,,,,,
4038378,NLM,MEDLINE,19850221,20190619,0008-543X (Print) 0008-543X (Linking),55,3,1985 Feb 1,Erythrocyte mean corpuscular volume during cytotoxic therapy and the risk of secondary leukemia.,493-5,"Erythrocyte mean corpuscular volume (MCV) evolution during cytotoxic therapy of Hodgkin's disease, lymphoma, multiple myeloma, ovarian cancer, and breast cancer was studied. The fastest and the highest MCV increases were observed in the diseases and with the therapies the most frequently involved in secondary leukemia: Hodgkin's disease treated with MOPP (mechlorethamine, vincristine, procarbazine, prednisone), and multiple myeloma and ovarian cancer treated with melphalan. On the contrary, with cytotoxic regimens not linked to a high frequency of secondary leukemia such as CMF (cyclophosphamide, methotrexate, 5-fluorouracil) used in ovarian or breast cancer, MCV increase was moderate. As the MCV increase reflects the bone marrow reaction to cytotoxic therapy, an unusually high increase could indicate bone marrow damages which could lead to secondary leukemia.","['de Gramont, A', 'Rioux, E', 'Drolet, Y', 'Delage, J M']","['de Gramont A', 'Rioux E', 'Drolet Y', 'Delage JM']",['eng'],"['Comparative Study', 'Journal Article']",United States,Cancer,Cancer,0374236,IM,"['Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Breast Neoplasms/drug therapy', 'Erythrocyte Indices/*drug effects', 'Female', 'Follow-Up Studies', 'Hodgkin Disease/drug therapy/radiotherapy', 'Humans', 'Leukemia/*chemically induced', 'Lymphoma/drug therapy', 'Multiple Myeloma/drug therapy', 'Ovarian Neoplasms/drug therapy']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']",['10.1002/1097-0142(19850201)55:3<493::aid-cncr2820550302>3.0.co;2-5 [doi]'],ppublish,Cancer. 1985 Feb 1;55(3):493-5. doi: 10.1002/1097-0142(19850201)55:3<493::aid-cncr2820550302>3.0.co;2-5.,,,,,,,,,,,,
4038010,NLM,MEDLINE,19851023,20081121,0365-6233 (Print) 0365-6233 (Linking),318,7,1985 Jul,[Synthesis of flavones cytotoxic against L1210 cells].,659-61,,"['Ryu, S H', 'Yoo, B T', 'Ahn, B Z', 'Pack, M Y']","['Ryu SH', 'Yoo BT', 'Ahn BZ', 'Pack MY']",['ger'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Arch Pharm (Weinheim),Archiv der Pharmazie,0330167,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Cell Line', 'Chemical Phenomena', 'Chemistry', 'Flavonoids/*chemical synthesis/therapeutic use', 'Leukemia L1210/drug therapy', 'Mice']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Arch Pharm (Weinheim). 1985 Jul;318(7):659-61.,"['0 (Antineoplastic Agents)', '0 (Flavonoids)']",,Synthese einiger gegen L1210-Zellen cytotoxischer Flavone.,,,,,,,,,
4036961,NLM,MEDLINE,19851016,20190815,0272-6386 (Print) 0272-6386 (Linking),6,3,1985 Sep,Cryoglobulinemia and immune-mediated glomerulonephritis in association with hairy cell leukemia.,181-4,"The nephrotic syndrome in association with hairy cell leukemia is typically seen in the setting of amyloidosis. This report describes a patient with the nephrotic syndrome and hairy cell leukemia in whom cryoglobulinemia and an immune-mediated glomerulonephritis were seen. While hairy cells have the capacity for immunoglobulin production, we were unable to demonstrate a teleological link between these cells and the renal lesion. In contrast, there is speculative evidence to suggest that indolent infections may have played a causative role in cryoglobulin production and the subsequent immune-mediated glomerulonephritis.","['Douglas, M F', 'Schwartz, M M', 'Sharon, Z']","['Douglas MF', 'Schwartz MM', 'Sharon Z']",['eng'],"['Case Reports', 'Journal Article']",United States,Am J Kidney Dis,American journal of kidney diseases : the official journal of the National Kidney Foundation,8110075,IM,"['Cryoglobulinemia/*complications', 'Enterobacter', 'Enterobacteriaceae Infections/complications', 'Female', 'Glomerulonephritis/*complications/immunology/pathology', 'Humans', 'Immunoglobulins/analysis', 'Kidney Cortex/pathology', 'Kidney Glomerulus/immunology', 'Leukemia, Hairy Cell/*complications', 'Middle Aged', 'Nephrotic Syndrome/complications/pathology', 'Proteinuria/complications', 'Sepsis/complications']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['S0272638685000889 [pii]', '10.1016/s0272-6386(85)80024-x [doi]']",ppublish,Am J Kidney Dis. 1985 Sep;6(3):181-4. doi: 10.1016/s0272-6386(85)80024-x.,['0 (Immunoglobulins)'],,,,,,,,,,,
4036958,NLM,MEDLINE,19851018,20190820,0361-8609 (Print) 0361-8609 (Linking),20,2,1985 Oct,Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia.,191-3,"Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19% (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78%) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.","['Alessandrino, E P', 'Orlandi, E', 'Brusamolino, E', 'Lazzarino, M', 'Bernasconi, C']","['Alessandrino EP', 'Orlandi E', 'Brusamolino E', 'Lazzarino M', 'Bernasconi C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Am J Hematol,American journal of hematology,7610369,IM,"['Acute Disease', 'Adult', 'Aged', 'Cytarabine/*administration & dosage/therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Leukemia/*drug therapy/etiology', 'Middle Aged', 'Myeloproliferative Disorders/*complications', 'Preleukemia/drug therapy']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/ajh.2830200215 [doi]'],ppublish,Am J Hematol. 1985 Oct;20(2):191-3. doi: 10.1002/ajh.2830200215.,['04079A1RDZ (Cytarabine)'],,,['N01-CO 65341/CO/NCI NIH HHS/United States'],,,,,,,,
4036957,NLM,MEDLINE,19851018,20190820,0361-8609 (Print) 0361-8609 (Linking),20,2,1985 Oct,Terminal deoxynucleotidyl transferase-positive acute leukemias evolving from a myelodysplastic syndrome.,187-90,"We have analyzed the distribution of terminal deoxynucleotidyl transferase (TdT) in 30 patients with myelodysplastic syndromes (MDS), in connection with morphology, cytochemistry, and cytogenetics. All cases in preleukemic phase were strictly TdT-negative. At variance, 4 (19%) of 21 cases with subsequent leukemia were TdT-positive and showed a pure lymphoid (one case) or a mixed lymphoid-myelomonocytic (three cases) morphology. The TdT enzymatic activity ranged from 2 to 21 U/10(8) cells and the percent of positive cells in the immunofluorescence test ranged from 10 to 80% of total. All cases were Philadelphia chromosome-negative. The clonal origin of MDS from the pluripotent stem cell, capable of originating both a lymphoid and myeloid progeny, is further corroborated.","['Brusamolino, E', 'Isernia, P', 'Alessandrino, E P', 'Scovassi, A I', 'Bertazzoni, U', 'Bernasconi, C']","['Brusamolino E', 'Isernia P', 'Alessandrino EP', 'Scovassi AI', 'Bertazzoni U', 'Bernasconi C']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Am J Hematol,American journal of hematology,7610369,IM,"['Acute Disease', 'Adult', 'Cytarabine/therapeutic use', 'DNA Nucleotidylexotransferase/*analysis', 'DNA Nucleotidyltransferases/*analysis', 'Humans', 'Leukemia/*enzymology', 'Myeloproliferative Disorders/*complications/drug therapy', 'Preleukemia/pathology']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/ajh.2830200214 [doi]'],ppublish,Am J Hematol. 1985 Oct;20(2):187-90. doi: 10.1002/ajh.2830200214.,"['04079A1RDZ (Cytarabine)', 'EC 2.7.7.- (DNA Nucleotidyltransferases)', 'EC 2.7.7.31 (DNA Nucleotidylexotransferase)']",,,,,,,,,,,
4036709,NLM,MEDLINE,19851021,20190622,0065-2598 (Print) 0065-2598 (Linking),184,,1985,Aberrant oxygen metabolism in neoplastic cells injured by cytotoxic macrophages.,51-63,,"['Granger, D L', 'Lehninger, A L', 'Hibbs, J B Jr']","['Granger DL', 'Lehninger AL', 'Hibbs JB Jr']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Adv Exp Med Biol,Advances in experimental medicine and biology,0121103,IM,"['Animals', 'Cell Division', 'Cell Survival', '*Cytotoxicity, Immunologic', 'Free Radicals', 'In Vitro Techniques', 'Leukemia L1210/immunology/*metabolism/pathology', 'Macrophages/*immunology', 'Mice', 'Mitochondria/metabolism', 'Oxidative Phosphorylation', '*Oxygen Consumption']",,1985/01/01 00:00,2001/03/28 10:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-1-4684-8326-0_4 [doi]'],ppublish,Adv Exp Med Biol. 1985;184:51-63. doi: 10.1007/978-1-4684-8326-0_4.,['0 (Free Radicals)'],,,['CA35893/CA/NCI NIH HHS/United States'],,,,,,,,
4036624,NLM,MEDLINE,19851003,20061115,0513-4870 (Print) 0513-4870 (Linking),20,2,1985 Feb,[A comparative study on the photodynamic inactivation of tumor cells in the presence of several hematoporphyrin derivatives].,94-9,,"['Xu, C X', 'Zhan, H S', 'Lin, L', 'Wang, Y Q', 'Han, R']","['Xu CX', 'Zhan HS', 'Lin L', 'Wang YQ', 'Han R']",['chi'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",China,Yao Xue Xue Bao,Yao xue xue bao = Acta pharmaceutica Sinica,21710340R,IM,"['Animals', 'Cell Line', 'Hematoporphyrins/*pharmacology', 'Leukemia L1210/*pathology', 'Melanoma/*pathology', 'Mice', 'Ultraviolet Rays']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']",,ppublish,Yao Xue Xue Bao. 1985 Feb;20(2):94-9.,['0 (Hematoporphyrins)'],,,,,,,,,,,
4036522,NLM,MEDLINE,19851002,20110728,0001-5806 (Print) 0001-5806 (Linking),48,3,1985 May,[Research on the immune status in patients with clonal hemopathy].,811-22,,"['Aoyagi, Y']",['Aoyagi Y'],['jpn'],"['English Abstract', 'Journal Article']",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Adult', 'Aged', 'Anemia, Aplastic/*immunology', 'Female', 'Hemoglobinuria, Paroxysmal/immunology', 'Humans', 'Immunity, Cellular', 'Killer Cells, Natural/*immunology', 'Leukemia/immunology', 'Lymphocyte Activation', 'Male', 'Middle Aged', 'Myeloproliferative Disorders/*immunology', 'Neoplasm Proteins/analysis']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 May;48(3):811-22.,"['0 (Neoplasm Proteins)', '0 (immunosuppressive acidic protein)']",,,,,,,,,,,
4036519,NLM,MEDLINE,19851002,20110728,0001-5806 (Print) 0001-5806 (Linking),48,3,1985 May,[Estimation of prevalence of hematological diseases in Japan].,695-709,,"['Kubo, N', 'Aoki, K', 'Nagai, M']","['Kubo N', 'Aoki K', 'Nagai M']",['jpn'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Japan,Nihon Ketsueki Gakkai Zasshi,Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,2984803R,IM,"['Adolescent', 'Adult', 'Aged', 'Anemia, Aplastic/epidemiology', 'Anemia, Hemolytic/epidemiology', 'Child', 'Child, Preschool', 'Female', 'Hematologic Diseases/*epidemiology', 'Humans', 'Infant', 'Japan', 'Leukemia/epidemiology', 'Lymphoma/epidemiology', 'Male', 'Middle Aged']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Nihon Ketsueki Gakkai Zasshi. 1985 May;48(3):695-709.,,,,,,,,,,,,
4036023,NLM,MEDLINE,19850930,20131121,0042-773X (Print) 0042-773X (Linking),31,6,1985 Jun,[Ketoconazole in the prevention of mycotic complications during cytostatic treatment of leukemias and lymphomas].,567-71,,"['Krcova, V', 'Krc, I', 'Kubis, M', 'Mlcochova, E', 'Podivinska, I']","['Krcova V', 'Krc I', 'Kubis M', 'Mlcochova E', 'Podivinska I']",['cze'],"['English Abstract', 'Journal Article']",Czech Republic,Vnitr Lek,Vnitrni lekarstvi,0413602,IM,"['Female', 'Humans', 'Ketoconazole/*therapeutic use', 'Leukemia/complications/*drug therapy', 'Lymphoma/complications/*drug therapy', 'Male', 'Mycoses/epidemiology/etiology/*prevention & control']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Vnitr Lek. 1985 Jun;31(6):567-71.,['R9400W927I (Ketoconazole)'],,Ketokonazol v prevenci mykotickych komplikaci behem cytostaticke lecby leukemie a lymfomu.,,,,,,,,,
4035941,NLM,MEDLINE,19851003,20170214,0300-9858 (Print) 0300-9858 (Linking),22,4,1985 Jul,Pelger-Huet anomaly in cats.,370-4,"Pelger-Huet anomaly was diagnosed in a young male cat on the basis of persistent nuclear hyposegmentation of blood granulocytes, absence of clinical disease or feline leukemia virus infection, and demonstration of genetic transmission of the anomaly. Neutrophils, eosinophils, basophils, and monocytes had significantly less nuclear segmentation when compared to similar leukocyte types from a control cat. On smears of bone marrow, megakaryocytes also appeared hyposegmented. A test mating with an unaffected queen produced a litter of five kittens (three males, two females). One male and one female kitten had the Pelger-Huet trait on examination of blood smears. Autosomal dominant transmission of this anomaly is suspected based on these findings.","['Latimer, K S', 'Rakich, P M', 'Thompson, D F']","['Latimer KS', 'Rakich PM', 'Thompson DF']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Vet Pathol,Veterinary pathology,0312020,IM,"['Animals', 'Cat Diseases/*blood/genetics', 'Cats', 'Cell Nucleus/ultrastructure', 'Genes, Dominant', 'Granulocytes/ultrastructure', 'Leukocyte Count/veterinary', 'Male', 'Pelger-Huet Anomaly/blood/genetics/*veterinary']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1177/030098588502200412 [doi]'],ppublish,Vet Pathol. 1985 Jul;22(4):370-4. doi: 10.1177/030098588502200412.,,,,,,,,,,,,
4035782,NLM,MEDLINE,19850930,20041117,0041-3232 (Print) 0041-3232 (Linking),37,2,1985 Jun,"Malignant bone tumours, experience at King Fahd University Hospital Al-Khobar, Saudi Arabia.",165-6,"Reports show striking regional and ethnic variations in the incidence and pattern of certain malignancies in the Middle East. In view of this, a study of 19 cases of malignant tumours of the bone seen at King Fahd University Hospital during the period 1981-1983 was carried out. Of these eight were primary and eleven secondary tumours. Lymphoma and Ewing's sarcoma formed 50% of the primary tumours. Breast and lungs were the chief sources of secondary deposits in the bone.","['Ali, M S', 'Kutty, M S', 'Corea, J R', 'Kutty, M K']","['Ali MS', 'Kutty MS', 'Corea JR', 'Kutty MK']",['eng'],['Journal Article'],Netherlands,Trop Geogr Med,Tropical and geographical medicine,0376231,IM,"['Adult', 'Bone Neoplasms/*epidemiology', 'Female', 'Humans', 'Leukemia/epidemiology', 'Lymphoma/epidemiology', 'Male', 'Saudi Arabia']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Trop Geogr Med. 1985 Jun;37(2):165-6.,,,,,,,,,,,,
4035687,NLM,MEDLINE,19851023,20190727,0041-008X (Print) 0041-008X (Linking),79,3,1985 Jul,Toxicologic and antitumor studies on 5-hydroxymethyldeoxyuridine.,423-35,"Toxic effects of 5-hydroxymethyldeoxyuridine (HMUdR) were studied in white Swiss mice. Pathological, hematological, and clinical chemistry parameters were examined. Systemic toxicity was not observed in mice after ip administration of HMUdR in single doses up to 2000 mg/kg. Mice administered HMUdR daily for 15 days at 200 mg/kg, ip, manifested loss of weight, rough hair coat, diarrhea, swollen abdomens, weakness, lethargy, and a 20% mortality rate. Hematological and clinical chemistry parameters of all mice receiving HMUdR were within normal limits. At necropsy, all organs were grossly normal but microscopic examination of tissues of treated mice revealed the presence of shortened, thickened villi in the small intestine, nuclear vacuolation and necrosis of intestinal crypt epithelial cells, and some cytoplasmic vacuolation causing nuclear margination in hepatocytes. All histological lesions were reversible with cessation of treatment. HMUdR was active against murine L1210 and L5178Y leukemias in cell culture. The concentrations required to inhibit cell growth 50% compared to untreated cells was 2 and 4 microM, respectively. When HMUdR was administered ip at 50, 100, or 200 mg/kg in five daily doses to mice implanted with L1210 cells, life spans increased 20, 30, or 33% over placebo-treated controls.","['Meldrum, J B', 'Gupta, V S', 'Lowes, N R', 'Paterson, A R']","['Meldrum JB', 'Gupta VS', 'Lowes NR', 'Paterson AR']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Toxicol Appl Pharmacol,Toxicology and applied pharmacology,0416575,IM,"['Animals', 'Antineoplastic Agents/therapeutic use/*toxicity', 'Body Weight/drug effects', 'Humans', 'Intestine, Small/drug effects', 'Leukemia L1210/drug therapy', 'Leukemia L5178/drug therapy', 'Liver/drug effects', 'Male', 'Mice', 'Mice, Inbred DBA', 'Mice, Inbred Strains', 'Neoplasm Transplantation', 'Thymidine/*analogs & derivatives/therapeutic use/toxicity']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1016/0041-008x(85)90140-1 [doi]'],ppublish,Toxicol Appl Pharmacol. 1985 Jul;79(3):423-35. doi: 10.1016/0041-008x(85)90140-1.,"['0 (Antineoplastic Agents)', ""5116-24-5 (5-hydroxymethyl-2'-deoxyuridine)"", 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4035595,NLM,MEDLINE,19851003,20111117,0040-4470 (Print) 0040-4470 (Linking),81,7,1985 Jul,Granulomatous disease complicating hairy cell leukemia.,31-3,,"['Rex, J H', 'Harris, R L', 'Wheeler, T', 'White, M', 'Bradshaw, W', 'Williams, T W Jr']","['Rex JH', 'Harris RL', 'Wheeler T', 'White M', 'Bradshaw W', 'Williams TW Jr']",['eng'],"['Case Reports', 'Journal Article']",United States,Tex Med,Texas medicine,0051012,IM,"['Aged', 'Histoplasmosis/*diagnosis', 'Humans', 'Leukemia, Hairy Cell/*complications', 'Male', 'Mycobacterium Infections/*diagnosis', 'Mycobacterium Infections, Nontuberculous/*diagnosis']",,1985/07/01 00:00,2001/03/28 10:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/07/01 00:00 [entrez]']",,ppublish,Tex Med. 1985 Jul;81(7):31-3.,,,,,,,,,,,,
4035525,NLM,MEDLINE,19851003,20061115,0036-4355 (Print) 0036-4355 (Linking),30,3,1985,[Trends in leukemia mortality for child and adolescent age groups in Spain (1951-1979)].,302-7,,"['Gonzalez Arraez, J I', 'Saiz Sanchez, C', 'Cortina Greus, P']","['Gonzalez Arraez JI', 'Saiz Sanchez C', 'Cortina Greus P']",['spa'],"['English Abstract', 'Journal Article']",Spain,Sangre (Barc),Sangre,0404373,IM,"['Adolescent', 'Adult', 'Age Factors', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Infant, Newborn', 'Leukemia/*mortality/therapy', 'Spain']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Sangre (Barc). 1985;30(3):302-7.,,,Evolucion de la mortalidad por leucemias de edades infanto-juveniles en Espana (1951-1979).,,,,,,,,,
4035060,NLM,MEDLINE,19850930,20071115,0034-1193 (Print) 0034-1193 (Linking),76,4,1985 Apr,[Plasma cell leukemia: clinical and morphocytochemical aspects in 5 cases].,199-205,,"['Grande, M']",['Grande M'],['ita'],"['Case Reports', 'English Abstract', 'Journal Article']",Italy,Recenti Prog Med,Recenti progressi in medicina,0401271,IM,"['Adult', 'Aged', 'Female', 'Histocytochemistry', 'Humans', 'Leukemia, Plasma Cell/blood/*diagnosis/drug therapy', 'Male', 'Middle Aged', 'Multiple Myeloma/complications', 'Plasma Cells/pathology']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",,ppublish,Recenti Prog Med. 1985 Apr;76(4):199-205.,,,Leucemia plasmacellulare: aspetti clinici e morfocitochimici in 5 casi.,,,,,,,,,
4035054,NLM,MEDLINE,19851018,20131121,0034-9402 (Print) 0034-9402 (Linking),41,2,1985 Jun,Oil-stop method as an alternative to filtration for transport studies on plasma membrane vesicles. A preliminary report.,177-82,"The oil-stop procedure applied in transport studies on whole cells was adapted for isolated plasma membrane vesicles. The advantages of the proposed technique with respect to the commonly used filtration method are the reduction of the period of the termination step, the increase in the allowed membrane content of the samples and the absence of the leakage of substrates from the intravesicular space.","['Torrent-Quetglas, M']",['Torrent-Quetglas M'],['eng'],['Journal Article'],Spain,Rev Esp Fisiol,Revista espanola de fisiologia,0404475,IM,"['Animals', '*Biological Transport', 'Cell Fractionation/*methods', 'Cell Membrane/*metabolism', 'Dibutyl Phthalate', 'Diethylhexyl Phthalate', 'Leukemia L5178/metabolism', 'Mice', 'Thymidine/metabolism', 'Ultrafiltration']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Rev Esp Fisiol. 1985 Jun;41(2):177-82.,"['2286E5R2KE (Dibutyl Phthalate)', 'C42K0PH13C (Diethylhexyl Phthalate)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4034634,NLM,MEDLINE,19851007,20191030,0031-7144 (Print) 0031-7144 (Linking),40,5,1985 May,"5-(2-Oxo-3-indolinylidene)thiazolidine-2,4-dione-1,3-di-Mannich base derivatives: synthesis and evaluation for antileukemic activity.",320-2,"A novel series of 5-(2-oxo-3-indolinylidene)thiazolidine-2,4-dione, having the 1- and 3-positions of the isatin and thiazolidine rings respectively, substituted by various Mannich bases, was prepared. Five compounds were evaluated for antileukemic activity against P388 lymphocytic leukemia in the mouse. The di-Mannich base with a dimethylamino component exhibited the highest activity of the tested compounds. Introduction of bromine into the aromatic moiety of isatin ring (position 5) increased the activity of the parent molecule to a smaller extent.","['Eshba, N H', 'Salama, H M']","['Eshba NH', 'Salama HM']",['eng'],['Journal Article'],Germany,Pharmazie,Die Pharmazie,9800766,IM,"['Amines/*chemical synthesis', 'Animals', 'Antineoplastic Agents/*chemical synthesis/therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Leukemia P388/*drug therapy', 'Leukemia, Experimental/*drug therapy', 'Mannich Bases/*chemical synthesis/therapeutic use', 'Mice', 'Mice, Inbred C57BL']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1002/chin.198537199 [doi]'],ppublish,Pharmazie. 1985 May;40(5):320-2. doi: 10.1002/chin.198537199.,"['0 (Amines)', '0 (Antineoplastic Agents)', '0 (Mannich Bases)']",,,,,,,,,,,
4034458,NLM,MEDLINE,19851017,20190501,0032-5473 (Print) 0032-5473 (Linking),61,718,1985 Aug,Pyoderma gangrenosum in myelodysplasia and acute leukaemia.,689-94,"Pyoderma gangrenosum is a rare occurrence in patients with haematological malignancy. This characteristic but nonspecific inflammatory process with skin destruction occurred in 4 patients with myelodysplasia, in one with acute leukaemic transformation of myelofibrosis, and in de novo acute myeloblastic leukaemia in another. Clinically, the cutaneous lesion in these patients differed from that associated with inflammatory bowel disease, arthritis, or the idiopathic type of pyoderma gangrenosum by having the vesiculo-bullous borders. Histopathological differences were also evident since more superficial layers of the skin were involved in the ulceration than typically encountered in patients with non-malignant systemic disease. Despite the less penetrating nature of this variant, treatment of the pyoderma gangrenosum is unsatisfactory and in the absence of effective therapy for the underlying disease, healing occurred only in the patient with acute leukaemia who achieved complete remission in response to chemotherapy.","['Jacobs, P', 'Palmer, S', 'Gordon-Smith, E C']","['Jacobs P', 'Palmer S', 'Gordon-Smith EC']",['eng'],"['Case Reports', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Postgrad Med J,Postgraduate medical journal,0234135,IM,"['Acute Disease', 'Adult', 'Aged', 'Female', 'Humans', 'Leukemia/*complications/drug therapy', 'Male', 'Middle Aged', 'Neural Tube Defects/*complications', 'Pyoderma/drug therapy/*etiology/pathology', 'Skin Ulcer/drug therapy/*etiology/pathology']",PMC2418352,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1136/pgmj.61.718.689 [doi]'],ppublish,Postgrad Med J. 1985 Aug;61(718):689-94. doi: 10.1136/pgmj.61.718.689.,,,,,,,,,,,,
4034291,NLM,MEDLINE,19851023,20061115,0031-3939 (Print) 0031-3939 (Linking),60,1,1985 Jan,[Participation of a physician in the cooperation between a sick child and his family during treatment of neoplastic blood disease].,45-9,,"['Zdebska, S', 'Armata, J']","['Zdebska S', 'Armata J']",['pol'],"['English Abstract', 'Journal Article']",Poland,Pediatr Pol,Pediatria polska,2985039R,IM,"['Humans', 'Leukemia/*therapy', '*Parent-Child Relations', '*Patient Care Team', ""Physician's Role"", '*Physician-Patient Relations']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Pediatr Pol. 1985 Jan;60(1):45-9.,,,Udzial lekarza we wspolpracy z chorym dzieckiem i jego rodzina podczas leczenia nowotworowej choroby krwi.,,,,,,,,,
4034147,NLM,MEDLINE,19851004,20180216,0030-2414 (Print) 0030-2414 (Linking),42,5,1985,Cell surface alterations in murine leukaemia P388 adriamycin-resistant cells: studies on lectin-induced agglutination and rearrangement of lectin receptors.,328-31,"Cell surface alteration was studied in a subline of murine lymphocytic leukaemia resistant to the broad-spectrum anticancer agent adriamycin (P388/ADR) employing concanavalin A(Con A)-induced agglutination and rearrangement of lectin receptors. Con A induced more agglutination of P388/ADR when compared to the drug-sensitive parental cell line (P388/S). Studies on the redistribution of Con A and Ricinus communis agglutinin-I revealed a high percentage of P388/ADR showing internalized fluorescence, while a majority of P388/S displayed a uniform distribution of fluorescence on the cell surface.","['Basrur, V S', 'Chitnis, M P', 'Menon, R S']","['Basrur VS', 'Chitnis MP', 'Menon RS']",['eng'],['Journal Article'],Switzerland,Oncology,Oncology,0135054,IM,"['Animals', 'Cell Aggregation/drug effects', 'Cell Line', 'Cell Membrane/*drug effects/ultrastructure', 'Cell Membrane Permeability/drug effects', 'Concanavalin A/pharmacology', 'Doxorubicin/pharmacology', 'Drug Resistance', 'Leukemia P388/*genetics/pathology', 'Leukemia, Experimental/*genetics', 'Mice', 'Mutation', 'Receptors, Concanavalin A/*analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1159/000226055 [doi]'],ppublish,Oncology. 1985;42(5):328-31. doi: 10.1159/000226055.,"['0 (Receptors, Concanavalin A)', '11028-71-0 (Concanavalin A)', '80168379AG (Doxorubicin)']",,,,,,,,,,,
4033929,NLM,MEDLINE,19851021,20190514,0028-3878 (Print) 0028-3878 (Linking),35,10,1985 Oct,Central nervous system toxicity with high-dose Ara-C.,1475-9,"We evaluated the CNS complications in 118 adults with acute leukemia who received IV high-dose Ara-C therapy. Fourteen (12%) had cerebellar signs, encephalopathy, seizures, or leukoencephalopathy. Symptoms usually occurred within 24 hours after the last treatment. Patients receiving a cumulative dose in excess of 24 g/m2 had more severe or irreversible symptoms. After lower cumulative doses, symptoms often resolved even though treatment was continued. The incidence of CNS complications of high-dose Ara-C is acceptable and is potentially reversible if appropriate precautions are taken.","['Hwang, T L', 'Yung, W K', 'Estey, E H', 'Fields, W S']","['Hwang TL', 'Yung WK', 'Estey EH', 'Fields WS']",['eng'],['Journal Article'],United States,Neurology,Neurology,0401060,IM,"['Adolescent', 'Adult', 'Aged', 'Brain Diseases/chemically induced', 'Central Nervous System Diseases/*chemically induced', 'Cerebellar Diseases/chemically induced', 'Cytarabine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Leukemia/drug therapy', 'Male', 'Middle Aged']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1212/wnl.35.10.1475 [doi]'],ppublish,Neurology. 1985 Oct;35(10):1475-9. doi: 10.1212/wnl.35.10.1475.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4033801,NLM,MEDLINE,19851024,20190824,0028-1042 (Print) 0028-1042 (Linking),72,7,1985 Jul,1-Monolinolenoylglycerol specifically potentiates antitumour activity of daphnane orthoesters.,373-5,,"['Tyler, M I', 'Howden, M E']","['Tyler MI', 'Howden ME']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Naturwissenschaften,Die Naturwissenschaften,0400767,IM,"['Animals', 'Antineoplastic Agents/*therapeutic use', '*Diterpenes', 'Drug Synergism', 'Glycerides/pharmacology/*therapeutic use', 'Leukemia P388/*drug therapy', 'Leukemia, Experimental/*drug therapy', 'Mice', 'Structure-Activity Relationship', 'Terpenes/*therapeutic use']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1007/BF00410601 [doi]'],ppublish,Naturwissenschaften. 1985 Jul;72(7):373-5. doi: 10.1007/BF00410601.,"['0 (Antineoplastic Agents)', '0 (Diterpenes)', '0 (Glycerides)', '0 (Terpenes)', '34807-41-5 (mezerein)']",,,,,,,,,,,
4033677,NLM,MEDLINE,19851004,20190702,0027-5107 (Print) 0027-5107 (Linking),146,2,1985 Sep,DNA repair in lymphocytes from patients with secondary leukemia as measured by strand rejoining and unscheduled DNA synthesis.,219-25,"The ability to repair damage to DNA was compared in 2 groups of patients having undergone treatment for leukemia, one of which developed secondary leukemia (SL), and the other without signs of secondary malignancy (treated controls). Both were related to normal controls. DNA repair was assessed in isolated peripheral lymphocytes from the patients by measuring the rejoining of strand breaks following alkylation damage to the lymphocytes or by measuring unscheduled DNA synthesis. Day-to-day variability in the assays was considerable, but findings were that 5 out of 7 SL patients had repair deficiencies as measured by their ability to rejoin strand breaks, and 5 out of 7 had increased unscheduled DNA synthesis compared to treated and normal controls. All patients with SL and 4 out of 8 treated controls had inherent strand breaks in their DNA as compared to the normal controls when measured by alkaline elution.","['Bohr, V', 'Kober, L']","['Bohr V', 'Kober L']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Netherlands,Mutat Res,Mutation research,0400763,IM,"['Adult', 'Aged', 'Alkylating Agents/*adverse effects/pharmacology/therapeutic use', 'Antineoplastic Agents/*adverse effects/therapeutic use', '*DNA Repair', 'DNA, Neoplasm/metabolism', 'Female', 'Humans', 'Leukemia/chemically induced/drug therapy/*genetics', 'Lymphocytes/drug effects/ultrastructure', 'Lymphoma/drug therapy', 'Male', 'Middle Aged', 'Neoplasms/drug therapy', 'Neoplasms, Multiple Primary/*genetics', 'Xeroderma Pigmentosum/genetics']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['0167-8817(85)90014-8 [pii]', '10.1016/0167-8817(85)90014-8 [doi]']",ppublish,Mutat Res. 1985 Sep;146(2):219-25. doi: 10.1016/0167-8817(85)90014-8.,"['0 (Alkylating Agents)', '0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)']",,,,,,,,,,,
4033089,NLM,MEDLINE,19851021,20041117,0037-5683 (Print) 0037-5683 (Linking),27,1-2,1985,Hospital mortality in a Singapore paediatric unit. A 20 year review (1964-1983).,82-8,,"['Tay, J S', 'Low, P S', 'Yip, W C', 'Wong, H B']","['Tay JS', 'Low PS', 'Yip WC', 'Wong HB']",['eng'],['Journal Article'],Singapore,J Singapore Paediatr Soc,The Journal of the Singapore Paediatric Society,7507223,IM,"['Gastroenteritis/mortality', 'Heart Defects, Congenital/mortality', '*Hospital Departments', 'Humans', 'Infant', '*Infant Mortality', 'Infant, Newborn', 'Leukemia/mortality', 'Neoplasms/mortality', '*Pediatrics', 'Pneumonia/mortality', 'Singapore']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,J Singapore Paediatr Soc. 1985;27(1-2):82-8.,,,,,,,,,,,,
4032942,NLM,MEDLINE,19851017,20191022,0022-9717 (Print) 0022-9717 (Linking),34,1,1985 Mar,Prognostic factor analysis in adult acute leukemia during the period of 1973 to 1983.,17-23,,"['Miyachi, H', 'Takemura, Y', 'Toyama, K', 'Higashi, T']","['Miyachi H', 'Takemura Y', 'Toyama K', 'Higashi T']",['eng'],['Journal Article'],Japan,Keio J Med,The Keio journal of medicine,0376354,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Female', 'Follow-Up Studies', 'Humans', 'Leukemia/*mortality', 'Male', 'Middle Aged', 'Prognosis']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",['10.2302/kjm.34.17 [doi]'],ppublish,Keio J Med. 1985 Mar;34(1):17-23. doi: 10.2302/kjm.34.17.,,,,,,,,,,,,
4032756,NLM,MEDLINE,19851016,20161123,0021-4949 (Print) 0021-4949 (Linking),31,6 Suppl,1985 May,[SM-108].,757-66,"The purpose of this paper is to analyze the available data on SM-108 (4-carbamoylimidazolium 5-olate) with respect to its clinical usefulness, optimal method of administration, and side effects. Successful remission induction was achieved in atypical leukemia using low dose SM-108. To analyze the action of SM-108, freshly isolated leukemic cells and cells from human leukemic cell line were cultured in the presence of SM-108. Minimal evidence of differentiation induction was observed. SM-108 in a higher dose, alone or in combination with other drugs was advocated for the treatment of adult ALL. Side effect including myelotoxicity and gastrointestinal toxicity was minimal.","['Uzuka, Y', 'Saito, Y']","['Uzuka Y', 'Saito Y']",['jpn'],['Journal Article'],Japan,Gan No Rinsho,Gan no rinsho. Japan journal of cancer clinics,1257753,IM,"['Adult', 'Aged', 'Antineoplastic Agents/administration & dosage/pharmacology/*therapeutic use', 'Breast Neoplasms/drug therapy', 'Cell Line', 'Drug Administration Schedule', 'Drug Evaluation', 'Female', 'Humans', 'Imidazoles/administration & dosage/pharmacology/*therapeutic use', 'Leukemia/*drug therapy/pathology', 'Lung Neoplasms/drug therapy', 'Male', 'Middle Aged', 'Neoplasms/*drug therapy', 'Ovarian Neoplasms/drug therapy', 'Stomach Neoplasms/drug therapy', 'Tumor Stem Cell Assay', 'Uterine Cervical Neoplasms/drug therapy']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Gan No Rinsho. 1985 May;31(6 Suppl):757-66.,"['0 (Antineoplastic Agents)', '0 (Imidazoles)', 'U6IZ97918F (4-carbamoylimidazolium 5-olate)']",,,,,,,,,,,
4032755,NLM,MEDLINE,19851016,20131121,0021-4949 (Print) 0021-4949 (Linking),31,6 Suppl,1985 May,[590-S].,739-45,"590-S (1-phthalidyl-5-fluorouracil) is a derivative of 5-fluorouracil and shows a several characteristics in experimental studies. That is, good absorption from the intestine, high blood levels of 5-fluorouracil, its rapid clearance, low toxicities, excellent tumor inhibition and broad anticancer spectrum, etc. From preliminary studies and phase I studies, MTD is thought to be 750-800 mg/m2 in daily administration. Mild G.I. toxicities was encountered in a few cases. However, CNS toxicities were not experienced in any of our cases.","['Furue, H']",['Furue H'],['jpn'],"['English Abstract', 'Journal Article']",Japan,Gan No Rinsho,Gan no rinsho. Japan journal of cancer clinics,1257753,IM,"['Administration, Oral', 'Adult', 'Animals', 'Anorexia/chemically induced', 'Antineoplastic Agents/adverse effects/metabolism/*therapeutic use', 'Drug Administration Schedule', 'Drug Evaluation', 'Female', 'Fluorouracil/*analogs & derivatives/metabolism/therapeutic use', 'Humans', 'Leukemia, Experimental/drug therapy/metabolism', 'Liver Neoplasms, Experimental/drug therapy/metabolism', 'Male', 'Mice', 'Middle Aged', 'Nausea/chemically induced', 'Neoplasms, Experimental/*drug therapy/metabolism', 'Rabbits', 'Rats', 'Sarcoma, Experimental/drug therapy/metabolism', 'Stomach Neoplasms/*drug therapy/metabolism']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Gan No Rinsho. 1985 May;31(6 Suppl):739-45.,"['0 (Antineoplastic Agents)', '81820-68-0 (1-phthalidyl-5-fluorouracil)', 'U3P01618RT (Fluorouracil)']",,,,,,,,,,,
4032436,NLM,MEDLINE,19851017,20190709,0022-2623 (Print) 0022-2623 (Linking),28,9,1985 Sep,In the search for new anticancer drugs. 13. Phosphonic and phosphinic analogues of ornithine.,1350-4,"Phosphonic (4a,b) and phosphinic (5a-d) analogues of ornithine were synthesized and evaluated for their inhibitory activity against ornithine decarboxylase and against the lymphocytic leukemia P388. The title compounds possess a low degree of inhibition against rat liver ornithine decarboxylase as compared to alpha-(difluoromethyl)ornithine. Thus, compounds 4a and 5a inhibit by 40% the ornithine decarboxylase activity at a 5 mM concentration. The other derivatives are less potent. Compounds 4a, 4b, 5b, and 5d are inactive against P388 tumor in CD2F1 mice at doses of 50 and 150 mg/kg.","['Sosnovsky, G', 'Lukszo, J', 'Gravela, E', 'Zuretti, M F']","['Sosnovsky G', 'Lukszo J', 'Gravela E', 'Zuretti MF']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis/pharmacology', 'Chemical Phenomena', 'Chemistry', 'Leukemia P388/drug therapy', 'Liver/enzymology', 'Male', 'Mice', '*Organophosphonates', 'Ornithine/*analogs & derivatives', 'Ornithine Decarboxylase Inhibitors', '*Phosphinic Acids', 'Rats', 'Rats, Inbred Strains']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1021/jm00147a041 [doi]'],ppublish,J Med Chem. 1985 Sep;28(9):1350-4. doi: 10.1021/jm00147a041.,"['0 (Antineoplastic Agents)', '0 (Organophosphonates)', '0 (Ornithine Decarboxylase Inhibitors)', '0 (Phosphinic Acids)', 'E524N2IXA3 (Ornithine)']",,,,,,,,,,,
4032435,NLM,MEDLINE,19851017,20190709,0022-2623 (Print) 0022-2623 (Linking),28,9,1985 Sep,New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.,1346-50,"Three chemical pathways were used for the synthesis of four new N'-(2-chloroethyl)-N-[2-(methylsulfinyl)ethyl]- and N'-(2-chloroethyl)-N-[2-(methylsulfonyl)ethyl]-N- or N'-nitrosoureas. These compounds are plasma metabolites of CNCC, a promising antineoplastic (2-chloroethyl)nitrosourea. Preliminary antitumor evaluation was performed against L1210 leukemia implanted intraperitoneally in mice. Among these compounds, two of them exhibited a greater antitumor activity compared to that of the parent mixture.","['Madelmont, J C', 'Godeneche, D', 'Parry, D', 'Duprat, J', 'Chabard, J L', 'Plagne, R', 'Mathe, G', 'Meyniel, G']","['Madelmont JC', 'Godeneche D', 'Parry D', 'Duprat J', 'Chabard JL', 'Plagne R', 'Mathe G', 'Meyniel G']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Chemical Phenomena', 'Chemistry', 'Cysteamine/analogs & derivatives/chemical synthesis/therapeutic use', 'Leukemia L1210/*drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Nitrosourea Compounds/administration & dosage/chemical synthesis/*therapeutic use']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1021/jm00147a040 [doi]'],ppublish,J Med Chem. 1985 Sep;28(9):1346-50. doi: 10.1021/jm00147a040.,"['0 (Nitrosourea Compounds)', '5UX2SD1KE2 (Cysteamine)']",,,,,,,,,,,
4032424,NLM,MEDLINE,19851017,20190709,0022-2623 (Print) 0022-2623 (Linking),28,9,1985 Sep,N-(Aminoalkyl)imide antineoplastic agents. Synthesis and biological activity.,1216-22,"The similarity of the side-chain characteristics of 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- anthraquinone (DHAQ), discovered by us in 1978, and those of the N-substituted imides of 3-nitro-1,8-naphthalic acid, discovered by other investigators recently, led us to conduct a systematic study on the N-(aminoalkyl)-substituted derivatives of a variety of imides. Areas of study included (a) selection of the ring system, (b) modification of the side chain, (c) substitution on certain chosen ring systems, and (d) combinations of the aforementioned variants. Preliminary biological activity screening indicated that N-(dialkylaminoethyl)imides of the 3,6-dinitro- and 3,6-diamino-1,8-naphthalic acid system possessed prominent antileukemia and antimelanoma activity in both in vitro and in vivo experimental tumor systems.","['Zee-Cheng, R K', 'Cheng, C C']","['Zee-Cheng RK', 'Cheng CC']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Adenocarcinoma/drug therapy', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Colonic Neoplasms/drug therapy', 'Humans', 'Imides/chemical synthesis/*therapeutic use', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Melanoma/drug therapy', 'Neoplasms/*drug therapy', 'Structure-Activity Relationship']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1021/jm00147a016 [doi]'],ppublish,J Med Chem. 1985 Sep;28(9):1216-22. doi: 10.1021/jm00147a016.,['0 (Imides)'],,,,,,,,,,,
4032423,NLM,MEDLINE,19851017,20190709,0022-2623 (Print) 0022-2623 (Linking),28,9,1985 Sep,"Synthesis and biological effects of novel thiocolchicines. 3. Evaluation of N-acyldeacetylthiocolchicines, N-(alkoxycarbonyl) deacetylthiocolchicines, and O-ethyldemethylthiocolchicines. New synthesis of thiodemecolcine and antileukemic effects of 2-demethyl- and 3-demethylthiocolchicine.",1204-8,"Novel and known analogues of thiocolchicine were evaluated in vitro in a tubulin binding assay and in vivo in mice for acute toxicity and in the P388 lymphocytic leukemia assay. This evaluation included N-acyldeacetylthiocolchicines, N-(alkoxycarbonyl)deacetylthiocolchicines, thiodemecolcine and its methyl carbamate, and O-ethyl ethers of demethylthiocolchicines. Selective ether cleavage of thiodemecolcine with concentrated sulfuric acid at 50 degree C afforded the 2-demethyl congener, characterized as its N,O-diacetyl derivative. Several of the compounds showed high potency in the tubulin binding assay, matching the potency of colchicine. Several N-(alkoxycarbonyl)deacetylcolchicines (carbamates) exhibited strong binding affinity to tubulin but had only weak activities against the P388 tumor system, suggesting that other factors besides tubulin binding may be important for the biological effects. The compounds potent in the tubulin binding assay and in the P388 leukemia assay in mice were generally also toxic to mice in the acute toxicity test, showing thus a similar behavior of thiocolchicines to that observed earlier with colchicines. A considerable amount of data collected for 2-demethyl- and 3-demethylthiocolchicine suggests that the latter represents a broad-spectrum antitumor agent of considerable promise and possibly a less toxic substitute for colchicine.","['Kerekes, P', 'Sharma, P N', 'Brossi, A', 'Chignell, C F', 'Quinn, F R']","['Kerekes P', 'Sharma PN', 'Brossi A', 'Chignell CF', 'Quinn FR']",['eng'],"['Comparative Study', 'Journal Article']",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Binding, Competitive', 'Chemical Phenomena', 'Chemistry', 'Colchicine/*analogs & derivatives/chemical synthesis/metabolism/therapeutic use/toxicity', 'Demecolcine/analogs & derivatives/chemical synthesis/therapeutic use', 'Drug Evaluation', 'Lethal Dose 50', 'Leukemia P388/*drug therapy', 'Leukemia, Experimental/*drug therapy', 'Mice', 'Structure-Activity Relationship', 'Tubulin/*metabolism']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1021/jm00147a014 [doi]'],ppublish,J Med Chem. 1985 Sep;28(9):1204-8. doi: 10.1021/jm00147a014.,"['0 (Tubulin)', '18LC87Z10L (3-demethylthiocolchicine)', '47541468FI (thiocholchicine)', '76129-11-8 (thiodemecolcine)', '87424-26-8 (2-demethylthiocolchicine)', 'SML2Y3J35T (Colchicine)', 'Z01IVE25KI (Demecolcine)']",,,,,,,,,,,
4032367,NLM,MEDLINE,19851010,20191030,0197-5110 (Print) 0197-5110 (Linking),5,2-3,1985,Characterization of low density lipoprotein receptors in freshly isolated leukemic guinea pig lymphocytes (L2C).,171-92,"The present study shows that L2C leukemic guinea pig lymphocytes have 10 times as many low density lipoprotein (LDL) receptors per cell as normal lymphocytes. The affinity of these receptors is higher for guinea pig LDL than for human LDL. In contrast to normal cells, in which the degradation of the receptor-bound LDL is quite efficient, the leukemic cells only degraded a small fraction of these same receptor-bound LDL. Thus, the internalization index was nearly 4 times higher in the normal cells than in the leukemic cells. In L2C cells, cholesterol homeostasis derived 38% of its cholesterol input from receptor-mediated degradation of LDL and 62% from cholesterol synthesis, whereas in normal cells, these fractions were 97% and 3% respectively.","['Sainte-Marie, J', 'Vidal, M', 'Philippot, J R', 'Bienvenue, A']","['Sainte-Marie J', 'Vidal M', 'Philippot JR', 'Bienvenue A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Recept Res,Journal of receptor research,8008358,IM,"['Animals', 'Cell Line', 'Guinea Pigs', 'Humans', 'Kinetics', 'Leukemia, Experimental/*metabolism', 'Lipoproteins, LDL/blood/*metabolism', 'Lymphocytes/*metabolism', 'Receptors, LDL/*metabolism', 'Reference Values', 'Species Specificity']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.3109/10799898509041878 [doi]'],ppublish,J Recept Res. 1985;5(2-3):171-92. doi: 10.3109/10799898509041878.,"['0 (Lipoproteins, LDL)', '0 (Receptors, LDL)']",,,,,,,,,,,
4032265,NLM,MEDLINE,19851024,20190711,0022-3549 (Print) 0022-3549 (Linking),74,8,1985 Aug,Computer-assisted structure--anticancer activity correlations of carbamates and thiocarbamates.,831-6,"With the aid of the computer, approximately 8000 compounds that incorporate a carbamate or thiocarbamate moiety, which have been tested as potential anticancer agents at the National Cancer Institute (NCI), were classified and their structure-activity correlations against the in vivo P-388 and L-1210 leukemias were evaluated. Aromatic carbamates and thiocarbamates have shown good activity against P-388 and poor activity against L-1210. The majority of active compounds in this series of aromatic carbamates possess a 2- or 4-heteroatom-substituted phenyl attached to the carbamate oxygen atom or the thiocarbamate sulfur atom with the carbamate nitrogen atom as NHMe. The N-phenyl carbamates were much less active against P-388 than the phenyl carbamates; only bis-N-phenyl carbamates with a methylene bridge between the two phenyl groups showed good activity against both P-388 and L-1210 leukemias. Except for the mycophenolic acid carbamates, the fused phenyl carbamates showed poor activity against both P-388 and L-1210 leukemias. Certain nitrogen-heterocyclic carbamates and carbamates with heteroatom substituents have been selected by the NCI for development toward clinical trials. The nature of the heterocyclic carrier and the position of attachment to the carbamate moiety have a major role on the mode of action of the antitumor activity of these compounds.","['Nasr, M', 'Paull, K D', 'Narayanan, V L']","['Nasr M', 'Paull KD', 'Narayanan VL']",['eng'],['Journal Article'],United States,J Pharm Sci,Journal of pharmaceutical sciences,2985195R,IM,"['Animals', 'Antineoplastic Agents/*pharmacology', 'Carbamates/*pharmacology', 'Computers', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Mice', 'Models, Biological', 'Structure-Activity Relationship', 'Thiocarbamates/*pharmacology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['S0022-3549(15)46801-7 [pii]', '10.1002/jps.2600740806 [doi]']",ppublish,J Pharm Sci. 1985 Aug;74(8):831-6. doi: 10.1002/jps.2600740806.,"['0 (Antineoplastic Agents)', '0 (Carbamates)', '0 (Thiocarbamates)']",,,,,,,,,,,
4031970,NLM,MEDLINE,19851015,20190908,0167-594X (Print) 0167-594X (Linking),3,2,1985,Central nervous system pharmacokinetics of high-dose cytosine arabinoside.,119-24,"The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.1 micrograms /ml) was about 7% of the plasma concentration (30 micrograms/ml). A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.","['Lopez, J A', 'Nassif, E', 'Vannicola, P', 'Krikorian, J G', 'Agarwal, R P']","['Lopez JA', 'Nassif E', 'Vannicola P', 'Krikorian JG', 'Agarwal RP']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Neurooncol,Journal of neuro-oncology,8309335,IM,"['Adult', 'Aged', 'Brain Neoplasms/blood/cerebrospinal fluid/*secondary', 'Chromatography, High Pressure Liquid', 'Cytarabine/blood/*cerebrospinal fluid', 'Female', 'Humans', 'Kinetics', 'Male', 'Middle Aged', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF02228887 [doi]'],ppublish,J Neurooncol. 1985;3(2):119-24. doi: 10.1007/BF02228887.,['04079A1RDZ (Cytarabine)'],,,,,,,,,,,
4031900,NLM,MEDLINE,19851017,20190903,0163-3864 (Print) 0163-3864 (Linking),48,3,1985 May-Jun,Antineoplastic and piscicidal 1-alkyldaphnane orthoesters from Pimelea species.,440-5,"Five biologically active daphnane orthoesters have been isolated from Pimelea species (Thymelaeaceae). Four of these possessing antineoplastic activity against in vivo murine P-388 lymphocytic leukemia are gnidimacrin from P. ligustrina, simpleximacrin from P. simplex, linimacrin d and Pimelea factor P3 from P. linifolia. Linimacrin c from P. linifolia and the other four compounds showed piscicidal activity. Gnidimacrin and Pimelea factor P3 have previously been isolated from other members of the Thymelaeaceae. Simpleximacrin and linimacrins c and d are new compounds.","['Tyler, M I', 'Howden, M E']","['Tyler MI', 'Howden ME']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Nat Prod,Journal of natural products,7906882,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*isolation & purification', '*Fishes', 'Leukemia P388/drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice', 'Plant Extracts/toxicity', 'Plants, Medicinal/*analysis', 'Spectrophotometry, Ultraviolet']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1021/np50039a012 [doi]'],ppublish,J Nat Prod. 1985 May-Jun;48(3):440-5. doi: 10.1021/np50039a012.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Plant Extracts)']",,,,,,,,,,,
4031899,NLM,MEDLINE,19851017,20190903,0163-3864 (Print) 0163-3864 (Linking),48,3,1985 May-Jun,Constituents of Erysimum inconspicuum. Two sulfur-containing lactone compounds.,424-8,"The alcohol extract of Erysimum inconspicuum fruits, which exhibited cytotoxic activity against the KB cell line and some activity against the P-388 lymphocytic leukemia in vivo, was studied. Strophanthidin, uzarigenin, and two sulfur-containing lactones, erysulfone[6-methylsulfonyl-4-hydroxyhexanoic acid lactone] and erysulfoxide[6-methylsulfinyl-4-hydroxyhexanoic acid lactone], were isolated and characterized by spectral data.","['Piatak, D M', 'Tang, P F', 'Sorensen, P D']","['Piatak DM', 'Tang PF', 'Sorensen PD']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Nat Prod,Journal of natural products,7906882,IM,"['Antineoplastic Agents, Phytogenic/*analysis', 'Chemical Phenomena', 'Chemistry', 'Humans', 'KB Cells/drug effects', 'Lactones/*analysis', 'Magnetic Resonance Spectroscopy', 'Plant Extracts/analysis', 'Plants, Medicinal/*analysis', 'Strophanthidin/analysis']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1021/np50039a009 [doi]'],ppublish,J Nat Prod. 1985 May-Jun;48(3):424-8. doi: 10.1021/np50039a009.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Lactones)', '0 (Plant Extracts)', '66-28-4 (Strophanthidin)', '98043-36-8 (erysulfone)', '98043-37-9 (erysulfoxide)']",,,['CA 12618/CA/NCI NIH HHS/United States'],,,,,,,,
4031895,NLM,MEDLINE,19851017,20190903,0163-3864 (Print) 0163-3864 (Linking),48,3,1985 May-Jun,"[Preparation, stereochemical study and evaluation of the antileukemic activity of glucoside derivatives of (-)-steganol].",345-56,"The optically active lignan (-)-steganol was prepared from natural (-)-steganacin by selective deacetylation and was transformed, via a three-step sequence, into the corresponding 4', 6'-O-ethylidene- and thenylidene-beta-D-glucopyranosides, 3b and 3c, respectively, which are the analogues, in the steganol series, of the podophyllotoxin derived, and clinically useful, anticancer drugs, VP16-213 and VM26. Formation of the dimeric compound distegyl ether as a minor by-product was established. Complete elucidation of all the asymmetric centres was performed with the help of high resolution 1H-nmr studies at 400 MHz, COSY experiment at 500 MHz and X-ray analysis. Contrary to the podophyllotoxin series, the glycosylation of (-)-steganol occurred with retention of configuration, and all the synthesized compounds, including distegyl ether, exhibited the starting natural R configuration at C-5.","['Houlbert, N', 'Brown, E', 'Robin, J P', 'Davoust, D', 'Chiaroni, A', 'Prange, T', 'Riche, C']","['Houlbert N', 'Brown E', 'Robin JP', 'Davoust D', 'Chiaroni A', 'Prange T', 'Riche C']",['fre'],"['English Abstract', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Nat Prod,Journal of natural products,7906882,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*analysis/chemical synthesis/therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Dealkylation', 'Glucosides', 'Lactones/analysis', 'Leukemia, Experimental/drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice', 'Molecular Conformation', 'Stereoisomerism']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1021/np50039a001 [doi]'],ppublish,J Nat Prod. 1985 May-Jun;48(3):345-56. doi: 10.1021/np50039a001.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (Glucosides)', '0 (Lactones)']",,"Preparation, etude stereochimique et evaluation de l'activite antileucemique de derives glucosidiques du (-)-steganol.",,,,,,,,,
4031003,NLM,MEDLINE,19850927,20190829,0021-9681 (Print) 0021-9681 (Linking),38,9,1985,Multiple tumor incidence in patients with rheumatoid arthritis or allied disorders.,775-9,"The incidence of multiple malignant neoplasms in 55,279 patients with rheumatoid arthritis (RA) or allied disorders was studied by linking two separate nationwide data registers covering the whole Finnish population. The linking of the Social Insurance Institution's Population Register and the Finnish Cancer Registry resulted in 2106 cancer patients in whom both cancer (diagnosed in 1967-1978) and rheumatoid arthritis or allied disorders (diagnosed before cancer) were diagnosed. In 1974, the allied disorders (ankylosing spondylitis or systemic connective tissue diseases) accounted for 3.9% of all the diagnoses in the Social Insurance Institution's Population Register. The incidence of multiple neoplasms was slightly but not significantly higher in cancer patients with RA or allied disorders than in the general population or in all cancer patients taken together. The risk of leukemia was four times higher in the rheumatoid or allied disease cancer patients than in all the cancer patients. The results are consistent with previous results showing that the leukemia incidence in RA patients is higher than expected.","['Hakulinen, T', 'Isomaki, H A', 'Knekt, P']","['Hakulinen T', 'Isomaki HA', 'Knekt P']",['eng'],['Journal Article'],England,J Chronic Dis,Journal of chronic diseases,2985123R,IM,"['Adult', 'Aged', 'Arthritis, Rheumatoid/*complications', 'Female', 'Finland', 'Humans', 'Leukemia/complications/epidemiology', 'Male', 'Middle Aged', 'Neoplasms, Multiple Primary/*complications/epidemiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0021-9681(85)90120-1 [doi]'],ppublish,J Chronic Dis. 1985;38(9):775-9. doi: 10.1016/0021-9681(85)90120-1.,,,,,,,,,,,,
4030506,NLM,MEDLINE,19851023,20190723,0021-8820 (Print) 0021-8820 (Linking),38,7,1985 Jul,"New antitumor antibiotic, FR-900405. III. Mechanism of action of FR-900405.",955-6,,"['Kiyoto, S', 'Shibata, T', 'Kawai, Y', 'Hori, Y', 'Nakayama, O', 'Terano, H', 'Kohsaka, M', 'Aoki, H', 'Imanaka, H']","['Kiyoto S', 'Shibata T', 'Kawai Y', 'Hori Y', 'Nakayama O', 'Terano H', 'Kohsaka M', 'Aoki H', 'Imanaka H']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Antibiotics, Antineoplastic/*pharmacology', 'Cells, Cultured', 'DNA, Neoplasm/biosynthesis', 'Depression, Chemical', 'Leukemia L1210/*metabolism', 'Macromolecular Substances', 'Mice', 'RNA, Neoplasm/biosynthesis', 'ortho-Aminobenzoates/pharmacology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.7164/antibiotics.38.955 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Jul;38(7):955-6. doi: 10.7164/antibiotics.38.955.,"['0 (Antibiotics, Antineoplastic)', '0 (DNA, Neoplasm)', '0 (Macromolecular Substances)', '0 (RNA, Neoplasm)', '0 (ortho-Aminobenzoates)', '97955-49-2 (FR 900405)']",,,,,,,,,,,
4030502,NLM,MEDLINE,19851023,20190723,0021-8820 (Print) 0021-8820 (Linking),38,7,1985 Jul,Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety.,886-98,"Many analogues and derivatives of an antitumor antibiotic, spergualin, were synthesized, and the relationships between the structure and the activity against mouse L-1210 tumor were studied. Both modification of the 15-hydroxyl group and alteration of chain-length of the omega-guanidinoacyl moiety affected the activity. 15-Deoxyspergualin (18, 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-d ion e) and its analogue 25 (1-amino-21-guanidino-11-hydroxy-4,9,12-triazauneicosane-10,13-dio ne) had strong activity, superior to that of spergualin.","['Umeda, Y', 'Moriguchi, M', 'Kuroda, H', 'Nakamura, T', 'Iinuma, H', 'Takeuchi, T', 'Umezawa, H']","['Umeda Y', 'Moriguchi M', 'Kuroda H', 'Nakamura T', 'Iinuma H', 'Takeuchi T', 'Umezawa H']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Antibiotics, Antineoplastic/*chemical synthesis/therapeutic use', 'Carboxylic Acids', 'Catalysis', 'Drug Evaluation, Preclinical', 'Guanidines/chemical synthesis/therapeutic use', 'Leukemia L1210/drug therapy', 'Male', 'Mice', 'Spermidine/analogs & derivatives/chemical synthesis', 'Structure-Activity Relationship']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.7164/antibiotics.38.886 [doi]'],ppublish,J Antibiot (Tokyo). 1985 Jul;38(7):886-98. doi: 10.7164/antibiotics.38.886.,"['0 (Antibiotics, Antineoplastic)', '0 (Carboxylic Acids)', '0 (Guanidines)', '71O2A541CU (spergualin)', '80926-66-5 (glyoxylylspermidine)', 'U87FK77H25 (Spermidine)']",,,,,,,,,,,
4030390,NLM,MEDLINE,19851007,20190903,0018-2214 (Print) 0018-2214 (Linking),17,5,1985 May,Cytochemical and immunological profiles of fresh and cultured leukaemic cells.,541-4,,"['Klobusicka, M', 'Babusikova, O']","['Klobusicka M', 'Babusikova O']",['eng'],"['Comparative Study', 'Journal Article']",Netherlands,Histochem J,The Histochemical journal,0163161,IM,"['Antigens, Neoplasm/*analysis', 'Antigens, Surface/analysis', 'Bone Marrow/pathology', 'Cell Line', 'Cell Membrane/immunology', 'Humans', 'Leukemia/*immunology/pathology', 'Phenotype', 'Receptors, Antigen, B-Cell/*analysis', 'Rosette Formation']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1007/BF01003185 [doi]'],ppublish,Histochem J. 1985 May;17(5):541-4. doi: 10.1007/BF01003185.,"['0 (Antigens, Neoplasm)', '0 (Antigens, Surface)', '0 (Receptors, Antigen, B-Cell)']",,,,,,,,,,,
4030346,NLM,MEDLINE,19851004,20071115,0017-9078 (Print) 0017-9078 (Linking),49,3,1985 Sep,"Low-level radiation, malignant disease, extrapolation and 'official science'.",536-8,,"['Hickey, R J']",['Hickey RJ'],['eng'],['Letter'],United States,Health Phys,Health physics,2985093R,IM,"['Adult', 'Child', '*Government Agencies', 'Humans', 'Leukemia, Radiation-Induced/*etiology', 'Statistics as Topic', 'United States']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Health Phys. 1985 Sep;49(3):536-8.,,,,,,,,,,,,
4030345,NLM,MEDLINE,19851004,20041117,0017-9078 (Print) 0017-9078 (Linking),49,3,1985 Sep,Confirm or deny: nuclear submarine workers at Portsmouth Naval Shipyard had excess leukemia.,535-6,,"['Bross, I D']",['Bross ID'],['eng'],['Letter'],United States,Health Phys,Health physics,2985093R,IM,"['Humans', 'Leukemia, Radiation-Induced/*etiology', 'New Hampshire', '*Nuclear Reactors', 'Occupational Diseases/*etiology', '*Submarine Medicine']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Health Phys. 1985 Sep;49(3):535-6.,,,,,['NASA: 85288222'],,,,,,,
4029944,NLM,MEDLINE,19851018,20190722,0046-8177 (Print) 0046-8177 (Linking),16,9,1985 Sep,Unexpected heterogeneity in acute leukemia: mixed lineages and lineage switch.,864-6,,"['Stass, S', 'Mirro, J']","['Stass S', 'Mirro J']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Hum Pathol,Human pathology,9421547,IM,"['Acute Disease', 'Cell Line', 'Cell Transformation, Neoplastic', 'Gene Expression Regulation', 'Genes', 'Hematopoietic Stem Cells/pathology', 'Humans', 'Leukemia/classification/*genetics/pathology', 'Models, Biological', 'Terminology as Topic']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['S0046-8177(85)80125-8 [pii]', '10.1016/s0046-8177(85)80125-8 [doi]']",ppublish,Hum Pathol. 1985 Sep;16(9):864-6. doi: 10.1016/s0046-8177(85)80125-8.,,,,"['CA 20180/CA/NCI NIH HHS/United States', 'CA 21765/CA/NCI NIH HHS/United States', 'RR-05584-18/RR/NCRR NIH HHS/United States']",,,,,,,,
4029758,NLM,MEDLINE,19851003,20071115,0017-6559 (Print) 0017-6559 (Linking),18,2,1985,Bone marrow patterns in chronic lymphocytic leukaemia related to various clinical and haematological findings. A preliminary report.,115-25,"In a retrospective study of 55 CLL cases subjected to bone-marrow biopsy, the histological pattern of the bone-marrow was correlated to the clinical and haematological data. Instead of the four histological patterns described by Rozman et al., five patterns have been established. The clinical staging according to the Montserrat score, compared with the bone-marrow pattern, showed a good correlation, when maintenance or replacement of normal haematopoiesis was considered. The bone-marrow pattern with maintained haematopoiesis was predicting a favourable clinical correlation; those with replaced haematopoiesis corresponded to a poor prognosis. The correlation is a useful index of severity and prognosis of CLL.","['Gingold, N', 'Dosius, L', 'Berceanu, S']","['Gingold N', 'Dosius L', 'Berceanu S']",['eng'],"['Comparative Study', 'Journal Article']",Netherlands,Haematologia (Budap),Haematologia,0130266,IM,"['Adult', 'Aged', 'Biopsy', 'Bone Marrow/*pathology', 'Female', 'Hematopoiesis', 'Humans', 'Leukemia, Lymphoid/blood/classification/*pathology/physiopathology', 'Male', 'Middle Aged', 'Prognosis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Haematologia (Budap). 1985;18(2):115-25.,,,,,,,,,,,,
4029741,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,Mechanisms of drug resistance in human leukemia.,90-5,,"['Bertino, J R', 'Srimatkandada, S', 'Carman, M D', 'Mini, E', 'Jastreboff, M', 'Moroson, B A', 'Dube, S K']","['Bertino JR', 'Srimatkandada S', 'Carman MD', 'Mini E', 'Jastreboff M', 'Moroson BA', 'Dube SK']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Antineoplastic Agents/*therapeutic use', 'Cell Line', 'Drug Resistance', '*Gene Amplification', 'Humans', 'Leukemia/*drug therapy/enzymology/genetics', 'Methotrexate/therapeutic use', 'Tetrahydrofolate Dehydrogenase/genetics']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_22 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:90-5. doi: 10.1007/978-3-642-70385-0_22.,"['0 (Antineoplastic Agents)', 'EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)', 'YL5FZ2Y5U1 (Methotrexate)']",,,"['CA 08010/CA/NCI NIH HHS/United States', 'CA 08341/CA/NCI NIH HHS/United States']",,,,,,,,
4029735,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,"Self-renewal of haemopoietic stem cells: the roles of the environment, of growth factors and of the src oncogene.",363-71,,"['Dexter, T M', 'Boettiger, D', 'Spooncer, E']","['Dexter TM', 'Boettiger D', 'Spooncer E']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Animals', 'Bone Marrow Cells', 'Cell Division', 'Cell Line', 'Cell Transformation, Neoplastic', 'Culture Techniques/methods', 'Growth Substances/*physiology', 'Hematopoietic Stem Cells/*cytology', 'Humans', 'Leukemia/genetics/*pathology', '*Oncogenes']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_75 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:363-71. doi: 10.1007/978-3-642-70385-0_75.,['0 (Growth Substances)'],,,,,,,,,,,
4029734,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,Normal regulators of growth and differentiation and the reversal of malignancy in leukemia.,353-62,,"['Sachs, L']",['Sachs L'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Bone Marrow Cells', 'Cell Differentiation', 'Cell Division', 'Cell Survival', 'Cells, Cultured', 'Clone Cells', 'Growth Substances/*physiology', 'Hematopoietic Stem Cells/cytology', 'Humans', 'Leukemia/genetics/*pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_74 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:353-62. doi: 10.1007/978-3-642-70385-0_74.,['0 (Growth Substances)'],,,,,,,,,,,
4029730,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,"Discrimination of leukemias, lymphomas, and non-neoplastic controls by retroviral serum markers.",207-14,,"['Hehlmann, R', 'Schreiber, M A', 'Kreeb, G', 'Erfle, V', 'Weber, W', 'Obrecht, P']","['Hehlmann R', 'Schreiber MA', 'Kreeb G', 'Erfle V', 'Weber W', 'Obrecht P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Antibodies, Viral/*analysis', 'Antigen-Antibody Complex/*analysis', 'Antigens, Viral/*analysis', 'Enzyme-Linked Immunosorbent Assay', 'Humans', 'Leukemia/*diagnosis/immunology/microbiology', 'Lymphoma/*diagnosis/immunology/microbiology', 'Prognosis', 'Reference Values', 'Retroviridae/*immunology', 'Viral Proteins/*analysis']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_48 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:207-14. doi: 10.1007/978-3-642-70385-0_48.,"['0 (Antibodies, Viral)', '0 (Antigen-Antibody Complex)', '0 (Antigens, Viral)', '0 (Viral Proteins)']",,,,,,,,,,,
4029727,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,Single donor platelet transfusion.,132-6,,"['Schiffer, C A']",['Schiffer CA'],['eng'],['Journal Article'],Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Blood Grouping and Crossmatching', '*Blood Transfusion', 'Female', 'HLA Antigens/analysis', 'Humans', 'Leukemia/drug therapy/therapy', '*Platelet Transfusion', 'Pregnancy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_29 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:132-6. doi: 10.1007/978-3-642-70385-0_29.,['0 (HLA Antigens)'],,,,,,,,,,,
4029724,NLM,MEDLINE,19851011,20191022,0171-7111 (Print) 0171-7111 (Linking),29,,1985,Red cell transfusions for polytransfused patients.,102-6,,"['Goldmann, S F']",['Goldmann SF'],['eng'],['Journal Article'],Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Anemia/*therapy', '*Blood Transfusion', 'Cell Separation', '*Erythrocyte Transfusion', 'Erythrocytes/cytology', 'Humans', 'Leukemia/*therapy', 'Leukocyte Transfusion', 'Lymphoma/*therapy', 'Platelet Transfusion']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/978-3-642-70385-0_24 [doi]'],ppublish,Haematol Blood Transfus. 1985;29:102-6. doi: 10.1007/978-3-642-70385-0_24.,,,,,,,,,,,,
4029723,NLM,MEDLINE,19851011,20041117,0171-7111 (Print) 0171-7111 (Linking),29,,1985,Modern trends in human leukemia VI. New results in clinical and biological research including pediatric oncology.,1-521,,,,['eng'],['Journal Article'],Germany,Haematol Blood Transfus,Haematology and blood transfusion,101169459,IM,"['Animals', 'Child', 'Humans', '*Leukemia']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Haematol Blood Transfus. 1985;29:1-521.,,,,,,,,,,,,
4029481,NLM,MEDLINE,19851003,20190829,0020-711X (Print) 0020-711X (Linking),17,5,1985,Cyanopyrazoles as analogs of purine precursors--II. Effects on macromolecular synthesis and cell cycle progression.,619-24,"The cytotoxic and cytokinetic effects, and in vitro inhibition of macromolecular synthesis by cyanopyrazoles were studied using Friend leukemia and Ehrlich ascites tumor cells. At concentrations in the range of 2.5 mM to 50 microM analog 3(5)-amino-4-cyano-5(3)-trichloromethylpyrazole (I) was highly cytotoxic and completely inhibited thymidine, uridine and leucine incorporation into macromolecular material. 24 hr incubation of FL cells with cytostatic concentrations of compound I (in the range of 2 to 0.5 microM) resulted in an accumulation of cells in the G2 + M phase. Analogs N-hydroxyethyl-3(5)-amino-4-cyano-5(3)-trichloromethylpyrazole (II) and 3(5)-amino-4-cyanopyrazole (III) were not cytotoxic at concentrations up to 5 mM and did not substantially inhibit precursor incorporation into macromolecules but exhibited a cytostatic activity. These compounds caused a decrease of FL cells in the G2 + M phase and an accumulation in the S phase. Analogs I and II displayed a similar in vivo inhibitory effect on thymidine incorporation into DNA in EAT cells. The results indicate that the cytotoxicity of cyanopyrazoles correlates with their ability to inhibit precursor incorporation into macromolecular material. On the other hand, the cytostatic action of compound I is not coupled to a block of nucleic acid synthesis.","['Grancharov, K C', 'Gorneva, G A', 'Spassova, M K', 'Mladenova, J P']","['Grancharov KC', 'Gorneva GA', 'Spassova MK', 'Mladenova JP']",['eng'],['Journal Article'],England,Int J Biochem,The International journal of biochemistry,0250365,IM,"['Animals', 'Antimetabolites, Antineoplastic/*pharmacology', 'Carcinoma, Ehrlich Tumor/metabolism', 'Cell Cycle/*drug effects', 'Cell Line', 'DNA, Neoplasm/biosynthesis', 'Friend murine leukemia virus', 'Kinetics', 'Leukemia, Experimental/metabolism', '*Macromolecular Substances', 'Mice', 'Neoplasm Proteins/biosynthesis', 'Purines/*biosynthesis', 'Pyrazoles/*pharmacology', 'RNA, Neoplasm/biosynthesis', 'Thymidine/metabolism']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0020-711x(85)90294-0 [doi]'],ppublish,Int J Biochem. 1985;17(5):619-24. doi: 10.1016/0020-711x(85)90294-0.,"['0 (Antimetabolites, Antineoplastic)', '0 (DNA, Neoplasm)', '0 (Macromolecular Substances)', '0 (Neoplasm Proteins)', '0 (Purines)', '0 (Pyrazoles)', '0 (RNA, Neoplasm)', 'VC2W18DGKR (Thymidine)']",,,,,,,,,,,
4029081,NLM,MEDLINE,19851021,20161123,0013-7227 (Print) 0013-7227 (Linking),117,4,1985 Oct,[3H]cortivazol: a unique high affinity ligand for the glucocorticoid receptor.,1355-62,"Cortivazol (CVZ) and deacylcortivazol (DAC) are pyrazolosteroids with potent glucocorticoid activity. In previous work we showed that DAC is 40-fold more potent than dexamethasone (DEX) in lysing leukemic lymphoblasts. To assess the interaction between these atypical steroids and the glucocorticoid receptor, we examined the binding of [3H]CVZ to cytosol from glucocorticoid-sensitive and -resistant variants of the human leukemic cell line CEM C7. In glucocorticoid-sensitive cells [3H]CVZ causes a 2-fold induction of glutamine synthetase and binds to a protein in the 4.6 S region of high salt sucrose gradients. On DEAE-cellulose chromatography, [3H]CVZ-receptor complexes show a shift from high (0.25 M KP) to low salt (0.09 M KP) eluting forms upon activation. CVZ competes for a 97,000-dalton protein labeled by [3H]dexamethasone mesylate. Scatchard analysis of the binding of [3H]CVZ in glucocorticoid-sensitive cells revealed a curvilinear plot which resolved into high (0.4 nM) and low (11 nM) affinity components. The receptor concentration of the low affinity site (0.30 pmol/mg protein) was approximately twice that of the high affinity site (0.14 pmol/mg protein). Dissociation experiments with dilution and/or excess unlabeled CVZ supported the presence of independent sites. In contrast, the binding of [3H]DEX to C7 cytosol revealed a single class of binding sites (Kd = 1.9 nM; receptor concentration, 0.46 pmol/mg protein). Examination of the binding of [3H]CVZ using 10(-5) M DEX as the competing ligand showed that DEX binds only to the low affinity site detected by [3H]CVZ. In cytosol from a glucocorticoid-resistant cell line with virtually no [3H]DEX binding, [3H]CVZ detected a single high affinity binding site that was similar in dissociation constant (0.8 nM) and receptor concentration (0.13 pmol/mg protein) to the high affinity site detected in the glucocorticoid-sensitive cell line C7.","['Schlechte, J A', 'Simons, S S Jr', 'Lewis, D A', 'Thompson, E B']","['Schlechte JA', 'Simons SS Jr', 'Lewis DA', 'Thompson EB']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Endocrinology,Endocrinology,0375040,IM,"['Binding, Competitive', 'Cell Line', 'Chromatography, DEAE-Cellulose', 'Cytosol/metabolism', 'Dexamethasone/metabolism', 'Electrophoresis, Polyacrylamide Gel', 'Humans', 'Leukemia/metabolism', 'Lymphocytes/metabolism', 'Pregnatrienes/*metabolism', 'Receptors, Glucocorticoid/*metabolism', 'Receptors, Steroid/*metabolism']",,1985/10/01 00:00,2001/03/28 10:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1210/endo-117-4-1355 [doi]'],ppublish,Endocrinology. 1985 Oct;117(4):1355-62. doi: 10.1210/endo-117-4-1355.,"['0 (Pregnatrienes)', '0 (Receptors, Glucocorticoid)', '0 (Receptors, Steroid)', '3JO09QT49F (deacylcortivazol)', '7S5I7G3JQL (Dexamethasone)', 'YM183K0H63 (cortivazol)']",,,['MH-34714/MH/NIMH NIH HHS/United States'],,,,,,,,
4028974,NLM,MEDLINE,19851002,20131121,0343-2432 (Print) 0343-2432 (Linking),33,3,1985,[Multiple bowenoid arsenic keratoses].,99-101,Case report of multiple keratoses and chronic lymphatic leukemia after arsenic poisoning 30 years ago during a one-year exposure to copper acetoarsenate in a pesticide factory. Absorption through the skin with local arsenic skin damage is discussed. Etretinate therapy (1 mg/kg b. w.) was ineffective.,"['Leyh, F', 'Rothlaender, J P']","['Leyh F', 'Rothlaender JP']",['ger'],"['Case Reports', 'English Abstract', 'Journal Article']",Germany,Derm Beruf Umwelt,Dermatosen in Beruf und Umwelt. Occupation and environment,7802820,IM,"['Aged', '*Arsenic Poisoning', '*Arsenites', 'Environmental Exposure', 'Etretinate/therapeutic use', 'Humans', 'Insecticides/*adverse effects', 'Keratosis/*chemically induced/drug therapy', 'Leukemia, Lymphoid/*chemically induced', 'Male', 'Precancerous Conditions/*chemically induced/drug therapy', 'Skin Absorption', 'Skin Neoplasms/*chemically induced/drug therapy']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Derm Beruf Umwelt. 1985;33(3):99-101.,"['0 (Arsenites)', '0 (Insecticides)', '12002-03-8 (Paris green)', '65M2UDR9AG (Etretinate)']",,Multiple bowenoide Arsen-Keratosen.,,,,,,,,,
4028190,NLM,MEDLINE,19851003,20191210,0309-1651 (Print) 0309-1651 (Linking),9,7,1985 Jul,Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture.,619-25,"Previous studies showed that a cartilage-derived anti-tumor factor (CATF), which was extracted from bovine cartilage with 1 M guanidine hydrochloride, inhibited the growth of solid sarcoma 180, but not the growth of ascites tumors of sarcoma 180 [Suzuki, F. et al. Jpn. J. Bone Metab., 2, 231-235 (1984)]. This study showed that CATF inhibited the proliferation and DNA synthesis of endothelial cells isolated from bovine pulmonary artery, but not the proliferations of sarcoma 180, L1210 and L cells. These results suggest that CATF has anti-angiogenic properties, thereby inhibiting the growth of solid tumors.","['Takigawa, M', 'Shirai, E', 'Enomoto, M', 'Hiraki, Y', 'Fukuya, M', 'Suzuki, F', 'Shiio, T', 'Yugari, Y']","['Takigawa M', 'Shirai E', 'Enomoto M', 'Hiraki Y', 'Fukuya M', 'Suzuki F', 'Shiio T', 'Yugari Y']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Cell Biol Int Rep,Cell biology international reports,7708050,IM,"['Animals', 'Antineoplastic Agents/isolation & purification/*pharmacology', 'Cartilage/*physiology', 'Cattle', 'Cell Division/drug effects', 'Cells, Cultured', 'DNA Replication/drug effects', 'Endothelium/cytology', 'Kinetics', 'L Cells/cytology', 'Leukemia L1210/pathology', 'Pulmonary Artery/*cytology', 'Sarcoma 180/pathology', 'Tissue Extracts/isolation & purification/*pharmacology']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1016/0309-1651(85)90054-2 [doi]'],ppublish,Cell Biol Int Rep. 1985 Jul;9(7):619-25. doi: 10.1016/0309-1651(85)90054-2.,"['0 (Antineoplastic Agents)', '0 (Tissue Extracts)']",,,,,,,,,,,
4028161,NLM,MEDLINE,19850927,20190705,0092-8674 (Print) 0092-8674 (Linking),42,2,1985 Sep,Mutants and pseudorevertants of Moloney murine leukemia virus with alterations at the integration site.,573-80,"Soon after infection, retroviruses synthesize a DNA copy of the genomic RNA and insert that DNA into the cellular genome by recombination at inverted repeat sequences at the termini of the viral genome. We have generated mutations that alter one terminus of the genome of Moloney murine leukemia virus (M-MuLV). Some mutations did not prevent integration of the viral DNA even though the very terminal bases were disrupted. Other mutations had dramatic effects on the efficiency of infection; in these cases the formation of preintegrative DNA was normal but the establishment of the productive provirus was prevented. One of these defective mutants gave rise to a pseudorevertant which differed from the wild type but displayed normal infectivity. An unusual number of bases of viral DNA were removed during the integration reaction carried out by this virus.","['Colicelli, J', 'Goff, S P']","['Colicelli J', 'Goff SP']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cell,Cell,0413066,IM,"['Animals', 'Cell Line', 'DNA, Viral/genetics', 'Genes, Viral', 'Mice', 'Moloney murine leukemia virus/*genetics/physiology', 'Mutation', 'Rats', '*Recombination, Genetic', 'Repetitive Sequences, Nucleic Acid', 'Virus Replication']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['0092-8674(85)90114-X [pii]', '10.1016/0092-8674(85)90114-x [doi]']",ppublish,Cell. 1985 Sep;42(2):573-80. doi: 10.1016/0092-8674(85)90114-x.,"['0 (DNA, Viral)']",,,['CA 30488/CA/NCI NIH HHS/United States'],,,,,,,,
4028035,NLM,MEDLINE,19851015,20131121,0361-5960 (Print) 0361-5960 (Linking),69,9,1985 Sep,Antitumor activity of trans-bis(salicylaldoximato)copper(II): a novel antiproliferative metal complex.,1021-2,"trans-Bis(salicylaldoximato)copper(II) (CuSAO2), the parent compound of a new group of antiproliferative copper(II) complexes, was studied in vivo. It had marked antitumor activity against Ehrlich ascites carcinoma in NMRI mice. Survival was considerably increased, and, in some cases, total cures were encountered. No activity against leukemia L1210 was found in female DBA/2J mice, although CuSAO2 is equally effective against L1210 and Ehrlich carcinoma cells in vitro. The side effects of CuSAO2 included weight loss, weakness, acrodynia, and blindness; all of these side effects were transient.","['Elo, H O', 'Lumme, P O']","['Elo HO', 'Lumme PO']",['eng'],['Journal Article'],United States,Cancer Treat Rep,Cancer treatment reports,7607107,IM,"['Acrodynia/chemically induced', 'Animals', '*Antineoplastic Agents', 'Blindness/chemically induced', 'Body Weight/drug effects', 'Carcinoma, Ehrlich Tumor/*drug therapy/pathology', 'Copper/adverse effects/*therapeutic use', 'Female', 'Leukemia L1210/*drug therapy/pathology', 'Mice', 'Organometallic Compounds/adverse effects/*therapeutic use', 'Time Factors']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Treat Rep. 1985 Sep;69(9):1021-2.,"['0 (Antineoplastic Agents)', '0 (Organometallic Compounds)', '0 (bis(salicylaldoximato)copper(II))', '789U1901C5 (Copper)']",,,,,,,,,,,
4028022,NLM,MEDLINE,19850930,20071114,0008-5472 (Print) 0008-5472 (Linking),45,9,1985 Sep,Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation.,4380-6,"A variety of cell lines have been prepared by fusion of the murine WEH1 3B cell line with peripheral blood leukocytes from a patient with chronic granulocytic leukemia. Fusion products were selected for their ability to produce a leukemia-associated antigen (CAMAL) previously described. One such line which originally produced CAMAL subsequently lost this ability and was used as a negative control. A number of antibodies were conjugated to hematoporphyrin (HP) and tested for their ability to bind to cell lines as detected by either fluorescence or by their ability to kill cells after light activation. The antibodies used were: rabbit anti-Hu (a conventional rabbit antiserum raised to membrane preparations from normal human peripheral blood leukocytes which served as a positive control); CAMAL-1 (a monoclonal gamma 1 antibody with specificity for the CAMAL antigen); and L1210 (an irrelevant monoclonal gamma 1 antibody). HP was conjugated to the antibodies by a carbodiimide procedure. When labeled cells were examined by fluorescence microscopy, it was apparent that both the rabbit antibody and CAMAL-1:HP showed positive labeling. The ability of the antibody:HP conjugates to kill labeled cells following light activation was tested. It was shown that rabbit anti-Hu:HP and CAMAL-1:HP conjugates were capable of killing significant numbers of cells when HP concentrations were as low as 1.2 ng/10(6) cells, whereas similarly treated cells exposed to either L1210:HP or HP alone did not exhibit significant killing until concentrations reached 240 and 120 ng/10(6) cells, respectively. Further experiments in which other cell lines were tested, all at HP concentrations of 12 ng/10(6) cells, demonstrated that those lines producing CAMAL were killed, whereas negative lines were not.","['Mew, D', 'Lum, V', 'Wat, C K', 'Towers, G H', 'Sun, C H', 'Walter, R J', 'Wright, W', 'Berns, M W', 'Levy, J G']","['Mew D', 'Lum V', 'Wat CK', 'Towers GH', 'Sun CH', 'Walter RJ', 'Wright W', 'Berns MW', 'Levy JG']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Antibodies, Monoclonal/*administration & dosage', 'Antigens, Neoplasm/analysis', 'Cell Line', 'Hematoporphyrins/*administration & dosage/therapeutic use', 'Humans', 'Immune Sera/*administration & dosage', 'Leukemia/immunology', 'Mice', 'Neoplasms/immunology/*therapy', '*Photochemotherapy', 'Rabbits']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Sep;45(9):4380-6.,"['0 (Antibodies, Monoclonal)', '0 (Antigens, Neoplasm)', '0 (Hematoporphyrins)', '0 (Immune Sera)']",,,"['CA32248/CA/NCI NIH HHS/United States', 'RR01192/RR/NCRR NIH HHS/United States']",,,,,,,,
4028017,NLM,MEDLINE,19850930,20131121,0008-5472 (Print) 0008-5472 (Linking),45,9,1985 Sep,Relationship of queuine-lacking transfer RNA to the grade of malignancy in human leukemias and lymphomas.,4308-14,,"['Emmerich, B', 'Zubrod, E', 'Weber, H', 'Maubach, P A', 'Kersten, H', 'Kersten, W']","['Emmerich B', 'Zubrod E', 'Weber H', 'Maubach PA', 'Kersten H', 'Kersten W']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Adolescent', 'Adult', 'Aged', 'Cell Differentiation', 'Child', 'Female', 'Guanine/*analogs & derivatives/analysis', 'Humans', 'Lactates/metabolism', 'Lactic Acid', 'Leukemia/*pathology', 'Lymphoma/*analysis/pathology', 'Male', 'Middle Aged', 'Neoplasm Staging', 'RNA, Transfer/*analysis']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Sep;45(9):4308-14.,"['0 (Lactates)', '33X04XA5AT (Lactic Acid)', '5Z93L87A1R (Guanine)', '72496-59-4 (queuine)', '9014-25-9 (RNA, Transfer)']",,,,,,,,,,,
4028016,NLM,MEDLINE,19850930,20061115,0008-5472 (Print) 0008-5472 (Linking),45,9,1985 Sep,Comparison of the morphology and enzyme activity of mononuclear cells from Fischer 344 rats with either spontaneous or transplanted leukemia.,4301-7,"Mononuclear cell (MNC) leukemia was identified in 26-month-old F344 rats by splenomegaly, reduced red blood cell counts, and elevated white blood cell counts. Atypical MNC were predominant in spleen and blood with acentric nuclei and red cytoplasmic granules. Pentose shunt, glycolytic, and Krebs cycle enzyme activities were elevated 2- to 11-fold in the enriched MNC fraction (Ficoll-Paque density gradients, 1.077 g/ml) isolated from spleen. A leukemic MNC line was derived from one of the spontaneously leukemic donors and then maintained in vivo by s.c. transfer of 2 X 10(7) spleen cells into 7-8-week-old syngeneic recipients. In these serial transplantation experiments leukemia that was clinically and morphologically indistinguishable from spontaneous leukemia in 104-week-old rats was induced in 22-24-week-old rats. Enhanced enzyme activity in MNC was not essential to maintain the phenotypic expression of Fischer rat leukemia. The pattern of biochemical response in spleen MNC from transplanted cases was the opposite of that previously noted in spontaneously leukemic rats, with 50-70% decreases in the specific activities of pentose shunt enzymes and malate dehydrogenase. Reversal of the expression of these enzymes in MNC may be related to a difference in the growth rate of the tumors or to selective proliferation of the transplanted leukemic cells. In addition acetylcholinesterase activity decreased 35-85% in MNC of spleen and blood. Transplantable MNC from F344 rats provide abundant tumorigenic material with a novel biochemical expression that may be useful in the study of chemotherapeutic intervention.","['Dieter, M P', 'Maronpot, R R', 'French, J E']","['Dieter MP', 'Maronpot RR', 'French JE']",['eng'],"['Comparative Study', 'Journal Article']",United States,Cancer Res,Cancer research,2984705R,IM,"['Acetylcholinesterase/blood', 'Animals', 'Body Weight', 'Glycolysis', 'Leukemia, Experimental/*enzymology/pathology', 'Lymphocytes/*enzymology', 'Male', 'Neoplasm Transplantation', 'Organ Size', 'Pentose Phosphate Pathway', 'Proteins/analysis', 'Rats', 'Rats, Inbred F344', 'Spleen/pathology']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Sep;45(9):4301-7.,"['0 (Proteins)', 'EC 3.1.1.7 (Acetylcholinesterase)']",,,,,,,,,,,
4028003,NLM,MEDLINE,19850930,20151119,0008-5472 (Print) 0008-5472 (Linking),45,9,1985 Sep,Effect of amphotericin B on Adriamycin transport in P388 cells.,4097-102,"In Adriamycin-sensitive and -resistant P388 cells, coincubation with amphotericin B causes a marked increase in Adriamycin retention, as determined by laser flow cytometry. P388/S cells were generally more affected than were P388/R cells. Preincubation with amphotericin B had a greater effect on Adriamycin retention than did co- or postincubation. In splenocytes, bone marrow, and ascites from mice, enhanced Adriamycin retention was seen in all the tissues. However, bone marrow cells showed heterogeneous response, with some populations being more sensitive than others.","['Krishan, A', 'Sauerteig, A', 'Gordon, K']","['Krishan A', 'Sauerteig A', 'Gordon K']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Amphotericin B/*pharmacology', 'Animals', 'Biological Transport/drug effects', 'Cell Division/drug effects', 'Cells, Cultured', 'Doxorubicin/*metabolism', 'Fluorometry', 'Lasers', 'Leukemia P388/*metabolism', 'Leukemia, Experimental/*metabolism', 'Mice', 'Phenothiazines/pharmacology']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Sep;45(9):4097-102.,"['0 (Phenothiazines)', '7XU7A7DROE (Amphotericin B)', '80168379AG (Doxorubicin)']",,,['CA-29360/CA/NCI NIH HHS/United States'],,,,,,,,
4027999,NLM,MEDLINE,19850930,20141120,0008-5472 (Print) 0008-5472 (Linking),45,9,1985 Sep,Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.,4020-5,"We compared the pharmacokinetics of daunomycin (7.5 mg/kg i.v. bolus injection) in normal and leukemic rats using a leukemia model which resembles acute myeloid leukemia in humans. Due to a more rapid decrease in plasma concentration, the area under the plasma concentration/time curve (AUC) for up to 2 h after drug injection was smaller (2.2 times) in the leukemic rats than that for normals. However, due to higher plasma levels during the drug elimination phase, the total AUC0----infinity was somewhat larger (1.3 times) in the leukemic rats. In the leukemia-infiltrated organs (spleen, liver, and lungs), significantly higher daunomycin concentrations (per gram wet weight) were found than in those obtained from normal rats. In contrast, femoral bone marrow from leukemic rats contained less daunomycin (per 10(9) nucleated cells) than did normal marrow. Quantification of the daunomycin uptake in vitro by flow cytometry showed that leukemic cells from bone marrow and spleen have an equal net drug uptake. Our data suggest that, in the presence of a high leukemic cell load, the intravenously injected daunomycin is rapidly taken up and retained by the leukemic tumor mass in, e.g., spleen, liver, and lungs, and that, as a consequence of this, the femoral marrow functions as a kind of pharmacological sanctuary.","['Nooter, K', 'Sonneveld, P', 'Martens, A']","['Nooter K', 'Sonneveld P', 'Martens A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Bile/metabolism', 'Bone Marrow/metabolism', 'Daunorubicin/*metabolism', 'Doxorubicin/metabolism', 'Female', 'Fluorescence', 'In Vitro Techniques', 'Kinetics', 'Leukemia, Experimental/*metabolism', 'Rats', 'Rats, Inbred Strains', 'Spleen/metabolism', 'Tissue Distribution']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Sep;45(9):4020-5.,"['80168379AG (Doxorubicin)', 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4027995,NLM,MEDLINE,19851023,20151119,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.,5186-92,"Twenty-seven patients with acute leukemia have been treated by sequential 6-day courses of thymidine (30 g/m2 by i.v. continuous infusion, days 1 and 4) and 1-beta-D-arabinofuranosylcytosine (ara-C) (200 mg/m2 by i.v. continuous infusion, days 2,3,5, and 6). Of 25 evaluable patients 4 achieved a complete remission: one of 9 for acute myelogenous leukemia; and 3 of 14 in the blastic crisis of chronic myelocytic leukemia. Six minor responses were also observed. Toxicity was mainly hematological and did not appear to be higher than that expected from ara-C alone. However, thymidine infusions gave rise to headache and somnolence. The clinical benefit of such treatment seems to be limited to the blastic crisis of chronic myelocytic leukemia. Parallel cytokinetic and biochemical studies were performed in order to assess the cytokinetic and metabolic changes induced by both drugs and to correlate them with the clinical response. Recruitment of cells into the S-phase fraction was observed following the first thymidine infusion in the two complete responders and in three of the five nonresponders studied. In contrast to this high pretherapeutic levels of S-phase fraction were observed in most minor responders and in some nonresponders with further decrease following the thymidine infusion. Recruitment of cells into S phase therefore appeared to be an important but not sufficient factor for prediction of complete response to ara-C. Responders in contrast to most nonresponders were characterized by a higher intracellular level of ara-C and its metabolites following the first 24-h infusion of the drug. Deoxythymidine triphosphate and deoxycytidine triphosphate pools were also measured before and during treatment in order to assess if nucleotide pool variations induced by the administration of thymidine can in fact correlate with the intracellular alteration in ara-C metabolism and with clinical response. The level of deoxycytidine triphosphate pools before treatment showed marked interpatient variations but did not correlate with response. As expected, thymidine infusion induced a rise in the deoxythymidine triphosphate pool and a decrease in deoxycytidine triphosphate. The pools, however, generally returned promptly to the pretherapeutic level 24 h after the end of the infusion of thymidine. There were no significant differences between responders and nonresponders in the modulation of these pools.","['Zittoun, R', 'Zittoun, J', 'Marquet, J', 'Rustum, Y', 'Creaven, P']","['Zittoun R', 'Zittoun J', 'Marquet J', 'Rustum Y', 'Creaven P']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Acute Disease', 'Cytarabine/*administration & dosage/adverse effects/metabolism', 'DNA/metabolism', 'Deoxycytosine Nucleotides/analysis', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Leukemia/*drug therapy/metabolism', 'Thymidine/*administration & dosage/adverse effects', 'Thymine Nucleotides/analysis']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):5186-92.,"['0 (Deoxycytosine Nucleotides)', '0 (Thymine Nucleotides)', '04079A1RDZ (Cytarabine)', ""2056-98-6 (2'-deoxycytidine 5'-triphosphate)"", '9007-49-2 (DNA)', ""QOP4K539MU (thymidine 5'-triphosphate)"", 'VC2W18DGKR (Thymidine)']",,,['CA21071/CA/NCI NIH HHS/United States'],,,,,,,,
4027981,NLM,MEDLINE,19851023,20071114,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,Characterization of mammalian phosphoribosylglycineamide formyltransferase from transformed cells.,4990-7,"Phosphoribosylglycineamide formyltransferase levels were studied in several mammalian tissues and were found to be elevated 3- to 6-fold in some anaplastic cells, including rat hepatoma H-35 and mouse leukemia L1210, as compared to their corresponding normal tissues. The enzyme was found to reside in the cytosol of chicken liver and L1210 cells. The enzyme was purified to near homogeneity, as judged by a single band on polyacrylamide gels after electrophoresis in the presence of sodium dodecyl sulfate, from two mammalian sources, mouse L1210 and mouse Sarcoma 180. Comparison of the digestion patterns of L1210 enzyme and chicken liver enzyme upon exposure to chymotrypsin showed some similarity between the two, as did cross-reactivity in Western blots of the chicken enzyme with antibodies raised to the L1210 enzyme. Subunit molecular weight of the L1210 and Sarcoma 180 phosphoribosylglycineamide formyltransferases is about 117,000. Steady-state kinetics was performed with the purified murine enzyme in the presence of 5'-phosphoribosyl-N-glycineamide and 10-formyltetrahydrofolate and with 5'-phosphoribosyl-N-glycineamide and 10-formyl-5,8-deazafolate, establishing that these mammalian enzymes utilize 10-formyltetrahydrofolate as the actual cofactor. 11-Formyltetrahydrohomofolate was found to be an inhibitor of the murine and human (HeLa) enzymes, competitive with respect to 10-formyltetrahydrofolate, with KiS of 1 and 3 microM, respectively. 11-Formyldihydrohomofolate was an inhibitor of HeLa cell growth with a 50% effective dose of 8-11 microM.","['Daubner, S C', 'Benkovic, S J']","['Daubner SC', 'Benkovic SJ']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Acyltransferases/*analysis/isolation & purification', 'Animals', 'Cells, Cultured', 'Chickens', 'Female', 'HeLa Cells', 'Humans', '*Hydroxymethyl and Formyl Transferases', 'Kinetics', 'Mice', 'Mice, Inbred DBA', 'Molecular Weight', 'Neoplasms, Experimental/*enzymology', 'Phosphoribosylglycinamide Formyltransferase', 'Rats']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):4990-7.,"['EC 2.1.2.- (Hydroxymethyl and Formyl Transferases)', 'EC 2.1.2.2 (Phosphoribosylglycinamide Formyltransferase)', 'EC 2.3.- (Acyltransferases)']",,,"['GM 09114/GM/NIGMS NIH HHS/United States', 'GM 24129/GM/NIGMS NIH HHS/United States']",,,,,,,,
4027978,NLM,MEDLINE,19851023,20131121,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.,4915-20,"1,4-Dihydroxy-5,8-bis(2-[(2-hydroxyethyl)aminoethyl]amino)-9, 10-anthracenedione (mitoxantrone) and 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2y)hydrazone] dihydrochloride (bisantrene) were evaluated for their abilities to cause cytotoxicity and interact with cellular DNA using leukemic L1210 cells. On a molar basis mitoxantrone has been found to be 7-fold more toxic than bisantrene. Using a nucleoid sedimentation technique, bisantrene caused changes in DNA supercoiling which were characteristic of an intercalating drug, but mitoxantrone did not induce these changes. Both drugs were found to interact with cellular DNA with tight but noncovalent binding. Both drugs also induced protein-associated double- and single-strand DNA breaks, but with mitoxantrone only some of the DNA single-strand breaks were protein associated, whereas with bisantrene all the DNA single-strand breaks were protein associated. The cytotoxicity produced by bisantrene at a given frequency of protein-associated DNA strand breaks was low. However, with mitoxantrone at an equivalent DNA strand break frequency, the cytotoxicity was high. Treatment of isolated L1210 nuclei with either drug did not result in DNA single-strand breaks. It can be concluded that bisantrene binds DNA in whole cells by an intercalative mechanism, whereas mitoxantrone binds DNA by a nonintercalative, electrostatic interaction and induces non-protein-associated DNA strand breaks.","['Bowden, G T', 'Roberts, R', 'Alberts, D S', 'Peng, Y M', 'Garcia, D']","['Bowden GT', 'Roberts R', 'Alberts DS', 'Peng YM', 'Garcia D']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Anthracenes/metabolism/pharmacology', 'Anthraquinones/metabolism/*pharmacology', 'Antineoplastic Agents/*pharmacology', 'Cell Nucleus/drug effects', 'Cell Survival/drug effects', 'DNA, Neoplasm/metabolism', 'DNA, Single-Stranded', 'DNA, Superhelical/analysis', 'Leukemia L1210/*metabolism/pathology', 'Mice', 'Mitoxantrone']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):4915-20.,"['0 (Anthracenes)', '0 (Anthraquinones)', '0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (DNA, Single-Stranded)', '0 (DNA, Superhelical)', '39C34M111K (bisantrene)', 'BZ114NVM5P (Mitoxantrone)']",,,"['CA-17094/CA/NCI NIH HHS/United States', 'CA-17343/CA/NCI NIH HHS/United States', 'CA-23014/CA/NCI NIH HHS/United States']",,,,,,,,
4027962,NLM,MEDLINE,19851023,20151119,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,Characterization of L1210 cell growth inhibition by the bacterial iron chelators parabactin and compound II.,4754-9,"Microbial siderophores represent a class of iron chelators characterized by their high affinity (i.e., formation constants, greater than 10(40) M) for ferric iron. Previously, we demonstrated that the bacterial siderophores, N-[3-(2,3-dihydroxybenzamido)propyl]-N-[4-(2, 3-dihydroxybenzamino)butryl]-2-(2-hydroxyphenyl) trans-5-methyloxazoline-4-carboxamide (Parabactin) and N1,N8-bis(2,3-dihydroxybenzoyl)spermidine (Compound II), inhibit the growth of L1210 cells and the replication of DNA (but not RNA) viruses at low micromolar concentrations (Biochem. Biophys. Res. Commun., 121: 848-854, 1984). The basis for this antiproliferative effect on L1210 cells has now been investigated further. Onset of growth inhibition induced by 5 microM Parabactin occurs much earlier than with an equimolar concentration of Compound II but, once established by either chelator, inhibition appears to be irreversible. Growth inhibition was fully preventable with exogenous FeCl3 when given at the same time as the chelators. Flow cytometric analysis revealed a G1-S cycle block following treatment for 4 h with either 5 microM Parabactin or 30 microM Compound II. The block was readily reversed with exogenous FeCl3, allowing cells to progress to mid-S phase by 3 h and to G1 again by 9 h. Thereafter, cells accumulated at a second block located at S phase. The treatment conditions required for the initial cell cycle block (at 4 h) were adapted for subsequent studies. Clonogenicity of L1210 cells in soft agar following a 4-h exposure was reduced to 22% of control by 5 microM Parabactin and to 16% by 30 microM Compound II. Neither growth inhibition in suspension culture nor decreased clonogenicity in soft agar could be reversed with exogenous iron, following treatment with the chelators. Both chelators caused an early and significant decrease in [14C]thymidine incorporation over the 4-h period (50% inhibitory concentration at 4 h, 0.4 microM for Parabactin and 6.0 microM for Compound II). [3H]Uridine incorporation was inhibited later than [14C]thymidine and to a much lesser extent, while [3H]leucine incorporation was not significantly affected. Treatment of cells with 5 microM Parabactin or Compound II for 4 h decreased deoxy-adenosine triphosphate pools by 38 and 70%, respectively, and increased deoxythymidine triphosphate pools by 67 and 36%, respectively, suggesting interference with ribonucleotide reductase. Indeed, extracts of cells treated for 4 h with either 5 microM Parabactin or 30 microM Compound II exhibit a 97 to 98% decrease in cytidine-5'-diphosphate reductase activity compared to control, whereas DNA polymerase was elevated slightly.(ABSTRACT TRUNCATED AT 400 WORDS)","['Cavanaugh, P F Jr', 'Porter, C W', 'Tukalo, D', 'Frankfurt, O S', 'Pavelic, Z P', 'Bergeron, R J']","['Cavanaugh PF Jr', 'Porter CW', 'Tukalo D', 'Frankfurt OS', 'Pavelic ZP', 'Bergeron RJ']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, Non-P.H.S."", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Cell Cycle/drug effects', 'DNA/biosynthesis', 'Iron Chelating Agents/*pharmacology', 'Leukemia L1210/*pathology', 'Mice', 'Oxazoles/*pharmacology', 'Ribonucleoside Diphosphate Reductase/antagonists & inhibitors', 'Spermidine/*analogs & derivatives/pharmacology', 'Thymidine/metabolism', 'Thymine Nucleotides/analysis', 'Tritium']",,1985/10/01 00:00,2001/03/28 10:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):4754-9.,"['0 (Iron Chelating Agents)', '0 (Oxazoles)', '0 (Thymine Nucleotides)', '10028-17-8 (Tritium)', '54135-84-1 (N(1),N(8)-bis(2,3-dihydroxybenzoyl)spermidine)', '74149-70-5 (parabactin)', '9007-49-2 (DNA)', 'EC 1.17.4.- (CDP reductase)', 'EC 1.17.4.1 (Ribonucleoside Diphosphate Reductase)', ""QOP4K539MU (thymidine 5'-triphosphate)"", 'U87FK77H25 (Spermidine)', 'VC2W18DGKR (Thymidine)']",,,"['AM-29936/AM/NIADDK NIH HHS/United States', 'CA-33321/CA/NCI NIH HHS/United States', 'CA-37606/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4027961,NLM,MEDLINE,19851023,20131121,0008-5472 (Print) 0008-5472 (Linking),45,10,1985 Oct,Depletion of extracellular cysteine with hydroxocobalamin and ascorbate in experimental murine cancer chemotherapy.,4727-31,"Treatment of mice bearing P388 lymphocytic leukemia with combined hydroxocobalamin (0.1 mmol/kg) and sodium ascorbate (1.0 mmol/kg) for 10 consecutive days resulted in 70% increase in survival. Treatment with dehydroascorbate (1.0 mmol/kg) similarly increased survival. The extended treatment for 15 days posttumor inoculation failed to improve survival as did lowering the tumor inocula from 10(6) to 10(4) cells in similarly treated mice. P388 cells in primary culture with cystine as a source of cysteine require exogenous thiols or disulfides for growth and also grow with cysteine but only when trace copper is sequestered with bathocuproine sulfonate. This is due to the copper catalyzed oxidation of cysteine to cystine, which these cells cannot utilize. Cells grew in medium preincubated for 8 h with cysteine and bathocuproine sulfonate, but lysed when the preincubated medium included hydroxocobalamin (10 microM) and sodium ascorbate (100 microM). This defect was corrected by resupplementation with cysteine or cystine plus bishydroxyethyl disulfide after addition of the cells. Further support for cysteine depletion as a factor in therapy is obtained by therapeutic interference with 4-thiamethionine (25 mumol/kg). This mixed disulfide of cysteine and methyl mercaptan enters cells as a methionine analogue, is reduced to supply cysteine, and thus withstands the oxidative environment that limits the utilization of cysteine as a nutrient. These results suggest that dehydroascorbate is generated from combined hydroxocobalamin and ascorbate and accounts for the thiol-prive activity of combined hydroxocobalamin and ascorbate therapy. The ultimate failure of therapy by thiol oxidation may be due to the increased availability of cysteine produced by host tissues, possibly infiltrating macrophages, that occurs independently of extended treatment and the size of the tumor inoculum.","['Pierson, H F', 'Fisher, J M', 'Rabinovitz, M']","['Pierson HF', 'Fisher JM', 'Rabinovitz M']",['eng'],['Journal Article'],United States,Cancer Res,Cancer research,2984705R,IM,"['Animals', 'Ascorbic Acid/*therapeutic use', 'Cells, Cultured', 'Cysteine/*metabolism', 'Dehydroascorbic Acid/metabolism', 'Drug Therapy, Combination', 'Female', 'Hydroxocobalamin/*therapeutic use', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Neoplasms, Experimental/*drug therapy', 'Oxidation-Reduction', 'Sulfhydryl Compounds/metabolism']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",,ppublish,Cancer Res. 1985 Oct;45(10):4727-31.,"['0 (Sulfhydryl Compounds)', 'K848JZ4886 (Cysteine)', 'PQ6CK8PD0R (Ascorbic Acid)', 'Q40X8H422O (Hydroxocobalamin)', 'Y2Z3ZTP9UM (Dehydroascorbic Acid)']",,,,,,,,,,,
4027955,NLM,MEDLINE,19851017,20190720,0304-3835 (Print) 0304-3835 (Linking),28,1,1985 Aug,Selenocystine is not a cystine antimetabolite in L1210 cells.,43-6,"Selenocystine inhibited the growth in culture of murine L1210 leukemia cells to a greater extent when the cells were supplemented with a high concentration of cystine for optimal growth. Cells which grew suboptimally in a limiting cystine concentration were inhibited to a lesser extent. In this case, the time of onset of selenocystine inhibition coincided with the time of termination of growth at the lower cystine concentration. These observations are contrary to expectation for action of an antimetabolite, and it is concluded that selenocystine cannot be considered a cystine antagonist.","['Fisher, J M', 'Rabinovitz, M']","['Fisher JM', 'Rabinovitz M']",['eng'],['Journal Article'],Ireland,Cancer Lett,Cancer letters,7600053,IM,"['Animals', 'Antimetabolites/*pharmacology', 'Cells, Cultured', 'Cystine/*analogs & derivatives/*antagonists & inhibitors/pharmacology', 'Leukemia L1210/*metabolism/pathology', 'Mice', '*Organoselenium Compounds', 'Selenium/*pharmacology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['0304-3835(85)90090-4 [pii]', '10.1016/0304-3835(85)90090-4 [doi]']",ppublish,Cancer Lett. 1985 Aug;28(1):43-6. doi: 10.1016/0304-3835(85)90090-4.,"['0 (Antimetabolites)', '0 (Organoselenium Compounds)', '1464-43-3 (selenocystine)', '48TCX9A1VT (Cystine)', 'H6241UJ22B (Selenium)']",,,,,,,,,,,
4027947,NLM,MEDLINE,19851001,20190816,0165-4608 (Print) 0165-4608 (Linking),18,1,1985 Sep,"The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders.",1-10,"Bone marrow aspirates from 90 patients suspected of having a hematologic disorder were processed by using different cytogenetic methods to determine if any procedure was more likely to reveal a chromosomally abnormal clone or produce better-quality metaphases. All specimens were processed by a direct technique and 24-hr culture without mitogens; 50 specimens were also processed by an amethopterin mitotic synchronization method. In each case, the microscope slides were coded by the processing technologist and analyzed by two other experienced cytogenetic technologists. The results were not known to any of the investigators until all 90 specimens were analyzed. With the exception of one specimen, in which a chromosomally abnormal clone was identified only in the direct preparation, no apparent differences were found in the karyotypes among the three methods. Also, the differences in the quality or number of metaphases found among the three methods were not statistically significant; however, 24-hr unstimulated cultures produced more metaphases than the mitotic synchronization procedure. The greatest source of discordance was caused by one test yielding either no metaphases or an uncertain result when the other tests produced a successful study. We suggest that in routine practice at least two different methods should be used, and it may be best if at least one of these methods is a direct technique.","['Dewald, G W', 'Broderick, D J', 'Tom, W W', 'Hagstrom, J E', 'Pierre, R V']","['Dewald GW', 'Broderick DJ', 'Tom WW', 'Hagstrom JE', 'Pierre RV']",['eng'],['Journal Article'],United States,Cancer Genet Cytogenet,Cancer genetics and cytogenetics,7909240,IM,"['Bone Marrow/*pathology/ultrastructure', 'Cells, Cultured', '*Chromosome Aberrations', 'Humans', 'Karyotyping', 'Leukemia/*genetics/pathology', 'Metaphase', 'Methods', '*Mitosis', 'Myeloproliferative Disorders/*genetics/pathology', 'Time Factors']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']","['0165-4608(85)90032-9 [pii]', '10.1016/0165-4608(85)90032-9 [doi]']",ppublish,Cancer Genet Cytogenet. 1985 Sep;18(1):1-10. doi: 10.1016/0165-4608(85)90032-9.,,,,,,,,,,,,
4027940,NLM,MEDLINE,19851024,20211203,0008-543X (Print) 0008-543X (Linking),56,8,1985 Oct 15,Multiple myeloma and family history of cancer. A case-control study.,2133-9,"A hospital-based case-control study was done to examine the hypothesis that persons with a family history of multiple myeloma (MM) or other cancers are at increased risk of multiple myeloma. Study members were 439 cases of multiple myeloma and 1317 matched controls seen at the Duke University Medical Center. Only 3 cases and 4 controls reported multiple myeloma in their families. The relative risk (RR) was 2.3, but the 95% confidence interval (CI) was 0.5-10.1, allowing no firm conclusion about the risk associated with familial MM. A family history of cancer of any type resulted in a relative risk of MM of 1.4 (CI: 1.1-1.8). This association was strongest (RR = 2.5, CI: 1.1-5.3) among young study members (age less than or equal to 49). A family history of hematologic malignancy (ICD 200-208) resulted in a RR of 2.4 (95% CI: 1.4-4.0). The data also suggested that a family history of lung cancer, breast cancer, and genitourinary cancer may be associated with increased risk of myeloma in older persons.","['Bourguet, C C', 'Grufferman, S', 'Delzell, E', 'DeLong, E R', 'Cohen, H J']","['Bourguet CC', 'Grufferman S', 'Delzell E', 'DeLong ER', 'Cohen HJ']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer,Cancer,0374236,IM,"['*Epidemiologic Methods', 'Family Characteristics', 'Female', 'Humans', 'Leukemia/genetics', 'Lymphoma/genetics', 'Male', 'Medical History Taking', 'Middle Aged', 'Multiple Myeloma/*genetics', 'Pedigree', 'Racial Groups', 'Risk']",,1985/10/15 00:00,1985/10/15 00:01,['1985/10/15 00:00'],"['1985/10/15 00:00 [pubmed]', '1985/10/15 00:01 [medline]', '1985/10/15 00:00 [entrez]']",['10.1002/1097-0142(19851015)56:8<2133::aid-cncr2820560842>3.0.co;2-f [doi]'],ppublish,Cancer. 1985 Oct 15;56(8):2133-9. doi: 10.1002/1097-0142(19851015)56:8<2133::aid-cncr2820560842>3.0.co;2-f.,,,,"['K07 CA00726/CA/NCI NIH HHS/United States', 'P30 CA14236/CA/NCI NIH HHS/United States', 'R01 CA22104/CA/NCI NIH HHS/United States']",,,,,,,,
4027935,NLM,MEDLINE,19851024,20190619,0008-543X (Print) 0008-543X (Linking),56,8,1985 Oct 15,"Meningeal involvement in patients with acute nonlymphocytic leukemia. Incidence, management, and predictive factors.",2078-82,"Between 1977 and 1983, symptomatic meningeal leukemia was diagnosed in 9 of 93 adult patients with acute nonlymphocytic leukemia (10%). All cases occurred after complete remission had been achieved (46 patients), either as the only site of relapse (3 patients), or together with a first bone marrow relapse (3 patients), or after a bone marrow relapse (3 patients). Extramedullary involvement at initial diagnosis was the only independent predictive factor (P = 0.005), the number of patients with initial hyperleukocytosis being too small (three) for evaluation. Remission of the meningeal leukemia was obtained after treatment in four of eight patients. The presence of meningeal leukemia and the response to therapy had no influence on survival. However, the morbidity and therapy related toxicity of meningeal leukemia were impressive. Some recommendations for prophylactic treatment are suggested.","['Dekker, A W', 'Elderson, A', 'Punt, K', 'Sixma, J J']","['Dekker AW', 'Elderson A', 'Punt K', 'Sixma JJ']",['eng'],['Journal Article'],United States,Cancer,Cancer,0374236,IM,"['Actuarial Analysis', 'Acute Disease', 'Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Cytarabine/administration & dosage', 'Female', 'Humans', 'Leukemia/*pathology/therapy', 'Male', 'Meningeal Neoplasms/mortality/*pathology/therapy', 'Methotrexate/administration & dosage', 'Middle Aged', 'Prognosis']",,1985/10/15 00:00,1985/10/15 00:01,['1985/10/15 00:00'],"['1985/10/15 00:00 [pubmed]', '1985/10/15 00:01 [medline]', '1985/10/15 00:00 [entrez]']",['10.1002/1097-0142(19851015)56:8<2078::aid-cncr2820560832>3.0.co;2-0 [doi]'],ppublish,Cancer. 1985 Oct 15;56(8):2078-82. doi: 10.1002/1097-0142(19851015)56:8<2078::aid-cncr2820560832>3.0.co;2-0.,"['04079A1RDZ (Cytarabine)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4027890,NLM,MEDLINE,19851015,20190619,0008-543X (Print) 0008-543X (Linking),56,7,1985 Oct 1,Comparison of peripheral blood lymphocyte C3 receptor capping properties in patients with chronic lymphocytic leukemia and lymphoma.,1538-42,"Bacteria-antibody complexes were used to study capping of receptors for the activated third component of complement on peripheral blood lymphocytes. The impairment of C3d receptor capping improves in patients with chronic lymphocytic leukemia responding to therapy, but this does not necessarily correspond to the fall in peripheral lymphocytosis. Following lymphapheresis, increased capping appears to be due to selective removal of noncapping cells, but the mechanisms of improvement remain unexplained following other therapeutic measures. Lymphoma capping at 37 degrees C was normal in untreated patients but impaired after treatment, suggesting that this is related to the therapy itself. A high proportion of lymphocytes had receptors in the capped configuration in the basal state before incubation. In non-Hodgkin's lymphoma this was unrelated to treatment status, but it occurred only in untreated patients with Hodgkin's lymphoma with no further increment in capping after incubation. These receptors may exist in the aggregated state without the addition of exogenous ligand.","['Hendrick, A M', 'Gormus, B J', 'Leech, S H']","['Hendrick AM', 'Gormus BJ', 'Leech SH']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer,Cancer,0374236,IM,"['*Complement C3', 'Humans', 'Leukemia, Lymphoid/*immunology', 'Lymphocytes/*immunology', 'Lymphoma/*immunology', '*Receptor Aggregation', 'Receptors, Complement/*analysis']",,1985/10/01 00:00,1985/10/01 00:01,['1985/10/01 00:00'],"['1985/10/01 00:00 [pubmed]', '1985/10/01 00:01 [medline]', '1985/10/01 00:00 [entrez]']",['10.1002/1097-0142(19851001)56:7<1538::aid-cncr2820560712>3.0.co;2-9 [doi]'],ppublish,Cancer. 1985 Oct 1;56(7):1538-42. doi: 10.1002/1097-0142(19851001)56:7<1538::aid-cncr2820560712>3.0.co;2-9.,"['0 (Complement C3)', '0 (Receptors, Complement)']",,,"['CA25668/CA/NCI NIH HHS/United States', 'RR00164/RR/NCRR NIH HHS/United States']",,,,,,,,
4027881,NLM,MEDLINE,19851004,20190619,0008-543X (Print) 0008-543X (Linking),56,6,1985 Sep 15,Second malignancies in hairy cell leukemia.,1462-7,"Among 172 patients with hairy cell leukemia (HCL) seen at the University of Chicago over a 10-year period, 15 were found to have a second malignancy. Neoplasia of the skin was noted most frequently; there were three cases of basal cell carcinoma, one case of anaplastic squamous cell carcinoma, and one case of malignant melanoma. This was followed in frequency by three cases of carcinoma of the lung. The clinical characteristics of these 15 patients did not differ from those of the general population of patients with HCL. A variety of second hematologic malignant disorders and solid tumors were identified. In one case, the second neoplasm occurred before the diagnosis of HCL; six were diagnosed concurrently; and eight followed the diagnosis of HCL. Since HCL is a well-defined clinicopathologic entity, patients with HCL who exhibit unusual features of the disease should be investigated further for the presence of second malignancies.","['Jacobs, R H', 'Vokes, E E', 'Golomb, H M']","['Jacobs RH', 'Vokes EE', 'Golomb HM']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,Cancer,Cancer,0374236,IM,"['Adult', 'Aged', 'Female', 'Humans', 'Leukemia, Hairy Cell/blood/*complications', 'Lung Neoplasms/complications', 'Male', 'Middle Aged', '*Neoplasms, Multiple Primary', 'Skin Neoplasms/complications']",,1985/09/15 00:00,1985/09/15 00:01,['1985/09/15 00:00'],"['1985/09/15 00:00 [pubmed]', '1985/09/15 00:01 [medline]', '1985/09/15 00:00 [entrez]']",['10.1002/1097-0142(19850915)56:6<1462::aid-cncr2820560639>3.0.co;2-6 [doi]'],ppublish,Cancer. 1985 Sep 15;56(6):1462-7. doi: 10.1002/1097-0142(19850915)56:6<1462::aid-cncr2820560639>3.0.co;2-6.,,,,['5-P01-CA19266/CA/NCI NIH HHS/United States'],,,,,,,,
4027197,NLM,MEDLINE,19851004,20190704,0007-1048 (Print) 0007-1048 (Linking),60,4,1985 Aug,Prolymphocytic leukemia treated by leukapheresis with relief of respiratory symptoms.,766-8,,"['Shoaf, F', 'Simpkins, H', 'Wilson, A F', 'Armentrout, S A']","['Shoaf F', 'Simpkins H', 'Wilson AF', 'Armentrout SA']",['eng'],"['Case Reports', 'Letter']",England,Br J Haematol,British journal of haematology,0372544,IM,"['Aged', 'Female', 'Humans', '*Leukapheresis', 'Leukemia, Lymphoid/*complications', 'Lung Diseases, Obstructive/*therapy']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1111/j.1365-2141.1985.tb07482.x [doi]'],ppublish,Br J Haematol. 1985 Aug;60(4):766-8. doi: 10.1111/j.1365-2141.1985.tb07482.x.,,,,,,,,,,,,
4026794,NLM,MEDLINE,19850904,20061115,0005-9366 (Print) 0005-9366 (Linking),98,6,1985 Jun 1,[Equine leukosis. 2. Clinical aspects and pathology in our own patients].,202-8,,"['Jaeschke, G', 'Rudolph, R']","['Jaeschke G', 'Rudolph R']",['ger'],"['Case Reports', 'English Abstract', 'Journal Article']",Germany,Berl Munch Tierarztl Wochenschr,Berliner und Munchener tierarztliche Wochenschrift,0003163,IM,"['Animals', 'Horse Diseases/pathology/*physiopathology', 'Horses', 'Humans', 'Leukemia/pathology/physiopathology/*veterinary', 'Lymph Nodes/pathology', 'Male', 'Mediastinum/pathology', 'Mesentery/pathology']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Berl Munch Tierarztl Wochenschr. 1985 Jun 1;98(6):202-8.,,,Die Leukose des Pferdes. 2. Klinik und Pathologie eigener Patienten.,,,,,,,,,
4026623,NLM,MEDLINE,19850923,20190717,0003-9942 (Print) 0003-9942 (Linking),42,9,1985 Sep,Involvement of the nervous system in hairy cell leukemia.,839,,"['Le Bezu, M', 'Pinaudeau, Y', 'Poirier, J', 'Dreyfus, B']","['Le Bezu M', 'Pinaudeau Y', 'Poirier J', 'Dreyfus B']",['eng'],"['Case Reports', 'Letter']",United States,Arch Neurol,Archives of neurology,0372436,IM,"['Adult', 'Brain/*pathology', 'Humans', 'Leukemia, Hairy Cell/*pathology', 'Male']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1001/archneur.1985.04060080017005 [doi]'],ppublish,Arch Neurol. 1985 Sep;42(9):839. doi: 10.1001/archneur.1985.04060080017005.,,,,,,,,,,,,
4026540,NLM,MEDLINE,19850911,20190903,0365-6233 (Print) 0365-6233 (Linking),318,5,1985 May,"[A one-step process for the preparation of gamma-ylidene-alpha,beta-butenolides].",459-64,,"['Reisch, J', 'Mester, Z']","['Reisch J', 'Mester Z']",['ger'],"['English Abstract', 'Journal Article']",Germany,Arch Pharm (Weinheim),Archiv der Pharmazie,0330167,IM,"['4-Butyrolactone/analogs & derivatives', 'Aldehydes/*chemical synthesis/therapeutic use', 'Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Furans/*chemical synthesis/therapeutic use', 'Leukemia P388/drug therapy', 'Mice']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1002/ardp.19853180513 [doi]'],ppublish,Arch Pharm (Weinheim). 1985 May;318(5):459-64. doi: 10.1002/ardp.19853180513.,"['0 (Aldehydes)', '0 (Antineoplastic Agents)', '0 (Furans)', '8KXK25H388 (butenolide)', 'OL659KIY4X (4-Butyrolactone)']",,"Ein einstufiges Verfahren zur Darstellung von gamma-Yliden-alpha,beta-butenoliden.",,,,,,,,,
4026539,NLM,MEDLINE,19850911,20190903,0365-6233 (Print) 0365-6233 (Linking),318,5,1985 May,"Synthesis of 1,5-dihydro-5-(4-methoxyphenyl)-4H-pyrazolo[3,4-d]pyrimidin-4-ones and their ribosides and Mannich bases.",452-9,,"['Finlander, P', 'Pedersen, E B']","['Finlander P', 'Pedersen EB']",['eng'],['Journal Article'],Germany,Arch Pharm (Weinheim),Archiv der Pharmazie,0330167,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Leukemia, Experimental/drug therapy', 'Mannich Bases/chemical synthesis', 'Mice', 'Pyrazoles/*chemical synthesis/therapeutic use', 'Pyrimidinones/*chemical synthesis/therapeutic use']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1002/ardp.19853180512 [doi]'],ppublish,Arch Pharm (Weinheim). 1985 May;318(5):452-9. doi: 10.1002/ardp.19853180512.,"['0 (Antineoplastic Agents)', '0 (Mannich Bases)', '0 (Pyrazoles)', '0 (Pyrimidinones)']",,,,,,,,,,,
4026297,NLM,MEDLINE,19850903,20190629,0003-9861 (Print) 0003-9861 (Linking),240,2,1985 Aug 1,Glutathione changes occurring after S-adenosylhomocysteine hydrolase inhibition.,621-6,"Freshly isolated rat hepatocytes, which metabolize methionine through the cystathionine pathway, and cultured L5178Y cells, which do not, were compared for their response to the inhibition of S-adenosylhomocysteine (SAH) hydrolase (EC 3.3.1.1). When cells were incubated in Fischer's medium lacking cystine but containing 0.67 mM methionine and 10% serum, the addition of periodate-oxidized adenosine (POA), an inhibitor of SAH hydrolase, increased the level of SAH approximately 4-fold in L5178Y cells (5 mM POA) and 30-fold in hepatocytes (1 mM POA). POA treatment also decreased the amount of intracellular glutathione (GSH) in hepatocytes by 6-fold, and in L5178Y cells by 3-fold. Incubation of hepatocytes with adenosine plus homocysteine, 2-chloroadenosine, or 2',3'-acyclic adenosine increased intracellular SAH and also lowered GSH levels. Neither GSH oxidation nor efflux of GSH or GSH conjugates appeared to account for the GSH loss. Intracellular GSH, covalently bound to proteins as mixed disulfides, increased when hepatocytes were incubated with POA, but the increase was insufficient to account for the total GSH loss. In hepatocytes with prelabeled [35S]GSH, POA caused the cellular GSH content to decrease while the specific activity of [35S]GSH remained constant, suggesting that inhibitor treatments that caused elevated SAH levels may have increased the degradation of GSH while GSH synthesis was inhibited.","['Brodie, A E', 'Reed, D J']","['Brodie AE', 'Reed DJ']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Arch Biochem Biophys,Archives of biochemistry and biophysics,0372430,IM,"['Adenosine/metabolism', 'Adenosylhomocysteinase', 'Animals', 'Antigens, Neoplasm/pharmacology', 'Cells, Cultured', 'Cystathionine/metabolism', 'Glutathione/*metabolism', 'Homocysteine/metabolism', 'Hydrolases/*antagonists & inhibitors', 'Leukemia L5178/metabolism', 'Liver/metabolism', 'Male', 'Methionine/metabolism', 'Oxidation-Reduction', 'Rats', 'Rats, Inbred Strains', 'Time Factors']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['0003-9861(85)90069-4 [pii]', '10.1016/0003-9861(85)90069-4 [doi]']",ppublish,Arch Biochem Biophys. 1985 Aug 1;240(2):621-6. doi: 10.1016/0003-9861(85)90069-4.,"['0 (Antigens, Neoplasm)', '0 (oncofetal antigens)', '0LVT1QZ0BA (Homocysteine)', '375YFJ481O (Cystathionine)', 'AE28F7PNPL (Methionine)', 'EC 3.- (Hydrolases)', 'EC 3.3.1.1 (Adenosylhomocysteinase)', 'GAN16C9B8O (Glutathione)', 'K72T3FS567 (Adenosine)']",,,,,,,,,,,
4025817,NLM,MEDLINE,19850829,20190628,0003-2697 (Print) 0003-2697 (Linking),147,1,1985 May 15,Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography.,197-209,"An anion-exchange high-performance liquid chromatography method has been used to quantitate the intracellular purine and pyrimidine nucleotides in extracts of pure lymphocytes, monocytes, neutrophils, eosinophils, erythrocytes, and platelets isolated from the blood of healthy human donors. For accurate and reproducible measurements of the nucleotide profiles in different types of pure leukocytes, the cell suspensions have to be free of platelets and erythrocytes. Incubation of the purified leukocytes for 1 h at 0 degrees C did not alter the nucleotide concentrations but reduced the interdonor variation to 10%. Incubation of purified lymphocytes for 1 h at 37 degrees C caused considerable changes in the relative concentrations of the adenine, guanine, uracil, and cytosine nucleotides. During this incubation the cell viability, the cell number, and the ATP:ADP ratio decreased. Incubation of monocytes and granulocytes for 1 h at 37 degrees C caused considerable loss of cells and/or cell death. For erythrocytes and platelets reproducible nucleotide concentrations were obtained after extraction of freshly isolated cells. During storage of erythrocytes, both at 0 degrees C and at 37 degrees C, a decrease in the ATP:ADP ratio was detected. In all cell types the predominant nucleotides were purine nucleotides, especially adenosine triphosphate. The relative concentrations of the adenine, guanine, uracil, and cytosine nucleotides were very reproducible per cell type and appeared to be characteristic for each cell type. The total nucleotide content was nearly the same for all cell types except erythrocytes, when expressed per microgram of protein. The described methods for purification and storage of blood cells will be useful for comparison of blood cells from healthy donors with those of patients, for example, leukemia patients, in which deviations of the purine and pyrimidine metabolic enzymes have already been described.","['de Korte, D', 'Haverkort, W A', 'van Gennip, A H', 'Roos, D']","['de Korte D', 'Haverkort WA', 'van Gennip AH', 'Roos D']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Anal Biochem,Analytical biochemistry,0370535,IM,"['Blood Cells/*analysis', 'Blood Platelets/analysis', 'Cell Separation/methods', 'Chromatography, High Pressure Liquid', 'Chromatography, Ion Exchange', 'Eosinophils/analysis', 'Erythrocytes/analysis', 'Humans', 'Leukocytes/analysis', 'Lymphocytes/analysis', 'Monocytes/analysis', 'Neutrophils/analysis', 'Nucleotides/*blood', 'Purine Nucleotides/blood', 'Pyrimidine Nucleotides/blood', 'Specimen Handling']",,1985/05/15 00:00,1985/05/15 00:01,['1985/05/15 00:00'],"['1985/05/15 00:00 [pubmed]', '1985/05/15 00:01 [medline]', '1985/05/15 00:00 [entrez]']","['0003-2697(85)90028-4 [pii]', '10.1016/0003-2697(85)90028-4 [doi]']",ppublish,Anal Biochem. 1985 May 15;147(1):197-209. doi: 10.1016/0003-2697(85)90028-4.,"['0 (Nucleotides)', '0 (Purine Nucleotides)', '0 (Pyrimidine Nucleotides)']",,,,,,,,,,,
4025342,NLM,MEDLINE,19850919,20190829,0271-3586 (Print) 0271-3586 (Linking),8,1,1985,Benzene as a leukemogenic and carcinogenic agent.,9-20,"Today there seems to be sufficient data to incriminate benzene as a potent carcinogenic agent causing leukemia, malignant lymphoma, multiple myeloma and lung cancer, as well as numerous disorders of the bone marrow depression. Other factors (such as genetic and individual susceptibility) may have a role in the development of these different types of malignancies and hematologic disorders. In this paper, data concerning all these problems are presented and discussed.","['Aksoy, M']",['Aksoy M'],['eng'],['Journal Article'],United States,Am J Ind Med,American journal of industrial medicine,8101110,IM,"['Benzene/*adverse effects', 'Hodgkin Disease/chemically induced', 'Humans', 'Leukemia/*chemically induced/epidemiology/genetics', 'Lung Neoplasms/chemically induced', 'Lymphoma/*chemically induced', 'Multiple Myeloma/chemically induced', 'Occupational Diseases/chemically induced', 'Pancytopenia/chemically induced', 'Time Factors']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1002/ajim.4700080103 [doi]'],ppublish,Am J Ind Med. 1985;8(1):9-20. doi: 10.1002/ajim.4700080103.,['J64922108F (Benzene)'],,,,,,,,,,,
4025339,NLM,MEDLINE,19850919,20190829,0271-3586 (Print) 0271-3586 (Linking),8,1,1985,A proportional mortality study of the acting profession.,57-66,"Proportional mortality of actors and actresses was studied because cancers of many sites have been linked to hair dyes and cosmetics of which actors have been frequent users. Death records (1950-1978) for 2,618 white male and 838 white female members of Actors Equity and the Screen Actors Guild were compared with the U.S. mortality rats. Among males, significantly elevated proportional mortality ratios (PMR) were found for suicide (1.58), cirrhosis of the liver (1.99), all malignancies (1.15), and cancers of the colon/rectum (1.32), pancreas (1.51), and testes (2.37). Colon/rectum and pancreas cancers were not significantly elevated by proportional cancer mortality. Among females, significantly elevated PMRs were found for suicide (2.02) and lung cancer (2.20). Suicide in either sex was much more common in California than in New York. The elevated lung cancer in females was confined to Equity members. No elevations were found for cancers that have been related to hair dye or cosmetic use--ie, breast, ovary, bladder, leukemia, and lymphomas.","['Depue, R H', 'Kagey, B T', 'Heid, M F']","['Depue RH', 'Kagey BT', 'Heid MF']",['eng'],['Journal Article'],United States,Am J Ind Med,American journal of industrial medicine,8101110,IM,"['Cosmetics/adverse effects', 'Drama', 'Female', 'Hair Preparations/adverse effects', 'Humans', 'Male', 'Neoplasms/chemically induced/*mortality', 'Occupational Diseases/*mortality', 'Smoking', 'Suicide/epidemiology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1002/ajim.4700080108 [doi]'],ppublish,Am J Ind Med. 1985;8(1):57-66. doi: 10.1002/ajim.4700080108.,"['0 (Cosmetics)', '0 (Hair Preparations)']",,,,,,,,,,,
4025323,NLM,MEDLINE,19850926,20190820,0361-8609 (Print) 0361-8609 (Linking),20,1,1985 Sep,More on biphenotypic leukemias and the 5q-syndrome.,91-2,,"['Haubenstock, A', 'Pipala, J H', 'Zalusky, R']","['Haubenstock A', 'Pipala JH', 'Zalusky R']",['eng'],"['Case Reports', 'Letter']",United States,Am J Hematol,American journal of hematology,7610369,IM,"['Acute Disease', 'Aged', '*Chromosome Deletion', '*Chromosomes, Human, 4-5', 'Female', 'Humans', 'Leukemia/*genetics']",,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1002/ajh.2830200114 [doi]'],ppublish,Am J Hematol. 1985 Sep;20(1):91-2. doi: 10.1002/ajh.2830200114.,,,,,,,,,,,,
4025317,NLM,MEDLINE,19850828,20190820,0361-8609 (Print) 0361-8609 (Linking),19,4,1985 Aug,Salmonella infection in hairy cell leukemia: report of a case.,423-5,"A patient with hairy cell leukemia who developed mediastinal mass and fever is described. A CT-guided aspiration of the mass yielded Salmonella tiphymurium. Granulocyte response to infection was intact and could explain the favorable course of this unusual Salmonella infection. Although several reports deal with salmonellosis as a complication of immunodeficiency states, this type of infection is of rare occurrence in hairy cell leukemia.","['Tilly, H', 'Gardembas, M', 'Berry, M', 'Gray, C', 'Monconduit, M', 'Piguet, H']","['Tilly H', 'Gardembas M', 'Berry M', 'Gray C', 'Monconduit M', 'Piguet H']",['eng'],"['Case Reports', 'Journal Article']",United States,Am J Hematol,American journal of hematology,7610369,IM,"['Humans', 'Leukemia, Hairy Cell/*complications/immunology', 'Male', 'Middle Aged', 'Salmonella Infections/*etiology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1002/ajh.2830190414 [doi]'],ppublish,Am J Hematol. 1985 Aug;19(4):423-5. doi: 10.1002/ajh.2830190414.,,,,,,,,,,,,
4024602,NLM,MEDLINE,19850924,20091111,0506-2772 (Print) 0506-2772 (Linking),24,1,1985,[Invasive aspergillosis in patients who died from acute leukemia].,127-33,"The necropsy material with acute leukosis (166 deceased) was studied in order to establish the incidence of invasive aspergillosis. It was established in 16 of the deceased (9,64%): aspergillosis pneumonia--in 5 cases, aspergillosis sepsis--in II, with invasion of lungs, brain, spleen, liver, myocardium and other organs. Clinically aspergillosis was not distinguished. Continuous septic temperature, not influenced by antibiotic therapy should draw the attention to the presence of aspergillosis. The factors, preconditioning aspergillosis infection are stressed upon: immune-suppressive treatment in acute leukosis, granulocytopenia, continuous preceding antibiotic therapy, etc. The difficulties in the clinical differentiation of the infection are emphasized. With a view to the high incidence and lethality of aspergillosis in acute leukosis, the introduction of modern diagnostic methods and treatment are underlined to be necessary.","['Gerdzhikova, P', 'Krustev, D', 'Georgieva, B']","['Gerdzhikova P', 'Krustev D', 'Georgieva B']",['bul'],"['English Abstract', 'Journal Article']",Bulgaria,Vutr Boles,Vutreshni bolesti,0032666,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aspergillosis/diagnosis/*pathology', 'Humans', 'Leukemia/complications/*pathology', 'Lung Diseases, Fungal/diagnosis/pathology', 'Pneumonia/diagnosis/pathology', 'Prospective Studies', 'Retrospective Studies']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vutr Boles. 1985;24(1):127-33.,,,Invazivna aspergiloza u pochinali s ostra levkoza.,,,,,,,,,
4024564,NLM,MEDLINE,19850919,20061115,0507-3758 (Print) 0507-3758 (Linking),31,7,1985,[Central nervous system lesions in leukemia in children].,73-6,"Initial morphologic manifestations of neuroleukemia consisted in tumor cell infiltration of the fat tissue of the epidural space (mainly, the lumbar region of the spine) and dura and pia mater spinalis. Leukemia infiltration of the central nervous system was due to tumor cell migration from the bone marrow via perivascular spaces.","[""Vasil'ev, A V""]","[""Vasil'ev AV""]",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Vopr Onkol,Voprosy onkologii,0413775,IM,"['Child', 'Humans', 'Leukemia/*pathology', 'Sella Turcica/pathology', 'Spinal Cord/pathology', 'Spinal Cord Neoplasms/pathology/*secondary', 'Spinal Neoplasms/pathology/secondary', 'Spine/pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vopr Onkol. 1985;31(7):73-6.,,,Porazhenie tsentral'noi nervnoi sistemy pri leikozakh u detei.,,,,,,,,,
4024549,NLM,MEDLINE,19850828,20131121,0507-3758 (Print) 0507-3758 (Linking),31,6,1985,[Effect of age on carcinogenesis in female rats induced by methyl (acetoxymethyl) nitrosamine].,68-73,"A single intraperitoneal injection of methyl-acetoxymethyl-nitrosamine produced tumors in 85.7% of 3 month-old female rats and in 62.5% of 14 month-old ones matched by 26.5% in controls. Intestinal tumors developed most frequently. Also, tumors of the pituitary, thyroid, breast, uterus as well as leukemia were detected. Multiple intestinal tumors were more frequent in the young age group (1.43 and 1.00), tumor-free interval in older animals being 217 days longer. Studies on DNA alkylation and repair were carried out using intraperitoneal injections of 14C-methyl-acetoxymethyl-nitrosamine. Young animals showed higher levels of methylpurines in organ tissues other than those of small intestine 3 hrs after treatment. The rate of methylpurine excretion in young rats was higher, too. However, liver tissue of old rats showed a higher rate of O6-methylguanine repair than that in younger ones.","['Anisimov, V N', 'Likhachev, A Ia', 'Ovsiannikov, A I']","['Anisimov VN', 'Likhachev AIa', 'Ovsiannikov AI']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Vopr Onkol,Voprosy onkologii,0413775,IM,"['Aging/*drug effects', 'Alkylation', 'Animals', 'Carcinogens/metabolism/*toxicity', 'DNA, Neoplasm/metabolism', 'Dimethylnitrosamine/*analogs & derivatives/metabolism/toxicity', 'Male', 'Methylation', 'Neoplasms, Experimental/*chemically induced/metabolism', 'Purines/metabolism', 'Rats', 'Time Factors', 'Tissue Distribution']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Vopr Onkol. 1985;31(6):68-73.,"['0 (Carcinogens)', '0 (DNA, Neoplasm)', '0 (Purines)', '56856-83-8 (methyl(acetoxymethyl)nitrosamine)', 'M43H21IO8R (Dimethylnitrosamine)']",,"Vliianie vozrasta na kantserogenez, indutsirovannyi u samok krys metilatsetoksimetilnitrozaminom.",,,,,,,,,
4024421,NLM,MEDLINE,19850904,20190702,0042-4900 (Print) 0042-4900 (Linking),116,21,1985 May 25,Eosinophilic leukaemia in the cat: a case report.,567,,"['Finlay, D']",['Finlay D'],['eng'],"['Case Reports', 'Journal Article']",England,Vet Rec,The Veterinary record,0031164,IM,"['Animals', 'Cat Diseases/*blood', 'Cats', 'Eosinophils', 'Leukemia/blood/*veterinary', 'Leukocyte Count/veterinary', 'Male']",,1985/05/25 00:00,1985/05/25 00:01,['1985/05/25 00:00'],"['1985/05/25 00:00 [pubmed]', '1985/05/25 00:01 [medline]', '1985/05/25 00:00 [entrez]']",['10.1136/vr.116.21.567 [doi]'],ppublish,Vet Rec. 1985 May 25;116(21):567. doi: 10.1136/vr.116.21.567.,,,,,,,,,,,,
4024369,NLM,MEDLINE,19850917,20091111,0041-6959 (Print) 0041-6959 (Linking),114,6,1985 Jun,"[Familial cancer. 2. The S.B.L.A. syndrome: sarcoma of the breast, brain, leukemia and adrenals].",476-80,,"['Philippe, P']",['Philippe P'],['fre'],"['English Abstract', 'Journal Article']",Canada,Union Med Can,L'union medicale du Canada,0030444,IM,"['Adenocarcinoma/genetics', 'Adult', 'Brain Neoplasms/genetics', 'Breast Neoplasms/genetics', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/diagnosis/etiology/*genetics', 'Rhabdomyosarcoma/genetics', 'Risk', 'Syndrome']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Union Med Can. 1985 Jun;114(6):476-80.,,,Le cancer familial. 2. Le syndrome S.B.L.A.,,,,,,,,,
4024280,NLM,MEDLINE,19850903,20171213,0300-8916 (Print) 0300-8916 (Linking),71,3,1985 Jun 30,Inhibition of macromolecular synthesis in P388 mouse leukemia ascites cells by bouvardin (NSC 259968).,261-6,"Bouvardin, a new antineoplastic plant product, inhibits macromolecular synthesis in P388 cells in a dose-dependent manner. At the same concentration of bouvardin, protein synthesis was inhibited to a greater extent than the synthesis of DNA and RNA. There was a reversal of inhibition of both DNA and RNA synthesis after the cells were washed free of bouvardin. However, there was partial reversal of inhibition of protein synthesis when the cells were washed free of the drug.","['Chitnis, M', 'Menon, R', 'Adwankar, M', 'Satyamoorthy, K']","['Chitnis M', 'Menon R', 'Adwankar M', 'Satyamoorthy K']",['eng'],['Journal Article'],United States,Tumori,Tumori,0111356,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*pharmacology', 'DNA, Neoplasm/*biosynthesis', 'Depression, Chemical', 'Dose-Response Relationship, Drug', 'Leucine/metabolism', 'Leukemia P388/drug therapy/*metabolism', 'Leukemia, Experimental/*metabolism', 'Mice', 'Mice, Inbred DBA', 'Neoplasm Proteins/*biosynthesis', 'Peptides, Cyclic/*pharmacology', 'RNA, Neoplasm/*biosynthesis', 'Thymidine/metabolism', 'Uridine/metabolism']",,1985/06/30 00:00,1985/06/30 00:01,['1985/06/30 00:00'],"['1985/06/30 00:00 [pubmed]', '1985/06/30 00:01 [medline]', '1985/06/30 00:00 [entrez]']",,ppublish,Tumori. 1985 Jun 30;71(3):261-6.,"['0 (Antineoplastic Agents, Phytogenic)', '0 (DNA, Neoplasm)', '0 (Neoplasm Proteins)', '0 (Peptides, Cyclic)', '0 (RNA, Neoplasm)', '22AY1D3UAX (bouvardin)', 'GMW67QNF9C (Leucine)', 'VC2W18DGKR (Thymidine)', 'WHI7HQ7H85 (Uridine)']",,,,,,,,,,,
4024279,NLM,MEDLINE,19850903,20171213,0300-8916 (Print) 0300-8916 (Linking),71,3,1985 Jun 30,"Trends in cancer mortality in Italy, 1955-1978.",201-18,"Trends in age-specific and age-standardized cancer death certification rates in Italy from 1955 to 1978 were analyzed. In males total cancer mortality rates increased in all age groups. However, when respiratory and other tobacco-related neoplasms were excluded, death certification rates were roughly stable up to age 64. Moderate decreases in overall cancer mortality have been apparent at younger ages (35-44) since the early 1970's. In females, all the age-specific and the age standardized, under-65 death certification rates decreased; the downward trends were more pronounced (-18.5%) in the younger age group considered (35-44 years). Respiratory cancer mortality increased sharply in males: lung cancer death rates reached a plateau in the early 1970's in the 35-44-year age group, but increased at all subsequent ages. In females, the increase in lung cancer mortality was about 50% in the 45-54 and 55-64-year age groups, but no upward trend was evident in younger women. Other tobacco-related cancers (mouth or pharynx, larynx, esophagus, pancreas, kidney and bladder) also rose considerably. In both sexes, gastric cancer mortality dropped about 50% below age 65, but mortality rates from cancer of the stomach were still considerably higher than in other Western countries. Likewise, mortality from cancer of the (cervix) uteri decreased markedly, mostly in younger age groups. Upward trends in death certification rates were evident for cancers of the bowel (colon and rectum, about 50% in males, and 35% in females below age 65), and of the breast in females. However, these trends have levelled off since the late 1960's, at least in the younger age groups. Certified death rates from cancer of the skin (melanoma) increased over all the periods considered in the young of both sexes. Cancer mortality rates showed marked increases in older (greater than or equal to 65) males, but this can be partially explained in terms of better case ascertainment and more accurate death certification.","['La Vecchia, C', 'Decarli, A']","['La Vecchia C', 'Decarli A']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,Tumori,Tumori,0111356,IM,"['Adult', 'Age Factors', 'Aged', 'Brain Neoplasms/mortality', 'Digestive System Neoplasms/mortality', 'Female', 'Genital Neoplasms, Female/mortality', 'Genital Neoplasms, Male/mortality', 'Humans', 'Italy', 'Leukemia/mortality', 'Lung Neoplasms/mortality', 'Male', 'Middle Aged', 'Neoplasms/*mortality', 'Pleural Neoplasms/mortality', 'Sex Factors', 'Skin Neoplasms/mortality', 'Smoking', 'Stomach Neoplasms/mortality', 'Urologic Neoplasms/mortality']",,1985/06/30 00:00,1985/06/30 00:01,['1985/06/30 00:00'],"['1985/06/30 00:00 [pubmed]', '1985/06/30 00:01 [medline]', '1985/06/30 00:00 [entrez]']",,ppublish,Tumori. 1985 Jun 30;71(3):201-18.,,,,,"['IND: 9014523', 'POP: 00153947']",,,['PIP'],"['*Age Factors', '*Cancer', '*Causes Of Death', 'Demographic Factors', 'Developed Countries', '*Differential Mortality', 'Diseases', 'Europe', 'Italy', 'Mediterranean Countries', '*Mortality', 'Neoplasms', 'Population', 'Population Characteristics', 'Population Dynamics', '*Research Report', 'Respiratory Insufficiency', '*Sex Factors', 'Smoking', '*Southern Europe']",['PIP: TJ: TUMORI'],,
4024076,NLM,MEDLINE,19850919,20190727,0040-8727 (Print) 0040-8727 (Linking),145,4,1985 Apr,Immunoprotective capability of somatic hybrid cells in comparison with parental tumor cells maintained in vitro.,447-53,"The immunogenicity of X-irradiated hybrid cells derived from fusion of ASL-1 leukemia (A origin) and LM (TK-) fibroblasts (C3H origin) was compared to X-irradiated parental ASL-1 leukemia cells maintained in vivo (V-ASL-1) and to X-irradiated ASL-1 leukemia cells maintained in vitro (C-ASL-1). Immunization with hybrid cells induced transplantation resistance against tumor rechallenge with V-ASL-1 more effectively than did immunization with V-ASL-1 tumor cells. Immunization with X-irradiated C-ASL-1 cells produced the same, or slightly stronger level of transplantation resistance than that with X-irradiated hybrid cells. These findings were observed both in A/J and in (C3H/HeJ X A/J)F1 mice. These results raise a question about whether the apparent increased immunogenicity of hybrid cells is due to a result of cell fusion or a result of their growth in vitro.","['Mizushima, Y', 'Cohen, E P']","['Mizushima Y', 'Cohen EP']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",Japan,Tohoku J Exp Med,The Tohoku journal of experimental medicine,0417355,IM,"['Animals', 'Cells, Cultured/radiation effects', 'Hybrid Cells/*immunology/radiation effects', 'Immunization', 'Leukemia, Experimental/*immunology', 'Mice', 'Mice, Inbred A', 'Mice, Inbred C3H', 'Neoplasm Transplantation', 'Transplantation Immunology']",,1985/04/01 00:00,1985/04/01 00:01,['1985/04/01 00:00'],"['1985/04/01 00:00 [pubmed]', '1985/04/01 00:01 [medline]', '1985/04/01 00:00 [entrez]']",['10.1620/tjem.145.447 [doi]'],ppublish,Tohoku J Exp Med. 1985 Apr;145(4):447-53. doi: 10.1620/tjem.145.447.,,,,['CA 27579-04/CA/NCI NIH HHS/United States'],,,,,,,,
4023936,NLM,MEDLINE,19850923,20041117,0040-3660 (Print) 0040-3660 (Linking),57,5,1985,[Secondary pneumonia--an old and new problem].,20-3,,"['Gogin, E E']",['Gogin EE'],['rus'],['Journal Article'],Russia (Federation),Ter Arkh,Terapevticheskii arkhiv,2984818R,IM,"['Humans', 'Ischemia/complications', 'Leukemia/complications', 'Lung/blood supply', 'Military Medicine', 'Pneumonia, Pneumococcal/*etiology', 'Pulmonary Embolism/complications', 'Wounds and Injuries/complications']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Ter Arkh. 1985;57(5):20-3.,,,Vtorichnye pnevmonii--staraia i novaia problema.,,,,,,,,,
4023630,NLM,MEDLINE,19850826,20190818,0300-9475 (Print) 0300-9475 (Linking),21,6,1985 Jun,"In vivo activation of mouse macrophages with beta-1,3-D-glucan-derivatized plastic beads.",601-5,"Macrophages obtained from animals treated with beta-1,3-D-glucan-derivatized plastic beads were greatly stimulated, as judged by morphology, esterase release, and cytostatic effect on L-929 tumour cells in vitro. The pretreatment of mice with such beads conferred an apparent absolute local resistance to an otherwise lethal pneumococcal infection but had no effect on the growth of intraperitoneal AA ascites sarcoma. Moreover, peritoneal cells from animals pretreated with glucan beads did not protect the animals in a Winn assay.","['Seljelid, R', 'Bogwald, J', 'Rasmussen, L T', 'Larm, O', 'Hoffman, J', 'Berge, A', 'Ugelstad, J']","['Seljelid R', 'Bogwald J', 'Rasmussen LT', 'Larm O', 'Hoffman J', 'Berge A', 'Ugelstad J']",['eng'],['Journal Article'],England,Scand J Immunol,Scandinavian journal of immunology,0323767,IM,"['Animals', 'Cell Division', 'Cell Line', 'Esterases/metabolism', 'Glucans/*administration & dosage', 'Leukemia/pathology/therapy', 'Macrophage Activation/*drug effects', 'Macrophages/enzymology/*immunology/ultrastructure', 'Melanoma/therapy', 'Mice', 'Mice, Inbred C57BL', 'Microspheres', 'Pneumococcal Infections/therapy', '*beta-Glucans']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",['10.1111/j.1365-3083.1985.tb01850.x [doi]'],ppublish,Scand J Immunol. 1985 Jun;21(6):601-5. doi: 10.1111/j.1365-3083.1985.tb01850.x.,"['0 (Glucans)', '0 (beta-Glucans)', '9051-97-2 (beta-1,3-glucan)', 'EC 3.1.- (Esterases)']",,,,,,,,,,,
4023526,NLM,MEDLINE,19850827,20190829,0162-0886 (Print) 0162-0886 (Linking),7,3,1985 May-Jun,Bacteremia caused by Aeromonas species in hospitalized cancer patients.,314-20,"Bacteremia caused by Aeromonas species occurred in 24 hospitalized patients in a cancer institute during a 13-year period. All but one of these patients had a malignancy (88% had leukemia), and most were receiving chemotherapy for cancer. There was a striking numerical predominance of male patients (82%). Unlike some previously described patients with infections due to this organism, none of these 24 patients had recently been exposed to fresh or salt water or to fish. The source of the infecting organism was thought to be endogenous--i.e., from patients' own gastrointestinal tracts. The clinical presentation of sepsis caused by this organism was nonspecific, except that ecthyma gangrenosum occurred in several patients. The overall mortality rate was 28%. The combination of an aminoglycoside and a cephalosporin is appropriate therapy for bacteremia caused by Aeromonas species.","['Harris, R L', 'Fainstein, V', 'Elting, L', 'Hopfer, R L', 'Bodey, G P']","['Harris RL', 'Fainstein V', 'Elting L', 'Hopfer RL', 'Bodey GP']",['eng'],['Journal Article'],United States,Rev Infect Dis,Reviews of infectious diseases,7905878,IM,"['Acute Disease', 'Adolescent', 'Adult', 'Aeromonas', 'Aged', 'Aminoglycosides/therapeutic use', 'Bacterial Infections/*complications/drug therapy', 'Cephalosporins/therapeutic use', 'Chronic Disease', 'Female', 'Hospitalization', 'Humans', 'Leukemia/complications', 'Male', 'Middle Aged', 'Neoplasms/*complications', 'Prognosis', 'Sepsis/*complications/drug therapy']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.1093/clinids/7.3.314 [doi]'],ppublish,Rev Infect Dis. 1985 May-Jun;7(3):314-20. doi: 10.1093/clinids/7.3.314.,"['0 (Aminoglycosides)', '0 (Cephalosporins)']",,,,,,,,,,,
4023415,NLM,MEDLINE,19850919,20131121,0034-5164 (Print) 0034-5164 (Linking),48,2,1985 May,Effects of calcium and verapamil on normal and tumor murine leukocytes.,305-8,"Although no differences in membrane stabilization by calcium were noted between leukemic (P-388) and normal murine leukocytes, tumor cells were shown to be more resistant to damage by ethanol but not by desmethylchlorpromazine. Furthermore, verapamil protected tumor cells but not normal cells against the disruptive effect of desmethylchlorpromazine but not that of ethanol. The protective action of verapamil was evident even in the absence of calcium. Thus leukemic cells appear to be altered so that the effects of certain membrane active agents are changed but the membrane stabilizing function of calcium is normal.","['Borowitz, J L', 'Hadley, R', 'Stebbins, G']","['Borowitz JL', 'Hadley R', 'Stebbins G']",['eng'],['Journal Article'],United States,Res Commun Chem Pathol Pharmacol,Research communications in chemical pathology and pharmacology,0244734,IM,"['Animals', 'Calcium/*pharmacology', 'Chlorpromazine/analogs & derivatives/toxicity', 'Ethanol/toxicity', 'Leukemia P388/*blood', 'Leukemia, Experimental/*blood', 'Leukocytes/*drug effects', 'Mice', 'Verapamil/*pharmacology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Res Commun Chem Pathol Pharmacol. 1985 May;48(2):305-8.,"['3K9958V90M (Ethanol)', 'CJ0O37KU29 (Verapamil)', 'O1G7LW1I5H (norchlorpromazine)', 'SY7Q814VUP (Calcium)', 'U42B7VYA4P (Chlorpromazine)']",,,,,,,,,,,
4023301,NLM,MEDLINE,19850924,20071115,0379-1629 (Print) 0379-1629 (Linking),10,2,1985 May,[Evaluation of the chronic lymphocytic leukemias].,93-7,,"['Altafulla, M', 'Vasquez de Bernal, J']","['Altafulla M', 'Vasquez de Bernal J']",['spa'],"['English Abstract', 'Journal Article']",Panama,Rev Med Panama,Revista medica de Panama,7706654,IM,"['Aged', 'Antigen-Antibody Complex/analysis', 'Female', 'Hemoglobins/analysis', 'Humans', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/blood/*immunology/pathology', 'Leukocyte Count', 'Lymphocytes/classification', 'Male', 'Middle Aged', 'Platelet Count', 'Prognosis']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Rev Med Panama. 1985 May;10(2):93-7.,"['0 (Antigen-Antibody Complex)', '0 (Hemoglobins)', '0 (Immunoglobulins)']",,Evaluacion de las leucemias linfociticas cronicas.,,,,,,,,,
4023032,NLM,MEDLINE,19850828,20191030,0031-7144 (Print) 0031-7144 (Linking),40,3,1985 Mar,Novel bis(5-arylamino-2-oxo-4-thiazolidinylidene)hydrazine derivatives as potential antineoplastic agents.,174-6,"A new series of N,N'-bis(5-arylamino-3-benzyl-2-oxo-4-thiazolidinylidene)hydrazine s has been prepared for potential anticancer activity. The synthesis was achieved by reacting 3-benzylthiazolidin-2-one-4-thione with its 4-hydrazone derivative to give N,N'-bis(3-benzyl-2-oxo-4-thiazolidinylidene)hydrazine, which was subjected to dibromination followed by reaction with various primary aromatic amines. Some compounds were evaluated against leukemia P 388 in the mouse. No significant antitumor activity was observed.","['Salama, H M', 'Eshba, N H']","['Salama HM', 'Eshba NH']",['eng'],['Journal Article'],Germany,Pharmazie,Die Pharmazie,9800766,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Chemical Phenomena', 'Chemistry', 'Hydrazines/*chemical synthesis/therapeutic use', 'Leukemia P388/drug therapy', 'Mice', 'Thiazoles/*chemical synthesis/therapeutic use']",,1985/03/01 00:00,1985/03/01 00:01,['1985/03/01 00:00'],"['1985/03/01 00:00 [pubmed]', '1985/03/01 00:01 [medline]', '1985/03/01 00:00 [entrez]']",['10.1002/chin.198535187 [doi]'],ppublish,Pharmazie. 1985 Mar;40(3):174-6. doi: 10.1002/chin.198535187.,"['0 (Antineoplastic Agents)', '0 (Hydrazines)', '0 (Thiazoles)']",,,,,,,,,,,
4022983,NLM,MEDLINE,19850919,20131121,0361-7742 (Print) 0361-7742 (Linking),181,,1985,Forecast of antibiotic susceptibility of translocating strains of enterobacteria and pseudomonas in leukemic neutropenic patients.,275-7,,"['Tancrede, C H', 'Andremont, A O']","['Tancrede CH', 'Andremont AO']",['eng'],['Journal Article'],United States,Prog Clin Biol Res,Progress in clinical and biological research,7605701,IM,"['Agranulocytosis/*microbiology', 'Amikacin/pharmacology', 'Ampicillin/pharmacology', 'Anti-Bacterial Agents/*pharmacology', 'Cefotaxime/pharmacology', 'Enterobacteriaceae/*drug effects', 'Feces/microbiology', 'Gentamicins/pharmacology', 'Humans', 'Leukemia/*complications', 'Microbial Sensitivity Tests', 'Neutropenia/etiology/*microbiology', 'Pseudomonas/*drug effects']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Prog Clin Biol Res. 1985;181:275-7.,"['0 (Anti-Bacterial Agents)', '0 (Gentamicins)', '7C782967RD (Ampicillin)', '84319SGC3C (Amikacin)', 'N2GI8B1GK7 (Cefotaxime)']",,,,,,,,,,,
4022840,NLM,MEDLINE,19850923,20061115,0344-0338 (Print) 0344-0338 (Linking),179,6,1985 May,Nuclear chromatin condensation of mouse lymphoma (L-1210) cells by methylnitrosourea. An electron microscopic and biochemical study.,634-44,"When the mouse lymphoma (L-1210) cells are treated with methylnitrosourea (MNU) at 37 degrees C for 30 min and then cultured for 4 h in a normal medium nuclear structure and functions of the cells are changed. We have investigated the mechanism as to how nuclear structure and functions are changed by MNU. In MNU-treated cells euchromatin area diminishes and chromatin condensation occurs. [3H]thymidine and [3H]uridine uptakes of the MNU-treated cells decrease. In contrast, when the MNU-treated cells are cultured in the presence of 3-aminobenzamide, a specific inhibitor of poly(ADP-ribose) synthetase changes of nuclear structure do not appear. [3H]Thymidine and [3H]uridine uptakes are partially and almost completely recovered, respectively. Autoradiographs of the cells labelled with [3H]NAD, a substrate of poly(ADP-ribose) synthetase show that silver grains due to [3H]ADP-ribose are densely located only in the cells where chromatin condensation occurs. Chromatin-bound proteins of molecular masses 20-25 X 10(3) daltons are specifically poly(ADP-ribosyl)ated in the MNU-treated cells. These results suggest that MNU-induced chromatin condensation is caused by poly(ADP-ribosyl)ation of chromatinbound proteins.","['Enzan, H', 'Hara, H', 'Taniguchi, T', 'Shizuta, Y']","['Enzan H', 'Hara H', 'Taniguchi T', 'Shizuta Y']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",Germany,Pathol Res Pract,"Pathology, research and practice",7806109,IM,"['Animals', 'Cell Nucleus/drug effects/metabolism/ultrastructure', 'Cells, Cultured', 'Chromatin/drug effects/*metabolism/ultrastructure', 'Leukemia L1210/metabolism/*pathology', 'Methylnitrosourea/*pharmacology', 'Mice', 'Microscopy, Electron', 'Nitrosourea Compounds/*pharmacology']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']","['S0344-0338(85)80210-7 [pii]', '10.1016/S0344-0338(85)80210-7 [doi]']",ppublish,Pathol Res Pract. 1985 May;179(6):634-44. doi: 10.1016/S0344-0338(85)80210-7.,"['0 (Chromatin)', '0 (Nitrosourea Compounds)', '684-93-5 (Methylnitrosourea)']",,,,,,,,,,,
4022828,NLM,MEDLINE,19850919,20080620,0032-3756 (Print) 0032-3756 (Linking),40,20,1985 May 20,[Sedimentation leukapheresis in the treatment of resistant forms of lymphocytic leukemia].,561-3,,"['Gola, A', 'Partyka, T', 'Werynska, B', 'Muszynska, M']","['Gola A', 'Partyka T', 'Werynska B', 'Muszynska M']",['pol'],"['Case Reports', 'English Abstract', 'Journal Article']",Poland,Pol Tyg Lek,"Polski tygodnik lekarski (Warsaw, Poland : 1960)",9705468,IM,"['Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Drug Resistance', 'Humans', 'Leukapheresis/*methods', 'Leukemia, Lymphoid/*therapy', 'Male', 'Middle Aged']",,1985/05/20 00:00,1985/05/20 00:01,['1985/05/20 00:00'],"['1985/05/20 00:00 [pubmed]', '1985/05/20 00:01 [medline]', '1985/05/20 00:00 [entrez]']",,ppublish,Pol Tyg Lek. 1985 May 20;40(20):561-3.,,,Leukafereza sedymentacyjna w leczeniu opornych postaci przewleklej bialaczki limfatycznej.,,,,,,,,,
4022799,NLM,MEDLINE,19850924,20170306,,73,2,1985 Feb,[Hypereosinophilia syndrome or eosinophilic leukemia?].,123-7,,"['Przybylowski, J', 'Hanski, W', 'Stefanowa-Urbaniak, A', 'Siedlecki, J']","['Przybylowski J', 'Hanski W', 'Stefanowa-Urbaniak A', 'Siedlecki J']",['pol'],"['Comparative Study', 'English Abstract', 'Journal Article']",Poland,Pol Arch Med Wewn,Polskie Archiwum Medycyny Wewnetrznej,0401225,IM,"['Bone Marrow/pathology', 'Diagnosis, Differential', 'Eosinophilia/*diagnosis', 'Eosinophils/pathology', 'Humans', 'Leukemia/*diagnosis', 'Leukocyte Count']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']",,ppublish,Pol Arch Med Wewn. 1985 Feb;73(2):123-7.,,,"Zespol hipereozynofilii, czy bialaczka eozynochlonna?",,,,,,,,,
4021681,NLM,MEDLINE,19850830,20211203,0023-852X (Print) 0023-852X (Linking),95,8,1985 Aug,Invasive Aspergillus of the head and neck.,898-9,Invasive fungal infections of the head and neck are uncommon. The most common organism is Mucor which is classically seen in diabetic individuals in or immediately after a bout of ketoacidosis. This report outlines our experience of four cases of invasive fungal disease caused by the Aspergillus species. All four patients in this series were profoundly granulocytopenic. Three of the four patients remained profoundly immunocompromised and succumbed to infections. One patient recovered immune competence and became a long term survivor after antifungal chemotherapy and debridement of necrotic tissue. The literature on invasive Aspergillus of the head and neck is reviewed. Some recent insights in the medicine literature concerning the epidemiology of the more common pulmonary form of this invasive disease are also discussed.,"['Colman, M F']",['Colman MF'],['eng'],"['Case Reports', 'Journal Article']",United States,Laryngoscope,The Laryngoscope,8607378,IM,"['Adult', 'Agranulocytosis/complications', 'Anemia, Aplastic/complications', 'Antifungal Agents/therapeutic use', 'Aspergillosis/*diagnosis/etiology/therapy', 'Debridement', 'Female', '*Head', 'Humans', 'Immunosuppression Therapy/adverse effects', 'Leukemia/complications', 'Male', 'Middle Aged', '*Neck', 'Nose Diseases/diagnosis/etiology/therapy']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1288/00005537-198508000-00002 [doi]'],ppublish,Laryngoscope. 1985 Aug;95(8):898-9. doi: 10.1288/00005537-198508000-00002.,['0 (Antifungal Agents)'],,,,,,,,,,,
4021540,NLM,MEDLINE,19850903,20190824,0145-2126 (Print) 0145-2126 (Linking),9,7,1985,Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.,935-9,"We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxicity assay. Direct cytotoxic tests and competitive inhibition tests using tumor cells such as P388, LS-1 and L5178Y as target or inhibitor cells showed that the cell-mediated immunity is specific to L1210 leukemia. In the process of this study, we found that the CD2F1 mice hyperimmune to L1210 leukemia cells developed co-existing humoral anti-L1210 leukemia immunity. In an in vitro complement-dependent cytotoxicity test and absorption test, antisera from hyperimmune mice reacted specifically to L1210 leukemia cells, but not other tumor cells such as P388, L5178Y, LS-1, DB27C and BW5147 or normal cells from various tissues of DBA/2, BALB/c and AKR mice. In an in vitro cytotoxicity blocking test, the cytotoxic antisera specifically reactive to L1210 cells totally failed to inhibit lysis of L1210 cells by cytotoxic cells, suggesting that antigens recognized by cell-mediated cytotoxicity assays are not identical to serologically defined tumor-cell surface antigens.","['Kawashima, K', 'Isobe, K', 'Nagase, F', 'Yokochi, T', 'Nagura, E', 'Hasegawa, Y', 'Morishita, H', 'Yamada, K', 'Nakashima, I']","['Kawashima K', 'Isobe K', 'Nagase F', 'Yokochi T', 'Nagura E', 'Hasegawa Y', 'Morishita H', 'Yamada K', 'Nakashima I']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Leuk Res,Leukemia research,7706787,IM,"['Animals', 'Antibody Formation', 'Antigens, Neoplasm/immunology', 'Cytotoxicity, Immunologic', 'Female', 'Histocompatibility Antigens/immunology', 'Immunity, Cellular', 'Leukemia L1210/*immunology', 'Mice', 'Mice, Inbred Strains']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1016/0145-2126(85)90316-9 [doi]'],ppublish,Leuk Res. 1985;9(7):935-9. doi: 10.1016/0145-2126(85)90316-9.,"['0 (Antigens, Neoplasm)', '0 (Histocompatibility Antigens)', '0 (tumor-associated transplantation antigen)']",,,,,,,,,,,
4021445,NLM,MEDLINE,19850916,20071115,0023-6837 (Print) 0023-6837 (Linking),53,2,1985 Aug,Behavior of transplanted large granular lymphocyte leukemia in Fischer 344 rats.,200-8,"The behavior of transplanted large granular lymphocyte leukemia was studied by isogeneic inoculation of 55 young F344 rats. A high percentage of transplants were successful, showing a dose-dependent latent phase followed by weight loss, exponential increase of tumor cells, and widespread infiltration. Serial passage of tumor cells appeared to increase malignancy by decreasing longevity. Grossly, there was splenomegaly, variable lymphadenopathy, and petechial hemorrhages on the lungs, lymph nodes, and brain. Diffuse infiltration of tumor cells caused morphologic changes identical with spontaneous large granular lymphocyte leukemia including splenic lymphoid depletion, hepatocellular necrosis, tumor cell erythrophagocytosis, and femoral medullary endosteal bone proliferation. Clinicopathologic features were also similar to spontaneous large granular lymphocyte leukemia. There was immune-mediated hemolytic anemia and thrombocytopenia, which coincided with development of leukemia, as well as hyperbilirubinemia and elevated serum enzymes, indicative of liver disease. It was concluded that isogeneic transplantation of large granular lymphocyte leukemia is not only highly successful but reproduces the pattern and clinical syndrome of the spontaneous tumor including the important paraneoplastic syndrome of hemolytic anemia and thrombocytopenia.","['Stromberg, P C', 'Vogtsberger, L M', 'McMurray, D N', 'Marsh, L R', 'Kotur, M S', 'Brown, C A']","['Stromberg PC', 'Vogtsberger LM', 'McMurray DN', 'Marsh LR', 'Kotur MS', 'Brown CA']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Lab Invest,Laboratory investigation; a journal of technical methods and pathology,0376617,IM,"['Anemia, Hemolytic, Autoimmune/etiology', 'Animals', 'Bone Marrow/pathology', 'Leukemia, Lymphoid/blood/complications/*pathology', 'Liver/pathology', 'Lymphoid Tissue/pathology', 'Neoplasm Transplantation', 'Paraneoplastic Syndromes/etiology', 'Rats', 'Rats, Inbred F344', 'Thrombocytopenia/etiology', 'Transplantation, Isogeneic']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",,ppublish,Lab Invest. 1985 Aug;53(2):200-8.,,,,['55352-7/PHS HHS/United States'],,,,,,,,
4021122,NLM,MEDLINE,19850830,20061115,0368-2811 (Print) 0368-2811 (Linking),15,2,1985 Jun,Second primary malignancies in lymphoma patients.,443-9,"We evaluated the occurrence and the type of second malignancies among 74 patients with Hodgkin's disease (HD) and 407 patients with non-Hodgkin's lymphoma (NHL) who were treated at the National Cancer Center Hospital for more than one year. Fifteen patients developed a second malignancy. In 10 of these patients the second cancer was gastric cancer, but no cases of acute nonlymphocytic leukemia were encountered. The observed number of second cancers in females among the HD patients was significantly (p less than 0.005) greater than the expected incidence based upon the number of age-adjusted person-years both for all cancers and for stomach cancer. However, no significant differences between males and females in the NHL patients were found. Furthermore, no significant differences were seen in any of the groups between the observed and expected numbers of second malignancies according to the treatment.","['Takenaka, T', 'Konda, C', 'Sakano, T', 'Shimoyama, M', 'Kitahara, T', 'Minato, K', 'Watanabe, S']","['Takenaka T', 'Konda C', 'Sakano T', 'Shimoyama M', 'Kitahara T', 'Minato K', 'Watanabe S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Jpn J Clin Oncol,Japanese journal of clinical oncology,0313225,IM,"['Adult', 'Aged', 'Female', 'Follow-Up Studies', 'Hodgkin Disease/pathology/therapy', 'Humans', 'Japan', 'Lymphoma/*pathology/therapy', 'Male', 'Middle Aged', 'Neoplasms, Multiple Primary/*epidemiology/etiology']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Jpn J Clin Oncol. 1985 Jun;15(2):443-9.,,,,,,,,,,,,
4021118,NLM,MEDLINE,19850830,20061115,0368-2811 (Print) 0368-2811 (Linking),15,2,1985 Jun,A descriptive epidemiological study of hematopoietic neoplasms in Japan.,347-64,"In 1982, the number of deaths from hematopoietic neoplasms was 5,885 for males and 4,237 for females, which corresponded to about 6% of all malignant neoplasms. The increase in the age-adjusted death rate in the last 10 years was highest for lymphatic leukemia (1.8 times), followed by multiple myeloma (1.7 times), malignant lymphomas (1.3 times) and myelogenous leukemia (1.1 times). In the old-age group, i.e., over 70, the death rate for all types of hematopoietic neoplasms markedly during this period, particularly for multiple myeloma. In children, however, an increase in lymphatic leukemia and a decrease in decrease in myelogenous leukemia were observed. Geographical marked excess in the death rates for malignant lymphomas and lymphatic leukemia in the Kyushu district, especially in the middle- and old-age groups. This may be attributed to the high incidence of adult T-cell leukemia/lymphoma in the southwestern part of Japan. The age-adjusted death rate for malignant lymphomas was slightly higher in rural areas than in urban areas in males in Kyushu.","['Kato, I', 'Tajima, K', 'Hirose, K', 'Nakagawa, N', 'Kuroishi, T', 'Tominaga, S']","['Kato I', 'Tajima K', 'Hirose K', 'Nakagawa N', 'Kuroishi T', 'Tominaga S']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't""]",England,Jpn J Clin Oncol,Japanese journal of clinical oncology,0313225,IM,"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Child', 'Child, Preschool', 'Female', 'Hodgkin Disease/mortality', 'Humans', 'Infant', 'Japan', 'Leukemia/etiology/*mortality', 'Lymphoma/etiology/*mortality', 'Male', 'Middle Aged', 'Multiple Myeloma/mortality', 'Residence Characteristics', 'Sex Factors', 'Time Factors']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Jpn J Clin Oncol. 1985 Jun;15(2):347-64.,,,,,,,,,,,,
4021036,NLM,MEDLINE,19850904,20161017,0098-7484 (Print) 0098-7484 (Linking),254,8,1985 Aug 23-30,Guidelines for handling parenteral antineoplastics.,1033-4,,"['Randall, M E', 'Constable, W C']","['Randall ME', 'Constable WC']",['eng'],['Letter'],United States,JAMA,JAMA,7501160,IM,"['Antineoplastic Agents/*adverse effects', 'Hodgkin Disease/therapy', 'Humans', 'Leukemia/*chemically induced', '*Leukemia, Radiation-Induced']",,1985/08/23 00:00,1985/08/23 00:01,['1985/08/23 00:00'],"['1985/08/23 00:00 [pubmed]', '1985/08/23 00:01 [medline]', '1985/08/23 00:00 [entrez]']",,ppublish,JAMA. 1985 Aug 23-30;254(8):1033-4.,['0 (Antineoplastic Agents)'],,,,,,,,,,,
4020968,NLM,MEDLINE,19850924,20200724,0022-538X (Print) 0022-538X (Linking),55,3,1985 Sep,Infectious entry of murine retroviruses into mouse cells: evidence of a postadsorption step inhibited by acidic pH.,806-12,"The entry into cells by many enveloped RNA viruses is accomplished by endocytosis and subsequent penetration of the endosomal membrane by an acidic pH-dependent fusion event. In the current study, we examined early events in the infectious entry of mouse retroviruses, using as a framework the observation that infection of a mouse tail skin cell line by the ecotropic virus Friend murine leukemia virus was inhibited at mildly acidic pH (pH 6). This inhibition operated on a postadsorption step, since binding of virus was unaffected at this pH. The rate of penetration of preadsorbed virus, which displayed first-order kinetics, was markedly affected by changes in the pH of the medium. The half-time for disappearance of infectious cell surface virus at 37 degrees C was approximately 10 min at pH 7.6. At pH 6.0, however, greater than 98% of the adsorbed infectivity remained at the cell surface after 45 min. This cell surface virus, though not infecting the cell at pH 6.0, retained its capacity to enter and infect the cell when the pH of the medium was raised. Acidic pH had little effect on the rate of fluid uptake by the cells, as measured by internalization of [3H]sucrose, indicating that global inhibition of endocytosis had not occurred. In contrast, cell fusion induced by Friend murine leukemia virus was optimal at pH 7.6 but markedly inhibited at a pH of less than 6.4. This inhibitory effect of acidic pH on membrane fusion is unique among the enveloped viruses which have been studied and would preclude entry of Friend murine leukemia virus from within acidified endocytic vesicles. Entry of other members of the ecotropic, mink cell focus-forming, and xenotropic host range groups displayed similar pH sensitivity. However, one xenotropic virus was relatively resistant to the effect of acidic pH, suggesting that differences might exist in the requirements for entry of different retroviruses.","['Portis, J L', 'McAtee, F J', 'Evans, L H']","['Portis JL', 'McAtee FJ', 'Evans LH']",['eng'],['Journal Article'],United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Cell Fusion', 'Cells, Cultured', 'Endocytosis', 'Friend murine leukemia virus/*pathogenicity', '*Hydrogen-Ion Concentration', 'Kinetics', 'Membrane Fusion', 'Mice']",PMC255065,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1128/JVI.55.3.806-812.1985 [doi]'],ppublish,J Virol. 1985 Sep;55(3):806-12. doi: 10.1128/JVI.55.3.806-812.1985.,,,,,,,,,,,,
4020966,NLM,MEDLINE,19850924,20200724,0022-538X (Print) 0022-538X (Linking),55,3,1985 Sep,"ts1, a Paralytogenic mutant of Moloney murine leukemia virus TB, has an enhanced ability to replicate in the central nervous system and primary nerve cell culture.",760-7,"A temperature-sensitive mutant of Moloney murine leukemia virus TB (MoMuLV-TB), ts1, which is defective in intracellular processing of envelope precursor protein (Pr80env), also possesses the ability to induce hind-limb paralysis in infected mice. To investigate whether ts1 has acquired neurotropism and to determine to what extent it can replicate in the central nervous system, we compared viral titers in the spleen, plasma, spinal cord, and brain throughout the course of infection of mice infected with ts1 and parental wild-type (wt) MoMuLV-TB. In both the ts1- and wt-inoculated mice, the concentrations of infectious virus recovered from the plasma and spleen increased rapidly and reached a plateau by 10 days postinfection (p.i.). In contrast, virus concentrations in the spinal cord and brain of ts1-inoculated mice increased gradually and reached a titer comparable to that in the spleen and exceeding that in the plasma only at 25 to 30 days p.i. At this time, the virus titer was approximately 200X greater in ts1-infected spinal cord tissue and approximately 20X greater in ts1-infected brain tissue than in the same wt-infected tissues. Paralysis became evident at 25 to 30 days p.i. in ts1-inoculated mice, whereas the wt-inoculated mice were normal. In addition, a substantial amount of Pr80env was detected in the spinal cords of ts1-inoculated mice compared with that found in the spinal cords of wt-inoculated mice. The infectious virus isolated from ts1-infected nerve tissue was found to possess the characteristic phenotype of the ts1 virus. Microscopic lesions of ts1-inoculated mice at 30 days p.i. consisted of vacuolar degeneration of motor neurons and spongy change of white matter in the brain stem and spinal cord. Similar but less severe lesions were observed in wt-inoculated mice. With primary cultures of central nervous system tissue we showed that ts1 can infect and replicate in both neuron and glial cells. In contrast, although wt MoMuLV-TB replicated in glial cell-rich culture, viral replication was barely detectable in neuron-rich culture.","['Wong, P K', 'Knupp, C', 'Yuen, P H', 'Soong, M M', 'Zachary, J F', 'Tompkins, W A']","['Wong PK', 'Knupp C', 'Yuen PH', 'Soong MM', 'Zachary JF', 'Tompkins WA']",['eng'],"['Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Virol,Journal of virology,0113724,IM,"['Animals', 'Animals, Newborn', 'Blood/microbiology', 'Brain/microbiology', 'Cells, Cultured', 'Central Nervous System/*microbiology', 'Mice', 'Moloney murine leukemia virus/*growth & development', 'Mutation', 'Neurons/microbiology', 'Paralysis/*etiology', 'Spinal Cord/microbiology', 'Spleen/microbiology', 'Virus Replication']",PMC255060,1985/09/01 00:00,1985/09/01 00:01,['1985/09/01 00:00'],"['1985/09/01 00:00 [pubmed]', '1985/09/01 00:01 [medline]', '1985/09/01 00:00 [entrez]']",['10.1128/JVI.55.3.760-767.1985 [doi]'],ppublish,J Virol. 1985 Sep;55(3):760-7. doi: 10.1128/JVI.55.3.760-767.1985.,,,,"['CA 09067/CA/NCI NIH HHS/United States', 'CA 36293/CA/NCI NIH HHS/United States']",,,,,,,,
4020903,NLM,MEDLINE,19850830,20190908,0388-1350 (Print) 0388-1350 (Linking),10,1,1985 Feb,A preliminary study on long term toxicity test. Age-related alterations of bone marrow cellularity in Sprague-Dawley and Wistar rats.,11-20,"Age-related alterations in bone marrow cellularity were examined on SD and Wistar SPF rats. Six rats/strain/sex were sacrificed at 58, 83, 109 and 123 or 135 weeks of age and quantitative assessment and categorization of the bone marrow cells were performed. One male and two female SD rats suffering from leukemia were excluded from statistics. Age-related increases of myeloblasts and plasma cells were observed in rats of either strain and either sex. Age-related decreases in percentages of lymphocytes were noticed in SD, but not in Wistar rats. Age-related alterations in absolute numbers of marrow lymphocytes were equivocal in either strain.","['Kanazu, A', 'Udaka, K']","['Kanazu A', 'Udaka K']",['eng'],['Journal Article'],Japan,J Toxicol Sci,The Journal of toxicological sciences,7805798,IM,"['*Aging', 'Animals', '*Bone Marrow Cells', 'Female', 'Male', 'Rats', 'Rats, Inbred Strains']",,1985/02/01 00:00,1985/02/01 00:01,['1985/02/01 00:00'],"['1985/02/01 00:00 [pubmed]', '1985/02/01 00:01 [medline]', '1985/02/01 00:00 [entrez]']",['10.2131/jts.10.11 [doi]'],ppublish,J Toxicol Sci. 1985 Feb;10(1):11-20. doi: 10.2131/jts.10.11.,,,,,,,,,,,,
4020835,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,"Synthesis and antineoplastic evaluations of 5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10-diones.",1124-6,"Several 5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10-diones have been synthesized and evaluated for antitumor activity against L1210 leukemia both in vitro and in vivo. Comparisons are made to the corresponding carbocyclic analogues. One of the aza analogues showed modest in vivo activity.","['Krapcho, A P', 'Landi, J J Jr', 'Hacker, M P', 'McCormack, J J']","['Krapcho AP', 'Landi JJ Jr', 'Hacker MP', 'McCormack JJ']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Anthracenes/chemical synthesis/*pharmacology', 'Antineoplastic Agents/*chemical synthesis', 'Cell Division/drug effects', 'Leukemia L1210/drug therapy', 'Mice', 'Structure-Activity Relationship']",,1985/08/01 00:00,2001/03/28 10:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '2001/03/28 10:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a029 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1124-6. doi: 10.1021/jm00146a029.,"['0 (Anthracenes)', '0 (Antineoplastic Agents)']",,,['CA 24543/CA/NCI NIH HHS/United States'],,,,,,,,
4020833,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,Activity of platinum(II) intercalating agents against murine leukemia L1210.,1113-6,"Four series of intercalating, square-planar Pt(II) complexes derived from the ligands 2,2'-bipyridine, 2,2':6',2""-terpyridine, 1,10-phenanthroline, and 3,4,7,8-tetramethyl-1,10-phenanthroline were synthesized and aspects of their activity against murine leukemia L1210 cells investigated. The 2,2':6',2""-terpyridine-thiolato complexes are growth inhibitory in culture, with IC50 values in the range 6-32 microM, and cause cell lysis at high concentrations. Of the remaining three series, the 2,2'-bipyridine complexes are the least potent in their effects. There is a general enhancement in activity on moving from the 1,10-phenanthroline complexes to the 3,4,7,8-tetramethyl-1,10-phenanthroline analogues. Flow cytometric analysis on representative complexes shows that they are not cell cycle specific. Alkaline elution experiments indicate no damage to DNA of cells exposed to (thiophenolato)(2,2':6',2""-terpyridine)platinum(II) chloride monohydrate and (ethylenediamine)(1,10-phenanthroline)platinum(II) dichloride dihydrate although (ethylenediamine)(3,4,7,8-tetramethyl-1,10-phenanthroline)platinum(II) dichloride dihydrate causes both single-strand breaks and DNA cross-links. Compounds 2a, 5a, and 6a showed no antitumor activity against L1210 in mice.","['McFadyen, W D', 'Wakelin, L P', 'Roos, I A', 'Leopold, V A']","['McFadyen WD', 'Wakelin LP', 'Roos IA', 'Leopold VA']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Cell Division/drug effects', 'Cells, Cultured', 'DNA, Neoplasm/metabolism', 'Intercalating Agents/*chemical synthesis', 'Leukemia L1210/*drug therapy/metabolism', 'Male', 'Mice', 'Organoplatinum Compounds/chemical synthesis/*pharmacology', 'Structure-Activity Relationship']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a026 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1113-6. doi: 10.1021/jm00146a026.,"['0 (Antineoplastic Agents)', '0 (DNA, Neoplasm)', '0 (Intercalating Agents)', '0 (Organoplatinum Compounds)']",,,,,,,,,,,
4020828,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,"Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.",1079-88,"The dimeric alkaloids vinblastine (VLB) and vincristine (VCR) differ structurally only in the functional group on the dihydroindole nitrogen. The semisynthetic derivative vindesine (VDS) differs slightly from VLB by having an amide group instead of an ester group. However, these minor distinctions are responsible for profound differences in the oncolytic spectrum, potency, and toxicity of these compounds. Vinblastin-23-oyl amino acid derivatives were synthesized by linking amino acid carboxylic esters to the vinblastin-23-oyl moiety through an amide linkage. Studies were extended to explore the influence of the nature of the amino acid, the ester alkyl chain lengths, the stereoisomerism of the amino acid, or the reacetylation of the hydroxyl group (position O-4) of the vindoline moiety. The present study deals with the synthesis of 21 vinblastin-23-oyl amino acid derivatives, some of their physicochemical data, the acute toxicity in mice, and therapeutic activities of these derivatives against the P388 and L1210 leukemias in comparison with VDS, VBL, and VCR.","['Bhushana Rao, K S', 'Collard, M P', 'Dejonghe, J P', 'Atassi, G', 'Hannart, J A', 'Trouet, A']","['Bhushana Rao KS', 'Collard MP', 'Dejonghe JP', 'Atassi G', 'Hannart JA', 'Trouet A']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Antineoplastic Agents, Phytogenic/*chemical synthesis', 'Female', 'Lethal Dose 50', 'Leukemia L1210/drug therapy', 'Leukemia P388/drug therapy', 'Mice', 'Mice, Inbred DBA', 'Structure-Activity Relationship', 'Vinblastine/analogs & derivatives/pharmacology', 'Vincristine/pharmacology', 'Vindesine']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a017 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1079-88. doi: 10.1021/jm00146a017.,"['0 (Antineoplastic Agents, Phytogenic)', '5J49Q6B70F (Vincristine)', '5V9KLZ54CY (Vinblastine)', 'RSA8KO39WH (Vindesine)']",,,,,,,,,,,
4020826,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,Synthesis and antitumor activity of structural analogues of the anticancer benzophenanthridine alkaloid fagaronine chloride.,1031-6,"The indenoisoquinoline analogue 4 of fagaronine chloride (2) has been prepared, as well as its positional isomer 20 and the corresponding mesylated derivatives 16 and 19. Compounds 4, 16, and 20 were tested against P388 lymphocytic leukemia and found to possess significant activity. A tricyclic analogue 24 was also synthesized and was devoid of cytotoxicity in the KB cancer cell culture system. The change in the substitution pattern of the A-ring on going from 4 to 20 was tolerated without producing a significant decrease in antitumor activity.","['Cushman, M', 'Mohan, P']","['Cushman M', 'Mohan P']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Alkaloids/chemical synthesis/*pharmacology', 'Animals', 'Antineoplastic Agents, Phytogenic/*chemical synthesis', 'Cell Line', 'Cell Survival/drug effects', 'Humans', 'Leukemia P388/drug therapy', 'Mice', 'Structure-Activity Relationship']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a010 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1031-6. doi: 10.1021/jm00146a010.,"['0 (Alkaloids)', '0 (Antineoplastic Agents, Phytogenic)']",,,['GM30932/GM/NIGMS NIH HHS/United States'],,,,,,,,
4020825,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,Synthesis and antitumor activity of tropolone derivatives. 2.,1026-31,"Structural requirement for antitumor activity of tropolone derivatives 2-4 was explored. Isochroman derivatives (6-17, 20, and 23) and alpha, alpha-disubstituted compounds 26-30 were synthesized and their antitumor activities were tested. These nontroponoid derivatives were all inactive, implying that a tropolone ring is essential for the activity. Several compounds related to the monotropolone analogue 3 were synthesized. Among them, 31-33 showed significant activity, but their potencies were considerably weaker than those of binary tropolone analogues 4.","['Yamato, M', 'Hashigaki, K', 'Ishikawa, S', 'Kokubu, N', 'Inoue, Y', 'Tsuruo, T', 'Tashiro, T']","['Yamato M', 'Hashigaki K', 'Ishikawa S', 'Kokubu N', 'Inoue Y', 'Tsuruo T', 'Tashiro T']",['eng'],"['Comparative Study', 'Journal Article']",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Antineoplastic Agents/*chemical synthesis', 'Cell Division/drug effects', 'Cell Line', 'Cycloheptanes/*pharmacology', 'Humans', 'Leukemia P388/drug therapy', 'Mice', 'Structure-Activity Relationship', 'Tropolone/analogs & derivatives/chemical synthesis/*pharmacology']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a009 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1026-31. doi: 10.1021/jm00146a009.,"['0 (Antineoplastic Agents)', '0 (Cycloheptanes)', '7L6DL16P1T (Tropolone)']",,,,,,,,,,,
4020824,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,"Syntheses and evaluation as antifolates of MTX analogues derived from 2, omega-diaminoalkanoic acids.",1016-25,"Methotrexate (MTX) analogues 27a-c bearing 2, omega-diaminoalkanoic acids (ornithine and its two lower homologues) in place of glutamic acid were synthesized by routes proceeding through N2-[4-(methylamino)benzoyl]-N omega-[(1,1-dimethylethoxy)carbonyl]-2, omega-diaminoalkanoic acid ethyl esters and N2-[4-(methylamino)benzoyl]-N5-[(1,1-dimethylethoxy)carbonyl]-2, 5-diaminopentanoic acid followed by alkylation with 6-(bromomethyl)-2, 4-pteridinediamine hydrobromide. Reactions at the terminal amino group of 27-type analogues or of appropriate precursors led to other MTX derivatives whose side chains terminate in ureido, methylureido, N-methyl-N-nitrosoureido, N-(2-chloroethyl)-N-nitrosoureido, and 4-chlorobenzamido groups. Also prepared were unsymmetrically disubstituted ureido types resulting from addition of ethyl isocyanatoacetate and diethyl 2-isocyanatoglutarate to the ethyl esters of 27a,b. Of these ureido adducts (32a,b and 33a,b, respectively), only 33a was successfully hydrolyzed to the corresponding pure acid, in this instance the tricarboxylic acid 34, a pseudo-peptide analogue of the MTX metabolite MTX-gamma-Glu. Biological evaluations of the prepared compounds affirmed previous findings that the gamma-carboxyl is not required for tight binding to dihydrofolate reductase (DHFR) but is operative in the carrier-mediated transport of classical antifolates through cell membranes. High tolerance levels observed in studies against L1210 leukemia in mice suggest the reduced potency may be due not only to lower transport efficacy but also to loss of the function of intracellular gamma-polyglutamylation. The N-nitrosoureas 30 and 31 showed appreciable activity in vivo vs. L1210, but the activity did not appear to be due to antifolate action as evidenced by their poor inhibition of both L1210 DHFR and cell growth in vitro.","['Piper, J R', 'McCaleb, G S', 'Montgomery, J A', 'Schmid, F A', 'Sirotnak, F M']","['Piper JR', 'McCaleb GS', 'Montgomery JA', 'Schmid FA', 'Sirotnak FM']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Carboxylic Acids', 'Cell Division/drug effects', 'Cells, Cultured', 'Folic Acid Antagonists/*chemical synthesis', 'Leukemia L1210/drug therapy/metabolism', 'Methotrexate/*analogs & derivatives/chemical synthesis/pharmacology', 'Mice', 'Structure-Activity Relationship', 'Tetrahydrofolate Dehydrogenase/metabolism']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a008 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1016-25. doi: 10.1021/jm00146a008.,"['0 (Carboxylic Acids)', '0 (Folic Acid Antagonists)', 'EC 1.5.1.3 (Tetrahydrofolate Dehydrogenase)', 'YL5FZ2Y5U1 (Methotrexate)']",,,"['CA08748/CA/NCI NIH HHS/United States', 'CA18856/CA/NCI NIH HHS/United States', 'CA22764/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4020823,NLM,MEDLINE,19850912,20190709,0022-2623 (Print) 0022-2623 (Linking),28,8,1985 Aug,"Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.",1010-6,"Several 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides were prepared and tested for their biological activity. High-temperature glycosylation of 3,6-dibromoallopurinol with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose in the presence of BF3 X OEt2, followed by ammonolysis, provided 6-amino-3-bromo-1-beta-D-ribofuranosylpyrazolo-[3,4-d]pyrimidin-4(5H)-on e. Similar glycosylation of either 3-bromo-4(5H)-oxopyrazolo [3,4-d]pyrimidin-6-yl methyl sulfoxide or 6-amino-3-bromopyrazolo [3,4-d]pyrimidin-4(5H)-one, and subsequent ammonolysis, also gave 7a. The structural assignment of 7a was on the basis of spectral studies, as well as its conversion to the reported guanosine analogue 1d. Application of this glycosylation procedure to 6-(methylthio)-4(5H)-oxopyrazolo[3,4-d]pyrimidine-3-carboxamide gave the corresponding N-1 glycosyl derivative. Dethiation and debenzoylation of 16a provided an alternate route to the recently reported 3-carbamoylallopurinol ribonucleoside thus confirming the structural assignment of 16a and the nucleosides derived therefrom. Oxidation of 16a and subsequent ammonolysis afforded 6-amino-1-beta-D-ribofuranosyl-4(5H)-oxopyrazolo[3, 4-d]pyrimidine-3-carboxamide. Alkaline treatment of 15a gave 6-azacadeguomycin. Acetylation of 15a, followed by dehydration with phosgene, provided the versatile intermediate 6-amino-1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-4(5H)-oxopyrazolo [3, 4-d]pyrimidine-3-carbonitrile. Deacetylation of 19 gave 6-amino-1-beta-D-ribofuranosyl-4(5H)-oxopyrazolo[3, 4-d]pyrimidine-3-carbonitrile. Reaction of 19 with H2S gave 6-amino-1-beta-D-ribofuranosyl-4(5H)-oxopyrazolo[3, 4-d]pyrimidine-3-thiocarboxamide. All of these compounds were tested in vitro against certain viruses and tumor cells. Among these compounds, the guanosine analogues 7a and 20a showed significant activity against measles in vitro and were found to exhibit moderate antitumor activity in vitro against L1210 and P388 leukemia. 6-Azacadeguomycin and all other compounds were inactive against the viruses and tumor cells tested in vitro.","['Petrie, C R 3rd', 'Cottam, H B', 'McKernan, P A', 'Robins, R K', 'Revankar, G R']","['Petrie CR 3rd', 'Cottam HB', 'McKernan PA', 'Robins RK', 'Revankar GR']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, U.S. Gov't, Non-P.H.S.""]",United States,J Med Chem,Journal of medicinal chemistry,9716531,IM,"['Animals', 'Antibiotics, Antineoplastic/chemical synthesis', 'Antineoplastic Agents/*chemical synthesis', 'Antiviral Agents/*chemical synthesis', 'Cells, Cultured', 'Cytopathogenic Effect, Viral/drug effects', 'Guanosine/analogs & derivatives/chemical synthesis/pharmacology', 'Leukemia, Experimental/drug therapy', 'Methotrexate/analogs & derivatives', 'Mice', 'Ribonucleosides/chemical synthesis/*pharmacology', 'Structure-Activity Relationship']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']",['10.1021/jm00146a007 [doi]'],ppublish,J Med Chem. 1985 Aug;28(8):1010-6. doi: 10.1021/jm00146a007.,"['0 (Antibiotics, Antineoplastic)', '0 (Antineoplastic Agents)', '0 (Antiviral Agents)', '0 (Ribonucleosides)', '12133JR80S (Guanosine)', '96555-48-5 (6-azacadeguomycin)', 'YL5FZ2Y5U1 (Methotrexate)']",,,,,,,,,,,
4020503,NLM,MEDLINE,19850906,20061115,0096-1736 (Print) 0096-1736 (Linking),27,6,1985 Jun,"Texaco mortality study. I. Mortality among refinery, petrochemical, and research workers.",445-7,"The Texaco mortality study is a retrospective follow-up study of all persons who were employed for at least five years in a refining, petrochemical, or research facility and who worked at some time during the period 1947 through 1977. Of the 19,077 white men in the cohort, 14,609 were alive, 4,024 were known to be dead, and the vital status of the remaining 444 was unknown as of Dec. 31, 1977. The standardized mortality ratio (SMR) of 75 for all causes was significantly low, on the basis of 5,332 expected deaths. Statistically significant deficits also were seen for all major causes of death and for cancer of many sites, including lung, stomach, bladder, and colon. The SMR was greater than 100 for six causes of death: pancreas cancer, brain cancer, leukemia, Hodgkin's disease, other lymphatic cancer, and benign neoplasms. However, none of these increases was statistically significant, and all SMRs except that for benign neoplasms (SMR = 148) were under 119.","['Divine, B J', 'Barron, V', 'Kaplan, S D']","['Divine BJ', 'Barron V', 'Kaplan SD']",['eng'],['Journal Article'],United States,J Occup Med,Journal of occupational medicine. : official publication of the Industrial Medical Association,7502807,IM,"['Adult', '*Chemical Industry', 'Humans', 'Male', 'Neoplasms/mortality', 'Occupational Diseases/*mortality', '*Petroleum', 'United States']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,J Occup Med. 1985 Jun;27(6):445-7.,['0 (Petroleum)'],,,,,,,,,,,
4020409,NLM,MEDLINE,19850826,20170210,0732-183X (Print) 0732-183X (Linking),3,7,1985 Jul,Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.,982-91,"Preleukemic syndromes compose a group of acquired bone marrow disorders characterized by dysplastic maturation of hematopoietic cells and peripheral blood cytopenias. These syndromes have been generally considered untreatable. We administered low doses of cytosine arabinoside by continuous infusion for 14 to 21 days (20 mg/m2/d) to 16 patients with preleukemia in various stages of evolution to acute leukemia. Steady state plasma cytosine arabinoside levels ranged from 41.8 to 64.2 nmol/L. Eleven patients demonstrated marked improvement in hematopoiesis and loss of transfusion requirements for periods ranging from two to 27 + months. All but one responding patient developed recurrent pancytopenia, but additional responses to low-dose cytosine arabinoside were achieved in five of five retreated patients. Median overall survival time is 12 months for the 11 responding cases, and nine months for nonresponders. The major toxicity of low-dose cytosine arabinoside is myelosuppression, and most patients required platelet transfusion support and administration of antibiotics. Chromosome analyses demonstrated evolution to a new clone of hematopoietic cells in three patients, and persistence of the same abnormal clone in another patient. These results suggest that low-dose cytosine arabinoside therapy may result in improved hematopoiesis by promoting maturation or by selecting new stem cell clones. Low-dose cytosine arabinoside therapy thus deserves further evaluation both as a single agent and in combination with other agents in the treatment of myelodysplastic syndromes.","['Griffin, J D', 'Spriggs, D', 'Wisch, J S', 'Kufe, D W']","['Griffin JD', 'Spriggs D', 'Wisch JS', 'Kufe DW']",['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,J Clin Oncol,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,8309333,IM,"['Adult', 'Aged', 'Bone Marrow/drug effects/pathology', 'Chromosome Aberrations', 'Colony-Forming Units Assay', 'Cytarabine/*administration & dosage/adverse effects/blood', 'Drug Evaluation', 'Female', 'Hematopoiesis/drug effects', 'Humans', 'Infusions, Parenteral', 'Male', 'Middle Aged', 'Preleukemia/blood/*drug therapy/mortality', 'Syndrome', 'Time Factors']",,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1200/JCO.1985.3.7.982 [doi]'],ppublish,J Clin Oncol. 1985 Jul;3(7):982-91. doi: 10.1200/JCO.1985.3.7.982.,['04079A1RDZ (Cytarabine)'],,,"['CA19389/CA/NCI NIH HHS/United States', 'CA29431/CA/NCI NIH HHS/United States', 'CA36167/CA/NCI NIH HHS/United States', 'etc.']",,,,,,,,
4019894,NLM,MEDLINE,19850919,20080213,0002-3329 (Print) 0002-3329 (Linking),,3,1985 May-Jun,[Numerical model of lymphocyte population in animals in normal state and in lymphocytic leukemia].,412-22,,"['Feofanova, T V', 'Stepanova, N V', 'Aleshchenko, A V', 'Nikolaeva, N V']","['Feofanova TV', 'Stepanova NV', 'Aleshchenko AV', 'Nikolaeva NV']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Russia (Federation),Izv Akad Nauk SSSR Biol,Izvestiia Akademii nauk SSSR. Seriia biologicheskaia,7505543,IM,"['Animals', 'Cattle', 'Cell Division', 'Female', '*Hematopoiesis', 'Leukemia, Lymphoid/*blood', 'Leukocyte Count', 'Lymphocytes/*cytology/pathology', 'Mathematics', 'Models, Biological']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Izv Akad Nauk SSSR Biol. 1985 May-Jun;(3):412-22.,,,Model' chislennosti populiatsii limfotsitov v norme i pri limfoleikoze zhivotnykh.,,,,,,,,,
4019807,NLM,MEDLINE,19850906,20190501,0021-9746 (Print) 0021-9746 (Linking),38,7,1985 Jul,Expression of leucocyte common antigen and epithelial membrane antigen in plasmacytic malignancies.,843-4,,"['Salter, D M', 'Krajewski, A S', 'Miller, E P', 'Dewar, A E']","['Salter DM', 'Krajewski AS', 'Miller EP', 'Dewar AE']",['eng'],"['Letter', ""Research Support, Non-U.S. Gov't""]",England,J Clin Pathol,Journal of clinical pathology,0376601,IM,"['Antigens, Neoplasm/*analysis', 'Epithelium/immunology', 'Humans', 'Leukemia, Plasma Cell/immunology', 'Leukocytes/*immunology', 'Lymphoma/*immunology', 'Multiple Myeloma/immunology']",PMC499319,1985/07/01 00:00,1985/07/01 00:01,['1985/07/01 00:00'],"['1985/07/01 00:00 [pubmed]', '1985/07/01 00:01 [medline]', '1985/07/01 00:00 [entrez]']",['10.1136/jcp.38.7.843 [doi]'],ppublish,J Clin Pathol. 1985 Jul;38(7):843-4. doi: 10.1136/jcp.38.7.843.,"['0 (Antigens, Neoplasm)']",,,,,,,,,,,
4019314,NLM,MEDLINE,19850828,20190723,0021-8820 (Print) 0021-8820 (Linking),38,5,1985 May,"Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin.",683-6,,"['Cheung, T M', 'Horton, D', 'Priebe, W', 'Turner, W R', 'Weckerle, W']","['Cheung TM', 'Horton D', 'Priebe W', 'Turner WR', 'Weckerle W']",['eng'],['Journal Article'],Japan,J Antibiot (Tokyo),The Journal of antibiotics,0151115,IM,"['Animals', 'Antibiotics, Antineoplastic/*chemical synthesis/pharmacology', 'Daunorubicin/*analogs & derivatives/*chemical synthesis/pharmacology', 'Leukemia P388/drug therapy', 'Magnetic Resonance Spectroscopy', 'Mice']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",['10.7164/antibiotics.38.683 [doi]'],ppublish,J Antibiot (Tokyo). 1985 May;38(5):683-6. doi: 10.7164/antibiotics.38.683.,"['0 (Antibiotics, Antineoplastic)', ""66322-65-4 (3'-epidaunorubicin)"", ""98103-10-7 (3',6'-dihydroxy-3',5'-diepidaunorubicin)"", ""98103-13-0 (3'-hydroxy-3',5'-diepidaunorubicin)"", 'ZS7284E0ZP (Daunorubicin)']",,,,,,,,,,,
4019142,NLM,MEDLINE,19850923,20211203,0021-2180 (Print) 0021-2180 (Linking),21,6,1985 Jun,Multivariate analysis of prognostic factors in chronic lymphocytic leukemia.,490-8,"Prognostic factors in a group of 90 patients with chronic lymphocytic leukemia were studied by methods of survival analysis. The relationship between survival and a set of demographic, clinical and laboratory variables, and identification of subsets of variables that are associated with survival, was tested by multivariate analysis, which is based upon Cox proportional hazards regression models in a stepwise procedure. Six variables showed significant correlation with survival: lymph node enlargement, splenomegaly, hepatomegaly, increased percentage (greater than 80%) of lymphocytes, hyperuricemia, and anemia. Stepwise analysis showed that the number of coexistent risk factors was a better predictor of survival than any single risk marker (P less than 0.001). Median survival of patients with 0 or 1 risk marker was 120 months; with 2 or 3, 96 months; with 4, 36 months; and with 5 or 6, only 24 months. Comparison of staging by number of risk markers with staging of the same patients by the Rai system showed a significant trend of decreasing survival with increasing number of risk markers within the same Rai stage. Staging by the number of coexistent risk markers is a simple and readily available method, which may complement existing methods to provide a more accurate assessment of prognosis in patients with chronic lymphocytic leukemia.","['Prokocimer, M', 'Modan, M', 'Lusky, A', 'Hershko, C']","['Prokocimer M', 'Modan M', 'Lusky A', 'Hershko C']",['eng'],"['Comparative Study', 'Journal Article']",Israel,Isr J Med Sci,Israel journal of medical sciences,0013105,IM,"['Adult', 'Aged', 'Anemia/etiology', 'Ethnicity', 'Female', 'Hemoglobins/analysis', 'Hepatomegaly/etiology', 'Humans', 'Leukemia, Lymphoid/complications/*mortality/pathology', 'Leukocyte Count', 'Lymph Nodes/pathology', 'Male', 'Middle Aged', 'Neoplasm Staging/methods', 'Prognosis', 'Retrospective Studies', 'Risk', 'Splenomegaly/etiology', 'Statistics as Topic', 'Uric Acid/urine']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Isr J Med Sci. 1985 Jun;21(6):490-8.,"['0 (Hemoglobins)', '268B43MJ25 (Uric Acid)']",,,,,,,,,,,
4019122,NLM,MEDLINE,19850905,20191022,0167-6997 (Print) 0167-6997 (Linking),3,2,1985,Mitoxantrone in refractory acute leukemia in children: a phase I study.,191-5,"Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. All the children had leukemia which was resistant to conventional therapy and all but one patient had received anthracycline therapy prior to the initiation of this trial. Three patients (two with ANLL, one with ALL) received the drug at a dose of 6 mg/m2/day i.v. for 5 days. Both patients with ANLL achieved partial remissions (PR) (105 and 87 days duration). The child with ALL failed to respond to two courses of the drug, and died of progressive disease 45 days after the institution of therapy. Twenty-one patients (14 with ALL, seven with ANLL) were treated with 8 mg/m2/day i.v. mitoxantrone for 5 days. There were three early deaths (all ALL) which were not felt to be secondary to drug toxicity. Four of the 18 children achieved complete remission (CR) (one ANLL - 35 days; three ALL - 39, 31 and 13 days). One child with ANLL achieved a PR (13 days) and one child with ALL showed improvement in his bone marrow status. Twelve children failed to respond to this therapy. Dose-limiting toxicity was not seen among the patients who received 6 mg/m2/day for 5 days. There were five patients who had mucositis and one patient who had nausea and vomiting among those patients who received 8 mg/m2/day for 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)","['Starling, K A', 'Mulne, A F', 'Vats, T S', 'Schoch, I', 'Dukart, G']","['Starling KA', 'Mulne AF', 'Vats TS', 'Schoch I', 'Dukart G']",['eng'],['Journal Article'],United States,Invest New Drugs,Investigational new drugs,8309330,IM,"['Acute Disease', 'Adolescent', 'Alopecia/chemically induced', 'Anthraquinones/adverse effects/*therapeutic use', '*Antineoplastic Agents/adverse effects', 'Child', 'Child, Preschool', 'Drug Evaluation', 'Female', 'Gastric Mucosa/drug effects', 'Heart/drug effects', 'Humans', 'Infant', 'Leukemia/*drug therapy', 'Male', 'Mitoxantrone']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",['10.1007/BF00174169 [doi]'],ppublish,Invest New Drugs. 1985;3(2):191-5. doi: 10.1007/BF00174169.,"['0 (Anthraquinones)', '0 (Antineoplastic Agents)', 'BZ114NVM5P (Mitoxantrone)']",,,,,,,,,,,
4018913,NLM,MEDLINE,19850919,20190708,0020-7136 (Print) 0020-7136 (Linking),36,2,1985 Aug 15,Differentiation of Abelson murine leukemia virus-infected promonocytic leukemia cells.,233-9,"Virus-producing, tumorigenic, promonocytic leukemia cell lines were derived from Abelson murine leukemia virus-infected mice. This study shows that, of these 25 cloned lines, 22 were capable of extensive differentiation. It also shows that granulocyte-macrophage colony-stimulating activity increased the proportion of differentiating cells in 17/22 lines. Cells from agar colonies with a diffuse colony morphology had an increased expression of mature macrophage phenotypic characteristics, and a reduced proliferative capacity in vitro, compared to cells from agar colonies with a compact colony morphology. Cells from diffuse colonies also produced less Abelson virus, and were less tumorigenic in vivo than cells from compact colonies. Together, these results suggest some Abelson virus-producing leukemic cells are not blocked in their capacity to differentiate and are capable of reversing the transformed phenotype.","['Hines, D L']",['Hines DL'],['eng'],"['Journal Article', ""Research Support, Non-U.S. Gov't"", ""Research Support, U.S. Gov't, P.H.S.""]",United States,Int J Cancer,International journal of cancer,0042124,IM,"['Abelson murine leukemia virus/physiology', 'Animals', 'Cell Differentiation', 'Cell Line', 'Clone Cells', 'Colony-Forming Units Assay', 'Leukemia, Experimental/*blood/microbiology', 'Macrophages/pathology', 'Mice', 'Mice, Inbred BALB C', 'Monocytes/microbiology/*pathology', 'Virus Replication']",,1985/08/15 00:00,1985/08/15 00:01,['1985/08/15 00:00'],"['1985/08/15 00:00 [pubmed]', '1985/08/15 00:01 [medline]', '1985/08/15 00:00 [entrez]']",['10.1002/ijc.2910360216 [doi]'],ppublish,Int J Cancer. 1985 Aug 15;36(2):233-9. doi: 10.1002/ijc.2910360216.,,,,"['CA-25234/CA/NCI NIH HHS/United States', 'CA-25391/CA/NCI NIH HHS/United States']",,,,,,,,
4018784,NLM,MEDLINE,19850911,20190722,0046-8177 (Print) 0046-8177 (Linking),16,8,1985 Aug,Gastrointestinal Richter's syndrome.,854-7,"The development of a diffuse large cell lymphoma of the stomach in a patient who had chronic lymphocytic leukemia is reported. Richter's syndrome localized to the gut has not been described previously. Morphologic and immunologic studies suggest that the diffuse large cell lymphoma arose from the same clonal proliferation, IgG lambda, as the initially detected serum monoclonal protein associated with the chronic lymphocytic leukemia.","['Brousse, N', 'Solal-Celigny, P', 'Herrera, A', 'Breil, P', 'Molas, G', 'Flejou, J F', 'Boivin, P', 'Potet, F']","['Brousse N', 'Solal-Celigny P', 'Herrera A', 'Breil P', 'Molas G', 'Flejou JF', 'Boivin P', 'Potet F']",['eng'],"['Case Reports', 'Journal Article']",United States,Hum Pathol,Human pathology,9421547,IM,"['Aged', 'Humans', 'Immunoglobulins/analysis', 'Leukemia, Lymphoid/complications/*pathology', 'Lymphoma/complications/*pathology', 'Male', 'Stomach Neoplasms/complications/*pathology', 'Syndrome']",,1985/08/01 00:00,1985/08/01 00:01,['1985/08/01 00:00'],"['1985/08/01 00:00 [pubmed]', '1985/08/01 00:01 [medline]', '1985/08/01 00:00 [entrez]']","['S0046-8177(85)80261-6 [pii]', '10.1016/s0046-8177(85)80261-6 [doi]']",ppublish,Hum Pathol. 1985 Aug;16(8):854-7. doi: 10.1016/s0046-8177(85)80261-6.,['0 (Immunoglobulins)'],,,,,,,,,,,
4018711,NLM,MEDLINE,19850923,20141120,0367-6102 (Print) 0367-6102 (Linking),60,3,1985 May,A study on an artifact introduced by fetal bovine serum-supplemented medium.,321-6,"The antiserum raised in (C3H/HeJ X A/J)F1 mice by repeated immunization with mitomycin c(MMC)-treated ASL-1 leukemia cells maintained in vivo reacted with all tumor and normal cell lines maintained in vitro, but not with cell lines maintained in vivo. The common antigens detected in tissue-culture cells (CATC) turned negative after short in vivo cultivation of in vitro ASL-1 cells, and turned positive after short in vitro cultivation of in vivo ASL-1 cells. Treatment of cultured cells with antibiotics (kanamycin, gentamycin) did not alter the reactivity to the a-CATC serum. However, the activity of a-CATC serum was reduced by mixing the anti serum with fetal bovine serum (FBS), and an antigen antibody precipitation reaction occurred between the serum and FBS. Antigens which reacted with this antiserum were indicated to be FBS-related. The antibody against FBS was incidentally produced by immunization with weakly immunogenic tumor cells treated with MMC in FBS-supplemented medium. This study reinforms that the presence of FBS bound to cell membranes can introduce artifacts in the serological analysis of antiserum.","['Mizushima, Y', 'Cohen, E P']","['Mizushima Y', 'Cohen EP']",['eng'],['Journal Article'],Japan,Hokkaido Igaku Zasshi,[Hokkaido igaku zasshi] The Hokkaido journal of medical science,17410290R,IM,"['Animals', 'Antigen-Antibody Reactions', 'Blood Proteins/*immunology', 'Cattle/*blood', 'Cells, Cultured', 'Fetal Blood/*immunology', 'Immune Sera/immunology', 'In Vitro Techniques', 'Leukemia, Experimental/*immunology', 'Mice', 'Mice, Inbred A', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Mice, Inbred C3H', 'Mice, Inbred C57BL']",,1985/05/01 00:00,1985/05/01 00:01,['1985/05/01 00:00'],"['1985/05/01 00:00 [pubmed]', '1985/05/01 00:01 [medline]', '1985/05/01 00:00 [entrez]']",,ppublish,Hokkaido Igaku Zasshi. 1985 May;60(3):321-6.,"['0 (Blood Proteins)', '0 (Immune Sera)']",,,,,,,,,,,
4018529,NLM,MEDLINE,19850917,20200713,0234-5730 (Print) 0234-5730 (Linking),30,6,1985 Jun,[Immunity factors and nonspecific anti-infection defense in hairy cell leukemia].,30-4,,"['Akhmedov, A G', 'Ermakova, G L', 'Samoiloba, R S', 'Sandulova, Iu F', 'Ponomareva, N G']","['Akhmedov AG', 'Ermakova GL', 'Samoiloba RS', 'Sandulova IuF', 'Ponomareva NG']",['rus'],"['English Abstract', 'Journal Article']",Russia (Federation),Gematol Transfuziol,Gematologiia i transfuziologiia,8301796,IM,"['Adult', 'Aged', 'Female', 'Humans', 'Leukemia, Hairy Cell/*immunology', 'Lymphopenia/immunology', 'Male', 'Middle Aged', 'Phagocytosis']",,1985/06/01 00:00,1985/06/01 00:01,['1985/06/01 00:00'],"['1985/06/01 00:00 [pubmed]', '1985/06/01 00:01 [medline]', '1985/06/01 00:00 [entrez]']",,ppublish,Gematol Transfuziol. 1985 Jun;30(6):30-4.,,,Faktory immuniteta i nespetsificheskoi protivoinfektsionnoi zashchity pri volosatokletochnom leikoze.,,,,,,,,,
4018306,NLM,MEDLINE,19850912,20061115,0015-5500 (Print) 0015-5500 (Linking),31,3,1985,Alterations in CFU-GM growth in preleukaemic and leukaemic AKR/J mice.,193-9,"The behaviour of committed CFU-GM bone marrow cells was investigated in leukaemic and preleukaemic AKR/J mice. The number of bone marrow CFU-GM decreased in the leukaemic stage of spontaneous AKR/J leukaemia. The addition of AKR/J leukaemic cells inhibited CFU-GM growth from normal target bone marrow. The bone marrow CFU-GM growth was also reduced in late preleukaemic AKR/J mice, whereas no modification in the CFU-GM number in early preleukaemic animals was found.","['Alonso, M C', 'Torres, A', 'Solana, R', 'Manzanares, M R', 'Garcia-Castellano, J M', 'Pena, J']","['Alonso MC', 'Torres A', 'Solana R', 'Manzanares MR', 'Garcia-Castellano JM', 'Pena J']",['eng'],"['Comparative Study', 'Journal Article', ""Research Support, Non-U.S. Gov't""]",Czech Republic,Folia Biol (Praha),Folia biologica,0234640,IM,"['Animals', 'Cells, Cultured', 'Colony-Forming Units Assay', 'Granulocytes/*pathology', 'Hematopoietic Stem Cells/*pathology', 'Leukemia, Experimental/*pathology', 'Macrophages/*pathology', 'Mice', 'Mice, Inbred AKR', 'Mice, Inbred BALB C', 'Preleukemia/*pathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Folia Biol (Praha). 1985;31(3):193-9.,,,,,,,,,,,,
4018232,NLM,MEDLINE,19850926,20190629,0014-4754 (Print) 0014-4754 (Linking),41,8,1985 Aug 15,Endogenous copper is cytotoxic to a lymphoma in primary culture which requires thiols for growth.,1064-6,"With the use of bathocuproine sulfonate, a copper-specific chelator as an indicator, we have demonstrated that copper ions, present as a natural medium constituent are toxic to the growth of a lymphoma in primary culture and are principally responsible for the growth requirement of mercaptoethanol and other thiols. By chelating trace copper normally present in the medium, bathocuproine sulfonate retarded the oxidation of cysteine to poorly utilized cystine, thus permitting its direct utilization by the cells for growth.","['Mohindru, A', 'Fisher, J M', 'Rabinovitz, M']","['Mohindru A', 'Fisher JM', 'Rabinovitz M']",['eng'],['Journal Article'],Switzerland,Experientia,Experientia,0376547,IM,"['Animals', 'Cell Division/drug effects', 'Chelating Agents/pharmacology', 'Copper/*toxicity', 'Cysteine/metabolism', 'Leukemia L1210/*pathology', 'Mice', 'Oxidation-Reduction', 'Phenanthrolines/*pharmacology', 'Sulfhydryl Compounds/physiology']",,1985/08/15 00:00,1985/08/15 00:01,['1985/08/15 00:00'],"['1985/08/15 00:00 [pubmed]', '1985/08/15 00:01 [medline]', '1985/08/15 00:00 [entrez]']",['10.1007/BF01952146 [doi]'],ppublish,Experientia. 1985 Aug 15;41(8):1064-6. doi: 10.1007/BF01952146.,"['0 (Chelating Agents)', '0 (Phenanthrolines)', '0 (Sulfhydryl Compounds)', '73348-75-1 (bathocuproine sulfonate)', '789U1901C5 (Copper)', 'K848JZ4886 (Cysteine)']",,,,,,,,,,,
4017934,NLM,MEDLINE,19850919,20061115,0204-3564 (Print) 0204-3564 (Linking),7,3,1985,[Changes in the chemotherapy sensitivity of leukemia L1210 cells during the development of diazan resistance].,56-9,"L 1210 leukemia strain resistant to diazan (L 1210/D1) was studied for its drug sensitivity in comparison with the parent strain. The resistant strain exhibited significantly higher sensitivity to nine drugs: dopan, sarcolysine, apirazidin, cyclophosphane, 6-mercaptopurine, thiophosphamide, rubomycin, vinblastine and vincristine. L 1210/D1 gained cross resistance to four drugs: 1-(2-chloroethyl)-3-(2, 6-dioxy-3-piperidyl)-1-nitrosourea, methotrexate, 5-fluorouracil and ftorafur. The resistant strain sensitivity remained unchanged (in comparison with the parent strain) to seven drugs: degranol, prospidin, nitrosomethylurea, chlorozotocin, deazauridine, bleomycin and L-asparaginase (crasnitine).","['Goncharova, S A', 'Shevtsova, V N', 'Demidova, N S', 'Konovalova, N P']","['Goncharova SA', 'Shevtsova VN', 'Demidova NS', 'Konovalova NP']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Ukraine,Eksp Onkol,Eksperimental'naia onkologiia,8406659,IM,"['Animals', 'Antineoplastic Agents/*antagonists & inhibitors', 'Diazonium Compounds/*antagonists & inhibitors', 'Drug Evaluation, Preclinical', 'Drug Resistance', 'Leukemia L1210/*drug therapy', 'Mice']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Eksp Onkol. 1985;7(3):56-9.,"['0 (Antineoplastic Agents)', '0 (Diazonium Compounds)', '19690-35-8 (diazan)']",,Izmenenie chuvstvitel'nosti k khimioterapii kletok leikoza L1210 pri razvitii ustoichivosti k diazanu.,,,,,,,,,
4017931,NLM,MEDLINE,19850919,20071115,0204-3564 (Print) 0204-3564 (Linking),7,3,1985,[Comparative characteristics of the adrenal and gonadal functions in human beings and hamadryas baboons with hemoblastosis].,47-50,"Adrenal and gonad steroid hormones were investigated in the peripheral blood plasma of human beings and hamadryas baboons (Papio hamadryas) with hemoblastosis. The similar hormonal dysfunction of adrenal glands and gonads was found in human beings and monkeys. The dehydroepiandrosterone level was found to decrease significantly, while the cortisol level increased markedly. Changes in the androgen level were sex-dependent. The testosterone and 5 alpha-dihydrotestosterone levels were found to decrease markedly in men and male baboons while the testosterone level in women and females was found to increase significantly with 5 alpha-dihydrotestosterone unchanged.","['Goncharova, N D', 'Goncharov, N P']","['Goncharova ND', 'Goncharov NP']",['rus'],"['Comparative Study', 'English Abstract', 'Journal Article']",Ukraine,Eksp Onkol,Eksperimental'naia onkologiia,8406659,IM,"['Acute Disease', 'Adrenal Cortex Hormones/blood', 'Adrenal Glands/*physiopathology', 'Adult', 'Aged', 'Animals', 'Female', 'Gonadal Steroid Hormones/blood', 'Humans', 'Leukemia/blood/*physiopathology', 'Leukemia, Experimental/blood/*physiopathology', 'Leukemia, Lymphoid/blood/physiopathology', 'Male', 'Middle Aged', 'Ovary/*physiopathology', 'Testis/*physiopathology']",,1985/01/01 00:00,1985/01/01 00:01,['1985/01/01 00:00'],"['1985/01/01 00:00 [pubmed]', '1985/01/01 00:01 [medline]', '1985/01/01 00:00 [entrez]']",,ppublish,Eksp Onkol. 1985;7(3):47-50.,"['0 (Adrenal Cortex Hormones)', '0 (Gonadal Steroid Hormones)']",,"Sravnitel'naia kharateristika gormonal'noi funktsii nadpochechnikovykh i polovykh zhelez u liudei i pavianov gamadrilov, bol'nykh gemoblastozom.",,,,,,,,,
